id	sid	tid	token	lemma	pos
10_1101-2020_09_02_279521	1	1	Simulating	simulate	VBG
10_1101-2020_09_02_279521	1	2	the	the	DT
10_1101-2020_09_02_279521	1	3	outcome	outcome	NN
10_1101-2020_09_02_279521	1	4	of	of	IN
10_1101-2020_09_02_279521	1	5	amyloid	amyloid	NN
10_1101-2020_09_02_279521	1	6	treatments	treatment	NNS
10_1101-2020_09_02_279521	1	7	in	in	IN
10_1101-2020_09_02_279521	1	8	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	1	9	’s	’s	POS
10_1101-2020_09_02_279521	1	10	disease	disease	NN
10_1101-2020_09_02_279521	1	11	from	from	IN
10_1101-2020_09_02_279521	1	12	imaging	imaging	NN
10_1101-2020_09_02_279521	1	13	and	and	CC
10_1101-2020_09_02_279521	1	14	clinical	clinical	JJ
10_1101-2020_09_02_279521	1	15	data	datum	NNS
10_1101-2020_09_02_279521	1	16	Simulating	simulate	VBG
10_1101-2020_09_02_279521	1	17	the	the	DT
10_1101-2020_09_02_279521	1	18	outcome	outcome	NN
10_1101-2020_09_02_279521	1	19	of	of	IN
10_1101-2020_09_02_279521	1	20	amyloid	amyloid	NN
10_1101-2020_09_02_279521	1	21	treatments	treatment	NNS
10_1101-2020_09_02_279521	1	22	in	in	IN
10_1101-2020_09_02_279521	1	23	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	1	24	's	's	POS
10_1101-2020_09_02_279521	1	25	disease	disease	NN
10_1101-2020_09_02_279521	1	26	from	from	IN
10_1101-2020_09_02_279521	1	27	imaging	imaging	NN
10_1101-2020_09_02_279521	1	28	and	and	CC
10_1101-2020_09_02_279521	1	29	clinical	clinical	JJ
10_1101-2020_09_02_279521	1	30	data	datum	NNS
10_1101-2020_09_02_279521	1	31	Clément	Clément	NNP
10_1101-2020_09_02_279521	1	32	Abi	Abi	NNP
10_1101-2020_09_02_279521	1	33	Nader1	Nader1	NNP
10_1101-2020_09_02_279521	1	34	,	,	,
10_1101-2020_09_02_279521	1	35	Nicholas	Nicholas	NNP
10_1101-2020_09_02_279521	1	36	Ayache1	Ayache1	NNP
10_1101-2020_09_02_279521	1	37	,	,	,
10_1101-2020_09_02_279521	1	38	Giovanni	Giovanni	NNP
10_1101-2020_09_02_279521	1	39	B.	B.	NNP
10_1101-2020_09_02_279521	1	40	Frisoni2	Frisoni2	NNP
10_1101-2020_09_02_279521	1	41	,	,	,
10_1101-2020_09_02_279521	1	42	Philippe	Philippe	NNP
10_1101-2020_09_02_279521	1	43	Robert3	Robert3	NNP
10_1101-2020_09_02_279521	1	44	,	,	,
10_1101-2020_09_02_279521	1	45	Marco	Marco	NNP
10_1101-2020_09_02_279521	1	46	Lorenzi1	Lorenzi1	NNP
10_1101-2020_09_02_279521	1	47	,	,	,
10_1101-2020_09_02_279521	1	48	for	for	IN
10_1101-2020_09_02_279521	1	49	the	the	DT
10_1101-2020_09_02_279521	1	50	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	1	51	’s	’s	POS
10_1101-2020_09_02_279521	1	52	Disease	Disease	NNP
10_1101-2020_09_02_279521	1	53	Neuroimaging	Neuroimaging	NNP
10_1101-2020_09_02_279521	1	54	Initiative	Initiative	NNP
10_1101-2020_09_02_279521	1	55	*	*	NFP
10_1101-2020_09_02_279521	1	56	In	in	IN
10_1101-2020_09_02_279521	1	57	this	this	DT
10_1101-2020_09_02_279521	1	58	study	study	NN
10_1101-2020_09_02_279521	1	59	we	-PRON-	PRP
10_1101-2020_09_02_279521	1	60	investigate	investigate	VBP
10_1101-2020_09_02_279521	1	61	a	a	DT
10_1101-2020_09_02_279521	1	62	novel	novel	JJ
10_1101-2020_09_02_279521	1	63	quantitative	quantitative	JJ
10_1101-2020_09_02_279521	1	64	instrument	instrument	NN
10_1101-2020_09_02_279521	1	65	for	for	IN
10_1101-2020_09_02_279521	1	66	the	the	DT
10_1101-2020_09_02_279521	1	67	development	development	NN
10_1101-2020_09_02_279521	1	68	of	of	IN
10_1101-2020_09_02_279521	1	69	intervention	intervention	NN
10_1101-2020_09_02_279521	1	70	strategies	strategy	NNS
10_1101-2020_09_02_279521	1	71	for	for	IN
10_1101-2020_09_02_279521	1	72	disease	disease	NN
10_1101-2020_09_02_279521	1	73	modifying	modify	VBG
10_1101-2020_09_02_279521	1	74	drugs	drug	NNS
10_1101-2020_09_02_279521	1	75	in	in	IN
10_1101-2020_09_02_279521	1	76	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	1	77	's	's	POS
10_1101-2020_09_02_279521	1	78	disease	disease	NN
10_1101-2020_09_02_279521	1	79	.	.	.
10_1101-2020_09_02_279521	2	1	Our	-PRON-	PRP$
10_1101-2020_09_02_279521	2	2	framework	framework	NN
10_1101-2020_09_02_279521	2	3	is	be	VBZ
10_1101-2020_09_02_279521	2	4	based	base	VBN
10_1101-2020_09_02_279521	2	5	on	on	IN
10_1101-2020_09_02_279521	2	6	the	the	DT
10_1101-2020_09_02_279521	2	7	modeling	modeling	NN
10_1101-2020_09_02_279521	2	8	of	of	IN
10_1101-2020_09_02_279521	2	9	the	the	DT
10_1101-2020_09_02_279521	2	10	spatio	spatio	NN
10_1101-2020_09_02_279521	2	11	-	-	HYPH
10_1101-2020_09_02_279521	2	12	temporal	temporal	JJ
10_1101-2020_09_02_279521	2	13	dynamics	dynamic	NNS
10_1101-2020_09_02_279521	2	14	governing	govern	VBG
10_1101-2020_09_02_279521	2	15	the	the	DT
10_1101-2020_09_02_279521	2	16	joint	joint	JJ
10_1101-2020_09_02_279521	2	17	evolution	evolution	NN
10_1101-2020_09_02_279521	2	18	of	of	IN
10_1101-2020_09_02_279521	2	19	imaging	imaging	NN
10_1101-2020_09_02_279521	2	20	and	and	CC
10_1101-2020_09_02_279521	2	21	clinical	clinical	JJ
10_1101-2020_09_02_279521	2	22	biomarkers	biomarker	NNS
10_1101-2020_09_02_279521	2	23	along	along	IN
10_1101-2020_09_02_279521	2	24	the	the	DT
10_1101-2020_09_02_279521	2	25	history	history	NN
10_1101-2020_09_02_279521	2	26	of	of	IN
10_1101-2020_09_02_279521	2	27	the	the	DT
10_1101-2020_09_02_279521	2	28	disease	disease	NN
10_1101-2020_09_02_279521	2	29	,	,	,
10_1101-2020_09_02_279521	2	30	and	and	CC
10_1101-2020_09_02_279521	2	31	allows	allow	VBZ
10_1101-2020_09_02_279521	2	32	the	the	DT
10_1101-2020_09_02_279521	2	33	simulation	simulation	NN
10_1101-2020_09_02_279521	2	34	of	of	IN
10_1101-2020_09_02_279521	2	35	the	the	DT
10_1101-2020_09_02_279521	2	36	effect	effect	NN
10_1101-2020_09_02_279521	2	37	of	of	IN
10_1101-2020_09_02_279521	2	38	intervention	intervention	NN
10_1101-2020_09_02_279521	2	39	time	time	NN
10_1101-2020_09_02_279521	2	40	and	and	CC
10_1101-2020_09_02_279521	2	41	drug	drug	NN
10_1101-2020_09_02_279521	2	42	dosage	dosage	NN
10_1101-2020_09_02_279521	2	43	on	on	IN
10_1101-2020_09_02_279521	2	44	the	the	DT
10_1101-2020_09_02_279521	2	45	biomarkers	biomarker	NNS
10_1101-2020_09_02_279521	2	46	'	'	POS
10_1101-2020_09_02_279521	2	47	progression	progression	NN
10_1101-2020_09_02_279521	2	48	.	.	.
10_1101-2020_09_02_279521	3	1	When	when	WRB
10_1101-2020_09_02_279521	3	2	applied	apply	VBN
10_1101-2020_09_02_279521	3	3	to	to	IN
10_1101-2020_09_02_279521	3	4	multi-	multi-	NNP
10_1101-2020_09_02_279521	3	5	modal	modal	NNP
10_1101-2020_09_02_279521	3	6	imaging	imaging	NNP
10_1101-2020_09_02_279521	3	7	and	and	CC
10_1101-2020_09_02_279521	3	8	clinical	clinical	JJ
10_1101-2020_09_02_279521	3	9	data	datum	NNS
10_1101-2020_09_02_279521	3	10	from	from	IN
10_1101-2020_09_02_279521	3	11	the	the	DT
10_1101-2020_09_02_279521	3	12	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	3	13	's	's	POS
10_1101-2020_09_02_279521	3	14	Disease	Disease	NNP
10_1101-2020_09_02_279521	3	15	Neuroimaging	Neuroimaging	NNP
10_1101-2020_09_02_279521	3	16	Initiative	Initiative	NNP
10_1101-2020_09_02_279521	3	17	our	-PRON-	PRP$
10_1101-2020_09_02_279521	3	18	method	method	NN
10_1101-2020_09_02_279521	3	19	enables	enable	VBZ
10_1101-2020_09_02_279521	3	20	to	to	TO
10_1101-2020_09_02_279521	3	21	generate	generate	VB
10_1101-2020_09_02_279521	3	22	hypothetical	hypothetical	JJ
10_1101-2020_09_02_279521	3	23	scenarios	scenario	NNS
10_1101-2020_09_02_279521	3	24	of	of	IN
10_1101-2020_09_02_279521	3	25	amyloid	amyloid	NN
10_1101-2020_09_02_279521	3	26	lowering	lowering	NN
10_1101-2020_09_02_279521	3	27	interventions	intervention	NNS
10_1101-2020_09_02_279521	3	28	.	.	.
10_1101-2020_09_02_279521	4	1	The	the	DT
10_1101-2020_09_02_279521	4	2	results	result	NNS
10_1101-2020_09_02_279521	4	3	quantify	quantify	VBP
10_1101-2020_09_02_279521	4	4	the	the	DT
10_1101-2020_09_02_279521	4	5	crucial	crucial	JJ
10_1101-2020_09_02_279521	4	6	role	role	NN
10_1101-2020_09_02_279521	4	7	of	of	IN
10_1101-2020_09_02_279521	4	8	intervention	intervention	NN
10_1101-2020_09_02_279521	4	9	time	time	NN
10_1101-2020_09_02_279521	4	10	,	,	,
10_1101-2020_09_02_279521	4	11	and	and	CC
10_1101-2020_09_02_279521	4	12	provide	provide	VB
10_1101-2020_09_02_279521	4	13	a	a	DT
10_1101-2020_09_02_279521	4	14	theoretical	theoretical	JJ
10_1101-2020_09_02_279521	4	15	justification	justification	NN
10_1101-2020_09_02_279521	4	16	for	for	IN
10_1101-2020_09_02_279521	4	17	testing	testing	NN
10_1101-2020_09_02_279521	4	18	amyloid	amyloid	NN
10_1101-2020_09_02_279521	4	19	modifying	modify	VBG
10_1101-2020_09_02_279521	4	20	drugs	drug	NNS
10_1101-2020_09_02_279521	4	21	in	in	IN
10_1101-2020_09_02_279521	4	22	the	the	DT
10_1101-2020_09_02_279521	4	23	pre	pre	JJ
10_1101-2020_09_02_279521	4	24	-	-	JJ
10_1101-2020_09_02_279521	4	25	clinical	clinical	JJ
10_1101-2020_09_02_279521	4	26	stage	stage	NN
10_1101-2020_09_02_279521	4	27	.	.	.
10_1101-2020_09_02_279521	5	1	Our	-PRON-	PRP$
10_1101-2020_09_02_279521	5	2	experimental	experimental	JJ
10_1101-2020_09_02_279521	5	3	simulations	simulation	NNS
10_1101-2020_09_02_279521	5	4	are	be	VBP
10_1101-2020_09_02_279521	5	5	compatible	compatible	JJ
10_1101-2020_09_02_279521	5	6	with	with	IN
10_1101-2020_09_02_279521	5	7	the	the	DT
10_1101-2020_09_02_279521	5	8	outcomes	outcome	NNS
10_1101-2020_09_02_279521	5	9	observed	observe	VBN
10_1101-2020_09_02_279521	5	10	in	in	IN
10_1101-2020_09_02_279521	5	11	past	past	JJ
10_1101-2020_09_02_279521	5	12	clinical	clinical	JJ
10_1101-2020_09_02_279521	5	13	trials	trial	NNS
10_1101-2020_09_02_279521	5	14	,	,	,
10_1101-2020_09_02_279521	5	15	and	and	CC
10_1101-2020_09_02_279521	5	16	suggest	suggest	VBP
10_1101-2020_09_02_279521	5	17	that	that	IN
10_1101-2020_09_02_279521	5	18	anti	anti	JJ
10_1101-2020_09_02_279521	5	19	-	-	JJ
10_1101-2020_09_02_279521	5	20	amyloid	amyloid	JJ
10_1101-2020_09_02_279521	5	21	treatments	treatment	NNS
10_1101-2020_09_02_279521	5	22	should	should	MD
10_1101-2020_09_02_279521	5	23	be	be	VB
10_1101-2020_09_02_279521	5	24	administered	administer	VBN
10_1101-2020_09_02_279521	5	25	at	at	IN
10_1101-2020_09_02_279521	5	26	least	least	RBS
10_1101-2020_09_02_279521	5	27	7	7	CD
10_1101-2020_09_02_279521	5	28	years	year	NNS
10_1101-2020_09_02_279521	5	29	earlier	early	RBR
10_1101-2020_09_02_279521	5	30	than	than	IN
10_1101-2020_09_02_279521	5	31	what	what	WP
10_1101-2020_09_02_279521	5	32	is	be	VBZ
10_1101-2020_09_02_279521	5	33	currently	currently	RB
10_1101-2020_09_02_279521	5	34	being	be	VBG
10_1101-2020_09_02_279521	5	35	done	do	VBN
10_1101-2020_09_02_279521	5	36	in	in	IN
10_1101-2020_09_02_279521	5	37	order	order	NN
10_1101-2020_09_02_279521	5	38	to	to	TO
10_1101-2020_09_02_279521	5	39	obtain	obtain	VB
10_1101-2020_09_02_279521	5	40	statistically	statistically	RB
10_1101-2020_09_02_279521	5	41	powered	power	VBN
10_1101-2020_09_02_279521	5	42	improvement	improvement	NN
10_1101-2020_09_02_279521	5	43	of	of	IN
10_1101-2020_09_02_279521	5	44	clinical	clinical	JJ
10_1101-2020_09_02_279521	5	45	endpoints	endpoint	NNS
10_1101-2020_09_02_279521	5	46	.	.	.
10_1101-2020_09_02_279521	6	1	1	1	CD
10_1101-2020_09_02_279521	6	2	Université	Université	NNP
10_1101-2020_09_02_279521	6	3	Côte	Côte	NNP
10_1101-2020_09_02_279521	6	4	d'Azur	d'Azur	NNP
10_1101-2020_09_02_279521	6	5	,	,	,
10_1101-2020_09_02_279521	6	6	INRIA	INRIA	NNP
10_1101-2020_09_02_279521	6	7	Sophia	Sophia	NNP
10_1101-2020_09_02_279521	6	8	Antipolis	Antipolis	NNP
10_1101-2020_09_02_279521	6	9	,	,	,
10_1101-2020_09_02_279521	6	10	EPIONE	EPIONE	NNP
10_1101-2020_09_02_279521	6	11	Research	Research	NNP
10_1101-2020_09_02_279521	6	12	Project	Project	NNP
10_1101-2020_09_02_279521	6	13	,	,	,
10_1101-2020_09_02_279521	6	14	France	France	NNP
10_1101-2020_09_02_279521	6	15	.	.	.
10_1101-2020_09_02_279521	7	1	2	2	CD
10_1101-2020_09_02_279521	7	2	Memory	Memory	NNP
10_1101-2020_09_02_279521	7	3	Clinic	Clinic	NNP
10_1101-2020_09_02_279521	7	4	and	and	CC
10_1101-2020_09_02_279521	7	5	LANVIE	LANVIE	NNP
10_1101-2020_09_02_279521	7	6	-	-	HYPH
10_1101-2020_09_02_279521	7	7	Laboratory	Laboratory	NNP
10_1101-2020_09_02_279521	7	8	of	of	IN
10_1101-2020_09_02_279521	7	9	Neuroimaging	Neuroimaging	NNP
10_1101-2020_09_02_279521	7	10	of	of	IN
10_1101-2020_09_02_279521	7	11	Aging	age	VBG
10_1101-2020_09_02_279521	7	12	,	,	,
10_1101-2020_09_02_279521	7	13	Hospitals	Hospitals	NNPS
10_1101-2020_09_02_279521	7	14	and	and	CC
10_1101-2020_09_02_279521	7	15	University	University	NNP
10_1101-2020_09_02_279521	7	16	of	of	IN
10_1101-2020_09_02_279521	7	17	Geneva	Geneva	NNP
10_1101-2020_09_02_279521	7	18	,	,	,
10_1101-2020_09_02_279521	7	19	Geneva	Geneva	NNP
10_1101-2020_09_02_279521	7	20	,	,	,
10_1101-2020_09_02_279521	7	21	Switzerland	Switzerland	NNP
10_1101-2020_09_02_279521	7	22	3	3	CD
10_1101-2020_09_02_279521	7	23	Université	Université	NNP
10_1101-2020_09_02_279521	7	24	Côte	Côte	NNP
10_1101-2020_09_02_279521	7	25	d'Azur	d'Azur	NNP
10_1101-2020_09_02_279521	7	26	,	,	,
10_1101-2020_09_02_279521	7	27	CoBTeK	cobtek	JJ
10_1101-2020_09_02_279521	7	28	lab	lab	NN
10_1101-2020_09_02_279521	7	29	,	,	,
10_1101-2020_09_02_279521	7	30	MNC3	MNC3	NNP
10_1101-2020_09_02_279521	7	31	program	program	NN
10_1101-2020_09_02_279521	7	32	,	,	,
10_1101-2020_09_02_279521	7	33	France	France	NNP
10_1101-2020_09_02_279521	7	34	.	.	.
10_1101-2020_09_02_279521	8	1	*	*	NFP
10_1101-2020_09_02_279521	8	2	Data	datum	NNS
10_1101-2020_09_02_279521	8	3	used	use	VBN
10_1101-2020_09_02_279521	8	4	in	in	IN
10_1101-2020_09_02_279521	8	5	preparation	preparation	NN
10_1101-2020_09_02_279521	8	6	of	of	IN
10_1101-2020_09_02_279521	8	7	this	this	DT
10_1101-2020_09_02_279521	8	8	article	article	NN
10_1101-2020_09_02_279521	8	9	were	be	VBD
10_1101-2020_09_02_279521	8	10	obtained	obtain	VBN
10_1101-2020_09_02_279521	8	11	from	from	IN
10_1101-2020_09_02_279521	8	12	the	the	DT
10_1101-2020_09_02_279521	8	13	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	8	14	’s	’s	POS
10_1101-2020_09_02_279521	8	15	Disease	Disease	NNP
10_1101-2020_09_02_279521	8	16	Neuroimaging	Neuroimaging	NNP
10_1101-2020_09_02_279521	8	17	Initiative	Initiative	NNP
10_1101-2020_09_02_279521	8	18	(	(	-LRB-
10_1101-2020_09_02_279521	8	19	ADNI	ADNI	NNP
10_1101-2020_09_02_279521	8	20	)	)	-RRB-
10_1101-2020_09_02_279521	8	21	database	database	NN
10_1101-2020_09_02_279521	8	22	(	(	-LRB-
10_1101-2020_09_02_279521	8	23	adni.loni.usc.edu	adni.loni.usc.edu	NN
10_1101-2020_09_02_279521	8	24	)	)	-RRB-
10_1101-2020_09_02_279521	8	25	.	.	.
10_1101-2020_09_02_279521	9	1	As	as	IN
10_1101-2020_09_02_279521	9	2	such	such	JJ
10_1101-2020_09_02_279521	9	3	,	,	,
10_1101-2020_09_02_279521	9	4	the	the	DT
10_1101-2020_09_02_279521	9	5	investigators	investigator	NNS
10_1101-2020_09_02_279521	9	6	within	within	IN
10_1101-2020_09_02_279521	9	7	the	the	DT
10_1101-2020_09_02_279521	9	8	ADNI	ADNI	NNP
10_1101-2020_09_02_279521	9	9	contributed	contribute	VBD
10_1101-2020_09_02_279521	9	10	to	to	IN
10_1101-2020_09_02_279521	9	11	the	the	DT
10_1101-2020_09_02_279521	9	12	design	design	NN
10_1101-2020_09_02_279521	9	13	and	and	CC
10_1101-2020_09_02_279521	9	14	implementation	implementation	NN
10_1101-2020_09_02_279521	9	15	of	of	IN
10_1101-2020_09_02_279521	9	16	ADNI	ADNI	NNP
10_1101-2020_09_02_279521	9	17	and/or	and/or	CC
10_1101-2020_09_02_279521	9	18	provided	provide	VBD
10_1101-2020_09_02_279521	9	19	data	datum	NNS
10_1101-2020_09_02_279521	9	20	but	but	CC
10_1101-2020_09_02_279521	9	21	did	do	VBD
10_1101-2020_09_02_279521	9	22	not	not	RB
10_1101-2020_09_02_279521	9	23	participate	participate	VB
10_1101-2020_09_02_279521	9	24	in	in	IN
10_1101-2020_09_02_279521	9	25	analysis	analysis	NN
10_1101-2020_09_02_279521	9	26	or	or	CC
10_1101-2020_09_02_279521	9	27	writing	writing	NN
10_1101-2020_09_02_279521	9	28	of	of	IN
10_1101-2020_09_02_279521	9	29	this	this	DT
10_1101-2020_09_02_279521	9	30	report	report	NN
10_1101-2020_09_02_279521	9	31	.	.	.
10_1101-2020_09_02_279521	10	1	A	a	DT
10_1101-2020_09_02_279521	10	2	complete	complete	JJ
10_1101-2020_09_02_279521	10	3	listing	listing	NN
10_1101-2020_09_02_279521	10	4	of	of	IN
10_1101-2020_09_02_279521	10	5	ADNI	ADNI	NNP
10_1101-2020_09_02_279521	10	6	investigators	investigator	NNS
10_1101-2020_09_02_279521	10	7	can	can	MD
10_1101-2020_09_02_279521	10	8	be	be	VB
10_1101-2020_09_02_279521	10	9	found	find	VBN
10_1101-2020_09_02_279521	10	10	at	at	IN
10_1101-2020_09_02_279521	10	11	:	:	:
10_1101-2020_09_02_279521	10	12	http://adni.loni.usc.edu/wpcontent/uploads/how_to_apply/ADNI_Acknowledgement_textunderscore	http://adni.loni.usc.edu/wpcontent/uploads/how_to_apply/adni_acknowledgement_textunderscore	NN
10_1101-2020_09_02_279521	10	13	List.pdf	List.pdf	NNP
10_1101-2020_09_02_279521	10	14	.	.	.
10_1101-2020_09_02_279521	11	1	.CC	.CC	NFP
10_1101-2020_09_02_279521	11	2	-	-	:
10_1101-2020_09_02_279521	11	3	BY	by	IN
10_1101-2020_09_02_279521	11	4	4.0	4.0	CD
10_1101-2020_09_02_279521	11	5	International	international	JJ
10_1101-2020_09_02_279521	11	6	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	11	7	.	.	.
10_1101-2020_09_02_279521	12	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	12	2	is	be	VBZ
10_1101-2020_09_02_279521	12	3	made	make	VBN
10_1101-2020_09_02_279521	12	4	available	available	JJ
10_1101-2020_09_02_279521	12	5	under	under	IN
10_1101-2020_09_02_279521	12	6	a	a	DT
10_1101-2020_09_02_279521	12	7	preprint	preprint	NN
10_1101-2020_09_02_279521	12	8	(	(	-LRB-
10_1101-2020_09_02_279521	12	9	which	which	WDT
10_1101-2020_09_02_279521	12	10	was	be	VBD
10_1101-2020_09_02_279521	12	11	not	not	RB
10_1101-2020_09_02_279521	12	12	certified	certify	VBN
10_1101-2020_09_02_279521	12	13	by	by	IN
10_1101-2020_09_02_279521	12	14	peer	peer	NN
10_1101-2020_09_02_279521	12	15	review	review	NN
10_1101-2020_09_02_279521	12	16	)	)	-RRB-
10_1101-2020_09_02_279521	12	17	is	be	VBZ
10_1101-2020_09_02_279521	12	18	the	the	DT
10_1101-2020_09_02_279521	12	19	author	author	NN
10_1101-2020_09_02_279521	12	20	/	/	SYM
10_1101-2020_09_02_279521	12	21	funder	funder	NN
10_1101-2020_09_02_279521	12	22	,	,	,
10_1101-2020_09_02_279521	12	23	who	who	WP
10_1101-2020_09_02_279521	12	24	has	have	VBZ
10_1101-2020_09_02_279521	12	25	granted	grant	VBN
10_1101-2020_09_02_279521	12	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	12	27	a	a	DT
10_1101-2020_09_02_279521	12	28	license	license	NN
10_1101-2020_09_02_279521	12	29	to	to	TO
10_1101-2020_09_02_279521	12	30	display	display	VB
10_1101-2020_09_02_279521	12	31	the	the	DT
10_1101-2020_09_02_279521	12	32	preprint	preprint	NN
10_1101-2020_09_02_279521	12	33	in	in	IN
10_1101-2020_09_02_279521	12	34	The	the	DT
10_1101-2020_09_02_279521	12	35	copyright	copyright	NN
10_1101-2020_09_02_279521	12	36	holder	holder	NN
10_1101-2020_09_02_279521	12	37	for	for	IN
10_1101-2020_09_02_279521	12	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	12	39	version	version	NN
10_1101-2020_09_02_279521	12	40	posted	post	VBD
10_1101-2020_09_02_279521	12	41	February	February	NNP
10_1101-2020_09_02_279521	12	42	10	10	CD
10_1101-2020_09_02_279521	12	43	,	,	,
10_1101-2020_09_02_279521	12	44	2021	2021	CD
10_1101-2020_09_02_279521	12	45	.	.	.
10_1101-2020_09_02_279521	12	46	;	;	:
10_1101-2020_09_02_279521	12	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	12	48	:	:	:
10_1101-2020_09_02_279521	12	49	bioRxiv	biorxiv	NN
10_1101-2020_09_02_279521	12	50	preprint	preprint	NN
10_1101-2020_09_02_279521	12	51	http://adni.loni.usc.edu/wpcontent/uploads/how_to_apply/ADNI_Acknowledgement_textunderscore%20List.pdf	http://adni.loni.usc.edu/wpcontent/uploads/how_to_apply/adni_acknowledgement_textunderscore%20list.pdf	VB
10_1101-2020_09_02_279521	12	52	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	PRP$
10_1101-2020_09_02_279521	12	53	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	ADD
10_1101-2020_09_02_279521	12	54	Correspondence	correspondence	NN
10_1101-2020_09_02_279521	12	55	to	to	IN
10_1101-2020_09_02_279521	12	56	:	:	:
10_1101-2020_09_02_279521	12	57	Clément	Clément	NNP
10_1101-2020_09_02_279521	12	58	Abi	Abi	NNP
10_1101-2020_09_02_279521	12	59	Nader	Nader	NNP
10_1101-2020_09_02_279521	12	60	EPIONE	EPIONE	NNP
10_1101-2020_09_02_279521	12	61	Research	Research	NNP
10_1101-2020_09_02_279521	12	62	Project	Project	NNP
10_1101-2020_09_02_279521	12	63	,	,	,
10_1101-2020_09_02_279521	12	64	INRIA	INRIA	NNP
10_1101-2020_09_02_279521	12	65	Sophia	Sophia	NNP
10_1101-2020_09_02_279521	12	66	-	-	HYPH
10_1101-2020_09_02_279521	12	67	Antipolis	Antipolis	NNP
10_1101-2020_09_02_279521	12	68	,	,	,
10_1101-2020_09_02_279521	12	69	2004	2004	CD
10_1101-2020_09_02_279521	12	70	,	,	,
10_1101-2020_09_02_279521	12	71	route	route	NN
10_1101-2020_09_02_279521	12	72	des	des	NNP
10_1101-2020_09_02_279521	12	73	Lucioles	Lucioles	NNP
10_1101-2020_09_02_279521	12	74	,	,	,
10_1101-2020_09_02_279521	12	75	06902	06902	CD
10_1101-2020_09_02_279521	12	76	Sophia-	Sophia-	NNP
10_1101-2020_09_02_279521	12	77	Antipolis	Antipolis	NNP
10_1101-2020_09_02_279521	12	78	,	,	,
10_1101-2020_09_02_279521	12	79	France	France	NNP
10_1101-2020_09_02_279521	12	80	.	.	.
10_1101-2020_09_02_279521	13	1	E	e	NN
10_1101-2020_09_02_279521	13	2	-	-	NN
10_1101-2020_09_02_279521	13	3	mail	mail	NN
10_1101-2020_09_02_279521	13	4	:	:	:
10_1101-2020_09_02_279521	13	5	clement.abi-nader@inria.fr	clement.abi-nader@inria.fr	NNP
10_1101-2020_09_02_279521	13	6	Keywords	keyword	NNS
10_1101-2020_09_02_279521	13	7	:	:	:
10_1101-2020_09_02_279521	13	8	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	13	9	’s	’s	POS
10_1101-2020_09_02_279521	13	10	Disease	Disease	NNP
10_1101-2020_09_02_279521	13	11	;	;	:
10_1101-2020_09_02_279521	13	12	Clinical	clinical	JJ
10_1101-2020_09_02_279521	13	13	trials	trial	NNS
10_1101-2020_09_02_279521	13	14	;	;	:
10_1101-2020_09_02_279521	13	15	Disease	Disease	NNP
10_1101-2020_09_02_279521	13	16	progression	progression	NN
10_1101-2020_09_02_279521	13	17	;	;	:
10_1101-2020_09_02_279521	13	18	Amyloid	Amyloid	NNP
10_1101-2020_09_02_279521	13	19	hypothesis	hypothesis	NN
10_1101-2020_09_02_279521	13	20	;	;	:
10_1101-2020_09_02_279521	13	21	Biomarkers	Biomarkers	NNPS
10_1101-2020_09_02_279521	13	22	Abbreviations	Abbreviations	NNPS
10_1101-2020_09_02_279521	13	23	:	:	:
10_1101-2020_09_02_279521	13	24	DPM	DPM	NNP
10_1101-2020_09_02_279521	13	25	=	=	SYM
10_1101-2020_09_02_279521	13	26	Disease	Disease	NNP
10_1101-2020_09_02_279521	13	27	Progression	Progression	NNP
10_1101-2020_09_02_279521	13	28	Model	Model	NNP
10_1101-2020_09_02_279521	13	29	;	;	:
10_1101-2020_09_02_279521	13	30	ODE	ODE	NNP
10_1101-2020_09_02_279521	13	31	=	=	SYM
10_1101-2020_09_02_279521	13	32	Ordinary	Ordinary	NNP
10_1101-2020_09_02_279521	13	33	Differential	Differential	NNP
10_1101-2020_09_02_279521	13	34	Equations	Equations	NNPS
10_1101-2020_09_02_279521	13	35	;	;	:
10_1101-2020_09_02_279521	13	36	ADNI	ADNI	NNP
10_1101-2020_09_02_279521	13	37	=	=	SYM
10_1101-2020_09_02_279521	13	38	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	13	39	's	's	POS
10_1101-2020_09_02_279521	13	40	Disease	Disease	NNP
10_1101-2020_09_02_279521	13	41	Neuroimaging	Neuroimaging	NNP
10_1101-2020_09_02_279521	13	42	Initiative	Initiative	NNP
10_1101-2020_09_02_279521	13	43	;	;	:
10_1101-2020_09_02_279521	13	44	NL	NL	NNP
10_1101-2020_09_02_279521	13	45	=	=	SYM
10_1101-2020_09_02_279521	13	46	Healthy	healthy	JJ
10_1101-2020_09_02_279521	13	47	;	;	:
10_1101-2020_09_02_279521	13	48	MCI	MCI	NNP
10_1101-2020_09_02_279521	13	49	=	=	SYM
10_1101-2020_09_02_279521	13	50	Mild	Mild	NNP
10_1101-2020_09_02_279521	13	51	Cognitive	cognitive	JJ
10_1101-2020_09_02_279521	13	52	Impairment	impairment	NN
10_1101-2020_09_02_279521	13	53	;	;	:
10_1101-2020_09_02_279521	13	54	AD	ad	NN
10_1101-2020_09_02_279521	13	55	=	=	SYM
10_1101-2020_09_02_279521	13	56	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	13	57	's	's	POS
10_1101-2020_09_02_279521	13	58	dementia	dementia	NN
10_1101-2020_09_02_279521	13	59	;	;	:
10_1101-2020_09_02_279521	13	60	AV45	AV45	NNP
10_1101-2020_09_02_279521	13	61	=	=	NFP
10_1101-2020_09_02_279521	13	62	(	(	-LRB-
10_1101-2020_09_02_279521	13	63	18)F	18)f	IN
10_1101-2020_09_02_279521	13	64	-	-	HYPH
10_1101-2020_09_02_279521	13	65	florbetapir	florbetapir	NN
10_1101-2020_09_02_279521	13	66	Amyloid	Amyloid	NNP
10_1101-2020_09_02_279521	13	67	;	;	:
10_1101-2020_09_02_279521	13	68	FDG	FDG	NNP
10_1101-2020_09_02_279521	13	69	=	=	NFP
10_1101-2020_09_02_279521	13	70	(	(	-LRB-
10_1101-2020_09_02_279521	13	71	18)F-	18)F-	NNP
10_1101-2020_09_02_279521	13	72	fluorodeoxyglucose	fluorodeoxyglucose	NN
10_1101-2020_09_02_279521	13	73	;	;	:
10_1101-2020_09_02_279521	13	74	ADAS11	adas11	NN
10_1101-2020_09_02_279521	13	75	=	=	SYM
10_1101-2020_09_02_279521	13	76	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	13	77	's	's	POS
10_1101-2020_09_02_279521	13	78	Disease	Disease	NNP
10_1101-2020_09_02_279521	13	79	Assessment	Assessment	NNP
10_1101-2020_09_02_279521	13	80	Scale	Scale	NNP
10_1101-2020_09_02_279521	13	81	;	;	:
10_1101-2020_09_02_279521	13	82	MMSE	MMSE	NNP
10_1101-2020_09_02_279521	13	83	=	=	SYM
10_1101-2020_09_02_279521	13	84	Mini-	Mini-	NNP
10_1101-2020_09_02_279521	13	85	Mental	Mental	NNP
10_1101-2020_09_02_279521	13	86	State	State	NNP
10_1101-2020_09_02_279521	13	87	Examination	Examination	NNP
10_1101-2020_09_02_279521	13	88	;	;	:
10_1101-2020_09_02_279521	13	89	FAQ	FAQ	NNP
10_1101-2020_09_02_279521	13	90	=	=	SYM
10_1101-2020_09_02_279521	13	91	Functional	Functional	NNP
10_1101-2020_09_02_279521	13	92	Assessment	Assessment	NNP
10_1101-2020_09_02_279521	13	93	Questionnaire	Questionnaire	NNP
10_1101-2020_09_02_279521	13	94	;	;	:
10_1101-2020_09_02_279521	13	95	RAVLT	RAVLT	NNP
10_1101-2020_09_02_279521	13	96	=	=	SYM
10_1101-2020_09_02_279521	13	97	Rey	Rey	NNP
10_1101-2020_09_02_279521	13	98	Auditory	Auditory	NNP
10_1101-2020_09_02_279521	13	99	Verbal	Verbal	NNP
10_1101-2020_09_02_279521	13	100	Learning	Learning	NNP
10_1101-2020_09_02_279521	13	101	Test	Test	NNP
10_1101-2020_09_02_279521	13	102	;	;	:
10_1101-2020_09_02_279521	13	103	CDRSB	cdrsb	NN
10_1101-2020_09_02_279521	13	104	=	=	SYM
10_1101-2020_09_02_279521	13	105	Clinical	Clinical	NNP
10_1101-2020_09_02_279521	13	106	Dementia	Dementia	NNP
10_1101-2020_09_02_279521	13	107	Rating	Rating	NNP
10_1101-2020_09_02_279521	13	108	Scale	Scale	NNP
10_1101-2020_09_02_279521	13	109	Sum	Sum	NNP
10_1101-2020_09_02_279521	13	110	of	of	IN
10_1101-2020_09_02_279521	13	111	Boxes	box	NNS
10_1101-2020_09_02_279521	13	112	Introduction	introduction	NN
10_1101-2020_09_02_279521	13	113	The	the	DT
10_1101-2020_09_02_279521	13	114	number	number	NN
10_1101-2020_09_02_279521	13	115	of	of	IN
10_1101-2020_09_02_279521	13	116	people	people	NNS
10_1101-2020_09_02_279521	13	117	affected	affect	VBN
10_1101-2020_09_02_279521	13	118	by	by	IN
10_1101-2020_09_02_279521	13	119	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	13	120	's	's	POS
10_1101-2020_09_02_279521	13	121	disease	disease	NN
10_1101-2020_09_02_279521	13	122	has	have	VBZ
10_1101-2020_09_02_279521	13	123	recently	recently	RB
10_1101-2020_09_02_279521	13	124	exceeded	exceed	VBN
10_1101-2020_09_02_279521	13	125	46	46	CD
10_1101-2020_09_02_279521	13	126	millions	million	NNS
10_1101-2020_09_02_279521	13	127	and	and	CC
10_1101-2020_09_02_279521	13	128	is	be	VBZ
10_1101-2020_09_02_279521	13	129	expected	expect	VBN
10_1101-2020_09_02_279521	13	130	to	to	TO
10_1101-2020_09_02_279521	13	131	double	double	VB
10_1101-2020_09_02_279521	13	132	every	every	DT
10_1101-2020_09_02_279521	13	133	20	20	CD
10_1101-2020_09_02_279521	13	134	years	year	NNS
10_1101-2020_09_02_279521	13	135	(	(	-LRB-
10_1101-2020_09_02_279521	13	136	Prince	Prince	NNP
10_1101-2020_09_02_279521	13	137	et	et	FW
10_1101-2020_09_02_279521	13	138	al	al	NNP
10_1101-2020_09_02_279521	13	139	.	.	NNP
10_1101-2020_09_02_279521	13	140	,	,	,
10_1101-2020_09_02_279521	13	141	2015	2015	CD
10_1101-2020_09_02_279521	13	142	)	)	-RRB-
10_1101-2020_09_02_279521	13	143	,	,	,
10_1101-2020_09_02_279521	13	144	thus	thus	RB
10_1101-2020_09_02_279521	13	145	posing	pose	VBG
10_1101-2020_09_02_279521	13	146	significant	significant	JJ
10_1101-2020_09_02_279521	13	147	healthcare	healthcare	NN
10_1101-2020_09_02_279521	13	148	challenges	challenge	NNS
10_1101-2020_09_02_279521	13	149	.	.	.
10_1101-2020_09_02_279521	14	1	Yet	yet	RB
10_1101-2020_09_02_279521	14	2	,	,	,
10_1101-2020_09_02_279521	14	3	while	while	IN
10_1101-2020_09_02_279521	14	4	the	the	DT
10_1101-2020_09_02_279521	14	5	disease	disease	NN
10_1101-2020_09_02_279521	14	6	mechanisms	mechanism	NNS
10_1101-2020_09_02_279521	14	7	remain	remain	VBP
10_1101-2020_09_02_279521	14	8	in	in	IN
10_1101-2020_09_02_279521	14	9	large	large	JJ
10_1101-2020_09_02_279521	14	10	part	part	NN
10_1101-2020_09_02_279521	14	11	unknown	unknown	JJ
10_1101-2020_09_02_279521	14	12	,	,	,
10_1101-2020_09_02_279521	14	13	there	there	EX
10_1101-2020_09_02_279521	14	14	are	be	VBP
10_1101-2020_09_02_279521	14	15	still	still	RB
10_1101-2020_09_02_279521	14	16	no	no	DT
10_1101-2020_09_02_279521	14	17	effective	effective	JJ
10_1101-2020_09_02_279521	14	18	pharmacological	pharmacological	JJ
10_1101-2020_09_02_279521	14	19	treatments	treatment	NNS
10_1101-2020_09_02_279521	14	20	leading	lead	VBG
10_1101-2020_09_02_279521	14	21	to	to	IN
10_1101-2020_09_02_279521	14	22	tangible	tangible	JJ
10_1101-2020_09_02_279521	14	23	improvements	improvement	NNS
10_1101-2020_09_02_279521	14	24	of	of	IN
10_1101-2020_09_02_279521	14	25	patients	patient	NNS
10_1101-2020_09_02_279521	14	26	'	'	POS
10_1101-2020_09_02_279521	14	27	clinical	clinical	JJ
10_1101-2020_09_02_279521	14	28	progression	progression	NN
10_1101-2020_09_02_279521	14	29	.	.	.
10_1101-2020_09_02_279521	15	1	One	one	CD
10_1101-2020_09_02_279521	15	2	of	of	IN
10_1101-2020_09_02_279521	15	3	the	the	DT
10_1101-2020_09_02_279521	15	4	main	main	JJ
10_1101-2020_09_02_279521	15	5	challenges	challenge	NNS
10_1101-2020_09_02_279521	15	6	in	in	IN
10_1101-2020_09_02_279521	15	7	understanding	understand	VBG
10_1101-2020_09_02_279521	15	8	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	15	9	's	's	POS
10_1101-2020_09_02_279521	15	10	disease	disease	NN
10_1101-2020_09_02_279521	15	11	is	be	VBZ
10_1101-2020_09_02_279521	15	12	that	that	IN
10_1101-2020_09_02_279521	15	13	its	-PRON-	PRP$
10_1101-2020_09_02_279521	15	14	progression	progression	NN
10_1101-2020_09_02_279521	15	15	goes	go	VBZ
10_1101-2020_09_02_279521	15	16	through	through	IN
10_1101-2020_09_02_279521	15	17	a	a	DT
10_1101-2020_09_02_279521	15	18	silent	silent	JJ
10_1101-2020_09_02_279521	15	19	asymptomatic	asymptomatic	JJ
10_1101-2020_09_02_279521	15	20	phase	phase	NN
10_1101-2020_09_02_279521	15	21	that	that	WDT
10_1101-2020_09_02_279521	15	22	can	can	MD
10_1101-2020_09_02_279521	15	23	stretch	stretch	VB
10_1101-2020_09_02_279521	15	24	over	over	RP
10_1101-2020_09_02_279521	15	25	decades	decade	NNS
10_1101-2020_09_02_279521	15	26	before	before	IN
10_1101-2020_09_02_279521	15	27	a	a	DT
10_1101-2020_09_02_279521	15	28	clinical	clinical	JJ
10_1101-2020_09_02_279521	15	29	diagnosis	diagnosis	NN
10_1101-2020_09_02_279521	15	30	can	can	MD
10_1101-2020_09_02_279521	15	31	be	be	VB
10_1101-2020_09_02_279521	15	32	established	establish	VBN
10_1101-2020_09_02_279521	15	33	based	base	VBN
10_1101-2020_09_02_279521	15	34	on	on	IN
10_1101-2020_09_02_279521	15	35	cognitive	cognitive	JJ
10_1101-2020_09_02_279521	15	36	and	and	CC
10_1101-2020_09_02_279521	15	37	behavioral	behavioral	JJ
10_1101-2020_09_02_279521	15	38	symptoms	symptom	NNS
10_1101-2020_09_02_279521	15	39	.	.	.
10_1101-2020_09_02_279521	16	1	To	to	TO
10_1101-2020_09_02_279521	16	2	help	help	VB
10_1101-2020_09_02_279521	16	3	designing	design	VBG
10_1101-2020_09_02_279521	16	4	appropriate	appropriate	JJ
10_1101-2020_09_02_279521	16	5	intervention	intervention	NN
10_1101-2020_09_02_279521	16	6	strategies	strategy	NNS
10_1101-2020_09_02_279521	16	7	,	,	,
10_1101-2020_09_02_279521	16	8	hypothetical	hypothetical	JJ
10_1101-2020_09_02_279521	16	9	models	model	NNS
10_1101-2020_09_02_279521	16	10	of	of	IN
10_1101-2020_09_02_279521	16	11	the	the	DT
10_1101-2020_09_02_279521	16	12	disease	disease	NN
10_1101-2020_09_02_279521	16	13	history	history	NN
10_1101-2020_09_02_279521	16	14	have	have	VBP
10_1101-2020_09_02_279521	16	15	been	be	VBN
10_1101-2020_09_02_279521	16	16	proposed	propose	VBN
10_1101-2020_09_02_279521	16	17	,	,	,
10_1101-2020_09_02_279521	16	18	characterizing	characterize	VBG
10_1101-2020_09_02_279521	16	19	the	the	DT
10_1101-2020_09_02_279521	16	20	progression	progression	NN
10_1101-2020_09_02_279521	16	21	by	by	IN
10_1101-2020_09_02_279521	16	22	a	a	DT
10_1101-2020_09_02_279521	16	23	cascade	cascade	NN
10_1101-2020_09_02_279521	16	24	of	of	IN
10_1101-2020_09_02_279521	16	25	morphological	morphological	JJ
10_1101-2020_09_02_279521	16	26	and	and	CC
10_1101-2020_09_02_279521	16	27	molecular	molecular	JJ
10_1101-2020_09_02_279521	16	28	changes	change	NNS
10_1101-2020_09_02_279521	16	29	affecting	affect	VBG
10_1101-2020_09_02_279521	16	30	the	the	DT
10_1101-2020_09_02_279521	16	31	brain	brain	NN
10_1101-2020_09_02_279521	16	32	,	,	,
10_1101-2020_09_02_279521	16	33	ultimately	ultimately	RB
10_1101-2020_09_02_279521	16	34	leading	lead	VBG
10_1101-2020_09_02_279521	16	35	to	to	IN
10_1101-2020_09_02_279521	16	36	cognitive	cognitive	JJ
10_1101-2020_09_02_279521	16	37	impairment	impairment	NN
10_1101-2020_09_02_279521	16	38	(	(	-LRB-
10_1101-2020_09_02_279521	16	39	Jack	Jack	NNP
10_1101-2020_09_02_279521	16	40	et	et	NNP
10_1101-2020_09_02_279521	16	41	al	al	NNP
10_1101-2020_09_02_279521	16	42	.	.	NNP
10_1101-2020_09_02_279521	16	43	,	,	,
10_1101-2020_09_02_279521	16	44	2013	2013	CD
10_1101-2020_09_02_279521	16	45	;	;	:
10_1101-2020_09_02_279521	16	46	Jack	Jack	NNP
10_1101-2020_09_02_279521	16	47	&	&	CC
10_1101-2020_09_02_279521	16	48	Holtzman	Holtzman	NNP
10_1101-2020_09_02_279521	16	49	,	,	,
10_1101-2020_09_02_279521	16	50	2013	2013	CD
10_1101-2020_09_02_279521	16	51	)	)	-RRB-
10_1101-2020_09_02_279521	16	52	.	.	.
10_1101-2020_09_02_279521	17	1	The	the	DT
10_1101-2020_09_02_279521	17	2	dominant	dominant	JJ
10_1101-2020_09_02_279521	17	3	hypothesis	hypothesis	NN
10_1101-2020_09_02_279521	17	4	is	be	VBZ
10_1101-2020_09_02_279521	17	5	that	that	IN
10_1101-2020_09_02_279521	17	6	disease	disease	NN
10_1101-2020_09_02_279521	17	7	dynamics	dynamic	NNS
10_1101-2020_09_02_279521	17	8	along	along	IN
10_1101-2020_09_02_279521	17	9	the	the	DT
10_1101-2020_09_02_279521	17	10	asymptomatic	asymptomatic	JJ
10_1101-2020_09_02_279521	17	11	period	period	NN
10_1101-2020_09_02_279521	17	12	are	be	VBP
10_1101-2020_09_02_279521	17	13	driven	drive	VBN
10_1101-2020_09_02_279521	17	14	by	by	IN
10_1101-2020_09_02_279521	17	15	the	the	DT
10_1101-2020_09_02_279521	17	16	deposition	deposition	NN
10_1101-2020_09_02_279521	17	17	in	in	IN
10_1101-2020_09_02_279521	17	18	the	the	DT
10_1101-2020_09_02_279521	17	19	brain	brain	NN
10_1101-2020_09_02_279521	17	20	of	of	IN
10_1101-2020_09_02_279521	17	21	the	the	DT
10_1101-2020_09_02_279521	17	22	amyloid	amyloid	NN
10_1101-2020_09_02_279521	17	23			NN
10_1101-2020_09_02_279521	17	24	peptide	peptide	NN
10_1101-2020_09_02_279521	17	25	,	,	,
10_1101-2020_09_02_279521	17	26	triggering	trigger	VBG
10_1101-2020_09_02_279521	17	27	the	the	DT
10_1101-2020_09_02_279521	17	28	so-	so-	NN
10_1101-2020_09_02_279521	17	29	called	call	VBN
10_1101-2020_09_02_279521	17	30	“	"	``
10_1101-2020_09_02_279521	17	31	amyloid	amyloid	NN
10_1101-2020_09_02_279521	17	32	cascade	cascade	NN
10_1101-2020_09_02_279521	17	33	”	"	''
10_1101-2020_09_02_279521	17	34	(	(	-LRB-
10_1101-2020_09_02_279521	17	35	Bateman	Bateman	NNP
10_1101-2020_09_02_279521	17	36	et	et	FW
10_1101-2020_09_02_279521	17	37	al	al	NNP
10_1101-2020_09_02_279521	17	38	.	.	NNP
10_1101-2020_09_02_279521	17	39	,	,	,
10_1101-2020_09_02_279521	17	40	2012	2012	CD
10_1101-2020_09_02_279521	17	41	;	;	:
10_1101-2020_09_02_279521	17	42	Braak	Braak	NNP
10_1101-2020_09_02_279521	17	43	&	&	CC
10_1101-2020_09_02_279521	17	44	Braak	Braak	NNP
10_1101-2020_09_02_279521	17	45	,	,	,
10_1101-2020_09_02_279521	17	46	1991	1991	CD
10_1101-2020_09_02_279521	17	47	;	;	:
10_1101-2020_09_02_279521	17	48	Delacourte	Delacourte	NNP
10_1101-2020_09_02_279521	17	49	et	et	FW
10_1101-2020_09_02_279521	17	50	al	al	NNP
10_1101-2020_09_02_279521	17	51	.	.	NNP
10_1101-2020_09_02_279521	17	52	,	,	,
10_1101-2020_09_02_279521	17	53	1999	1999	CD
10_1101-2020_09_02_279521	17	54	;	;	:
10_1101-2020_09_02_279521	17	55	Murphy	Murphy	NNP
10_1101-2020_09_02_279521	17	56	&	&	CC
10_1101-2020_09_02_279521	17	57	LeVine	LeVine	NNP
10_1101-2020_09_02_279521	17	58	,	,	,
10_1101-2020_09_02_279521	17	59	2010	2010	CD
10_1101-2020_09_02_279521	17	60	;	;	:
10_1101-2020_09_02_279521	17	61	Villemagne	Villemagne	NNP
10_1101-2020_09_02_279521	17	62	et	et	FW
10_1101-2020_09_02_279521	17	63	al	al	NNP
10_1101-2020_09_02_279521	17	64	.	.	NNP
10_1101-2020_09_02_279521	17	65	,	,	,
10_1101-2020_09_02_279521	17	66	2013	2013	CD
10_1101-2020_09_02_279521	17	67	)	)	-RRB-
10_1101-2020_09_02_279521	17	68	.	.	.
10_1101-2020_09_02_279521	18	1	Based	base	VBN
10_1101-2020_09_02_279521	18	2	on	on	IN
10_1101-2020_09_02_279521	18	3	this	this	DT
10_1101-2020_09_02_279521	18	4	rationale	rationale	JJ
10_1101-2020_09_02_279521	18	5	,	,	,
10_1101-2020_09_02_279521	18	6	clinical	clinical	JJ
10_1101-2020_09_02_279521	18	7	trials	trial	NNS
10_1101-2020_09_02_279521	18	8	have	have	VBP
10_1101-2020_09_02_279521	18	9	been	be	VBN
10_1101-2020_09_02_279521	18	10	focusing	focus	VBG
10_1101-2020_09_02_279521	18	11	on	on	IN
10_1101-2020_09_02_279521	18	12	the	the	DT
10_1101-2020_09_02_279521	18	13	development	development	NN
10_1101-2020_09_02_279521	18	14	and	and	CC
10_1101-2020_09_02_279521	18	15	testing	testing	NN
10_1101-2020_09_02_279521	18	16	of	of	IN
10_1101-2020_09_02_279521	18	17	disease	disease	NN
10_1101-2020_09_02_279521	18	18	modifiers	modifier	NNS
10_1101-2020_09_02_279521	18	19	targeting	targeting	NN
10_1101-2020_09_02_279521	18	20	amyloid	amyloid	NN
10_1101-2020_09_02_279521	18	21			NNP
10_1101-2020_09_02_279521	18	22	aggregates	aggregate	NNS
10_1101-2020_09_02_279521	18	23	(	(	-LRB-
10_1101-2020_09_02_279521	18	24	Cummings	Cummings	NNP
10_1101-2020_09_02_279521	18	25	,	,	,
10_1101-2020_09_02_279521	18	26	Lee	Lee	NNP
10_1101-2020_09_02_279521	18	27	,	,	,
10_1101-2020_09_02_279521	18	28	et	et	NNP
10_1101-2020_09_02_279521	18	29	al	al	NNP
10_1101-2020_09_02_279521	18	30	.	.	NNP
10_1101-2020_09_02_279521	18	31	,	,	,
10_1101-2020_09_02_279521	18	32	2019	2019	CD
10_1101-2020_09_02_279521	18	33	)	)	-RRB-
10_1101-2020_09_02_279521	18	34	,	,	,
10_1101-2020_09_02_279521	18	35	for	for	IN
10_1101-2020_09_02_279521	18	36	example	example	NN
10_1101-2020_09_02_279521	18	37	by	by	IN
10_1101-2020_09_02_279521	18	38	increasing	increase	VBG
10_1101-2020_09_02_279521	18	39	its	-PRON-	PRP$
10_1101-2020_09_02_279521	18	40	clearance	clearance	NN
10_1101-2020_09_02_279521	18	41	or	or	CC
10_1101-2020_09_02_279521	18	42	blocking	block	VBG
10_1101-2020_09_02_279521	18	43	its	-PRON-	PRP$
10_1101-2020_09_02_279521	18	44	accumulation	accumulation	NN
10_1101-2020_09_02_279521	18	45	.	.	.
10_1101-2020_09_02_279521	19	1	Although	although	IN
10_1101-2020_09_02_279521	19	2	the	the	DT
10_1101-2020_09_02_279521	19	3	amyloid	amyloid	NN
10_1101-2020_09_02_279521	19	4	hypothesis	hypothesis	NN
10_1101-2020_09_02_279521	19	5	has	have	VBZ
10_1101-2020_09_02_279521	19	6	been	be	VBN
10_1101-2020_09_02_279521	19	7	recently	recently	RB
10_1101-2020_09_02_279521	19	8	invigorated	invigorate	VBN
10_1101-2020_09_02_279521	19	9	by	by	IN
10_1101-2020_09_02_279521	19	10	a	a	DT
10_1101-2020_09_02_279521	19	11	post	post	JJ
10_1101-2020_09_02_279521	19	12	-	-	JJ
10_1101-2020_09_02_279521	19	13	hoc	hoc	JJ
10_1101-2020_09_02_279521	19	14	.CC	.CC	NFP
10_1101-2020_09_02_279521	19	15	-	-	:
10_1101-2020_09_02_279521	19	16	BY	by	IN
10_1101-2020_09_02_279521	19	17	4.0	4.0	CD
10_1101-2020_09_02_279521	19	18	International	international	JJ
10_1101-2020_09_02_279521	19	19	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	19	20	.	.	.
10_1101-2020_09_02_279521	20	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	20	2	is	be	VBZ
10_1101-2020_09_02_279521	20	3	made	make	VBN
10_1101-2020_09_02_279521	20	4	available	available	JJ
10_1101-2020_09_02_279521	20	5	under	under	IN
10_1101-2020_09_02_279521	20	6	a	a	DT
10_1101-2020_09_02_279521	20	7	preprint	preprint	NN
10_1101-2020_09_02_279521	20	8	(	(	-LRB-
10_1101-2020_09_02_279521	20	9	which	which	WDT
10_1101-2020_09_02_279521	20	10	was	be	VBD
10_1101-2020_09_02_279521	20	11	not	not	RB
10_1101-2020_09_02_279521	20	12	certified	certify	VBN
10_1101-2020_09_02_279521	20	13	by	by	IN
10_1101-2020_09_02_279521	20	14	peer	peer	NN
10_1101-2020_09_02_279521	20	15	review	review	NN
10_1101-2020_09_02_279521	20	16	)	)	-RRB-
10_1101-2020_09_02_279521	20	17	is	be	VBZ
10_1101-2020_09_02_279521	20	18	the	the	DT
10_1101-2020_09_02_279521	20	19	author	author	NN
10_1101-2020_09_02_279521	20	20	/	/	SYM
10_1101-2020_09_02_279521	20	21	funder	funder	NN
10_1101-2020_09_02_279521	20	22	,	,	,
10_1101-2020_09_02_279521	20	23	who	who	WP
10_1101-2020_09_02_279521	20	24	has	have	VBZ
10_1101-2020_09_02_279521	20	25	granted	grant	VBN
10_1101-2020_09_02_279521	20	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	20	27	a	a	DT
10_1101-2020_09_02_279521	20	28	license	license	NN
10_1101-2020_09_02_279521	20	29	to	to	TO
10_1101-2020_09_02_279521	20	30	display	display	VB
10_1101-2020_09_02_279521	20	31	the	the	DT
10_1101-2020_09_02_279521	20	32	preprint	preprint	NN
10_1101-2020_09_02_279521	20	33	in	in	IN
10_1101-2020_09_02_279521	20	34	The	the	DT
10_1101-2020_09_02_279521	20	35	copyright	copyright	NN
10_1101-2020_09_02_279521	20	36	holder	holder	NN
10_1101-2020_09_02_279521	20	37	for	for	IN
10_1101-2020_09_02_279521	20	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	20	39	version	version	NN
10_1101-2020_09_02_279521	20	40	posted	post	VBD
10_1101-2020_09_02_279521	20	41	February	February	NNP
10_1101-2020_09_02_279521	20	42	10	10	CD
10_1101-2020_09_02_279521	20	43	,	,	,
10_1101-2020_09_02_279521	20	44	2021	2021	CD
10_1101-2020_09_02_279521	20	45	.	.	.
10_1101-2020_09_02_279521	20	46	;	;	:
10_1101-2020_09_02_279521	20	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	20	48	:	:	:
10_1101-2020_09_02_279521	20	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	20	50	preprint	preprint	NN
10_1101-2020_09_02_279521	20	51	mailto:clement.abi-nader@inria.fr	mailto:clement.abi-nader@inria.fr	NN
10_1101-2020_09_02_279521	20	52	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	NN
10_1101-2020_09_02_279521	20	53	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	ADD
10_1101-2020_09_02_279521	20	54	analysis	analysis	NN
10_1101-2020_09_02_279521	20	55	of	of	IN
10_1101-2020_09_02_279521	20	56	the	the	DT
10_1101-2020_09_02_279521	20	57	aducanumab	aducanumab	JJ
10_1101-2020_09_02_279521	20	58	trial	trial	NN
10_1101-2020_09_02_279521	20	59	(	(	-LRB-
10_1101-2020_09_02_279521	20	60	Howard	Howard	NNP
10_1101-2020_09_02_279521	20	61	&	&	CC
10_1101-2020_09_02_279521	20	62	Liu	Liu	NNP
10_1101-2020_09_02_279521	20	63	,	,	,
10_1101-2020_09_02_279521	20	64	2020	2020	CD
10_1101-2020_09_02_279521	20	65	)	)	-RRB-
10_1101-2020_09_02_279521	20	66	,	,	,
10_1101-2020_09_02_279521	20	67	clinical	clinical	JJ
10_1101-2020_09_02_279521	20	68	trials	trial	NNS
10_1101-2020_09_02_279521	20	69	failed	fail	VBD
10_1101-2020_09_02_279521	20	70	so	so	RB
10_1101-2020_09_02_279521	20	71	far	far	RB
10_1101-2020_09_02_279521	20	72	to	to	TO
10_1101-2020_09_02_279521	20	73	show	show	VB
10_1101-2020_09_02_279521	20	74	efficacy	efficacy	NN
10_1101-2020_09_02_279521	20	75	of	of	IN
10_1101-2020_09_02_279521	20	76	this	this	DT
10_1101-2020_09_02_279521	20	77	kind	kind	NN
10_1101-2020_09_02_279521	20	78	of	of	IN
10_1101-2020_09_02_279521	20	79	treatments	treatment	NNS
10_1101-2020_09_02_279521	20	80	(	(	-LRB-
10_1101-2020_09_02_279521	20	81	Schwarz	Schwarz	NNP
10_1101-2020_09_02_279521	20	82	et	et	NNP
10_1101-2020_09_02_279521	20	83	al	al	NNP
10_1101-2020_09_02_279521	20	84	.	.	NNP
10_1101-2020_09_02_279521	20	85	,	,	,
10_1101-2020_09_02_279521	20	86	2019	2019	CD
10_1101-2020_09_02_279521	20	87	)	)	-RRB-
10_1101-2020_09_02_279521	20	88	,	,	,
10_1101-2020_09_02_279521	20	89	as	as	IN
10_1101-2020_09_02_279521	20	90	the	the	DT
10_1101-2020_09_02_279521	20	91	clinical	clinical	JJ
10_1101-2020_09_02_279521	20	92	primary	primary	JJ
10_1101-2020_09_02_279521	20	93	endpoints	endpoint	NNS
10_1101-2020_09_02_279521	20	94	were	be	VBD
10_1101-2020_09_02_279521	20	95	not	not	RB
10_1101-2020_09_02_279521	20	96	met	meet	VBN
10_1101-2020_09_02_279521	20	97	(	(	-LRB-
10_1101-2020_09_02_279521	20	98	Egan	Egan	NNP
10_1101-2020_09_02_279521	20	99	et	et	NNP
10_1101-2020_09_02_279521	20	100	al	al	NNP
10_1101-2020_09_02_279521	20	101	.	.	NNP
10_1101-2020_09_02_279521	20	102	,	,	,
10_1101-2020_09_02_279521	20	103	2019	2019	CD
10_1101-2020_09_02_279521	20	104	;	;	:
10_1101-2020_09_02_279521	20	105	Honig	Honig	NNP
10_1101-2020_09_02_279521	20	106	et	et	NNP
10_1101-2020_09_02_279521	20	107	al	al	NNP
10_1101-2020_09_02_279521	20	108	.	.	NNP
10_1101-2020_09_02_279521	20	109	,	,	,
10_1101-2020_09_02_279521	20	110	2018	2018	CD
10_1101-2020_09_02_279521	20	111	;	;	:
10_1101-2020_09_02_279521	20	112	Wessels	Wessels	NNP
10_1101-2020_09_02_279521	20	113	et	et	NNP
10_1101-2020_09_02_279521	20	114	al	al	NNP
10_1101-2020_09_02_279521	20	115	.	.	NNP
10_1101-2020_09_02_279521	20	116	,	,	,
10_1101-2020_09_02_279521	20	117	2019	2019	CD
10_1101-2020_09_02_279521	20	118	)	)	-RRB-
10_1101-2020_09_02_279521	20	119	,	,	,
10_1101-2020_09_02_279521	20	120	or	or	CC
10_1101-2020_09_02_279521	20	121	because	because	IN
10_1101-2020_09_02_279521	20	122	of	of	IN
10_1101-2020_09_02_279521	20	123	unacceptable	unacceptable	JJ
10_1101-2020_09_02_279521	20	124	adverse	adverse	JJ
10_1101-2020_09_02_279521	20	125	effects	effect	NNS
10_1101-2020_09_02_279521	20	126	(	(	-LRB-
10_1101-2020_09_02_279521	20	127	Henley	Henley	NNP
10_1101-2020_09_02_279521	20	128	et	et	NNP
10_1101-2020_09_02_279521	20	129	al	al	NNP
10_1101-2020_09_02_279521	20	130	.	.	NNP
10_1101-2020_09_02_279521	20	131	,	,	,
10_1101-2020_09_02_279521	20	132	2019	2019	CD
10_1101-2020_09_02_279521	20	133	)	)	-RRB-
10_1101-2020_09_02_279521	20	134	.	.	.
10_1101-2020_09_02_279521	21	1	In	in	IN
10_1101-2020_09_02_279521	21	2	the	the	DT
10_1101-2020_09_02_279521	21	3	past	past	JJ
10_1101-2020_09_02_279521	21	4	years	year	NNS
10_1101-2020_09_02_279521	21	5	,	,	,
10_1101-2020_09_02_279521	21	6	growing	grow	VBG
10_1101-2020_09_02_279521	21	7	consensus	consensus	NN
10_1101-2020_09_02_279521	21	8	emerged	emerge	VBD
10_1101-2020_09_02_279521	21	9	about	about	IN
10_1101-2020_09_02_279521	21	10	the	the	DT
10_1101-2020_09_02_279521	21	11	critical	critical	JJ
10_1101-2020_09_02_279521	21	12	importance	importance	NN
10_1101-2020_09_02_279521	21	13	of	of	IN
10_1101-2020_09_02_279521	21	14	intervention	intervention	NN
10_1101-2020_09_02_279521	21	15	time	time	NN
10_1101-2020_09_02_279521	21	16	,	,	,
10_1101-2020_09_02_279521	21	17	and	and	CC
10_1101-2020_09_02_279521	21	18	about	about	IN
10_1101-2020_09_02_279521	21	19	the	the	DT
10_1101-2020_09_02_279521	21	20	need	need	NN
10_1101-2020_09_02_279521	21	21	of	of	IN
10_1101-2020_09_02_279521	21	22	starting	start	VBG
10_1101-2020_09_02_279521	21	23	anti	anti	JJ
10_1101-2020_09_02_279521	21	24	-	-	JJ
10_1101-2020_09_02_279521	21	25	amyloid	amyloid	JJ
10_1101-2020_09_02_279521	21	26	treatments	treatment	NNS
10_1101-2020_09_02_279521	21	27	during	during	IN
10_1101-2020_09_02_279521	21	28	the	the	DT
10_1101-2020_09_02_279521	21	29	pre	pre	JJ
10_1101-2020_09_02_279521	21	30	-	-	JJ
10_1101-2020_09_02_279521	21	31	symptomatic	symptomatic	JJ
10_1101-2020_09_02_279521	21	32	stages	stage	NNS
10_1101-2020_09_02_279521	21	33	of	of	IN
10_1101-2020_09_02_279521	21	34	the	the	DT
10_1101-2020_09_02_279521	21	35	disease	disease	NN
10_1101-2020_09_02_279521	21	36	(	(	-LRB-
10_1101-2020_09_02_279521	21	37	Aisen	Aisen	NNP
10_1101-2020_09_02_279521	21	38	et	et	NNP
10_1101-2020_09_02_279521	21	39	al	al	NNP
10_1101-2020_09_02_279521	21	40	.	.	NNP
10_1101-2020_09_02_279521	21	41	,	,	,
10_1101-2020_09_02_279521	21	42	2018	2018	CD
10_1101-2020_09_02_279521	21	43	)	)	-RRB-
10_1101-2020_09_02_279521	21	44	.	.	.
10_1101-2020_09_02_279521	22	1	Nevertheless	nevertheless	RB
10_1101-2020_09_02_279521	22	2	,	,	,
10_1101-2020_09_02_279521	22	3	the	the	DT
10_1101-2020_09_02_279521	22	4	design	design	NN
10_1101-2020_09_02_279521	22	5	of	of	IN
10_1101-2020_09_02_279521	22	6	optimal	optimal	JJ
10_1101-2020_09_02_279521	22	7	intervention	intervention	NN
10_1101-2020_09_02_279521	22	8	strategies	strategy	NNS
10_1101-2020_09_02_279521	22	9	is	be	VBZ
10_1101-2020_09_02_279521	22	10	currently	currently	RB
10_1101-2020_09_02_279521	22	11	not	not	RB
10_1101-2020_09_02_279521	22	12	supported	support	VBN
10_1101-2020_09_02_279521	22	13	by	by	IN
10_1101-2020_09_02_279521	22	14	quantitative	quantitative	JJ
10_1101-2020_09_02_279521	22	15	analysis	analysis	NN
10_1101-2020_09_02_279521	22	16	methods	method	NNS
10_1101-2020_09_02_279521	22	17	allowing	allow	VBG
10_1101-2020_09_02_279521	22	18	to	to	TO
10_1101-2020_09_02_279521	22	19	model	model	VB
10_1101-2020_09_02_279521	22	20	and	and	CC
10_1101-2020_09_02_279521	22	21	assess	assess	VB
10_1101-2020_09_02_279521	22	22	the	the	DT
10_1101-2020_09_02_279521	22	23	effect	effect	NN
10_1101-2020_09_02_279521	22	24	of	of	IN
10_1101-2020_09_02_279521	22	25	intervention	intervention	NN
10_1101-2020_09_02_279521	22	26	time	time	NN
10_1101-2020_09_02_279521	22	27	and	and	CC
10_1101-2020_09_02_279521	22	28	dosing	dosing	NN
10_1101-2020_09_02_279521	22	29	(	(	-LRB-
10_1101-2020_09_02_279521	22	30	Klein	Klein	NNP
10_1101-2020_09_02_279521	22	31	et	et	NNP
10_1101-2020_09_02_279521	22	32	al	al	NNP
10_1101-2020_09_02_279521	22	33	.	.	NNP
10_1101-2020_09_02_279521	22	34	,	,	,
10_1101-2020_09_02_279521	22	35	2019	2019	CD
10_1101-2020_09_02_279521	22	36	)	)	-RRB-
10_1101-2020_09_02_279521	22	37	.	.	.
10_1101-2020_09_02_279521	23	1	The	the	DT
10_1101-2020_09_02_279521	23	2	availability	availability	NN
10_1101-2020_09_02_279521	23	3	of	of	IN
10_1101-2020_09_02_279521	23	4	models	model	NNS
10_1101-2020_09_02_279521	23	5	of	of	IN
10_1101-2020_09_02_279521	23	6	the	the	DT
10_1101-2020_09_02_279521	23	7	pathophysiology	pathophysiology	NN
10_1101-2020_09_02_279521	23	8	of	of	IN
10_1101-2020_09_02_279521	23	9	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	23	10	’s	’s	POS
10_1101-2020_09_02_279521	23	11	disease	disease	NN
10_1101-2020_09_02_279521	23	12	would	would	MD
10_1101-2020_09_02_279521	23	13	entail	entail	VB
10_1101-2020_09_02_279521	23	14	great	great	JJ
10_1101-2020_09_02_279521	23	15	potential	potential	NN
10_1101-2020_09_02_279521	23	16	to	to	TO
10_1101-2020_09_02_279521	23	17	test	test	VB
10_1101-2020_09_02_279521	23	18	and	and	CC
10_1101-2020_09_02_279521	23	19	analyze	analyze	VB
10_1101-2020_09_02_279521	23	20	clinical	clinical	JJ
10_1101-2020_09_02_279521	23	21	hypothesis	hypothesis	NN
10_1101-2020_09_02_279521	23	22	characterizing	characterize	VBG
10_1101-2020_09_02_279521	23	23	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	23	24	’s	’s	POS
10_1101-2020_09_02_279521	23	25	disease	disease	NN
10_1101-2020_09_02_279521	23	26	mechanisms	mechanism	NNS
10_1101-2020_09_02_279521	23	27	,	,	,
10_1101-2020_09_02_279521	23	28	progression	progression	NN
10_1101-2020_09_02_279521	23	29	,	,	,
10_1101-2020_09_02_279521	23	30	and	and	CC
10_1101-2020_09_02_279521	23	31	intervention	intervention	NN
10_1101-2020_09_02_279521	23	32	scenarios	scenario	NNS
10_1101-2020_09_02_279521	23	33	.	.	.
10_1101-2020_09_02_279521	24	1	Within	within	IN
10_1101-2020_09_02_279521	24	2	this	this	DT
10_1101-2020_09_02_279521	24	3	context	context	NN
10_1101-2020_09_02_279521	24	4	,	,	,
10_1101-2020_09_02_279521	24	5	quantitative	quantitative	JJ
10_1101-2020_09_02_279521	24	6	models	model	NNS
10_1101-2020_09_02_279521	24	7	of	of	IN
10_1101-2020_09_02_279521	24	8	disease	disease	NN
10_1101-2020_09_02_279521	24	9	progression	progression	NN
10_1101-2020_09_02_279521	24	10	,	,	,
10_1101-2020_09_02_279521	24	11	Disease	Disease	NNP
10_1101-2020_09_02_279521	24	12	progression	progression	NN
10_1101-2020_09_02_279521	24	13	Models	model	NNS
10_1101-2020_09_02_279521	24	14	referred	refer	VBD
10_1101-2020_09_02_279521	24	15	to	to	IN
10_1101-2020_09_02_279521	24	16	as	as	IN
10_1101-2020_09_02_279521	24	17	DPMs	DPMs	NNPS
10_1101-2020_09_02_279521	24	18	,	,	,
10_1101-2020_09_02_279521	24	19	have	have	VBP
10_1101-2020_09_02_279521	24	20	been	be	VBN
10_1101-2020_09_02_279521	24	21	proposed	propose	VBN
10_1101-2020_09_02_279521	24	22	(	(	-LRB-
10_1101-2020_09_02_279521	24	23	Fonteijn	Fonteijn	NNP
10_1101-2020_09_02_279521	24	24	et	et	NNP
10_1101-2020_09_02_279521	24	25	al	al	NNP
10_1101-2020_09_02_279521	24	26	.	.	NNP
10_1101-2020_09_02_279521	24	27	,	,	,
10_1101-2020_09_02_279521	24	28	2012	2012	CD
10_1101-2020_09_02_279521	24	29	;	;	:
10_1101-2020_09_02_279521	24	30	Jedynak	Jedynak	NNP
10_1101-2020_09_02_279521	24	31	et	et	FW
10_1101-2020_09_02_279521	24	32	al	al	NNP
10_1101-2020_09_02_279521	24	33	.	.	NNP
10_1101-2020_09_02_279521	24	34	,	,	,
10_1101-2020_09_02_279521	24	35	2012	2012	CD
10_1101-2020_09_02_279521	24	36	;	;	:
10_1101-2020_09_02_279521	24	37	Nader	Nader	NNP
10_1101-2020_09_02_279521	24	38	et	et	FW
10_1101-2020_09_02_279521	24	39	al	al	NNP
10_1101-2020_09_02_279521	24	40	.	.	NNP
10_1101-2020_09_02_279521	24	41	,	,	,
10_1101-2020_09_02_279521	24	42	2020	2020	CD
10_1101-2020_09_02_279521	24	43	;	;	:
10_1101-2020_09_02_279521	24	44	Oxtoby	Oxtoby	NNP
10_1101-2020_09_02_279521	24	45	et	et	FW
10_1101-2020_09_02_279521	24	46	al	al	NNP
10_1101-2020_09_02_279521	24	47	.	.	NNP
10_1101-2020_09_02_279521	24	48	,	,	,
10_1101-2020_09_02_279521	24	49	2017	2017	CD
10_1101-2020_09_02_279521	24	50	;	;	:
10_1101-2020_09_02_279521	24	51	Schiratti	Schiratti	NNP
10_1101-2020_09_02_279521	24	52	et	et	NNP
10_1101-2020_09_02_279521	24	53	al	al	NNP
10_1101-2020_09_02_279521	24	54	.	.	NNP
10_1101-2020_09_02_279521	24	55	,	,	,
10_1101-2020_09_02_279521	24	56	2015	2015	CD
10_1101-2020_09_02_279521	24	57	)	)	-RRB-
10_1101-2020_09_02_279521	24	58	,	,	,
10_1101-2020_09_02_279521	24	59	to	to	TO
10_1101-2020_09_02_279521	24	60	quantify	quantify	VB
10_1101-2020_09_02_279521	24	61	the	the	DT
10_1101-2020_09_02_279521	24	62	dynamics	dynamic	NNS
10_1101-2020_09_02_279521	24	63	of	of	IN
10_1101-2020_09_02_279521	24	64	the	the	DT
10_1101-2020_09_02_279521	24	65	changes	change	NNS
10_1101-2020_09_02_279521	24	66	affecting	affect	VBG
10_1101-2020_09_02_279521	24	67	the	the	DT
10_1101-2020_09_02_279521	24	68	brain	brain	NN
10_1101-2020_09_02_279521	24	69	during	during	IN
10_1101-2020_09_02_279521	24	70	the	the	DT
10_1101-2020_09_02_279521	24	71	whole	whole	JJ
10_1101-2020_09_02_279521	24	72	disease	disease	NN
10_1101-2020_09_02_279521	24	73	span	span	NN
10_1101-2020_09_02_279521	24	74	.	.	.
10_1101-2020_09_02_279521	25	1	These	these	DT
10_1101-2020_09_02_279521	25	2	models	model	NNS
10_1101-2020_09_02_279521	25	3	rely	rely	VBP
10_1101-2020_09_02_279521	25	4	on	on	IN
10_1101-2020_09_02_279521	25	5	the	the	DT
10_1101-2020_09_02_279521	25	6	statistical	statistical	JJ
10_1101-2020_09_02_279521	25	7	analysis	analysis	NN
10_1101-2020_09_02_279521	25	8	of	of	IN
10_1101-2020_09_02_279521	25	9	large	large	JJ
10_1101-2020_09_02_279521	25	10	datasets	dataset	NNS
10_1101-2020_09_02_279521	25	11	of	of	IN
10_1101-2020_09_02_279521	25	12	different	different	JJ
10_1101-2020_09_02_279521	25	13	data	data	NN
10_1101-2020_09_02_279521	25	14	modalities	modality	NNS
10_1101-2020_09_02_279521	25	15	,	,	,
10_1101-2020_09_02_279521	25	16	such	such	JJ
10_1101-2020_09_02_279521	25	17	as	as	IN
10_1101-2020_09_02_279521	25	18	clinical	clinical	JJ
10_1101-2020_09_02_279521	25	19	scores	score	NNS
10_1101-2020_09_02_279521	25	20	,	,	,
10_1101-2020_09_02_279521	25	21	or	or	CC
10_1101-2020_09_02_279521	25	22	brain	brain	NN
10_1101-2020_09_02_279521	25	23	imaging	imaging	NN
10_1101-2020_09_02_279521	25	24	measures	measure	NNS
10_1101-2020_09_02_279521	25	25	derived	derive	VBN
10_1101-2020_09_02_279521	25	26	from	from	IN
10_1101-2020_09_02_279521	25	27	MRI	MRI	NNP
10_1101-2020_09_02_279521	25	28	,	,	,
10_1101-2020_09_02_279521	25	29	Amyloid-	Amyloid-	NNP
10_1101-2020_09_02_279521	25	30	and	and	CC
10_1101-2020_09_02_279521	25	31	Fluorodeoxyglucose-	Fluorodeoxyglucose-	NNP
10_1101-2020_09_02_279521	25	32	PET	PET	NNP
10_1101-2020_09_02_279521	25	33	(	(	-LRB-
10_1101-2020_09_02_279521	25	34	Bilgel	Bilgel	NNP
10_1101-2020_09_02_279521	25	35	et	et	FW
10_1101-2020_09_02_279521	25	36	al	al	NNP
10_1101-2020_09_02_279521	25	37	.	.	NNP
10_1101-2020_09_02_279521	25	38	,	,	,
10_1101-2020_09_02_279521	25	39	2015	2015	CD
10_1101-2020_09_02_279521	25	40	;	;	:
10_1101-2020_09_02_279521	25	41	Burnham	Burnham	NNP
10_1101-2020_09_02_279521	25	42	et	et	NNP
10_1101-2020_09_02_279521	25	43	al	al	NNP
10_1101-2020_09_02_279521	25	44	.	.	NNP
10_1101-2020_09_02_279521	25	45	,	,	,
10_1101-2020_09_02_279521	25	46	2020	2020	CD
10_1101-2020_09_02_279521	25	47	;	;	:
10_1101-2020_09_02_279521	25	48	Donohue	Donohue	NNP
10_1101-2020_09_02_279521	25	49	et	et	NNP
10_1101-2020_09_02_279521	25	50	al	al	NNP
10_1101-2020_09_02_279521	25	51	.	.	NNP
10_1101-2020_09_02_279521	25	52	,	,	,
10_1101-2020_09_02_279521	25	53	2014	2014	CD
10_1101-2020_09_02_279521	25	54	;	;	:
10_1101-2020_09_02_279521	25	55	Y	Y	NNP
10_1101-2020_09_02_279521	25	56	Iturria	Iturria	NNP
10_1101-2020_09_02_279521	25	57	-	-	HYPH
10_1101-2020_09_02_279521	25	58	Medina	Medina	NNP
10_1101-2020_09_02_279521	25	59	et	et	NNP
10_1101-2020_09_02_279521	25	60	al	al	NNP
10_1101-2020_09_02_279521	25	61	.	.	NNP
10_1101-2020_09_02_279521	25	62	,	,	,
10_1101-2020_09_02_279521	25	63	2016	2016	CD
10_1101-2020_09_02_279521	25	64	;	;	:
10_1101-2020_09_02_279521	25	65	Koval	Koval	NNP
10_1101-2020_09_02_279521	25	66	et	et	NNP
10_1101-2020_09_02_279521	25	67	al	al	NNP
10_1101-2020_09_02_279521	25	68	.	.	NNP
10_1101-2020_09_02_279521	25	69	,	,	,
10_1101-2020_09_02_279521	25	70	2018	2018	CD
10_1101-2020_09_02_279521	25	71	)	)	-RRB-
10_1101-2020_09_02_279521	25	72	.	.	.
10_1101-2020_09_02_279521	26	1	In	in	IN
10_1101-2020_09_02_279521	26	2	general	general	JJ
10_1101-2020_09_02_279521	26	3	,	,	,
10_1101-2020_09_02_279521	26	4	DPMs	dpm	NNS
10_1101-2020_09_02_279521	26	5	estimate	estimate	VBP
10_1101-2020_09_02_279521	26	6	a	a	DT
10_1101-2020_09_02_279521	26	7	long	long	JJ
10_1101-2020_09_02_279521	26	8	-	-	HYPH
10_1101-2020_09_02_279521	26	9	term	term	NN
10_1101-2020_09_02_279521	26	10	disease	disease	NN
10_1101-2020_09_02_279521	26	11	evolution	evolution	NN
10_1101-2020_09_02_279521	26	12	from	from	IN
10_1101-2020_09_02_279521	26	13	the	the	DT
10_1101-2020_09_02_279521	26	14	joint	joint	JJ
10_1101-2020_09_02_279521	26	15	analysis	analysis	NN
10_1101-2020_09_02_279521	26	16	of	of	IN
10_1101-2020_09_02_279521	26	17	multivariate	multivariate	JJ
10_1101-2020_09_02_279521	26	18	time	time	NN
10_1101-2020_09_02_279521	26	19	-	-	HYPH
10_1101-2020_09_02_279521	26	20	series	series	NN
10_1101-2020_09_02_279521	26	21	acquired	acquire	VBN
10_1101-2020_09_02_279521	26	22	on	on	IN
10_1101-2020_09_02_279521	26	23	a	a	DT
10_1101-2020_09_02_279521	26	24	short	short	JJ
10_1101-2020_09_02_279521	26	25	-	-	HYPH
10_1101-2020_09_02_279521	26	26	term	term	NN
10_1101-2020_09_02_279521	26	27	time	time	NN
10_1101-2020_09_02_279521	26	28	-	-	HYPH
10_1101-2020_09_02_279521	26	29	scale	scale	NN
10_1101-2020_09_02_279521	26	30	.	.	.
10_1101-2020_09_02_279521	27	1	Due	due	IN
10_1101-2020_09_02_279521	27	2	to	to	IN
10_1101-2020_09_02_279521	27	3	the	the	DT
10_1101-2020_09_02_279521	27	4	temporal	temporal	JJ
10_1101-2020_09_02_279521	27	5	delay	delay	NN
10_1101-2020_09_02_279521	27	6	between	between	IN
10_1101-2020_09_02_279521	27	7	the	the	DT
10_1101-2020_09_02_279521	27	8	disease	disease	NN
10_1101-2020_09_02_279521	27	9	onset	onset	NN
10_1101-2020_09_02_279521	27	10	and	and	CC
10_1101-2020_09_02_279521	27	11	the	the	DT
10_1101-2020_09_02_279521	27	12	appearance	appearance	NN
10_1101-2020_09_02_279521	27	13	of	of	IN
10_1101-2020_09_02_279521	27	14	the	the	DT
10_1101-2020_09_02_279521	27	15	first	first	JJ
10_1101-2020_09_02_279521	27	16	symptoms	symptom	NNS
10_1101-2020_09_02_279521	27	17	,	,	,
10_1101-2020_09_02_279521	27	18	DPMs	DPMs	NNPS
10_1101-2020_09_02_279521	27	19	rely	rely	VBP
10_1101-2020_09_02_279521	27	20	on	on	IN
10_1101-2020_09_02_279521	27	21	the	the	DT
10_1101-2020_09_02_279521	27	22	identification	identification	NN
10_1101-2020_09_02_279521	27	23	of	of	IN
10_1101-2020_09_02_279521	27	24	an	an	DT
10_1101-2020_09_02_279521	27	25	appropriate	appropriate	JJ
10_1101-2020_09_02_279521	27	26	temporal	temporal	JJ
10_1101-2020_09_02_279521	27	27	reference	reference	NN
10_1101-2020_09_02_279521	27	28	to	to	TO
10_1101-2020_09_02_279521	27	29	describe	describe	VB
10_1101-2020_09_02_279521	27	30	the	the	DT
10_1101-2020_09_02_279521	27	31	long	long	JJ
10_1101-2020_09_02_279521	27	32	-	-	HYPH
10_1101-2020_09_02_279521	27	33	term	term	NN
10_1101-2020_09_02_279521	27	34	disease	disease	NN
10_1101-2020_09_02_279521	27	35	evolution	evolution	NN
10_1101-2020_09_02_279521	27	36	(	(	-LRB-
10_1101-2020_09_02_279521	27	37	Lorenzi	Lorenzi	NNP
10_1101-2020_09_02_279521	27	38	et	et	NNP
10_1101-2020_09_02_279521	27	39	al	al	NNP
10_1101-2020_09_02_279521	27	40	.	.	NNP
10_1101-2020_09_02_279521	27	41	,	,	,
10_1101-2020_09_02_279521	27	42	2017	2017	CD
10_1101-2020_09_02_279521	27	43	;	;	:
10_1101-2020_09_02_279521	27	44	Marinescu	Marinescu	NNP
10_1101-2020_09_02_279521	27	45	et	et	NNP
10_1101-2020_09_02_279521	27	46	al	al	NNP
10_1101-2020_09_02_279521	27	47	.	.	NNP
10_1101-2020_09_02_279521	27	48	,	,	,
10_1101-2020_09_02_279521	27	49	2019	2019	CD
10_1101-2020_09_02_279521	27	50	)	)	-RRB-
10_1101-2020_09_02_279521	27	51	.	.	.
10_1101-2020_09_02_279521	28	1	These	these	DT
10_1101-2020_09_02_279521	28	2	tools	tool	NNS
10_1101-2020_09_02_279521	28	3	are	be	VBP
10_1101-2020_09_02_279521	28	4	promising	promise	VBG
10_1101-2020_09_02_279521	28	5	approaches	approach	NNS
10_1101-2020_09_02_279521	28	6	for	for	IN
10_1101-2020_09_02_279521	28	7	the	the	DT
10_1101-2020_09_02_279521	28	8	analysis	analysis	NN
10_1101-2020_09_02_279521	28	9	of	of	IN
10_1101-2020_09_02_279521	28	10	clinical	clinical	JJ
10_1101-2020_09_02_279521	28	11	trials	trial	NNS
10_1101-2020_09_02_279521	28	12	data	datum	NNS
10_1101-2020_09_02_279521	28	13	,	,	,
10_1101-2020_09_02_279521	28	14	as	as	IN
10_1101-2020_09_02_279521	28	15	they	-PRON-	PRP
10_1101-2020_09_02_279521	28	16	allow	allow	VBP
10_1101-2020_09_02_279521	28	17	to	to	TO
10_1101-2020_09_02_279521	28	18	represent	represent	VB
10_1101-2020_09_02_279521	28	19	the	the	DT
10_1101-2020_09_02_279521	28	20	longitudinal	longitudinal	JJ
10_1101-2020_09_02_279521	28	21	evolution	evolution	NN
10_1101-2020_09_02_279521	28	22	of	of	IN
10_1101-2020_09_02_279521	28	23	multiple	multiple	JJ
10_1101-2020_09_02_279521	28	24	biomarkers	biomarker	NNS
10_1101-2020_09_02_279521	28	25	through	through	IN
10_1101-2020_09_02_279521	28	26	a	a	DT
10_1101-2020_09_02_279521	28	27	global	global	JJ
10_1101-2020_09_02_279521	28	28	model	model	NN
10_1101-2020_09_02_279521	28	29	of	of	IN
10_1101-2020_09_02_279521	28	30	disease	disease	NN
10_1101-2020_09_02_279521	28	31	progression	progression	NN
10_1101-2020_09_02_279521	28	32	.	.	.
10_1101-2020_09_02_279521	29	1	Such	such	PDT
10_1101-2020_09_02_279521	29	2	a	a	DT
10_1101-2020_09_02_279521	29	3	model	model	NN
10_1101-2020_09_02_279521	29	4	can	can	MD
10_1101-2020_09_02_279521	29	5	be	be	VB
10_1101-2020_09_02_279521	29	6	subsequently	subsequently	RB
10_1101-2020_09_02_279521	29	7	used	use	VBN
10_1101-2020_09_02_279521	29	8	as	as	IN
10_1101-2020_09_02_279521	29	9	a	a	DT
10_1101-2020_09_02_279521	29	10	reference	reference	NN
10_1101-2020_09_02_279521	29	11	in	in	IN
10_1101-2020_09_02_279521	29	12	order	order	NN
10_1101-2020_09_02_279521	29	13	to	to	TO
10_1101-2020_09_02_279521	29	14	stage	stage	VB
10_1101-2020_09_02_279521	29	15	subjects	subject	NNS
10_1101-2020_09_02_279521	29	16	and	and	CC
10_1101-2020_09_02_279521	29	17	quantify	quantify	VB
10_1101-2020_09_02_279521	29	18	their	-PRON-	PRP$
10_1101-2020_09_02_279521	29	19	relative	relative	JJ
10_1101-2020_09_02_279521	29	20	progression	progression	NN
10_1101-2020_09_02_279521	29	21	speed	speed	NN
10_1101-2020_09_02_279521	29	22	(	(	-LRB-
10_1101-2020_09_02_279521	29	23	Insel	Insel	NNP
10_1101-2020_09_02_279521	29	24	et	et	NNP
10_1101-2020_09_02_279521	29	25	al	al	NNP
10_1101-2020_09_02_279521	29	26	.	.	NNP
10_1101-2020_09_02_279521	29	27	,	,	,
10_1101-2020_09_02_279521	29	28	2020	2020	CD
10_1101-2020_09_02_279521	29	29	;	;	:
10_1101-2020_09_02_279521	29	30	Li	Li	NNP
10_1101-2020_09_02_279521	29	31	et	et	NNP
10_1101-2020_09_02_279521	29	32	al	al	NNP
10_1101-2020_09_02_279521	29	33	.	.	NNP
10_1101-2020_09_02_279521	29	34	,	,	,
10_1101-2020_09_02_279521	29	35	2019	2019	CD
10_1101-2020_09_02_279521	29	36	;	;	:
10_1101-2020_09_02_279521	29	37	Oxtoby	Oxtoby	NNP
10_1101-2020_09_02_279521	29	38	et	et	FW
10_1101-2020_09_02_279521	29	39	al	al	NNP
10_1101-2020_09_02_279521	29	40	.	.	NNP
10_1101-2020_09_02_279521	29	41	,	,	,
10_1101-2020_09_02_279521	29	42	2018	2018	CD
10_1101-2020_09_02_279521	29	43	;	;	:
10_1101-2020_09_02_279521	29	44	Young	Young	NNP
10_1101-2020_09_02_279521	29	45	et	et	NNP
10_1101-2020_09_02_279521	29	46	al	al	NNP
10_1101-2020_09_02_279521	29	47	.	.	NNP
10_1101-2020_09_02_279521	29	48	,	,	,
10_1101-2020_09_02_279521	29	49	2014	2014	CD
10_1101-2020_09_02_279521	29	50	)	)	-RRB-
10_1101-2020_09_02_279521	29	51	.	.	.
10_1101-2020_09_02_279521	30	1	However	however	RB
10_1101-2020_09_02_279521	30	2	,	,	,
10_1101-2020_09_02_279521	30	3	these	these	DT
10_1101-2020_09_02_279521	30	4	approaches	approach	NNS
10_1101-2020_09_02_279521	30	5	remain	remain	VBP
10_1101-2020_09_02_279521	30	6	purely	purely	RB
10_1101-2020_09_02_279521	30	7	descriptive	descriptive	JJ
10_1101-2020_09_02_279521	30	8	as	as	IN
10_1101-2020_09_02_279521	30	9	they	-PRON-	PRP
10_1101-2020_09_02_279521	30	10	do	do	VBP
10_1101-2020_09_02_279521	30	11	n't	not	RB
10_1101-2020_09_02_279521	30	12	account	account	VB
10_1101-2020_09_02_279521	30	13	for	for	IN
10_1101-2020_09_02_279521	30	14	causal	causal	JJ
10_1101-2020_09_02_279521	30	15	relationships	relationship	NNS
10_1101-2020_09_02_279521	30	16	among	among	IN
10_1101-2020_09_02_279521	30	17	biomarkers	biomarker	NNS
10_1101-2020_09_02_279521	30	18	.	.	.
10_1101-2020_09_02_279521	31	1	Therefore	therefore	RB
10_1101-2020_09_02_279521	31	2	,	,	,
10_1101-2020_09_02_279521	31	3	they	-PRON-	PRP
10_1101-2020_09_02_279521	31	4	generally	generally	RB
10_1101-2020_09_02_279521	31	5	do	do	VBP
10_1101-2020_09_02_279521	31	6	n't	not	RB
10_1101-2020_09_02_279521	31	7	allow	allow	VB
10_1101-2020_09_02_279521	31	8	to	to	TO
10_1101-2020_09_02_279521	31	9	simulate	simulate	VB
10_1101-2020_09_02_279521	31	10	progression	progression	NN
10_1101-2020_09_02_279521	31	11	scenarios	scenario	NNS
10_1101-2020_09_02_279521	31	12	based	base	VBN
10_1101-2020_09_02_279521	31	13	on	on	IN
10_1101-2020_09_02_279521	31	14	hypothetical	hypothetical	JJ
10_1101-2020_09_02_279521	31	15	intervention	intervention	NN
10_1101-2020_09_02_279521	31	16	strategies	strategy	NNS
10_1101-2020_09_02_279521	31	17	,	,	,
10_1101-2020_09_02_279521	31	18	thus	thus	RB
10_1101-2020_09_02_279521	31	19	providing	provide	VBG
10_1101-2020_09_02_279521	31	20	a	a	DT
10_1101-2020_09_02_279521	31	21	limited	limited	JJ
10_1101-2020_09_02_279521	31	22	interpretation	interpretation	NN
10_1101-2020_09_02_279521	31	23	of	of	IN
10_1101-2020_09_02_279521	31	24	the	the	DT
10_1101-2020_09_02_279521	31	25	pathological	pathological	JJ
10_1101-2020_09_02_279521	31	26	dynamics	dynamic	NNS
10_1101-2020_09_02_279521	31	27	.	.	.
10_1101-2020_09_02_279521	32	1	This	this	DT
10_1101-2020_09_02_279521	32	2	latter	latter	JJ
10_1101-2020_09_02_279521	32	3	capability	capability	NN
10_1101-2020_09_02_279521	32	4	is	be	VBZ
10_1101-2020_09_02_279521	32	5	of	of	IN
10_1101-2020_09_02_279521	32	6	utmost	utmost	JJ
10_1101-2020_09_02_279521	32	7	importance	importance	NN
10_1101-2020_09_02_279521	32	8	for	for	IN
10_1101-2020_09_02_279521	32	9	planning	planning	NN
10_1101-2020_09_02_279521	32	10	and	and	CC
10_1101-2020_09_02_279521	32	11	assessment	assessment	NN
10_1101-2020_09_02_279521	32	12	of	of	IN
10_1101-2020_09_02_279521	32	13	disease	disease	NNP
10_1101-2020_09_02_279521	32	14	modifying	modifying	NNP
10_1101-2020_09_02_279521	32	15	treatments	treatment	NNS
10_1101-2020_09_02_279521	32	16	.	.	.
10_1101-2020_09_02_279521	33	1	.CC	.CC	NFP
10_1101-2020_09_02_279521	33	2	-	-	:
10_1101-2020_09_02_279521	33	3	BY	by	IN
10_1101-2020_09_02_279521	33	4	4.0	4.0	CD
10_1101-2020_09_02_279521	33	5	International	international	JJ
10_1101-2020_09_02_279521	33	6	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	33	7	.	.	.
10_1101-2020_09_02_279521	34	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	34	2	is	be	VBZ
10_1101-2020_09_02_279521	34	3	made	make	VBN
10_1101-2020_09_02_279521	34	4	available	available	JJ
10_1101-2020_09_02_279521	34	5	under	under	IN
10_1101-2020_09_02_279521	34	6	a	a	DT
10_1101-2020_09_02_279521	34	7	preprint	preprint	NN
10_1101-2020_09_02_279521	34	8	(	(	-LRB-
10_1101-2020_09_02_279521	34	9	which	which	WDT
10_1101-2020_09_02_279521	34	10	was	be	VBD
10_1101-2020_09_02_279521	34	11	not	not	RB
10_1101-2020_09_02_279521	34	12	certified	certify	VBN
10_1101-2020_09_02_279521	34	13	by	by	IN
10_1101-2020_09_02_279521	34	14	peer	peer	NN
10_1101-2020_09_02_279521	34	15	review	review	NN
10_1101-2020_09_02_279521	34	16	)	)	-RRB-
10_1101-2020_09_02_279521	34	17	is	be	VBZ
10_1101-2020_09_02_279521	34	18	the	the	DT
10_1101-2020_09_02_279521	34	19	author	author	NN
10_1101-2020_09_02_279521	34	20	/	/	SYM
10_1101-2020_09_02_279521	34	21	funder	funder	NN
10_1101-2020_09_02_279521	34	22	,	,	,
10_1101-2020_09_02_279521	34	23	who	who	WP
10_1101-2020_09_02_279521	34	24	has	have	VBZ
10_1101-2020_09_02_279521	34	25	granted	grant	VBN
10_1101-2020_09_02_279521	34	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	34	27	a	a	DT
10_1101-2020_09_02_279521	34	28	license	license	NN
10_1101-2020_09_02_279521	34	29	to	to	TO
10_1101-2020_09_02_279521	34	30	display	display	VB
10_1101-2020_09_02_279521	34	31	the	the	DT
10_1101-2020_09_02_279521	34	32	preprint	preprint	NN
10_1101-2020_09_02_279521	34	33	in	in	IN
10_1101-2020_09_02_279521	34	34	The	the	DT
10_1101-2020_09_02_279521	34	35	copyright	copyright	NN
10_1101-2020_09_02_279521	34	36	holder	holder	NN
10_1101-2020_09_02_279521	34	37	for	for	IN
10_1101-2020_09_02_279521	34	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	34	39	version	version	NN
10_1101-2020_09_02_279521	34	40	posted	post	VBD
10_1101-2020_09_02_279521	34	41	February	February	NNP
10_1101-2020_09_02_279521	34	42	10	10	CD
10_1101-2020_09_02_279521	34	43	,	,	,
10_1101-2020_09_02_279521	34	44	2021	2021	CD
10_1101-2020_09_02_279521	34	45	.	.	.
10_1101-2020_09_02_279521	34	46	;	;	:
10_1101-2020_09_02_279521	34	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	34	48	:	:	:
10_1101-2020_09_02_279521	34	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	34	50	preprint	preprint	NN
10_1101-2020_09_02_279521	34	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	UH
10_1101-2020_09_02_279521	34	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	ADD
10_1101-2020_09_02_279521	34	53	To	to	TO
10_1101-2020_09_02_279521	34	54	fill	fill	VB
10_1101-2020_09_02_279521	34	55	this	this	DT
10_1101-2020_09_02_279521	34	56	gap	gap	NN
10_1101-2020_09_02_279521	34	57	,	,	,
10_1101-2020_09_02_279521	34	58	recent	recent	JJ
10_1101-2020_09_02_279521	34	59	works	work	NNS
10_1101-2020_09_02_279521	34	60	such	such	JJ
10_1101-2020_09_02_279521	34	61	as	as	IN
10_1101-2020_09_02_279521	34	62	(	(	-LRB-
10_1101-2020_09_02_279521	34	63	Hao	Hao	NNP
10_1101-2020_09_02_279521	34	64	&	&	CC
10_1101-2020_09_02_279521	34	65	Friedman	Friedman	NNP
10_1101-2020_09_02_279521	34	66	,	,	,
10_1101-2020_09_02_279521	34	67	2016	2016	CD
10_1101-2020_09_02_279521	34	68	;	;	:
10_1101-2020_09_02_279521	34	69	Petrella	Petrella	NNP
10_1101-2020_09_02_279521	34	70	et	et	FW
10_1101-2020_09_02_279521	34	71	al	al	NNP
10_1101-2020_09_02_279521	34	72	.	.	NNP
10_1101-2020_09_02_279521	34	73	,	,	,
10_1101-2020_09_02_279521	34	74	2019	2019	CD
10_1101-2020_09_02_279521	34	75	)	)	-RRB-
10_1101-2020_09_02_279521	34	76	proposed	propose	VBD
10_1101-2020_09_02_279521	34	77	to	to	TO
10_1101-2020_09_02_279521	34	78	model	model	VB
10_1101-2020_09_02_279521	34	79	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	34	80	’s	’s	POS
10_1101-2020_09_02_279521	34	81	disease	disease	NN
10_1101-2020_09_02_279521	34	82	progression	progression	NN
10_1101-2020_09_02_279521	34	83	based	base	VBN
10_1101-2020_09_02_279521	34	84	on	on	IN
10_1101-2020_09_02_279521	34	85	specific	specific	JJ
10_1101-2020_09_02_279521	34	86	assumptions	assumption	NNS
10_1101-2020_09_02_279521	34	87	on	on	IN
10_1101-2020_09_02_279521	34	88	the	the	DT
10_1101-2020_09_02_279521	34	89	biochemical	biochemical	JJ
10_1101-2020_09_02_279521	34	90	processes	process	NNS
10_1101-2020_09_02_279521	34	91	of	of	IN
10_1101-2020_09_02_279521	34	92	pathological	pathological	JJ
10_1101-2020_09_02_279521	34	93	protein	protein	NN
10_1101-2020_09_02_279521	34	94	propagation	propagation	NN
10_1101-2020_09_02_279521	34	95	.	.	.
10_1101-2020_09_02_279521	35	1	These	these	DT
10_1101-2020_09_02_279521	35	2	approaches	approach	NNS
10_1101-2020_09_02_279521	35	3	explicitly	explicitly	RB
10_1101-2020_09_02_279521	35	4	define	define	VBP
10_1101-2020_09_02_279521	35	5	biomarkers	biomarker	NNS
10_1101-2020_09_02_279521	35	6	interactions	interaction	NNS
10_1101-2020_09_02_279521	35	7	through	through	IN
10_1101-2020_09_02_279521	35	8	the	the	DT
10_1101-2020_09_02_279521	35	9	specification	specification	NN
10_1101-2020_09_02_279521	35	10	of	of	IN
10_1101-2020_09_02_279521	35	11	sets	set	NNS
10_1101-2020_09_02_279521	35	12	of	of	IN
10_1101-2020_09_02_279521	35	13	Ordinary	Ordinary	NNP
10_1101-2020_09_02_279521	35	14	Differential	Differential	NNP
10_1101-2020_09_02_279521	35	15	Equations	equation	NNS
10_1101-2020_09_02_279521	35	16	(	(	-LRB-
10_1101-2020_09_02_279521	35	17	ODEs	ODEs	NNPS
10_1101-2020_09_02_279521	35	18	)	)	-RRB-
10_1101-2020_09_02_279521	35	19	,	,	,
10_1101-2020_09_02_279521	35	20	and	and	CC
10_1101-2020_09_02_279521	35	21	are	be	VBP
10_1101-2020_09_02_279521	35	22	ideally	ideally	RB
10_1101-2020_09_02_279521	35	23	suited	suit	VBN
10_1101-2020_09_02_279521	35	24	to	to	TO
10_1101-2020_09_02_279521	35	25	simulate	simulate	VB
10_1101-2020_09_02_279521	35	26	the	the	DT
10_1101-2020_09_02_279521	35	27	effect	effect	NN
10_1101-2020_09_02_279521	35	28	of	of	IN
10_1101-2020_09_02_279521	35	29	drug	drug	NN
10_1101-2020_09_02_279521	35	30	interventions	intervention	NNS
10_1101-2020_09_02_279521	35	31	(	(	-LRB-
10_1101-2020_09_02_279521	35	32	Yasser	Yasser	NNP
10_1101-2020_09_02_279521	35	33	Iturria	Iturria	NNP
10_1101-2020_09_02_279521	35	34	-	-	HYPH
10_1101-2020_09_02_279521	35	35	Medina	Medina	NNP
10_1101-2020_09_02_279521	35	36	et	et	NNP
10_1101-2020_09_02_279521	35	37	al	al	NNP
10_1101-2020_09_02_279521	35	38	.	.	NNP
10_1101-2020_09_02_279521	35	39	,	,	,
10_1101-2020_09_02_279521	35	40	2017	2017	CD
10_1101-2020_09_02_279521	35	41	)	)	-RRB-
10_1101-2020_09_02_279521	35	42	.	.	.
10_1101-2020_09_02_279521	36	1	However	however	RB
10_1101-2020_09_02_279521	36	2	,	,	,
10_1101-2020_09_02_279521	36	3	these	these	DT
10_1101-2020_09_02_279521	36	4	methods	method	NNS
10_1101-2020_09_02_279521	36	5	are	be	VBP
10_1101-2020_09_02_279521	36	6	mostly	mostly	RB
10_1101-2020_09_02_279521	36	7	based	base	VBN
10_1101-2020_09_02_279521	36	8	on	on	IN
10_1101-2020_09_02_279521	36	9	the	the	DT
10_1101-2020_09_02_279521	36	10	arbitrary	arbitrary	JJ
10_1101-2020_09_02_279521	36	11	choices	choice	NNS
10_1101-2020_09_02_279521	36	12	of	of	IN
10_1101-2020_09_02_279521	36	13	pre	pre	JJ
10_1101-2020_09_02_279521	36	14	-	-	JJ
10_1101-2020_09_02_279521	36	15	defined	define	VBN
10_1101-2020_09_02_279521	36	16	evolution	evolution	NN
10_1101-2020_09_02_279521	36	17	models	model	NNS
10_1101-2020_09_02_279521	36	18	,	,	,
10_1101-2020_09_02_279521	36	19	which	which	WDT
10_1101-2020_09_02_279521	36	20	are	be	VBP
10_1101-2020_09_02_279521	36	21	not	not	RB
10_1101-2020_09_02_279521	36	22	inferred	infer	VBN
10_1101-2020_09_02_279521	36	23	from	from	IN
10_1101-2020_09_02_279521	36	24	data	datum	NNS
10_1101-2020_09_02_279521	36	25	.	.	.
10_1101-2020_09_02_279521	37	1	This	this	DT
10_1101-2020_09_02_279521	37	2	issue	issue	NN
10_1101-2020_09_02_279521	37	3	was	be	VBD
10_1101-2020_09_02_279521	37	4	recently	recently	RB
10_1101-2020_09_02_279521	37	5	addressed	address	VBN
10_1101-2020_09_02_279521	37	6	by	by	IN
10_1101-2020_09_02_279521	37	7	(	(	-LRB-
10_1101-2020_09_02_279521	37	8	Garbarino	Garbarino	NNP
10_1101-2020_09_02_279521	37	9	&	&	CC
10_1101-2020_09_02_279521	37	10	Lorenzi	Lorenzi	NNP
10_1101-2020_09_02_279521	37	11	,	,	,
10_1101-2020_09_02_279521	37	12	2019	2019	CD
10_1101-2020_09_02_279521	37	13	)	)	-RRB-
10_1101-2020_09_02_279521	37	14	,	,	,
10_1101-2020_09_02_279521	37	15	where	where	WRB
10_1101-2020_09_02_279521	37	16	the	the	DT
10_1101-2020_09_02_279521	37	17	authors	author	NNS
10_1101-2020_09_02_279521	37	18	proposed	propose	VBD
10_1101-2020_09_02_279521	37	19	an	an	DT
10_1101-2020_09_02_279521	37	20	hybrid	hybrid	JJ
10_1101-2020_09_02_279521	37	21	modeling	modeling	NN
10_1101-2020_09_02_279521	37	22	method	method	NN
10_1101-2020_09_02_279521	37	23	combining	combine	VBG
10_1101-2020_09_02_279521	37	24	traditional	traditional	JJ
10_1101-2020_09_02_279521	37	25	DPMs	dpm	NNS
10_1101-2020_09_02_279521	37	26	with	with	IN
10_1101-2020_09_02_279521	37	27	dynamical	dynamical	JJ
10_1101-2020_09_02_279521	37	28	models	model	NNS
10_1101-2020_09_02_279521	37	29	of	of	IN
10_1101-2020_09_02_279521	37	30	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	37	31	’s	’s	POS
10_1101-2020_09_02_279521	37	32	disease	disease	NNP
10_1101-2020_09_02_279521	37	33	progression	progression	NN
10_1101-2020_09_02_279521	37	34	.	.	.
10_1101-2020_09_02_279521	38	1	Still	still	RB
10_1101-2020_09_02_279521	38	2	,	,	,
10_1101-2020_09_02_279521	38	3	since	since	IN
10_1101-2020_09_02_279521	38	4	this	this	DT
10_1101-2020_09_02_279521	38	5	approach	approach	NN
10_1101-2020_09_02_279521	38	6	requires	require	VBZ
10_1101-2020_09_02_279521	38	7	to	to	TO
10_1101-2020_09_02_279521	38	8	design	design	VB
10_1101-2020_09_02_279521	38	9	suitable	suitable	JJ
10_1101-2020_09_02_279521	38	10	models	model	NNS
10_1101-2020_09_02_279521	38	11	of	of	IN
10_1101-2020_09_02_279521	38	12	protein	protein	NN
10_1101-2020_09_02_279521	38	13	propagation	propagation	NN
10_1101-2020_09_02_279521	38	14	across	across	IN
10_1101-2020_09_02_279521	38	15	brain	brain	NN
10_1101-2020_09_02_279521	38	16	regions	region	NNS
10_1101-2020_09_02_279521	38	17	,	,	,
10_1101-2020_09_02_279521	38	18	extending	extend	VBG
10_1101-2020_09_02_279521	38	19	this	this	DT
10_1101-2020_09_02_279521	38	20	method	method	NN
10_1101-2020_09_02_279521	38	21	to	to	TO
10_1101-2020_09_02_279521	38	22	jointly	jointly	RB
10_1101-2020_09_02_279521	38	23	account	account	VB
10_1101-2020_09_02_279521	38	24	for	for	IN
10_1101-2020_09_02_279521	38	25	spatio	spatio	NN
10_1101-2020_09_02_279521	38	26	-	-	HYPH
10_1101-2020_09_02_279521	38	27	temporal	temporal	JJ
10_1101-2020_09_02_279521	38	28	interactions	interaction	NNS
10_1101-2020_09_02_279521	38	29	between	between	IN
10_1101-2020_09_02_279521	38	30	several	several	JJ
10_1101-2020_09_02_279521	38	31	processes	process	NNS
10_1101-2020_09_02_279521	38	32	,	,	,
10_1101-2020_09_02_279521	38	33	such	such	JJ
10_1101-2020_09_02_279521	38	34	as	as	IN
10_1101-2020_09_02_279521	38	35	amyloid	amyloid	NN
10_1101-2020_09_02_279521	38	36	propagation	propagation	NN
10_1101-2020_09_02_279521	38	37	,	,	,
10_1101-2020_09_02_279521	38	38	glucose	glucose	VB
10_1101-2020_09_02_279521	38	39	metabolism	metabolism	NN
10_1101-2020_09_02_279521	38	40	,	,	,
10_1101-2020_09_02_279521	38	41	and	and	CC
10_1101-2020_09_02_279521	38	42	brain	brain	NN
10_1101-2020_09_02_279521	38	43	atrophy	atrophy	NN
10_1101-2020_09_02_279521	38	44	,	,	,
10_1101-2020_09_02_279521	38	45	is	be	VBZ
10_1101-2020_09_02_279521	38	46	considerably	considerably	RB
10_1101-2020_09_02_279521	38	47	more	more	RBR
10_1101-2020_09_02_279521	38	48	complex	complex	JJ
10_1101-2020_09_02_279521	38	49	.	.	.
10_1101-2020_09_02_279521	39	1	Finally	finally	RB
10_1101-2020_09_02_279521	39	2	,	,	,
10_1101-2020_09_02_279521	39	3	these	these	DT
10_1101-2020_09_02_279521	39	4	methods	method	NNS
10_1101-2020_09_02_279521	39	5	are	be	VBP
10_1101-2020_09_02_279521	39	6	usually	usually	RB
10_1101-2020_09_02_279521	39	7	designed	design	VBN
10_1101-2020_09_02_279521	39	8	to	to	TO
10_1101-2020_09_02_279521	39	9	account	account	VB
10_1101-2020_09_02_279521	39	10	for	for	IN
10_1101-2020_09_02_279521	39	11	imaging	image	VBG
10_1101-2020_09_02_279521	39	12	data	datum	NNS
10_1101-2020_09_02_279521	39	13	only	only	RB
10_1101-2020_09_02_279521	39	14	,	,	,
10_1101-2020_09_02_279521	39	15	which	which	WDT
10_1101-2020_09_02_279521	39	16	prevents	prevent	VBZ
10_1101-2020_09_02_279521	39	17	to	to	TO
10_1101-2020_09_02_279521	39	18	jointly	jointly	RB
10_1101-2020_09_02_279521	39	19	simulate	simulate	VB
10_1101-2020_09_02_279521	39	20	heterogeneous	heterogeneous	JJ
10_1101-2020_09_02_279521	39	21	measures	measure	NNS
10_1101-2020_09_02_279521	39	22	(	(	-LRB-
10_1101-2020_09_02_279521	39	23	Antelmi	Antelmi	NNP
10_1101-2020_09_02_279521	39	24	et	et	NNP
10_1101-2020_09_02_279521	39	25	al	al	NNP
10_1101-2020_09_02_279521	39	26	.	.	NNP
10_1101-2020_09_02_279521	39	27	,	,	,
10_1101-2020_09_02_279521	39	28	2019	2019	CD
10_1101-2020_09_02_279521	39	29	)	)	-RRB-
10_1101-2020_09_02_279521	39	30	,	,	,
10_1101-2020_09_02_279521	39	31	such	such	JJ
10_1101-2020_09_02_279521	39	32	as	as	IN
10_1101-2020_09_02_279521	39	33	image	image	NN
10_1101-2020_09_02_279521	39	34	-	-	HYPH
10_1101-2020_09_02_279521	39	35	based	base	VBN
10_1101-2020_09_02_279521	39	36	biomarkers	biomarker	NNS
10_1101-2020_09_02_279521	39	37	and	and	CC
10_1101-2020_09_02_279521	39	38	clinical	clinical	JJ
10_1101-2020_09_02_279521	39	39	outcomes	outcome	NNS
10_1101-2020_09_02_279521	39	40	,	,	,
10_1101-2020_09_02_279521	39	41	the	the	DT
10_1101-2020_09_02_279521	39	42	latter	latter	JJ
10_1101-2020_09_02_279521	39	43	remaining	remain	VBG
10_1101-2020_09_02_279521	39	44	the	the	DT
10_1101-2020_09_02_279521	39	45	reference	reference	NN
10_1101-2020_09_02_279521	39	46	markers	marker	NNS
10_1101-2020_09_02_279521	39	47	for	for	IN
10_1101-2020_09_02_279521	39	48	patients	patient	NNS
10_1101-2020_09_02_279521	39	49	and	and	CC
10_1101-2020_09_02_279521	39	50	clinicians	clinician	NNS
10_1101-2020_09_02_279521	39	51	.	.	.
10_1101-2020_09_02_279521	40	1	In	in	IN
10_1101-2020_09_02_279521	40	2	this	this	DT
10_1101-2020_09_02_279521	40	3	work	work	NN
10_1101-2020_09_02_279521	40	4	we	-PRON-	PRP
10_1101-2020_09_02_279521	40	5	present	present	VBP
10_1101-2020_09_02_279521	40	6	a	a	DT
10_1101-2020_09_02_279521	40	7	novel	novel	JJ
10_1101-2020_09_02_279521	40	8	computational	computational	JJ
10_1101-2020_09_02_279521	40	9	model	model	NN
10_1101-2020_09_02_279521	40	10	of	of	IN
10_1101-2020_09_02_279521	40	11	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	40	12	’s	’s	POS
10_1101-2020_09_02_279521	40	13	disease	disease	NN
10_1101-2020_09_02_279521	40	14	progression	progression	NN
10_1101-2020_09_02_279521	40	15	allowing	allow	VBG
10_1101-2020_09_02_279521	40	16	to	to	TO
10_1101-2020_09_02_279521	40	17	simulate	simulate	VB
10_1101-2020_09_02_279521	40	18	intervention	intervention	NN
10_1101-2020_09_02_279521	40	19	strategies	strategy	NNS
10_1101-2020_09_02_279521	40	20	across	across	IN
10_1101-2020_09_02_279521	40	21	the	the	DT
10_1101-2020_09_02_279521	40	22	history	history	NN
10_1101-2020_09_02_279521	40	23	of	of	IN
10_1101-2020_09_02_279521	40	24	the	the	DT
10_1101-2020_09_02_279521	40	25	disease	disease	NN
10_1101-2020_09_02_279521	40	26	.	.	.
10_1101-2020_09_02_279521	41	1	The	the	DT
10_1101-2020_09_02_279521	41	2	model	model	NN
10_1101-2020_09_02_279521	41	3	is	be	VBZ
10_1101-2020_09_02_279521	41	4	here	here	RB
10_1101-2020_09_02_279521	41	5	used	use	VBN
10_1101-2020_09_02_279521	41	6	to	to	TO
10_1101-2020_09_02_279521	41	7	quantify	quantify	VB
10_1101-2020_09_02_279521	41	8	the	the	DT
10_1101-2020_09_02_279521	41	9	potential	potential	JJ
10_1101-2020_09_02_279521	41	10	effect	effect	NN
10_1101-2020_09_02_279521	41	11	of	of	IN
10_1101-2020_09_02_279521	41	12	amyloid	amyloid	JJ
10_1101-2020_09_02_279521	41	13	modifiers	modifier	NNS
10_1101-2020_09_02_279521	41	14	on	on	IN
10_1101-2020_09_02_279521	41	15	the	the	DT
10_1101-2020_09_02_279521	41	16	progression	progression	NN
10_1101-2020_09_02_279521	41	17	of	of	IN
10_1101-2020_09_02_279521	41	18	brain	brain	NN
10_1101-2020_09_02_279521	41	19	atrophy	atrophy	NN
10_1101-2020_09_02_279521	41	20	,	,	,
10_1101-2020_09_02_279521	41	21	glucose	glucose	VB
10_1101-2020_09_02_279521	41	22	metabolism	metabolism	NN
10_1101-2020_09_02_279521	41	23	,	,	,
10_1101-2020_09_02_279521	41	24	and	and	CC
10_1101-2020_09_02_279521	41	25	ultimately	ultimately	RB
10_1101-2020_09_02_279521	41	26	on	on	IN
10_1101-2020_09_02_279521	41	27	the	the	DT
10_1101-2020_09_02_279521	41	28	clinical	clinical	JJ
10_1101-2020_09_02_279521	41	29	outcomes	outcome	NNS
10_1101-2020_09_02_279521	41	30	for	for	IN
10_1101-2020_09_02_279521	41	31	different	different	JJ
10_1101-2020_09_02_279521	41	32	scenarios	scenario	NNS
10_1101-2020_09_02_279521	41	33	of	of	IN
10_1101-2020_09_02_279521	41	34	intervention	intervention	NN
10_1101-2020_09_02_279521	41	35	.	.	.
10_1101-2020_09_02_279521	42	1	To	to	IN
10_1101-2020_09_02_279521	42	2	this	this	DT
10_1101-2020_09_02_279521	42	3	end	end	NN
10_1101-2020_09_02_279521	42	4	,	,	,
10_1101-2020_09_02_279521	42	5	we	-PRON-	PRP
10_1101-2020_09_02_279521	42	6	model	model	VBP
10_1101-2020_09_02_279521	42	7	the	the	DT
10_1101-2020_09_02_279521	42	8	joint	joint	JJ
10_1101-2020_09_02_279521	42	9	spatio	spatio	NN
10_1101-2020_09_02_279521	42	10	-	-	HYPH
10_1101-2020_09_02_279521	42	11	temporal	temporal	JJ
10_1101-2020_09_02_279521	42	12	variation	variation	NN
10_1101-2020_09_02_279521	42	13	of	of	IN
10_1101-2020_09_02_279521	42	14	different	different	JJ
10_1101-2020_09_02_279521	42	15	modalities	modality	NNS
10_1101-2020_09_02_279521	42	16	along	along	IN
10_1101-2020_09_02_279521	42	17	the	the	DT
10_1101-2020_09_02_279521	42	18	history	history	NN
10_1101-2020_09_02_279521	42	19	of	of	IN
10_1101-2020_09_02_279521	42	20	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	42	21	’s	’s	POS
10_1101-2020_09_02_279521	42	22	disease	disease	NN
10_1101-2020_09_02_279521	42	23	by	by	IN
10_1101-2020_09_02_279521	42	24	identifying	identify	VBG
10_1101-2020_09_02_279521	42	25	a	a	DT
10_1101-2020_09_02_279521	42	26	system	system	NN
10_1101-2020_09_02_279521	42	27	of	of	IN
10_1101-2020_09_02_279521	42	28	ODEs	ode	NNS
10_1101-2020_09_02_279521	42	29	governing	govern	VBG
10_1101-2020_09_02_279521	42	30	the	the	DT
10_1101-2020_09_02_279521	42	31	pathological	pathological	JJ
10_1101-2020_09_02_279521	42	32	progression	progression	NN
10_1101-2020_09_02_279521	42	33	.	.	.
10_1101-2020_09_02_279521	43	1	This	this	DT
10_1101-2020_09_02_279521	43	2	latent	latent	NN
10_1101-2020_09_02_279521	43	3	ODEs	ode	NNS
10_1101-2020_09_02_279521	43	4	system	system	NN
10_1101-2020_09_02_279521	43	5	is	be	VBZ
10_1101-2020_09_02_279521	43	6	specified	specify	VBN
10_1101-2020_09_02_279521	43	7	within	within	IN
10_1101-2020_09_02_279521	43	8	an	an	DT
10_1101-2020_09_02_279521	43	9	interpretable	interpretable	JJ
10_1101-2020_09_02_279521	43	10	low-	low-	NN
10_1101-2020_09_02_279521	43	11	dimensional	dimensional	JJ
10_1101-2020_09_02_279521	43	12	space	space	NN
10_1101-2020_09_02_279521	43	13	relating	relate	VBG
10_1101-2020_09_02_279521	43	14	multi	multi	JJ
10_1101-2020_09_02_279521	43	15	-	-	JJ
10_1101-2020_09_02_279521	43	16	modal	modal	JJ
10_1101-2020_09_02_279521	43	17	information	information	NN
10_1101-2020_09_02_279521	43	18	,	,	,
10_1101-2020_09_02_279521	43	19	and	and	CC
10_1101-2020_09_02_279521	43	20	combines	combine	VBZ
10_1101-2020_09_02_279521	43	21	clinically	clinically	RB
10_1101-2020_09_02_279521	43	22	-	-	HYPH
10_1101-2020_09_02_279521	43	23	inspired	inspire	VBN
10_1101-2020_09_02_279521	43	24	constraints	constraint	NNS
10_1101-2020_09_02_279521	43	25	with	with	IN
10_1101-2020_09_02_279521	43	26	unknown	unknown	JJ
10_1101-2020_09_02_279521	43	27	interactions	interaction	NNS
10_1101-2020_09_02_279521	43	28	that	that	WDT
10_1101-2020_09_02_279521	43	29	we	-PRON-	PRP
10_1101-2020_09_02_279521	43	30	wish	wish	VBP
10_1101-2020_09_02_279521	43	31	to	to	TO
10_1101-2020_09_02_279521	43	32	estimate	estimate	VB
10_1101-2020_09_02_279521	43	33	.	.	.
10_1101-2020_09_02_279521	44	1	The	the	DT
10_1101-2020_09_02_279521	44	2	interpretability	interpretability	NN
10_1101-2020_09_02_279521	44	3	of	of	IN
10_1101-2020_09_02_279521	44	4	the	the	DT
10_1101-2020_09_02_279521	44	5	relationships	relationship	NNS
10_1101-2020_09_02_279521	44	6	in	in	IN
10_1101-2020_09_02_279521	44	7	the	the	DT
10_1101-2020_09_02_279521	44	8	latent	latent	NN
10_1101-2020_09_02_279521	44	9	space	space	NN
10_1101-2020_09_02_279521	44	10	is	be	VBZ
10_1101-2020_09_02_279521	44	11	ensured	ensure	VBN
10_1101-2020_09_02_279521	44	12	by	by	IN
10_1101-2020_09_02_279521	44	13	mapping	map	VBG
10_1101-2020_09_02_279521	44	14	each	each	DT
10_1101-2020_09_02_279521	44	15	data	data	NN
10_1101-2020_09_02_279521	44	16	modality	modality	NN
10_1101-2020_09_02_279521	44	17	to	to	IN
10_1101-2020_09_02_279521	44	18	a	a	DT
10_1101-2020_09_02_279521	44	19	specific	specific	JJ
10_1101-2020_09_02_279521	44	20	latent	latent	NN
10_1101-2020_09_02_279521	44	21	coordinate	coordinate	NN
10_1101-2020_09_02_279521	44	22	.	.	.
10_1101-2020_09_02_279521	45	1	The	the	DT
10_1101-2020_09_02_279521	45	2	model	model	NN
10_1101-2020_09_02_279521	45	3	is	be	VBZ
10_1101-2020_09_02_279521	45	4	formulated	formulate	VBN
10_1101-2020_09_02_279521	45	5	within	within	IN
10_1101-2020_09_02_279521	45	6	a	a	DT
10_1101-2020_09_02_279521	45	7	Bayesian	bayesian	JJ
10_1101-2020_09_02_279521	45	8	framework	framework	NN
10_1101-2020_09_02_279521	45	9	,	,	,
10_1101-2020_09_02_279521	45	10	where	where	WRB
10_1101-2020_09_02_279521	45	11	the	the	DT
10_1101-2020_09_02_279521	45	12	latent	latent	NN
10_1101-2020_09_02_279521	45	13	representation	representation	NN
10_1101-2020_09_02_279521	45	14	and	and	CC
10_1101-2020_09_02_279521	45	15	dynamics	dynamic	NNS
10_1101-2020_09_02_279521	45	16	are	be	VBP
10_1101-2020_09_02_279521	45	17	efficiently	efficiently	RB
10_1101-2020_09_02_279521	45	18	estimated	estimate	VBN
10_1101-2020_09_02_279521	45	19	through	through	IN
10_1101-2020_09_02_279521	45	20	stochastic	stochastic	JJ
10_1101-2020_09_02_279521	45	21	variational	variational	JJ
10_1101-2020_09_02_279521	45	22	inference	inference	NN
10_1101-2020_09_02_279521	45	23	.	.	.
10_1101-2020_09_02_279521	46	1	To	to	TO
10_1101-2020_09_02_279521	46	2	generate	generate	VB
10_1101-2020_09_02_279521	46	3	hypothetical	hypothetical	JJ
10_1101-2020_09_02_279521	46	4	scenarios	scenario	NNS
10_1101-2020_09_02_279521	46	5	of	of	IN
10_1101-2020_09_02_279521	46	6	amyloid	amyloid	NN
10_1101-2020_09_02_279521	46	7	lowering	lower	VBG
10_1101-2020_09_02_279521	46	8	interventions	intervention	NNS
10_1101-2020_09_02_279521	46	9	,	,	,
10_1101-2020_09_02_279521	46	10	we	-PRON-	PRP
10_1101-2020_09_02_279521	46	11	apply	apply	VBP
10_1101-2020_09_02_279521	46	12	our	-PRON-	PRP$
10_1101-2020_09_02_279521	46	13	approach	approach	NN
10_1101-2020_09_02_279521	46	14	to	to	IN
10_1101-2020_09_02_279521	46	15	multi	multi	JJ
10_1101-2020_09_02_279521	46	16	-	-	JJ
10_1101-2020_09_02_279521	46	17	modal	modal	JJ
10_1101-2020_09_02_279521	46	18	imaging	imaging	NN
10_1101-2020_09_02_279521	46	19	and	and	CC
10_1101-2020_09_02_279521	46	20	clinical	clinical	JJ
10_1101-2020_09_02_279521	46	21	data	datum	NNS
10_1101-2020_09_02_279521	46	22	from	from	IN
10_1101-2020_09_02_279521	46	23	the	the	DT
10_1101-2020_09_02_279521	46	24	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	46	25	’s	’s	POS
10_1101-2020_09_02_279521	46	26	Disease	Disease	NNP
10_1101-2020_09_02_279521	46	27	Neuroimaging	Neuroimaging	NNP
10_1101-2020_09_02_279521	46	28	Initiative	Initiative	NNP
10_1101-2020_09_02_279521	46	29	(	(	-LRB-
10_1101-2020_09_02_279521	46	30	ADNI	ADNI	NNP
10_1101-2020_09_02_279521	46	31	)	)	-RRB-
10_1101-2020_09_02_279521	46	32	.	.	.
10_1101-2020_09_02_279521	47	1	Our	-PRON-	PRP$
10_1101-2020_09_02_279521	47	2	results	result	NNS
10_1101-2020_09_02_279521	47	3	provide	provide	VBP
10_1101-2020_09_02_279521	47	4	a	a	DT
10_1101-2020_09_02_279521	47	5	meaningful	meaningful	JJ
10_1101-2020_09_02_279521	47	6	quantification	quantification	NN
10_1101-2020_09_02_279521	47	7	of	of	IN
10_1101-2020_09_02_279521	47	8	different	different	JJ
10_1101-2020_09_02_279521	47	9	intervention	intervention	NN
10_1101-2020_09_02_279521	47	10	strategies	strategy	NNS
10_1101-2020_09_02_279521	47	11	,	,	,
10_1101-2020_09_02_279521	47	12	compatible	compatible	JJ
10_1101-2020_09_02_279521	47	13	with	with	IN
10_1101-2020_09_02_279521	47	14	findings	finding	NNS
10_1101-2020_09_02_279521	47	15	previously	previously	RB
10_1101-2020_09_02_279521	47	16	reported	report	VBN
10_1101-2020_09_02_279521	47	17	in	in	IN
10_1101-2020_09_02_279521	47	18	clinical	clinical	JJ
10_1101-2020_09_02_279521	47	19	studies	study	NNS
10_1101-2020_09_02_279521	47	20	.	.	.
10_1101-2020_09_02_279521	48	1	For	for	IN
10_1101-2020_09_02_279521	48	2	example	example	NN
10_1101-2020_09_02_279521	48	3	,	,	,
10_1101-2020_09_02_279521	48	4	we	-PRON-	PRP
10_1101-2020_09_02_279521	48	5	.CC	.CC	:
10_1101-2020_09_02_279521	48	6	-	-	:
10_1101-2020_09_02_279521	48	7	BY	by	IN
10_1101-2020_09_02_279521	48	8	4.0	4.0	CD
10_1101-2020_09_02_279521	48	9	International	international	JJ
10_1101-2020_09_02_279521	48	10	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	48	11	.	.	.
10_1101-2020_09_02_279521	49	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	49	2	is	be	VBZ
10_1101-2020_09_02_279521	49	3	made	make	VBN
10_1101-2020_09_02_279521	49	4	available	available	JJ
10_1101-2020_09_02_279521	49	5	under	under	IN
10_1101-2020_09_02_279521	49	6	a	a	DT
10_1101-2020_09_02_279521	49	7	preprint	preprint	NN
10_1101-2020_09_02_279521	49	8	(	(	-LRB-
10_1101-2020_09_02_279521	49	9	which	which	WDT
10_1101-2020_09_02_279521	49	10	was	be	VBD
10_1101-2020_09_02_279521	49	11	not	not	RB
10_1101-2020_09_02_279521	49	12	certified	certify	VBN
10_1101-2020_09_02_279521	49	13	by	by	IN
10_1101-2020_09_02_279521	49	14	peer	peer	NN
10_1101-2020_09_02_279521	49	15	review	review	NN
10_1101-2020_09_02_279521	49	16	)	)	-RRB-
10_1101-2020_09_02_279521	49	17	is	be	VBZ
10_1101-2020_09_02_279521	49	18	the	the	DT
10_1101-2020_09_02_279521	49	19	author	author	NN
10_1101-2020_09_02_279521	49	20	/	/	SYM
10_1101-2020_09_02_279521	49	21	funder	funder	NN
10_1101-2020_09_02_279521	49	22	,	,	,
10_1101-2020_09_02_279521	49	23	who	who	WP
10_1101-2020_09_02_279521	49	24	has	have	VBZ
10_1101-2020_09_02_279521	49	25	granted	grant	VBN
10_1101-2020_09_02_279521	49	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	49	27	a	a	DT
10_1101-2020_09_02_279521	49	28	license	license	NN
10_1101-2020_09_02_279521	49	29	to	to	TO
10_1101-2020_09_02_279521	49	30	display	display	VB
10_1101-2020_09_02_279521	49	31	the	the	DT
10_1101-2020_09_02_279521	49	32	preprint	preprint	NN
10_1101-2020_09_02_279521	49	33	in	in	IN
10_1101-2020_09_02_279521	49	34	The	the	DT
10_1101-2020_09_02_279521	49	35	copyright	copyright	NN
10_1101-2020_09_02_279521	49	36	holder	holder	NN
10_1101-2020_09_02_279521	49	37	for	for	IN
10_1101-2020_09_02_279521	49	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	49	39	version	version	NN
10_1101-2020_09_02_279521	49	40	posted	post	VBD
10_1101-2020_09_02_279521	49	41	February	February	NNP
10_1101-2020_09_02_279521	49	42	10	10	CD
10_1101-2020_09_02_279521	49	43	,	,	,
10_1101-2020_09_02_279521	49	44	2021	2021	CD
10_1101-2020_09_02_279521	49	45	.	.	.
10_1101-2020_09_02_279521	49	46	;	;	:
10_1101-2020_09_02_279521	49	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	49	48	:	:	:
10_1101-2020_09_02_279521	49	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	49	50	preprint	preprint	NN
10_1101-2020_09_02_279521	49	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	ADD
10_1101-2020_09_02_279521	49	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	ADD
10_1101-2020_09_02_279521	49	53	estimate	estimate	VB
10_1101-2020_09_02_279521	49	54	that	that	IN
10_1101-2020_09_02_279521	49	55	in	in	IN
10_1101-2020_09_02_279521	49	56	a	a	DT
10_1101-2020_09_02_279521	49	57	study	study	NN
10_1101-2020_09_02_279521	49	58	with	with	IN
10_1101-2020_09_02_279521	49	59	100	100	CD
10_1101-2020_09_02_279521	49	60	individuals	individual	NNS
10_1101-2020_09_02_279521	49	61	per	per	IN
10_1101-2020_09_02_279521	49	62	arm	arm	NN
10_1101-2020_09_02_279521	49	63	,	,	,
10_1101-2020_09_02_279521	49	64	statistically	statistically	RB
10_1101-2020_09_02_279521	49	65	powered	power	VBN
10_1101-2020_09_02_279521	49	66	improvement	improvement	NN
10_1101-2020_09_02_279521	49	67	of	of	IN
10_1101-2020_09_02_279521	49	68	clinical	clinical	JJ
10_1101-2020_09_02_279521	49	69	endpoints	endpoint	NNS
10_1101-2020_09_02_279521	49	70	can	can	MD
10_1101-2020_09_02_279521	49	71	be	be	VB
10_1101-2020_09_02_279521	49	72	obtained	obtain	VBN
10_1101-2020_09_02_279521	49	73	by	by	IN
10_1101-2020_09_02_279521	49	74	completely	completely	RB
10_1101-2020_09_02_279521	49	75	arresting	arrest	VBG
10_1101-2020_09_02_279521	49	76	amyloid	amyloid	NN
10_1101-2020_09_02_279521	49	77	accumulation	accumulation	NN
10_1101-2020_09_02_279521	49	78	at	at	IN
10_1101-2020_09_02_279521	49	79	least	least	JJS
10_1101-2020_09_02_279521	49	80	11	11	CD
10_1101-2020_09_02_279521	49	81	years	year	NNS
10_1101-2020_09_02_279521	49	82	before	before	IN
10_1101-2020_09_02_279521	49	83	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	49	84	's	's	POS
10_1101-2020_09_02_279521	49	85	dementia	dementia	NN
10_1101-2020_09_02_279521	49	86	.	.	.
10_1101-2020_09_02_279521	50	1	The	the	DT
10_1101-2020_09_02_279521	50	2	minimum	minimum	JJ
10_1101-2020_09_02_279521	50	3	intervention	intervention	NN
10_1101-2020_09_02_279521	50	4	time	time	NN
10_1101-2020_09_02_279521	50	5	decreases	decrease	VBZ
10_1101-2020_09_02_279521	50	6	to	to	IN
10_1101-2020_09_02_279521	50	7	7	7	CD
10_1101-2020_09_02_279521	50	8	years	year	NNS
10_1101-2020_09_02_279521	50	9	for	for	IN
10_1101-2020_09_02_279521	50	10	studies	study	NNS
10_1101-2020_09_02_279521	50	11	based	base	VBN
10_1101-2020_09_02_279521	50	12	on	on	IN
10_1101-2020_09_02_279521	50	13	1000	1000	CD
10_1101-2020_09_02_279521	50	14	individuals	individual	NNS
10_1101-2020_09_02_279521	50	15	per	per	IN
10_1101-2020_09_02_279521	50	16	arm	arm	NN
10_1101-2020_09_02_279521	50	17	.	.	.
10_1101-2020_09_02_279521	51	1	Materials	material	NNS
10_1101-2020_09_02_279521	51	2	and	and	CC
10_1101-2020_09_02_279521	51	3	methods	method	NNS
10_1101-2020_09_02_279521	51	4	In	in	IN
10_1101-2020_09_02_279521	51	5	the	the	DT
10_1101-2020_09_02_279521	51	6	following	follow	VBG
10_1101-2020_09_02_279521	51	7	sections	section	NNS
10_1101-2020_09_02_279521	51	8	,	,	,
10_1101-2020_09_02_279521	51	9	healthy	healthy	JJ
10_1101-2020_09_02_279521	51	10	individuals	individual	NNS
10_1101-2020_09_02_279521	51	11	will	will	MD
10_1101-2020_09_02_279521	51	12	be	be	VB
10_1101-2020_09_02_279521	51	13	denoted	denote	VBN
10_1101-2020_09_02_279521	51	14	as	as	IN
10_1101-2020_09_02_279521	51	15	NL	NL	NNP
10_1101-2020_09_02_279521	51	16	stable	stable	JJ
10_1101-2020_09_02_279521	51	17	,	,	,
10_1101-2020_09_02_279521	51	18	subjects	subject	NNS
10_1101-2020_09_02_279521	51	19	with	with	IN
10_1101-2020_09_02_279521	51	20	mild	mild	JJ
10_1101-2020_09_02_279521	51	21	cognitive	cognitive	JJ
10_1101-2020_09_02_279521	51	22	impairment	impairment	NN
10_1101-2020_09_02_279521	51	23	as	as	IN
10_1101-2020_09_02_279521	51	24	MCI	MCI	NNP
10_1101-2020_09_02_279521	51	25	stable	stable	NN
10_1101-2020_09_02_279521	51	26	,	,	,
10_1101-2020_09_02_279521	51	27	subjects	subject	NNS
10_1101-2020_09_02_279521	51	28	diagnosed	diagnose	VBN
10_1101-2020_09_02_279521	51	29	with	with	IN
10_1101-2020_09_02_279521	51	30	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	51	31	's	's	POS
10_1101-2020_09_02_279521	51	32	dementia	dementia	NN
10_1101-2020_09_02_279521	51	33	as	as	IN
10_1101-2020_09_02_279521	51	34	AD	ad	NN
10_1101-2020_09_02_279521	51	35	.	.	.
10_1101-2020_09_02_279521	52	1	We	-PRON-	PRP
10_1101-2020_09_02_279521	52	2	define	define	VBP
10_1101-2020_09_02_279521	52	3	conversion	conversion	NN
10_1101-2020_09_02_279521	52	4	as	as	IN
10_1101-2020_09_02_279521	52	5	the	the	DT
10_1101-2020_09_02_279521	52	6	change	change	NN
10_1101-2020_09_02_279521	52	7	of	of	IN
10_1101-2020_09_02_279521	52	8	diagnosis	diagnosis	NN
10_1101-2020_09_02_279521	52	9	towards	towards	IN
10_1101-2020_09_02_279521	52	10	a	a	DT
10_1101-2020_09_02_279521	52	11	more	more	RBR
10_1101-2020_09_02_279521	52	12	pathological	pathological	JJ
10_1101-2020_09_02_279521	52	13	state	state	NN
10_1101-2020_09_02_279521	52	14	.	.	.
10_1101-2020_09_02_279521	53	1	Therefore	therefore	RB
10_1101-2020_09_02_279521	53	2	,	,	,
10_1101-2020_09_02_279521	53	3	NL	NL	NNP
10_1101-2020_09_02_279521	53	4	converters	converter	NNS
10_1101-2020_09_02_279521	53	5	are	be	VBP
10_1101-2020_09_02_279521	53	6	subjects	subject	NNS
10_1101-2020_09_02_279521	53	7	who	who	WP
10_1101-2020_09_02_279521	53	8	were	be	VBD
10_1101-2020_09_02_279521	53	9	diagnosed	diagnose	VBN
10_1101-2020_09_02_279521	53	10	as	as	IN
10_1101-2020_09_02_279521	53	11	cognitively	cognitively	RB
10_1101-2020_09_02_279521	53	12	normal	normal	JJ
10_1101-2020_09_02_279521	53	13	at	at	IN
10_1101-2020_09_02_279521	53	14	baseline	baseline	NNP
10_1101-2020_09_02_279521	53	15	and	and	CC
10_1101-2020_09_02_279521	53	16	whose	whose	WP$
10_1101-2020_09_02_279521	53	17	diagnosis	diagnosis	NN
10_1101-2020_09_02_279521	53	18	changed	change	VBD
10_1101-2020_09_02_279521	53	19	either	either	CC
10_1101-2020_09_02_279521	53	20	in	in	IN
10_1101-2020_09_02_279521	53	21	MCI	MCI	NNP
10_1101-2020_09_02_279521	53	22	or	or	CC
10_1101-2020_09_02_279521	53	23	AD	ad	NN
10_1101-2020_09_02_279521	53	24	during	during	IN
10_1101-2020_09_02_279521	53	25	their	-PRON-	PRP$
10_1101-2020_09_02_279521	53	26	follow	follow	VB
10_1101-2020_09_02_279521	53	27	-	-	HYPH
10_1101-2020_09_02_279521	53	28	up	up	RP
10_1101-2020_09_02_279521	53	29	visits	visit	NNS
10_1101-2020_09_02_279521	53	30	.	.	.
10_1101-2020_09_02_279521	54	1	MCI	mci	NN
10_1101-2020_09_02_279521	54	2	converters	converter	NNS
10_1101-2020_09_02_279521	54	3	are	be	VBP
10_1101-2020_09_02_279521	54	4	subjects	subject	NNS
10_1101-2020_09_02_279521	54	5	who	who	WP
10_1101-2020_09_02_279521	54	6	were	be	VBD
10_1101-2020_09_02_279521	54	7	diagnosed	diagnose	VBN
10_1101-2020_09_02_279521	54	8	as	as	IN
10_1101-2020_09_02_279521	54	9	MCI	MCI	NNP
10_1101-2020_09_02_279521	54	10	at	at	IN
10_1101-2020_09_02_279521	54	11	baseline	baseline	NN
10_1101-2020_09_02_279521	54	12	and	and	CC
10_1101-2020_09_02_279521	54	13	subsequently	subsequently	RB
10_1101-2020_09_02_279521	54	14	progressed	progress	VBN
10_1101-2020_09_02_279521	54	15	to	to	IN
10_1101-2020_09_02_279521	54	16	AD	ad	NN
10_1101-2020_09_02_279521	54	17	.	.	.
10_1101-2020_09_02_279521	55	1	Diagnosis	diagnosis	NN
10_1101-2020_09_02_279521	55	2	was	be	VBD
10_1101-2020_09_02_279521	55	3	established	establish	VBN
10_1101-2020_09_02_279521	55	4	using	use	VBG
10_1101-2020_09_02_279521	55	5	the	the	DT
10_1101-2020_09_02_279521	55	6	DX	DX	NNP
10_1101-2020_09_02_279521	55	7	column	column	NN
10_1101-2020_09_02_279521	55	8	from	from	IN
10_1101-2020_09_02_279521	55	9	the	the	DT
10_1101-2020_09_02_279521	55	10	ADNIMERGE	ADNIMERGE	NNP
10_1101-2020_09_02_279521	55	11	file	file	NN
10_1101-2020_09_02_279521	55	12	(	(	-LRB-
10_1101-2020_09_02_279521	55	13	https://adni.bitbucket.io/index.html	https://adni.bitbucket.io/index.html	NNP
10_1101-2020_09_02_279521	55	14	)	)	-RRB-
10_1101-2020_09_02_279521	55	15	,	,	,
10_1101-2020_09_02_279521	55	16	which	which	WDT
10_1101-2020_09_02_279521	55	17	reflects	reflect	VBZ
10_1101-2020_09_02_279521	55	18	the	the	DT
10_1101-2020_09_02_279521	55	19	standard	standard	JJ
10_1101-2020_09_02_279521	55	20	ADNI	ADNI	NNP
10_1101-2020_09_02_279521	55	21	clinical	clinical	JJ
10_1101-2020_09_02_279521	55	22	assessment	assessment	NN
10_1101-2020_09_02_279521	55	23	based	base	VBN
10_1101-2020_09_02_279521	55	24	on	on	IN
10_1101-2020_09_02_279521	55	25	Wechsler	Wechsler	NNP
10_1101-2020_09_02_279521	55	26	Memory	Memory	NNP
10_1101-2020_09_02_279521	55	27	Scale	Scale	NNP
10_1101-2020_09_02_279521	55	28	,	,	,
10_1101-2020_09_02_279521	55	29	Mini	Mini	NNP
10_1101-2020_09_02_279521	55	30	-	-	HYPH
10_1101-2020_09_02_279521	55	31	Mental	mental	JJ
10_1101-2020_09_02_279521	55	32	State	State	NNP
10_1101-2020_09_02_279521	55	33	Examination	Examination	NNP
10_1101-2020_09_02_279521	55	34	,	,	,
10_1101-2020_09_02_279521	55	35	and	and	CC
10_1101-2020_09_02_279521	55	36	Clinical	Clinical	NNP
10_1101-2020_09_02_279521	55	37	Dementia	Dementia	NNP
10_1101-2020_09_02_279521	55	38	Rating	Rating	NNP
10_1101-2020_09_02_279521	55	39	.	.	.
10_1101-2020_09_02_279521	56	1	Amyloid	amyloid	JJ
10_1101-2020_09_02_279521	56	2	concentration	concentration	NN
10_1101-2020_09_02_279521	56	3	and	and	CC
10_1101-2020_09_02_279521	56	4	glucose	glucose	VB
10_1101-2020_09_02_279521	56	5	metabolism	metabolism	NN
10_1101-2020_09_02_279521	56	6	are	be	VBP
10_1101-2020_09_02_279521	56	7	respectively	respectively	RB
10_1101-2020_09_02_279521	56	8	measured	measure	VBN
10_1101-2020_09_02_279521	56	9	by	by	IN
10_1101-2020_09_02_279521	56	10	(	(	-LRB-
10_1101-2020_09_02_279521	56	11	18)F-	18)F-	NNP
10_1101-2020_09_02_279521	56	12	florbetapir	florbetapir	NN
10_1101-2020_09_02_279521	56	13	Amyloid	Amyloid	NNP
10_1101-2020_09_02_279521	56	14	(	(	-LRB-
10_1101-2020_09_02_279521	56	15	AV45)-PET	av45)-pet	UH
10_1101-2020_09_02_279521	56	16	and	and	CC
10_1101-2020_09_02_279521	56	17	(	(	-LRB-
10_1101-2020_09_02_279521	56	18	18)F	18)f	NN
10_1101-2020_09_02_279521	56	19	-	-	HYPH
10_1101-2020_09_02_279521	56	20	fluorodeoxyglucose	fluorodeoxyglucose	NN
10_1101-2020_09_02_279521	56	21	(	(	-LRB-
10_1101-2020_09_02_279521	56	22	FDG)-PET	FDG)-PET	NNS
10_1101-2020_09_02_279521	56	23	imaging	imaging	NN
10_1101-2020_09_02_279521	56	24	.	.	.
10_1101-2020_09_02_279521	57	1	Cognitive	cognitive	JJ
10_1101-2020_09_02_279521	57	2	and	and	CC
10_1101-2020_09_02_279521	57	3	functional	functional	JJ
10_1101-2020_09_02_279521	57	4	abilities	ability	NNS
10_1101-2020_09_02_279521	57	5	are	be	VBP
10_1101-2020_09_02_279521	57	6	assessed	assess	VBN
10_1101-2020_09_02_279521	57	7	by	by	IN
10_1101-2020_09_02_279521	57	8	the	the	DT
10_1101-2020_09_02_279521	57	9	following	following	JJ
10_1101-2020_09_02_279521	57	10	neuro	neuro	NNP
10_1101-2020_09_02_279521	57	11	-	-	HYPH
10_1101-2020_09_02_279521	57	12	psychological	psychological	JJ
10_1101-2020_09_02_279521	57	13	tests	test	NNS
10_1101-2020_09_02_279521	57	14	:	:	:
10_1101-2020_09_02_279521	57	15	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	57	16	's	's	POS
10_1101-2020_09_02_279521	57	17	Disease	Disease	NNP
10_1101-2020_09_02_279521	57	18	Assessment	Assessment	NNP
10_1101-2020_09_02_279521	57	19	Scale	Scale	NNP
10_1101-2020_09_02_279521	57	20	(	(	-LRB-
10_1101-2020_09_02_279521	57	21	ADAS11	ADAS11	NNP
10_1101-2020_09_02_279521	57	22	)	)	-RRB-
10_1101-2020_09_02_279521	57	23	,	,	,
10_1101-2020_09_02_279521	57	24	Mini	Mini	NNP
10_1101-2020_09_02_279521	57	25	-	-	HYPH
10_1101-2020_09_02_279521	57	26	Mental	mental	JJ
10_1101-2020_09_02_279521	57	27	State	state	NN
10_1101-2020_09_02_279521	57	28	Examination	Examination	NNP
10_1101-2020_09_02_279521	57	29	(	(	-LRB-
10_1101-2020_09_02_279521	57	30	MMSE	MMSE	NNP
10_1101-2020_09_02_279521	57	31	)	)	-RRB-
10_1101-2020_09_02_279521	57	32	,	,	,
10_1101-2020_09_02_279521	57	33	Functional	Functional	NNP
10_1101-2020_09_02_279521	57	34	Assessment	Assessment	NNP
10_1101-2020_09_02_279521	57	35	Questionnaire	Questionnaire	NNP
10_1101-2020_09_02_279521	57	36	(	(	-LRB-
10_1101-2020_09_02_279521	57	37	FAQ	FAQ	NNP
10_1101-2020_09_02_279521	57	38	)	)	-RRB-
10_1101-2020_09_02_279521	57	39	,	,	,
10_1101-2020_09_02_279521	57	40	Rey	Rey	NNP
10_1101-2020_09_02_279521	57	41	Auditory	Auditory	NNP
10_1101-2020_09_02_279521	57	42	Verbal	Verbal	NNP
10_1101-2020_09_02_279521	57	43	Learning	Learning	NNP
10_1101-2020_09_02_279521	57	44	Test	Test	NNP
10_1101-2020_09_02_279521	57	45	(	(	-LRB-
10_1101-2020_09_02_279521	57	46	RAVLT	RAVLT	NNP
10_1101-2020_09_02_279521	57	47	)	)	-RRB-
10_1101-2020_09_02_279521	57	48	immediate	immediate	JJ
10_1101-2020_09_02_279521	57	49	,	,	,
10_1101-2020_09_02_279521	57	50	RAVLT	ravlt	NN
10_1101-2020_09_02_279521	57	51	learning	learning	NN
10_1101-2020_09_02_279521	57	52	,	,	,
10_1101-2020_09_02_279521	57	53	RAVLT	RAVLT	NNP
10_1101-2020_09_02_279521	57	54	forgetting	forgetting	NN
10_1101-2020_09_02_279521	57	55	,	,	,
10_1101-2020_09_02_279521	57	56	and	and	CC
10_1101-2020_09_02_279521	57	57	Clinical	Clinical	NNP
10_1101-2020_09_02_279521	57	58	Dementia	Dementia	NNP
10_1101-2020_09_02_279521	57	59	Rating	Rating	NNP
10_1101-2020_09_02_279521	57	60	Scale	Scale	NNP
10_1101-2020_09_02_279521	57	61	Sum	Sum	NNP
10_1101-2020_09_02_279521	57	62	of	of	IN
10_1101-2020_09_02_279521	57	63	Boxes	box	NNS
10_1101-2020_09_02_279521	57	64	(	(	-LRB-
10_1101-2020_09_02_279521	57	65	CDRSB	CDRSB	NNP
10_1101-2020_09_02_279521	57	66	)	)	-RRB-
10_1101-2020_09_02_279521	57	67	.	.	.
10_1101-2020_09_02_279521	58	1	Study	study	NN
10_1101-2020_09_02_279521	58	2	cohort	cohort	NN
10_1101-2020_09_02_279521	58	3	and	and	CC
10_1101-2020_09_02_279521	58	4	biomarkers	biomarker	NNS
10_1101-2020_09_02_279521	58	5	'	'	POS
10_1101-2020_09_02_279521	58	6	changes	change	NNS
10_1101-2020_09_02_279521	58	7	across	across	IN
10_1101-2020_09_02_279521	58	8	clinical	clinical	JJ
10_1101-2020_09_02_279521	58	9	groups	group	NNS
10_1101-2020_09_02_279521	58	10	Our	-PRON-	PRP$
10_1101-2020_09_02_279521	58	11	study	study	NN
10_1101-2020_09_02_279521	58	12	is	be	VBZ
10_1101-2020_09_02_279521	58	13	based	base	VBN
10_1101-2020_09_02_279521	58	14	on	on	IN
10_1101-2020_09_02_279521	58	15	a	a	DT
10_1101-2020_09_02_279521	58	16	cohort	cohort	NN
10_1101-2020_09_02_279521	58	17	of	of	IN
10_1101-2020_09_02_279521	58	18	442	442	CD
10_1101-2020_09_02_279521	58	19	amyloid	amyloid	NN
10_1101-2020_09_02_279521	58	20	positive	positive	JJ
10_1101-2020_09_02_279521	58	21	individuals	individual	NNS
10_1101-2020_09_02_279521	58	22	composed	compose	VBN
10_1101-2020_09_02_279521	58	23	of	of	IN
10_1101-2020_09_02_279521	58	24	71	71	CD
10_1101-2020_09_02_279521	58	25	NL	NL	NNP
10_1101-2020_09_02_279521	58	26	stable	stable	JJ
10_1101-2020_09_02_279521	58	27	subjects	subject	NNS
10_1101-2020_09_02_279521	58	28	,	,	,
10_1101-2020_09_02_279521	58	29	33	33	CD
10_1101-2020_09_02_279521	58	30	NL	NL	NNP
10_1101-2020_09_02_279521	58	31	converters	converter	NNS
10_1101-2020_09_02_279521	58	32	subjects	subject	NNS
10_1101-2020_09_02_279521	58	33	,	,	,
10_1101-2020_09_02_279521	58	34	131	131	CD
10_1101-2020_09_02_279521	58	35	subjects	subject	NNS
10_1101-2020_09_02_279521	58	36	diagnosed	diagnose	VBN
10_1101-2020_09_02_279521	58	37	with	with	IN
10_1101-2020_09_02_279521	58	38	MCI	MCI	NNP
10_1101-2020_09_02_279521	58	39	,	,	,
10_1101-2020_09_02_279521	58	40	105	105	CD
10_1101-2020_09_02_279521	58	41	MCI	MCI	NNP
10_1101-2020_09_02_279521	58	42	converters	converter	NNS
10_1101-2020_09_02_279521	58	43	subjects	subject	NNS
10_1101-2020_09_02_279521	58	44	,	,	,
10_1101-2020_09_02_279521	58	45	and	and	CC
10_1101-2020_09_02_279521	58	46	102	102	CD
10_1101-2020_09_02_279521	58	47	AD	ad	NN
10_1101-2020_09_02_279521	58	48	patients	patient	NNS
10_1101-2020_09_02_279521	58	49	.	.	.
10_1101-2020_09_02_279521	59	1	Among	among	IN
10_1101-2020_09_02_279521	59	2	the	the	DT
10_1101-2020_09_02_279521	59	3	131	131	CD
10_1101-2020_09_02_279521	59	4	MCI	MCI	NNP
10_1101-2020_09_02_279521	59	5	subjects	subject	NNS
10_1101-2020_09_02_279521	59	6	,	,	,
10_1101-2020_09_02_279521	59	7	78	78	CD
10_1101-2020_09_02_279521	59	8	were	be	VBD
10_1101-2020_09_02_279521	59	9	early	early	JJ
10_1101-2020_09_02_279521	59	10	MCI	MCI	NNP
10_1101-2020_09_02_279521	59	11	and	and	CC
10_1101-2020_09_02_279521	59	12	53	53	CD
10_1101-2020_09_02_279521	59	13	were	be	VBD
10_1101-2020_09_02_279521	59	14	late	late	JJ
10_1101-2020_09_02_279521	59	15	MCI	MCI	NNP
10_1101-2020_09_02_279521	59	16	.	.	.
10_1101-2020_09_02_279521	60	1	Concerning	concern	VBG
10_1101-2020_09_02_279521	60	2	the	the	DT
10_1101-2020_09_02_279521	60	3	group	group	NN
10_1101-2020_09_02_279521	60	4	of	of	IN
10_1101-2020_09_02_279521	60	5	MCI	MCI	NNP
10_1101-2020_09_02_279521	60	6	converters	converter	NNS
10_1101-2020_09_02_279521	60	7	,	,	,
10_1101-2020_09_02_279521	60	8	80	80	CD
10_1101-2020_09_02_279521	60	9	subjects	subject	NNS
10_1101-2020_09_02_279521	60	10	were	be	VBD
10_1101-2020_09_02_279521	60	11	late	late	JJ
10_1101-2020_09_02_279521	60	12	MCI	MCI	NNP
10_1101-2020_09_02_279521	60	13	at	at	IN
10_1101-2020_09_02_279521	60	14	baseline	baseline	NN
10_1101-2020_09_02_279521	60	15	and	and	CC
10_1101-2020_09_02_279521	60	16	25	25	CD
10_1101-2020_09_02_279521	60	17	were	be	VBD
10_1101-2020_09_02_279521	60	18	early	early	JJ
10_1101-2020_09_02_279521	60	19	MCI	MCI	NNP
10_1101-2020_09_02_279521	60	20	.	.	.
10_1101-2020_09_02_279521	61	1	The	the	DT
10_1101-2020_09_02_279521	61	2	term	term	NN
10_1101-2020_09_02_279521	61	3	`	`	''
10_1101-2020_09_02_279521	61	4	`	`	''
10_1101-2020_09_02_279521	61	5	amyloid	amyloid	VBP
10_1101-2020_09_02_279521	61	6	positive	positive	JJ
10_1101-2020_09_02_279521	61	7	'	'	''
10_1101-2020_09_02_279521	61	8	'	'	''
10_1101-2020_09_02_279521	61	9	refers	refer	VBZ
10_1101-2020_09_02_279521	61	10	to	to	IN
10_1101-2020_09_02_279521	61	11	subjects	subject	NNS
10_1101-2020_09_02_279521	61	12	whose	whose	WP$
10_1101-2020_09_02_279521	61	13	amyloid	amyloid	NN
10_1101-2020_09_02_279521	61	14	level	level	NN
10_1101-2020_09_02_279521	61	15	in	in	IN
10_1101-2020_09_02_279521	61	16	the	the	DT
10_1101-2020_09_02_279521	61	17	CSF	csf	NN
10_1101-2020_09_02_279521	61	18	was	be	VBD
10_1101-2020_09_02_279521	61	19	below	below	IN
10_1101-2020_09_02_279521	61	20	the	the	DT
10_1101-2020_09_02_279521	61	21	nominal	nominal	JJ
10_1101-2020_09_02_279521	61	22	cutoff	cutoff	NN
10_1101-2020_09_02_279521	61	23	of	of	IN
10_1101-2020_09_02_279521	61	24	192	192	CD
10_1101-2020_09_02_279521	61	25	pg	pg	NN
10_1101-2020_09_02_279521	61	26	/	/	SYM
10_1101-2020_09_02_279521	61	27	ml	ml	NNP
10_1101-2020_09_02_279521	61	28	(	(	-LRB-
10_1101-2020_09_02_279521	61	29	Gamberger	Gamberger	NNP
10_1101-2020_09_02_279521	61	30	et	et	NNP
10_1101-2020_09_02_279521	61	31	al	al	NNP
10_1101-2020_09_02_279521	61	32	.	.	NNP
10_1101-2020_09_02_279521	61	33	,	,	,
10_1101-2020_09_02_279521	61	34	2017	2017	CD
10_1101-2020_09_02_279521	61	35	)	)	-RRB-
10_1101-2020_09_02_279521	61	36	either	either	CC
10_1101-2020_09_02_279521	61	37	at	at	IN
10_1101-2020_09_02_279521	61	38	baseline	baseline	NN
10_1101-2020_09_02_279521	61	39	,	,	,
10_1101-2020_09_02_279521	61	40	or	or	CC
10_1101-2020_09_02_279521	61	41	during	during	IN
10_1101-2020_09_02_279521	61	42	any	any	DT
10_1101-2020_09_02_279521	61	43	follow	follow	VB
10_1101-2020_09_02_279521	61	44	-	-	HYPH
10_1101-2020_09_02_279521	61	45	up	up	RP
10_1101-2020_09_02_279521	61	46	visit	visit	NN
10_1101-2020_09_02_279521	61	47	,	,	,
10_1101-2020_09_02_279521	61	48	and	and	CC
10_1101-2020_09_02_279521	61	49	conversion	conversion	NN
10_1101-2020_09_02_279521	61	50	to	to	IN
10_1101-2020_09_02_279521	61	51	AD	ad	NN
10_1101-2020_09_02_279521	61	52	was	be	VBD
10_1101-2020_09_02_279521	61	53	determined	determine	VBN
10_1101-2020_09_02_279521	61	54	using	use	VBG
10_1101-2020_09_02_279521	61	55	the	the	DT
10_1101-2020_09_02_279521	61	56	last	last	JJ
10_1101-2020_09_02_279521	61	57	available	available	JJ
10_1101-2020_09_02_279521	61	58	follow	follow	VB
10_1101-2020_09_02_279521	61	59	-	-	HYPH
10_1101-2020_09_02_279521	61	60	up	up	RP
10_1101-2020_09_02_279521	61	61	information	information	NN
10_1101-2020_09_02_279521	61	62	.	.	.
10_1101-2020_09_02_279521	62	1	This	this	DT
10_1101-2020_09_02_279521	62	2	preliminary	preliminary	JJ
10_1101-2020_09_02_279521	62	3	selection	selection	NN
10_1101-2020_09_02_279521	62	4	of	of	IN
10_1101-2020_09_02_279521	62	5	patients	patient	NNS
10_1101-2020_09_02_279521	62	6	aims	aim	VBZ
10_1101-2020_09_02_279521	62	7	at	at	IN
10_1101-2020_09_02_279521	62	8	constituting	constitute	VBG
10_1101-2020_09_02_279521	62	9	a	a	DT
10_1101-2020_09_02_279521	62	10	cohort	cohort	NN
10_1101-2020_09_02_279521	62	11	of	of	IN
10_1101-2020_09_02_279521	62	12	.CC	.CC	NFP
10_1101-2020_09_02_279521	62	13	-	-	:
10_1101-2020_09_02_279521	62	14	BY	by	IN
10_1101-2020_09_02_279521	62	15	4.0	4.0	CD
10_1101-2020_09_02_279521	62	16	International	international	JJ
10_1101-2020_09_02_279521	62	17	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	62	18	.	.	.
10_1101-2020_09_02_279521	63	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	63	2	is	be	VBZ
10_1101-2020_09_02_279521	63	3	made	make	VBN
10_1101-2020_09_02_279521	63	4	available	available	JJ
10_1101-2020_09_02_279521	63	5	under	under	IN
10_1101-2020_09_02_279521	63	6	a	a	DT
10_1101-2020_09_02_279521	63	7	preprint	preprint	NN
10_1101-2020_09_02_279521	63	8	(	(	-LRB-
10_1101-2020_09_02_279521	63	9	which	which	WDT
10_1101-2020_09_02_279521	63	10	was	be	VBD
10_1101-2020_09_02_279521	63	11	not	not	RB
10_1101-2020_09_02_279521	63	12	certified	certify	VBN
10_1101-2020_09_02_279521	63	13	by	by	IN
10_1101-2020_09_02_279521	63	14	peer	peer	NN
10_1101-2020_09_02_279521	63	15	review	review	NN
10_1101-2020_09_02_279521	63	16	)	)	-RRB-
10_1101-2020_09_02_279521	63	17	is	be	VBZ
10_1101-2020_09_02_279521	63	18	the	the	DT
10_1101-2020_09_02_279521	63	19	author	author	NN
10_1101-2020_09_02_279521	63	20	/	/	SYM
10_1101-2020_09_02_279521	63	21	funder	funder	NN
10_1101-2020_09_02_279521	63	22	,	,	,
10_1101-2020_09_02_279521	63	23	who	who	WP
10_1101-2020_09_02_279521	63	24	has	have	VBZ
10_1101-2020_09_02_279521	63	25	granted	grant	VBN
10_1101-2020_09_02_279521	63	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	63	27	a	a	DT
10_1101-2020_09_02_279521	63	28	license	license	NN
10_1101-2020_09_02_279521	63	29	to	to	TO
10_1101-2020_09_02_279521	63	30	display	display	VB
10_1101-2020_09_02_279521	63	31	the	the	DT
10_1101-2020_09_02_279521	63	32	preprint	preprint	NN
10_1101-2020_09_02_279521	63	33	in	in	IN
10_1101-2020_09_02_279521	63	34	The	the	DT
10_1101-2020_09_02_279521	63	35	copyright	copyright	NN
10_1101-2020_09_02_279521	63	36	holder	holder	NN
10_1101-2020_09_02_279521	63	37	for	for	IN
10_1101-2020_09_02_279521	63	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	63	39	version	version	NN
10_1101-2020_09_02_279521	63	40	posted	post	VBD
10_1101-2020_09_02_279521	63	41	February	February	NNP
10_1101-2020_09_02_279521	63	42	10	10	CD
10_1101-2020_09_02_279521	63	43	,	,	,
10_1101-2020_09_02_279521	63	44	2021	2021	CD
10_1101-2020_09_02_279521	63	45	.	.	.
10_1101-2020_09_02_279521	63	46	;	;	:
10_1101-2020_09_02_279521	63	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	63	48	:	:	:
10_1101-2020_09_02_279521	63	49	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	63	50	preprint	preprint	NN
10_1101-2020_09_02_279521	63	51	https://adni.bitbucket.io/index.html	https://adni.bitbucket.io/index.html	HYPH
10_1101-2020_09_02_279521	63	52	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	NN
10_1101-2020_09_02_279521	63	53	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	NN
10_1101-2020_09_02_279521	63	54	subjects	subject	NNS
10_1101-2020_09_02_279521	63	55	for	for	IN
10_1101-2020_09_02_279521	63	56	whom	whom	WP
10_1101-2020_09_02_279521	63	57	it	-PRON-	PRP
10_1101-2020_09_02_279521	63	58	is	be	VBZ
10_1101-2020_09_02_279521	63	59	more	more	RBR
10_1101-2020_09_02_279521	63	60	likely	likely	JJ
10_1101-2020_09_02_279521	63	61	to	to	TO
10_1101-2020_09_02_279521	63	62	observe	observe	VB
10_1101-2020_09_02_279521	63	63	“	"	``
10_1101-2020_09_02_279521	63	64	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	63	65	’s	’s	POS
10_1101-2020_09_02_279521	63	66	pathological	pathological	JJ
10_1101-2020_09_02_279521	63	67	changes	change	NNS
10_1101-2020_09_02_279521	63	68	”	"	''
10_1101-2020_09_02_279521	63	69	(	(	-LRB-
10_1101-2020_09_02_279521	63	70	Jack	Jack	NNP
10_1101-2020_09_02_279521	63	71	et	et	NNP
10_1101-2020_09_02_279521	63	72	al	al	NNP
10_1101-2020_09_02_279521	63	73	.	.	NNP
10_1101-2020_09_02_279521	63	74	,	,	,
10_1101-2020_09_02_279521	63	75	2018	2018	CD
10_1101-2020_09_02_279521	63	76	)	)	-RRB-
10_1101-2020_09_02_279521	63	77	.	.	.
10_1101-2020_09_02_279521	64	1	The	the	DT
10_1101-2020_09_02_279521	64	2	length	length	NN
10_1101-2020_09_02_279521	64	3	of	of	IN
10_1101-2020_09_02_279521	64	4	follow	follow	VB
10_1101-2020_09_02_279521	64	5	-	-	HYPH
10_1101-2020_09_02_279521	64	6	up	up	RP
10_1101-2020_09_02_279521	64	7	varies	varie	NNS
10_1101-2020_09_02_279521	64	8	between	between	IN
10_1101-2020_09_02_279521	64	9	0	0	CD
10_1101-2020_09_02_279521	64	10	and	and	CC
10_1101-2020_09_02_279521	64	11	16	16	CD
10_1101-2020_09_02_279521	64	12	years	year	NNS
10_1101-2020_09_02_279521	64	13	.	.	.
10_1101-2020_09_02_279521	65	1	Further	further	JJ
10_1101-2020_09_02_279521	65	2	information	information	NN
10_1101-2020_09_02_279521	65	3	about	about	IN
10_1101-2020_09_02_279521	65	4	the	the	DT
10_1101-2020_09_02_279521	65	5	data	datum	NNS
10_1101-2020_09_02_279521	65	6	are	be	VBP
10_1101-2020_09_02_279521	65	7	available	available	JJ
10_1101-2020_09_02_279521	65	8	on	on	IN
10_1101-2020_09_02_279521	65	9	https://adni.bitbucket.io/reference/	https://adni.bitbucket.io/reference/	NNP
10_1101-2020_09_02_279521	65	10	,	,	,
10_1101-2020_09_02_279521	65	11	while	while	IN
10_1101-2020_09_02_279521	65	12	details	detail	NNS
10_1101-2020_09_02_279521	65	13	on	on	IN
10_1101-2020_09_02_279521	65	14	data	datum	NNS
10_1101-2020_09_02_279521	65	15	acquisition	acquisition	NN
10_1101-2020_09_02_279521	65	16	and	and	CC
10_1101-2020_09_02_279521	65	17	processing	processing	NN
10_1101-2020_09_02_279521	65	18	are	be	VBP
10_1101-2020_09_02_279521	65	19	provided	provide	VBN
10_1101-2020_09_02_279521	65	20	in	in	IN
10_1101-2020_09_02_279521	65	21	Section	Section	NNP
10_1101-2020_09_02_279521	65	22	Data	Data	NNP
10_1101-2020_09_02_279521	65	23	acquisition	acquisition	NN
10_1101-2020_09_02_279521	65	24	and	and	CC
10_1101-2020_09_02_279521	65	25	preprocessing	preprocessing	NN
10_1101-2020_09_02_279521	65	26	.	.	.
10_1101-2020_09_02_279521	66	1	We	-PRON-	PRP
10_1101-2020_09_02_279521	66	2	show	show	VBP
10_1101-2020_09_02_279521	66	3	in	in	IN
10_1101-2020_09_02_279521	66	4	Table	table	NN
10_1101-2020_09_02_279521	66	5	1A	1a	CD
10_1101-2020_09_02_279521	66	6	socio	socio	JJ
10_1101-2020_09_02_279521	66	7	-	-	HYPH
10_1101-2020_09_02_279521	66	8	demographic	demographic	JJ
10_1101-2020_09_02_279521	66	9	information	information	NN
10_1101-2020_09_02_279521	66	10	for	for	IN
10_1101-2020_09_02_279521	66	11	the	the	DT
10_1101-2020_09_02_279521	66	12	training	training	NN
10_1101-2020_09_02_279521	66	13	cohort	cohort	NN
10_1101-2020_09_02_279521	66	14	across	across	IN
10_1101-2020_09_02_279521	66	15	the	the	DT
10_1101-2020_09_02_279521	66	16	different	different	JJ
10_1101-2020_09_02_279521	66	17	clinical	clinical	JJ
10_1101-2020_09_02_279521	66	18	groups	group	NNS
10_1101-2020_09_02_279521	66	19	.	.	.
10_1101-2020_09_02_279521	67	1	Table	table	NN
10_1101-2020_09_02_279521	67	2	1B	1b	NN
10_1101-2020_09_02_279521	67	3	shows	show	VBZ
10_1101-2020_09_02_279521	67	4	baseline	baseline	JJ
10_1101-2020_09_02_279521	67	5	values	value	NNS
10_1101-2020_09_02_279521	67	6	and	and	CC
10_1101-2020_09_02_279521	67	7	annual	annual	JJ
10_1101-2020_09_02_279521	67	8	rates	rate	NNS
10_1101-2020_09_02_279521	67	9	of	of	IN
10_1101-2020_09_02_279521	67	10	change	change	NN
10_1101-2020_09_02_279521	67	11	across	across	IN
10_1101-2020_09_02_279521	67	12	clinical	clinical	JJ
10_1101-2020_09_02_279521	67	13	groups	group	NNS
10_1101-2020_09_02_279521	67	14	for	for	IN
10_1101-2020_09_02_279521	67	15	amyloid	amyloid	NN
10_1101-2020_09_02_279521	67	16	burden	burden	NNP
10_1101-2020_09_02_279521	67	17	(	(	-LRB-
10_1101-2020_09_02_279521	67	18	average	average	JJ
10_1101-2020_09_02_279521	67	19	normalized	normalized	JJ
10_1101-2020_09_02_279521	67	20	AV45	AV45	NNP
10_1101-2020_09_02_279521	67	21	uptake	uptake	NN
10_1101-2020_09_02_279521	67	22	in	in	IN
10_1101-2020_09_02_279521	67	23	frontal	frontal	JJ
10_1101-2020_09_02_279521	67	24	cortex	cortex	NN
10_1101-2020_09_02_279521	67	25	,	,	,
10_1101-2020_09_02_279521	67	26	anterior	anterior	NNP
10_1101-2020_09_02_279521	67	27	cingulate	cingulate	NN
10_1101-2020_09_02_279521	67	28	,	,	,
10_1101-2020_09_02_279521	67	29	precuneus	precuneus	NN
10_1101-2020_09_02_279521	67	30	and	and	CC
10_1101-2020_09_02_279521	67	31	parietal	parietal	JJ
10_1101-2020_09_02_279521	67	32	cortex	cortex	NN
10_1101-2020_09_02_279521	67	33	)	)	-RRB-
10_1101-2020_09_02_279521	67	34	,	,	,
10_1101-2020_09_02_279521	67	35	glucose	glucose	VB
10_1101-2020_09_02_279521	67	36	metabolism	metabolism	NN
10_1101-2020_09_02_279521	67	37	(	(	-LRB-
10_1101-2020_09_02_279521	67	38	average	average	JJ
10_1101-2020_09_02_279521	67	39	normalized	normalized	JJ
10_1101-2020_09_02_279521	67	40	FDG	FDG	NNP
10_1101-2020_09_02_279521	67	41	uptake	uptake	NN
10_1101-2020_09_02_279521	67	42	in	in	IN
10_1101-2020_09_02_279521	67	43	frontal	frontal	JJ
10_1101-2020_09_02_279521	67	44	cortex	cortex	NN
10_1101-2020_09_02_279521	67	45	,	,	,
10_1101-2020_09_02_279521	67	46	anterior	anterior	NNP
10_1101-2020_09_02_279521	67	47	cingulate	cingulate	NN
10_1101-2020_09_02_279521	67	48	,	,	,
10_1101-2020_09_02_279521	67	49	precuneus	precuneus	NN
10_1101-2020_09_02_279521	67	50	and	and	CC
10_1101-2020_09_02_279521	67	51	parietal	parietal	JJ
10_1101-2020_09_02_279521	67	52	cortex	cortex	NN
10_1101-2020_09_02_279521	67	53	)	)	-RRB-
10_1101-2020_09_02_279521	67	54	,	,	,
10_1101-2020_09_02_279521	67	55	for	for	IN
10_1101-2020_09_02_279521	67	56	hippocampal	hippocampal	NNP
10_1101-2020_09_02_279521	67	57	and	and	CC
10_1101-2020_09_02_279521	67	58	medial	medial	JJ
10_1101-2020_09_02_279521	67	59	temporal	temporal	JJ
10_1101-2020_09_02_279521	67	60	lobe	lobe	NN
10_1101-2020_09_02_279521	67	61	volumes	volume	NNS
10_1101-2020_09_02_279521	67	62	,	,	,
10_1101-2020_09_02_279521	67	63	and	and	CC
10_1101-2020_09_02_279521	67	64	for	for	IN
10_1101-2020_09_02_279521	67	65	the	the	DT
10_1101-2020_09_02_279521	67	66	cognitive	cognitive	JJ
10_1101-2020_09_02_279521	67	67	ability	ability	NN
10_1101-2020_09_02_279521	67	68	as	as	IN
10_1101-2020_09_02_279521	67	69	measured	measure	VBN
10_1101-2020_09_02_279521	67	70	by	by	IN
10_1101-2020_09_02_279521	67	71	ADAS11	ADAS11	NNP
10_1101-2020_09_02_279521	67	72	.	.	.
10_1101-2020_09_02_279521	68	1	Compatibly	compatibly	RB
10_1101-2020_09_02_279521	68	2	with	with	IN
10_1101-2020_09_02_279521	68	3	previously	previously	RB
10_1101-2020_09_02_279521	68	4	reported	report	VBN
10_1101-2020_09_02_279521	68	5	results	result	NNS
10_1101-2020_09_02_279521	68	6	(	(	-LRB-
10_1101-2020_09_02_279521	68	7	Cash	Cash	NNP
10_1101-2020_09_02_279521	68	8	et	et	FW
10_1101-2020_09_02_279521	68	9	al	al	NNP
10_1101-2020_09_02_279521	68	10	.	.	NNP
10_1101-2020_09_02_279521	68	11	,	,	,
10_1101-2020_09_02_279521	68	12	2015	2015	CD
10_1101-2020_09_02_279521	68	13	;	;	:
10_1101-2020_09_02_279521	68	14	Schuff	Schuff	NNP
10_1101-2020_09_02_279521	68	15	et	et	FW
10_1101-2020_09_02_279521	68	16	al	al	NNP
10_1101-2020_09_02_279521	68	17	.	.	NNP
10_1101-2020_09_02_279521	68	18	,	,	,
10_1101-2020_09_02_279521	68	19	2009	2009	CD
10_1101-2020_09_02_279521	68	20	)	)	-RRB-
10_1101-2020_09_02_279521	68	21	,	,	,
10_1101-2020_09_02_279521	68	22	we	-PRON-	PRP
10_1101-2020_09_02_279521	68	23	observe	observe	VBP
10_1101-2020_09_02_279521	68	24	that	that	IN
10_1101-2020_09_02_279521	68	25	while	while	IN
10_1101-2020_09_02_279521	68	26	regional	regional	JJ
10_1101-2020_09_02_279521	68	27	atrophy	atrophy	NN
10_1101-2020_09_02_279521	68	28	,	,	,
10_1101-2020_09_02_279521	68	29	glucose	glucose	VB
10_1101-2020_09_02_279521	68	30	metabolism	metabolism	NN
10_1101-2020_09_02_279521	68	31	and	and	CC
10_1101-2020_09_02_279521	68	32	cognition	cognition	NN
10_1101-2020_09_02_279521	68	33	show	show	NN
10_1101-2020_09_02_279521	68	34	increasing	increase	VBG
10_1101-2020_09_02_279521	68	35	rate	rate	NN
10_1101-2020_09_02_279521	68	36	of	of	IN
10_1101-2020_09_02_279521	68	37	change	change	NN
10_1101-2020_09_02_279521	68	38	when	when	WRB
10_1101-2020_09_02_279521	68	39	moving	move	VBG
10_1101-2020_09_02_279521	68	40	from	from	IN
10_1101-2020_09_02_279521	68	41	healthy	healthy	JJ
10_1101-2020_09_02_279521	68	42	to	to	IN
10_1101-2020_09_02_279521	68	43	pathological	pathological	JJ
10_1101-2020_09_02_279521	68	44	conditions	condition	NNS
10_1101-2020_09_02_279521	68	45	,	,	,
10_1101-2020_09_02_279521	68	46	the	the	DT
10_1101-2020_09_02_279521	68	47	change	change	NN
10_1101-2020_09_02_279521	68	48	of	of	IN
10_1101-2020_09_02_279521	68	49	AV45	AV45	NNP
10_1101-2020_09_02_279521	68	50	is	be	VBZ
10_1101-2020_09_02_279521	68	51	maximum	maximum	JJ
10_1101-2020_09_02_279521	68	52	in	in	IN
10_1101-2020_09_02_279521	68	53	NL	NL	NNP
10_1101-2020_09_02_279521	68	54	stable	stable	JJ
10_1101-2020_09_02_279521	68	55	,	,	,
10_1101-2020_09_02_279521	68	56	NL	NL	NNP
10_1101-2020_09_02_279521	68	57	converters	converter	NNS
10_1101-2020_09_02_279521	68	58	and	and	CC
10_1101-2020_09_02_279521	68	59	MCI	MCI	NNP
10_1101-2020_09_02_279521	68	60	stable	stable	JJ
10_1101-2020_09_02_279521	68	61	subjects	subject	NNS
10_1101-2020_09_02_279521	68	62	.	.	.
10_1101-2020_09_02_279521	69	1	We	-PRON-	PRP
10_1101-2020_09_02_279521	69	2	also	also	RB
10_1101-2020_09_02_279521	69	3	notice	notice	VBP
10_1101-2020_09_02_279521	69	4	the	the	DT
10_1101-2020_09_02_279521	69	5	increased	increased	JJ
10_1101-2020_09_02_279521	69	6	magnitude	magnitude	NN
10_1101-2020_09_02_279521	69	7	of	of	IN
10_1101-2020_09_02_279521	69	8	ADAS11	ADAS11	NNP
10_1101-2020_09_02_279521	69	9	in	in	IN
10_1101-2020_09_02_279521	69	10	AD	AD	NNP
10_1101-2020_09_02_279521	69	11	as	as	IN
10_1101-2020_09_02_279521	69	12	compared	compare	VBN
10_1101-2020_09_02_279521	69	13	to	to	IN
10_1101-2020_09_02_279521	69	14	the	the	DT
10_1101-2020_09_02_279521	69	15	other	other	JJ
10_1101-2020_09_02_279521	69	16	clinical	clinical	JJ
10_1101-2020_09_02_279521	69	17	groups	group	NNS
10_1101-2020_09_02_279521	69	18	.	.	.
10_1101-2020_09_02_279521	70	1	Finally	finally	RB
10_1101-2020_09_02_279521	70	2	,	,	,
10_1101-2020_09_02_279521	70	3	we	-PRON-	PRP
10_1101-2020_09_02_279521	70	4	note	note	VBP
10_1101-2020_09_02_279521	70	5	that	that	IN
10_1101-2020_09_02_279521	70	6	glucose	glucose	VBP
10_1101-2020_09_02_279521	70	7	metabolism	metabolism	NN
10_1101-2020_09_02_279521	70	8	and	and	CC
10_1101-2020_09_02_279521	70	9	regional	regional	JJ
10_1101-2020_09_02_279521	70	10	atrophy	atrophy	NN
10_1101-2020_09_02_279521	70	11	show	show	NN
10_1101-2020_09_02_279521	70	12	comparable	comparable	JJ
10_1101-2020_09_02_279521	70	13	magnitudes	magnitude	NNS
10_1101-2020_09_02_279521	70	14	of	of	IN
10_1101-2020_09_02_279521	70	15	change	change	NN
10_1101-2020_09_02_279521	70	16	.	.	.
10_1101-2020_09_02_279521	71	1	The	the	DT
10_1101-2020_09_02_279521	71	2	observations	observation	NNS
10_1101-2020_09_02_279521	71	3	presented	present	VBN
10_1101-2020_09_02_279521	71	4	in	in	IN
10_1101-2020_09_02_279521	71	5	Table	table	NN
10_1101-2020_09_02_279521	71	6	1	1	CD
10_1101-2020_09_02_279521	71	7	provide	provide	VB
10_1101-2020_09_02_279521	71	8	us	-PRON-	PRP
10_1101-2020_09_02_279521	71	9	with	with	IN
10_1101-2020_09_02_279521	71	10	a	a	DT
10_1101-2020_09_02_279521	71	11	coarse	coarse	JJ
10_1101-2020_09_02_279521	71	12	representation	representation	NN
10_1101-2020_09_02_279521	71	13	of	of	IN
10_1101-2020_09_02_279521	71	14	the	the	DT
10_1101-2020_09_02_279521	71	15	biomarkers	biomarker	NNS
10_1101-2020_09_02_279521	71	16	'	'	POS
10_1101-2020_09_02_279521	71	17	trajectories	trajectory	NNS
10_1101-2020_09_02_279521	71	18	characterizing	characterize	VBG
10_1101-2020_09_02_279521	71	19	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	71	20	’s	’s	POS
10_1101-2020_09_02_279521	71	21	disease	disease	NN
10_1101-2020_09_02_279521	71	22	.	.	.
10_1101-2020_09_02_279521	72	1	The	the	DT
10_1101-2020_09_02_279521	72	2	complexity	complexity	NN
10_1101-2020_09_02_279521	72	3	of	of	IN
10_1101-2020_09_02_279521	72	4	the	the	DT
10_1101-2020_09_02_279521	72	5	dynamical	dynamical	JJ
10_1101-2020_09_02_279521	72	6	changes	change	NNS
10_1101-2020_09_02_279521	72	7	we	-PRON-	PRP
10_1101-2020_09_02_279521	72	8	may	may	MD
10_1101-2020_09_02_279521	72	9	infer	infer	VB
10_1101-2020_09_02_279521	72	10	is	be	VBZ
10_1101-2020_09_02_279521	72	11	limited	limit	VBN
10_1101-2020_09_02_279521	72	12	,	,	,
10_1101-2020_09_02_279521	72	13	as	as	IN
10_1101-2020_09_02_279521	72	14	the	the	DT
10_1101-2020_09_02_279521	72	15	clinical	clinical	JJ
10_1101-2020_09_02_279521	72	16	stages	stage	NNS
10_1101-2020_09_02_279521	72	17	roughly	roughly	RB
10_1101-2020_09_02_279521	72	18	approximate	approximate	VBP
10_1101-2020_09_02_279521	72	19	a	a	DT
10_1101-2020_09_02_279521	72	20	temporal	temporal	JJ
10_1101-2020_09_02_279521	72	21	scale	scale	NN
10_1101-2020_09_02_279521	72	22	describing	describe	VBG
10_1101-2020_09_02_279521	72	23	the	the	DT
10_1101-2020_09_02_279521	72	24	disease	disease	NN
10_1101-2020_09_02_279521	72	25	history	history	NN
10_1101-2020_09_02_279521	72	26	,	,	,
10_1101-2020_09_02_279521	72	27	while	while	IN
10_1101-2020_09_02_279521	72	28	very	very	RB
10_1101-2020_09_02_279521	72	29	little	little	JJ
10_1101-2020_09_02_279521	72	30	insights	insight	NNS
10_1101-2020_09_02_279521	72	31	can	can	MD
10_1101-2020_09_02_279521	72	32	be	be	VB
10_1101-2020_09_02_279521	72	33	obtained	obtain	VBN
10_1101-2020_09_02_279521	72	34	about	about	IN
10_1101-2020_09_02_279521	72	35	the	the	DT
10_1101-2020_09_02_279521	72	36	biomarkers	biomarker	NNS
10_1101-2020_09_02_279521	72	37	'	'	POS
10_1101-2020_09_02_279521	72	38	interactions	interaction	NNS
10_1101-2020_09_02_279521	72	39	.	.	.
10_1101-2020_09_02_279521	73	1	Within	within	IN
10_1101-2020_09_02_279521	73	2	this	this	DT
10_1101-2020_09_02_279521	73	3	context	context	NN
10_1101-2020_09_02_279521	73	4	,	,	,
10_1101-2020_09_02_279521	73	5	our	-PRON-	PRP$
10_1101-2020_09_02_279521	73	6	model	model	NN
10_1101-2020_09_02_279521	73	7	allows	allow	VBZ
10_1101-2020_09_02_279521	73	8	the	the	DT
10_1101-2020_09_02_279521	73	9	quantification	quantification	NN
10_1101-2020_09_02_279521	73	10	of	of	IN
10_1101-2020_09_02_279521	73	11	the	the	DT
10_1101-2020_09_02_279521	73	12	fine	fine	RB
10_1101-2020_09_02_279521	73	13	-	-	HYPH
10_1101-2020_09_02_279521	73	14	grained	grain	VBN
10_1101-2020_09_02_279521	73	15	dynamical	dynamical	JJ
10_1101-2020_09_02_279521	73	16	relationships	relationship	NNS
10_1101-2020_09_02_279521	73	17	across	across	IN
10_1101-2020_09_02_279521	73	18	biomarkers	biomarker	NNS
10_1101-2020_09_02_279521	73	19	at	at	IN
10_1101-2020_09_02_279521	73	20	stake	stake	NN
10_1101-2020_09_02_279521	73	21	during	during	IN
10_1101-2020_09_02_279521	73	22	the	the	DT
10_1101-2020_09_02_279521	73	23	history	history	NN
10_1101-2020_09_02_279521	73	24	of	of	IN
10_1101-2020_09_02_279521	73	25	the	the	DT
10_1101-2020_09_02_279521	73	26	disease	disease	NN
10_1101-2020_09_02_279521	73	27	.	.	.
10_1101-2020_09_02_279521	74	1	Investigation	investigation	NN
10_1101-2020_09_02_279521	74	2	of	of	IN
10_1101-2020_09_02_279521	74	3	intervention	intervention	NN
10_1101-2020_09_02_279521	74	4	scenarios	scenario	NNS
10_1101-2020_09_02_279521	74	5	can	can	MD
10_1101-2020_09_02_279521	74	6	be	be	VB
10_1101-2020_09_02_279521	74	7	subsequently	subsequently	RB
10_1101-2020_09_02_279521	74	8	carried	carry	VBN
10_1101-2020_09_02_279521	74	9	out	out	RP
10_1101-2020_09_02_279521	74	10	by	by	IN
10_1101-2020_09_02_279521	74	11	opportunely	opportunely	RB
10_1101-2020_09_02_279521	74	12	modulating	modulate	VBG
10_1101-2020_09_02_279521	74	13	the	the	DT
10_1101-2020_09_02_279521	74	14	estimated	estimate	VBN
10_1101-2020_09_02_279521	74	15	dynamics	dynamic	NNS
10_1101-2020_09_02_279521	74	16	parameters	parameter	NNS
10_1101-2020_09_02_279521	74	17	according	accord	VBG
10_1101-2020_09_02_279521	74	18	to	to	IN
10_1101-2020_09_02_279521	74	19	specific	specific	JJ
10_1101-2020_09_02_279521	74	20	intervention	intervention	NN
10_1101-2020_09_02_279521	74	21	hypothesis	hypothesis	NN
10_1101-2020_09_02_279521	74	22	(	(	-LRB-
10_1101-2020_09_02_279521	74	23	e.g.	e.g.	RB
10_1101-2020_09_02_279521	75	1	amyloid	amyloid	NNP
10_1101-2020_09_02_279521	75	2	lowering	lower	VBG
10_1101-2020_09_02_279521	75	3	at	at	IN
10_1101-2020_09_02_279521	75	4	a	a	DT
10_1101-2020_09_02_279521	75	5	certain	certain	JJ
10_1101-2020_09_02_279521	75	6	time	time	NN
10_1101-2020_09_02_279521	75	7	)	)	-RRB-
10_1101-2020_09_02_279521	75	8	.	.	.
10_1101-2020_09_02_279521	76	1	Model	model	NN
10_1101-2020_09_02_279521	76	2	overview	overview	NN
10_1101-2020_09_02_279521	76	3	We	-PRON-	PRP
10_1101-2020_09_02_279521	76	4	provide	provide	VBP
10_1101-2020_09_02_279521	76	5	in	in	IN
10_1101-2020_09_02_279521	76	6	Figure	figure	NN
10_1101-2020_09_02_279521	76	7	1	1	CD
10_1101-2020_09_02_279521	76	8	an	an	DT
10_1101-2020_09_02_279521	76	9	overview	overview	NN
10_1101-2020_09_02_279521	76	10	of	of	IN
10_1101-2020_09_02_279521	76	11	the	the	DT
10_1101-2020_09_02_279521	76	12	presented	present	VBN
10_1101-2020_09_02_279521	76	13	method	method	NN
10_1101-2020_09_02_279521	76	14	.	.	.
10_1101-2020_09_02_279521	77	1	Baseline	Baseline	NNP
10_1101-2020_09_02_279521	77	2	multi	multi	JJ
10_1101-2020_09_02_279521	77	3	-	-	JJ
10_1101-2020_09_02_279521	77	4	modal	modal	JJ
10_1101-2020_09_02_279521	77	5	imaging	imaging	NN
10_1101-2020_09_02_279521	77	6	and	and	CC
10_1101-2020_09_02_279521	77	7	clinical	clinical	JJ
10_1101-2020_09_02_279521	77	8	information	information	NN
10_1101-2020_09_02_279521	77	9	for	for	IN
10_1101-2020_09_02_279521	77	10	a	a	DT
10_1101-2020_09_02_279521	77	11	given	give	VBN
10_1101-2020_09_02_279521	77	12	subject	subject	NN
10_1101-2020_09_02_279521	77	13	are	be	VBP
10_1101-2020_09_02_279521	77	14	transformed	transform	VBN
10_1101-2020_09_02_279521	77	15	into	into	IN
10_1101-2020_09_02_279521	77	16	a	a	DT
10_1101-2020_09_02_279521	77	17	latent	latent	NN
10_1101-2020_09_02_279521	77	18	variable	variable	NN
10_1101-2020_09_02_279521	77	19	composed	compose	VBN
10_1101-2020_09_02_279521	77	20	of	of	IN
10_1101-2020_09_02_279521	77	21	four	four	CD
10_1101-2020_09_02_279521	77	22	z	z	NN
10_1101-2020_09_02_279521	77	23	-	-	HYPH
10_1101-2020_09_02_279521	77	24	scores	score	NNS
10_1101-2020_09_02_279521	77	25	quantifying	quantify	VBG
10_1101-2020_09_02_279521	77	26	respectively	respectively	RB
10_1101-2020_09_02_279521	77	27	the	the	DT
10_1101-2020_09_02_279521	77	28	overall	overall	JJ
10_1101-2020_09_02_279521	77	29	severity	severity	NN
10_1101-2020_09_02_279521	77	30	of	of	IN
10_1101-2020_09_02_279521	77	31	atrophy	atrophy	NN
10_1101-2020_09_02_279521	77	32	,	,	,
10_1101-2020_09_02_279521	77	33	glucose	glucose	VB
10_1101-2020_09_02_279521	77	34	metabolism	metabolism	NN
10_1101-2020_09_02_279521	77	35	,	,	,
10_1101-2020_09_02_279521	77	36	amyloid	amyloid	NN
10_1101-2020_09_02_279521	77	37	burden	burden	NN
10_1101-2020_09_02_279521	77	38	,	,	,
10_1101-2020_09_02_279521	77	39	and	and	CC
10_1101-2020_09_02_279521	77	40	cognitive	cognitive	JJ
10_1101-2020_09_02_279521	77	41	and	and	CC
10_1101-2020_09_02_279521	77	42	functional	functional	JJ
10_1101-2020_09_02_279521	77	43	assessment	assessment	NN
10_1101-2020_09_02_279521	77	44	.	.	.
10_1101-2020_09_02_279521	78	1	The	the	DT
10_1101-2020_09_02_279521	78	2	model	model	NN
10_1101-2020_09_02_279521	78	3	estimates	estimate	VBZ
10_1101-2020_09_02_279521	78	4	the	the	DT
10_1101-2020_09_02_279521	78	5	dynamical	dynamical	JJ
10_1101-2020_09_02_279521	78	6	relationships	relationship	NNS
10_1101-2020_09_02_279521	78	7	across	across	IN
10_1101-2020_09_02_279521	78	8	these	these	DT
10_1101-2020_09_02_279521	78	9	z	z	NNS
10_1101-2020_09_02_279521	78	10	-	-	:
10_1101-2020_09_02_279521	78	11	scores	score	NNS
10_1101-2020_09_02_279521	78	12	to	to	TO
10_1101-2020_09_02_279521	78	13	optimally	optimally	RB
10_1101-2020_09_02_279521	78	14	describe	describe	VB
10_1101-2020_09_02_279521	78	15	the	the	DT
10_1101-2020_09_02_279521	78	16	temporal	temporal	JJ
10_1101-2020_09_02_279521	78	17	transitions	transition	NNS
10_1101-2020_09_02_279521	78	18	between	between	IN
10_1101-2020_09_02_279521	78	19	follow	follow	VB
10_1101-2020_09_02_279521	78	20	-	-	HYPH
10_1101-2020_09_02_279521	78	21	up	up	RP
10_1101-2020_09_02_279521	78	22	observations	observation	NNS
10_1101-2020_09_02_279521	78	23	.	.	.
10_1101-2020_09_02_279521	79	1	These	these	DT
10_1101-2020_09_02_279521	79	2	transition	transition	NN
10_1101-2020_09_02_279521	79	3	rules	rule	NNS
10_1101-2020_09_02_279521	79	4	are	be	VBP
10_1101-2020_09_02_279521	79	5	here	here	RB
10_1101-2020_09_02_279521	79	6	mathematically	mathematically	RB
10_1101-2020_09_02_279521	79	7	defined	define	VBN
10_1101-2020_09_02_279521	79	8	by	by	IN
10_1101-2020_09_02_279521	79	9	the	the	DT
10_1101-2020_09_02_279521	79	10	.CC	.CC	:
10_1101-2020_09_02_279521	79	11	-	-	:
10_1101-2020_09_02_279521	79	12	BY	by	IN
10_1101-2020_09_02_279521	79	13	4.0	4.0	CD
10_1101-2020_09_02_279521	79	14	International	international	JJ
10_1101-2020_09_02_279521	79	15	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	79	16	.	.	.
10_1101-2020_09_02_279521	80	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	80	2	is	be	VBZ
10_1101-2020_09_02_279521	80	3	made	make	VBN
10_1101-2020_09_02_279521	80	4	available	available	JJ
10_1101-2020_09_02_279521	80	5	under	under	IN
10_1101-2020_09_02_279521	80	6	a	a	DT
10_1101-2020_09_02_279521	80	7	preprint	preprint	NN
10_1101-2020_09_02_279521	80	8	(	(	-LRB-
10_1101-2020_09_02_279521	80	9	which	which	WDT
10_1101-2020_09_02_279521	80	10	was	be	VBD
10_1101-2020_09_02_279521	80	11	not	not	RB
10_1101-2020_09_02_279521	80	12	certified	certify	VBN
10_1101-2020_09_02_279521	80	13	by	by	IN
10_1101-2020_09_02_279521	80	14	peer	peer	NN
10_1101-2020_09_02_279521	80	15	review	review	NN
10_1101-2020_09_02_279521	80	16	)	)	-RRB-
10_1101-2020_09_02_279521	80	17	is	be	VBZ
10_1101-2020_09_02_279521	80	18	the	the	DT
10_1101-2020_09_02_279521	80	19	author	author	NN
10_1101-2020_09_02_279521	80	20	/	/	SYM
10_1101-2020_09_02_279521	80	21	funder	funder	NN
10_1101-2020_09_02_279521	80	22	,	,	,
10_1101-2020_09_02_279521	80	23	who	who	WP
10_1101-2020_09_02_279521	80	24	has	have	VBZ
10_1101-2020_09_02_279521	80	25	granted	grant	VBN
10_1101-2020_09_02_279521	80	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	80	27	a	a	DT
10_1101-2020_09_02_279521	80	28	license	license	NN
10_1101-2020_09_02_279521	80	29	to	to	TO
10_1101-2020_09_02_279521	80	30	display	display	VB
10_1101-2020_09_02_279521	80	31	the	the	DT
10_1101-2020_09_02_279521	80	32	preprint	preprint	NN
10_1101-2020_09_02_279521	80	33	in	in	IN
10_1101-2020_09_02_279521	80	34	The	the	DT
10_1101-2020_09_02_279521	80	35	copyright	copyright	NN
10_1101-2020_09_02_279521	80	36	holder	holder	NN
10_1101-2020_09_02_279521	80	37	for	for	IN
10_1101-2020_09_02_279521	80	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	80	39	version	version	NN
10_1101-2020_09_02_279521	80	40	posted	post	VBD
10_1101-2020_09_02_279521	80	41	February	February	NNP
10_1101-2020_09_02_279521	80	42	10	10	CD
10_1101-2020_09_02_279521	80	43	,	,	,
10_1101-2020_09_02_279521	80	44	2021	2021	CD
10_1101-2020_09_02_279521	80	45	.	.	.
10_1101-2020_09_02_279521	80	46	;	;	:
10_1101-2020_09_02_279521	80	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	80	48	:	:	:
10_1101-2020_09_02_279521	80	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	80	50	preprint	preprint	NN
10_1101-2020_09_02_279521	80	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	NN
10_1101-2020_09_02_279521	80	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	-LRB-
10_1101-2020_09_02_279521	80	53	parameters	parameter	NNS
10_1101-2020_09_02_279521	80	54	of	of	IN
10_1101-2020_09_02_279521	80	55	a	a	DT
10_1101-2020_09_02_279521	80	56	system	system	NN
10_1101-2020_09_02_279521	80	57	of	of	IN
10_1101-2020_09_02_279521	80	58	ODEs	ode	NNS
10_1101-2020_09_02_279521	80	59	,	,	,
10_1101-2020_09_02_279521	80	60	which	which	WDT
10_1101-2020_09_02_279521	80	61	is	be	VBZ
10_1101-2020_09_02_279521	80	62	estimated	estimate	VBN
10_1101-2020_09_02_279521	80	63	from	from	IN
10_1101-2020_09_02_279521	80	64	the	the	DT
10_1101-2020_09_02_279521	80	65	data	datum	NNS
10_1101-2020_09_02_279521	80	66	.	.	.
10_1101-2020_09_02_279521	81	1	This	this	DT
10_1101-2020_09_02_279521	81	2	dynamical	dynamical	JJ
10_1101-2020_09_02_279521	81	3	system	system	NN
10_1101-2020_09_02_279521	81	4	allows	allow	VBZ
10_1101-2020_09_02_279521	81	5	to	to	TO
10_1101-2020_09_02_279521	81	6	compute	compute	VB
10_1101-2020_09_02_279521	81	7	the	the	DT
10_1101-2020_09_02_279521	81	8	evolution	evolution	NN
10_1101-2020_09_02_279521	81	9	of	of	IN
10_1101-2020_09_02_279521	81	10	the	the	DT
10_1101-2020_09_02_279521	81	11	z	z	NN
10_1101-2020_09_02_279521	81	12	-	-	:
10_1101-2020_09_02_279521	81	13	scores	score	NNS
10_1101-2020_09_02_279521	81	14	over	over	IN
10_1101-2020_09_02_279521	81	15	time	time	NN
10_1101-2020_09_02_279521	81	16	from	from	IN
10_1101-2020_09_02_279521	81	17	any	any	DT
10_1101-2020_09_02_279521	81	18	baseline	baseline	JJ
10_1101-2020_09_02_279521	81	19	observation	observation	NN
10_1101-2020_09_02_279521	81	20	,	,	,
10_1101-2020_09_02_279521	81	21	and	and	CC
10_1101-2020_09_02_279521	81	22	to	to	TO
10_1101-2020_09_02_279521	81	23	predict	predict	VB
10_1101-2020_09_02_279521	81	24	the	the	DT
10_1101-2020_09_02_279521	81	25	associated	associate	VBN
10_1101-2020_09_02_279521	81	26	multi	multi	JJ
10_1101-2020_09_02_279521	81	27	-	-	JJ
10_1101-2020_09_02_279521	81	28	modal	modal	JJ
10_1101-2020_09_02_279521	81	29	imaging	imaging	NN
10_1101-2020_09_02_279521	81	30	and	and	CC
10_1101-2020_09_02_279521	81	31	clinical	clinical	JJ
10_1101-2020_09_02_279521	81	32	measures	measure	NNS
10_1101-2020_09_02_279521	81	33	.	.	.
10_1101-2020_09_02_279521	82	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	82	2	is	be	VBZ
10_1101-2020_09_02_279521	82	3	important	important	JJ
10_1101-2020_09_02_279521	82	4	to	to	TO
10_1101-2020_09_02_279521	82	5	note	note	VB
10_1101-2020_09_02_279521	82	6	that	that	IN
10_1101-2020_09_02_279521	82	7	this	this	DT
10_1101-2020_09_02_279521	82	8	modelling	modelling	NN
10_1101-2020_09_02_279521	82	9	choice	choice	NN
10_1101-2020_09_02_279521	82	10	requires	require	VBZ
10_1101-2020_09_02_279521	82	11	to	to	TO
10_1101-2020_09_02_279521	82	12	have	have	VB
10_1101-2020_09_02_279521	82	13	at	at	RB
10_1101-2020_09_02_279521	82	14	least	least	RBS
10_1101-2020_09_02_279521	82	15	one	one	CD
10_1101-2020_09_02_279521	82	16	visit	visit	NN
10_1101-2020_09_02_279521	82	17	per	per	IN
10_1101-2020_09_02_279521	82	18	patient	patient	NN
10_1101-2020_09_02_279521	82	19	for	for	IN
10_1101-2020_09_02_279521	82	20	which	which	WDT
10_1101-2020_09_02_279521	82	21	all	all	PDT
10_1101-2020_09_02_279521	82	22	the	the	DT
10_1101-2020_09_02_279521	82	23	measures	measure	NNS
10_1101-2020_09_02_279521	82	24	are	be	VBP
10_1101-2020_09_02_279521	82	25	available	available	JJ
10_1101-2020_09_02_279521	82	26	,	,	,
10_1101-2020_09_02_279521	82	27	in	in	IN
10_1101-2020_09_02_279521	82	28	order	order	NN
10_1101-2020_09_02_279521	82	29	to	to	TO
10_1101-2020_09_02_279521	82	30	compute	compute	VB
10_1101-2020_09_02_279521	82	31	the	the	DT
10_1101-2020_09_02_279521	82	32	z	z	NN
10_1101-2020_09_02_279521	82	33	-	-	HYPH
10_1101-2020_09_02_279521	82	34	scores	score	NNS
10_1101-2020_09_02_279521	82	35	temporal	temporal	JJ
10_1101-2020_09_02_279521	82	36	evolution	evolution	NN
10_1101-2020_09_02_279521	82	37	.	.	.
10_1101-2020_09_02_279521	83	1	Table1	Table1	NNP
10_1101-2020_09_02_279521	83	2	A	a	DT
10_1101-2020_09_02_279521	83	3	:	:	:
10_1101-2020_09_02_279521	83	4	Baseline	Baseline	NNP
10_1101-2020_09_02_279521	83	5	socio	socio	JJ
10_1101-2020_09_02_279521	83	6	-	-	HYPH
10_1101-2020_09_02_279521	83	7	demographic	demographic	JJ
10_1101-2020_09_02_279521	83	8	information	information	NN
10_1101-2020_09_02_279521	83	9	for	for	IN
10_1101-2020_09_02_279521	83	10	training	train	VBG
10_1101-2020_09_02_279521	83	11	cohort	cohort	NN
10_1101-2020_09_02_279521	83	12	(	(	-LRB-
10_1101-2020_09_02_279521	83	13	442	442	CD
10_1101-2020_09_02_279521	83	14	subjects	subject	NNS
10_1101-2020_09_02_279521	83	15	for	for	IN
10_1101-2020_09_02_279521	83	16	2781	2781	CD
10_1101-2020_09_02_279521	83	17	data	datum	NNS
10_1101-2020_09_02_279521	83	18	points	point	NNS
10_1101-2020_09_02_279521	83	19	,	,	,
10_1101-2020_09_02_279521	83	20	follow	follow	NN
10_1101-2020_09_02_279521	83	21	-	-	HYPH
10_1101-2020_09_02_279521	83	22	up	up	NN
10_1101-2020_09_02_279521	83	23	from	from	IN
10_1101-2020_09_02_279521	83	24	0	0	CD
10_1101-2020_09_02_279521	83	25	to	to	IN
10_1101-2020_09_02_279521	83	26	16	16	CD
10_1101-2020_09_02_279521	83	27	years	year	NNS
10_1101-2020_09_02_279521	83	28	depending	depend	VBG
10_1101-2020_09_02_279521	83	29	on	on	IN
10_1101-2020_09_02_279521	83	30	subjects	subject	NNS
10_1101-2020_09_02_279521	83	31	)	)	-RRB-
10_1101-2020_09_02_279521	83	32	.	.	.
10_1101-2020_09_02_279521	84	1	Average	average	JJ
10_1101-2020_09_02_279521	84	2	values	value	NNS
10_1101-2020_09_02_279521	84	3	,	,	,
10_1101-2020_09_02_279521	84	4	standard	standard	JJ
10_1101-2020_09_02_279521	84	5	deviation	deviation	NN
10_1101-2020_09_02_279521	84	6	in	in	IN
10_1101-2020_09_02_279521	84	7	parenthesis	parenthesis	NN
10_1101-2020_09_02_279521	84	8	.	.	.
10_1101-2020_09_02_279521	85	1	B	b	NN
10_1101-2020_09_02_279521	85	2	:	:	:
10_1101-2020_09_02_279521	85	3	Baseline	baseline	JJ
10_1101-2020_09_02_279521	85	4	values	value	NNS
10_1101-2020_09_02_279521	85	5	(	(	-LRB-
10_1101-2020_09_02_279521	85	6	bl	bl	NNP
10_1101-2020_09_02_279521	85	7	)	)	-RRB-
10_1101-2020_09_02_279521	85	8	and	and	CC
10_1101-2020_09_02_279521	85	9	annual	annual	JJ
10_1101-2020_09_02_279521	85	10	rates	rate	NNS
10_1101-2020_09_02_279521	85	11	of	of	IN
10_1101-2020_09_02_279521	85	12	change	change	NN
10_1101-2020_09_02_279521	85	13	(	(	-LRB-
10_1101-2020_09_02_279521	85	14	\%	\%	NNP
10_1101-2020_09_02_279521	85	15	change	change	NNP
10_1101-2020_09_02_279521	85	16	/	/	SYM
10_1101-2020_09_02_279521	85	17	year	year	NN
10_1101-2020_09_02_279521	85	18	)	)	-RRB-
10_1101-2020_09_02_279521	85	19	of	of	IN
10_1101-2020_09_02_279521	85	20	amyloid	amyloid	NN
10_1101-2020_09_02_279521	85	21	burden	burden	NNP
10_1101-2020_09_02_279521	85	22	(	(	-LRB-
10_1101-2020_09_02_279521	85	23	average	average	JJ
10_1101-2020_09_02_279521	85	24	normalized	normalized	JJ
10_1101-2020_09_02_279521	85	25	AV45	AV45	NNP
10_1101-2020_09_02_279521	85	26	uptake	uptake	NN
10_1101-2020_09_02_279521	85	27	in	in	IN
10_1101-2020_09_02_279521	85	28	frontal	frontal	JJ
10_1101-2020_09_02_279521	85	29	cortex	cortex	NN
10_1101-2020_09_02_279521	85	30	,	,	,
10_1101-2020_09_02_279521	85	31	anterior	anterior	NNP
10_1101-2020_09_02_279521	85	32	cingulate	cingulate	NN
10_1101-2020_09_02_279521	85	33	,	,	,
10_1101-2020_09_02_279521	85	34	precuneus	precuneus	NN
10_1101-2020_09_02_279521	85	35	and	and	CC
10_1101-2020_09_02_279521	85	36	parietal	parietal	JJ
10_1101-2020_09_02_279521	85	37	cortex	cortex	NN
10_1101-2020_09_02_279521	85	38	)	)	-RRB-
10_1101-2020_09_02_279521	85	39	,	,	,
10_1101-2020_09_02_279521	85	40	glucose	glucose	VB
10_1101-2020_09_02_279521	85	41	metabolism	metabolism	NN
10_1101-2020_09_02_279521	85	42	(	(	-LRB-
10_1101-2020_09_02_279521	85	43	average	average	JJ
10_1101-2020_09_02_279521	85	44	normalized	normalized	JJ
10_1101-2020_09_02_279521	85	45	FDG	FDG	NNP
10_1101-2020_09_02_279521	85	46	uptake	uptake	NN
10_1101-2020_09_02_279521	85	47	in	in	IN
10_1101-2020_09_02_279521	85	48	frontal	frontal	JJ
10_1101-2020_09_02_279521	85	49	cortex	cortex	NN
10_1101-2020_09_02_279521	85	50	,	,	,
10_1101-2020_09_02_279521	85	51	anterior	anterior	NNP
10_1101-2020_09_02_279521	85	52	cingulate	cingulate	NN
10_1101-2020_09_02_279521	85	53	,	,	,
10_1101-2020_09_02_279521	85	54	precuneus	precuneus	NN
10_1101-2020_09_02_279521	85	55	and	and	CC
10_1101-2020_09_02_279521	85	56	parietal	parietal	JJ
10_1101-2020_09_02_279521	85	57	cortex	cortex	NN
10_1101-2020_09_02_279521	85	58	)	)	-RRB-
10_1101-2020_09_02_279521	85	59	,	,	,
10_1101-2020_09_02_279521	85	60	hippocampus	hippocampus	NNP
10_1101-2020_09_02_279521	85	61	volume	volume	NN
10_1101-2020_09_02_279521	85	62	,	,	,
10_1101-2020_09_02_279521	85	63	medial	medial	JJ
10_1101-2020_09_02_279521	85	64	temporal	temporal	JJ
10_1101-2020_09_02_279521	85	65	lobe	lobe	NN
10_1101-2020_09_02_279521	85	66	volume	volume	NN
10_1101-2020_09_02_279521	85	67	,	,	,
10_1101-2020_09_02_279521	85	68	and	and	CC
10_1101-2020_09_02_279521	85	69	ADAS11	adas11	NN
10_1101-2020_09_02_279521	85	70	score	score	NN
10_1101-2020_09_02_279521	85	71	for	for	IN
10_1101-2020_09_02_279521	85	72	the	the	DT
10_1101-2020_09_02_279521	85	73	different	different	JJ
10_1101-2020_09_02_279521	85	74	clinical	clinical	JJ
10_1101-2020_09_02_279521	85	75	groups	group	NNS
10_1101-2020_09_02_279521	85	76	.	.	.
10_1101-2020_09_02_279521	86	1	Median	median	JJ
10_1101-2020_09_02_279521	86	2	values	value	NNS
10_1101-2020_09_02_279521	86	3	,	,	,
10_1101-2020_09_02_279521	86	4	interquartile	interquartile	NN
10_1101-2020_09_02_279521	86	5	range	range	NN
10_1101-2020_09_02_279521	86	6	below	below	RB
10_1101-2020_09_02_279521	86	7	.	.	.
10_1101-2020_09_02_279521	87	1	The	the	DT
10_1101-2020_09_02_279521	87	2	volumes	volume	NNS
10_1101-2020_09_02_279521	87	3	of	of	IN
10_1101-2020_09_02_279521	87	4	the	the	DT
10_1101-2020_09_02_279521	87	5	hippocampus	hippocampus	NN
10_1101-2020_09_02_279521	87	6	and	and	CC
10_1101-2020_09_02_279521	87	7	the	the	DT
10_1101-2020_09_02_279521	87	8	medial	medial	JJ
10_1101-2020_09_02_279521	87	9	temporal	temporal	JJ
10_1101-2020_09_02_279521	87	10	lobe	lobe	NN
10_1101-2020_09_02_279521	87	11	are	be	VBP
10_1101-2020_09_02_279521	87	12	averaged	average	VBN
10_1101-2020_09_02_279521	87	13	across	across	IN
10_1101-2020_09_02_279521	87	14	left	left	JJ
10_1101-2020_09_02_279521	87	15	and	and	CC
10_1101-2020_09_02_279521	87	16	right	right	JJ
10_1101-2020_09_02_279521	87	17	hemispheres	hemisphere	NNS
10_1101-2020_09_02_279521	87	18	.	.	.
10_1101-2020_09_02_279521	88	1	NL	NL	NNP
10_1101-2020_09_02_279521	88	2	:	:	:
10_1101-2020_09_02_279521	88	3	healthy	healthy	JJ
10_1101-2020_09_02_279521	88	4	individuals	individual	NNS
10_1101-2020_09_02_279521	88	5	,	,	,
10_1101-2020_09_02_279521	88	6	MCI	MCI	NNP
10_1101-2020_09_02_279521	88	7	:	:	:
10_1101-2020_09_02_279521	88	8	individuals	individual	NNS
10_1101-2020_09_02_279521	88	9	with	with	IN
10_1101-2020_09_02_279521	88	10	mild	mild	JJ
10_1101-2020_09_02_279521	88	11	cognitive	cognitive	JJ
10_1101-2020_09_02_279521	88	12	impairment	impairment	NN
10_1101-2020_09_02_279521	88	13	,	,	,
10_1101-2020_09_02_279521	88	14	AD	ad	NN
10_1101-2020_09_02_279521	88	15	:	:	:
10_1101-2020_09_02_279521	88	16	patients	patient	NNS
10_1101-2020_09_02_279521	88	17	with	with	IN
10_1101-2020_09_02_279521	88	18	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	88	19	's	's	POS
10_1101-2020_09_02_279521	88	20	dementia	dementia	NN
10_1101-2020_09_02_279521	88	21	.	.	.
10_1101-2020_09_02_279521	89	1	APOE4	apoe4	RB
10_1101-2020_09_02_279521	89	2	:	:	:
10_1101-2020_09_02_279521	89	3	apolipoprotein	apolipoprotein	NNP
10_1101-2020_09_02_279521	89	4	E	E	NNP
10_1101-2020_09_02_279521	89	5	ε4	ε4	NN
10_1101-2020_09_02_279521	89	6	.	.	.
10_1101-2020_09_02_279521	90	1	FDG	FDG	NNP
10_1101-2020_09_02_279521	90	2	:	:	:
10_1101-2020_09_02_279521	90	3	(	(	-LRB-
10_1101-2020_09_02_279521	90	4	18)F	18)f	NN
10_1101-2020_09_02_279521	90	5	-	-	HYPH
10_1101-2020_09_02_279521	90	6	fluorodeoxyglucose	fluorodeoxyglucose	NN
10_1101-2020_09_02_279521	90	7	Positron	Positron	NNP
10_1101-2020_09_02_279521	90	8	Emission	Emission	NNP
10_1101-2020_09_02_279521	90	9	Tomography	Tomography	NNP
10_1101-2020_09_02_279521	90	10	(	(	-LRB-
10_1101-2020_09_02_279521	90	11	PET	PET	NNP
10_1101-2020_09_02_279521	90	12	)	)	-RRB-
10_1101-2020_09_02_279521	90	13	imaging	imaging	NN
10_1101-2020_09_02_279521	90	14	.	.	.
10_1101-2020_09_02_279521	91	1	AV45	av45	NN
10_1101-2020_09_02_279521	91	2	:	:	:
10_1101-2020_09_02_279521	91	3	(	(	-LRB-
10_1101-2020_09_02_279521	91	4	18)F	18)f	JJ
10_1101-2020_09_02_279521	91	5	-	-	HYPH
10_1101-2020_09_02_279521	91	6	florbetapir	florbetapir	NN
10_1101-2020_09_02_279521	91	7	Amyloid	Amyloid	NNP
10_1101-2020_09_02_279521	91	8	PET	PET	NNP
10_1101-2020_09_02_279521	91	9	imaging	imaging	NN
10_1101-2020_09_02_279521	91	10	.	.	.
10_1101-2020_09_02_279521	92	1	SUVR	SUVR	NNP
10_1101-2020_09_02_279521	92	2	:	:	:
10_1101-2020_09_02_279521	92	3	Standardized	standardize	VBN
10_1101-2020_09_02_279521	92	4	Uptake	Uptake	NNP
10_1101-2020_09_02_279521	92	5	Value	Value	NNP
10_1101-2020_09_02_279521	92	6	Ratio	Ratio	NNP
10_1101-2020_09_02_279521	92	7	.	.	.
10_1101-2020_09_02_279521	93	1	MTL	MTL	NNP
10_1101-2020_09_02_279521	93	2	:	:	:
10_1101-2020_09_02_279521	93	3	Medial	Medial	NNP
10_1101-2020_09_02_279521	93	4	Temporal	Temporal	NNP
10_1101-2020_09_02_279521	93	5	Lobe	Lobe	NNP
10_1101-2020_09_02_279521	93	6	.	.	.
10_1101-2020_09_02_279521	94	1	ADAS11	adas11	NN
10_1101-2020_09_02_279521	94	2	:	:	:
10_1101-2020_09_02_279521	94	3	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	94	4	's	's	POS
10_1101-2020_09_02_279521	94	5	Disease	Disease	NNP
10_1101-2020_09_02_279521	94	6	Assessment	Assessment	NNP
10_1101-2020_09_02_279521	94	7	Scale	Scale	NNP
10_1101-2020_09_02_279521	94	8	-	-	HYPH
10_1101-2020_09_02_279521	94	9	cognitive	cognitive	JJ
10_1101-2020_09_02_279521	94	10	subscale	subscale	NN
10_1101-2020_09_02_279521	94	11	,	,	,
10_1101-2020_09_02_279521	94	12	11	11	CD
10_1101-2020_09_02_279521	94	13	items	item	NNS
10_1101-2020_09_02_279521	94	14	.	.	.
10_1101-2020_09_02_279521	95	1	A	a	DT
10_1101-2020_09_02_279521	95	2	:	:	:
10_1101-2020_09_02_279521	95	3	Socio	Socio	NNP
10_1101-2020_09_02_279521	95	4	-	-	HYPH
10_1101-2020_09_02_279521	95	5	demographics	demographic	NNS
10_1101-2020_09_02_279521	95	6	NL	NL	NNP
10_1101-2020_09_02_279521	95	7	NL	NL	NNP
10_1101-2020_09_02_279521	95	8	MCI	MCI	NNP
10_1101-2020_09_02_279521	95	9	MCI	MCI	NNP
10_1101-2020_09_02_279521	95	10	AD	ad	NN
10_1101-2020_09_02_279521	95	11	stable	stable	JJ
10_1101-2020_09_02_279521	95	12	converters	converter	NNS
10_1101-2020_09_02_279521	95	13	stable	stable	JJ
10_1101-2020_09_02_279521	95	14	converters	converter	NNS
10_1101-2020_09_02_279521	95	15	N	n	CD
10_1101-2020_09_02_279521	95	16	71	71	CD
10_1101-2020_09_02_279521	95	17	33	33	CD
10_1101-2020_09_02_279521	95	18	131	131	CD
10_1101-2020_09_02_279521	95	19	105	105	CD
10_1101-2020_09_02_279521	95	20	102	102	CD
10_1101-2020_09_02_279521	95	21	Age	Age	NNP
10_1101-2020_09_02_279521	95	22	(	(	-LRB-
10_1101-2020_09_02_279521	95	23	yrs	yrs	NN
10_1101-2020_09_02_279521	95	24	)	)	-RRB-
10_1101-2020_09_02_279521	95	25	74	74	CD
10_1101-2020_09_02_279521	95	26	(	(	-LRB-
10_1101-2020_09_02_279521	95	27	6	6	CD
10_1101-2020_09_02_279521	95	28	)	)	-RRB-
10_1101-2020_09_02_279521	95	29	76	76	CD
10_1101-2020_09_02_279521	95	30	(	(	-LRB-
10_1101-2020_09_02_279521	95	31	4	4	CD
10_1101-2020_09_02_279521	95	32	)	)	-RRB-
10_1101-2020_09_02_279521	95	33	72	72	CD
10_1101-2020_09_02_279521	95	34	(	(	-LRB-
10_1101-2020_09_02_279521	95	35	8)	8)	CD
10_1101-2020_09_02_279521	95	36	73	73	CD
10_1101-2020_09_02_279521	95	37	(	(	-LRB-
10_1101-2020_09_02_279521	95	38	7	7	CD
10_1101-2020_09_02_279521	95	39	)	)	-RRB-
10_1101-2020_09_02_279521	95	40	74	74	CD
10_1101-2020_09_02_279521	95	41	(	(	-LRB-
10_1101-2020_09_02_279521	95	42	8)	8)	CD
10_1101-2020_09_02_279521	95	43	Education	Education	NNP
10_1101-2020_09_02_279521	95	44	(	(	-LRB-
10_1101-2020_09_02_279521	95	45	yrs	yrs	NN
10_1101-2020_09_02_279521	95	46	)	)	-RRB-
10_1101-2020_09_02_279521	95	47	16	16	CD
10_1101-2020_09_02_279521	95	48	(	(	-LRB-
10_1101-2020_09_02_279521	95	49	2	2	CD
10_1101-2020_09_02_279521	95	50	)	)	-RRB-
10_1101-2020_09_02_279521	95	51	17	17	CD
10_1101-2020_09_02_279521	95	52	(	(	-LRB-
10_1101-2020_09_02_279521	95	53	2	2	CD
10_1101-2020_09_02_279521	95	54	)	)	-RRB-
10_1101-2020_09_02_279521	95	55	16	16	CD
10_1101-2020_09_02_279521	95	56	(	(	-LRB-
10_1101-2020_09_02_279521	95	57	3	3	CD
10_1101-2020_09_02_279521	95	58	)	)	-RRB-
10_1101-2020_09_02_279521	95	59	16	16	CD
10_1101-2020_09_02_279521	95	60	(	(	-LRB-
10_1101-2020_09_02_279521	95	61	3	3	CD
10_1101-2020_09_02_279521	95	62	)	)	-RRB-
10_1101-2020_09_02_279521	95	63	16	16	CD
10_1101-2020_09_02_279521	95	64	(	(	-LRB-
10_1101-2020_09_02_279521	95	65	2	2	CD
10_1101-2020_09_02_279521	95	66	)	)	-RRB-
10_1101-2020_09_02_279521	95	67	APOE4-carrier	apoe4-carrier	NN
10_1101-2020_09_02_279521	95	68	(	(	-LRB-
10_1101-2020_09_02_279521	95	69	%	%	NN
10_1101-2020_09_02_279521	95	70	)	)	-RRB-
10_1101-2020_09_02_279521	95	71	41	41	CD
10_1101-2020_09_02_279521	95	72	51	51	CD
10_1101-2020_09_02_279521	95	73	61	61	CD
10_1101-2020_09_02_279521	95	74	75	75	CD
10_1101-2020_09_02_279521	95	75	71	71	CD
10_1101-2020_09_02_279521	95	76	B	b	NN
10_1101-2020_09_02_279521	95	77	:	:	:
10_1101-2020_09_02_279521	95	78	Biomarkers	biomarker	NNS
10_1101-2020_09_02_279521	95	79	and	and	CC
10_1101-2020_09_02_279521	95	80	rates	rate	NNS
10_1101-2020_09_02_279521	95	81	of	of	IN
10_1101-2020_09_02_279521	95	82	change	change	NN
10_1101-2020_09_02_279521	95	83	NL	NL	NNP
10_1101-2020_09_02_279521	95	84	NL	NL	NNP
10_1101-2020_09_02_279521	95	85	MCI	MCI	NNP
10_1101-2020_09_02_279521	95	86	MCI	MCI	NNP
10_1101-2020_09_02_279521	95	87	AD	ad	NN
10_1101-2020_09_02_279521	95	88	stable	stable	JJ
10_1101-2020_09_02_279521	95	89	converters	converter	NNS
10_1101-2020_09_02_279521	95	90	stable	stable	JJ
10_1101-2020_09_02_279521	95	91	converters	converter	NNS
10_1101-2020_09_02_279521	95	92	bl	bl	NNP
10_1101-2020_09_02_279521	95	93	%	%	NN
10_1101-2020_09_02_279521	95	94	change	change	NN
10_1101-2020_09_02_279521	95	95	/	/	SYM
10_1101-2020_09_02_279521	95	96	bl	bl	NNP
10_1101-2020_09_02_279521	95	97	%	%	NN
10_1101-2020_09_02_279521	95	98	change	change	NN
10_1101-2020_09_02_279521	95	99	/	/	SYM
10_1101-2020_09_02_279521	95	100	bl	bl	NNP
10_1101-2020_09_02_279521	95	101	%	%	NN
10_1101-2020_09_02_279521	95	102	change	change	NN
10_1101-2020_09_02_279521	95	103	/	/	SYM
10_1101-2020_09_02_279521	95	104	bl	bl	NNP
10_1101-2020_09_02_279521	95	105	%	%	NN
10_1101-2020_09_02_279521	95	106	change	change	NN
10_1101-2020_09_02_279521	95	107	/	/	SYM
10_1101-2020_09_02_279521	95	108	bl	bl	NNP
10_1101-2020_09_02_279521	95	109	%	%	NN
10_1101-2020_09_02_279521	95	110	change	change	NN
10_1101-2020_09_02_279521	95	111	/	/	SYM
10_1101-2020_09_02_279521	95	112	year	year	NNP
10_1101-2020_09_02_279521	95	113	year	year	NNP
10_1101-2020_09_02_279521	95	114	year	year	NNP
10_1101-2020_09_02_279521	95	115	year	year	NNP
10_1101-2020_09_02_279521	95	116	year	year	NN
10_1101-2020_09_02_279521	95	117	Global	Global	NNP
10_1101-2020_09_02_279521	95	118	AV45	AV45	NNP
10_1101-2020_09_02_279521	95	119	1.21	1.21	CD
10_1101-2020_09_02_279521	95	120	0.80	0.80	CD
10_1101-2020_09_02_279521	95	121	1.36	1.36	CD
10_1101-2020_09_02_279521	95	122	1.24	1.24	CD
10_1101-2020_09_02_279521	95	123	1.27	1.27	CD
10_1101-2020_09_02_279521	95	124	1.21	1.21	CD
10_1101-2020_09_02_279521	95	125	1.41	1.41	CD
10_1101-2020_09_02_279521	95	126	0.03	0.03	CD
10_1101-2020_09_02_279521	95	127	1.45	1.45	CD
10_1101-2020_09_02_279521	95	128	0.06	0.06	CD
10_1101-2020_09_02_279521	95	129	(	(	-LRB-
10_1101-2020_09_02_279521	95	130	SUVR	SUVR	NNP
10_1101-2020_09_02_279521	95	131	)	)	-RRB-
10_1101-2020_09_02_279521	95	132	[	[	-LRB-
10_1101-2020_09_02_279521	95	133	1.06	1.06	CD
10_1101-2020_09_02_279521	95	134	;	;	:
10_1101-2020_09_02_279521	95	135	1.37	1.37	CD
10_1101-2020_09_02_279521	95	136	]	]	-RRB-
10_1101-2020_09_02_279521	95	137	[	[	-LRB-
10_1101-2020_09_02_279521	95	138	0.1	0.1	CD
10_1101-2020_09_02_279521	95	139	;	;	:
10_1101-2020_09_02_279521	95	140	2.2	2.2	CD
10_1101-2020_09_02_279521	95	141	]	]	-RRB-
10_1101-2020_09_02_279521	95	142	[	[	-LRB-
10_1101-2020_09_02_279521	95	143	1.28	1.28	CD
10_1101-2020_09_02_279521	95	144	;	;	:
10_1101-2020_09_02_279521	95	145	1.55	1.55	CD
10_1101-2020_09_02_279521	95	146	]	]	-RRB-
10_1101-2020_09_02_279521	95	147	[	[	-LRB-
10_1101-2020_09_02_279521	95	148	0.43	0.43	CD
10_1101-2020_09_02_279521	95	149	;	;	:
10_1101-2020_09_02_279521	95	150	2.2	2.2	CD
10_1101-2020_09_02_279521	95	151	]	]	-RRB-
10_1101-2020_09_02_279521	95	152	[	[	-LRB-
10_1101-2020_09_02_279521	95	153	1.12	1.12	CD
10_1101-2020_09_02_279521	95	154	;	;	:
10_1101-2020_09_02_279521	95	155	1.44	1.44	CD
10_1101-2020_09_02_279521	95	156	]	]	-RRB-
10_1101-2020_09_02_279521	95	157	[	[	-LRB-
10_1101-2020_09_02_279521	95	158	0.1	0.1	CD
10_1101-2020_09_02_279521	95	159	;	;	:
10_1101-2020_09_02_279521	95	160	2.5	2.5	CD
10_1101-2020_09_02_279521	95	161	]	]	-RRB-
10_1101-2020_09_02_279521	95	162	[	[	-LRB-
10_1101-2020_09_02_279521	95	163	1.29	1.29	CD
10_1101-2020_09_02_279521	95	164	;	;	:
10_1101-2020_09_02_279521	95	165	1.53	1.53	CD
10_1101-2020_09_02_279521	95	166	]	]	-RRB-
10_1101-2020_09_02_279521	95	167	[	[	-LRB-
10_1101-2020_09_02_279521	95	168	-1.5	-1.5	NN
10_1101-2020_09_02_279521	95	169	;	;	:
10_1101-2020_09_02_279521	95	170	1.4	1.4	LS
10_1101-2020_09_02_279521	95	171	]	]	-RRB-
10_1101-2020_09_02_279521	95	172	[	[	-LRB-
10_1101-2020_09_02_279521	95	173	1.34	1.34	CD
10_1101-2020_09_02_279521	95	174	;	;	:
10_1101-2020_09_02_279521	95	175	1.57	1.57	CD
10_1101-2020_09_02_279521	95	176	]	]	-RRB-
10_1101-2020_09_02_279521	95	177	[	[	-LRB-
10_1101-2020_09_02_279521	95	178	-1.9	-1.9	NN
10_1101-2020_09_02_279521	95	179	;	;	:
10_1101-2020_09_02_279521	95	180	3.3	3.3	LS
10_1101-2020_09_02_279521	95	181	]	]	-RRB-
10_1101-2020_09_02_279521	95	182	Global	global	JJ
10_1101-2020_09_02_279521	95	183	FDG	fdg	NN
10_1101-2020_09_02_279521	95	184	1.27	1.27	CD
10_1101-2020_09_02_279521	95	185	-0.47	-0.47	CD
10_1101-2020_09_02_279521	95	186	1.22	1.22	CD
10_1101-2020_09_02_279521	95	187	-1.6	-1.6	NN
10_1101-2020_09_02_279521	95	188	1.28	1.28	CD
10_1101-2020_09_02_279521	95	189	-0.92	-0.92	CD
10_1101-2020_09_02_279521	95	190	1.16	1.16	CD
10_1101-2020_09_02_279521	95	191	-3.1	-3.1	NNP
10_1101-2020_09_02_279521	95	192	1.04	1.04	CD
10_1101-2020_09_02_279521	95	193	-5.0	-5.0	:
10_1101-2020_09_02_279521	95	194	(	(	-LRB-
10_1101-2020_09_02_279521	95	195	SUVR	SUVR	NNP
10_1101-2020_09_02_279521	95	196	)	)	-RRB-
10_1101-2020_09_02_279521	95	197	[	[	-LRB-
10_1101-2020_09_02_279521	95	198	1.19	1.19	CD
10_1101-2020_09_02_279521	95	199	;	;	:
10_1101-2020_09_02_279521	95	200	1.34	1.34	CD
10_1101-2020_09_02_279521	95	201	]	]	-RRB-
10_1101-2020_09_02_279521	95	202	[	[	-LRB-
10_1101-2020_09_02_279521	95	203	-1.8	-1.8	NN
10_1101-2020_09_02_279521	95	204	;	;	:
10_1101-2020_09_02_279521	95	205	0.9	0.9	CD
10_1101-2020_09_02_279521	95	206	]	]	-RRB-
10_1101-2020_09_02_279521	95	207	[	[	-LRB-
10_1101-2020_09_02_279521	95	208	1.16	1.16	CD
10_1101-2020_09_02_279521	95	209	;	;	:
10_1101-2020_09_02_279521	95	210	1.33	1.33	CD
10_1101-2020_09_02_279521	95	211	]	]	-RRB-
10_1101-2020_09_02_279521	95	212	[	[	-LRB-
10_1101-2020_09_02_279521	95	213	-2.2	-2.2	NN
10_1101-2020_09_02_279521	95	214	;	;	:
10_1101-2020_09_02_279521	95	215	-1.0	-1.0	NFP
10_1101-2020_09_02_279521	95	216	]	]	-RRB-
10_1101-2020_09_02_279521	95	217	[	[	-LRB-
10_1101-2020_09_02_279521	95	218	1.19	1.19	CD
10_1101-2020_09_02_279521	95	219	;	;	:
10_1101-2020_09_02_279521	95	220	1.36	1.36	CD
10_1101-2020_09_02_279521	95	221	]	]	-RRB-
10_1101-2020_09_02_279521	95	222	[	[	-LRB-
10_1101-2020_09_02_279521	95	223	-2.9	-2.9	NNP
10_1101-2020_09_02_279521	95	224	;	;	:
10_1101-2020_09_02_279521	95	225	0.0	0.0	LS
10_1101-2020_09_02_279521	95	226	]	]	-RRB-
10_1101-2020_09_02_279521	95	227	[	[	-LRB-
10_1101-2020_09_02_279521	95	228	1.05	1.05	CD
10_1101-2020_09_02_279521	95	229	;	;	:
10_1101-2020_09_02_279521	95	230	1.25	1.25	CD
10_1101-2020_09_02_279521	95	231	]	]	-RRB-
10_1101-2020_09_02_279521	95	232	[	[	-LRB-
10_1101-2020_09_02_279521	95	233	-4.8	-4.8	NN
10_1101-2020_09_02_279521	95	234	;	;	:
10_1101-2020_09_02_279521	95	235	-1.4	-1.4	NN
10_1101-2020_09_02_279521	95	236	]	]	-RRB-
10_1101-2020_09_02_279521	95	237	[	[	-LRB-
10_1101-2020_09_02_279521	95	238	0.97	0.97	CD
10_1101-2020_09_02_279521	95	239	;	;	:
10_1101-2020_09_02_279521	95	240	1.14	1.14	CD
10_1101-2020_09_02_279521	95	241	]	]	-RRB-
10_1101-2020_09_02_279521	95	242	[	[	-LRB-
10_1101-2020_09_02_279521	95	243	-7.9	-7.9	NN
10_1101-2020_09_02_279521	95	244	;	;	:
10_1101-2020_09_02_279521	95	245	-2.0	-2.0	.
10_1101-2020_09_02_279521	95	246	]	]	-RRB-
10_1101-2020_09_02_279521	95	247	Hippocampus	Hippocampus	NNP
10_1101-2020_09_02_279521	95	248	3.7	3.7	CD
10_1101-2020_09_02_279521	95	249	-1.6	-1.6	NN
10_1101-2020_09_02_279521	95	250	3.5	3.5	CD
10_1101-2020_09_02_279521	95	251	-1.8	-1.8	CD
10_1101-2020_09_02_279521	95	252	3.5	3.5	CD
10_1101-2020_09_02_279521	95	253	-1.5	-1.5	CD
10_1101-2020_09_02_279521	95	254	3.1	3.1	CD
10_1101-2020_09_02_279521	95	255	-3.8	-3.8	NNP
10_1101-2020_09_02_279521	95	256	2.8	2.8	CD
10_1101-2020_09_02_279521	95	257	-4.5	-4.5	CD
10_1101-2020_09_02_279521	95	258	(	(	-LRB-
10_1101-2020_09_02_279521	95	259	ml	ml	NN
10_1101-2020_09_02_279521	95	260	)	)	-RRB-
10_1101-2020_09_02_279521	95	261	[	[	-LRB-
10_1101-2020_09_02_279521	95	262	3.4	3.4	CD
10_1101-2020_09_02_279521	95	263	;	;	:
10_1101-2020_09_02_279521	95	264	4.0	4.0	CD
10_1101-2020_09_02_279521	95	265	]	]	-RRB-
10_1101-2020_09_02_279521	95	266	[	[	-LRB-
10_1101-2020_09_02_279521	95	267	-2.2	-2.2	NN
10_1101-2020_09_02_279521	95	268	;	;	:
10_1101-2020_09_02_279521	95	269	-0.4	-0.4	NFP
10_1101-2020_09_02_279521	95	270	]	]	-RRB-
10_1101-2020_09_02_279521	95	271	[	[	-LRB-
10_1101-2020_09_02_279521	95	272	3.1	3.1	CD
10_1101-2020_09_02_279521	95	273	;	;	:
10_1101-2020_09_02_279521	95	274	3.8	3.8	CD
10_1101-2020_09_02_279521	95	275	]	]	-RRB-
10_1101-2020_09_02_279521	95	276	[	[	-LRB-
10_1101-2020_09_02_279521	95	277	-3.3	-3.3	NN
10_1101-2020_09_02_279521	95	278	;	;	:
10_1101-2020_09_02_279521	95	279	-2.2	-2.2	,
10_1101-2020_09_02_279521	95	280	]	]	-RRB-
10_1101-2020_09_02_279521	95	281	[	[	-LRB-
10_1101-2020_09_02_279521	95	282	3.1	3.1	CD
10_1101-2020_09_02_279521	95	283	;	;	:
10_1101-2020_09_02_279521	95	284	3.8	3.8	CD
10_1101-2020_09_02_279521	95	285	]	]	-RRB-
10_1101-2020_09_02_279521	95	286	[	[	-LRB-
10_1101-2020_09_02_279521	95	287	-3.3	-3.3	NN
10_1101-2020_09_02_279521	95	288	;	;	:
10_1101-2020_09_02_279521	95	289	-0.7	-0.7	NN
10_1101-2020_09_02_279521	95	290	]	]	-RRB-
10_1101-2020_09_02_279521	95	291	[	[	-LRB-
10_1101-2020_09_02_279521	95	292	2.7	2.7	CD
10_1101-2020_09_02_279521	95	293	;	;	:
10_1101-2020_09_02_279521	95	294	3.4	3.4	CD
10_1101-2020_09_02_279521	95	295	]	]	-RRB-
10_1101-2020_09_02_279521	95	296	[	[	-LRB-
10_1101-2020_09_02_279521	95	297	-5.1	-5.1	NN
10_1101-2020_09_02_279521	95	298	;	;	:
10_1101-2020_09_02_279521	95	299	-2.3	-2.3	:
10_1101-2020_09_02_279521	95	300	]	]	-RRB-
10_1101-2020_09_02_279521	95	301	[	[	-LRB-
10_1101-2020_09_02_279521	95	302	2.5	2.5	CD
10_1101-2020_09_02_279521	95	303	;	;	:
10_1101-2020_09_02_279521	95	304	3.2	3.2	CD
10_1101-2020_09_02_279521	95	305	]	]	-RRB-
10_1101-2020_09_02_279521	95	306	[	[	-LRB-
10_1101-2020_09_02_279521	95	307	-6.8	-6.8	NNP
10_1101-2020_09_02_279521	95	308	;	;	:
10_1101-2020_09_02_279521	95	309	-2.0	-2.0	:
10_1101-2020_09_02_279521	95	310	]	]	-RRB-
10_1101-2020_09_02_279521	95	311	MTL	MTL	NNP
10_1101-2020_09_02_279521	95	312	10.0	10.0	CD
10_1101-2020_09_02_279521	95	313	-0.8	-0.8	CD
10_1101-2020_09_02_279521	95	314	9.8	9.8	CD
10_1101-2020_09_02_279521	95	315	-1.3	-1.3	CD
10_1101-2020_09_02_279521	95	316	10.4	10.4	CD
10_1101-2020_09_02_279521	95	317	-1.0	-1.0	CD
10_1101-2020_09_02_279521	95	318	9.1	9.1	CD
10_1101-2020_09_02_279521	95	319	-2.9	-2.9	NNP
10_1101-2020_09_02_279521	95	320	8.5	8.5	CD
10_1101-2020_09_02_279521	95	321	-5.0	-5.0	NN
10_1101-2020_09_02_279521	95	322	(	(	-LRB-
10_1101-2020_09_02_279521	95	323	ml	ml	NN
10_1101-2020_09_02_279521	95	324	)	)	-RRB-
10_1101-2020_09_02_279521	95	325	[	[	-LRB-
10_1101-2020_09_02_279521	95	326	9.3	9.3	CD
10_1101-2020_09_02_279521	95	327	;	;	:
10_1101-2020_09_02_279521	95	328	10.5	10.5	CD
10_1101-2020_09_02_279521	95	329	]	]	-RRB-
10_1101-2020_09_02_279521	95	330	[	[	-LRB-
10_1101-2020_09_02_279521	95	331	-2.0	-2.0	NN
10_1101-2020_09_02_279521	95	332	;	;	:
10_1101-2020_09_02_279521	95	333	0.1	0.1	CD
10_1101-2020_09_02_279521	95	334	]	]	-RRB-
10_1101-2020_09_02_279521	95	335	[	[	-LRB-
10_1101-2020_09_02_279521	95	336	8.5	8.5	CD
10_1101-2020_09_02_279521	95	337	;	;	,
10_1101-2020_09_02_279521	95	338	10.5	10.5	CD
10_1101-2020_09_02_279521	95	339	]	]	-RRB-
10_1101-2020_09_02_279521	95	340	[	[	-LRB-
10_1101-2020_09_02_279521	95	341	-2.3	-2.3	NN
10_1101-2020_09_02_279521	95	342	;	;	:
10_1101-2020_09_02_279521	95	343	-0.7	-0.7	NN
10_1101-2020_09_02_279521	95	344	]	]	-RRB-
10_1101-2020_09_02_279521	95	345	[	[	-LRB-
10_1101-2020_09_02_279521	95	346	9.8	9.8	CD
10_1101-2020_09_02_279521	95	347	;	;	:
10_1101-2020_09_02_279521	95	348	11.2	11.2	CD
10_1101-2020_09_02_279521	95	349	]	]	-RRB-
10_1101-2020_09_02_279521	95	350	[	[	-LRB-
10_1101-2020_09_02_279521	95	351	-2.2	-2.2	NN
10_1101-2020_09_02_279521	95	352	;	;	:
10_1101-2020_09_02_279521	95	353	0.4	0.4	LS
10_1101-2020_09_02_279521	95	354	]	]	-RRB-
10_1101-2020_09_02_279521	95	355	[	[	-LRB-
10_1101-2020_09_02_279521	95	356	8.2	8.2	CD
10_1101-2020_09_02_279521	95	357	;	;	:
10_1101-2020_09_02_279521	95	358	10.1	10.1	CD
10_1101-2020_09_02_279521	95	359	]	]	-RRB-
10_1101-2020_09_02_279521	95	360	[	[	-LRB-
10_1101-2020_09_02_279521	95	361	-4.7	-4.7	NN
10_1101-2020_09_02_279521	95	362	;	;	:
10_1101-2020_09_02_279521	95	363	-1.5	-1.5	NN
10_1101-2020_09_02_279521	95	364	]	]	-RRB-
10_1101-2020_09_02_279521	95	365	[	[	-LRB-
10_1101-2020_09_02_279521	95	366	7.6	7.6	CD
10_1101-2020_09_02_279521	95	367	;	;	:
10_1101-2020_09_02_279521	95	368	9.3	9.3	CD
10_1101-2020_09_02_279521	95	369	]	]	-RRB-
10_1101-2020_09_02_279521	95	370	[	[	-LRB-
10_1101-2020_09_02_279521	95	371	-7.9	-7.9	NN
10_1101-2020_09_02_279521	95	372	;	;	:
10_1101-2020_09_02_279521	95	373	-1.9	-1.9	NNP
10_1101-2020_09_02_279521	95	374	]	]	-RRB-
10_1101-2020_09_02_279521	95	375	ADAS11	ADAS11	NNP
10_1101-2020_09_02_279521	95	376	5.0	5.0	CD
10_1101-2020_09_02_279521	95	377	0.1	0.1	CD
10_1101-2020_09_02_279521	95	378	8.0	8.0	CD
10_1101-2020_09_02_279521	95	379	1.7	1.7	CD
10_1101-2020_09_02_279521	95	380	9.0	9.0	CD
10_1101-2020_09_02_279521	95	381	1.2	1.2	CD
10_1101-2020_09_02_279521	95	382	14.3	14.3	CD
10_1101-2020_09_02_279521	95	383	5.0	5.0	CD
10_1101-2020_09_02_279521	95	384	22.0	22.0	CD
10_1101-2020_09_02_279521	95	385	10.3	10.3	CD
10_1101-2020_09_02_279521	95	386	[	[	-LRB-
10_1101-2020_09_02_279521	95	387	3.1	3.1	CD
10_1101-2020_09_02_279521	95	388	;	;	:
10_1101-2020_09_02_279521	95	389	7.0	7.0	CD
10_1101-2020_09_02_279521	95	390	]	]	-RRB-
10_1101-2020_09_02_279521	95	391	[	[	-LRB-
10_1101-2020_09_02_279521	95	392	-0.2	-0.2	NN
10_1101-2020_09_02_279521	95	393	;	;	:
10_1101-2020_09_02_279521	95	394	0.8	0.8	LS
10_1101-2020_09_02_279521	95	395	]	]	-RRB-
10_1101-2020_09_02_279521	95	396	[	[	-LRB-
10_1101-2020_09_02_279521	95	397	5.0	5.0	CD
10_1101-2020_09_02_279521	95	398	;	;	:
10_1101-2020_09_02_279521	95	399	12.2	12.2	CD
10_1101-2020_09_02_279521	95	400	]	]	-RRB-
10_1101-2020_09_02_279521	95	401	[	[	-LRB-
10_1101-2020_09_02_279521	95	402	-0.6	-0.6	NN
10_1101-2020_09_02_279521	95	403	;	;	:
10_1101-2020_09_02_279521	95	404	2.8	2.8	CD
10_1101-2020_09_02_279521	95	405	]	]	-RRB-
10_1101-2020_09_02_279521	95	406	[	[	-LRB-
10_1101-2020_09_02_279521	95	407	6.0	6.0	CD
10_1101-2020_09_02_279521	95	408	;	;	:
10_1101-2020_09_02_279521	95	409	11.6	11.6	CD
10_1101-2020_09_02_279521	95	410	]	]	-RRB-
10_1101-2020_09_02_279521	95	411	[	[	-LRB-
10_1101-2020_09_02_279521	95	412	0.3	0.3	CD
10_1101-2020_09_02_279521	95	413	;	;	:
10_1101-2020_09_02_279521	95	414	2.8	2.8	CD
10_1101-2020_09_02_279521	95	415	]	]	-RRB-
10_1101-2020_09_02_279521	95	416	[	[	-LRB-
10_1101-2020_09_02_279521	95	417	11.0	11.0	CD
10_1101-2020_09_02_279521	95	418	;	;	:
10_1101-2020_09_02_279521	95	419	20.0	20.0	CD
10_1101-2020_09_02_279521	95	420	]	]	-RRB-
10_1101-2020_09_02_279521	95	421	[	[	-LRB-
10_1101-2020_09_02_279521	95	422	2.3	2.3	CD
10_1101-2020_09_02_279521	95	423	;	;	:
10_1101-2020_09_02_279521	95	424	8.4	8.4	CD
10_1101-2020_09_02_279521	95	425	]	]	-RRB-
10_1101-2020_09_02_279521	95	426	[	[	-LRB-
10_1101-2020_09_02_279521	95	427	17.0	17.0	CD
10_1101-2020_09_02_279521	95	428	;	;	:
10_1101-2020_09_02_279521	95	429	28.0	28.0	CD
10_1101-2020_09_02_279521	95	430	]	]	-RRB-
10_1101-2020_09_02_279521	95	431	[	[	-LRB-
10_1101-2020_09_02_279521	95	432	4.1	4.1	CD
10_1101-2020_09_02_279521	95	433	;	;	,
10_1101-2020_09_02_279521	95	434	21.0	21.0	CD
10_1101-2020_09_02_279521	95	435	]	]	-RRB-
10_1101-2020_09_02_279521	95	436	The	the	DT
10_1101-2020_09_02_279521	95	437	model	model	NN
10_1101-2020_09_02_279521	95	438	thus	thus	RB
10_1101-2020_09_02_279521	95	439	enables	enable	VBZ
10_1101-2020_09_02_279521	95	440	to	to	TO
10_1101-2020_09_02_279521	95	441	simulate	simulate	VB
10_1101-2020_09_02_279521	95	442	the	the	DT
10_1101-2020_09_02_279521	95	443	pathological	pathological	JJ
10_1101-2020_09_02_279521	95	444	progression	progression	NN
10_1101-2020_09_02_279521	95	445	of	of	IN
10_1101-2020_09_02_279521	95	446	biomarkers	biomarker	NNS
10_1101-2020_09_02_279521	95	447	across	across	IN
10_1101-2020_09_02_279521	95	448	the	the	DT
10_1101-2020_09_02_279521	95	449	entire	entire	JJ
10_1101-2020_09_02_279521	95	450	history	history	NN
10_1101-2020_09_02_279521	95	451	of	of	IN
10_1101-2020_09_02_279521	95	452	the	the	DT
10_1101-2020_09_02_279521	95	453	disease	disease	NN
10_1101-2020_09_02_279521	95	454	.	.	.
10_1101-2020_09_02_279521	96	1	Once	once	IN
10_1101-2020_09_02_279521	96	2	the	the	DT
10_1101-2020_09_02_279521	96	3	model	model	NN
10_1101-2020_09_02_279521	96	4	is	be	VBZ
10_1101-2020_09_02_279521	96	5	estimated	estimate	VBN
10_1101-2020_09_02_279521	96	6	,	,	,
10_1101-2020_09_02_279521	96	7	we	-PRON-	PRP
10_1101-2020_09_02_279521	96	8	can	can	MD
10_1101-2020_09_02_279521	96	9	modify	modify	VB
10_1101-2020_09_02_279521	96	10	the	the	DT
10_1101-2020_09_02_279521	96	11	ODEs	ode	NNS
10_1101-2020_09_02_279521	96	12	parameters	parameter	NNS
10_1101-2020_09_02_279521	96	13	to	to	TO
10_1101-2020_09_02_279521	96	14	simulate	simulate	VB
10_1101-2020_09_02_279521	96	15	different	different	JJ
10_1101-2020_09_02_279521	96	16	evolution	evolution	NN
10_1101-2020_09_02_279521	96	17	scenarios	scenario	NNS
10_1101-2020_09_02_279521	96	18	according	accord	VBG
10_1101-2020_09_02_279521	96	19	to	to	IN
10_1101-2020_09_02_279521	96	20	specific	specific	JJ
10_1101-2020_09_02_279521	96	21	hypothesis	hypothesis	NN
10_1101-2020_09_02_279521	96	22	.	.	.
10_1101-2020_09_02_279521	97	1	For	for	IN
10_1101-2020_09_02_279521	97	2	example	example	NN
10_1101-2020_09_02_279521	97	3	,	,	,
10_1101-2020_09_02_279521	97	4	by	by	IN
10_1101-2020_09_02_279521	97	5	reducing	reduce	VBG
10_1101-2020_09_02_279521	97	6	the	the	DT
10_1101-2020_09_02_279521	97	7	parameters	parameter	NNS
10_1101-2020_09_02_279521	97	8	associated	associate	VBN
10_1101-2020_09_02_279521	97	9	with	with	IN
10_1101-2020_09_02_279521	97	10	the	the	DT
10_1101-2020_09_02_279521	97	11	progression	progression	NN
10_1101-2020_09_02_279521	97	12	rate	rate	NN
10_1101-2020_09_02_279521	97	13	of	of	IN
10_1101-2020_09_02_279521	97	14	amyloid	amyloid	NN
10_1101-2020_09_02_279521	97	15	,	,	,
10_1101-2020_09_02_279521	97	16	we	-PRON-	PRP
10_1101-2020_09_02_279521	97	17	can	can	MD
10_1101-2020_09_02_279521	97	18	investigate	investigate	VB
10_1101-2020_09_02_279521	97	19	the	the	DT
10_1101-2020_09_02_279521	97	20	relative	relative	JJ
10_1101-2020_09_02_279521	97	21	change	change	NN
10_1101-2020_09_02_279521	97	22	in	in	IN
10_1101-2020_09_02_279521	97	23	the	the	DT
10_1101-2020_09_02_279521	97	24	evolution	evolution	NN
10_1101-2020_09_02_279521	97	25	of	of	IN
10_1101-2020_09_02_279521	97	26	the	the	DT
10_1101-2020_09_02_279521	97	27	other	other	JJ
10_1101-2020_09_02_279521	97	28	biomarkers	biomarker	NNS
10_1101-2020_09_02_279521	97	29	.	.	.
10_1101-2020_09_02_279521	98	1	This	this	DT
10_1101-2020_09_02_279521	98	2	setup	setup	NN
10_1101-2020_09_02_279521	98	3	thus	thus	RB
10_1101-2020_09_02_279521	98	4	.CC	.CC	:
10_1101-2020_09_02_279521	98	5	-	-	:
10_1101-2020_09_02_279521	98	6	BY	by	IN
10_1101-2020_09_02_279521	98	7	4.0	4.0	CD
10_1101-2020_09_02_279521	98	8	International	international	JJ
10_1101-2020_09_02_279521	98	9	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	98	10	.	.	.
10_1101-2020_09_02_279521	99	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	99	2	is	be	VBZ
10_1101-2020_09_02_279521	99	3	made	make	VBN
10_1101-2020_09_02_279521	99	4	available	available	JJ
10_1101-2020_09_02_279521	99	5	under	under	IN
10_1101-2020_09_02_279521	99	6	a	a	DT
10_1101-2020_09_02_279521	99	7	preprint	preprint	NN
10_1101-2020_09_02_279521	99	8	(	(	-LRB-
10_1101-2020_09_02_279521	99	9	which	which	WDT
10_1101-2020_09_02_279521	99	10	was	be	VBD
10_1101-2020_09_02_279521	99	11	not	not	RB
10_1101-2020_09_02_279521	99	12	certified	certify	VBN
10_1101-2020_09_02_279521	99	13	by	by	IN
10_1101-2020_09_02_279521	99	14	peer	peer	NN
10_1101-2020_09_02_279521	99	15	review	review	NN
10_1101-2020_09_02_279521	99	16	)	)	-RRB-
10_1101-2020_09_02_279521	99	17	is	be	VBZ
10_1101-2020_09_02_279521	99	18	the	the	DT
10_1101-2020_09_02_279521	99	19	author	author	NN
10_1101-2020_09_02_279521	99	20	/	/	SYM
10_1101-2020_09_02_279521	99	21	funder	funder	NN
10_1101-2020_09_02_279521	99	22	,	,	,
10_1101-2020_09_02_279521	99	23	who	who	WP
10_1101-2020_09_02_279521	99	24	has	have	VBZ
10_1101-2020_09_02_279521	99	25	granted	grant	VBN
10_1101-2020_09_02_279521	99	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	99	27	a	a	DT
10_1101-2020_09_02_279521	99	28	license	license	NN
10_1101-2020_09_02_279521	99	29	to	to	TO
10_1101-2020_09_02_279521	99	30	display	display	VB
10_1101-2020_09_02_279521	99	31	the	the	DT
10_1101-2020_09_02_279521	99	32	preprint	preprint	NN
10_1101-2020_09_02_279521	99	33	in	in	IN
10_1101-2020_09_02_279521	99	34	The	the	DT
10_1101-2020_09_02_279521	99	35	copyright	copyright	NN
10_1101-2020_09_02_279521	99	36	holder	holder	NN
10_1101-2020_09_02_279521	99	37	for	for	IN
10_1101-2020_09_02_279521	99	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	99	39	version	version	NN
10_1101-2020_09_02_279521	99	40	posted	post	VBD
10_1101-2020_09_02_279521	99	41	February	February	NNP
10_1101-2020_09_02_279521	99	42	10	10	CD
10_1101-2020_09_02_279521	99	43	,	,	,
10_1101-2020_09_02_279521	99	44	2021	2021	CD
10_1101-2020_09_02_279521	99	45	.	.	.
10_1101-2020_09_02_279521	99	46	;	;	:
10_1101-2020_09_02_279521	99	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	99	48	:	:	:
10_1101-2020_09_02_279521	99	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	99	50	preprint	preprint	NN
10_1101-2020_09_02_279521	99	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	ADD
10_1101-2020_09_02_279521	99	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	ADD
10_1101-2020_09_02_279521	99	53	provides	provide	VBZ
10_1101-2020_09_02_279521	99	54	us	-PRON-	PRP
10_1101-2020_09_02_279521	99	55	with	with	IN
10_1101-2020_09_02_279521	99	56	a	a	DT
10_1101-2020_09_02_279521	99	57	data	data	NN
10_1101-2020_09_02_279521	99	58	-	-	HYPH
10_1101-2020_09_02_279521	99	59	driven	drive	VBN
10_1101-2020_09_02_279521	99	60	system	system	NN
10_1101-2020_09_02_279521	99	61	enabling	enable	VBG
10_1101-2020_09_02_279521	99	62	the	the	DT
10_1101-2020_09_02_279521	99	63	exploration	exploration	NN
10_1101-2020_09_02_279521	99	64	of	of	IN
10_1101-2020_09_02_279521	99	65	hypothetical	hypothetical	JJ
10_1101-2020_09_02_279521	99	66	intervention	intervention	NN
10_1101-2020_09_02_279521	99	67	strategies	strategy	NNS
10_1101-2020_09_02_279521	99	68	,	,	,
10_1101-2020_09_02_279521	99	69	and	and	CC
10_1101-2020_09_02_279521	99	70	their	-PRON-	PRP$
10_1101-2020_09_02_279521	99	71	effect	effect	NN
10_1101-2020_09_02_279521	99	72	on	on	IN
10_1101-2020_09_02_279521	99	73	the	the	DT
10_1101-2020_09_02_279521	99	74	pathological	pathological	JJ
10_1101-2020_09_02_279521	99	75	cascade	cascade	NN
10_1101-2020_09_02_279521	99	76	.	.	.
10_1101-2020_09_02_279521	100	1	Data	datum	NNS
10_1101-2020_09_02_279521	100	2	modelling	model	VBG
10_1101-2020_09_02_279521	100	3	We	-PRON-	PRP
10_1101-2020_09_02_279521	100	4	consider	consider	VBP
10_1101-2020_09_02_279521	100	5	observations	observation	NNS
10_1101-2020_09_02_279521	100	6	1	1	CD
10_1101-2020_09_02_279521	100	7	2	2	CD
10_1101-2020_09_02_279521	100	8	(	(	-LRB-
10_1101-2020_09_02_279521	100	9	)	)	-RRB-
10_1101-2020_09_02_279521	100	10	[	[	-LRB-
10_1101-2020_09_02_279521	100	11	(	(	-LRB-
10_1101-2020_09_02_279521	100	12	)	)	-RRB-
10_1101-2020_09_02_279521	100	13	,	,	,
10_1101-2020_09_02_279521	100	14	(	(	-LRB-
10_1101-2020_09_02_279521	100	15	)	)	-RRB-
10_1101-2020_09_02_279521	100	16	,	,	,
10_1101-2020_09_02_279521	100	17	...	...	:
10_1101-2020_09_02_279521	100	18	,	,	,
10_1101-2020_09_02_279521	100	19	(	(	-LRB-
10_1101-2020_09_02_279521	100	20	)	)	-RRB-
10_1101-2020_09_02_279521	100	21	]	]	-RRB-
10_1101-2020_09_02_279521	100	22	M	M	NNP
10_1101-2020_09_02_279521	100	23	T	t	NN
10_1101-2020_09_02_279521	100	24	i	i	NN
10_1101-2020_09_02_279521	100	25	i	i	PRP
10_1101-2020_09_02_279521	100	26	i	i	PRP
10_1101-2020_09_02_279521	100	27	i	i	PRP
10_1101-2020_09_02_279521	100	28	t	t	VBP
10_1101-2020_09_02_279521	100	29	t	t	NNP
10_1101-2020_09_02_279521	100	30	t	t	NNP
10_1101-2020_09_02_279521	100	31	t	t	NNP
10_1101-2020_09_02_279521	100	32	=	=	SYM
10_1101-2020_09_02_279521	100	33	X	x	NN
10_1101-2020_09_02_279521	100	34	x	x	NN
10_1101-2020_09_02_279521	100	35	x	x	SYM
10_1101-2020_09_02_279521	100	36	x	x	NNS
10_1101-2020_09_02_279521	100	37	,	,	,
10_1101-2020_09_02_279521	100	38	which	which	WDT
10_1101-2020_09_02_279521	100	39	correspond	correspond	VBP
10_1101-2020_09_02_279521	100	40	to	to	IN
10_1101-2020_09_02_279521	100	41	multivariate	multivariate	JJ
10_1101-2020_09_02_279521	100	42	measures	measure	NNS
10_1101-2020_09_02_279521	100	43	derived	derive	VBN
10_1101-2020_09_02_279521	100	44	from	from	IN
10_1101-2020_09_02_279521	100	45	M	M	NNP
10_1101-2020_09_02_279521	100	46	different	different	JJ
10_1101-2020_09_02_279521	100	47	modalities	modality	NNS
10_1101-2020_09_02_279521	100	48	(	(	-LRB-
10_1101-2020_09_02_279521	100	49	e.g	e.g	NNP
10_1101-2020_09_02_279521	100	50	clinical	clinical	JJ
10_1101-2020_09_02_279521	100	51	scores	score	NNS
10_1101-2020_09_02_279521	100	52	,	,	,
10_1101-2020_09_02_279521	100	53	MRI	MRI	NNP
10_1101-2020_09_02_279521	100	54	,	,	,
10_1101-2020_09_02_279521	100	55	AV45	AV45	NNP
10_1101-2020_09_02_279521	100	56	,	,	,
10_1101-2020_09_02_279521	100	57	or	or	CC
10_1101-2020_09_02_279521	100	58	FDG	FDG	NNP
10_1101-2020_09_02_279521	100	59	measures	measure	NNS
10_1101-2020_09_02_279521	100	60	)	)	-RRB-
10_1101-2020_09_02_279521	100	61	at	at	IN
10_1101-2020_09_02_279521	100	62	time	time	NN
10_1101-2020_09_02_279521	100	63	t	t	NNP
10_1101-2020_09_02_279521	100	64	for	for	IN
10_1101-2020_09_02_279521	100	65	subject	subject	NN
10_1101-2020_09_02_279521	100	66	i.	i.	NN
10_1101-2020_09_02_279521	101	1	Each	each	DT
10_1101-2020_09_02_279521	101	2	vector	vector	NN
10_1101-2020_09_02_279521	101	3	(	(	-LRB-
10_1101-2020_09_02_279521	101	4	)	)	-RRB-
10_1101-2020_09_02_279521	101	5	m	m	NNP
10_1101-2020_09_02_279521	101	6	i	i	PRP
10_1101-2020_09_02_279521	101	7	tx	tx	NNP
10_1101-2020_09_02_279521	101	8	has	have	VBZ
10_1101-2020_09_02_279521	101	9	dimension	dimension	NN
10_1101-2020_09_02_279521	101	10	mD	mD	NNP
10_1101-2020_09_02_279521	101	11	.	.	.
10_1101-2020_09_02_279521	102	1	We	-PRON-	PRP
10_1101-2020_09_02_279521	102	2	postulate	postulate	VBP
10_1101-2020_09_02_279521	102	3	the	the	DT
10_1101-2020_09_02_279521	102	4	Figure	figure	NN
10_1101-2020_09_02_279521	102	5	1	1	CD
10_1101-2020_09_02_279521	102	6	Overview	Overview	NNP
10_1101-2020_09_02_279521	102	7	of	of	IN
10_1101-2020_09_02_279521	102	8	the	the	DT
10_1101-2020_09_02_279521	102	9	method	method	NN
10_1101-2020_09_02_279521	102	10	.	.	.
10_1101-2020_09_02_279521	103	1	a	a	LS
10_1101-2020_09_02_279521	103	2	)	)	-RRB-
10_1101-2020_09_02_279521	103	3	High	high	JJ
10_1101-2020_09_02_279521	103	4	-	-	HYPH
10_1101-2020_09_02_279521	103	5	dimensional	dimensional	JJ
10_1101-2020_09_02_279521	103	6	multi	multi	JJ
10_1101-2020_09_02_279521	103	7	-	-	JJ
10_1101-2020_09_02_279521	103	8	modal	modal	JJ
10_1101-2020_09_02_279521	103	9	measures	measure	NNS
10_1101-2020_09_02_279521	103	10	are	be	VBP
10_1101-2020_09_02_279521	103	11	projected	project	VBN
10_1101-2020_09_02_279521	103	12	into	into	IN
10_1101-2020_09_02_279521	103	13	a	a	DT
10_1101-2020_09_02_279521	103	14	4-dimensional	4-dimensional	CD
10_1101-2020_09_02_279521	103	15	latent	latent	NN
10_1101-2020_09_02_279521	103	16	space	space	NN
10_1101-2020_09_02_279521	103	17	.	.	.
10_1101-2020_09_02_279521	104	1	Each	each	DT
10_1101-2020_09_02_279521	104	2	data	data	NN
10_1101-2020_09_02_279521	104	3	modality	modality	NN
10_1101-2020_09_02_279521	104	4	is	be	VBZ
10_1101-2020_09_02_279521	104	5	transformed	transform	VBN
10_1101-2020_09_02_279521	104	6	in	in	IN
10_1101-2020_09_02_279521	104	7	a	a	DT
10_1101-2020_09_02_279521	104	8	corresponding	corresponding	JJ
10_1101-2020_09_02_279521	104	9	z	z	JJ
10_1101-2020_09_02_279521	104	10	-	-	HYPH
10_1101-2020_09_02_279521	104	11	score	score	NN
10_1101-2020_09_02_279521	104	12	zamy	zamy	NNP
10_1101-2020_09_02_279521	104	13	,	,	,
10_1101-2020_09_02_279521	104	14	zmet	zmet	NNP
10_1101-2020_09_02_279521	104	15	,	,	,
10_1101-2020_09_02_279521	104	16	zatr	zatr	NNP
10_1101-2020_09_02_279521	104	17	,	,	,
10_1101-2020_09_02_279521	104	18	zcli	zcli	NNP
10_1101-2020_09_02_279521	104	19	.	.	.
10_1101-2020_09_02_279521	105	1	b	b	LS
10_1101-2020_09_02_279521	105	2	)	)	-RRB-
10_1101-2020_09_02_279521	105	3	The	the	DT
10_1101-2020_09_02_279521	105	4	dynamical	dynamical	JJ
10_1101-2020_09_02_279521	105	5	system	system	NN
10_1101-2020_09_02_279521	105	6	describing	describe	VBG
10_1101-2020_09_02_279521	105	7	the	the	DT
10_1101-2020_09_02_279521	105	8	relationships	relationship	NNS
10_1101-2020_09_02_279521	105	9	between	between	IN
10_1101-2020_09_02_279521	105	10	the	the	DT
10_1101-2020_09_02_279521	105	11	z	z	NNP
10_1101-2020_09_02_279521	105	12	-	-	HYPH
10_1101-2020_09_02_279521	105	13	scores	score	NNS
10_1101-2020_09_02_279521	105	14	allows	allow	VBZ
10_1101-2020_09_02_279521	105	15	to	to	TO
10_1101-2020_09_02_279521	105	16	compute	compute	VB
10_1101-2020_09_02_279521	105	17	their	-PRON-	PRP$
10_1101-2020_09_02_279521	105	18	transition	transition	NN
10_1101-2020_09_02_279521	105	19	across	across	IN
10_1101-2020_09_02_279521	105	20	the	the	DT
10_1101-2020_09_02_279521	105	21	evolution	evolution	NN
10_1101-2020_09_02_279521	105	22	of	of	IN
10_1101-2020_09_02_279521	105	23	the	the	DT
10_1101-2020_09_02_279521	105	24	disease	disease	NN
10_1101-2020_09_02_279521	105	25	.	.	.
10_1101-2020_09_02_279521	106	1	c	c	LS
10_1101-2020_09_02_279521	106	2	)	)	-RRB-
10_1101-2020_09_02_279521	106	3	Given	give	VBN
10_1101-2020_09_02_279521	106	4	the	the	DT
10_1101-2020_09_02_279521	106	5	latent	latent	NN
10_1101-2020_09_02_279521	106	6	space	space	NN
10_1101-2020_09_02_279521	106	7	and	and	CC
10_1101-2020_09_02_279521	106	8	the	the	DT
10_1101-2020_09_02_279521	106	9	estimated	estimate	VBN
10_1101-2020_09_02_279521	106	10	dynamics	dynamic	NNS
10_1101-2020_09_02_279521	106	11	,	,	,
10_1101-2020_09_02_279521	106	12	the	the	DT
10_1101-2020_09_02_279521	106	13	follow	follow	NN
10_1101-2020_09_02_279521	106	14	-	-	HYPH
10_1101-2020_09_02_279521	106	15	up	up	RP
10_1101-2020_09_02_279521	106	16	measurements	measurement	NNS
10_1101-2020_09_02_279521	106	17	can	can	MD
10_1101-2020_09_02_279521	106	18	be	be	VB
10_1101-2020_09_02_279521	106	19	reconstructed	reconstruct	VBN
10_1101-2020_09_02_279521	106	20	to	to	TO
10_1101-2020_09_02_279521	106	21	match	match	VB
10_1101-2020_09_02_279521	106	22	the	the	DT
10_1101-2020_09_02_279521	106	23	observed	observed	JJ
10_1101-2020_09_02_279521	106	24	data	datum	NNS
10_1101-2020_09_02_279521	106	25	.	.	.
10_1101-2020_09_02_279521	107	1	.CC	.CC	NFP
10_1101-2020_09_02_279521	107	2	-	-	:
10_1101-2020_09_02_279521	107	3	BY	by	IN
10_1101-2020_09_02_279521	107	4	4.0	4.0	CD
10_1101-2020_09_02_279521	107	5	International	international	JJ
10_1101-2020_09_02_279521	107	6	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	107	7	.	.	.
10_1101-2020_09_02_279521	108	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	108	2	is	be	VBZ
10_1101-2020_09_02_279521	108	3	made	make	VBN
10_1101-2020_09_02_279521	108	4	available	available	JJ
10_1101-2020_09_02_279521	108	5	under	under	IN
10_1101-2020_09_02_279521	108	6	a	a	DT
10_1101-2020_09_02_279521	108	7	preprint	preprint	NN
10_1101-2020_09_02_279521	108	8	(	(	-LRB-
10_1101-2020_09_02_279521	108	9	which	which	WDT
10_1101-2020_09_02_279521	108	10	was	be	VBD
10_1101-2020_09_02_279521	108	11	not	not	RB
10_1101-2020_09_02_279521	108	12	certified	certify	VBN
10_1101-2020_09_02_279521	108	13	by	by	IN
10_1101-2020_09_02_279521	108	14	peer	peer	NN
10_1101-2020_09_02_279521	108	15	review	review	NN
10_1101-2020_09_02_279521	108	16	)	)	-RRB-
10_1101-2020_09_02_279521	108	17	is	be	VBZ
10_1101-2020_09_02_279521	108	18	the	the	DT
10_1101-2020_09_02_279521	108	19	author	author	NN
10_1101-2020_09_02_279521	108	20	/	/	SYM
10_1101-2020_09_02_279521	108	21	funder	funder	NN
10_1101-2020_09_02_279521	108	22	,	,	,
10_1101-2020_09_02_279521	108	23	who	who	WP
10_1101-2020_09_02_279521	108	24	has	have	VBZ
10_1101-2020_09_02_279521	108	25	granted	grant	VBN
10_1101-2020_09_02_279521	108	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	108	27	a	a	DT
10_1101-2020_09_02_279521	108	28	license	license	NN
10_1101-2020_09_02_279521	108	29	to	to	TO
10_1101-2020_09_02_279521	108	30	display	display	VB
10_1101-2020_09_02_279521	108	31	the	the	DT
10_1101-2020_09_02_279521	108	32	preprint	preprint	NN
10_1101-2020_09_02_279521	108	33	in	in	IN
10_1101-2020_09_02_279521	108	34	The	the	DT
10_1101-2020_09_02_279521	108	35	copyright	copyright	NN
10_1101-2020_09_02_279521	108	36	holder	holder	NN
10_1101-2020_09_02_279521	108	37	for	for	IN
10_1101-2020_09_02_279521	108	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	108	39	version	version	NN
10_1101-2020_09_02_279521	108	40	posted	post	VBD
10_1101-2020_09_02_279521	108	41	February	February	NNP
10_1101-2020_09_02_279521	108	42	10	10	CD
10_1101-2020_09_02_279521	108	43	,	,	,
10_1101-2020_09_02_279521	108	44	2021	2021	CD
10_1101-2020_09_02_279521	108	45	.	.	.
10_1101-2020_09_02_279521	108	46	;	;	:
10_1101-2020_09_02_279521	108	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	108	48	:	:	:
10_1101-2020_09_02_279521	108	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	108	50	preprint	preprint	NN
10_1101-2020_09_02_279521	108	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	ADD
10_1101-2020_09_02_279521	108	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	ADD
10_1101-2020_09_02_279521	108	53	following	follow	VBG
10_1101-2020_09_02_279521	108	54	generative	generative	JJ
10_1101-2020_09_02_279521	108	55	model	model	NN
10_1101-2020_09_02_279521	108	56	,	,	,
10_1101-2020_09_02_279521	108	57	in	in	IN
10_1101-2020_09_02_279521	108	58	which	which	WDT
10_1101-2020_09_02_279521	108	59	the	the	DT
10_1101-2020_09_02_279521	108	60	modalities	modality	NNS
10_1101-2020_09_02_279521	108	61	are	be	VBP
10_1101-2020_09_02_279521	108	62	assumed	assume	VBN
10_1101-2020_09_02_279521	108	63	to	to	TO
10_1101-2020_09_02_279521	108	64	be	be	VB
10_1101-2020_09_02_279521	108	65	independently	independently	RB
10_1101-2020_09_02_279521	108	66	generated	generate	VBN
10_1101-2020_09_02_279521	108	67	by	by	IN
10_1101-2020_09_02_279521	108	68	a	a	DT
10_1101-2020_09_02_279521	108	69	common	common	JJ
10_1101-2020_09_02_279521	108	70	latent	latent	NN
10_1101-2020_09_02_279521	108	71	representation	representation	NN
10_1101-2020_09_02_279521	108	72	of	of	IN
10_1101-2020_09_02_279521	108	73	the	the	DT
10_1101-2020_09_02_279521	108	74	data	datum	NNS
10_1101-2020_09_02_279521	108	75	(	(	-LRB-
10_1101-2020_09_02_279521	108	76	)	)	-RRB-
10_1101-2020_09_02_279521	108	77	i	i	PRP
10_1101-2020_09_02_279521	108	78	tz	tz	NN
10_1101-2020_09_02_279521	108	79	:	:	:
10_1101-2020_09_02_279521	108	80	2	2	CD
10_1101-2020_09_02_279521	108	81	2	2	CD
10_1101-2020_09_02_279521	108	82	0	0	CD
10_1101-2020_09_02_279521	108	83	0	0	CD
10_1101-2020_09_02_279521	108	84	0	0	CD
10_1101-2020_09_02_279521	108	85	(	(	-LRB-
10_1101-2020_09_02_279521	108	86	(	(	-LRB-
10_1101-2020_09_02_279521	108	87	)	)	-RRB-
10_1101-2020_09_02_279521	108	88	|	|	NNP
10_1101-2020_09_02_279521	108	89	(	(	-LRB-
10_1101-2020_09_02_279521	108	90	)	)	-RRB-
10_1101-2020_09_02_279521	108	91	,	,	,
10_1101-2020_09_02_279521	108	92	,	,	,
10_1101-2020_09_02_279521	108	93	)	)	-RRB-
10_1101-2020_09_02_279521	108	94	(	(	-LRB-
10_1101-2020_09_02_279521	108	95	(	(	-LRB-
10_1101-2020_09_02_279521	108	96	)	)	-RRB-
10_1101-2020_09_02_279521	108	97	|	|	NNP
10_1101-2020_09_02_279521	108	98	(	(	-LRB-
10_1101-2020_09_02_279521	108	99	)	)	-RRB-
10_1101-2020_09_02_279521	108	100	,	,	,
10_1101-2020_09_02_279521	108	101	,	,	,
10_1101-2020_09_02_279521	108	102	)	)	-RRB-
10_1101-2020_09_02_279521	108	103	(	(	-LRB-
10_1101-2020_09_02_279521	108	104	(	(	-LRB-
10_1101-2020_09_02_279521	108	105	(	(	-LRB-
10_1101-2020_09_02_279521	108	106	)	)	-RRB-
10_1101-2020_09_02_279521	108	107	,	,	,
10_1101-2020_09_02_279521	108	108	)	)	-RRB-
10_1101-2020_09_02_279521	108	109	,	,	,
10_1101-2020_09_02_279521	108	110	)	)	-RRB-
10_1101-2020_09_02_279521	108	111	,	,	,
10_1101-2020_09_02_279521	108	112	(	(	-LRB-
10_1101-2020_09_02_279521	108	113	)	)	-RRB-
10_1101-2020_09_02_279521	108	114	(	(	-LRB-
10_1101-2020_09_02_279521	108	115	(	(	-LRB-
10_1101-2020_09_02_279521	108	116	)	)	-RRB-
10_1101-2020_09_02_279521	108	117	,	,	,
10_1101-2020_09_02_279521	108	118	)	)	-RRB-
10_1101-2020_09_02_279521	108	119	,	,	,
10_1101-2020_09_02_279521	108	120	(	(	-LRB-
10_1101-2020_09_02_279521	108	121	)	)	-RRB-
10_1101-2020_09_02_279521	108	122	~	~	NFP
10_1101-2020_09_02_279521	108	123	(	(	-LRB-
10_1101-2020_09_02_279521	108	124	(	(	-LRB-
10_1101-2020_09_02_279521	108	125	)	)	-RRB-
10_1101-2020_09_02_279521	108	126	)	)	-RRB-
10_1101-2020_09_02_279521	108	127	,	,	,
10_1101-2020_09_02_279521	108	128	m	m	NNP
10_1101-2020_09_02_279521	108	129	i	i	NN
10_1101-2020_09_02_279521	108	130	i	i	PRP
10_1101-2020_09_02_279521	108	131	i	i	PRP
10_1101-2020_09_02_279521	108	132	i	i	PRP
10_1101-2020_09_02_279521	108	133	m	m	NN
10_1101-2020_09_02_279521	108	134	m	m	NNP
10_1101-2020_09_02_279521	108	135	m	m	NNP
10_1101-2020_09_02_279521	108	136	m	m	NNP
10_1101-2020_09_02_279521	108	137	i	i	NNP
10_1101-2020_09_02_279521	108	138	m	m	NNP
10_1101-2020_09_02_279521	108	139	m	m	NNP
10_1101-2020_09_02_279521	108	140	m	m	NNP
10_1101-2020_09_02_279521	108	141	i	i	NN
10_1101-2020_09_02_279521	108	142	i	i	PRP
10_1101-2020_09_02_279521	108	143	i	i	PRP
10_1101-2020_09_02_279521	108	144	p	p	VBP
10_1101-2020_09_02_279521	108	145	t	t	NNP
10_1101-2020_09_02_279521	108	146	t	t	NN
10_1101-2020_09_02_279521	108	147	p	p	NN
10_1101-2020_09_02_279521	108	148	t	t	NNP
10_1101-2020_09_02_279521	108	149	t	t	NNP
10_1101-2020_09_02_279521	108	150	t	t	NNP
10_1101-2020_09_02_279521	108	151	t	t	NNP
10_1101-2020_09_02_279521	108	152	t	t	NNP
10_1101-2020_09_02_279521	108	153	t	t	NNP
10_1101-2020_09_02_279521	108	154	t	t	NNP
10_1101-2020_09_02_279521	108	155	p	p	NN
10_1101-2020_09_02_279521	108	156	t	t	NN
10_1101-2020_09_02_279521	108	157			NNP
10_1101-2020_09_02_279521	108	158			NN
10_1101-2020_09_02_279521	108	159			NNP
10_1101-2020_09_02_279521	108	160			NN
10_1101-2020_09_02_279521	108	161			NNP
10_1101-2020_09_02_279521	108	162	=	=	SYM
10_1101-2020_09_02_279521	108	163	=	=	NFP
10_1101-2020_09_02_279521	108	164	=	=	NFP
10_1101-2020_09_02_279521	108	165			JJ
10_1101-2020_09_02_279521	108	166			ADD
10_1101-2020_09_02_279521	108	167			ADD
10_1101-2020_09_02_279521	108	168	2	2	CD
10_1101-2020_09_02_279521	108	169	i	i	PRP
10_1101-2020_09_02_279521	108	170	X	x	NN
10_1101-2020_09_02_279521	108	171	z	z	NN
10_1101-2020_09_02_279521	108	172	σ	σ	NN
10_1101-2020_09_02_279521	108	173	ψ	ψ	NNP
10_1101-2020_09_02_279521	108	174	x	x	SYM
10_1101-2020_09_02_279521	108	175	z	z	NNP
10_1101-2020_09_02_279521	108	176	z	z	NN
10_1101-2020_09_02_279521	108	177	z	z	NN
10_1101-2020_09_02_279521	108	178	z	z	NNP
10_1101-2020_09_02_279521	108	179	z	z	NNP
10_1101-2020_09_02_279521	108	180	z	z	NNP
10_1101-2020_09_02_279521	108	181	(	(	-LRB-
10_1101-2020_09_02_279521	108	182	1	1	CD
10_1101-2020_09_02_279521	108	183	)	)	-RRB-
10_1101-2020_09_02_279521	108	184	where	where	WRB
10_1101-2020_09_02_279521	108	185	2	2	CD
10_1101-2020_09_02_279521	108	186	m	m	NN
10_1101-2020_09_02_279521	108	187			NNP
10_1101-2020_09_02_279521	108	188	is	be	VBZ
10_1101-2020_09_02_279521	108	189	measurement	measurement	NN
10_1101-2020_09_02_279521	108	190	noise	noise	NN
10_1101-2020_09_02_279521	108	191	,	,	,
10_1101-2020_09_02_279521	108	192	while	while	IN
10_1101-2020_09_02_279521	108	193	m	m	NNP
10_1101-2020_09_02_279521	108	194			``
10_1101-2020_09_02_279521	108	195	are	be	VBP
10_1101-2020_09_02_279521	108	196	the	the	DT
10_1101-2020_09_02_279521	108	197	parameters	parameter	NNS
10_1101-2020_09_02_279521	108	198	of	of	IN
10_1101-2020_09_02_279521	108	199	the	the	DT
10_1101-2020_09_02_279521	108	200	function	function	NN
10_1101-2020_09_02_279521	108	201	m	m	NNP
10_1101-2020_09_02_279521	108	202			NNP
10_1101-2020_09_02_279521	108	203	which	which	WDT
10_1101-2020_09_02_279521	108	204	maps	map	VBZ
10_1101-2020_09_02_279521	108	205	the	the	DT
10_1101-2020_09_02_279521	108	206	latent	latent	NN
10_1101-2020_09_02_279521	108	207	state	state	NN
10_1101-2020_09_02_279521	108	208	to	to	IN
10_1101-2020_09_02_279521	108	209	the	the	DT
10_1101-2020_09_02_279521	108	210	data	data	NN
10_1101-2020_09_02_279521	108	211	space	space	NN
10_1101-2020_09_02_279521	108	212	for	for	IN
10_1101-2020_09_02_279521	108	213	the	the	DT
10_1101-2020_09_02_279521	108	214	modality	modality	NN
10_1101-2020_09_02_279521	108	215	m.	m.	NN
10_1101-2020_09_02_279521	108	216	For	for	IN
10_1101-2020_09_02_279521	108	217	simplicity	simplicity	NN
10_1101-2020_09_02_279521	108	218	of	of	IN
10_1101-2020_09_02_279521	108	219	notation	notation	NN
10_1101-2020_09_02_279521	108	220	we	-PRON-	PRP
10_1101-2020_09_02_279521	108	221	denote	denote	VBP
10_1101-2020_09_02_279521	108	222	(	(	-LRB-
10_1101-2020_09_02_279521	108	223	)	)	-RRB-
10_1101-2020_09_02_279521	108	224	i	i	PRP
10_1101-2020_09_02_279521	108	225	tz	tz	VBP
10_1101-2020_09_02_279521	108	226	by	by	RB
10_1101-2020_09_02_279521	108	227	(	(	-LRB-
10_1101-2020_09_02_279521	108	228	)	)	-RRB-
10_1101-2020_09_02_279521	108	229	tz	tz	UH
10_1101-2020_09_02_279521	108	230	.	.	.
10_1101-2020_09_02_279521	109	1	We	-PRON-	PRP
10_1101-2020_09_02_279521	109	2	assume	assume	VBP
10_1101-2020_09_02_279521	109	3	that	that	IN
10_1101-2020_09_02_279521	109	4	each	each	DT
10_1101-2020_09_02_279521	109	5	coordinate	coordinate	NN
10_1101-2020_09_02_279521	109	6	of	of	IN
10_1101-2020_09_02_279521	109	7	z	z	NN
10_1101-2020_09_02_279521	109	8	is	be	VBZ
10_1101-2020_09_02_279521	109	9	associated	associate	VBN
10_1101-2020_09_02_279521	109	10	to	to	IN
10_1101-2020_09_02_279521	109	11	a	a	DT
10_1101-2020_09_02_279521	109	12	specific	specific	JJ
10_1101-2020_09_02_279521	109	13	modality	modality	NN
10_1101-2020_09_02_279521	109	14	m	m	NN
10_1101-2020_09_02_279521	109	15	,	,	,
10_1101-2020_09_02_279521	109	16	leading	lead	VBG
10_1101-2020_09_02_279521	109	17	to	to	IN
10_1101-2020_09_02_279521	109	18	an	an	DT
10_1101-2020_09_02_279521	109	19	M	M	NNP
10_1101-2020_09_02_279521	109	20	-	-	HYPH
10_1101-2020_09_02_279521	109	21	dimensional	dimensional	JJ
10_1101-2020_09_02_279521	109	22	latent	latent	NN
10_1101-2020_09_02_279521	109	23	space	space	NN
10_1101-2020_09_02_279521	109	24	.	.	.
10_1101-2020_09_02_279521	110	1	The	the	DT
10_1101-2020_09_02_279521	110	2			NNP
10_1101-2020_09_02_279521	110	3	operator	operator	NN
10_1101-2020_09_02_279521	110	4	which	which	WDT
10_1101-2020_09_02_279521	110	5	gives	give	VBZ
10_1101-2020_09_02_279521	110	6	the	the	DT
10_1101-2020_09_02_279521	110	7	value	value	NN
10_1101-2020_09_02_279521	110	8	of	of	IN
10_1101-2020_09_02_279521	110	9	the	the	DT
10_1101-2020_09_02_279521	110	10	latent	latent	NN
10_1101-2020_09_02_279521	110	11	representation	representation	NN
10_1101-2020_09_02_279521	110	12	at	at	IN
10_1101-2020_09_02_279521	110	13	a	a	DT
10_1101-2020_09_02_279521	110	14	given	give	VBN
10_1101-2020_09_02_279521	110	15	time	time	NN
10_1101-2020_09_02_279521	110	16	t	t	NN
10_1101-2020_09_02_279521	110	17	,	,	,
10_1101-2020_09_02_279521	110	18	is	be	VBZ
10_1101-2020_09_02_279521	110	19	defined	define	VBN
10_1101-2020_09_02_279521	110	20	by	by	IN
10_1101-2020_09_02_279521	110	21	the	the	DT
10_1101-2020_09_02_279521	110	22	solution	solution	NN
10_1101-2020_09_02_279521	110	23	of	of	IN
10_1101-2020_09_02_279521	110	24	the	the	DT
10_1101-2020_09_02_279521	110	25	following	follow	VBG
10_1101-2020_09_02_279521	110	26	system	system	NN
10_1101-2020_09_02_279521	110	27	of	of	IN
10_1101-2020_09_02_279521	110	28	ODEs	ode	NNS
10_1101-2020_09_02_279521	110	29	:	:	:
10_1101-2020_09_02_279521	110	30	,	,	,
10_1101-2020_09_02_279521	110	31	(	(	-LRB-
10_1101-2020_09_02_279521	110	32	)	)	-RRB-
10_1101-2020_09_02_279521	110	33	(	(	-LRB-
10_1101-2020_09_02_279521	110	34	)	)	-RRB-
10_1101-2020_09_02_279521	110	35	(	(	-LRB-
10_1101-2020_09_02_279521	110	36	1	1	CD
10_1101-2020_09_02_279521	110	37	(	(	-LRB-
10_1101-2020_09_02_279521	110	38	)	)	-RRB-
10_1101-2020_09_02_279521	110	39	)	)	-RRB-
10_1101-2020_09_02_279521	110	40	(	(	-LRB-
10_1101-2020_09_02_279521	110	41	)	)	-RRB-
10_1101-2020_09_02_279521	110	42	,	,	,
10_1101-2020_09_02_279521	110	43	=	=	SYM
10_1101-2020_09_02_279521	110	44	1	1	CD
10_1101-2020_09_02_279521	110	45	,	,	,
10_1101-2020_09_02_279521	110	46	...	...	:
10_1101-2020_09_02_279521	110	47	,	,	,
10_1101-2020_09_02_279521	110	48	.	.	.
10_1101-2020_09_02_279521	111	1	m	m	NNP
10_1101-2020_09_02_279521	111	2	m	m	NNP
10_1101-2020_09_02_279521	111	3	m	m	NNP
10_1101-2020_09_02_279521	111	4	j	j	NNP
10_1101-2020_09_02_279521	111	5	m	m	NNP
10_1101-2020_09_02_279521	111	6	m	m	NNP
10_1101-2020_09_02_279521	111	7	j	j	NNP
10_1101-2020_09_02_279521	111	8	j	j	NNP
10_1101-2020_09_02_279521	111	9	m	m	NNP
10_1101-2020_09_02_279521	111	10	dz	dz	NNP
10_1101-2020_09_02_279521	111	11	t	t	NNP
10_1101-2020_09_02_279521	111	12	k	k	NNP
10_1101-2020_09_02_279521	111	13	z	z	NNP
10_1101-2020_09_02_279521	111	14	t	t	NNP
10_1101-2020_09_02_279521	111	15	z	z	NNP
10_1101-2020_09_02_279521	111	16	t	t	NNP
10_1101-2020_09_02_279521	111	17	z	z	NNP
10_1101-2020_09_02_279521	111	18	t	t	NNP
10_1101-2020_09_02_279521	111	19	m	m	NNP
10_1101-2020_09_02_279521	111	20	M	M	NNP
10_1101-2020_09_02_279521	111	21	dt	dt	NNP
10_1101-2020_09_02_279521	111	22			NNP
10_1101-2020_09_02_279521	111	23			NNP
10_1101-2020_09_02_279521	111	24	=	=	SYM
10_1101-2020_09_02_279521	111	25	−	−	NNP
10_1101-2020_09_02_279521	111	26	+	+	SYM
10_1101-2020_09_02_279521	111	27			NNP
10_1101-2020_09_02_279521	111	28	(	(	-LRB-
10_1101-2020_09_02_279521	111	29	2	2	CD
10_1101-2020_09_02_279521	111	30	)	)	-RRB-
10_1101-2020_09_02_279521	111	31	For	for	IN
10_1101-2020_09_02_279521	111	32	each	each	DT
10_1101-2020_09_02_279521	111	33	coordinate	coordinate	NN
10_1101-2020_09_02_279521	111	34	,	,	,
10_1101-2020_09_02_279521	111	35	the	the	DT
10_1101-2020_09_02_279521	111	36	first	first	JJ
10_1101-2020_09_02_279521	111	37	term	term	NN
10_1101-2020_09_02_279521	111	38	of	of	IN
10_1101-2020_09_02_279521	111	39	the	the	DT
10_1101-2020_09_02_279521	111	40	equation	equation	NN
10_1101-2020_09_02_279521	111	41	enforces	enforce	VBZ
10_1101-2020_09_02_279521	111	42	a	a	DT
10_1101-2020_09_02_279521	111	43	sigmoidal	sigmoidal	JJ
10_1101-2020_09_02_279521	111	44	evolution	evolution	NN
10_1101-2020_09_02_279521	111	45	with	with	IN
10_1101-2020_09_02_279521	111	46	a	a	DT
10_1101-2020_09_02_279521	111	47	progression	progression	NN
10_1101-2020_09_02_279521	111	48	rate	rate	NN
10_1101-2020_09_02_279521	111	49	mk	mk	IN
10_1101-2020_09_02_279521	111	50	,	,	,
10_1101-2020_09_02_279521	111	51	while	while	IN
10_1101-2020_09_02_279521	111	52	the	the	DT
10_1101-2020_09_02_279521	111	53	second	second	JJ
10_1101-2020_09_02_279521	111	54	term	term	NN
10_1101-2020_09_02_279521	111	55	accounts	account	VBZ
10_1101-2020_09_02_279521	111	56	for	for	IN
10_1101-2020_09_02_279521	111	57	the	the	DT
10_1101-2020_09_02_279521	111	58	relationship	relationship	NN
10_1101-2020_09_02_279521	111	59	between	between	IN
10_1101-2020_09_02_279521	111	60	modalities	modalities	NNP
10_1101-2020_09_02_279521	111	61	m	m	NNP
10_1101-2020_09_02_279521	111	62	and	and	CC
10_1101-2020_09_02_279521	111	63	j	j	NNP
10_1101-2020_09_02_279521	111	64	through	through	IN
10_1101-2020_09_02_279521	111	65	the	the	DT
10_1101-2020_09_02_279521	111	66	parameters	parameter	NNS
10_1101-2020_09_02_279521	111	67	,	,	,
10_1101-2020_09_02_279521	111	68	m	m	NNP
10_1101-2020_09_02_279521	111	69	j	j	NNP
10_1101-2020_09_02_279521	111	70			NNP
10_1101-2020_09_02_279521	111	71	.	.	.
10_1101-2020_09_02_279521	112	1	This	this	DT
10_1101-2020_09_02_279521	112	2	system	system	NN
10_1101-2020_09_02_279521	112	3	can	can	MD
10_1101-2020_09_02_279521	112	4	be	be	VB
10_1101-2020_09_02_279521	112	5	rewritten	rewrite	VBN
10_1101-2020_09_02_279521	112	6	as	as	IN
10_1101-2020_09_02_279521	112	7	:	:	:
10_1101-2020_09_02_279521	112	8	2	2	CD
10_1101-2020_09_02_279521	112	9	i	i	PRP
10_1101-2020_09_02_279521	112	10	,	,	,
10_1101-2020_09_02_279521	112	11	i	i	NNP
10_1101-2020_09_02_279521	112	12	,	,	,
10_1101-2020_09_02_279521	112	13	j	j	NNP
10_1101-2020_09_02_279521	112	14	,	,	,
10_1101-2020_09_02_279521	112	15	,	,	,
10_1101-2020_09_02_279521	112	16	(	(	-LRB-
10_1101-2020_09_02_279521	112	17	)	)	-RRB-
10_1101-2020_09_02_279521	112	18	(	(	-LRB-
10_1101-2020_09_02_279521	112	19	)	)	-RRB-
10_1101-2020_09_02_279521	112	20	(	(	-LRB-
10_1101-2020_09_02_279521	112	21	)	)	-RRB-
10_1101-2020_09_02_279521	112	22	(	(	-LRB-
10_1101-2020_09_02_279521	112	23	(	(	-LRB-
10_1101-2020_09_02_279521	112	24	)	)	-RRB-
10_1101-2020_09_02_279521	112	25	,	,	,
10_1101-2020_09_02_279521	112	26	)	)	-RRB-
10_1101-2020_09_02_279521	112	27	where	where	WRB
10_1101-2020_09_02_279521	112	28	,	,	,
10_1101-2020_09_02_279521	112	29	if	if	IN
10_1101-2020_09_02_279521	112	30	i	i	PRP
10_1101-2020_09_02_279521	112	31	=	=	SYM
10_1101-2020_09_02_279521	112	32	j	j	NNP
10_1101-2020_09_02_279521	112	33	,	,	,
10_1101-2020_09_02_279521	112	34	k	k	XX
10_1101-2020_09_02_279521	112	35	if	if	IN
10_1101-2020_09_02_279521	112	36	i	i	PRP
10_1101-2020_09_02_279521	112	37	=	=	SYM
10_1101-2020_09_02_279521	112	38	j	j	NNP
10_1101-2020_09_02_279521	112	39	and	and	CC
10_1101-2020_09_02_279521	112	40	=	=	SYM
10_1101-2020_09_02_279521	112	41	otherwise	otherwise	RB
10_1101-2020_09_02_279521	112	42	;	;	:
10_1101-2020_09_02_279521	112	43	0	0	CD
10_1101-2020_09_02_279521	112	44	otherwise	otherwise	RB
10_1101-2020_09_02_279521	112	45	,	,	,
10_1101-2020_09_02_279521	112	46	if	if	IN
10_1101-2020_09_02_279521	112	47	i	i	PRP
10_1101-2020_09_02_279521	112	48	=	=	SYM
10_1101-2020_09_02_279521	112	49	j	j	NNP
10_1101-2020_09_02_279521	112	50	0	0	CD
10_1101-2020_09_02_279521	112	51	otherwise	otherwise	RB
10_1101-2020_09_02_279521	112	52	.	.	.
10_1101-2020_09_02_279521	113	1	(	(	-LRB-
10_1101-2020_09_02_279521	113	2	)	)	-RRB-
10_1101-2020_09_02_279521	113	3	(	(	-LRB-
10_1101-2020_09_02_279521	113	4	)	)	-RRB-
10_1101-2020_09_02_279521	113	5	(	(	-LRB-
10_1101-2020_09_02_279521	113	6	)	)	-RRB-
10_1101-2020_09_02_279521	113	7	ODE	ODE	NNP
10_1101-2020_09_02_279521	113	8	i	i	PRP
10_1101-2020_09_02_279521	113	9	i	i	PRP
10_1101-2020_09_02_279521	113	10	j	j	VBP
10_1101-2020_09_02_279521	113	11	i	i	NN
10_1101-2020_09_02_279521	113	12	j	j	NNP
10_1101-2020_09_02_279521	113	13	i	i	PRP
10_1101-2020_09_02_279521	113	14	i	i	PRP
10_1101-2020_09_02_279521	113	15	j	j	NNP
10_1101-2020_09_02_279521	113	16	d	d	NNP
10_1101-2020_09_02_279521	113	17	t	t	NNP
10_1101-2020_09_02_279521	113	18	t	t	NNP
10_1101-2020_09_02_279521	113	19	t	t	NNP
10_1101-2020_09_02_279521	113	20	g	g	NNP
10_1101-2020_09_02_279521	113	21	t	t	NNP
10_1101-2020_09_02_279521	113	22	dt	dt	NNP
10_1101-2020_09_02_279521	113	23	k	k	NNP
10_1101-2020_09_02_279521	113	24	k	k	NNP
10_1101-2020_09_02_279521	113	25			NNP
10_1101-2020_09_02_279521	113	26			NNP
10_1101-2020_09_02_279521	113	27	=	=	SYM
10_1101-2020_09_02_279521	113	28	−	−	NNP
10_1101-2020_09_02_279521	113	29	=	=	SYM
10_1101-2020_09_02_279521	113	30			XX
10_1101-2020_09_02_279521	113	31			VBZ
10_1101-2020_09_02_279521	113	32	=	=	NFP
10_1101-2020_09_02_279521	113	33			NNP
10_1101-2020_09_02_279521	113	34			NNP
10_1101-2020_09_02_279521	113	35			NNP
10_1101-2020_09_02_279521	113	36			NN
10_1101-2020_09_02_279521	113	37	=	=	NFP
10_1101-2020_09_02_279521	113	38			JJ
10_1101-2020_09_02_279521	113	39			FW
10_1101-2020_09_02_279521	113	40	z	z	LS
10_1101-2020_09_02_279521	113	41	Wz	Wz	NNP
10_1101-2020_09_02_279521	113	42	Vz	Vz	NNP
10_1101-2020_09_02_279521	113	43	z	z	NNP
10_1101-2020_09_02_279521	113	44	W	w	NN
10_1101-2020_09_02_279521	113	45	V	v	NN
10_1101-2020_09_02_279521	113	46	V	v	NN
10_1101-2020_09_02_279521	113	47	(	(	-LRB-
10_1101-2020_09_02_279521	113	48	3	3	CD
10_1101-2020_09_02_279521	113	49	)	)	-RRB-
10_1101-2020_09_02_279521	113	50	ODE	ODE	NNP
10_1101-2020_09_02_279521	113	51			NN
10_1101-2020_09_02_279521	113	52	denotes	denote	VBZ
10_1101-2020_09_02_279521	113	53	the	the	DT
10_1101-2020_09_02_279521	113	54	parameters	parameter	NNS
10_1101-2020_09_02_279521	113	55	of	of	IN
10_1101-2020_09_02_279521	113	56	the	the	DT
10_1101-2020_09_02_279521	113	57	system	system	NN
10_1101-2020_09_02_279521	113	58	of	of	IN
10_1101-2020_09_02_279521	113	59	ODEs	ode	NNS
10_1101-2020_09_02_279521	113	60	,	,	,
10_1101-2020_09_02_279521	113	61	which	which	WDT
10_1101-2020_09_02_279521	113	62	correspond	correspond	VBP
10_1101-2020_09_02_279521	113	63	to	to	IN
10_1101-2020_09_02_279521	113	64	the	the	DT
10_1101-2020_09_02_279521	113	65	entries	entry	NNS
10_1101-2020_09_02_279521	113	66	of	of	IN
10_1101-2020_09_02_279521	113	67	the	the	DT
10_1101-2020_09_02_279521	113	68	matrices	matrix	NNS
10_1101-2020_09_02_279521	113	69	W	W	NNP
10_1101-2020_09_02_279521	113	70	and	and	CC
10_1101-2020_09_02_279521	113	71	V.	V.	NNP
10_1101-2020_09_02_279521	113	72	According	accord	VBG
10_1101-2020_09_02_279521	113	73	to	to	IN
10_1101-2020_09_02_279521	113	74	Equation	Equation	NNP
10_1101-2020_09_02_279521	113	75	(	(	-LRB-
10_1101-2020_09_02_279521	113	76	3	3	CD
10_1101-2020_09_02_279521	113	77	)	)	-RRB-
10_1101-2020_09_02_279521	113	78	,	,	,
10_1101-2020_09_02_279521	113	79	for	for	IN
10_1101-2020_09_02_279521	113	80	each	each	DT
10_1101-2020_09_02_279521	113	81	initial	initial	JJ
10_1101-2020_09_02_279521	113	82	condition	condition	NN
10_1101-2020_09_02_279521	113	83	(	(	-LRB-
10_1101-2020_09_02_279521	113	84	0)z	0)z	NFP
10_1101-2020_09_02_279521	113	85	,	,	,
10_1101-2020_09_02_279521	113	86	the	the	DT
10_1101-2020_09_02_279521	113	87	latent	latent	NN
10_1101-2020_09_02_279521	113	88	state	state	NN
10_1101-2020_09_02_279521	113	89	at	at	IN
10_1101-2020_09_02_279521	113	90	time	time	NN
10_1101-2020_09_02_279521	113	91	t	t	NNP
10_1101-2020_09_02_279521	113	92	can	can	MD
10_1101-2020_09_02_279521	113	93	be	be	VB
10_1101-2020_09_02_279521	113	94	computed	compute	VBN
10_1101-2020_09_02_279521	113	95	through	through	IN
10_1101-2020_09_02_279521	113	96	integration	integration	NN
10_1101-2020_09_02_279521	113	97	,	,	,
10_1101-2020_09_02_279521	113	98	0	0	NFP
10_1101-2020_09_02_279521	113	99	(	(	-LRB-
10_1101-2020_09_02_279521	113	100	)	)	-RRB-
10_1101-2020_09_02_279521	113	101	(	(	-LRB-
10_1101-2020_09_02_279521	113	102	0	0	NFP
10_1101-2020_09_02_279521	113	103	)	)	-RRB-
10_1101-2020_09_02_279521	113	104	(	(	-LRB-
10_1101-2020_09_02_279521	113	105	(	(	-LRB-
10_1101-2020_09_02_279521	113	106	)	)	-RRB-
10_1101-2020_09_02_279521	113	107	,	,	,
10_1101-2020_09_02_279521	113	108	)	)	-RRB-
10_1101-2020_09_02_279521	113	109	t	t	NN
10_1101-2020_09_02_279521	113	110	ODE	ODE	NNP
10_1101-2020_09_02_279521	113	111	t	t	NN
10_1101-2020_09_02_279521	113	112	g	g	NN
10_1101-2020_09_02_279521	113	113	x	x	NNS
10_1101-2020_09_02_279521	113	114	dx=	dx=	NNP
10_1101-2020_09_02_279521	113	115	+	+	DT
10_1101-2020_09_02_279521	113	116	z	z	NNP
10_1101-2020_09_02_279521	113	117	z	z	NNP
10_1101-2020_09_02_279521	113	118	z	z	XX
10_1101-2020_09_02_279521	113	119	.	.	.
10_1101-2020_09_02_279521	114	1	.CC	.CC	NFP
10_1101-2020_09_02_279521	114	2	-	-	:
10_1101-2020_09_02_279521	114	3	BY	by	IN
10_1101-2020_09_02_279521	114	4	4.0	4.0	CD
10_1101-2020_09_02_279521	114	5	International	international	JJ
10_1101-2020_09_02_279521	114	6	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	114	7	.	.	.
10_1101-2020_09_02_279521	115	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	115	2	is	be	VBZ
10_1101-2020_09_02_279521	115	3	made	make	VBN
10_1101-2020_09_02_279521	115	4	available	available	JJ
10_1101-2020_09_02_279521	115	5	under	under	IN
10_1101-2020_09_02_279521	115	6	a	a	DT
10_1101-2020_09_02_279521	115	7	preprint	preprint	NN
10_1101-2020_09_02_279521	115	8	(	(	-LRB-
10_1101-2020_09_02_279521	115	9	which	which	WDT
10_1101-2020_09_02_279521	115	10	was	be	VBD
10_1101-2020_09_02_279521	115	11	not	not	RB
10_1101-2020_09_02_279521	115	12	certified	certify	VBN
10_1101-2020_09_02_279521	115	13	by	by	IN
10_1101-2020_09_02_279521	115	14	peer	peer	NN
10_1101-2020_09_02_279521	115	15	review	review	NN
10_1101-2020_09_02_279521	115	16	)	)	-RRB-
10_1101-2020_09_02_279521	115	17	is	be	VBZ
10_1101-2020_09_02_279521	115	18	the	the	DT
10_1101-2020_09_02_279521	115	19	author	author	NN
10_1101-2020_09_02_279521	115	20	/	/	SYM
10_1101-2020_09_02_279521	115	21	funder	funder	NN
10_1101-2020_09_02_279521	115	22	,	,	,
10_1101-2020_09_02_279521	115	23	who	who	WP
10_1101-2020_09_02_279521	115	24	has	have	VBZ
10_1101-2020_09_02_279521	115	25	granted	grant	VBN
10_1101-2020_09_02_279521	115	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	115	27	a	a	DT
10_1101-2020_09_02_279521	115	28	license	license	NN
10_1101-2020_09_02_279521	115	29	to	to	TO
10_1101-2020_09_02_279521	115	30	display	display	VB
10_1101-2020_09_02_279521	115	31	the	the	DT
10_1101-2020_09_02_279521	115	32	preprint	preprint	NN
10_1101-2020_09_02_279521	115	33	in	in	IN
10_1101-2020_09_02_279521	115	34	The	the	DT
10_1101-2020_09_02_279521	115	35	copyright	copyright	NN
10_1101-2020_09_02_279521	115	36	holder	holder	NN
10_1101-2020_09_02_279521	115	37	for	for	IN
10_1101-2020_09_02_279521	115	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	115	39	version	version	NN
10_1101-2020_09_02_279521	115	40	posted	post	VBD
10_1101-2020_09_02_279521	115	41	February	February	NNP
10_1101-2020_09_02_279521	115	42	10	10	CD
10_1101-2020_09_02_279521	115	43	,	,	,
10_1101-2020_09_02_279521	115	44	2021	2021	CD
10_1101-2020_09_02_279521	115	45	.	.	.
10_1101-2020_09_02_279521	115	46	;	;	:
10_1101-2020_09_02_279521	115	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	115	48	:	:	:
10_1101-2020_09_02_279521	115	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	115	50	preprint	preprint	NN
10_1101-2020_09_02_279521	115	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	UH
10_1101-2020_09_02_279521	115	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	-LRB-
10_1101-2020_09_02_279521	115	53	We	-PRON-	PRP
10_1101-2020_09_02_279521	115	54	resort	resort	VBP
10_1101-2020_09_02_279521	115	55	to	to	IN
10_1101-2020_09_02_279521	115	56	variational	variational	JJ
10_1101-2020_09_02_279521	115	57	inference	inference	NN
10_1101-2020_09_02_279521	115	58	and	and	CC
10_1101-2020_09_02_279521	115	59	stochastic	stochastic	JJ
10_1101-2020_09_02_279521	115	60	gradient	gradient	JJ
10_1101-2020_09_02_279521	115	61	descent	descent	NN
10_1101-2020_09_02_279521	115	62	in	in	IN
10_1101-2020_09_02_279521	115	63	order	order	NN
10_1101-2020_09_02_279521	115	64	to	to	TO
10_1101-2020_09_02_279521	115	65	optimize	optimize	VB
10_1101-2020_09_02_279521	115	66	the	the	DT
10_1101-2020_09_02_279521	115	67	parameters	parameter	NNS
10_1101-2020_09_02_279521	115	68	of	of	IN
10_1101-2020_09_02_279521	115	69	the	the	DT
10_1101-2020_09_02_279521	115	70	model	model	NN
10_1101-2020_09_02_279521	115	71	.	.	.
10_1101-2020_09_02_279521	116	1	The	the	DT
10_1101-2020_09_02_279521	116	2	procedure	procedure	NN
10_1101-2020_09_02_279521	116	3	is	be	VBZ
10_1101-2020_09_02_279521	116	4	detailed	detail	VBN
10_1101-2020_09_02_279521	116	5	in	in	IN
10_1101-2020_09_02_279521	116	6	Sections	section	NNS
10_1101-2020_09_02_279521	116	7	Variational	variational	JJ
10_1101-2020_09_02_279521	116	8	inference	inference	NN
10_1101-2020_09_02_279521	116	9	and	and	CC
10_1101-2020_09_02_279521	116	10	Model	model	NN
10_1101-2020_09_02_279521	116	11	optimization	optimization	NN
10_1101-2020_09_02_279521	116	12	of	of	IN
10_1101-2020_09_02_279521	116	13	the	the	DT
10_1101-2020_09_02_279521	116	14	Supplementary	Supplementary	NNP
10_1101-2020_09_02_279521	116	15	Material	Material	NNP
10_1101-2020_09_02_279521	116	16	.	.	.
10_1101-2020_09_02_279521	117	1	Simulating	simulate	VBG
10_1101-2020_09_02_279521	117	2	the	the	DT
10_1101-2020_09_02_279521	117	3	long	long	JJ
10_1101-2020_09_02_279521	117	4	-	-	HYPH
10_1101-2020_09_02_279521	117	5	term	term	NN
10_1101-2020_09_02_279521	117	6	progression	progression	NN
10_1101-2020_09_02_279521	117	7	of	of	IN
10_1101-2020_09_02_279521	117	8	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	117	9	’s	’s	POS
10_1101-2020_09_02_279521	117	10	disease	disease	NN
10_1101-2020_09_02_279521	117	11	To	to	TO
10_1101-2020_09_02_279521	117	12	simulate	simulate	VB
10_1101-2020_09_02_279521	117	13	the	the	DT
10_1101-2020_09_02_279521	117	14	long	long	JJ
10_1101-2020_09_02_279521	117	15	-	-	HYPH
10_1101-2020_09_02_279521	117	16	term	term	NN
10_1101-2020_09_02_279521	117	17	progression	progression	NN
10_1101-2020_09_02_279521	117	18	of	of	IN
10_1101-2020_09_02_279521	117	19	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	117	20	’s	’s	POS
10_1101-2020_09_02_279521	117	21	disease	disease	NN
10_1101-2020_09_02_279521	117	22	we	-PRON-	PRP
10_1101-2020_09_02_279521	117	23	first	first	RB
10_1101-2020_09_02_279521	117	24	project	project	VBP
10_1101-2020_09_02_279521	117	25	the	the	DT
10_1101-2020_09_02_279521	117	26	AD	ad	NN
10_1101-2020_09_02_279521	117	27	subjects	subject	NNS
10_1101-2020_09_02_279521	117	28	in	in	IN
10_1101-2020_09_02_279521	117	29	the	the	DT
10_1101-2020_09_02_279521	117	30	latent	latent	NN
10_1101-2020_09_02_279521	117	31	space	space	NN
10_1101-2020_09_02_279521	117	32	via	via	IN
10_1101-2020_09_02_279521	117	33	the	the	DT
10_1101-2020_09_02_279521	117	34	encoding	encoding	NN
10_1101-2020_09_02_279521	117	35	functions	function	NNS
10_1101-2020_09_02_279521	117	36	.	.	.
10_1101-2020_09_02_279521	118	1	We	-PRON-	PRP
10_1101-2020_09_02_279521	118	2	can	can	MD
10_1101-2020_09_02_279521	118	3	subsequently	subsequently	RB
10_1101-2020_09_02_279521	118	4	follow	follow	VB
10_1101-2020_09_02_279521	118	5	the	the	DT
10_1101-2020_09_02_279521	118	6	trajectories	trajectory	NNS
10_1101-2020_09_02_279521	118	7	of	of	IN
10_1101-2020_09_02_279521	118	8	these	these	DT
10_1101-2020_09_02_279521	118	9	subjects	subject	NNS
10_1101-2020_09_02_279521	118	10	backward	backward	RB
10_1101-2020_09_02_279521	118	11	and	and	CC
10_1101-2020_09_02_279521	118	12	forward	forward	RB
10_1101-2020_09_02_279521	118	13	in	in	IN
10_1101-2020_09_02_279521	118	14	time	time	NN
10_1101-2020_09_02_279521	118	15	,	,	,
10_1101-2020_09_02_279521	118	16	in	in	IN
10_1101-2020_09_02_279521	118	17	order	order	NN
10_1101-2020_09_02_279521	118	18	to	to	TO
10_1101-2020_09_02_279521	118	19	estimate	estimate	VB
10_1101-2020_09_02_279521	118	20	the	the	DT
10_1101-2020_09_02_279521	118	21	associated	associated	JJ
10_1101-2020_09_02_279521	118	22	trajectory	trajectory	CD
10_1101-2020_09_02_279521	118	23	from	from	IN
10_1101-2020_09_02_279521	118	24	the	the	DT
10_1101-2020_09_02_279521	118	25	healthy	healthy	JJ
10_1101-2020_09_02_279521	118	26	to	to	IN
10_1101-2020_09_02_279521	118	27	their	-PRON-	PRP$
10_1101-2020_09_02_279521	118	28	respective	respective	JJ
10_1101-2020_09_02_279521	118	29	pathological	pathological	JJ
10_1101-2020_09_02_279521	118	30	condition	condition	NN
10_1101-2020_09_02_279521	118	31	.	.	.
10_1101-2020_09_02_279521	119	1	In	in	IN
10_1101-2020_09_02_279521	119	2	practice	practice	NN
10_1101-2020_09_02_279521	119	3	,	,	,
10_1101-2020_09_02_279521	119	4	a	a	DT
10_1101-2020_09_02_279521	119	5	Gaussian	Gaussian	NNP
10_1101-2020_09_02_279521	119	6	Mixture	Mixture	NNP
10_1101-2020_09_02_279521	119	7	Model	Model	NNP
10_1101-2020_09_02_279521	119	8	is	be	VBZ
10_1101-2020_09_02_279521	119	9	used	use	VBN
10_1101-2020_09_02_279521	119	10	to	to	TO
10_1101-2020_09_02_279521	119	11	fit	fit	VB
10_1101-2020_09_02_279521	119	12	the	the	DT
10_1101-2020_09_02_279521	119	13	empirical	empirical	JJ
10_1101-2020_09_02_279521	119	14	distribution	distribution	NN
10_1101-2020_09_02_279521	119	15	of	of	IN
10_1101-2020_09_02_279521	119	16	the	the	DT
10_1101-2020_09_02_279521	119	17	AD	ad	NN
10_1101-2020_09_02_279521	119	18	subjects	subject	NNS
10_1101-2020_09_02_279521	119	19	'	'	POS
10_1101-2020_09_02_279521	119	20	latent	latent	NN
10_1101-2020_09_02_279521	119	21	projection	projection	NN
10_1101-2020_09_02_279521	119	22	.	.	.
10_1101-2020_09_02_279521	120	1	The	the	DT
10_1101-2020_09_02_279521	120	2	number	number	NN
10_1101-2020_09_02_279521	120	3	of	of	IN
10_1101-2020_09_02_279521	120	4	components	component	NNS
10_1101-2020_09_02_279521	120	5	and	and	CC
10_1101-2020_09_02_279521	120	6	covariance	covariance	NN
10_1101-2020_09_02_279521	120	7	type	type	NN
10_1101-2020_09_02_279521	120	8	of	of	IN
10_1101-2020_09_02_279521	120	9	the	the	DT
10_1101-2020_09_02_279521	120	10	Gaussian	Gaussian	NNP
10_1101-2020_09_02_279521	120	11	Mixture	Mixture	NNP
10_1101-2020_09_02_279521	120	12	Model	Model	NNP
10_1101-2020_09_02_279521	120	13	is	be	VBZ
10_1101-2020_09_02_279521	120	14	selected	select	VBN
10_1101-2020_09_02_279521	120	15	by	by	IN
10_1101-2020_09_02_279521	120	16	relying	rely	VBG
10_1101-2020_09_02_279521	120	17	on	on	IN
10_1101-2020_09_02_279521	120	18	the	the	DT
10_1101-2020_09_02_279521	120	19	Akaike	Akaike	NNP
10_1101-2020_09_02_279521	120	20	information	information	NN
10_1101-2020_09_02_279521	120	21	criterion	criterion	NN
10_1101-2020_09_02_279521	120	22	(	(	-LRB-
10_1101-2020_09_02_279521	120	23	Akaike	Akaike	NNP
10_1101-2020_09_02_279521	120	24	,	,	,
10_1101-2020_09_02_279521	120	25	1998	1998	CD
10_1101-2020_09_02_279521	120	26	)	)	-RRB-
10_1101-2020_09_02_279521	120	27	.	.	.
10_1101-2020_09_02_279521	121	1	The	the	DT
10_1101-2020_09_02_279521	121	2	fitted	fitted	JJ
10_1101-2020_09_02_279521	121	3	Gaussian	Gaussian	NNP
10_1101-2020_09_02_279521	121	4	Mixture	Mixture	NNP
10_1101-2020_09_02_279521	121	5	Model	Model	NNP
10_1101-2020_09_02_279521	121	6	allows	allow	VBZ
10_1101-2020_09_02_279521	121	7	us	-PRON-	PRP
10_1101-2020_09_02_279521	121	8	to	to	TO
10_1101-2020_09_02_279521	121	9	sample	sample	VB
10_1101-2020_09_02_279521	121	10	pathological	pathological	JJ
10_1101-2020_09_02_279521	121	11	latent	latent	NN
10_1101-2020_09_02_279521	121	12	representations	representation	NNS
10_1101-2020_09_02_279521	121	13	0	0	NFP
10_1101-2020_09_02_279521	121	14	(	(	-LRB-
10_1101-2020_09_02_279521	121	15	)	)	-RRB-
10_1101-2020_09_02_279521	121	16	i	i	PRP
10_1101-2020_09_02_279521	121	17	tz	tz	VBP
10_1101-2020_09_02_279521	121	18	that	that	WDT
10_1101-2020_09_02_279521	121	19	can	can	MD
10_1101-2020_09_02_279521	121	20	be	be	VB
10_1101-2020_09_02_279521	121	21	integrated	integrate	VBN
10_1101-2020_09_02_279521	121	22	forward	forward	RB
10_1101-2020_09_02_279521	121	23	and	and	CC
10_1101-2020_09_02_279521	121	24	backward	backward	JJ
10_1101-2020_09_02_279521	121	25	in	in	IN
10_1101-2020_09_02_279521	121	26	time	time	NN
10_1101-2020_09_02_279521	121	27	thanks	thank	NNS
10_1101-2020_09_02_279521	121	28	to	to	IN
10_1101-2020_09_02_279521	121	29	the	the	DT
10_1101-2020_09_02_279521	121	30	estimated	estimate	VBN
10_1101-2020_09_02_279521	121	31	set	set	NN
10_1101-2020_09_02_279521	121	32	of	of	IN
10_1101-2020_09_02_279521	121	33	latent	latent	NN
10_1101-2020_09_02_279521	121	34	ODEs	ode	NNS
10_1101-2020_09_02_279521	121	35	,	,	,
10_1101-2020_09_02_279521	121	36	to	to	TO
10_1101-2020_09_02_279521	121	37	finally	finally	RB
10_1101-2020_09_02_279521	121	38	obtain	obtain	VB
10_1101-2020_09_02_279521	121	39	a	a	DT
10_1101-2020_09_02_279521	121	40	collection	collection	NN
10_1101-2020_09_02_279521	121	41	of	of	IN
10_1101-2020_09_02_279521	121	42	latent	latent	NN
10_1101-2020_09_02_279521	121	43	trajectories	trajectory	NNS
10_1101-2020_09_02_279521	121	44	1	1	CD
10_1101-2020_09_02_279521	121	45	(	(	-LRB-
10_1101-2020_09_02_279521	121	46	)	)	-RRB-
10_1101-2020_09_02_279521	121	47	[	[	-LRB-
10_1101-2020_09_02_279521	121	48	(	(	-LRB-
10_1101-2020_09_02_279521	121	49	)	)	-RRB-
10_1101-2020_09_02_279521	121	50	,	,	,
10_1101-2020_09_02_279521	121	51	...	...	:
10_1101-2020_09_02_279521	121	52	,	,	,
10_1101-2020_09_02_279521	121	53	(	(	-LRB-
10_1101-2020_09_02_279521	121	54	)	)	-RRB-
10_1101-2020_09_02_279521	121	55	]	]	-RRB-
10_1101-2020_09_02_279521	121	56	N	n	NN
10_1101-2020_09_02_279521	121	57	t	t	NN
10_1101-2020_09_02_279521	121	58	t	t	NN
10_1101-2020_09_02_279521	121	59	t	t	NN
10_1101-2020_09_02_279521	121	60	=	=	SYM
10_1101-2020_09_02_279521	121	61	Z	z	NN
10_1101-2020_09_02_279521	121	62	z	z	NN
10_1101-2020_09_02_279521	121	63	z	z	NN
10_1101-2020_09_02_279521	121	64	summarizing	summarize	VBG
10_1101-2020_09_02_279521	121	65	the	the	DT
10_1101-2020_09_02_279521	121	66	distribution	distribution	NN
10_1101-2020_09_02_279521	121	67	of	of	IN
10_1101-2020_09_02_279521	121	68	the	the	DT
10_1101-2020_09_02_279521	121	69	long	long	JJ
10_1101-2020_09_02_279521	121	70	-	-	HYPH
10_1101-2020_09_02_279521	121	71	term	term	NN
10_1101-2020_09_02_279521	121	72	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	121	73	’s	’s	POS
10_1101-2020_09_02_279521	121	74	disease	disease	NN
10_1101-2020_09_02_279521	121	75	evolution	evolution	NN
10_1101-2020_09_02_279521	121	76	.	.	.
10_1101-2020_09_02_279521	122	1	Simulating	simulate	VBG
10_1101-2020_09_02_279521	122	2	intervention	intervention	NN
10_1101-2020_09_02_279521	122	3	In	in	IN
10_1101-2020_09_02_279521	122	4	this	this	DT
10_1101-2020_09_02_279521	122	5	section	section	NN
10_1101-2020_09_02_279521	122	6	we	-PRON-	PRP
10_1101-2020_09_02_279521	122	7	assume	assume	VBP
10_1101-2020_09_02_279521	122	8	that	that	IN
10_1101-2020_09_02_279521	122	9	we	-PRON-	PRP
10_1101-2020_09_02_279521	122	10	computed	compute	VBD
10_1101-2020_09_02_279521	122	11	the	the	DT
10_1101-2020_09_02_279521	122	12	average	average	JJ
10_1101-2020_09_02_279521	122	13	latent	latent	NN
10_1101-2020_09_02_279521	122	14	progression	progression	NN
10_1101-2020_09_02_279521	122	15	of	of	IN
10_1101-2020_09_02_279521	122	16	the	the	DT
10_1101-2020_09_02_279521	122	17	disease	disease	NN
10_1101-2020_09_02_279521	122	18	(	(	-LRB-
10_1101-2020_09_02_279521	122	19	)	)	-RRB-
10_1101-2020_09_02_279521	122	20	tz	tz	UH
10_1101-2020_09_02_279521	122	21	.	.	.
10_1101-2020_09_02_279521	123	1	Thanks	thank	NNS
10_1101-2020_09_02_279521	123	2	to	to	IN
10_1101-2020_09_02_279521	123	3	the	the	DT
10_1101-2020_09_02_279521	123	4	modality	modality	NN
10_1101-2020_09_02_279521	123	5	-	-	HYPH
10_1101-2020_09_02_279521	123	6	wise	wise	JJ
10_1101-2020_09_02_279521	123	7	encoding	encoding	NN
10_1101-2020_09_02_279521	123	8	(	(	-LRB-
10_1101-2020_09_02_279521	123	9	cf	cf	NN
10_1101-2020_09_02_279521	123	10	.	.	.
10_1101-2020_09_02_279521	124	1	Supplementary	supplementary	JJ
10_1101-2020_09_02_279521	124	2	section	section	NN
10_1101-2020_09_02_279521	124	3	Variational	variational	JJ
10_1101-2020_09_02_279521	124	4	inference	inference	NN
10_1101-2020_09_02_279521	124	5	)	)	-RRB-
10_1101-2020_09_02_279521	124	6	each	each	DT
10_1101-2020_09_02_279521	124	7	coordinate	coordinate	NN
10_1101-2020_09_02_279521	124	8	of	of	IN
10_1101-2020_09_02_279521	124	9	the	the	DT
10_1101-2020_09_02_279521	124	10	latent	latent	NN
10_1101-2020_09_02_279521	124	11	representation	representation	NN
10_1101-2020_09_02_279521	124	12	can	can	MD
10_1101-2020_09_02_279521	124	13	be	be	VB
10_1101-2020_09_02_279521	124	14	interpreted	interpret	VBN
10_1101-2020_09_02_279521	124	15	as	as	IN
10_1101-2020_09_02_279521	124	16	representing	represent	VBG
10_1101-2020_09_02_279521	124	17	a	a	DT
10_1101-2020_09_02_279521	124	18	single	single	JJ
10_1101-2020_09_02_279521	124	19	data	data	NN
10_1101-2020_09_02_279521	124	20	modality	modality	NN
10_1101-2020_09_02_279521	124	21	.	.	.
10_1101-2020_09_02_279521	125	1	Therefore	therefore	RB
10_1101-2020_09_02_279521	125	2	,	,	,
10_1101-2020_09_02_279521	125	3	we	-PRON-	PRP
10_1101-2020_09_02_279521	125	4	propose	propose	VBP
10_1101-2020_09_02_279521	125	5	to	to	TO
10_1101-2020_09_02_279521	125	6	simulate	simulate	VB
10_1101-2020_09_02_279521	125	7	the	the	DT
10_1101-2020_09_02_279521	125	8	effect	effect	NN
10_1101-2020_09_02_279521	125	9	of	of	IN
10_1101-2020_09_02_279521	125	10	a	a	DT
10_1101-2020_09_02_279521	125	11	hypothetical	hypothetical	JJ
10_1101-2020_09_02_279521	125	12	intervention	intervention	NN
10_1101-2020_09_02_279521	125	13	on	on	IN
10_1101-2020_09_02_279521	125	14	the	the	DT
10_1101-2020_09_02_279521	125	15	disease	disease	NN
10_1101-2020_09_02_279521	125	16	progression	progression	NN
10_1101-2020_09_02_279521	125	17	,	,	,
10_1101-2020_09_02_279521	125	18	by	by	IN
10_1101-2020_09_02_279521	125	19	modulating	modulate	VBG
10_1101-2020_09_02_279521	125	20	the	the	DT
10_1101-2020_09_02_279521	125	21	vector	vector	NN
10_1101-2020_09_02_279521	125	22	(	(	-LRB-
10_1101-2020_09_02_279521	125	23	)	)	-RRB-
10_1101-2020_09_02_279521	125	24	d	d	NNP
10_1101-2020_09_02_279521	125	25	t	t	NNP
10_1101-2020_09_02_279521	125	26	dt	dt	NNP
10_1101-2020_09_02_279521	125	27	z	z	NN
10_1101-2020_09_02_279521	125	28	after	after	IN
10_1101-2020_09_02_279521	125	29	each	each	DT
10_1101-2020_09_02_279521	125	30	integration	integration	NN
10_1101-2020_09_02_279521	125	31	step	step	NN
10_1101-2020_09_02_279521	125	32	such	such	PDT
10_1101-2020_09_02_279521	125	33	that	that	IN
10_1101-2020_09_02_279521	125	34	:	:	:
10_1101-2020_09_02_279521	125	35	1	1	CD
10_1101-2020_09_02_279521	125	36	*	*	NFP
10_1101-2020_09_02_279521	125	37	m	m	NNP
10_1101-2020_09_02_279521	125	38	(	(	-LRB-
10_1101-2020_09_02_279521	125	39	)	)	-RRB-
10_1101-2020_09_02_279521	125	40	(	(	-LRB-
10_1101-2020_09_02_279521	125	41	)	)	-RRB-
10_1101-2020_09_02_279521	125	42	where	where	WRB
10_1101-2020_09_02_279521	125	43	,	,	,
10_1101-2020_09_02_279521	125	44	=	=	NFP
10_1101-2020_09_02_279521	125	45	.	.	.
10_1101-2020_09_02_279521	126	1	(	(	-LRB-
10_1101-2020_09_02_279521	126	2	)	)	-RRB-
10_1101-2020_09_02_279521	126	3	d	d	NNP
10_1101-2020_09_02_279521	126	4	t	t	NNP
10_1101-2020_09_02_279521	126	5	d	d	NNP
10_1101-2020_09_02_279521	126	6	t	t	NNP
10_1101-2020_09_02_279521	126	7	dt	dt	NN
10_1101-2020_09_02_279521	126	8	dt	dt	VB
10_1101-2020_09_02_279521	126	9			NNP
10_1101-2020_09_02_279521	126	10			NNP
10_1101-2020_09_02_279521	126	11			NNP
10_1101-2020_09_02_279521	126	12			NNP
10_1101-2020_09_02_279521	126	13			NNP
10_1101-2020_09_02_279521	126	14			NNPS
10_1101-2020_09_02_279521	126	15	=	=	SYM
10_1101-2020_09_02_279521	126	16			XX
10_1101-2020_09_02_279521	126	17			NNPS
10_1101-2020_09_02_279521	126	18			NNP
10_1101-2020_09_02_279521	126	19			NNP
10_1101-2020_09_02_279521	126	20			NNP
10_1101-2020_09_02_279521	126	21			NN
10_1101-2020_09_02_279521	126	22	z	z	NNP
10_1101-2020_09_02_279521	126	23	z	z	NN
10_1101-2020_09_02_279521	126	24	Γ	Γ	NNP
10_1101-2020_09_02_279521	126	25	Γ	Γ	NNP
10_1101-2020_09_02_279521	126	26	(	(	-LRB-
10_1101-2020_09_02_279521	126	27	4	4	CD
10_1101-2020_09_02_279521	126	28	)	)	-RRB-
10_1101-2020_09_02_279521	126	29	The	the	DT
10_1101-2020_09_02_279521	126	30	values	value	NNS
10_1101-2020_09_02_279521	126	31	m	m	CD
10_1101-2020_09_02_279521	126	32	are	be	VBP
10_1101-2020_09_02_279521	126	33	fixed	fix	VBN
10_1101-2020_09_02_279521	126	34	between	between	IN
10_1101-2020_09_02_279521	126	35	0	0	CD
10_1101-2020_09_02_279521	126	36	and	and	CC
10_1101-2020_09_02_279521	126	37	1	1	CD
10_1101-2020_09_02_279521	126	38	,	,	,
10_1101-2020_09_02_279521	126	39	allowing	allow	VBG
10_1101-2020_09_02_279521	126	40	to	to	TO
10_1101-2020_09_02_279521	126	41	control	control	VB
10_1101-2020_09_02_279521	126	42	the	the	DT
10_1101-2020_09_02_279521	126	43	influence	influence	NN
10_1101-2020_09_02_279521	126	44	of	of	IN
10_1101-2020_09_02_279521	126	45	the	the	DT
10_1101-2020_09_02_279521	126	46	corresponding	correspond	VBG
10_1101-2020_09_02_279521	126	47	modalities	modality	NNS
10_1101-2020_09_02_279521	126	48	on	on	IN
10_1101-2020_09_02_279521	126	49	the	the	DT
10_1101-2020_09_02_279521	126	50	system	system	NN
10_1101-2020_09_02_279521	126	51	evolution	evolution	NN
10_1101-2020_09_02_279521	126	52	,	,	,
10_1101-2020_09_02_279521	126	53	and	and	CC
10_1101-2020_09_02_279521	126	54	to	to	TO
10_1101-2020_09_02_279521	126	55	create	create	VB
10_1101-2020_09_02_279521	126	56	hypothetical	hypothetical	JJ
10_1101-2020_09_02_279521	126	57	scenarios	scenario	NNS
10_1101-2020_09_02_279521	126	58	of	of	IN
10_1101-2020_09_02_279521	126	59	evolution	evolution	NN
10_1101-2020_09_02_279521	126	60	.	.	.
10_1101-2020_09_02_279521	127	1	For	for	IN
10_1101-2020_09_02_279521	127	2	.CC	.CC	NFP
10_1101-2020_09_02_279521	127	3	-	-	:
10_1101-2020_09_02_279521	127	4	BY	by	IN
10_1101-2020_09_02_279521	127	5	4.0	4.0	CD
10_1101-2020_09_02_279521	127	6	International	international	JJ
10_1101-2020_09_02_279521	127	7	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	127	8	.	.	.
10_1101-2020_09_02_279521	128	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	128	2	is	be	VBZ
10_1101-2020_09_02_279521	128	3	made	make	VBN
10_1101-2020_09_02_279521	128	4	available	available	JJ
10_1101-2020_09_02_279521	128	5	under	under	IN
10_1101-2020_09_02_279521	128	6	a	a	DT
10_1101-2020_09_02_279521	128	7	preprint	preprint	NN
10_1101-2020_09_02_279521	128	8	(	(	-LRB-
10_1101-2020_09_02_279521	128	9	which	which	WDT
10_1101-2020_09_02_279521	128	10	was	be	VBD
10_1101-2020_09_02_279521	128	11	not	not	RB
10_1101-2020_09_02_279521	128	12	certified	certify	VBN
10_1101-2020_09_02_279521	128	13	by	by	IN
10_1101-2020_09_02_279521	128	14	peer	peer	NN
10_1101-2020_09_02_279521	128	15	review	review	NN
10_1101-2020_09_02_279521	128	16	)	)	-RRB-
10_1101-2020_09_02_279521	128	17	is	be	VBZ
10_1101-2020_09_02_279521	128	18	the	the	DT
10_1101-2020_09_02_279521	128	19	author	author	NN
10_1101-2020_09_02_279521	128	20	/	/	SYM
10_1101-2020_09_02_279521	128	21	funder	funder	NN
10_1101-2020_09_02_279521	128	22	,	,	,
10_1101-2020_09_02_279521	128	23	who	who	WP
10_1101-2020_09_02_279521	128	24	has	have	VBZ
10_1101-2020_09_02_279521	128	25	granted	grant	VBN
10_1101-2020_09_02_279521	128	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	128	27	a	a	DT
10_1101-2020_09_02_279521	128	28	license	license	NN
10_1101-2020_09_02_279521	128	29	to	to	TO
10_1101-2020_09_02_279521	128	30	display	display	VB
10_1101-2020_09_02_279521	128	31	the	the	DT
10_1101-2020_09_02_279521	128	32	preprint	preprint	NN
10_1101-2020_09_02_279521	128	33	in	in	IN
10_1101-2020_09_02_279521	128	34	The	the	DT
10_1101-2020_09_02_279521	128	35	copyright	copyright	NN
10_1101-2020_09_02_279521	128	36	holder	holder	NN
10_1101-2020_09_02_279521	128	37	for	for	IN
10_1101-2020_09_02_279521	128	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	128	39	version	version	NN
10_1101-2020_09_02_279521	128	40	posted	post	VBD
10_1101-2020_09_02_279521	128	41	February	February	NNP
10_1101-2020_09_02_279521	128	42	10	10	CD
10_1101-2020_09_02_279521	128	43	,	,	,
10_1101-2020_09_02_279521	128	44	2021	2021	CD
10_1101-2020_09_02_279521	128	45	.	.	.
10_1101-2020_09_02_279521	128	46	;	;	:
10_1101-2020_09_02_279521	128	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	128	48	:	:	:
10_1101-2020_09_02_279521	128	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	128	50	preprint	preprint	NN
10_1101-2020_09_02_279521	128	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	NN
10_1101-2020_09_02_279521	128	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	-LRB-
10_1101-2020_09_02_279521	128	53	example	example	NN
10_1101-2020_09_02_279521	128	54	,	,	,
10_1101-2020_09_02_279521	128	55	for	for	IN
10_1101-2020_09_02_279521	128	56	a	a	DT
10_1101-2020_09_02_279521	128	57	100	100	CD
10_1101-2020_09_02_279521	128	58	%	%	NN
10_1101-2020_09_02_279521	128	59	(	(	-LRB-
10_1101-2020_09_02_279521	128	60	resp	resp	NN
10_1101-2020_09_02_279521	128	61	.	.	.
10_1101-2020_09_02_279521	129	1	50	50	CD
10_1101-2020_09_02_279521	129	2	%	%	NN
10_1101-2020_09_02_279521	129	3	)	)	-RRB-
10_1101-2020_09_02_279521	129	4	amyloid	amyloid	NN
10_1101-2020_09_02_279521	129	5	lowering	lower	VBG
10_1101-2020_09_02_279521	129	6	intervention	intervention	NN
10_1101-2020_09_02_279521	129	7	we	-PRON-	PRP
10_1101-2020_09_02_279521	129	8	set	set	VBP
10_1101-2020_09_02_279521	129	9	0	0	NFP
10_1101-2020_09_02_279521	129	10	amy	amy	NNP
10_1101-2020_09_02_279521	129	11			NN
10_1101-2020_09_02_279521	129	12	=	=	NFP
10_1101-2020_09_02_279521	129	13	(	(	-LRB-
10_1101-2020_09_02_279521	129	14	resp	resp	NN
10_1101-2020_09_02_279521	129	15	.	.	.
10_1101-2020_09_02_279521	130	1	0.5	0.5	CD
10_1101-2020_09_02_279521	130	2	amy	amy	NNP
10_1101-2020_09_02_279521	130	3			NNP
10_1101-2020_09_02_279521	130	4	=	=	SYM
10_1101-2020_09_02_279521	130	5	)	)	-RRB-
10_1101-2020_09_02_279521	130	6	.	.	.
10_1101-2020_09_02_279521	131	1	Evaluating	evaluate	VBG
10_1101-2020_09_02_279521	131	2	disease	disease	NN
10_1101-2020_09_02_279521	131	3	severity	severity	NN
10_1101-2020_09_02_279521	131	4	Given	give	VBN
10_1101-2020_09_02_279521	131	5	an	an	DT
10_1101-2020_09_02_279521	131	6	evolution	evolution	NN
10_1101-2020_09_02_279521	131	7	(	(	-LRB-
10_1101-2020_09_02_279521	131	8	)	)	-RRB-
10_1101-2020_09_02_279521	131	9	tz	tz	IN
10_1101-2020_09_02_279521	131	10	describing	describe	VBG
10_1101-2020_09_02_279521	131	11	the	the	DT
10_1101-2020_09_02_279521	131	12	disease	disease	NN
10_1101-2020_09_02_279521	131	13	progression	progression	NN
10_1101-2020_09_02_279521	131	14	in	in	IN
10_1101-2020_09_02_279521	131	15	the	the	DT
10_1101-2020_09_02_279521	131	16	latent	latent	NN
10_1101-2020_09_02_279521	131	17	space	space	NN
10_1101-2020_09_02_279521	131	18	,	,	,
10_1101-2020_09_02_279521	131	19	we	-PRON-	PRP
10_1101-2020_09_02_279521	131	20	propose	propose	VBP
10_1101-2020_09_02_279521	131	21	to	to	TO
10_1101-2020_09_02_279521	131	22	consider	consider	VB
10_1101-2020_09_02_279521	131	23	this	this	DT
10_1101-2020_09_02_279521	131	24	trajectory	trajectory	NN
10_1101-2020_09_02_279521	131	25	as	as	IN
10_1101-2020_09_02_279521	131	26	a	a	DT
10_1101-2020_09_02_279521	131	27	reference	reference	NN
10_1101-2020_09_02_279521	131	28	and	and	CC
10_1101-2020_09_02_279521	131	29	to	to	TO
10_1101-2020_09_02_279521	131	30	use	use	VB
10_1101-2020_09_02_279521	131	31	it	-PRON-	PRP
10_1101-2020_09_02_279521	131	32	in	in	IN
10_1101-2020_09_02_279521	131	33	order	order	NN
10_1101-2020_09_02_279521	131	34	to	to	TO
10_1101-2020_09_02_279521	131	35	quantify	quantify	VB
10_1101-2020_09_02_279521	131	36	the	the	DT
10_1101-2020_09_02_279521	131	37	individual	individual	JJ
10_1101-2020_09_02_279521	131	38	disease	disease	NN
10_1101-2020_09_02_279521	131	39	severity	severity	NN
10_1101-2020_09_02_279521	131	40	of	of	IN
10_1101-2020_09_02_279521	131	41	a	a	DT
10_1101-2020_09_02_279521	131	42	subject	subject	JJ
10_1101-2020_09_02_279521	131	43	X	x	NN
10_1101-2020_09_02_279521	131	44	.	.	.
10_1101-2020_09_02_279521	132	1	This	this	DT
10_1101-2020_09_02_279521	132	2	is	be	VBZ
10_1101-2020_09_02_279521	132	3	done	do	VBN
10_1101-2020_09_02_279521	132	4	by	by	IN
10_1101-2020_09_02_279521	132	5	estimating	estimate	VBG
10_1101-2020_09_02_279521	132	6	a	a	DT
10_1101-2020_09_02_279521	132	7	time	time	NN
10_1101-2020_09_02_279521	132	8	-	-	HYPH
10_1101-2020_09_02_279521	132	9	shift	shift	NN
10_1101-2020_09_02_279521	132	10			NN
10_1101-2020_09_02_279521	132	11	defined	define	VBN
10_1101-2020_09_02_279521	132	12	as	as	IN
10_1101-2020_09_02_279521	132	13	:	:	:
10_1101-2020_09_02_279521	132	14	1	1	CD
10_1101-2020_09_02_279521	132	15	1	1	CD
10_1101-2020_09_02_279521	132	16	1	1	CD
10_1101-2020_09_02_279521	132	17	||	||	NNP
10_1101-2020_09_02_279521	132	18	(	(	-LRB-
10_1101-2020_09_02_279521	132	19	,	,	,
10_1101-2020_09_02_279521	132	20	)	)	-RRB-
10_1101-2020_09_02_279521	132	21	(	(	-LRB-
10_1101-2020_09_02_279521	132	22	)	)	-RRB-
10_1101-2020_09_02_279521	132	23	||	||	NNP
10_1101-2020_09_02_279521	132	24	|	|	NNP
10_1101-2020_09_02_279521	132	25	(	(	-LRB-
10_1101-2020_09_02_279521	132	26	,	,	,
10_1101-2020_09_02_279521	132	27	)	)	-RRB-
10_1101-2020_09_02_279521	132	28	(	(	-LRB-
10_1101-2020_09_02_279521	132	29	)	)	-RRB-
10_1101-2020_09_02_279521	132	30	|	|	NNP
10_1101-2020_09_02_279521	132	31	.	.	.
10_1101-2020_09_02_279521	133	1	argmin	argmin	NNP
10_1101-2020_09_02_279521	133	2	t	t	NNP
10_1101-2020_09_02_279521	133	3	m	m	NNP
10_1101-2020_09_02_279521	133	4	m	m	NNP
10_1101-2020_09_02_279521	133	5	m	m	NNP
10_1101-2020_09_02_279521	133	6	f	f	NNP
10_1101-2020_09_02_279521	133	7	t	t	NNP
10_1101-2020_09_02_279521	133	8	f	f	NNP
10_1101-2020_09_02_279521	133	9	z	z	NNP
10_1101-2020_09_02_279521	133	10	t	t	NNP
10_1101-2020_09_02_279521	133	11			NNP
10_1101-2020_09_02_279521	133	12			NNP
10_1101-2020_09_02_279521	133	13			NNP
10_1101-2020_09_02_279521	133	14	=	=	-RRB-
10_1101-2020_09_02_279521	133	15	−	−	NNP
10_1101-2020_09_02_279521	133	16	=	=	SYM
10_1101-2020_09_02_279521	133	17	−	−	NNP
10_1101-2020_09_02_279521	133	18	X	x	NN
10_1101-2020_09_02_279521	133	19	z	z	NN
10_1101-2020_09_02_279521	133	20	x	x	NNS
10_1101-2020_09_02_279521	133	21	(	(	-LRB-
10_1101-2020_09_02_279521	133	22	5	5	CD
10_1101-2020_09_02_279521	133	23	)	)	-RRB-
10_1101-2020_09_02_279521	133	24	This	this	DT
10_1101-2020_09_02_279521	133	25	time	time	NN
10_1101-2020_09_02_279521	133	26	-	-	HYPH
10_1101-2020_09_02_279521	133	27	shift	shift	NN
10_1101-2020_09_02_279521	133	28	allows	allow	VBZ
10_1101-2020_09_02_279521	133	29	to	to	TO
10_1101-2020_09_02_279521	133	30	quantify	quantify	VB
10_1101-2020_09_02_279521	133	31	the	the	DT
10_1101-2020_09_02_279521	133	32	pathological	pathological	JJ
10_1101-2020_09_02_279521	133	33	stage	stage	NN
10_1101-2020_09_02_279521	133	34	of	of	IN
10_1101-2020_09_02_279521	133	35	a	a	DT
10_1101-2020_09_02_279521	133	36	subject	subject	NN
10_1101-2020_09_02_279521	133	37	with	with	IN
10_1101-2020_09_02_279521	133	38	respect	respect	NN
10_1101-2020_09_02_279521	133	39	to	to	IN
10_1101-2020_09_02_279521	133	40	the	the	DT
10_1101-2020_09_02_279521	133	41	disease	disease	NN
10_1101-2020_09_02_279521	133	42	progression	progression	NN
10_1101-2020_09_02_279521	133	43	along	along	IN
10_1101-2020_09_02_279521	133	44	the	the	DT
10_1101-2020_09_02_279521	133	45	reference	reference	NN
10_1101-2020_09_02_279521	133	46	trajectory	trajectory	CD
10_1101-2020_09_02_279521	133	47	(	(	-LRB-
10_1101-2020_09_02_279521	133	48	)	)	-RRB-
10_1101-2020_09_02_279521	133	49	tz	tz	UH
10_1101-2020_09_02_279521	133	50	.	.	.
10_1101-2020_09_02_279521	134	1	Moreover	moreover	RB
10_1101-2020_09_02_279521	134	2	,	,	,
10_1101-2020_09_02_279521	134	3	the	the	DT
10_1101-2020_09_02_279521	134	4	time	time	NN
10_1101-2020_09_02_279521	134	5	-	-	HYPH
10_1101-2020_09_02_279521	134	6	shift	shift	NN
10_1101-2020_09_02_279521	134	7	can	can	MD
10_1101-2020_09_02_279521	134	8	still	still	RB
10_1101-2020_09_02_279521	134	9	be	be	VB
10_1101-2020_09_02_279521	134	10	estimated	estimate	VBN
10_1101-2020_09_02_279521	134	11	even	even	RB
10_1101-2020_09_02_279521	134	12	in	in	IN
10_1101-2020_09_02_279521	134	13	the	the	DT
10_1101-2020_09_02_279521	134	14	case	case	NN
10_1101-2020_09_02_279521	134	15	of	of	IN
10_1101-2020_09_02_279521	134	16	missing	miss	VBG
10_1101-2020_09_02_279521	134	17	data	data	NN
10_1101-2020_09_02_279521	134	18	modalities	modality	NNS
10_1101-2020_09_02_279521	134	19	,	,	,
10_1101-2020_09_02_279521	134	20	by	by	IN
10_1101-2020_09_02_279521	134	21	only	only	RB
10_1101-2020_09_02_279521	134	22	encoding	encode	VBG
10_1101-2020_09_02_279521	134	23	the	the	DT
10_1101-2020_09_02_279521	134	24	available	available	JJ
10_1101-2020_09_02_279521	134	25	measures	measure	NNS
10_1101-2020_09_02_279521	134	26	of	of	IN
10_1101-2020_09_02_279521	134	27	the	the	DT
10_1101-2020_09_02_279521	134	28	observed	observed	JJ
10_1101-2020_09_02_279521	134	29	subject	subject	NN
10_1101-2020_09_02_279521	134	30	.	.	.
10_1101-2020_09_02_279521	135	1	Statistical	statistical	JJ
10_1101-2020_09_02_279521	135	2	analysis	analysis	NN
10_1101-2020_09_02_279521	135	3	The	the	DT
10_1101-2020_09_02_279521	135	4	model	model	NN
10_1101-2020_09_02_279521	135	5	was	be	VBD
10_1101-2020_09_02_279521	135	6	implemented	implement	VBN
10_1101-2020_09_02_279521	135	7	using	use	VBG
10_1101-2020_09_02_279521	135	8	the	the	DT
10_1101-2020_09_02_279521	135	9	Pytorch	Pytorch	NNP
10_1101-2020_09_02_279521	135	10	library	library	NN
10_1101-2020_09_02_279521	135	11	(	(	-LRB-
10_1101-2020_09_02_279521	135	12	Paszke	Paszke	NNP
10_1101-2020_09_02_279521	135	13	et	et	NNP
10_1101-2020_09_02_279521	135	14	al	al	NNP
10_1101-2020_09_02_279521	135	15	.	.	NNP
10_1101-2020_09_02_279521	135	16	,	,	,
10_1101-2020_09_02_279521	135	17	2019	2019	CD
10_1101-2020_09_02_279521	135	18	)	)	-RRB-
10_1101-2020_09_02_279521	135	19	.	.	.
10_1101-2020_09_02_279521	136	1	The	the	DT
10_1101-2020_09_02_279521	136	2	estimated	estimated	JJ
10_1101-2020_09_02_279521	136	3	disease	disease	NN
10_1101-2020_09_02_279521	136	4	severity	severity	NN
10_1101-2020_09_02_279521	136	5	was	be	VBD
10_1101-2020_09_02_279521	136	6	compared	compare	VBN
10_1101-2020_09_02_279521	136	7	group	group	NN
10_1101-2020_09_02_279521	136	8	-	-	HYPH
10_1101-2020_09_02_279521	136	9	wise	wise	JJ
10_1101-2020_09_02_279521	136	10	via	via	IN
10_1101-2020_09_02_279521	136	11	two	two	CD
10_1101-2020_09_02_279521	136	12	-	-	HYPH
10_1101-2020_09_02_279521	136	13	sided	sided	JJ
10_1101-2020_09_02_279521	136	14	Wilcoxon	Wilcoxon	NNP
10_1101-2020_09_02_279521	136	15	-	-	HYPH
10_1101-2020_09_02_279521	136	16	Mann	Mann	NNP
10_1101-2020_09_02_279521	136	17	-	-	HYPH
10_1101-2020_09_02_279521	136	18	Whitney	Whitney	NNP
10_1101-2020_09_02_279521	136	19	test	test	NN
10_1101-2020_09_02_279521	136	20	(	(	-LRB-
10_1101-2020_09_02_279521	136	21	P	p	NN
10_1101-2020_09_02_279521	136	22	<	<	XX
10_1101-2020_09_02_279521	136	23	0.01	0.01	XX
10_1101-2020_09_02_279521	136	24	)	)	-RRB-
10_1101-2020_09_02_279521	136	25	.	.	.
10_1101-2020_09_02_279521	137	1	Differences	difference	NNS
10_1101-2020_09_02_279521	137	2	between	between	IN
10_1101-2020_09_02_279521	137	3	the	the	DT
10_1101-2020_09_02_279521	137	4	clinical	clinical	JJ
10_1101-2020_09_02_279521	137	5	outcomes	outcome	NNS
10_1101-2020_09_02_279521	137	6	distribution	distribution	NN
10_1101-2020_09_02_279521	137	7	after	after	IN
10_1101-2020_09_02_279521	137	8	simulation	simulation	NN
10_1101-2020_09_02_279521	137	9	of	of	IN
10_1101-2020_09_02_279521	137	10	intervention	intervention	NN
10_1101-2020_09_02_279521	137	11	were	be	VBD
10_1101-2020_09_02_279521	137	12	compared	compare	VBN
10_1101-2020_09_02_279521	137	13	via	via	IN
10_1101-2020_09_02_279521	137	14	two	two	CD
10_1101-2020_09_02_279521	137	15	-	-	HYPH
10_1101-2020_09_02_279521	137	16	sided	sided	JJ
10_1101-2020_09_02_279521	137	17	Student	student	NN
10_1101-2020_09_02_279521	137	18	’s	’s	POS
10_1101-2020_09_02_279521	137	19	T	t	NN
10_1101-2020_09_02_279521	137	20	-	-	HYPH
10_1101-2020_09_02_279521	137	21	test	test	NN
10_1101-2020_09_02_279521	137	22	(	(	-LRB-
10_1101-2020_09_02_279521	137	23	P	p	NN
10_1101-2020_09_02_279521	137	24	<	<	XX
10_1101-2020_09_02_279521	137	25	0.01	0.01	XX
10_1101-2020_09_02_279521	137	26	)	)	-RRB-
10_1101-2020_09_02_279521	137	27	.	.	.
10_1101-2020_09_02_279521	138	1	Shadowed	shadowed	JJ
10_1101-2020_09_02_279521	138	2	areas	area	NNS
10_1101-2020_09_02_279521	138	3	in	in	IN
10_1101-2020_09_02_279521	138	4	the	the	DT
10_1101-2020_09_02_279521	138	5	different	different	JJ
10_1101-2020_09_02_279521	138	6	figures	figure	NNS
10_1101-2020_09_02_279521	138	7	show	show	VBP
10_1101-2020_09_02_279521	138	8	±	±	CD
10_1101-2020_09_02_279521	138	9	standard	standard	JJ
10_1101-2020_09_02_279521	138	10	deviation	deviation	NN
10_1101-2020_09_02_279521	138	11	of	of	IN
10_1101-2020_09_02_279521	138	12	the	the	DT
10_1101-2020_09_02_279521	138	13	mean	mean	NN
10_1101-2020_09_02_279521	138	14	.	.	.
10_1101-2020_09_02_279521	139	1	Data	datum	NNS
10_1101-2020_09_02_279521	139	2	availability	availability	NN
10_1101-2020_09_02_279521	139	3	The	the	DT
10_1101-2020_09_02_279521	139	4	data	datum	NNS
10_1101-2020_09_02_279521	139	5	used	use	VBN
10_1101-2020_09_02_279521	139	6	in	in	IN
10_1101-2020_09_02_279521	139	7	this	this	DT
10_1101-2020_09_02_279521	139	8	study	study	NN
10_1101-2020_09_02_279521	139	9	are	be	VBP
10_1101-2020_09_02_279521	139	10	available	available	JJ
10_1101-2020_09_02_279521	139	11	from	from	IN
10_1101-2020_09_02_279521	139	12	the	the	DT
10_1101-2020_09_02_279521	139	13	ADNI	ADNI	NNP
10_1101-2020_09_02_279521	139	14	database	database	NN
10_1101-2020_09_02_279521	139	15	(	(	-LRB-
10_1101-2020_09_02_279521	139	16	adni.loni.usc.edu	adni.loni.usc.edu	NN
10_1101-2020_09_02_279521	139	17	)	)	-RRB-
10_1101-2020_09_02_279521	139	18	.	.	.
10_1101-2020_09_02_279521	140	1	Results	result	NNS
10_1101-2020_09_02_279521	140	2	In	in	IN
10_1101-2020_09_02_279521	140	3	the	the	DT
10_1101-2020_09_02_279521	140	4	following	following	NN
10_1101-2020_09_02_279521	140	5	,	,	,
10_1101-2020_09_02_279521	140	6	MRI	MRI	NNP
10_1101-2020_09_02_279521	140	7	,	,	,
10_1101-2020_09_02_279521	140	8	FDG	FDG	NNP
10_1101-2020_09_02_279521	140	9	-	-	HYPH
10_1101-2020_09_02_279521	140	10	PET	PET	NNP
10_1101-2020_09_02_279521	140	11	,	,	,
10_1101-2020_09_02_279521	140	12	and	and	CC
10_1101-2020_09_02_279521	140	13	AV45-PET	av45-pet	JJ
10_1101-2020_09_02_279521	140	14	images	image	NNS
10_1101-2020_09_02_279521	140	15	are	be	VBP
10_1101-2020_09_02_279521	140	16	processed	process	VBN
10_1101-2020_09_02_279521	140	17	in	in	IN
10_1101-2020_09_02_279521	140	18	order	order	NN
10_1101-2020_09_02_279521	140	19	to	to	TO
10_1101-2020_09_02_279521	140	20	respectively	respectively	RB
10_1101-2020_09_02_279521	140	21	extract	extract	VB
10_1101-2020_09_02_279521	140	22	regional	regional	JJ
10_1101-2020_09_02_279521	140	23	gray	gray	JJ
10_1101-2020_09_02_279521	140	24	matter	matter	NN
10_1101-2020_09_02_279521	140	25	density	density	NN
10_1101-2020_09_02_279521	140	26	,	,	,
10_1101-2020_09_02_279521	140	27	glucose	glucose	VB
10_1101-2020_09_02_279521	140	28	metabolism	metabolism	NN
10_1101-2020_09_02_279521	140	29	and	and	CC
10_1101-2020_09_02_279521	140	30	amyloid	amyloid	NN
10_1101-2020_09_02_279521	140	31	load	load	NN
10_1101-2020_09_02_279521	140	32	from	from	IN
10_1101-2020_09_02_279521	140	33	.CC	.CC	NFP
10_1101-2020_09_02_279521	140	34	-	-	:
10_1101-2020_09_02_279521	140	35	BY	by	IN
10_1101-2020_09_02_279521	140	36	4.0	4.0	CD
10_1101-2020_09_02_279521	140	37	International	international	JJ
10_1101-2020_09_02_279521	140	38	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	140	39	.	.	.
10_1101-2020_09_02_279521	141	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	141	2	is	be	VBZ
10_1101-2020_09_02_279521	141	3	made	make	VBN
10_1101-2020_09_02_279521	141	4	available	available	JJ
10_1101-2020_09_02_279521	141	5	under	under	IN
10_1101-2020_09_02_279521	141	6	a	a	DT
10_1101-2020_09_02_279521	141	7	preprint	preprint	NN
10_1101-2020_09_02_279521	141	8	(	(	-LRB-
10_1101-2020_09_02_279521	141	9	which	which	WDT
10_1101-2020_09_02_279521	141	10	was	be	VBD
10_1101-2020_09_02_279521	141	11	not	not	RB
10_1101-2020_09_02_279521	141	12	certified	certify	VBN
10_1101-2020_09_02_279521	141	13	by	by	IN
10_1101-2020_09_02_279521	141	14	peer	peer	NN
10_1101-2020_09_02_279521	141	15	review	review	NN
10_1101-2020_09_02_279521	141	16	)	)	-RRB-
10_1101-2020_09_02_279521	141	17	is	be	VBZ
10_1101-2020_09_02_279521	141	18	the	the	DT
10_1101-2020_09_02_279521	141	19	author	author	NN
10_1101-2020_09_02_279521	141	20	/	/	SYM
10_1101-2020_09_02_279521	141	21	funder	funder	NN
10_1101-2020_09_02_279521	141	22	,	,	,
10_1101-2020_09_02_279521	141	23	who	who	WP
10_1101-2020_09_02_279521	141	24	has	have	VBZ
10_1101-2020_09_02_279521	141	25	granted	grant	VBN
10_1101-2020_09_02_279521	141	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	141	27	a	a	DT
10_1101-2020_09_02_279521	141	28	license	license	NN
10_1101-2020_09_02_279521	141	29	to	to	TO
10_1101-2020_09_02_279521	141	30	display	display	VB
10_1101-2020_09_02_279521	141	31	the	the	DT
10_1101-2020_09_02_279521	141	32	preprint	preprint	NN
10_1101-2020_09_02_279521	141	33	in	in	IN
10_1101-2020_09_02_279521	141	34	The	the	DT
10_1101-2020_09_02_279521	141	35	copyright	copyright	NN
10_1101-2020_09_02_279521	141	36	holder	holder	NN
10_1101-2020_09_02_279521	141	37	for	for	IN
10_1101-2020_09_02_279521	141	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	141	39	version	version	NN
10_1101-2020_09_02_279521	141	40	posted	post	VBD
10_1101-2020_09_02_279521	141	41	February	February	NNP
10_1101-2020_09_02_279521	141	42	10	10	CD
10_1101-2020_09_02_279521	141	43	,	,	,
10_1101-2020_09_02_279521	141	44	2021	2021	CD
10_1101-2020_09_02_279521	141	45	.	.	.
10_1101-2020_09_02_279521	141	46	;	;	:
10_1101-2020_09_02_279521	141	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	141	48	:	:	:
10_1101-2020_09_02_279521	141	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	141	50	preprint	preprint	NN
10_1101-2020_09_02_279521	141	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	ADD
10_1101-2020_09_02_279521	141	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	ADD
10_1101-2020_09_02_279521	141	53	a	a	DT
10_1101-2020_09_02_279521	141	54	brain	brain	NN
10_1101-2020_09_02_279521	141	55	parcellation	parcellation	NN
10_1101-2020_09_02_279521	141	56	.	.	.
10_1101-2020_09_02_279521	142	1	The	the	DT
10_1101-2020_09_02_279521	142	2	z	z	NN
10_1101-2020_09_02_279521	142	3	-	-	HYPH
10_1101-2020_09_02_279521	142	4	scores	score	NNS
10_1101-2020_09_02_279521	142	5	of	of	IN
10_1101-2020_09_02_279521	142	6	gray	gray	JJ
10_1101-2020_09_02_279521	142	7	matter	matter	NNP
10_1101-2020_09_02_279521	142	8	atrophy	atrophy	NNP
10_1101-2020_09_02_279521	142	9	(	(	-LRB-
10_1101-2020_09_02_279521	142	10	zatr	zatr	NNP
10_1101-2020_09_02_279521	142	11	)	)	-RRB-
10_1101-2020_09_02_279521	142	12	,	,	,
10_1101-2020_09_02_279521	142	13	glucose	glucose	VB
10_1101-2020_09_02_279521	142	14	metabolism	metabolism	NN
10_1101-2020_09_02_279521	142	15	(	(	-LRB-
10_1101-2020_09_02_279521	142	16	zmet	zmet	NNP
10_1101-2020_09_02_279521	142	17	)	)	-RRB-
10_1101-2020_09_02_279521	142	18	,	,	,
10_1101-2020_09_02_279521	142	19	and	and	CC
10_1101-2020_09_02_279521	142	20	amyloid	amyloid	NN
10_1101-2020_09_02_279521	142	21	burden	burden	NN
10_1101-2020_09_02_279521	142	22	(	(	-LRB-
10_1101-2020_09_02_279521	142	23	zamy	zamy	NNP
10_1101-2020_09_02_279521	142	24	)	)	-RRB-
10_1101-2020_09_02_279521	142	25	,	,	,
10_1101-2020_09_02_279521	142	26	are	be	VBP
10_1101-2020_09_02_279521	142	27	computed	compute	VBN
10_1101-2020_09_02_279521	142	28	using	use	VBG
10_1101-2020_09_02_279521	142	29	the	the	DT
10_1101-2020_09_02_279521	142	30	measures	measure	NNS
10_1101-2020_09_02_279521	142	31	obtained	obtain	VBN
10_1101-2020_09_02_279521	142	32	by	by	IN
10_1101-2020_09_02_279521	142	33	this	this	DT
10_1101-2020_09_02_279521	142	34	pre	pre	JJ
10_1101-2020_09_02_279521	142	35	-	-	JJ
10_1101-2020_09_02_279521	142	36	processing	processing	JJ
10_1101-2020_09_02_279521	142	37	step	step	NN
10_1101-2020_09_02_279521	142	38	.	.	.
10_1101-2020_09_02_279521	143	1	The	the	DT
10_1101-2020_09_02_279521	143	2	clinical	clinical	JJ
10_1101-2020_09_02_279521	143	3	z	z	JJ
10_1101-2020_09_02_279521	143	4	-	-	HYPH
10_1101-2020_09_02_279521	143	5	score	score	NN
10_1101-2020_09_02_279521	143	6	zcli	zcli	NN
10_1101-2020_09_02_279521	143	7	is	be	VBZ
10_1101-2020_09_02_279521	143	8	derived	derive	VBN
10_1101-2020_09_02_279521	143	9	from	from	IN
10_1101-2020_09_02_279521	143	10	neuro	neuro	NNP
10_1101-2020_09_02_279521	143	11	-	-	HYPH
10_1101-2020_09_02_279521	143	12	psychological	psychological	JJ
10_1101-2020_09_02_279521	143	13	scores	score	NNS
10_1101-2020_09_02_279521	143	14	:	:	:
10_1101-2020_09_02_279521	143	15	ADAS11	adas11	NN
10_1101-2020_09_02_279521	143	16	,	,	,
10_1101-2020_09_02_279521	143	17	MMSE	MMSE	NNP
10_1101-2020_09_02_279521	143	18	,	,	,
10_1101-2020_09_02_279521	143	19	FAQ	FAQ	NNP
10_1101-2020_09_02_279521	143	20	,	,	,
10_1101-2020_09_02_279521	143	21	RAVLT	RAVLT	NNP
10_1101-2020_09_02_279521	143	22	immediate	immediate	JJ
10_1101-2020_09_02_279521	143	23	,	,	,
10_1101-2020_09_02_279521	143	24	RAVLT	RAVLT	NNP
10_1101-2020_09_02_279521	143	25	learning	learning	NN
10_1101-2020_09_02_279521	143	26	,	,	,
10_1101-2020_09_02_279521	143	27	RAVLT	RAVLT	NNP
10_1101-2020_09_02_279521	143	28	forgetting	forgetting	NN
10_1101-2020_09_02_279521	143	29	and	and	CC
10_1101-2020_09_02_279521	143	30	CDRSB	CDRSB	NNP
10_1101-2020_09_02_279521	143	31	.	.	.
10_1101-2020_09_02_279521	144	1	This	this	DT
10_1101-2020_09_02_279521	144	2	panel	panel	NN
10_1101-2020_09_02_279521	144	3	of	of	IN
10_1101-2020_09_02_279521	144	4	scores	score	NNS
10_1101-2020_09_02_279521	144	5	was	be	VBD
10_1101-2020_09_02_279521	144	6	chosen	choose	VBN
10_1101-2020_09_02_279521	144	7	to	to	TO
10_1101-2020_09_02_279521	144	8	provide	provide	VB
10_1101-2020_09_02_279521	144	9	a	a	DT
10_1101-2020_09_02_279521	144	10	comprehensive	comprehensive	JJ
10_1101-2020_09_02_279521	144	11	representation	representation	NN
10_1101-2020_09_02_279521	144	12	of	of	IN
10_1101-2020_09_02_279521	144	13	cognitive	cognitive	JJ
10_1101-2020_09_02_279521	144	14	,	,	,
10_1101-2020_09_02_279521	144	15	memory	memory	NN
10_1101-2020_09_02_279521	144	16	and	and	CC
10_1101-2020_09_02_279521	144	17	functional	functional	JJ
10_1101-2020_09_02_279521	144	18	abilities	ability	NNS
10_1101-2020_09_02_279521	144	19	.	.	.
10_1101-2020_09_02_279521	145	1	Data	datum	NNS
10_1101-2020_09_02_279521	145	2	acquisition	acquisition	NN
10_1101-2020_09_02_279521	145	3	and	and	CC
10_1101-2020_09_02_279521	145	4	preprocessing	preprocesse	VBG
10_1101-2020_09_02_279521	145	5	Data	Data	NNP
10_1101-2020_09_02_279521	145	6	used	use	VBN
10_1101-2020_09_02_279521	145	7	in	in	IN
10_1101-2020_09_02_279521	145	8	the	the	DT
10_1101-2020_09_02_279521	145	9	preparation	preparation	NN
10_1101-2020_09_02_279521	145	10	of	of	IN
10_1101-2020_09_02_279521	145	11	this	this	DT
10_1101-2020_09_02_279521	145	12	article	article	NN
10_1101-2020_09_02_279521	145	13	were	be	VBD
10_1101-2020_09_02_279521	145	14	obtained	obtain	VBN
10_1101-2020_09_02_279521	145	15	from	from	IN
10_1101-2020_09_02_279521	145	16	the	the	DT
10_1101-2020_09_02_279521	145	17	ADNI	ADNI	NNP
10_1101-2020_09_02_279521	145	18	database	database	NN
10_1101-2020_09_02_279521	145	19	.	.	.
10_1101-2020_09_02_279521	146	1	The	the	DT
10_1101-2020_09_02_279521	146	2	ADNI	ADNI	NNP
10_1101-2020_09_02_279521	146	3	was	be	VBD
10_1101-2020_09_02_279521	146	4	launched	launch	VBN
10_1101-2020_09_02_279521	146	5	in	in	IN
10_1101-2020_09_02_279521	146	6	2003	2003	CD
10_1101-2020_09_02_279521	146	7	as	as	IN
10_1101-2020_09_02_279521	146	8	a	a	DT
10_1101-2020_09_02_279521	146	9	public	public	JJ
10_1101-2020_09_02_279521	146	10	-	-	HYPH
10_1101-2020_09_02_279521	146	11	private	private	JJ
10_1101-2020_09_02_279521	146	12	partnership	partnership	NN
10_1101-2020_09_02_279521	146	13	,	,	,
10_1101-2020_09_02_279521	146	14	led	lead	VBN
10_1101-2020_09_02_279521	146	15	by	by	IN
10_1101-2020_09_02_279521	146	16	Principal	Principal	NNP
10_1101-2020_09_02_279521	146	17	Investigator	Investigator	NNP
10_1101-2020_09_02_279521	146	18	Michael	Michael	NNP
10_1101-2020_09_02_279521	146	19	W.	W.	NNP
10_1101-2020_09_02_279521	146	20	Weiner	Weiner	NNP
10_1101-2020_09_02_279521	146	21	,	,	,
10_1101-2020_09_02_279521	146	22	MD	MD	NNP
10_1101-2020_09_02_279521	146	23	.	.	.
10_1101-2020_09_02_279521	147	1	For	for	IN
10_1101-2020_09_02_279521	147	2	up	up	RB
10_1101-2020_09_02_279521	147	3	-	-	HYPH
10_1101-2020_09_02_279521	147	4	to	to	IN
10_1101-2020_09_02_279521	147	5	-	-	HYPH
10_1101-2020_09_02_279521	147	6	date	date	NN
10_1101-2020_09_02_279521	147	7	information	information	NN
10_1101-2020_09_02_279521	147	8	,	,	,
10_1101-2020_09_02_279521	147	9	see	see	VB
10_1101-2020_09_02_279521	147	10	www.adni-info.org	www.adni-info.org	,
10_1101-2020_09_02_279521	147	11	.	.	.
10_1101-2020_09_02_279521	148	1	We	-PRON-	PRP
10_1101-2020_09_02_279521	148	2	considered	consider	VBD
10_1101-2020_09_02_279521	148	3	four	four	CD
10_1101-2020_09_02_279521	148	4	types	type	NNS
10_1101-2020_09_02_279521	148	5	of	of	IN
10_1101-2020_09_02_279521	148	6	biomarkers	biomarker	NNS
10_1101-2020_09_02_279521	148	7	,	,	,
10_1101-2020_09_02_279521	148	8	related	relate	VBN
10_1101-2020_09_02_279521	148	9	to	to	IN
10_1101-2020_09_02_279521	148	10	clinical	clinical	JJ
10_1101-2020_09_02_279521	148	11	scores	score	NNS
10_1101-2020_09_02_279521	148	12	,	,	,
10_1101-2020_09_02_279521	148	13	gray	gray	JJ
10_1101-2020_09_02_279521	148	14	matter	matter	NN
10_1101-2020_09_02_279521	148	15	atrophy	atrophy	NN
10_1101-2020_09_02_279521	148	16	,	,	,
10_1101-2020_09_02_279521	148	17	amyloid	amyloid	NN
10_1101-2020_09_02_279521	148	18	load	load	NN
10_1101-2020_09_02_279521	148	19	and	and	CC
10_1101-2020_09_02_279521	148	20	glucose	glucose	VB
10_1101-2020_09_02_279521	148	21	metabolism	metabolism	NN
10_1101-2020_09_02_279521	148	22	,	,	,
10_1101-2020_09_02_279521	148	23	and	and	CC
10_1101-2020_09_02_279521	148	24	respectively	respectively	RB
10_1101-2020_09_02_279521	148	25	denoted	denote	VBN
10_1101-2020_09_02_279521	148	26	by	by	IN
10_1101-2020_09_02_279521	148	27	cli	cli	NNP
10_1101-2020_09_02_279521	148	28	,	,	,
10_1101-2020_09_02_279521	148	29	atr	atr	NNP
10_1101-2020_09_02_279521	148	30	,	,	,
10_1101-2020_09_02_279521	148	31	amy	amy	NNP
10_1101-2020_09_02_279521	148	32	and	and	CC
10_1101-2020_09_02_279521	148	33	met	meet	VBD
10_1101-2020_09_02_279521	148	34	.	.	.
10_1101-2020_09_02_279521	149	1	MRI	mri	NN
10_1101-2020_09_02_279521	149	2	images	image	NNS
10_1101-2020_09_02_279521	149	3	were	be	VBD
10_1101-2020_09_02_279521	149	4	processed	process	VBN
10_1101-2020_09_02_279521	149	5	following	follow	VBG
10_1101-2020_09_02_279521	149	6	the	the	DT
10_1101-2020_09_02_279521	149	7	longitudinal	longitudinal	JJ
10_1101-2020_09_02_279521	149	8	pipeline	pipeline	NN
10_1101-2020_09_02_279521	149	9	of	of	IN
10_1101-2020_09_02_279521	149	10	Freesurfer	Freesurfer	NNP
10_1101-2020_09_02_279521	149	11	(	(	-LRB-
10_1101-2020_09_02_279521	149	12	Reuter	Reuter	NNP
10_1101-2020_09_02_279521	149	13	et	et	FW
10_1101-2020_09_02_279521	149	14	al	al	NNP
10_1101-2020_09_02_279521	149	15	.	.	NNP
10_1101-2020_09_02_279521	149	16	,	,	,
10_1101-2020_09_02_279521	149	17	2012	2012	CD
10_1101-2020_09_02_279521	149	18	)	)	-RRB-
10_1101-2020_09_02_279521	149	19	,	,	,
10_1101-2020_09_02_279521	149	20	to	to	TO
10_1101-2020_09_02_279521	149	21	obtain	obtain	VB
10_1101-2020_09_02_279521	149	22	gray	gray	JJ
10_1101-2020_09_02_279521	149	23	matter	matter	NN
10_1101-2020_09_02_279521	149	24	volumes	volume	NNS
10_1101-2020_09_02_279521	149	25	in	in	IN
10_1101-2020_09_02_279521	149	26	a	a	DT
10_1101-2020_09_02_279521	149	27	standard	standard	JJ
10_1101-2020_09_02_279521	149	28	anatomical	anatomical	JJ
10_1101-2020_09_02_279521	149	29	space	space	NN
10_1101-2020_09_02_279521	149	30	.	.	.
10_1101-2020_09_02_279521	150	1	AV45-PET	av45-pet	JJ
10_1101-2020_09_02_279521	150	2	and	and	CC
10_1101-2020_09_02_279521	150	3	FDG	fdg	JJ
10_1101-2020_09_02_279521	150	4	-	-	HYPH
10_1101-2020_09_02_279521	150	5	PET	pet	JJ
10_1101-2020_09_02_279521	150	6	images	image	NNS
10_1101-2020_09_02_279521	150	7	were	be	VBD
10_1101-2020_09_02_279521	150	8	aligned	align	VBN
10_1101-2020_09_02_279521	150	9	to	to	IN
10_1101-2020_09_02_279521	150	10	the	the	DT
10_1101-2020_09_02_279521	150	11	closest	close	JJS
10_1101-2020_09_02_279521	150	12	MRI	mri	NN
10_1101-2020_09_02_279521	150	13	in	in	IN
10_1101-2020_09_02_279521	150	14	time	time	NN
10_1101-2020_09_02_279521	150	15	and	and	CC
10_1101-2020_09_02_279521	150	16	normalized	normalize	VBD
10_1101-2020_09_02_279521	150	17	to	to	IN
10_1101-2020_09_02_279521	150	18	the	the	DT
10_1101-2020_09_02_279521	150	19	cerebellum	cerebellum	NN
10_1101-2020_09_02_279521	150	20	uptake	uptake	NN
10_1101-2020_09_02_279521	150	21	.	.	.
10_1101-2020_09_02_279521	151	1	Regional	regional	JJ
10_1101-2020_09_02_279521	151	2	gray	gray	JJ
10_1101-2020_09_02_279521	151	3	matter	matter	NN
10_1101-2020_09_02_279521	151	4	density	density	NN
10_1101-2020_09_02_279521	151	5	,	,	,
10_1101-2020_09_02_279521	151	6	amyloid	amyloid	NN
10_1101-2020_09_02_279521	151	7	load	load	NN
10_1101-2020_09_02_279521	151	8	and	and	CC
10_1101-2020_09_02_279521	151	9	glucose	glucose	VB
10_1101-2020_09_02_279521	151	10	metabolism	metabolism	NN
10_1101-2020_09_02_279521	151	11	were	be	VBD
10_1101-2020_09_02_279521	151	12	extracted	extract	VBN
10_1101-2020_09_02_279521	151	13	from	from	IN
10_1101-2020_09_02_279521	151	14	the	the	DT
10_1101-2020_09_02_279521	151	15	Desikan	Desikan	NNP
10_1101-2020_09_02_279521	151	16	-	-	HYPH
10_1101-2020_09_02_279521	151	17	Killiany	Killiany	NNP
10_1101-2020_09_02_279521	151	18	parcellation	parcellation	NN
10_1101-2020_09_02_279521	151	19	(	(	-LRB-
10_1101-2020_09_02_279521	151	20	Desikan	Desikan	NNP
10_1101-2020_09_02_279521	151	21	et	et	FW
10_1101-2020_09_02_279521	151	22	al	al	NNP
10_1101-2020_09_02_279521	151	23	.	.	NNP
10_1101-2020_09_02_279521	151	24	,	,	,
10_1101-2020_09_02_279521	151	25	2006	2006	CD
10_1101-2020_09_02_279521	151	26	)	)	-RRB-
10_1101-2020_09_02_279521	151	27	.	.	.
10_1101-2020_09_02_279521	152	1	We	-PRON-	PRP
10_1101-2020_09_02_279521	152	2	discarded	discard	VBD
10_1101-2020_09_02_279521	152	3	white	white	JJ
10_1101-2020_09_02_279521	152	4	-	-	HYPH
10_1101-2020_09_02_279521	152	5	matter	matter	NN
10_1101-2020_09_02_279521	152	6	,	,	,
10_1101-2020_09_02_279521	152	7	ventricular	ventricular	JJ
10_1101-2020_09_02_279521	152	8	,	,	,
10_1101-2020_09_02_279521	152	9	and	and	CC
10_1101-2020_09_02_279521	152	10	cerebellar	cerebellar	JJ
10_1101-2020_09_02_279521	152	11	regions	region	NNS
10_1101-2020_09_02_279521	152	12	,	,	,
10_1101-2020_09_02_279521	152	13	thus	thus	RB
10_1101-2020_09_02_279521	152	14	obtaining	obtain	VBG
10_1101-2020_09_02_279521	152	15	82	82	CD
10_1101-2020_09_02_279521	152	16	regions	region	NNS
10_1101-2020_09_02_279521	152	17	that	that	WDT
10_1101-2020_09_02_279521	152	18	were	be	VBD
10_1101-2020_09_02_279521	152	19	averaged	average	VBN
10_1101-2020_09_02_279521	152	20	across	across	IN
10_1101-2020_09_02_279521	152	21	hemispheres	hemisphere	NNS
10_1101-2020_09_02_279521	152	22	.	.	.
10_1101-2020_09_02_279521	153	1	Therefore	therefore	RB
10_1101-2020_09_02_279521	153	2	,	,	,
10_1101-2020_09_02_279521	153	3	for	for	IN
10_1101-2020_09_02_279521	153	4	a	a	DT
10_1101-2020_09_02_279521	153	5	given	give	VBN
10_1101-2020_09_02_279521	153	6	subject	subject	NN
10_1101-2020_09_02_279521	153	7	,	,	,
10_1101-2020_09_02_279521	153	8	xatr	xatr	NNP
10_1101-2020_09_02_279521	153	9	,	,	,
10_1101-2020_09_02_279521	153	10	xamy	xamy	NNP
10_1101-2020_09_02_279521	153	11	and	and	CC
10_1101-2020_09_02_279521	153	12	xmet	xmet	NNP
10_1101-2020_09_02_279521	153	13	are	be	VBP
10_1101-2020_09_02_279521	153	14	respectively	respectively	RB
10_1101-2020_09_02_279521	153	15	41-dimensional	41-dimensional	CD
10_1101-2020_09_02_279521	153	16	vectors	vector	NNS
10_1101-2020_09_02_279521	153	17	.	.	.
10_1101-2020_09_02_279521	154	1	The	the	DT
10_1101-2020_09_02_279521	154	2	variable	variable	NN
10_1101-2020_09_02_279521	154	3	xcli	xcli	NNP
10_1101-2020_09_02_279521	154	4	is	be	VBZ
10_1101-2020_09_02_279521	154	5	composed	compose	VBN
10_1101-2020_09_02_279521	154	6	of	of	IN
10_1101-2020_09_02_279521	154	7	the	the	DT
10_1101-2020_09_02_279521	154	8	neuro	neuro	JJ
10_1101-2020_09_02_279521	154	9	-	-	HYPH
10_1101-2020_09_02_279521	154	10	psychological	psychological	JJ
10_1101-2020_09_02_279521	154	11	scores	score	NNS
10_1101-2020_09_02_279521	154	12	ADAS11	adas11	NN
10_1101-2020_09_02_279521	154	13	,	,	,
10_1101-2020_09_02_279521	154	14	MMSE	MMSE	NNP
10_1101-2020_09_02_279521	154	15	,	,	,
10_1101-2020_09_02_279521	154	16	RAVLT	RAVLT	NNP
10_1101-2020_09_02_279521	154	17	immediate	immediate	JJ
10_1101-2020_09_02_279521	154	18	,	,	,
10_1101-2020_09_02_279521	154	19	RAVLT	RAVLT	NNP
10_1101-2020_09_02_279521	154	20	learning	learning	NN
10_1101-2020_09_02_279521	154	21	,	,	,
10_1101-2020_09_02_279521	154	22	RAVLT	RAVLT	NNP
10_1101-2020_09_02_279521	154	23	forgetting	forgetting	NN
10_1101-2020_09_02_279521	154	24	,	,	,
10_1101-2020_09_02_279521	154	25	FAQ	FAQ	NNP
10_1101-2020_09_02_279521	154	26	,	,	,
10_1101-2020_09_02_279521	154	27	and	and	CC
10_1101-2020_09_02_279521	154	28	CDRSB	CDRSB	NNP
10_1101-2020_09_02_279521	154	29	.	.	.
10_1101-2020_09_02_279521	155	1	The	the	DT
10_1101-2020_09_02_279521	155	2	total	total	JJ
10_1101-2020_09_02_279521	155	3	number	number	NN
10_1101-2020_09_02_279521	155	4	of	of	IN
10_1101-2020_09_02_279521	155	5	measures	measure	NNS
10_1101-2020_09_02_279521	155	6	is	be	VBZ
10_1101-2020_09_02_279521	155	7	of	of	IN
10_1101-2020_09_02_279521	155	8	2781	2781	CD
10_1101-2020_09_02_279521	155	9	longitudinal	longitudinal	JJ
10_1101-2020_09_02_279521	155	10	data	data	NN
10_1101-2020_09_02_279521	155	11	points	point	NNS
10_1101-2020_09_02_279521	155	12	.	.	.
10_1101-2020_09_02_279521	156	1	We	-PRON-	PRP
10_1101-2020_09_02_279521	156	2	recall	recall	VBP
10_1101-2020_09_02_279521	156	3	that	that	IN
10_1101-2020_09_02_279521	156	4	the	the	DT
10_1101-2020_09_02_279521	156	5	model	model	NN
10_1101-2020_09_02_279521	156	6	estimation	estimation	NN
10_1101-2020_09_02_279521	156	7	requires	require	VBZ
10_1101-2020_09_02_279521	156	8	a	a	DT
10_1101-2020_09_02_279521	156	9	visit	visit	NN
10_1101-2020_09_02_279521	156	10	for	for	IN
10_1101-2020_09_02_279521	156	11	which	which	WDT
10_1101-2020_09_02_279521	156	12	all	all	PDT
10_1101-2020_09_02_279521	156	13	the	the	DT
10_1101-2020_09_02_279521	156	14	measures	measure	NNS
10_1101-2020_09_02_279521	156	15	are	be	VBP
10_1101-2020_09_02_279521	156	16	available	available	JJ
10_1101-2020_09_02_279521	156	17	in	in	IN
10_1101-2020_09_02_279521	156	18	order	order	NN
10_1101-2020_09_02_279521	156	19	to	to	TO
10_1101-2020_09_02_279521	156	20	obtain	obtain	VB
10_1101-2020_09_02_279521	156	21	the	the	DT
10_1101-2020_09_02_279521	156	22	z	z	NN
10_1101-2020_09_02_279521	156	23	-	-	HYPH
10_1101-2020_09_02_279521	156	24	scores	score	NNS
10_1101-2020_09_02_279521	156	25	evolution	evolution	NN
10_1101-2020_09_02_279521	156	26	of	of	IN
10_1101-2020_09_02_279521	156	27	a	a	DT
10_1101-2020_09_02_279521	156	28	given	give	VBN
10_1101-2020_09_02_279521	156	29	subject	subject	NN
10_1101-2020_09_02_279521	156	30	,	,	,
10_1101-2020_09_02_279521	156	31	but	but	CC
10_1101-2020_09_02_279521	156	32	can	can	MD
10_1101-2020_09_02_279521	156	33	handle	handle	VB
10_1101-2020_09_02_279521	156	34	missing	miss	VBG
10_1101-2020_09_02_279521	156	35	data	datum	NNS
10_1101-2020_09_02_279521	156	36	in	in	IN
10_1101-2020_09_02_279521	156	37	the	the	DT
10_1101-2020_09_02_279521	156	38	follow	follow	NN
10_1101-2020_09_02_279521	156	39	-	-	HYPH
10_1101-2020_09_02_279521	156	40	up	up	NN
10_1101-2020_09_02_279521	156	41	by	by	IN
10_1101-2020_09_02_279521	156	42	finding	find	VBG
10_1101-2020_09_02_279521	156	43	the	the	DT
10_1101-2020_09_02_279521	156	44	parameters	parameter	NNS
10_1101-2020_09_02_279521	156	45	that	that	WDT
10_1101-2020_09_02_279521	156	46	best	well	RBS
10_1101-2020_09_02_279521	156	47	match	match	VBP
10_1101-2020_09_02_279521	156	48	the	the	DT
10_1101-2020_09_02_279521	156	49	available	available	JJ
10_1101-2020_09_02_279521	156	50	measures	measure	NNS
10_1101-2020_09_02_279521	156	51	.	.	.
10_1101-2020_09_02_279521	157	1	Progression	progression	NN
10_1101-2020_09_02_279521	157	2	model	model	NN
10_1101-2020_09_02_279521	157	3	and	and	CC
10_1101-2020_09_02_279521	157	4	latent	latent	NN
10_1101-2020_09_02_279521	157	5	relationships	relationship	NNS
10_1101-2020_09_02_279521	157	6	We	-PRON-	PRP
10_1101-2020_09_02_279521	157	7	show	show	VBP
10_1101-2020_09_02_279521	157	8	in	in	IN
10_1101-2020_09_02_279521	157	9	Figure	figure	NN
10_1101-2020_09_02_279521	157	10	2	2	CD
10_1101-2020_09_02_279521	157	11	panel	panel	NN
10_1101-2020_09_02_279521	157	12	I	-PRON-	PRP
10_1101-2020_09_02_279521	157	13	)	)	-RRB-
10_1101-2020_09_02_279521	157	14	the	the	DT
10_1101-2020_09_02_279521	157	15	dynamical	dynamical	JJ
10_1101-2020_09_02_279521	157	16	relationships	relationship	NNS
10_1101-2020_09_02_279521	157	17	across	across	IN
10_1101-2020_09_02_279521	157	18	the	the	DT
10_1101-2020_09_02_279521	157	19	different	different	JJ
10_1101-2020_09_02_279521	157	20	z	z	NN
10_1101-2020_09_02_279521	157	21	-	-	HYPH
10_1101-2020_09_02_279521	157	22	scores	score	NNS
10_1101-2020_09_02_279521	157	23	estimated	estimate	VBN
10_1101-2020_09_02_279521	157	24	by	by	IN
10_1101-2020_09_02_279521	157	25	the	the	DT
10_1101-2020_09_02_279521	157	26	model	model	NN
10_1101-2020_09_02_279521	157	27	,	,	,
10_1101-2020_09_02_279521	157	28	where	where	WRB
10_1101-2020_09_02_279521	157	29	direction	direction	NN
10_1101-2020_09_02_279521	157	30	and	and	CC
10_1101-2020_09_02_279521	157	31	intensity	intensity	NN
10_1101-2020_09_02_279521	157	32	of	of	IN
10_1101-2020_09_02_279521	157	33	the	the	DT
10_1101-2020_09_02_279521	157	34	arrows	arrow	NNS
10_1101-2020_09_02_279521	157	35	quantify	quantify	VBP
10_1101-2020_09_02_279521	157	36	the	the	DT
10_1101-2020_09_02_279521	157	37	estimated	estimate	VBN
10_1101-2020_09_02_279521	157	38	increase	increase	NN
10_1101-2020_09_02_279521	157	39	of	of	IN
10_1101-2020_09_02_279521	157	40	one	one	CD
10_1101-2020_09_02_279521	157	41	variable	variable	NN
10_1101-2020_09_02_279521	157	42	with	with	IN
10_1101-2020_09_02_279521	157	43	respect	respect	NN
10_1101-2020_09_02_279521	157	44	to	to	IN
10_1101-2020_09_02_279521	157	45	the	the	DT
10_1101-2020_09_02_279521	157	46	other	other	JJ
10_1101-2020_09_02_279521	157	47	.	.	.
10_1101-2020_09_02_279521	158	1	Being	be	VBG
10_1101-2020_09_02_279521	158	2	the	the	DT
10_1101-2020_09_02_279521	158	3	scores	score	NNS
10_1101-2020_09_02_279521	158	4	adimensional	adimensional	JJ
10_1101-2020_09_02_279521	158	5	,	,	,
10_1101-2020_09_02_279521	158	6	they	-PRON-	PRP
10_1101-2020_09_02_279521	158	7	have	have	VBP
10_1101-2020_09_02_279521	158	8	been	be	VBN
10_1101-2020_09_02_279521	158	9	conveniently	conveniently	RB
10_1101-2020_09_02_279521	158	10	rescaled	rescale	VBN
10_1101-2020_09_02_279521	158	11	to	to	IN
10_1101-2020_09_02_279521	158	12	the	the	DT
10_1101-2020_09_02_279521	158	13	range	range	NN
10_1101-2020_09_02_279521	158	14	[	[	-LRB-
10_1101-2020_09_02_279521	158	15	0,1	0,1	NFP
10_1101-2020_09_02_279521	158	16	]	]	-RRB-
10_1101-2020_09_02_279521	158	17	indicating	indicate	VBG
10_1101-2020_09_02_279521	158	18	increasing	increase	VBG
10_1101-2020_09_02_279521	158	19	pathological	pathological	JJ
10_1101-2020_09_02_279521	158	20	levels	level	NNS
10_1101-2020_09_02_279521	158	21	.	.	.
10_1101-2020_09_02_279521	159	1	These	these	DT
10_1101-2020_09_02_279521	159	2	.CC	.CC	:
10_1101-2020_09_02_279521	159	3	-	-	:
10_1101-2020_09_02_279521	159	4	BY	by	IN
10_1101-2020_09_02_279521	159	5	4.0	4.0	CD
10_1101-2020_09_02_279521	159	6	International	international	JJ
10_1101-2020_09_02_279521	159	7	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	159	8	.	.	.
10_1101-2020_09_02_279521	160	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	160	2	is	be	VBZ
10_1101-2020_09_02_279521	160	3	made	make	VBN
10_1101-2020_09_02_279521	160	4	available	available	JJ
10_1101-2020_09_02_279521	160	5	under	under	IN
10_1101-2020_09_02_279521	160	6	a	a	DT
10_1101-2020_09_02_279521	160	7	preprint	preprint	NN
10_1101-2020_09_02_279521	160	8	(	(	-LRB-
10_1101-2020_09_02_279521	160	9	which	which	WDT
10_1101-2020_09_02_279521	160	10	was	be	VBD
10_1101-2020_09_02_279521	160	11	not	not	RB
10_1101-2020_09_02_279521	160	12	certified	certify	VBN
10_1101-2020_09_02_279521	160	13	by	by	IN
10_1101-2020_09_02_279521	160	14	peer	peer	NN
10_1101-2020_09_02_279521	160	15	review	review	NN
10_1101-2020_09_02_279521	160	16	)	)	-RRB-
10_1101-2020_09_02_279521	160	17	is	be	VBZ
10_1101-2020_09_02_279521	160	18	the	the	DT
10_1101-2020_09_02_279521	160	19	author	author	NN
10_1101-2020_09_02_279521	160	20	/	/	SYM
10_1101-2020_09_02_279521	160	21	funder	funder	NN
10_1101-2020_09_02_279521	160	22	,	,	,
10_1101-2020_09_02_279521	160	23	who	who	WP
10_1101-2020_09_02_279521	160	24	has	have	VBZ
10_1101-2020_09_02_279521	160	25	granted	grant	VBN
10_1101-2020_09_02_279521	160	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	160	27	a	a	DT
10_1101-2020_09_02_279521	160	28	license	license	NN
10_1101-2020_09_02_279521	160	29	to	to	TO
10_1101-2020_09_02_279521	160	30	display	display	VB
10_1101-2020_09_02_279521	160	31	the	the	DT
10_1101-2020_09_02_279521	160	32	preprint	preprint	NN
10_1101-2020_09_02_279521	160	33	in	in	IN
10_1101-2020_09_02_279521	160	34	The	the	DT
10_1101-2020_09_02_279521	160	35	copyright	copyright	NN
10_1101-2020_09_02_279521	160	36	holder	holder	NN
10_1101-2020_09_02_279521	160	37	for	for	IN
10_1101-2020_09_02_279521	160	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	160	39	version	version	NN
10_1101-2020_09_02_279521	160	40	posted	post	VBD
10_1101-2020_09_02_279521	160	41	February	February	NNP
10_1101-2020_09_02_279521	160	42	10	10	CD
10_1101-2020_09_02_279521	160	43	,	,	,
10_1101-2020_09_02_279521	160	44	2021	2021	CD
10_1101-2020_09_02_279521	160	45	.	.	.
10_1101-2020_09_02_279521	160	46	;	;	:
10_1101-2020_09_02_279521	160	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	160	48	:	:	:
10_1101-2020_09_02_279521	160	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	160	50	preprint	preprint	NN
10_1101-2020_09_02_279521	160	51	http://www.adni-info.org/	http://www.adni-info.org/	NNP
10_1101-2020_09_02_279521	160	52	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	UH
10_1101-2020_09_02_279521	160	53	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	-LRB-
10_1101-2020_09_02_279521	160	54	relationships	relationship	NNS
10_1101-2020_09_02_279521	160	55	extend	extend	VBP
10_1101-2020_09_02_279521	160	56	the	the	DT
10_1101-2020_09_02_279521	160	57	summary	summary	NN
10_1101-2020_09_02_279521	160	58	statistics	statistic	NNS
10_1101-2020_09_02_279521	160	59	reported	report	VBN
10_1101-2020_09_02_279521	160	60	in	in	IN
10_1101-2020_09_02_279521	160	61	Table	table	NN
10_1101-2020_09_02_279521	160	62	1	1	CD
10_1101-2020_09_02_279521	160	63	to	to	IN
10_1101-2020_09_02_279521	160	64	a	a	DT
10_1101-2020_09_02_279521	160	65	much	much	RB
10_1101-2020_09_02_279521	160	66	finer	fine	JJR
10_1101-2020_09_02_279521	160	67	temporal	temporal	JJ
10_1101-2020_09_02_279521	160	68	scale	scale	NN
10_1101-2020_09_02_279521	160	69	and	and	CC
10_1101-2020_09_02_279521	160	70	wider	wide	JJR
10_1101-2020_09_02_279521	160	71	range	range	NN
10_1101-2020_09_02_279521	160	72	of	of	IN
10_1101-2020_09_02_279521	160	73	possible	possible	JJ
10_1101-2020_09_02_279521	160	74	biomarkers	biomarker	NNS
10_1101-2020_09_02_279521	160	75	'	'	POS
10_1101-2020_09_02_279521	160	76	values	value	NNS
10_1101-2020_09_02_279521	160	77	.	.	.
10_1101-2020_09_02_279521	161	1	We	-PRON-	PRP
10_1101-2020_09_02_279521	161	2	observe	observe	VBP
10_1101-2020_09_02_279521	161	3	in	in	IN
10_1101-2020_09_02_279521	161	4	Figure	Figure	NNP
10_1101-2020_09_02_279521	161	5	2A	2a	NN
10_1101-2020_09_02_279521	161	6	,	,	,
10_1101-2020_09_02_279521	161	7	2B	2B	NNS
10_1101-2020_09_02_279521	161	8	and	and	CC
10_1101-2020_09_02_279521	161	9	2C	2c	NN
10_1101-2020_09_02_279521	161	10	that	that	IN
10_1101-2020_09_02_279521	161	11	large	large	JJ
10_1101-2020_09_02_279521	161	12	values	value	NNS
10_1101-2020_09_02_279521	161	13	of	of	IN
10_1101-2020_09_02_279521	161	14	the	the	DT
10_1101-2020_09_02_279521	161	15	amyloid	amyloid	NN
10_1101-2020_09_02_279521	161	16	score	score	NN
10_1101-2020_09_02_279521	161	17	zamy	zamy	NNP
10_1101-2020_09_02_279521	161	18	trigger	trigger	NN
10_1101-2020_09_02_279521	161	19	the	the	DT
10_1101-2020_09_02_279521	161	20	increase	increase	NN
10_1101-2020_09_02_279521	161	21	of	of	IN
10_1101-2020_09_02_279521	161	22	the	the	DT
10_1101-2020_09_02_279521	161	23	remaining	remain	VBG
10_1101-2020_09_02_279521	161	24	ones	one	NNS
10_1101-2020_09_02_279521	161	25	:	:	:
10_1101-2020_09_02_279521	161	26	zmet	zmet	NNP
10_1101-2020_09_02_279521	161	27	,	,	,
10_1101-2020_09_02_279521	161	28	zatr	zatr	NNP
10_1101-2020_09_02_279521	161	29	,	,	,
10_1101-2020_09_02_279521	161	30	and	and	CC
10_1101-2020_09_02_279521	161	31	zcli	zcli	NNP
10_1101-2020_09_02_279521	161	32	.	.	.
10_1101-2020_09_02_279521	162	1	Figure	figure	NN
10_1101-2020_09_02_279521	162	2	2D	2d	NN
10_1101-2020_09_02_279521	162	3	shows	show	VBZ
10_1101-2020_09_02_279521	162	4	that	that	IN
10_1101-2020_09_02_279521	162	5	large	large	JJ
10_1101-2020_09_02_279521	162	6	increase	increase	NN
10_1101-2020_09_02_279521	162	7	of	of	IN
10_1101-2020_09_02_279521	162	8	the	the	DT
10_1101-2020_09_02_279521	162	9	atrophy	atrophy	NN
10_1101-2020_09_02_279521	162	10	score	score	NN
10_1101-2020_09_02_279521	162	11	zatr	zatr	NNP
10_1101-2020_09_02_279521	162	12	is	be	VBZ
10_1101-2020_09_02_279521	162	13	associated	associate	VBN
10_1101-2020_09_02_279521	162	14	to	to	IN
10_1101-2020_09_02_279521	162	15	pathological	pathological	JJ
10_1101-2020_09_02_279521	162	16	glucose	glucose	NN
10_1101-2020_09_02_279521	162	17	metabolism	metabolism	NN
10_1101-2020_09_02_279521	162	18	indicated	indicate	VBN
10_1101-2020_09_02_279521	162	19	by	by	IN
10_1101-2020_09_02_279521	162	20	large	large	JJ
10_1101-2020_09_02_279521	162	21	values	value	NNS
10_1101-2020_09_02_279521	162	22	of	of	IN
10_1101-2020_09_02_279521	162	23	zmet	zmet	NN
10_1101-2020_09_02_279521	162	24	.	.	.
10_1101-2020_09_02_279521	163	1	Moreover	moreover	RB
10_1101-2020_09_02_279521	163	2	,	,	,
10_1101-2020_09_02_279521	163	3	we	-PRON-	PRP
10_1101-2020_09_02_279521	163	4	note	note	VBP
10_1101-2020_09_02_279521	163	5	that	that	IN
10_1101-2020_09_02_279521	163	6	high	high	JJ
10_1101-2020_09_02_279521	163	7	zmet	zmet	NN
10_1101-2020_09_02_279521	163	8	values	value	NNS
10_1101-2020_09_02_279521	163	9	also	also	RB
10_1101-2020_09_02_279521	163	10	contribute	contribute	VBP
10_1101-2020_09_02_279521	163	11	to	to	IN
10_1101-2020_09_02_279521	163	12	an	an	DT
10_1101-2020_09_02_279521	163	13	increase	increase	NN
10_1101-2020_09_02_279521	163	14	of	of	IN
10_1101-2020_09_02_279521	163	15	zcli	zcli	NN
10_1101-2020_09_02_279521	163	16	(	(	-LRB-
10_1101-2020_09_02_279521	163	17	Figure	figure	NN
10_1101-2020_09_02_279521	163	18	2E	2e	NN
10_1101-2020_09_02_279521	163	19	)	)	-RRB-
10_1101-2020_09_02_279521	163	20	.	.	.
10_1101-2020_09_02_279521	164	1	Finally	finally	RB
10_1101-2020_09_02_279521	164	2	,	,	,
10_1101-2020_09_02_279521	164	3	Figure	figure	NN
10_1101-2020_09_02_279521	164	4	2F	2f	NN
10_1101-2020_09_02_279521	164	5	shows	show	VBZ
10_1101-2020_09_02_279521	164	6	that	that	IN
10_1101-2020_09_02_279521	164	7	high	high	JJ
10_1101-2020_09_02_279521	164	8	atrophy	atrophy	NN
10_1101-2020_09_02_279521	164	9	values	value	NNS
10_1101-2020_09_02_279521	164	10	lead	lead	VBP
10_1101-2020_09_02_279521	164	11	to	to	IN
10_1101-2020_09_02_279521	164	12	an	an	DT
10_1101-2020_09_02_279521	164	13	increase	increase	NN
10_1101-2020_09_02_279521	164	14	mostly	mostly	RB
10_1101-2020_09_02_279521	164	15	along	along	IN
10_1101-2020_09_02_279521	164	16	the	the	DT
10_1101-2020_09_02_279521	164	17	clinical	clinical	JJ
10_1101-2020_09_02_279521	164	18	dimension	dimension	NN
10_1101-2020_09_02_279521	164	19	zcli	zcli	NN
10_1101-2020_09_02_279521	164	20	.	.	.
10_1101-2020_09_02_279521	165	1	This	this	DT
10_1101-2020_09_02_279521	165	2	chain	chain	NN
10_1101-2020_09_02_279521	165	3	of	of	IN
10_1101-2020_09_02_279521	165	4	relationships	relationship	NNS
10_1101-2020_09_02_279521	165	5	is	be	VBZ
10_1101-2020_09_02_279521	165	6	in	in	IN
10_1101-2020_09_02_279521	165	7	agreement	agreement	NN
10_1101-2020_09_02_279521	165	8	with	with	IN
10_1101-2020_09_02_279521	165	9	the	the	DT
10_1101-2020_09_02_279521	165	10	cascade	cascade	NN
10_1101-2020_09_02_279521	165	11	hypothesis	hypothesis	NN
10_1101-2020_09_02_279521	165	12	of	of	IN
10_1101-2020_09_02_279521	165	13	AD	AD	NNP
10_1101-2020_09_02_279521	165	14	(	(	-LRB-
10_1101-2020_09_02_279521	165	15	Jack	Jack	NNP
10_1101-2020_09_02_279521	165	16	et	et	NNP
10_1101-2020_09_02_279521	165	17	al	al	NNP
10_1101-2020_09_02_279521	165	18	.	.	NNP
10_1101-2020_09_02_279521	165	19	,	,	,
10_1101-2020_09_02_279521	165	20	2013	2013	CD
10_1101-2020_09_02_279521	165	21	;	;	:
10_1101-2020_09_02_279521	165	22	Jack	Jack	NNP
10_1101-2020_09_02_279521	165	23	&	&	CC
10_1101-2020_09_02_279521	165	24	Holtzman	Holtzman	NNP
10_1101-2020_09_02_279521	165	25	,	,	,
10_1101-2020_09_02_279521	165	26	2013	2013	CD
10_1101-2020_09_02_279521	165	27	)	)	-RRB-
10_1101-2020_09_02_279521	165	28	.	.	.
10_1101-2020_09_02_279521	166	1	Relying	rely	VBG
10_1101-2020_09_02_279521	166	2	on	on	IN
10_1101-2020_09_02_279521	166	3	the	the	DT
10_1101-2020_09_02_279521	166	4	dynamical	dynamical	JJ
10_1101-2020_09_02_279521	166	5	relationships	relationship	NNS
10_1101-2020_09_02_279521	166	6	shown	show	VBN
10_1101-2020_09_02_279521	166	7	in	in	IN
10_1101-2020_09_02_279521	166	8	Figure	figure	NN
10_1101-2020_09_02_279521	166	9	2	2	CD
10_1101-2020_09_02_279521	166	10	panel	panel	NN
10_1101-2020_09_02_279521	166	11	I	I	NNP
10_1101-2020_09_02_279521	166	12	)	)	-RRB-
10_1101-2020_09_02_279521	166	13	,	,	,
10_1101-2020_09_02_279521	166	14	starting	start	VBG
10_1101-2020_09_02_279521	166	15	from	from	IN
10_1101-2020_09_02_279521	166	16	any	any	DT
10_1101-2020_09_02_279521	166	17	initial	initial	JJ
10_1101-2020_09_02_279521	166	18	set	set	NN
10_1101-2020_09_02_279521	166	19	of	of	IN
10_1101-2020_09_02_279521	166	20	biomarkers	biomarker	NNS
10_1101-2020_09_02_279521	166	21	values	value	NNS
10_1101-2020_09_02_279521	166	22	we	-PRON-	PRP
10_1101-2020_09_02_279521	166	23	can	can	MD
10_1101-2020_09_02_279521	166	24	estimate	estimate	VB
10_1101-2020_09_02_279521	166	25	the	the	DT
10_1101-2020_09_02_279521	166	26	relative	relative	JJ
10_1101-2020_09_02_279521	166	27	trajectories	trajectory	NNS
10_1101-2020_09_02_279521	166	28	over	over	IN
10_1101-2020_09_02_279521	166	29	time	time	NN
10_1101-2020_09_02_279521	166	30	.	.	.
10_1101-2020_09_02_279521	167	1	Figure	figure	NN
10_1101-2020_09_02_279521	167	2	2	2	CD
10_1101-2020_09_02_279521	167	3	panel	panel	NN
10_1101-2020_09_02_279521	167	4	II	II	NNP
10_1101-2020_09_02_279521	167	5	)	)	-RRB-
10_1101-2020_09_02_279521	167	6	(	(	-LRB-
10_1101-2020_09_02_279521	167	7	left	leave	VBN
10_1101-2020_09_02_279521	167	8	)	)	-RRB-
10_1101-2020_09_02_279521	167	9	,	,	,
10_1101-2020_09_02_279521	167	10	shows	show	VBZ
10_1101-2020_09_02_279521	167	11	the	the	DT
10_1101-2020_09_02_279521	167	12	evolution	evolution	NN
10_1101-2020_09_02_279521	167	13	obtained	obtain	VBN
10_1101-2020_09_02_279521	167	14	by	by	IN
10_1101-2020_09_02_279521	167	15	extrapolating	extrapolate	VBG
10_1101-2020_09_02_279521	167	16	backward	backward	RB
10_1101-2020_09_02_279521	167	17	and	and	CC
10_1101-2020_09_02_279521	167	18	forward	forward	RB
10_1101-2020_09_02_279521	167	19	in	in	IN
10_1101-2020_09_02_279521	167	20	time	time	NN
10_1101-2020_09_02_279521	167	21	the	the	DT
10_1101-2020_09_02_279521	167	22	trajectory	trajectory	NN
10_1101-2020_09_02_279521	167	23	associated	associate	VBN
10_1101-2020_09_02_279521	167	24	to	to	IN
10_1101-2020_09_02_279521	167	25	the	the	DT
10_1101-2020_09_02_279521	167	26	z	z	NN
10_1101-2020_09_02_279521	167	27	-	-	HYPH
10_1101-2020_09_02_279521	167	28	scores	score	NNS
10_1101-2020_09_02_279521	167	29	of	of	IN
10_1101-2020_09_02_279521	167	30	the	the	DT
10_1101-2020_09_02_279521	167	31	AD	ad	NN
10_1101-2020_09_02_279521	167	32	group	group	NN
10_1101-2020_09_02_279521	167	33	.	.	.
10_1101-2020_09_02_279521	168	1	The	the	DT
10_1101-2020_09_02_279521	168	2	x	x	NN
10_1101-2020_09_02_279521	168	3	-	-	:
10_1101-2020_09_02_279521	168	4	axis	axis	RB
10_1101-2020_09_02_279521	168	5	represents	represent	VBZ
10_1101-2020_09_02_279521	168	6	the	the	DT
10_1101-2020_09_02_279521	168	7	years	year	NNS
10_1101-2020_09_02_279521	168	8	from	from	IN
10_1101-2020_09_02_279521	168	9	conversion	conversion	NN
10_1101-2020_09_02_279521	168	10	to	to	IN
10_1101-2020_09_02_279521	168	11	AD	ad	NN
10_1101-2020_09_02_279521	168	12	,	,	,
10_1101-2020_09_02_279521	168	13	where	where	WRB
10_1101-2020_09_02_279521	168	14	the	the	DT
10_1101-2020_09_02_279521	168	15	instant	instant	NN
10_1101-2020_09_02_279521	168	16	t=0	t=0	VBD
10_1101-2020_09_02_279521	168	17	corresponds	correspond	NNS
10_1101-2020_09_02_279521	168	18	to	to	IN
10_1101-2020_09_02_279521	168	19	the	the	DT
10_1101-2020_09_02_279521	168	20	average	average	JJ
10_1101-2020_09_02_279521	168	21	time	time	NN
10_1101-2020_09_02_279521	168	22	of	of	IN
10_1101-2020_09_02_279521	168	23	diagnosis	diagnosis	NN
10_1101-2020_09_02_279521	168	24	estimated	estimate	VBN
10_1101-2020_09_02_279521	168	25	for	for	IN
10_1101-2020_09_02_279521	168	26	the	the	DT
10_1101-2020_09_02_279521	168	27	group	group	NN
10_1101-2020_09_02_279521	168	28	of	of	IN
10_1101-2020_09_02_279521	168	29	MCI	MCI	NNP
10_1101-2020_09_02_279521	168	30	progressing	progress	VBG
10_1101-2020_09_02_279521	168	31	to	to	IN
10_1101-2020_09_02_279521	168	32	dementia	dementia	NN
10_1101-2020_09_02_279521	168	33	.	.	.
10_1101-2020_09_02_279521	169	1	As	as	IN
10_1101-2020_09_02_279521	169	2	observed	observe	VBN
10_1101-2020_09_02_279521	169	3	in	in	IN
10_1101-2020_09_02_279521	169	4	Figure	figure	NN
10_1101-2020_09_02_279521	169	5	2	2	CD
10_1101-2020_09_02_279521	169	6	panel	panel	NN
10_1101-2020_09_02_279521	169	7	I	I	NNP
10_1101-2020_09_02_279521	169	8	)	)	-RRB-
10_1101-2020_09_02_279521	169	9	and	and	CC
10_1101-2020_09_02_279521	169	10	Table	table	NN
10_1101-2020_09_02_279521	169	11	1	1	CD
10_1101-2020_09_02_279521	169	12	,	,	,
10_1101-2020_09_02_279521	169	13	the	the	DT
10_1101-2020_09_02_279521	169	14	amyloid	amyloid	NN
10_1101-2020_09_02_279521	169	15	score	score	NN
10_1101-2020_09_02_279521	169	16	zamy	zamy	NN
10_1101-2020_09_02_279521	169	17	increases	increase	NNS
10_1101-2020_09_02_279521	169	18	and	and	CC
10_1101-2020_09_02_279521	169	19	saturates	saturate	NNS
10_1101-2020_09_02_279521	169	20	first	first	RB
10_1101-2020_09_02_279521	169	21	,	,	,
10_1101-2020_09_02_279521	169	22	followed	follow	VBN
10_1101-2020_09_02_279521	169	23	by	by	IN
10_1101-2020_09_02_279521	169	24	zmet	zmet	NNP
10_1101-2020_09_02_279521	169	25	and	and	CC
10_1101-2020_09_02_279521	169	26	zatr	zatr	NNP
10_1101-2020_09_02_279521	169	27	scores	score	NNS
10_1101-2020_09_02_279521	169	28	whose	whose	WP$
10_1101-2020_09_02_279521	169	29	progression	progression	NN
10_1101-2020_09_02_279521	169	30	slows	slow	VBZ
10_1101-2020_09_02_279521	169	31	down	down	RB
10_1101-2020_09_02_279521	169	32	when	when	WRB
10_1101-2020_09_02_279521	169	33	reaching	reach	VBG
10_1101-2020_09_02_279521	169	34	clinical	clinical	JJ
10_1101-2020_09_02_279521	169	35	conversion	conversion	NN
10_1101-2020_09_02_279521	169	36	,	,	,
10_1101-2020_09_02_279521	169	37	while	while	IN
10_1101-2020_09_02_279521	169	38	the	the	DT
10_1101-2020_09_02_279521	169	39	clinical	clinical	JJ
10_1101-2020_09_02_279521	169	40	score	score	NN
10_1101-2020_09_02_279521	169	41	exhibits	exhibit	VBZ
10_1101-2020_09_02_279521	169	42	strong	strong	JJ
10_1101-2020_09_02_279521	169	43	acceleration	acceleration	NN
10_1101-2020_09_02_279521	169	44	in	in	IN
10_1101-2020_09_02_279521	169	45	the	the	DT
10_1101-2020_09_02_279521	169	46	latest	late	JJS
10_1101-2020_09_02_279521	169	47	progression	progression	NN
10_1101-2020_09_02_279521	169	48	stages	stage	NNS
10_1101-2020_09_02_279521	169	49	.	.	.
10_1101-2020_09_02_279521	170	1	Figure	figure	NN
10_1101-2020_09_02_279521	170	2	2	2	CD
10_1101-2020_09_02_279521	170	3	panel	panel	NN
10_1101-2020_09_02_279521	170	4	II	II	NNP
10_1101-2020_09_02_279521	170	5	)	)	-RRB-
10_1101-2020_09_02_279521	170	6	(	(	-LRB-
10_1101-2020_09_02_279521	170	7	right	right	UH
10_1101-2020_09_02_279521	170	8	)	)	-RRB-
10_1101-2020_09_02_279521	170	9	shows	show	VBZ
10_1101-2020_09_02_279521	170	10	the	the	DT
10_1101-2020_09_02_279521	170	11	group-	group-	JJ
10_1101-2020_09_02_279521	170	12	wise	wise	JJ
10_1101-2020_09_02_279521	170	13	distribution	distribution	NN
10_1101-2020_09_02_279521	170	14	of	of	IN
10_1101-2020_09_02_279521	170	15	the	the	DT
10_1101-2020_09_02_279521	170	16	disease	disease	NN
10_1101-2020_09_02_279521	170	17	severity	severity	NN
10_1101-2020_09_02_279521	170	18	estimated	estimate	VBN
10_1101-2020_09_02_279521	170	19	for	for	IN
10_1101-2020_09_02_279521	170	20	each	each	DT
10_1101-2020_09_02_279521	170	21	subject	subject	NN
10_1101-2020_09_02_279521	170	22	relatively	relatively	RB
10_1101-2020_09_02_279521	170	23	to	to	IN
10_1101-2020_09_02_279521	170	24	the	the	DT
10_1101-2020_09_02_279521	170	25	modelled	model	VBN
10_1101-2020_09_02_279521	170	26	long	long	JJ
10_1101-2020_09_02_279521	170	27	-	-	HYPH
10_1101-2020_09_02_279521	170	28	term	term	NN
10_1101-2020_09_02_279521	170	29	latent	latent	NN
10_1101-2020_09_02_279521	170	30	trajectories	trajectory	NNS
10_1101-2020_09_02_279521	170	31	.	.	.
10_1101-2020_09_02_279521	171	1	The	the	DT
10_1101-2020_09_02_279521	171	2	group	group	NN
10_1101-2020_09_02_279521	171	3	-	-	HYPH
10_1101-2020_09_02_279521	171	4	wise	wise	JJ
10_1101-2020_09_02_279521	171	5	difference	difference	NN
10_1101-2020_09_02_279521	171	6	of	of	IN
10_1101-2020_09_02_279521	171	7	disease	disease	NN
10_1101-2020_09_02_279521	171	8	severity	severity	NN
10_1101-2020_09_02_279521	171	9	across	across	IN
10_1101-2020_09_02_279521	171	10	groups	group	NNS
10_1101-2020_09_02_279521	171	11	is	be	VBZ
10_1101-2020_09_02_279521	171	12	statistically	statistically	RB
10_1101-2020_09_02_279521	171	13	significant	significant	JJ
10_1101-2020_09_02_279521	171	14	and	and	CC
10_1101-2020_09_02_279521	171	15	increases	increase	NNS
10_1101-2020_09_02_279521	171	16	when	when	WRB
10_1101-2020_09_02_279521	171	17	going	go	VBG
10_1101-2020_09_02_279521	171	18	from	from	IN
10_1101-2020_09_02_279521	171	19	healthy	healthy	JJ
10_1101-2020_09_02_279521	171	20	to	to	IN
10_1101-2020_09_02_279521	171	21	pathological	pathological	JJ
10_1101-2020_09_02_279521	171	22	stages	stage	NNS
10_1101-2020_09_02_279521	171	23	(	(	-LRB-
10_1101-2020_09_02_279521	171	24	Wilcoxon	Wilcoxon	NNP
10_1101-2020_09_02_279521	171	25	-	-	HYPH
10_1101-2020_09_02_279521	171	26	Mann	Mann	NNP
10_1101-2020_09_02_279521	171	27	-	-	HYPH
10_1101-2020_09_02_279521	171	28	Whitney	Whitney	NNP
10_1101-2020_09_02_279521	171	29	test	test	NN
10_1101-2020_09_02_279521	171	30	p	p	NN
10_1101-2020_09_02_279521	171	31	<	<	XX
10_1101-2020_09_02_279521	171	32	0.01	0.01	CD
10_1101-2020_09_02_279521	171	33	for	for	IN
10_1101-2020_09_02_279521	171	34	each	each	DT
10_1101-2020_09_02_279521	171	35	comparisons	comparison	NNS
10_1101-2020_09_02_279521	171	36	)	)	-RRB-
10_1101-2020_09_02_279521	171	37	.	.	.
10_1101-2020_09_02_279521	172	1	The	the	DT
10_1101-2020_09_02_279521	172	2	reliability	reliability	NN
10_1101-2020_09_02_279521	172	3	of	of	IN
10_1101-2020_09_02_279521	172	4	the	the	DT
10_1101-2020_09_02_279521	172	5	estimation	estimation	NN
10_1101-2020_09_02_279521	172	6	of	of	IN
10_1101-2020_09_02_279521	172	7	disease	disease	NN
10_1101-2020_09_02_279521	172	8	severity	severity	NN
10_1101-2020_09_02_279521	172	9	was	be	VBD
10_1101-2020_09_02_279521	172	10	further	further	RB
10_1101-2020_09_02_279521	172	11	assessed	assess	VBN
10_1101-2020_09_02_279521	172	12	through	through	IN
10_1101-2020_09_02_279521	172	13	testing	testing	NN
10_1101-2020_09_02_279521	172	14	on	on	IN
10_1101-2020_09_02_279521	172	15	an	an	DT
10_1101-2020_09_02_279521	172	16	independent	independent	JJ
10_1101-2020_09_02_279521	172	17	cohort	cohort	NN
10_1101-2020_09_02_279521	172	18	,	,	,
10_1101-2020_09_02_279521	172	19	and	and	CC
10_1101-2020_09_02_279521	172	20	by	by	IN
10_1101-2020_09_02_279521	172	21	comparison	comparison	NN
10_1101-2020_09_02_279521	172	22	with	with	IN
10_1101-2020_09_02_279521	172	23	a	a	DT
10_1101-2020_09_02_279521	172	24	previously	previously	RB
10_1101-2020_09_02_279521	172	25	proposed	propose	VBN
10_1101-2020_09_02_279521	172	26	disease	disease	NN
10_1101-2020_09_02_279521	172	27	progression	progression	NN
10_1101-2020_09_02_279521	172	28	modeling	modeling	NN
10_1101-2020_09_02_279521	172	29	method	method	NN
10_1101-2020_09_02_279521	172	30	from	from	IN
10_1101-2020_09_02_279521	172	31	the	the	DT
10_1101-2020_09_02_279521	172	32	state-	state-	NNP
10_1101-2020_09_02_279521	172	33	of	of	IN
10_1101-2020_09_02_279521	172	34	-	-	HYPH
10_1101-2020_09_02_279521	172	35	the	the	DT
10_1101-2020_09_02_279521	172	36	-	-	HYPH
10_1101-2020_09_02_279521	172	37	art	art	NN
10_1101-2020_09_02_279521	172	38	(	(	-LRB-
10_1101-2020_09_02_279521	172	39	Lorenzi	Lorenzi	NNP
10_1101-2020_09_02_279521	172	40	et	et	NNP
10_1101-2020_09_02_279521	172	41	al	al	NNP
10_1101-2020_09_02_279521	172	42	.	.	NNP
10_1101-2020_09_02_279521	172	43	,	,	,
10_1101-2020_09_02_279521	172	44	2017	2017	CD
10_1101-2020_09_02_279521	172	45	)	)	-RRB-
10_1101-2020_09_02_279521	172	46	.	.	.
10_1101-2020_09_02_279521	173	1	The	the	DT
10_1101-2020_09_02_279521	173	2	results	result	NNS
10_1101-2020_09_02_279521	173	3	are	be	VBP
10_1101-2020_09_02_279521	173	4	provided	provide	VBN
10_1101-2020_09_02_279521	173	5	in	in	IN
10_1101-2020_09_02_279521	173	6	section	section	NN
10_1101-2020_09_02_279521	173	7	Time	Time	NNP
10_1101-2020_09_02_279521	173	8	-	-	HYPH
10_1101-2020_09_02_279521	173	9	shift	shift	NN
10_1101-2020_09_02_279521	173	10	comparison	comparison	NN
10_1101-2020_09_02_279521	173	11	and	and	CC
10_1101-2020_09_02_279521	173	12	.CC	.CC	:
10_1101-2020_09_02_279521	173	13	-	-	:
10_1101-2020_09_02_279521	173	14	BY	by	IN
10_1101-2020_09_02_279521	173	15	4.0	4.0	CD
10_1101-2020_09_02_279521	173	16	International	international	JJ
10_1101-2020_09_02_279521	173	17	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	173	18	.	.	.
10_1101-2020_09_02_279521	174	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	174	2	is	be	VBZ
10_1101-2020_09_02_279521	174	3	made	make	VBN
10_1101-2020_09_02_279521	174	4	available	available	JJ
10_1101-2020_09_02_279521	174	5	under	under	IN
10_1101-2020_09_02_279521	174	6	a	a	DT
10_1101-2020_09_02_279521	174	7	preprint	preprint	NN
10_1101-2020_09_02_279521	174	8	(	(	-LRB-
10_1101-2020_09_02_279521	174	9	which	which	WDT
10_1101-2020_09_02_279521	174	10	was	be	VBD
10_1101-2020_09_02_279521	174	11	not	not	RB
10_1101-2020_09_02_279521	174	12	certified	certify	VBN
10_1101-2020_09_02_279521	174	13	by	by	IN
10_1101-2020_09_02_279521	174	14	peer	peer	NN
10_1101-2020_09_02_279521	174	15	review	review	NN
10_1101-2020_09_02_279521	174	16	)	)	-RRB-
10_1101-2020_09_02_279521	174	17	is	be	VBZ
10_1101-2020_09_02_279521	174	18	the	the	DT
10_1101-2020_09_02_279521	174	19	author	author	NN
10_1101-2020_09_02_279521	174	20	/	/	SYM
10_1101-2020_09_02_279521	174	21	funder	funder	NN
10_1101-2020_09_02_279521	174	22	,	,	,
10_1101-2020_09_02_279521	174	23	who	who	WP
10_1101-2020_09_02_279521	174	24	has	have	VBZ
10_1101-2020_09_02_279521	174	25	granted	grant	VBN
10_1101-2020_09_02_279521	174	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	174	27	a	a	DT
10_1101-2020_09_02_279521	174	28	license	license	NN
10_1101-2020_09_02_279521	174	29	to	to	TO
10_1101-2020_09_02_279521	174	30	display	display	VB
10_1101-2020_09_02_279521	174	31	the	the	DT
10_1101-2020_09_02_279521	174	32	preprint	preprint	NN
10_1101-2020_09_02_279521	174	33	in	in	IN
10_1101-2020_09_02_279521	174	34	The	the	DT
10_1101-2020_09_02_279521	174	35	copyright	copyright	NN
10_1101-2020_09_02_279521	174	36	holder	holder	NN
10_1101-2020_09_02_279521	174	37	for	for	IN
10_1101-2020_09_02_279521	174	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	174	39	version	version	NN
10_1101-2020_09_02_279521	174	40	posted	post	VBD
10_1101-2020_09_02_279521	174	41	February	February	NNP
10_1101-2020_09_02_279521	174	42	10	10	CD
10_1101-2020_09_02_279521	174	43	,	,	,
10_1101-2020_09_02_279521	174	44	2021	2021	CD
10_1101-2020_09_02_279521	174	45	.	.	.
10_1101-2020_09_02_279521	174	46	;	;	:
10_1101-2020_09_02_279521	174	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	174	48	:	:	:
10_1101-2020_09_02_279521	174	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	174	50	preprint	preprint	NN
10_1101-2020_09_02_279521	174	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	ADD
10_1101-2020_09_02_279521	174	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	ADD
10_1101-2020_09_02_279521	174	53	validation	validation	NN
10_1101-2020_09_02_279521	174	54	of	of	IN
10_1101-2020_09_02_279521	174	55	the	the	DT
10_1101-2020_09_02_279521	174	56	Supplementary	Supplementary	NNP
10_1101-2020_09_02_279521	174	57	Material	Material	NNP
10_1101-2020_09_02_279521	174	58	and	and	CC
10_1101-2020_09_02_279521	174	59	show	show	VB
10_1101-2020_09_02_279521	174	60	positive	positive	JJ
10_1101-2020_09_02_279521	174	61	generalization	generalization	NN
10_1101-2020_09_02_279521	174	62	results	result	NNS
10_1101-2020_09_02_279521	174	63	as	as	RB
10_1101-2020_09_02_279521	174	64	well	well	RB
10_1101-2020_09_02_279521	174	65	as	as	IN
10_1101-2020_09_02_279521	174	66	a	a	DT
10_1101-2020_09_02_279521	174	67	favorable	favorable	JJ
10_1101-2020_09_02_279521	174	68	comparison	comparison	NN
10_1101-2020_09_02_279521	174	69	with	with	IN
10_1101-2020_09_02_279521	174	70	the	the	DT
10_1101-2020_09_02_279521	174	71	benchmark	benchmark	NN
10_1101-2020_09_02_279521	174	72	method	method	NN
10_1101-2020_09_02_279521	174	73	.	.	.
10_1101-2020_09_02_279521	175	1	From	from	IN
10_1101-2020_09_02_279521	175	2	the	the	DT
10_1101-2020_09_02_279521	175	3	z	z	JJ
10_1101-2020_09_02_279521	175	4	-	-	HYPH
10_1101-2020_09_02_279521	175	5	score	score	NN
10_1101-2020_09_02_279521	175	6	trajectories	trajectory	NNS
10_1101-2020_09_02_279521	175	7	of	of	IN
10_1101-2020_09_02_279521	175	8	Figure	figure	NN
10_1101-2020_09_02_279521	175	9	2	2	CD
10_1101-2020_09_02_279521	175	10	panel	panel	NN
10_1101-2020_09_02_279521	175	11	II	II	NNP
10_1101-2020_09_02_279521	175	12	)	)	-RRB-
10_1101-2020_09_02_279521	175	13	(	(	-LRB-
10_1101-2020_09_02_279521	175	14	left	leave	VBN
10_1101-2020_09_02_279521	175	15	)	)	-RRB-
10_1101-2020_09_02_279521	175	16	we	-PRON-	PRP
10_1101-2020_09_02_279521	175	17	predict	predict	VBP
10_1101-2020_09_02_279521	175	18	the	the	DT
10_1101-2020_09_02_279521	175	19	progression	progression	NN
10_1101-2020_09_02_279521	175	20	of	of	IN
10_1101-2020_09_02_279521	175	21	imaging	imaging	NN
10_1101-2020_09_02_279521	175	22	and	and	CC
10_1101-2020_09_02_279521	175	23	clinical	clinical	JJ
10_1101-2020_09_02_279521	175	24	measures	measure	NNS
10_1101-2020_09_02_279521	175	25	shown	show	VBN
10_1101-2020_09_02_279521	175	26	in	in	IN
10_1101-2020_09_02_279521	175	27	Figure	Figure	NNP
10_1101-2020_09_02_279521	175	28	3	3	CD
10_1101-2020_09_02_279521	175	29	.	.	.
10_1101-2020_09_02_279521	176	1	We	-PRON-	PRP
10_1101-2020_09_02_279521	176	2	observe	observe	VBP
10_1101-2020_09_02_279521	176	3	that	that	DT
10_1101-2020_09_02_279521	176	4	amyloid	amyloid	NN
10_1101-2020_09_02_279521	176	5	load	load	NN
10_1101-2020_09_02_279521	176	6	globally	globally	RB
10_1101-2020_09_02_279521	176	7	increases	increase	VBZ
10_1101-2020_09_02_279521	176	8	and	and	CC
10_1101-2020_09_02_279521	176	9	saturates	saturate	NNS
10_1101-2020_09_02_279521	176	10	early	early	RB
10_1101-2020_09_02_279521	176	11	,	,	,
10_1101-2020_09_02_279521	176	12	compatibly	compatibly	RB
10_1101-2020_09_02_279521	176	13	with	with	IN
10_1101-2020_09_02_279521	176	14	the	the	DT
10_1101-2020_09_02_279521	176	15	positive	positive	JJ
10_1101-2020_09_02_279521	176	16	amyloid	amyloid	NN
10_1101-2020_09_02_279521	176	17	condition	condition	NN
10_1101-2020_09_02_279521	176	18	of	of	IN
10_1101-2020_09_02_279521	176	19	the	the	DT
10_1101-2020_09_02_279521	176	20	study	study	NN
10_1101-2020_09_02_279521	176	21	cohort	cohort	NN
10_1101-2020_09_02_279521	176	22	.	.	.
10_1101-2020_09_02_279521	177	1	Abnormal	abnormal	JJ
10_1101-2020_09_02_279521	177	2	glucose	glucose	VBP
10_1101-2020_09_02_279521	177	3	metabolism	metabolism	NN
10_1101-2020_09_02_279521	177	4	and	and	CC
10_1101-2020_09_02_279521	177	5	gray	gray	JJ
10_1101-2020_09_02_279521	177	6	matter	matter	NN
10_1101-2020_09_02_279521	177	7	atrophy	atrophy	NN
10_1101-2020_09_02_279521	177	8	are	be	VBP
10_1101-2020_09_02_279521	177	9	delayed	delay	VBN
10_1101-2020_09_02_279521	177	10	with	with	IN
10_1101-2020_09_02_279521	177	11	respect	respect	NN
10_1101-2020_09_02_279521	177	12	to	to	TO
10_1101-2020_09_02_279521	177	13	amyloid	amyloid	VB
10_1101-2020_09_02_279521	177	14	,	,	,
10_1101-2020_09_02_279521	177	15	and	and	CC
10_1101-2020_09_02_279521	177	16	tend	tend	VB
10_1101-2020_09_02_279521	177	17	to	to	TO
10_1101-2020_09_02_279521	177	18	map	map	VB
10_1101-2020_09_02_279521	177	19	prevalently	prevalently	RB
10_1101-2020_09_02_279521	177	20	temporal	temporal	JJ
10_1101-2020_09_02_279521	177	21	and	and	CC
10_1101-2020_09_02_279521	177	22	parietal	parietal	JJ
10_1101-2020_09_02_279521	177	23	regions	region	NNS
10_1101-2020_09_02_279521	177	24	.	.	.
10_1101-2020_09_02_279521	178	1	Finally	finally	RB
10_1101-2020_09_02_279521	178	2	,	,	,
10_1101-2020_09_02_279521	178	3	the	the	DT
10_1101-2020_09_02_279521	178	4	clinical	clinical	JJ
10_1101-2020_09_02_279521	178	5	measures	measure	NNS
10_1101-2020_09_02_279521	178	6	exhibit	exhibit	VBP
10_1101-2020_09_02_279521	178	7	a	a	DT
10_1101-2020_09_02_279521	178	8	non-	non-	NN
10_1101-2020_09_02_279521	178	9	Figure	figure	NN
10_1101-2020_09_02_279521	178	10	2	2	CD
10_1101-2020_09_02_279521	178	11	Dynamical	dynamical	JJ
10_1101-2020_09_02_279521	178	12	relationships	relationship	NNS
10_1101-2020_09_02_279521	178	13	,	,	,
10_1101-2020_09_02_279521	178	14	z	z	NN
10_1101-2020_09_02_279521	178	15	-	-	HYPH
10_1101-2020_09_02_279521	178	16	scores	score	NNS
10_1101-2020_09_02_279521	178	17	evolution	evolution	NN
10_1101-2020_09_02_279521	178	18	and	and	CC
10_1101-2020_09_02_279521	178	19	disease	disease	NN
10_1101-2020_09_02_279521	178	20	staging	staging	NN
10_1101-2020_09_02_279521	178	21	.	.	.
10_1101-2020_09_02_279521	179	1	Panel	panel	NN
10_1101-2020_09_02_279521	179	2	I	-PRON-	PRP
10_1101-2020_09_02_279521	179	3	:	:	:
10_1101-2020_09_02_279521	179	4	Estimated	estimate	VBN
10_1101-2020_09_02_279521	179	5	dynamical	dynamical	JJ
10_1101-2020_09_02_279521	179	6	relationships	relationship	NNS
10_1101-2020_09_02_279521	179	7	across	across	IN
10_1101-2020_09_02_279521	179	8	the	the	DT
10_1101-2020_09_02_279521	179	9	different	different	JJ
10_1101-2020_09_02_279521	179	10	z	z	NN
10_1101-2020_09_02_279521	179	11	-	-	HYPH
10_1101-2020_09_02_279521	179	12	scores	score	NNS
10_1101-2020_09_02_279521	179	13	(	(	-LRB-
10_1101-2020_09_02_279521	179	14	A	a	NN
10_1101-2020_09_02_279521	179	15	to	to	IN
10_1101-2020_09_02_279521	179	16	F	f	NN
10_1101-2020_09_02_279521	179	17	)	)	-RRB-
10_1101-2020_09_02_279521	179	18	.	.	.
10_1101-2020_09_02_279521	180	1	Given	give	VBN
10_1101-2020_09_02_279521	180	2	the	the	DT
10_1101-2020_09_02_279521	180	3	values	value	NNS
10_1101-2020_09_02_279521	180	4	of	of	IN
10_1101-2020_09_02_279521	180	5	two	two	CD
10_1101-2020_09_02_279521	180	6	z	z	NN
10_1101-2020_09_02_279521	180	7	-	-	HYPH
10_1101-2020_09_02_279521	180	8	scores	score	NNS
10_1101-2020_09_02_279521	180	9	,	,	,
10_1101-2020_09_02_279521	180	10	the	the	DT
10_1101-2020_09_02_279521	180	11	arrow	arrow	NN
10_1101-2020_09_02_279521	180	12	at	at	IN
10_1101-2020_09_02_279521	180	13	the	the	DT
10_1101-2020_09_02_279521	180	14	corresponding	correspond	VBG
10_1101-2020_09_02_279521	180	15	coordinates	coordinate	NNS
10_1101-2020_09_02_279521	180	16	indicates	indicate	VBZ
10_1101-2020_09_02_279521	180	17	how	how	WRB
10_1101-2020_09_02_279521	180	18	one	one	CD
10_1101-2020_09_02_279521	180	19	score	score	NN
10_1101-2020_09_02_279521	180	20	evolves	evolve	VBZ
10_1101-2020_09_02_279521	180	21	with	with	IN
10_1101-2020_09_02_279521	180	22	respect	respect	NN
10_1101-2020_09_02_279521	180	23	to	to	IN
10_1101-2020_09_02_279521	180	24	the	the	DT
10_1101-2020_09_02_279521	180	25	other	other	JJ
10_1101-2020_09_02_279521	180	26	.	.	.
10_1101-2020_09_02_279521	181	1	The	the	DT
10_1101-2020_09_02_279521	181	2	intensity	intensity	NN
10_1101-2020_09_02_279521	181	3	of	of	IN
10_1101-2020_09_02_279521	181	4	the	the	DT
10_1101-2020_09_02_279521	181	5	arrow	arrow	NN
10_1101-2020_09_02_279521	181	6	gives	give	VBZ
10_1101-2020_09_02_279521	181	7	the	the	DT
10_1101-2020_09_02_279521	181	8	strength	strength	NN
10_1101-2020_09_02_279521	181	9	of	of	IN
10_1101-2020_09_02_279521	181	10	the	the	DT
10_1101-2020_09_02_279521	181	11	relationship	relationship	NN
10_1101-2020_09_02_279521	181	12	between	between	IN
10_1101-2020_09_02_279521	181	13	the	the	DT
10_1101-2020_09_02_279521	181	14	two	two	CD
10_1101-2020_09_02_279521	181	15	scores	score	NNS
10_1101-2020_09_02_279521	181	16	.	.	.
10_1101-2020_09_02_279521	182	1	Panel	Panel	NNP
10_1101-2020_09_02_279521	182	2	II	II	NNP
10_1101-2020_09_02_279521	182	3	,	,	,
10_1101-2020_09_02_279521	182	4	left	leave	VBD
10_1101-2020_09_02_279521	182	5	:	:	:
10_1101-2020_09_02_279521	182	6	Estimated	estimate	VBN
10_1101-2020_09_02_279521	182	7	long	long	JJ
10_1101-2020_09_02_279521	182	8	-	-	HYPH
10_1101-2020_09_02_279521	182	9	term	term	NN
10_1101-2020_09_02_279521	182	10	latent	latent	NN
10_1101-2020_09_02_279521	182	11	dynamics	dynamic	NNS
10_1101-2020_09_02_279521	182	12	(	(	-LRB-
10_1101-2020_09_02_279521	182	13	time	time	NN
10_1101-2020_09_02_279521	182	14	is	be	VBZ
10_1101-2020_09_02_279521	182	15	relative	relative	JJ
10_1101-2020_09_02_279521	182	16	to	to	IN
10_1101-2020_09_02_279521	182	17	conversion	conversion	NN
10_1101-2020_09_02_279521	182	18	to	to	IN
10_1101-2020_09_02_279521	182	19	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	182	20	's	's	POS
10_1101-2020_09_02_279521	182	21	dementia	dementia	NN
10_1101-2020_09_02_279521	182	22	)	)	-RRB-
10_1101-2020_09_02_279521	182	23	.	.	.
10_1101-2020_09_02_279521	183	1	Shadowed	shadowed	JJ
10_1101-2020_09_02_279521	183	2	areas	area	NNS
10_1101-2020_09_02_279521	183	3	represent	represent	VBP
10_1101-2020_09_02_279521	183	4	the	the	DT
10_1101-2020_09_02_279521	183	5	standard	standard	JJ
10_1101-2020_09_02_279521	183	6	deviation	deviation	NN
10_1101-2020_09_02_279521	183	7	of	of	IN
10_1101-2020_09_02_279521	183	8	the	the	DT
10_1101-2020_09_02_279521	183	9	average	average	JJ
10_1101-2020_09_02_279521	183	10	trajectory	trajectory	CD
10_1101-2020_09_02_279521	183	11	.	.	.
10_1101-2020_09_02_279521	184	1	Panel	Panel	NNP
10_1101-2020_09_02_279521	184	2	II	II	NNP
10_1101-2020_09_02_279521	184	3	,	,	,
10_1101-2020_09_02_279521	184	4	right	right	UH
10_1101-2020_09_02_279521	184	5	:	:	:
10_1101-2020_09_02_279521	184	6	Distribution	distribution	NN
10_1101-2020_09_02_279521	184	7	of	of	IN
10_1101-2020_09_02_279521	184	8	the	the	DT
10_1101-2020_09_02_279521	184	9	estimated	estimate	VBN
10_1101-2020_09_02_279521	184	10	disease	disease	NN
10_1101-2020_09_02_279521	184	11	severity	severity	NN
10_1101-2020_09_02_279521	184	12	across	across	IN
10_1101-2020_09_02_279521	184	13	clinical	clinical	JJ
10_1101-2020_09_02_279521	184	14	stages	stage	NNS
10_1101-2020_09_02_279521	184	15	,	,	,
10_1101-2020_09_02_279521	184	16	relatively	relatively	RB
10_1101-2020_09_02_279521	184	17	to	to	IN
10_1101-2020_09_02_279521	184	18	the	the	DT
10_1101-2020_09_02_279521	184	19	long	long	JJ
10_1101-2020_09_02_279521	184	20	-	-	HYPH
10_1101-2020_09_02_279521	184	21	term	term	NN
10_1101-2020_09_02_279521	184	22	dynamics	dynamic	NNS
10_1101-2020_09_02_279521	184	23	on	on	IN
10_1101-2020_09_02_279521	184	24	the	the	DT
10_1101-2020_09_02_279521	184	25	left	left	NN
10_1101-2020_09_02_279521	184	26	.	.	.
10_1101-2020_09_02_279521	185	1	NL	NL	NNP
10_1101-2020_09_02_279521	185	2	:	:	:
10_1101-2020_09_02_279521	185	3	normal	normal	JJ
10_1101-2020_09_02_279521	185	4	individuals	individual	NNS
10_1101-2020_09_02_279521	185	5	,	,	,
10_1101-2020_09_02_279521	185	6	MCI	MCI	NNP
10_1101-2020_09_02_279521	185	7	:	:	:
10_1101-2020_09_02_279521	185	8	mild	mild	JJ
10_1101-2020_09_02_279521	185	9	cognitive	cognitive	JJ
10_1101-2020_09_02_279521	185	10	impairment	impairment	NN
10_1101-2020_09_02_279521	185	11	,	,	,
10_1101-2020_09_02_279521	185	12	AD	ad	NN
10_1101-2020_09_02_279521	185	13	:	:	:
10_1101-2020_09_02_279521	185	14	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	185	15	's	's	POS
10_1101-2020_09_02_279521	185	16	dementia	dementia	NN
10_1101-2020_09_02_279521	185	17	.	.	.
10_1101-2020_09_02_279521	186	1	.CC	.CC	NFP
10_1101-2020_09_02_279521	186	2	-	-	:
10_1101-2020_09_02_279521	186	3	BY	by	IN
10_1101-2020_09_02_279521	186	4	4.0	4.0	CD
10_1101-2020_09_02_279521	186	5	International	international	JJ
10_1101-2020_09_02_279521	186	6	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	186	7	.	.	.
10_1101-2020_09_02_279521	187	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	187	2	is	be	VBZ
10_1101-2020_09_02_279521	187	3	made	make	VBN
10_1101-2020_09_02_279521	187	4	available	available	JJ
10_1101-2020_09_02_279521	187	5	under	under	IN
10_1101-2020_09_02_279521	187	6	a	a	DT
10_1101-2020_09_02_279521	187	7	preprint	preprint	NN
10_1101-2020_09_02_279521	187	8	(	(	-LRB-
10_1101-2020_09_02_279521	187	9	which	which	WDT
10_1101-2020_09_02_279521	187	10	was	be	VBD
10_1101-2020_09_02_279521	187	11	not	not	RB
10_1101-2020_09_02_279521	187	12	certified	certify	VBN
10_1101-2020_09_02_279521	187	13	by	by	IN
10_1101-2020_09_02_279521	187	14	peer	peer	NN
10_1101-2020_09_02_279521	187	15	review	review	NN
10_1101-2020_09_02_279521	187	16	)	)	-RRB-
10_1101-2020_09_02_279521	187	17	is	be	VBZ
10_1101-2020_09_02_279521	187	18	the	the	DT
10_1101-2020_09_02_279521	187	19	author	author	NN
10_1101-2020_09_02_279521	187	20	/	/	SYM
10_1101-2020_09_02_279521	187	21	funder	funder	NN
10_1101-2020_09_02_279521	187	22	,	,	,
10_1101-2020_09_02_279521	187	23	who	who	WP
10_1101-2020_09_02_279521	187	24	has	have	VBZ
10_1101-2020_09_02_279521	187	25	granted	grant	VBN
10_1101-2020_09_02_279521	187	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	187	27	a	a	DT
10_1101-2020_09_02_279521	187	28	license	license	NN
10_1101-2020_09_02_279521	187	29	to	to	TO
10_1101-2020_09_02_279521	187	30	display	display	VB
10_1101-2020_09_02_279521	187	31	the	the	DT
10_1101-2020_09_02_279521	187	32	preprint	preprint	NN
10_1101-2020_09_02_279521	187	33	in	in	IN
10_1101-2020_09_02_279521	187	34	The	the	DT
10_1101-2020_09_02_279521	187	35	copyright	copyright	NN
10_1101-2020_09_02_279521	187	36	holder	holder	NN
10_1101-2020_09_02_279521	187	37	for	for	IN
10_1101-2020_09_02_279521	187	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	187	39	version	version	NN
10_1101-2020_09_02_279521	187	40	posted	post	VBD
10_1101-2020_09_02_279521	187	41	February	February	NNP
10_1101-2020_09_02_279521	187	42	10	10	CD
10_1101-2020_09_02_279521	187	43	,	,	,
10_1101-2020_09_02_279521	187	44	2021	2021	CD
10_1101-2020_09_02_279521	187	45	.	.	.
10_1101-2020_09_02_279521	187	46	;	;	:
10_1101-2020_09_02_279521	187	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	187	48	:	:	:
10_1101-2020_09_02_279521	187	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	187	50	preprint	preprint	NN
10_1101-2020_09_02_279521	187	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	UH
10_1101-2020_09_02_279521	187	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	ADD
10_1101-2020_09_02_279521	187	53	linear	linear	JJ
10_1101-2020_09_02_279521	187	54	pattern	pattern	NN
10_1101-2020_09_02_279521	187	55	of	of	IN
10_1101-2020_09_02_279521	187	56	change	change	NN
10_1101-2020_09_02_279521	187	57	,	,	,
10_1101-2020_09_02_279521	187	58	accelerating	accelerate	VBG
10_1101-2020_09_02_279521	187	59	during	during	IN
10_1101-2020_09_02_279521	187	60	the	the	DT
10_1101-2020_09_02_279521	187	61	latest	late	JJS
10_1101-2020_09_02_279521	187	62	progression	progression	NN
10_1101-2020_09_02_279521	187	63	stages	stage	NNS
10_1101-2020_09_02_279521	187	64	.	.	.
10_1101-2020_09_02_279521	188	1	These	these	DT
10_1101-2020_09_02_279521	188	2	dynamics	dynamic	NNS
10_1101-2020_09_02_279521	188	3	are	be	VBP
10_1101-2020_09_02_279521	188	4	compatible	compatible	JJ
10_1101-2020_09_02_279521	188	5	with	with	IN
10_1101-2020_09_02_279521	188	6	the	the	DT
10_1101-2020_09_02_279521	188	7	summary	summary	NN
10_1101-2020_09_02_279521	188	8	measures	measure	NNS
10_1101-2020_09_02_279521	188	9	on	on	IN
10_1101-2020_09_02_279521	188	10	the	the	DT
10_1101-2020_09_02_279521	188	11	raw	raw	JJ
10_1101-2020_09_02_279521	188	12	data	datum	NNS
10_1101-2020_09_02_279521	188	13	reported	report	VBN
10_1101-2020_09_02_279521	188	14	in	in	IN
10_1101-2020_09_02_279521	188	15	Table	table	NN
10_1101-2020_09_02_279521	188	16	1	1	CD
10_1101-2020_09_02_279521	188	17	.	.	.
10_1101-2020_09_02_279521	189	1	Simulating	simulate	VBG
10_1101-2020_09_02_279521	189	2	clinical	clinical	JJ
10_1101-2020_09_02_279521	189	3	intervention	intervention	NN
10_1101-2020_09_02_279521	189	4	This	this	DT
10_1101-2020_09_02_279521	189	5	experimental	experimental	JJ
10_1101-2020_09_02_279521	189	6	section	section	NN
10_1101-2020_09_02_279521	189	7	is	be	VBZ
10_1101-2020_09_02_279521	189	8	based	base	VBN
10_1101-2020_09_02_279521	189	9	on	on	IN
10_1101-2020_09_02_279521	189	10	two	two	CD
10_1101-2020_09_02_279521	189	11	intervention	intervention	NN
10_1101-2020_09_02_279521	189	12	scenarios	scenario	NNS
10_1101-2020_09_02_279521	189	13	:	:	:
10_1101-2020_09_02_279521	189	14	a	a	DT
10_1101-2020_09_02_279521	189	15	first	first	JJ
10_1101-2020_09_02_279521	189	16	one	one	CD
10_1101-2020_09_02_279521	189	17	in	in	IN
10_1101-2020_09_02_279521	189	18	which	which	WDT
10_1101-2020_09_02_279521	189	19	amyloid	amyloid	NN
10_1101-2020_09_02_279521	189	20	is	be	VBZ
10_1101-2020_09_02_279521	189	21	lowered	lower	VBN
10_1101-2020_09_02_279521	189	22	by	by	IN
10_1101-2020_09_02_279521	189	23	100	100	CD
10_1101-2020_09_02_279521	189	24	%	%	NN
10_1101-2020_09_02_279521	189	25	,	,	,
10_1101-2020_09_02_279521	189	26	and	and	CC
10_1101-2020_09_02_279521	189	27	a	a	DT
10_1101-2020_09_02_279521	189	28	second	second	JJ
10_1101-2020_09_02_279521	189	29	one	one	NN
10_1101-2020_09_02_279521	189	30	in	in	IN
10_1101-2020_09_02_279521	189	31	which	which	WDT
10_1101-2020_09_02_279521	189	32	it	-PRON-	PRP
10_1101-2020_09_02_279521	189	33	is	be	VBZ
10_1101-2020_09_02_279521	189	34	reduced	reduce	VBN
10_1101-2020_09_02_279521	189	35	by	by	IN
10_1101-2020_09_02_279521	189	36	50	50	CD
10_1101-2020_09_02_279521	189	37	%	%	NN
10_1101-2020_09_02_279521	189	38	with	with	IN
10_1101-2020_09_02_279521	189	39	respect	respect	NN
10_1101-2020_09_02_279521	189	40	to	to	IN
10_1101-2020_09_02_279521	189	41	the	the	DT
10_1101-2020_09_02_279521	189	42	estimated	estimate	VBN
10_1101-2020_09_02_279521	189	43	natural	natural	JJ
10_1101-2020_09_02_279521	189	44	progression	progression	NN
10_1101-2020_09_02_279521	189	45	.	.	.
10_1101-2020_09_02_279521	190	1	In	in	IN
10_1101-2020_09_02_279521	190	2	Figure	figure	NN
10_1101-2020_09_02_279521	190	3	4	4	CD
10_1101-2020_09_02_279521	190	4	we	-PRON-	PRP
10_1101-2020_09_02_279521	190	5	show	show	VBP
10_1101-2020_09_02_279521	190	6	the	the	DT
10_1101-2020_09_02_279521	190	7	latent	latent	NN
10_1101-2020_09_02_279521	190	8	z	z	NNP
10_1101-2020_09_02_279521	190	9	-	-	HYPH
10_1101-2020_09_02_279521	190	10	scores	score	NNS
10_1101-2020_09_02_279521	190	11	evolution	evolution	NN
10_1101-2020_09_02_279521	190	12	resulting	result	VBG
10_1101-2020_09_02_279521	190	13	from	from	IN
10_1101-2020_09_02_279521	190	14	either	either	CC
10_1101-2020_09_02_279521	190	15	100	100	CD
10_1101-2020_09_02_279521	190	16	%	%	NN
10_1101-2020_09_02_279521	190	17	or	or	CC
10_1101-2020_09_02_279521	190	18	50	50	CD
10_1101-2020_09_02_279521	190	19	%	%	NN
10_1101-2020_09_02_279521	190	20	amyloid	amyloid	NN
10_1101-2020_09_02_279521	190	21	lowering	lowering	NN
10_1101-2020_09_02_279521	190	22	performed	perform	VBN
10_1101-2020_09_02_279521	190	23	at	at	IN
10_1101-2020_09_02_279521	190	24	the	the	DT
10_1101-2020_09_02_279521	190	25	time	time	NN
10_1101-2020_09_02_279521	190	26	t=-20	t=-20	NNP
10_1101-2020_09_02_279521	190	27	years	year	NNS
10_1101-2020_09_02_279521	190	28	.	.	.
10_1101-2020_09_02_279521	191	1	According	accord	VBG
10_1101-2020_09_02_279521	191	2	to	to	IN
10_1101-2020_09_02_279521	191	3	these	these	DT
10_1101-2020_09_02_279521	191	4	scenarios	scenario	NNS
10_1101-2020_09_02_279521	191	5	,	,	,
10_1101-2020_09_02_279521	191	6	intervention	intervention	NN
10_1101-2020_09_02_279521	191	7	results	result	NNS
10_1101-2020_09_02_279521	191	8	in	in	IN
10_1101-2020_09_02_279521	191	9	a	a	DT
10_1101-2020_09_02_279521	191	10	sensitive	sensitive	JJ
10_1101-2020_09_02_279521	191	11	reduction	reduction	NN
10_1101-2020_09_02_279521	191	12	of	of	IN
10_1101-2020_09_02_279521	191	13	the	the	DT
10_1101-2020_09_02_279521	191	14	pathological	pathological	JJ
10_1101-2020_09_02_279521	191	15	progression	progression	NN
10_1101-2020_09_02_279521	191	16	for	for	IN
10_1101-2020_09_02_279521	191	17	Figure	Figure	NNP
10_1101-2020_09_02_279521	191	18	3	3	CD
10_1101-2020_09_02_279521	191	19	Model	Model	NNP
10_1101-2020_09_02_279521	191	20	-	-	HYPH
10_1101-2020_09_02_279521	191	21	based	base	VBN
10_1101-2020_09_02_279521	191	22	progression	progression	NN
10_1101-2020_09_02_279521	191	23	of	of	IN
10_1101-2020_09_02_279521	191	24	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	191	25	’s	’s	POS
10_1101-2020_09_02_279521	191	26	disease	disease	NN
10_1101-2020_09_02_279521	191	27	.	.	.
10_1101-2020_09_02_279521	192	1	Estimated	estimate	VBN
10_1101-2020_09_02_279521	192	2	long	long	JJ
10_1101-2020_09_02_279521	192	3	-	-	HYPH
10_1101-2020_09_02_279521	192	4	term	term	NN
10_1101-2020_09_02_279521	192	5	evolution	evolution	NN
10_1101-2020_09_02_279521	192	6	of	of	IN
10_1101-2020_09_02_279521	192	7	cortical	cortical	JJ
10_1101-2020_09_02_279521	192	8	measurements	measurement	NNS
10_1101-2020_09_02_279521	192	9	for	for	IN
10_1101-2020_09_02_279521	192	10	the	the	DT
10_1101-2020_09_02_279521	192	11	different	different	JJ
10_1101-2020_09_02_279521	192	12	types	type	NNS
10_1101-2020_09_02_279521	192	13	of	of	IN
10_1101-2020_09_02_279521	192	14	imaging	image	VBG
10_1101-2020_09_02_279521	192	15	markers	marker	NNS
10_1101-2020_09_02_279521	192	16	,	,	,
10_1101-2020_09_02_279521	192	17	and	and	CC
10_1101-2020_09_02_279521	192	18	clinical	clinical	JJ
10_1101-2020_09_02_279521	192	19	scores	score	NNS
10_1101-2020_09_02_279521	192	20	.	.	.
10_1101-2020_09_02_279521	193	1	Shadowed	shadowed	JJ
10_1101-2020_09_02_279521	193	2	areas	area	NNS
10_1101-2020_09_02_279521	193	3	represent	represent	VBP
10_1101-2020_09_02_279521	193	4	the	the	DT
10_1101-2020_09_02_279521	193	5	standard	standard	JJ
10_1101-2020_09_02_279521	193	6	deviation	deviation	NN
10_1101-2020_09_02_279521	193	7	of	of	IN
10_1101-2020_09_02_279521	193	8	the	the	DT
10_1101-2020_09_02_279521	193	9	average	average	JJ
10_1101-2020_09_02_279521	193	10	trajectory	trajectory	CD
10_1101-2020_09_02_279521	193	11	.	.	.
10_1101-2020_09_02_279521	194	1	Brain	brain	NN
10_1101-2020_09_02_279521	194	2	images	image	NNS
10_1101-2020_09_02_279521	194	3	were	be	VBD
10_1101-2020_09_02_279521	194	4	generated	generate	VBN
10_1101-2020_09_02_279521	194	5	using	use	VBG
10_1101-2020_09_02_279521	194	6	the	the	DT
10_1101-2020_09_02_279521	194	7	software	software	NN
10_1101-2020_09_02_279521	194	8	provided	provide	VBN
10_1101-2020_09_02_279521	194	9	in	in	IN
10_1101-2020_09_02_279521	194	10	(	(	-LRB-
10_1101-2020_09_02_279521	194	11	Marinescu	Marinescu	NNP
10_1101-2020_09_02_279521	194	12	et	et	FW
10_1101-2020_09_02_279521	194	13	al	al	NNP
10_1101-2020_09_02_279521	194	14	.	.	NNP
10_1101-2020_09_02_279521	194	15	,	,	,
10_1101-2020_09_02_279521	194	16	2019	2019	CD
10_1101-2020_09_02_279521	194	17	)	)	-RRB-
10_1101-2020_09_02_279521	194	18	.	.	.
10_1101-2020_09_02_279521	195	1	.CC	.CC	NFP
10_1101-2020_09_02_279521	195	2	-	-	:
10_1101-2020_09_02_279521	195	3	BY	by	IN
10_1101-2020_09_02_279521	195	4	4.0	4.0	CD
10_1101-2020_09_02_279521	195	5	International	international	JJ
10_1101-2020_09_02_279521	195	6	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	195	7	.	.	.
10_1101-2020_09_02_279521	196	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	196	2	is	be	VBZ
10_1101-2020_09_02_279521	196	3	made	make	VBN
10_1101-2020_09_02_279521	196	4	available	available	JJ
10_1101-2020_09_02_279521	196	5	under	under	IN
10_1101-2020_09_02_279521	196	6	a	a	DT
10_1101-2020_09_02_279521	196	7	preprint	preprint	NN
10_1101-2020_09_02_279521	196	8	(	(	-LRB-
10_1101-2020_09_02_279521	196	9	which	which	WDT
10_1101-2020_09_02_279521	196	10	was	be	VBD
10_1101-2020_09_02_279521	196	11	not	not	RB
10_1101-2020_09_02_279521	196	12	certified	certify	VBN
10_1101-2020_09_02_279521	196	13	by	by	IN
10_1101-2020_09_02_279521	196	14	peer	peer	NN
10_1101-2020_09_02_279521	196	15	review	review	NN
10_1101-2020_09_02_279521	196	16	)	)	-RRB-
10_1101-2020_09_02_279521	196	17	is	be	VBZ
10_1101-2020_09_02_279521	196	18	the	the	DT
10_1101-2020_09_02_279521	196	19	author	author	NN
10_1101-2020_09_02_279521	196	20	/	/	SYM
10_1101-2020_09_02_279521	196	21	funder	funder	NN
10_1101-2020_09_02_279521	196	22	,	,	,
10_1101-2020_09_02_279521	196	23	who	who	WP
10_1101-2020_09_02_279521	196	24	has	have	VBZ
10_1101-2020_09_02_279521	196	25	granted	grant	VBN
10_1101-2020_09_02_279521	196	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	196	27	a	a	DT
10_1101-2020_09_02_279521	196	28	license	license	NN
10_1101-2020_09_02_279521	196	29	to	to	TO
10_1101-2020_09_02_279521	196	30	display	display	VB
10_1101-2020_09_02_279521	196	31	the	the	DT
10_1101-2020_09_02_279521	196	32	preprint	preprint	NN
10_1101-2020_09_02_279521	196	33	in	in	IN
10_1101-2020_09_02_279521	196	34	The	the	DT
10_1101-2020_09_02_279521	196	35	copyright	copyright	NN
10_1101-2020_09_02_279521	196	36	holder	holder	NN
10_1101-2020_09_02_279521	196	37	for	for	IN
10_1101-2020_09_02_279521	196	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	196	39	version	version	NN
10_1101-2020_09_02_279521	196	40	posted	post	VBD
10_1101-2020_09_02_279521	196	41	February	February	NNP
10_1101-2020_09_02_279521	196	42	10	10	CD
10_1101-2020_09_02_279521	196	43	,	,	,
10_1101-2020_09_02_279521	196	44	2021	2021	CD
10_1101-2020_09_02_279521	196	45	.	.	.
10_1101-2020_09_02_279521	196	46	;	;	:
10_1101-2020_09_02_279521	196	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	196	48	:	:	:
10_1101-2020_09_02_279521	196	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	196	50	preprint	preprint	NN
10_1101-2020_09_02_279521	196	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	ADD
10_1101-2020_09_02_279521	196	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	ADD
10_1101-2020_09_02_279521	196	53	atrophy	atrophy	NN
10_1101-2020_09_02_279521	196	54	,	,	,
10_1101-2020_09_02_279521	196	55	glucose	glucose	VB
10_1101-2020_09_02_279521	196	56	metabolism	metabolism	NN
10_1101-2020_09_02_279521	196	57	and	and	CC
10_1101-2020_09_02_279521	196	58	clinical	clinical	JJ
10_1101-2020_09_02_279521	196	59	scores	score	NNS
10_1101-2020_09_02_279521	196	60	,	,	,
10_1101-2020_09_02_279521	196	61	albeit	albeit	IN
10_1101-2020_09_02_279521	196	62	with	with	IN
10_1101-2020_09_02_279521	196	63	a	a	DT
10_1101-2020_09_02_279521	196	64	stronger	strong	JJR
10_1101-2020_09_02_279521	196	65	effect	effect	NN
10_1101-2020_09_02_279521	196	66	in	in	IN
10_1101-2020_09_02_279521	196	67	case	case	NN
10_1101-2020_09_02_279521	196	68	of	of	IN
10_1101-2020_09_02_279521	196	69	total	total	JJ
10_1101-2020_09_02_279521	196	70	blockage	blockage	NN
10_1101-2020_09_02_279521	196	71	.	.	.
10_1101-2020_09_02_279521	197	1	We	-PRON-	PRP
10_1101-2020_09_02_279521	197	2	further	further	RB
10_1101-2020_09_02_279521	197	3	estimated	estimate	VBD
10_1101-2020_09_02_279521	197	4	the	the	DT
10_1101-2020_09_02_279521	197	5	resulting	result	VBG
10_1101-2020_09_02_279521	197	6	clinical	clinical	JJ
10_1101-2020_09_02_279521	197	7	endpoints	endpoint	NNS
10_1101-2020_09_02_279521	197	8	associated	associate	VBN
10_1101-2020_09_02_279521	197	9	with	with	IN
10_1101-2020_09_02_279521	197	10	the	the	DT
10_1101-2020_09_02_279521	197	11	two	two	CD
10_1101-2020_09_02_279521	197	12	amyloid	amyloid	NN
10_1101-2020_09_02_279521	197	13	lowering	lower	VBG
10_1101-2020_09_02_279521	197	14	scenarios	scenario	NNS
10_1101-2020_09_02_279521	197	15	,	,	,
10_1101-2020_09_02_279521	197	16	at	at	IN
10_1101-2020_09_02_279521	197	17	increasing	increase	VBG
10_1101-2020_09_02_279521	197	18	time	time	NN
10_1101-2020_09_02_279521	197	19	points	point	NNS
10_1101-2020_09_02_279521	197	20	and	and	CC
10_1101-2020_09_02_279521	197	21	for	for	IN
10_1101-2020_09_02_279521	197	22	different	different	JJ
10_1101-2020_09_02_279521	197	23	sample	sample	NN
10_1101-2020_09_02_279521	197	24	sizes	size	NNS
10_1101-2020_09_02_279521	197	25	.	.	.
10_1101-2020_09_02_279521	198	1	Clinical	clinical	JJ
10_1101-2020_09_02_279521	198	2	endpoints	endpoint	NNS
10_1101-2020_09_02_279521	198	3	consisted	consist	VBD
10_1101-2020_09_02_279521	198	4	in	in	IN
10_1101-2020_09_02_279521	198	5	the	the	DT
10_1101-2020_09_02_279521	198	6	simulated	simulated	JJ
10_1101-2020_09_02_279521	198	7	ADAS11	adas11	NN
10_1101-2020_09_02_279521	198	8	,	,	,
10_1101-2020_09_02_279521	198	9	MMSE	MMSE	NNP
10_1101-2020_09_02_279521	198	10	,	,	,
10_1101-2020_09_02_279521	198	11	FAQ	FAQ	NNP
10_1101-2020_09_02_279521	198	12	,	,	,
10_1101-2020_09_02_279521	198	13	RAVLT	RAVLT	NNP
10_1101-2020_09_02_279521	198	14	immediate	immediate	JJ
10_1101-2020_09_02_279521	198	15	,	,	,
10_1101-2020_09_02_279521	198	16	RAVLT	RAVLT	NNP
10_1101-2020_09_02_279521	198	17	learning	learning	NN
10_1101-2020_09_02_279521	198	18	,	,	,
10_1101-2020_09_02_279521	198	19	RAVLT	RAVLT	NNP
10_1101-2020_09_02_279521	198	20	forgetting	forgetting	NN
10_1101-2020_09_02_279521	198	21	and	and	CC
10_1101-2020_09_02_279521	198	22	CDRSB	cdrsb	JJ
10_1101-2020_09_02_279521	198	23	scores	score	NNS
10_1101-2020_09_02_279521	198	24	at	at	IN
10_1101-2020_09_02_279521	198	25	the	the	DT
10_1101-2020_09_02_279521	198	26	reference	reference	NN
10_1101-2020_09_02_279521	198	27	conversion	conversion	NN
10_1101-2020_09_02_279521	198	28	time	time	NN
10_1101-2020_09_02_279521	198	29	(	(	-LRB-
10_1101-2020_09_02_279521	198	30	t=0	t=0	NNP
10_1101-2020_09_02_279521	198	31	)	)	-RRB-
10_1101-2020_09_02_279521	198	32	.	.	.
10_1101-2020_09_02_279521	199	1	The	the	DT
10_1101-2020_09_02_279521	199	2	case	case	NN
10_1101-2020_09_02_279521	199	3	placebo	placebo	NN
10_1101-2020_09_02_279521	199	4	indicates	indicate	VBZ
10_1101-2020_09_02_279521	199	5	the	the	DT
10_1101-2020_09_02_279521	199	6	scenario	scenario	NN
10_1101-2020_09_02_279521	199	7	where	where	WRB
10_1101-2020_09_02_279521	199	8	clinical	clinical	JJ
10_1101-2020_09_02_279521	199	9	values	value	NNS
10_1101-2020_09_02_279521	199	10	were	be	VBD
10_1101-2020_09_02_279521	199	11	computed	compute	VBN
10_1101-2020_09_02_279521	199	12	at	at	IN
10_1101-2020_09_02_279521	199	13	conversion	conversion	NN
10_1101-2020_09_02_279521	199	14	time	time	NN
10_1101-2020_09_02_279521	199	15	from	from	IN
10_1101-2020_09_02_279521	199	16	the	the	DT
10_1101-2020_09_02_279521	199	17	estimated	estimate	VBN
10_1101-2020_09_02_279521	199	18	natural	natural	JJ
10_1101-2020_09_02_279521	199	19	progression	progression	NN
10_1101-2020_09_02_279521	199	20	shown	show	VBN
10_1101-2020_09_02_279521	199	21	in	in	IN
10_1101-2020_09_02_279521	199	22	Figure	figure	NN
10_1101-2020_09_02_279521	199	23	2	2	CD
10_1101-2020_09_02_279521	199	24	panel	panel	NN
10_1101-2020_09_02_279521	199	25	II	II	NNP
10_1101-2020_09_02_279521	199	26	)	)	-RRB-
10_1101-2020_09_02_279521	199	27	(	(	-LRB-
10_1101-2020_09_02_279521	199	28	left	leave	VBN
10_1101-2020_09_02_279521	199	29	)	)	-RRB-
10_1101-2020_09_02_279521	199	30	.	.	.
10_1101-2020_09_02_279521	200	1	Figure	figure	NN
10_1101-2020_09_02_279521	200	2	5	5	CD
10_1101-2020_09_02_279521	200	3	shows	show	VBZ
10_1101-2020_09_02_279521	200	4	the	the	DT
10_1101-2020_09_02_279521	200	5	change	change	NN
10_1101-2020_09_02_279521	200	6	in	in	IN
10_1101-2020_09_02_279521	200	7	statistical	statistical	JJ
10_1101-2020_09_02_279521	200	8	power	power	NN
10_1101-2020_09_02_279521	200	9	depending	depend	VBG
10_1101-2020_09_02_279521	200	10	on	on	IN
10_1101-2020_09_02_279521	200	11	intervention	intervention	NN
10_1101-2020_09_02_279521	200	12	time	time	NN
10_1101-2020_09_02_279521	200	13	and	and	CC
10_1101-2020_09_02_279521	200	14	sample	sample	NN
10_1101-2020_09_02_279521	200	15	sizes	size	NNS
10_1101-2020_09_02_279521	200	16	.	.	.
10_1101-2020_09_02_279521	201	1	For	for	IN
10_1101-2020_09_02_279521	201	2	large	large	JJ
10_1101-2020_09_02_279521	201	3	sample	sample	NN
10_1101-2020_09_02_279521	201	4	sizes	size	NNS
10_1101-2020_09_02_279521	201	5	(	(	-LRB-
10_1101-2020_09_02_279521	201	6	1000	1000	CD
10_1101-2020_09_02_279521	201	7	subjects	subject	NNS
10_1101-2020_09_02_279521	201	8	per	per	IN
10_1101-2020_09_02_279521	201	9	arm	arm	NN
10_1101-2020_09_02_279521	201	10	)	)	-RRB-
10_1101-2020_09_02_279521	201	11	a	a	DT
10_1101-2020_09_02_279521	201	12	power	power	NN
10_1101-2020_09_02_279521	201	13	greater	great	JJR
10_1101-2020_09_02_279521	201	14	than	than	IN
10_1101-2020_09_02_279521	201	15	0.8	0.8	CD
10_1101-2020_09_02_279521	201	16	can	can	MD
10_1101-2020_09_02_279521	201	17	be	be	VB
10_1101-2020_09_02_279521	201	18	obtained	obtain	VBN
10_1101-2020_09_02_279521	201	19	around	around	IN
10_1101-2020_09_02_279521	201	20	7	7	CD
10_1101-2020_09_02_279521	201	21	years	year	NNS
10_1101-2020_09_02_279521	201	22	before	before	IN
10_1101-2020_09_02_279521	201	23	conversion	conversion	NN
10_1101-2020_09_02_279521	201	24	,	,	,
10_1101-2020_09_02_279521	201	25	depending	depend	VBG
10_1101-2020_09_02_279521	201	26	on	on	IN
10_1101-2020_09_02_279521	201	27	the	the	DT
10_1101-2020_09_02_279521	201	28	outcome	outcome	NN
10_1101-2020_09_02_279521	201	29	score	score	NN
10_1101-2020_09_02_279521	201	30	,	,	,
10_1101-2020_09_02_279521	201	31	where	where	WRB
10_1101-2020_09_02_279521	201	32	in	in	IN
10_1101-2020_09_02_279521	201	33	general	general	JJ
10_1101-2020_09_02_279521	201	34	we	-PRON-	PRP
10_1101-2020_09_02_279521	201	35	observe	observe	VBP
10_1101-2020_09_02_279521	201	36	that	that	IN
10_1101-2020_09_02_279521	201	37	RAVLT	RAVLT	NNP
10_1101-2020_09_02_279521	201	38	forgetting	forget	VBG
10_1101-2020_09_02_279521	201	39	exhibits	exhibit	VBZ
10_1101-2020_09_02_279521	201	40	a	a	DT
10_1101-2020_09_02_279521	201	41	higher	high	JJR
10_1101-2020_09_02_279521	201	42	power	power	NN
10_1101-2020_09_02_279521	201	43	than	than	IN
10_1101-2020_09_02_279521	201	44	the	the	DT
10_1101-2020_09_02_279521	201	45	other	other	JJ
10_1101-2020_09_02_279521	201	46	scores	score	NNS
10_1101-2020_09_02_279521	201	47	.	.	.
10_1101-2020_09_02_279521	202	1	When	when	WRB
10_1101-2020_09_02_279521	202	2	sample	sample	NN
10_1101-2020_09_02_279521	202	3	size	size	NN
10_1101-2020_09_02_279521	202	4	is	be	VBZ
10_1101-2020_09_02_279521	202	5	lower	low	JJR
10_1101-2020_09_02_279521	202	6	than	than	IN
10_1101-2020_09_02_279521	202	7	100	100	CD
10_1101-2020_09_02_279521	202	8	subjects	subject	NNS
10_1101-2020_09_02_279521	202	9	per	per	IN
10_1101-2020_09_02_279521	202	10	arm	arm	NN
10_1101-2020_09_02_279521	202	11	,	,	,
10_1101-2020_09_02_279521	202	12	a	a	DT
10_1101-2020_09_02_279521	202	13	power	power	NN
10_1101-2020_09_02_279521	202	14	greater	great	JJR
10_1101-2020_09_02_279521	202	15	than	than	IN
10_1101-2020_09_02_279521	202	16	0.8	0.8	CD
10_1101-2020_09_02_279521	202	17	is	be	VBZ
10_1101-2020_09_02_279521	202	18	reached	reach	VBN
10_1101-2020_09_02_279521	202	19	if	if	IN
10_1101-2020_09_02_279521	202	20	intervention	intervention	NN
10_1101-2020_09_02_279521	202	21	is	be	VBZ
10_1101-2020_09_02_279521	202	22	performed	perform	VBN
10_1101-2020_09_02_279521	202	23	at	at	IN
10_1101-2020_09_02_279521	202	24	the	the	DT
10_1101-2020_09_02_279521	202	25	latest	late	JJS
10_1101-2020_09_02_279521	202	26	11	11	CD
10_1101-2020_09_02_279521	202	27	years	year	NNS
10_1101-2020_09_02_279521	202	28	before	before	IN
10_1101-2020_09_02_279521	202	29	conversion	conversion	NN
10_1101-2020_09_02_279521	202	30	,	,	,
10_1101-2020_09_02_279521	202	31	with	with	IN
10_1101-2020_09_02_279521	202	32	a	a	DT
10_1101-2020_09_02_279521	202	33	mild	mild	JJ
10_1101-2020_09_02_279521	202	34	variability	variability	NN
10_1101-2020_09_02_279521	202	35	depending	depend	VBG
10_1101-2020_09_02_279521	202	36	on	on	IN
10_1101-2020_09_02_279521	202	37	the	the	DT
10_1101-2020_09_02_279521	202	38	considered	consider	VBN
10_1101-2020_09_02_279521	202	39	clinical	clinical	JJ
10_1101-2020_09_02_279521	202	40	score	score	NN
10_1101-2020_09_02_279521	202	41	.	.	.
10_1101-2020_09_02_279521	203	1	We	-PRON-	PRP
10_1101-2020_09_02_279521	203	2	notice	notice	VBP
10_1101-2020_09_02_279521	203	3	that	that	IN
10_1101-2020_09_02_279521	203	4	in	in	IN
10_1101-2020_09_02_279521	203	5	the	the	DT
10_1101-2020_09_02_279521	203	6	case	case	NN
10_1101-2020_09_02_279521	203	7	of	of	IN
10_1101-2020_09_02_279521	203	8	50	50	CD
10_1101-2020_09_02_279521	203	9	%	%	NN
10_1101-2020_09_02_279521	203	10	amyloid	amyloid	NN
10_1101-2020_09_02_279521	203	11	lowering	lowering	NN
10_1101-2020_09_02_279521	203	12	,	,	,
10_1101-2020_09_02_279521	203	13	in	in	IN
10_1101-2020_09_02_279521	203	14	order	order	NN
10_1101-2020_09_02_279521	203	15	to	to	TO
10_1101-2020_09_02_279521	203	16	reach	reach	VB
10_1101-2020_09_02_279521	203	17	the	the	DT
10_1101-2020_09_02_279521	203	18	same	same	JJ
10_1101-2020_09_02_279521	203	19	power	power	NN
10_1101-2020_09_02_279521	203	20	intervention	intervention	NN
10_1101-2020_09_02_279521	203	21	needs	need	VBZ
10_1101-2020_09_02_279521	203	22	to	to	TO
10_1101-2020_09_02_279521	203	23	be	be	VB
10_1101-2020_09_02_279521	203	24	consistently	consistently	RB
10_1101-2020_09_02_279521	203	25	performed	perform	VBN
10_1101-2020_09_02_279521	203	26	earlier	early	RBR
10_1101-2020_09_02_279521	203	27	compared	compare	VBN
10_1101-2020_09_02_279521	203	28	to	to	IN
10_1101-2020_09_02_279521	203	29	the	the	DT
10_1101-2020_09_02_279521	203	30	scenario	scenario	NN
10_1101-2020_09_02_279521	203	31	of	of	IN
10_1101-2020_09_02_279521	203	32	100	100	CD
10_1101-2020_09_02_279521	203	33	%	%	NN
10_1101-2020_09_02_279521	203	34	amyloid	amyloid	NN
10_1101-2020_09_02_279521	203	35	lowering	lower	VBG
10_1101-2020_09_02_279521	203	36	for	for	IN
10_1101-2020_09_02_279521	203	37	the	the	DT
10_1101-2020_09_02_279521	203	38	same	same	JJ
10_1101-2020_09_02_279521	203	39	sample	sample	NN
10_1101-2020_09_02_279521	203	40	size	size	NN
10_1101-2020_09_02_279521	203	41	and	and	CC
10_1101-2020_09_02_279521	203	42	clinical	clinical	JJ
10_1101-2020_09_02_279521	203	43	score	score	NN
10_1101-2020_09_02_279521	203	44	.	.	.
10_1101-2020_09_02_279521	204	1	For	for	IN
10_1101-2020_09_02_279521	204	2	instance	instance	NN
10_1101-2020_09_02_279521	204	3	,	,	,
10_1101-2020_09_02_279521	204	4	if	if	IN
10_1101-2020_09_02_279521	204	5	we	-PRON-	PRP
10_1101-2020_09_02_279521	204	6	consider	consider	VBP
10_1101-2020_09_02_279521	204	7	ADAS11	ADAS11	NNP
10_1101-2020_09_02_279521	204	8	with	with	IN
10_1101-2020_09_02_279521	204	9	a	a	DT
10_1101-2020_09_02_279521	204	10	sample	sample	NN
10_1101-2020_09_02_279521	204	11	size	size	NN
10_1101-2020_09_02_279521	204	12	of	of	IN
10_1101-2020_09_02_279521	204	13	100	100	CD
10_1101-2020_09_02_279521	204	14	subjects	subject	NNS
10_1101-2020_09_02_279521	204	15	per	per	IN
10_1101-2020_09_02_279521	204	16	arm	arm	NN
10_1101-2020_09_02_279521	204	17	,	,	,
10_1101-2020_09_02_279521	204	18	a	a	DT
10_1101-2020_09_02_279521	204	19	power	power	NN
10_1101-2020_09_02_279521	204	20	of	of	IN
10_1101-2020_09_02_279521	204	21	0.8	0.8	CD
10_1101-2020_09_02_279521	204	22	is	be	VBZ
10_1101-2020_09_02_279521	204	23	obtained	obtain	VBN
10_1101-2020_09_02_279521	204	24	for	for	IN
10_1101-2020_09_02_279521	204	25	a	a	DT
10_1101-2020_09_02_279521	204	26	100	100	CD
10_1101-2020_09_02_279521	204	27	%	%	NN
10_1101-2020_09_02_279521	204	28	amyloid	amyloid	NN
10_1101-2020_09_02_279521	204	29	lowering	lower	VBG
10_1101-2020_09_02_279521	204	30	intervention	intervention	NN
10_1101-2020_09_02_279521	204	31	performed	perform	VBD
10_1101-2020_09_02_279521	204	32	11.5	11.5	CD
10_1101-2020_09_02_279521	204	33	years	year	NNS
10_1101-2020_09_02_279521	204	34	before	before	IN
10_1101-2020_09_02_279521	204	35	conversion	conversion	NN
10_1101-2020_09_02_279521	204	36	,	,	,
10_1101-2020_09_02_279521	204	37	while	while	IN
10_1101-2020_09_02_279521	204	38	in	in	IN
10_1101-2020_09_02_279521	204	39	case	case	NN
10_1101-2020_09_02_279521	204	40	of	of	IN
10_1101-2020_09_02_279521	204	41	a	a	DT
10_1101-2020_09_02_279521	204	42	50	50	CD
10_1101-2020_09_02_279521	204	43	%	%	NN
10_1101-2020_09_02_279521	204	44	amyloid	amyloid	NN
10_1101-2020_09_02_279521	204	45	lowering	lower	VBG
10_1101-2020_09_02_279521	204	46	the	the	DT
10_1101-2020_09_02_279521	204	47	equivalent	equivalent	JJ
10_1101-2020_09_02_279521	204	48	effect	effect	NN
10_1101-2020_09_02_279521	204	49	would	would	MD
10_1101-2020_09_02_279521	204	50	be	be	VB
10_1101-2020_09_02_279521	204	51	obtained	obtain	VBN
10_1101-2020_09_02_279521	204	52	by	by	IN
10_1101-2020_09_02_279521	204	53	intervening	intervene	VBG
10_1101-2020_09_02_279521	204	54	15	15	CD
10_1101-2020_09_02_279521	204	55	years	year	NNS
10_1101-2020_09_02_279521	204	56	before	before	IN
10_1101-2020_09_02_279521	204	57	conversion	conversion	NN
10_1101-2020_09_02_279521	204	58	.	.	.
10_1101-2020_09_02_279521	205	1	We	-PRON-	PRP
10_1101-2020_09_02_279521	205	2	provide	provide	VBP
10_1101-2020_09_02_279521	205	3	in	in	IN
10_1101-2020_09_02_279521	205	4	Table	table	NN
10_1101-2020_09_02_279521	205	5	2	2	CD
10_1101-2020_09_02_279521	205	6	the	the	DT
10_1101-2020_09_02_279521	205	7	estimated	estimate	VBN
10_1101-2020_09_02_279521	205	8	improvement	improvement	NN
10_1101-2020_09_02_279521	205	9	for	for	IN
10_1101-2020_09_02_279521	205	10	each	each	DT
10_1101-2020_09_02_279521	205	11	clinical	clinical	JJ
10_1101-2020_09_02_279521	205	12	score	score	NN
10_1101-2020_09_02_279521	205	13	at	at	IN
10_1101-2020_09_02_279521	205	14	conversion	conversion	NN
10_1101-2020_09_02_279521	205	15	with	with	IN
10_1101-2020_09_02_279521	205	16	a	a	DT
10_1101-2020_09_02_279521	205	17	sample	sample	NN
10_1101-2020_09_02_279521	205	18	size	size	NN
10_1101-2020_09_02_279521	205	19	of	of	IN
10_1101-2020_09_02_279521	205	20	100	100	CD
10_1101-2020_09_02_279521	205	21	subjects	subject	NNS
10_1101-2020_09_02_279521	205	22	per	per	IN
10_1101-2020_09_02_279521	205	23	arm	arm	NN
10_1101-2020_09_02_279521	205	24	for	for	IN
10_1101-2020_09_02_279521	205	25	both	both	DT
10_1101-2020_09_02_279521	205	26	100	100	CD
10_1101-2020_09_02_279521	205	27	%	%	NN
10_1101-2020_09_02_279521	205	28	and	and	CC
10_1101-2020_09_02_279521	205	29	50	50	CD
10_1101-2020_09_02_279521	205	30	%	%	NN
10_1101-2020_09_02_279521	205	31	amyloid	amyloid	NN
10_1101-2020_09_02_279521	205	32	lowering	lower	VBG
10_1101-2020_09_02_279521	205	33	depending	depend	VBG
10_1101-2020_09_02_279521	205	34	on	on	IN
10_1101-2020_09_02_279521	205	35	Figure	Figure	NNP
10_1101-2020_09_02_279521	205	36	4	4	CD
10_1101-2020_09_02_279521	205	37	Simulation	Simulation	NNP
10_1101-2020_09_02_279521	205	38	of	of	IN
10_1101-2020_09_02_279521	205	39	amyloid	amyloid	NN
10_1101-2020_09_02_279521	205	40	lowering	lower	VBG
10_1101-2020_09_02_279521	205	41	intervention	intervention	NN
10_1101-2020_09_02_279521	205	42	on	on	IN
10_1101-2020_09_02_279521	205	43	the	the	DT
10_1101-2020_09_02_279521	205	44	z	z	NNP
10_1101-2020_09_02_279521	205	45	-	-	HYPH
10_1101-2020_09_02_279521	205	46	scores	score	NNS
10_1101-2020_09_02_279521	205	47	evolution	evolution	NN
10_1101-2020_09_02_279521	205	48	.	.	.
10_1101-2020_09_02_279521	206	1	Hypothetical	hypothetical	JJ
10_1101-2020_09_02_279521	206	2	scenarios	scenario	NNS
10_1101-2020_09_02_279521	206	3	of	of	IN
10_1101-2020_09_02_279521	206	4	irreversible	irreversible	JJ
10_1101-2020_09_02_279521	206	5	amyloid	amyloid	NN
10_1101-2020_09_02_279521	206	6	lowering	lower	VBG
10_1101-2020_09_02_279521	206	7	interventions	intervention	NNS
10_1101-2020_09_02_279521	206	8	at	at	IN
10_1101-2020_09_02_279521	206	9	t=-20	t=-20	NNP
10_1101-2020_09_02_279521	206	10	years	year	NNS
10_1101-2020_09_02_279521	206	11	from	from	IN
10_1101-2020_09_02_279521	206	12	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	206	13	's	's	POS
10_1101-2020_09_02_279521	206	14	dementia	dementia	NN
10_1101-2020_09_02_279521	206	15	diagnosis	diagnosis	NN
10_1101-2020_09_02_279521	206	16	,	,	,
10_1101-2020_09_02_279521	206	17	with	with	IN
10_1101-2020_09_02_279521	206	18	a	a	DT
10_1101-2020_09_02_279521	206	19	rate	rate	NN
10_1101-2020_09_02_279521	206	20	of	of	IN
10_1101-2020_09_02_279521	206	21	100	100	CD
10_1101-2020_09_02_279521	206	22	%	%	NN
10_1101-2020_09_02_279521	206	23	(	(	-LRB-
10_1101-2020_09_02_279521	206	24	left	left	RB
10_1101-2020_09_02_279521	206	25	)	)	-RRB-
10_1101-2020_09_02_279521	206	26	or	or	CC
10_1101-2020_09_02_279521	206	27	50	50	CD
10_1101-2020_09_02_279521	206	28	%	%	NN
10_1101-2020_09_02_279521	206	29	(	(	-LRB-
10_1101-2020_09_02_279521	206	30	right	right	UH
10_1101-2020_09_02_279521	206	31	)	)	-RRB-
10_1101-2020_09_02_279521	206	32	.	.	.
10_1101-2020_09_02_279521	207	1	Shadowed	shadowed	JJ
10_1101-2020_09_02_279521	207	2	areas	area	NNS
10_1101-2020_09_02_279521	207	3	represent	represent	VBP
10_1101-2020_09_02_279521	207	4	the	the	DT
10_1101-2020_09_02_279521	207	5	standard	standard	JJ
10_1101-2020_09_02_279521	207	6	deviation	deviation	NN
10_1101-2020_09_02_279521	207	7	of	of	IN
10_1101-2020_09_02_279521	207	8	the	the	DT
10_1101-2020_09_02_279521	207	9	average	average	JJ
10_1101-2020_09_02_279521	207	10	trajectory	trajectory	CD
10_1101-2020_09_02_279521	207	11	.	.	.
10_1101-2020_09_02_279521	208	1	.CC	.CC	NFP
10_1101-2020_09_02_279521	208	2	-	-	:
10_1101-2020_09_02_279521	208	3	BY	by	IN
10_1101-2020_09_02_279521	208	4	4.0	4.0	CD
10_1101-2020_09_02_279521	208	5	International	international	JJ
10_1101-2020_09_02_279521	208	6	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	208	7	.	.	.
10_1101-2020_09_02_279521	209	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	209	2	is	be	VBZ
10_1101-2020_09_02_279521	209	3	made	make	VBN
10_1101-2020_09_02_279521	209	4	available	available	JJ
10_1101-2020_09_02_279521	209	5	under	under	IN
10_1101-2020_09_02_279521	209	6	a	a	DT
10_1101-2020_09_02_279521	209	7	preprint	preprint	NN
10_1101-2020_09_02_279521	209	8	(	(	-LRB-
10_1101-2020_09_02_279521	209	9	which	which	WDT
10_1101-2020_09_02_279521	209	10	was	be	VBD
10_1101-2020_09_02_279521	209	11	not	not	RB
10_1101-2020_09_02_279521	209	12	certified	certify	VBN
10_1101-2020_09_02_279521	209	13	by	by	IN
10_1101-2020_09_02_279521	209	14	peer	peer	NN
10_1101-2020_09_02_279521	209	15	review	review	NN
10_1101-2020_09_02_279521	209	16	)	)	-RRB-
10_1101-2020_09_02_279521	209	17	is	be	VBZ
10_1101-2020_09_02_279521	209	18	the	the	DT
10_1101-2020_09_02_279521	209	19	author	author	NN
10_1101-2020_09_02_279521	209	20	/	/	SYM
10_1101-2020_09_02_279521	209	21	funder	funder	NN
10_1101-2020_09_02_279521	209	22	,	,	,
10_1101-2020_09_02_279521	209	23	who	who	WP
10_1101-2020_09_02_279521	209	24	has	have	VBZ
10_1101-2020_09_02_279521	209	25	granted	grant	VBN
10_1101-2020_09_02_279521	209	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	209	27	a	a	DT
10_1101-2020_09_02_279521	209	28	license	license	NN
10_1101-2020_09_02_279521	209	29	to	to	TO
10_1101-2020_09_02_279521	209	30	display	display	VB
10_1101-2020_09_02_279521	209	31	the	the	DT
10_1101-2020_09_02_279521	209	32	preprint	preprint	NN
10_1101-2020_09_02_279521	209	33	in	in	IN
10_1101-2020_09_02_279521	209	34	The	the	DT
10_1101-2020_09_02_279521	209	35	copyright	copyright	NN
10_1101-2020_09_02_279521	209	36	holder	holder	NN
10_1101-2020_09_02_279521	209	37	for	for	IN
10_1101-2020_09_02_279521	209	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	209	39	version	version	NN
10_1101-2020_09_02_279521	209	40	posted	post	VBD
10_1101-2020_09_02_279521	209	41	February	February	NNP
10_1101-2020_09_02_279521	209	42	10	10	CD
10_1101-2020_09_02_279521	209	43	,	,	,
10_1101-2020_09_02_279521	209	44	2021	2021	CD
10_1101-2020_09_02_279521	209	45	.	.	.
10_1101-2020_09_02_279521	209	46	;	;	:
10_1101-2020_09_02_279521	209	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	209	48	:	:	:
10_1101-2020_09_02_279521	209	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	209	50	preprint	preprint	NN
10_1101-2020_09_02_279521	209	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	NN
10_1101-2020_09_02_279521	209	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	ADD
10_1101-2020_09_02_279521	209	53	the	the	DT
10_1101-2020_09_02_279521	209	54	intervention	intervention	NN
10_1101-2020_09_02_279521	209	55	time	time	NN
10_1101-2020_09_02_279521	209	56	.	.	.
10_1101-2020_09_02_279521	210	1	We	-PRON-	PRP
10_1101-2020_09_02_279521	210	2	observe	observe	VBP
10_1101-2020_09_02_279521	210	3	that	that	IN
10_1101-2020_09_02_279521	210	4	for	for	IN
10_1101-2020_09_02_279521	210	5	the	the	DT
10_1101-2020_09_02_279521	210	6	same	same	JJ
10_1101-2020_09_02_279521	210	7	intervention	intervention	NN
10_1101-2020_09_02_279521	210	8	time	time	NN
10_1101-2020_09_02_279521	210	9	,	,	,
10_1101-2020_09_02_279521	210	10	100	100	CD
10_1101-2020_09_02_279521	210	11	%	%	NN
10_1101-2020_09_02_279521	210	12	amyloid	amyloid	NN
10_1101-2020_09_02_279521	210	13	lowering	lowering	NN
10_1101-2020_09_02_279521	210	14	always	always	RB
10_1101-2020_09_02_279521	210	15	results	result	VBZ
10_1101-2020_09_02_279521	210	16	in	in	IN
10_1101-2020_09_02_279521	210	17	a	a	DT
10_1101-2020_09_02_279521	210	18	larger	large	JJR
10_1101-2020_09_02_279521	210	19	improvement	improvement	NN
10_1101-2020_09_02_279521	210	20	of	of	IN
10_1101-2020_09_02_279521	210	21	clinical	clinical	JJ
10_1101-2020_09_02_279521	210	22	endpoints	endpoint	NNS
10_1101-2020_09_02_279521	210	23	compared	compare	VBN
10_1101-2020_09_02_279521	210	24	to	to	IN
10_1101-2020_09_02_279521	210	25	50	50	CD
10_1101-2020_09_02_279521	210	26	%	%	NN
10_1101-2020_09_02_279521	210	27	amyloid	amyloid	NN
10_1101-2020_09_02_279521	210	28	lowering	lowering	NN
10_1101-2020_09_02_279521	210	29	.	.	.
10_1101-2020_09_02_279521	211	1	We	-PRON-	PRP
10_1101-2020_09_02_279521	211	2	also	also	RB
10_1101-2020_09_02_279521	211	3	note	note	VBP
10_1101-2020_09_02_279521	211	4	that	that	IN
10_1101-2020_09_02_279521	211	5	in	in	IN
10_1101-2020_09_02_279521	211	6	the	the	DT
10_1101-2020_09_02_279521	211	7	case	case	NN
10_1101-2020_09_02_279521	211	8	of	of	IN
10_1101-2020_09_02_279521	211	9	100	100	CD
10_1101-2020_09_02_279521	211	10	%	%	NN
10_1101-2020_09_02_279521	211	11	lowering	lowering	NN
10_1101-2020_09_02_279521	211	12	,	,	,
10_1101-2020_09_02_279521	211	13	clinical	clinical	JJ
10_1101-2020_09_02_279521	211	14	endpoints	endpoint	NNS
10_1101-2020_09_02_279521	211	15	obtained	obtain	VBN
10_1101-2020_09_02_279521	211	16	for	for	IN
10_1101-2020_09_02_279521	211	17	intervention	intervention	NN
10_1101-2020_09_02_279521	211	18	at	at	IN
10_1101-2020_09_02_279521	211	19	t=-15	t=-15	NNP
10_1101-2020_09_02_279521	211	20	years	year	NNS
10_1101-2020_09_02_279521	211	21	correspond	correspond	VBP
10_1101-2020_09_02_279521	211	22	to	to	IN
10_1101-2020_09_02_279521	211	23	typical	typical	JJ
10_1101-2020_09_02_279521	211	24	cutoff	cutoff	NN
10_1101-2020_09_02_279521	211	25	values	value	NNS
10_1101-2020_09_02_279521	211	26	for	for	IN
10_1101-2020_09_02_279521	211	27	inclusion	inclusion	NN
10_1101-2020_09_02_279521	211	28	into	into	IN
10_1101-2020_09_02_279521	211	29	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	211	30	’s	’s	POS
10_1101-2020_09_02_279521	211	31	disease	disease	NN
10_1101-2020_09_02_279521	211	32	trials	trial	NNS
10_1101-2020_09_02_279521	211	33	(	(	-LRB-
10_1101-2020_09_02_279521	211	34	ADAS11	ADAS11	NNP
10_1101-2020_09_02_279521	211	35	=	=	NFP
10_1101-2020_09_02_279521	211	36	13.7	13.7	CD
10_1101-2020_09_02_279521	211	37	±	±	CD
10_1101-2020_09_02_279521	211	38	5.8	5.8	CD
10_1101-2020_09_02_279521	211	39	,	,	,
10_1101-2020_09_02_279521	211	40	MMSE	MMSE	NNP
10_1101-2020_09_02_279521	211	41	=	=	SYM
10_1101-2020_09_02_279521	211	42	25.7±	25.7±	CD
10_1101-2020_09_02_279521	211	43	2.5	2.5	CD
10_1101-2020_09_02_279521	211	44	,	,	,
10_1101-2020_09_02_279521	211	45	see	see	VB
10_1101-2020_09_02_279521	211	46	Supplementary	Supplementary	NNP
10_1101-2020_09_02_279521	211	47	Table	Table	NNP
10_1101-2020_09_02_279521	211	48	2	2	CD
10_1101-2020_09_02_279521	211	49	)	)	-RRB-
10_1101-2020_09_02_279521	211	50	(	(	-LRB-
10_1101-2020_09_02_279521	211	51	Gamberger	Gamberger	NNP
10_1101-2020_09_02_279521	211	52	et	et	NNP
10_1101-2020_09_02_279521	211	53	al	al	NNP
10_1101-2020_09_02_279521	211	54	.	.	NNP
10_1101-2020_09_02_279521	211	55	,	,	,
10_1101-2020_09_02_279521	211	56	2017	2017	CD
10_1101-2020_09_02_279521	211	57	;	;	:
10_1101-2020_09_02_279521	211	58	Kochhann	Kochhann	NNP
10_1101-2020_09_02_279521	211	59	et	et	NNP
10_1101-2020_09_02_279521	211	60	al	al	NNP
10_1101-2020_09_02_279521	211	61	.	.	NNP
10_1101-2020_09_02_279521	211	62	,	,	,
10_1101-2020_09_02_279521	211	63	2010	2010	CD
10_1101-2020_09_02_279521	211	64	)	)	-RRB-
10_1101-2020_09_02_279521	211	65	.	.	.
10_1101-2020_09_02_279521	212	1	Discussion	Discussion	NNP
10_1101-2020_09_02_279521	212	2	We	-PRON-	PRP
10_1101-2020_09_02_279521	212	3	presented	present	VBD
10_1101-2020_09_02_279521	212	4	a	a	DT
10_1101-2020_09_02_279521	212	5	framework	framework	NN
10_1101-2020_09_02_279521	212	6	to	to	TO
10_1101-2020_09_02_279521	212	7	jointly	jointly	RB
10_1101-2020_09_02_279521	212	8	model	model	VB
10_1101-2020_09_02_279521	212	9	the	the	DT
10_1101-2020_09_02_279521	212	10	progression	progression	NN
10_1101-2020_09_02_279521	212	11	of	of	IN
10_1101-2020_09_02_279521	212	12	multi	multi	JJ
10_1101-2020_09_02_279521	212	13	-	-	JJ
10_1101-2020_09_02_279521	212	14	modal	modal	JJ
10_1101-2020_09_02_279521	212	15	imaging	imaging	NNP
10_1101-2020_09_02_279521	212	16	and	and	CC
10_1101-2020_09_02_279521	212	17	clinical	clinical	JJ
10_1101-2020_09_02_279521	212	18	data	datum	NNS
10_1101-2020_09_02_279521	212	19	,	,	,
10_1101-2020_09_02_279521	212	20	based	base	VBN
10_1101-2020_09_02_279521	212	21	on	on	IN
10_1101-2020_09_02_279521	212	22	the	the	DT
10_1101-2020_09_02_279521	212	23	estimation	estimation	NN
10_1101-2020_09_02_279521	212	24	of	of	IN
10_1101-2020_09_02_279521	212	25	latent	latent	NN
10_1101-2020_09_02_279521	212	26	biomarkers	biomarker	NNS
10_1101-2020_09_02_279521	212	27	'	'	POS
10_1101-2020_09_02_279521	212	28	relationships	relationship	NNS
10_1101-2020_09_02_279521	212	29	governing	govern	VBG
10_1101-2020_09_02_279521	212	30	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	212	31	’s	’s	POS
10_1101-2020_09_02_279521	212	32	disease	disease	NN
10_1101-2020_09_02_279521	212	33	progression	progression	NN
10_1101-2020_09_02_279521	212	34	.	.	.
10_1101-2020_09_02_279521	213	1	The	the	DT
10_1101-2020_09_02_279521	213	2	model	model	NN
10_1101-2020_09_02_279521	213	3	is	be	VBZ
10_1101-2020_09_02_279521	213	4	designed	design	VBN
10_1101-2020_09_02_279521	213	5	to	to	TO
10_1101-2020_09_02_279521	213	6	simulate	simulate	VB
10_1101-2020_09_02_279521	213	7	intervention	intervention	NN
10_1101-2020_09_02_279521	213	8	scenarios	scenario	NNS
10_1101-2020_09_02_279521	213	9	in	in	IN
10_1101-2020_09_02_279521	213	10	clinical	clinical	JJ
10_1101-2020_09_02_279521	213	11	trials	trial	NNS
10_1101-2020_09_02_279521	213	12	,	,	,
10_1101-2020_09_02_279521	213	13	and	and	CC
10_1101-2020_09_02_279521	213	14	in	in	IN
10_1101-2020_09_02_279521	213	15	this	this	DT
10_1101-2020_09_02_279521	213	16	study	study	NN
10_1101-2020_09_02_279521	213	17	we	-PRON-	PRP
10_1101-2020_09_02_279521	213	18	focused	focus	VBD
10_1101-2020_09_02_279521	213	19	on	on	IN
10_1101-2020_09_02_279521	213	20	assessing	assess	VBG
10_1101-2020_09_02_279521	213	21	the	the	DT
10_1101-2020_09_02_279521	213	22	effect	effect	NN
10_1101-2020_09_02_279521	213	23	of	of	IN
10_1101-2020_09_02_279521	213	24	anti	anti	JJ
10_1101-2020_09_02_279521	213	25	-	-	JJ
10_1101-2020_09_02_279521	213	26	amyloid	amyloid	JJ
10_1101-2020_09_02_279521	213	27	drugs	drug	NNS
10_1101-2020_09_02_279521	213	28	on	on	IN
10_1101-2020_09_02_279521	213	29	biomarkers	biomarker	NNS
10_1101-2020_09_02_279521	213	30	'	'	POS
10_1101-2020_09_02_279521	213	31	evolution	evolution	NN
10_1101-2020_09_02_279521	213	32	,	,	,
10_1101-2020_09_02_279521	213	33	by	by	IN
10_1101-2020_09_02_279521	213	34	quantifying	quantify	VBG
10_1101-2020_09_02_279521	213	35	the	the	DT
10_1101-2020_09_02_279521	213	36	effect	effect	NN
10_1101-2020_09_02_279521	213	37	of	of	IN
10_1101-2020_09_02_279521	213	38	intervention	intervention	NN
10_1101-2020_09_02_279521	213	39	time	time	NN
10_1101-2020_09_02_279521	213	40	and	and	CC
10_1101-2020_09_02_279521	213	41	drug	drug	NN
10_1101-2020_09_02_279521	213	42	efficacy	efficacy	NN
10_1101-2020_09_02_279521	213	43	on	on	IN
10_1101-2020_09_02_279521	213	44	clinical	clinical	JJ
10_1101-2020_09_02_279521	213	45	outcomes	outcome	NNS
10_1101-2020_09_02_279521	213	46	.	.	.
10_1101-2020_09_02_279521	214	1	Our	-PRON-	PRP$
10_1101-2020_09_02_279521	214	2	results	result	NNS
10_1101-2020_09_02_279521	214	3	underline	underline	VBP
10_1101-2020_09_02_279521	214	4	the	the	DT
10_1101-2020_09_02_279521	214	5	critical	critical	JJ
10_1101-2020_09_02_279521	214	6	importance	importance	NN
10_1101-2020_09_02_279521	214	7	of	of	IN
10_1101-2020_09_02_279521	214	8	intervention	intervention	NN
10_1101-2020_09_02_279521	214	9	time	time	NN
10_1101-2020_09_02_279521	214	10	,	,	,
10_1101-2020_09_02_279521	214	11	which	which	WDT
10_1101-2020_09_02_279521	214	12	should	should	MD
10_1101-2020_09_02_279521	214	13	be	be	VB
10_1101-2020_09_02_279521	214	14	performed	perform	VBN
10_1101-2020_09_02_279521	214	15	sensibly	sensibly	RB
10_1101-2020_09_02_279521	214	16	early	early	RB
10_1101-2020_09_02_279521	214	17	during	during	IN
10_1101-2020_09_02_279521	214	18	the	the	DT
10_1101-2020_09_02_279521	214	19	pathological	pathological	JJ
10_1101-2020_09_02_279521	214	20	history	history	NN
10_1101-2020_09_02_279521	214	21	to	to	TO
10_1101-2020_09_02_279521	214	22	effectively	effectively	RB
10_1101-2020_09_02_279521	214	23	appreciate	appreciate	VB
10_1101-2020_09_02_279521	214	24	the	the	DT
10_1101-2020_09_02_279521	214	25	effectiveness	effectiveness	NN
10_1101-2020_09_02_279521	214	26	of	of	IN
10_1101-2020_09_02_279521	214	27	disease	disease	NN
10_1101-2020_09_02_279521	214	28	modifiers	modifier	NNS
10_1101-2020_09_02_279521	214	29	.	.	.
10_1101-2020_09_02_279521	215	1	The	the	DT
10_1101-2020_09_02_279521	215	2	results	result	NNS
10_1101-2020_09_02_279521	215	3	obtained	obtain	VBN
10_1101-2020_09_02_279521	215	4	with	with	IN
10_1101-2020_09_02_279521	215	5	our	-PRON-	PRP$
10_1101-2020_09_02_279521	215	6	model	model	NN
10_1101-2020_09_02_279521	215	7	are	be	VBP
10_1101-2020_09_02_279521	215	8	compatible	compatible	JJ
10_1101-2020_09_02_279521	215	9	with	with	IN
10_1101-2020_09_02_279521	215	10	findings	finding	NNS
10_1101-2020_09_02_279521	215	11	reported	report	VBN
10_1101-2020_09_02_279521	215	12	in	in	IN
10_1101-2020_09_02_279521	215	13	recent	recent	JJ
10_1101-2020_09_02_279521	215	14	clinical	clinical	JJ
10_1101-2020_09_02_279521	215	15	studies	study	NNS
10_1101-2020_09_02_279521	215	16	(	(	-LRB-
10_1101-2020_09_02_279521	215	17	Egan	Egan	NNP
10_1101-2020_09_02_279521	215	18	et	et	NNP
10_1101-2020_09_02_279521	215	19	al	al	NNP
10_1101-2020_09_02_279521	215	20	.	.	NNP
10_1101-2020_09_02_279521	215	21	,	,	,
10_1101-2020_09_02_279521	215	22	2019	2019	CD
10_1101-2020_09_02_279521	215	23	;	;	:
10_1101-2020_09_02_279521	215	24	Honig	Honig	NNP
10_1101-2020_09_02_279521	215	25	et	et	NNP
10_1101-2020_09_02_279521	215	26	al	al	NNP
10_1101-2020_09_02_279521	215	27	.	.	NNP
10_1101-2020_09_02_279521	215	28	,	,	,
10_1101-2020_09_02_279521	215	29	2018	2018	CD
10_1101-2020_09_02_279521	215	30	;	;	:
10_1101-2020_09_02_279521	215	31	Wessels	Wessels	NNP
10_1101-2020_09_02_279521	215	32	et	et	NNP
10_1101-2020_09_02_279521	215	33	al	al	NNP
10_1101-2020_09_02_279521	215	34	.	.	NNP
10_1101-2020_09_02_279521	215	35	,	,	,
10_1101-2020_09_02_279521	215	36	2019	2019	CD
10_1101-2020_09_02_279521	215	37	)	)	-RRB-
10_1101-2020_09_02_279521	215	38	.	.	.
10_1101-2020_09_02_279521	216	1	For	for	IN
10_1101-2020_09_02_279521	216	2	example	example	NN
10_1101-2020_09_02_279521	216	3	,	,	,
10_1101-2020_09_02_279521	216	4	if	if	IN
10_1101-2020_09_02_279521	216	5	we	-PRON-	PRP
10_1101-2020_09_02_279521	216	6	consider	consider	VBP
10_1101-2020_09_02_279521	216	7	500	500	CD
10_1101-2020_09_02_279521	216	8	patients	patient	NNS
10_1101-2020_09_02_279521	216	9	per	per	IN
10_1101-2020_09_02_279521	216	10	arm	arm	NN
10_1101-2020_09_02_279521	216	11	and	and	CC
10_1101-2020_09_02_279521	216	12	perform	perform	VB
10_1101-2020_09_02_279521	216	13	a	a	DT
10_1101-2020_09_02_279521	216	14	100	100	CD
10_1101-2020_09_02_279521	216	15	%	%	NN
10_1101-2020_09_02_279521	216	16	amyloid	amyloid	NN
10_1101-2020_09_02_279521	216	17	lowering	lower	VBG
10_1101-2020_09_02_279521	216	18	intervention	intervention	NN
10_1101-2020_09_02_279521	216	19	for	for	IN
10_1101-2020_09_02_279521	216	20	2	2	CD
10_1101-2020_09_02_279521	216	21	years	year	NNS
10_1101-2020_09_02_279521	216	22	to	to	TO
10_1101-2020_09_02_279521	216	23	reproduce	reproduce	VB
10_1101-2020_09_02_279521	216	24	the	the	DT
10_1101-2020_09_02_279521	216	25	conditions	condition	NNS
10_1101-2020_09_02_279521	216	26	of	of	IN
10_1101-2020_09_02_279521	216	27	the	the	DT
10_1101-2020_09_02_279521	216	28	recent	recent	JJ
10_1101-2020_09_02_279521	216	29	trial	trial	NN
10_1101-2020_09_02_279521	216	30	of	of	IN
10_1101-2020_09_02_279521	216	31	Verubecestat	Verubecestat	NNP
10_1101-2020_09_02_279521	216	32	(	(	-LRB-
10_1101-2020_09_02_279521	216	33	Egan	Egan	NNP
10_1101-2020_09_02_279521	216	34	et	et	NNP
10_1101-2020_09_02_279521	216	35	al	al	NNP
10_1101-2020_09_02_279521	216	36	.	.	NNP
10_1101-2020_09_02_279521	216	37	,	,	,
10_1101-2020_09_02_279521	216	38	2019	2019	CD
10_1101-2020_09_02_279521	216	39	)	)	-RRB-
10_1101-2020_09_02_279521	216	40	,	,	,
10_1101-2020_09_02_279521	216	41	the	the	DT
10_1101-2020_09_02_279521	216	42	average	average	JJ
10_1101-2020_09_02_279521	216	43	improvement	improvement	NN
10_1101-2020_09_02_279521	216	44	of	of	IN
10_1101-2020_09_02_279521	216	45	MMSE	MMSE	NNP
10_1101-2020_09_02_279521	216	46	predicted	predict	VBN
10_1101-2020_09_02_279521	216	47	by	by	IN
10_1101-2020_09_02_279521	216	48	our	-PRON-	PRP$
10_1101-2020_09_02_279521	216	49	model	model	NN
10_1101-2020_09_02_279521	216	50	is	be	VBZ
10_1101-2020_09_02_279521	216	51	of	of	IN
10_1101-2020_09_02_279521	216	52	0.02	0.02	CD
10_1101-2020_09_02_279521	216	53	,	,	,
10_1101-2020_09_02_279521	216	54	falling	fall	VBG
10_1101-2020_09_02_279521	216	55	in	in	IN
10_1101-2020_09_02_279521	216	56	the	the	DT
10_1101-2020_09_02_279521	216	57	95	95	CD
10_1101-2020_09_02_279521	216	58	%	%	NN
10_1101-2020_09_02_279521	216	59	confidence	confidence	NN
10_1101-2020_09_02_279521	216	60	interval	interval	NN
10_1101-2020_09_02_279521	216	61	measured	measure	VBN
10_1101-2020_09_02_279521	216	62	during	during	IN
10_1101-2020_09_02_279521	216	63	that	that	DT
10_1101-2020_09_02_279521	216	64	study	study	NN
10_1101-2020_09_02_279521	216	65	(	(	-LRB-
10_1101-2020_09_02_279521	216	66	[	[	-LRB-
10_1101-2020_09_02_279521	216	67	-0.5	-0.5	CD
10_1101-2020_09_02_279521	216	68	;	;	:
10_1101-2020_09_02_279521	216	69	0.8	0.8	LS
10_1101-2020_09_02_279521	216	70	]	]	-RRB-
10_1101-2020_09_02_279521	216	71	)	)	-RRB-
10_1101-2020_09_02_279521	216	72	.	.	.
10_1101-2020_09_02_279521	217	1	While	while	IN
10_1101-2020_09_02_279521	217	2	recent	recent	JJ
10_1101-2020_09_02_279521	217	3	anti	anti	JJ
10_1101-2020_09_02_279521	217	4	-	-	JJ
10_1101-2020_09_02_279521	217	5	amyloid	amyloid	JJ
10_1101-2020_09_02_279521	217	6	trials	trial	NNS
10_1101-2020_09_02_279521	217	7	such	such	JJ
10_1101-2020_09_02_279521	217	8	as	as	IN
10_1101-2020_09_02_279521	217	9	(	(	-LRB-
10_1101-2020_09_02_279521	217	10	Egan	Egan	NNP
10_1101-2020_09_02_279521	217	11	et	et	NNP
10_1101-2020_09_02_279521	217	12	al	al	NNP
10_1101-2020_09_02_279521	217	13	.	.	NNP
10_1101-2020_09_02_279521	217	14	,	,	,
10_1101-2020_09_02_279521	217	15	2019	2019	CD
10_1101-2020_09_02_279521	217	16	;	;	:
10_1101-2020_09_02_279521	217	17	Honig	Honig	NNP
10_1101-2020_09_02_279521	217	18	et	et	NNP
10_1101-2020_09_02_279521	217	19	al	al	NNP
10_1101-2020_09_02_279521	217	20	.	.	NNP
10_1101-2020_09_02_279521	217	21	,	,	,
10_1101-2020_09_02_279521	217	22	2018	2018	CD
10_1101-2020_09_02_279521	217	23	;	;	:
10_1101-2020_09_02_279521	217	24	Wessels	Wessels	NNP
10_1101-2020_09_02_279521	217	25	et	et	NNP
10_1101-2020_09_02_279521	217	26	al	al	NNP
10_1101-2020_09_02_279521	217	27	.	.	NNP
10_1101-2020_09_02_279521	217	28	,	,	,
10_1101-2020_09_02_279521	217	29	2019	2019	CD
10_1101-2020_09_02_279521	217	30	)	)	-RRB-
10_1101-2020_09_02_279521	217	31	included	include	VBD
10_1101-2020_09_02_279521	217	32	between	between	IN
10_1101-2020_09_02_279521	217	33	500	500	CD
10_1101-2020_09_02_279521	217	34	and	and	CC
10_1101-2020_09_02_279521	217	35	1000	1000	CD
10_1101-2020_09_02_279521	217	36	mild	mild	JJ
10_1101-2020_09_02_279521	217	37	AD	ad	NN
10_1101-2020_09_02_279521	217	38	subjects	subject	NNS
10_1101-2020_09_02_279521	217	39	per	per	IN
10_1101-2020_09_02_279521	217	40	arm	arm	NN
10_1101-2020_09_02_279521	217	41	and	and	CC
10_1101-2020_09_02_279521	217	42	were	be	VBD
10_1101-2020_09_02_279521	217	43	conducted	conduct	VBN
10_1101-2020_09_02_279521	217	44	over	over	IN
10_1101-2020_09_02_279521	217	45	a	a	DT
10_1101-2020_09_02_279521	217	46	period	period	NN
10_1101-2020_09_02_279521	217	47	of	of	IN
10_1101-2020_09_02_279521	217	48	two	two	CD
10_1101-2020_09_02_279521	217	49	years	year	NNS
10_1101-2020_09_02_279521	217	50	at	at	IN
10_1101-2020_09_02_279521	217	51	most	most	JJS
10_1101-2020_09_02_279521	217	52	,	,	,
10_1101-2020_09_02_279521	217	53	our	-PRON-	PRP$
10_1101-2020_09_02_279521	217	54	analysis	analysis	NN
10_1101-2020_09_02_279521	217	55	suggests	suggest	VBZ
10_1101-2020_09_02_279521	217	56	that	that	IN
10_1101-2020_09_02_279521	217	57	clinical	clinical	JJ
10_1101-2020_09_02_279521	217	58	trials	trial	NNS
10_1101-2020_09_02_279521	217	59	performed	perform	VBD
10_1101-2020_09_02_279521	217	60	with	with	IN
10_1101-2020_09_02_279521	217	61	less	less	JJR
10_1101-2020_09_02_279521	217	62	than	than	IN
10_1101-2020_09_02_279521	217	63	1000	1000	CD
10_1101-2020_09_02_279521	217	64	subjects	subject	NNS
10_1101-2020_09_02_279521	217	65	with	with	IN
10_1101-2020_09_02_279521	217	66	mild	mild	JJ
10_1101-2020_09_02_279521	217	67	AD	ad	NN
10_1101-2020_09_02_279521	217	68	may	may	MD
10_1101-2020_09_02_279521	217	69	be	be	VB
10_1101-2020_09_02_279521	217	70	consistently	consistently	RB
10_1101-2020_09_02_279521	217	71	under	under	RB
10_1101-2020_09_02_279521	217	72	-	-	HYPH
10_1101-2020_09_02_279521	217	73	powered	powered	JJ
10_1101-2020_09_02_279521	217	74	.	.	.
10_1101-2020_09_02_279521	218	1	Indeed	indeed	RB
10_1101-2020_09_02_279521	218	2	,	,	,
10_1101-2020_09_02_279521	218	3	we	-PRON-	PRP
10_1101-2020_09_02_279521	218	4	see	see	VBP
10_1101-2020_09_02_279521	218	5	in	in	IN
10_1101-2020_09_02_279521	218	6	Figure	Figure	NNP
10_1101-2020_09_02_279521	218	7	5	5	CD
10_1101-2020_09_02_279521	218	8	that	that	DT
10_1101-2020_09_02_279521	218	9	with	with	IN
10_1101-2020_09_02_279521	218	10	a	a	DT
10_1101-2020_09_02_279521	218	11	sample	sample	NN
10_1101-2020_09_02_279521	218	12	size	size	NN
10_1101-2020_09_02_279521	218	13	of	of	IN
10_1101-2020_09_02_279521	218	14	1000	1000	CD
10_1101-2020_09_02_279521	218	15	subjects	subject	NNS
10_1101-2020_09_02_279521	218	16	per	per	IN
10_1101-2020_09_02_279521	218	17	arm	arm	NN
10_1101-2020_09_02_279521	218	18	and	and	CC
10_1101-2020_09_02_279521	218	19	a	a	DT
10_1101-2020_09_02_279521	218	20	total	total	JJ
10_1101-2020_09_02_279521	218	21	blockage	blockage	NN
10_1101-2020_09_02_279521	218	22	of	of	IN
10_1101-2020_09_02_279521	218	23	amyloid	amyloid	NN
10_1101-2020_09_02_279521	218	24	production	production	NN
10_1101-2020_09_02_279521	218	25	,	,	,
10_1101-2020_09_02_279521	218	26	a	a	DT
10_1101-2020_09_02_279521	218	27	power	power	NN
10_1101-2020_09_02_279521	218	28	of	of	IN
10_1101-2020_09_02_279521	218	29	0.8	0.8	CD
10_1101-2020_09_02_279521	218	30	can	can	MD
10_1101-2020_09_02_279521	218	31	be	be	VB
10_1101-2020_09_02_279521	218	32	obtained	obtain	VBN
10_1101-2020_09_02_279521	218	33	only	only	RB
10_1101-2020_09_02_279521	218	34	if	if	IN
10_1101-2020_09_02_279521	218	35	intervention	intervention	NN
10_1101-2020_09_02_279521	218	36	is	be	VBZ
10_1101-2020_09_02_279521	218	37	performed	perform	VBN
10_1101-2020_09_02_279521	218	38	at	at	IN
10_1101-2020_09_02_279521	218	39	least	least	JJS
10_1101-2020_09_02_279521	218	40	7	7	CD
10_1101-2020_09_02_279521	218	41	years	year	NNS
10_1101-2020_09_02_279521	218	42	before	before	IN
10_1101-2020_09_02_279521	218	43	conversion	conversion	NN
10_1101-2020_09_02_279521	218	44	.	.	.
10_1101-2020_09_02_279521	219	1	.CC	.CC	NFP
10_1101-2020_09_02_279521	219	2	-	-	:
10_1101-2020_09_02_279521	219	3	BY	by	IN
10_1101-2020_09_02_279521	219	4	4.0	4.0	CD
10_1101-2020_09_02_279521	219	5	International	international	JJ
10_1101-2020_09_02_279521	219	6	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	219	7	.	.	.
10_1101-2020_09_02_279521	220	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	220	2	is	be	VBZ
10_1101-2020_09_02_279521	220	3	made	make	VBN
10_1101-2020_09_02_279521	220	4	available	available	JJ
10_1101-2020_09_02_279521	220	5	under	under	IN
10_1101-2020_09_02_279521	220	6	a	a	DT
10_1101-2020_09_02_279521	220	7	preprint	preprint	NN
10_1101-2020_09_02_279521	220	8	(	(	-LRB-
10_1101-2020_09_02_279521	220	9	which	which	WDT
10_1101-2020_09_02_279521	220	10	was	be	VBD
10_1101-2020_09_02_279521	220	11	not	not	RB
10_1101-2020_09_02_279521	220	12	certified	certify	VBN
10_1101-2020_09_02_279521	220	13	by	by	IN
10_1101-2020_09_02_279521	220	14	peer	peer	NN
10_1101-2020_09_02_279521	220	15	review	review	NN
10_1101-2020_09_02_279521	220	16	)	)	-RRB-
10_1101-2020_09_02_279521	220	17	is	be	VBZ
10_1101-2020_09_02_279521	220	18	the	the	DT
10_1101-2020_09_02_279521	220	19	author	author	NN
10_1101-2020_09_02_279521	220	20	/	/	SYM
10_1101-2020_09_02_279521	220	21	funder	funder	NN
10_1101-2020_09_02_279521	220	22	,	,	,
10_1101-2020_09_02_279521	220	23	who	who	WP
10_1101-2020_09_02_279521	220	24	has	have	VBZ
10_1101-2020_09_02_279521	220	25	granted	grant	VBN
10_1101-2020_09_02_279521	220	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	220	27	a	a	DT
10_1101-2020_09_02_279521	220	28	license	license	NN
10_1101-2020_09_02_279521	220	29	to	to	TO
10_1101-2020_09_02_279521	220	30	display	display	VB
10_1101-2020_09_02_279521	220	31	the	the	DT
10_1101-2020_09_02_279521	220	32	preprint	preprint	NN
10_1101-2020_09_02_279521	220	33	in	in	IN
10_1101-2020_09_02_279521	220	34	The	the	DT
10_1101-2020_09_02_279521	220	35	copyright	copyright	NN
10_1101-2020_09_02_279521	220	36	holder	holder	NN
10_1101-2020_09_02_279521	220	37	for	for	IN
10_1101-2020_09_02_279521	220	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	220	39	version	version	NN
10_1101-2020_09_02_279521	220	40	posted	post	VBD
10_1101-2020_09_02_279521	220	41	February	February	NNP
10_1101-2020_09_02_279521	220	42	10	10	CD
10_1101-2020_09_02_279521	220	43	,	,	,
10_1101-2020_09_02_279521	220	44	2021	2021	CD
10_1101-2020_09_02_279521	220	45	.	.	.
10_1101-2020_09_02_279521	220	46	;	;	:
10_1101-2020_09_02_279521	220	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	220	48	:	:	:
10_1101-2020_09_02_279521	220	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	220	50	preprint	preprint	NN
10_1101-2020_09_02_279521	220	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	NN
10_1101-2020_09_02_279521	220	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	-LRB-
10_1101-2020_09_02_279521	220	53	Figure	figure	NN
10_1101-2020_09_02_279521	220	54	5	5	CD
10_1101-2020_09_02_279521	220	55	Evolution	evolution	NN
10_1101-2020_09_02_279521	220	56	of	of	IN
10_1101-2020_09_02_279521	220	57	the	the	DT
10_1101-2020_09_02_279521	220	58	statistical	statistical	JJ
10_1101-2020_09_02_279521	220	59	power	power	NN
10_1101-2020_09_02_279521	220	60	in	in	IN
10_1101-2020_09_02_279521	220	61	different	different	JJ
10_1101-2020_09_02_279521	220	62	intervention	intervention	NN
10_1101-2020_09_02_279521	220	63	scenarios	scenario	NNS
10_1101-2020_09_02_279521	220	64	.	.	.
10_1101-2020_09_02_279521	221	1	Statistical	statistical	JJ
10_1101-2020_09_02_279521	221	2	power	power	NN
10_1101-2020_09_02_279521	221	3	of	of	IN
10_1101-2020_09_02_279521	221	4	the	the	DT
10_1101-2020_09_02_279521	221	5	Student	Student	NNP
10_1101-2020_09_02_279521	221	6	t	t	NN
10_1101-2020_09_02_279521	221	7	-	-	HYPH
10_1101-2020_09_02_279521	221	8	test	test	NN
10_1101-2020_09_02_279521	221	9	comparing	compare	VBG
10_1101-2020_09_02_279521	221	10	the	the	DT
10_1101-2020_09_02_279521	221	11	estimated	estimate	VBN
10_1101-2020_09_02_279521	221	12	clinical	clinical	JJ
10_1101-2020_09_02_279521	221	13	outcomes	outcome	NNS
10_1101-2020_09_02_279521	221	14	at	at	IN
10_1101-2020_09_02_279521	221	15	conversion	conversion	NN
10_1101-2020_09_02_279521	221	16	time	time	NN
10_1101-2020_09_02_279521	221	17	between	between	IN
10_1101-2020_09_02_279521	221	18	placebo	placebo	NN
10_1101-2020_09_02_279521	221	19	and	and	CC
10_1101-2020_09_02_279521	221	20	treated	treat	VBN
10_1101-2020_09_02_279521	221	21	scenarios	scenario	NNS
10_1101-2020_09_02_279521	221	22	,	,	,
10_1101-2020_09_02_279521	221	23	according	accord	VBG
10_1101-2020_09_02_279521	221	24	to	to	IN
10_1101-2020_09_02_279521	221	25	the	the	DT
10_1101-2020_09_02_279521	221	26	year	year	NN
10_1101-2020_09_02_279521	221	27	of	of	IN
10_1101-2020_09_02_279521	221	28	simulated	simulate	VBN
10_1101-2020_09_02_279521	221	29	intervention	intervention	NN
10_1101-2020_09_02_279521	221	30	(	(	-LRB-
10_1101-2020_09_02_279521	221	31	100	100	CD
10_1101-2020_09_02_279521	221	32	%	%	NN
10_1101-2020_09_02_279521	221	33	and	and	CC
10_1101-2020_09_02_279521	221	34	50	50	CD
10_1101-2020_09_02_279521	221	35	%	%	NN
10_1101-2020_09_02_279521	221	36	amyloid	amyloid	NN
10_1101-2020_09_02_279521	221	37	lowering	lowering	NN
10_1101-2020_09_02_279521	221	38	)	)	-RRB-
10_1101-2020_09_02_279521	221	39	and	and	CC
10_1101-2020_09_02_279521	221	40	sample	sample	VB
10_1101-2020_09_02_279521	221	41	size	size	NN
10_1101-2020_09_02_279521	221	42	.	.	.
10_1101-2020_09_02_279521	222	1	.CC	.CC	NFP
10_1101-2020_09_02_279521	222	2	-	-	:
10_1101-2020_09_02_279521	222	3	BY	by	IN
10_1101-2020_09_02_279521	222	4	4.0	4.0	CD
10_1101-2020_09_02_279521	222	5	International	international	JJ
10_1101-2020_09_02_279521	222	6	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	222	7	.	.	.
10_1101-2020_09_02_279521	223	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	223	2	is	be	VBZ
10_1101-2020_09_02_279521	223	3	made	make	VBN
10_1101-2020_09_02_279521	223	4	available	available	JJ
10_1101-2020_09_02_279521	223	5	under	under	IN
10_1101-2020_09_02_279521	223	6	a	a	DT
10_1101-2020_09_02_279521	223	7	preprint	preprint	NN
10_1101-2020_09_02_279521	223	8	(	(	-LRB-
10_1101-2020_09_02_279521	223	9	which	which	WDT
10_1101-2020_09_02_279521	223	10	was	be	VBD
10_1101-2020_09_02_279521	223	11	not	not	RB
10_1101-2020_09_02_279521	223	12	certified	certify	VBN
10_1101-2020_09_02_279521	223	13	by	by	IN
10_1101-2020_09_02_279521	223	14	peer	peer	NN
10_1101-2020_09_02_279521	223	15	review	review	NN
10_1101-2020_09_02_279521	223	16	)	)	-RRB-
10_1101-2020_09_02_279521	223	17	is	be	VBZ
10_1101-2020_09_02_279521	223	18	the	the	DT
10_1101-2020_09_02_279521	223	19	author	author	NN
10_1101-2020_09_02_279521	223	20	/	/	SYM
10_1101-2020_09_02_279521	223	21	funder	funder	NN
10_1101-2020_09_02_279521	223	22	,	,	,
10_1101-2020_09_02_279521	223	23	who	who	WP
10_1101-2020_09_02_279521	223	24	has	have	VBZ
10_1101-2020_09_02_279521	223	25	granted	grant	VBN
10_1101-2020_09_02_279521	223	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	223	27	a	a	DT
10_1101-2020_09_02_279521	223	28	license	license	NN
10_1101-2020_09_02_279521	223	29	to	to	TO
10_1101-2020_09_02_279521	223	30	display	display	VB
10_1101-2020_09_02_279521	223	31	the	the	DT
10_1101-2020_09_02_279521	223	32	preprint	preprint	NN
10_1101-2020_09_02_279521	223	33	in	in	IN
10_1101-2020_09_02_279521	223	34	The	the	DT
10_1101-2020_09_02_279521	223	35	copyright	copyright	NN
10_1101-2020_09_02_279521	223	36	holder	holder	NN
10_1101-2020_09_02_279521	223	37	for	for	IN
10_1101-2020_09_02_279521	223	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	223	39	version	version	NN
10_1101-2020_09_02_279521	223	40	posted	post	VBD
10_1101-2020_09_02_279521	223	41	February	February	NNP
10_1101-2020_09_02_279521	223	42	10	10	CD
10_1101-2020_09_02_279521	223	43	,	,	,
10_1101-2020_09_02_279521	223	44	2021	2021	CD
10_1101-2020_09_02_279521	223	45	.	.	.
10_1101-2020_09_02_279521	223	46	;	;	:
10_1101-2020_09_02_279521	223	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	223	48	:	:	:
10_1101-2020_09_02_279521	223	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	223	50	preprint	preprint	NN
10_1101-2020_09_02_279521	223	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	ADD
10_1101-2020_09_02_279521	223	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	ADD
10_1101-2020_09_02_279521	223	53	Amyloid	Amyloid	NNP
10_1101-2020_09_02_279521	223	54	lowering	lower	VBG
10_1101-2020_09_02_279521	223	55	intervention	intervention	NN
10_1101-2020_09_02_279521	223	56	100	100	CD
10_1101-2020_09_02_279521	223	57	%	%	NN
10_1101-2020_09_02_279521	223	58	Point	Point	NNP
10_1101-2020_09_02_279521	223	59	improvement	improvement	NN
10_1101-2020_09_02_279521	223	60	per	per	IN
10_1101-2020_09_02_279521	223	61	intervention	intervention	NN
10_1101-2020_09_02_279521	223	62	time	time	NN
10_1101-2020_09_02_279521	223	63	-20	-20	NNP
10_1101-2020_09_02_279521	223	64	-15	-15	NNP
10_1101-2020_09_02_279521	223	65	-12.5	-12.5	:
10_1101-2020_09_02_279521	223	66	-10	-10	NNP
10_1101-2020_09_02_279521	223	67	-5	-5	NNP
10_1101-2020_09_02_279521	223	68	-3	-3	:
10_1101-2020_09_02_279521	223	69	-2	-2	NFP
10_1101-2020_09_02_279521	223	70	-1	-1	NFP
10_1101-2020_09_02_279521	223	71	ADAS11	ADAS11	NNP
10_1101-2020_09_02_279521	223	72	11.1	11.1	CD
10_1101-2020_09_02_279521	223	73	,	,	,
10_1101-2020_09_02_279521	223	74	(	(	-LRB-
10_1101-2020_09_02_279521	223	75	6.4	6.4	CD
10_1101-2020_09_02_279521	223	76	)	)	-RRB-
10_1101-2020_09_02_279521	223	77	5.2	5.2	CD
10_1101-2020_09_02_279521	223	78	,	,	,
10_1101-2020_09_02_279521	223	79	(	(	-LRB-
10_1101-2020_09_02_279521	223	80	2.9	2.9	CD
10_1101-2020_09_02_279521	223	81	)	)	-RRB-
10_1101-2020_09_02_279521	223	82	3.0	3.0	CD
10_1101-2020_09_02_279521	223	83	,	,	,
10_1101-2020_09_02_279521	223	84	(	(	-LRB-
10_1101-2020_09_02_279521	223	85	1.7	1.7	CD
10_1101-2020_09_02_279521	223	86	)	)	-RRB-
10_1101-2020_09_02_279521	223	87	1.6	1.6	CD
10_1101-2020_09_02_279521	223	88	,	,	,
10_1101-2020_09_02_279521	223	89	(	(	-LRB-
10_1101-2020_09_02_279521	223	90	1.0	1.0	CD
10_1101-2020_09_02_279521	223	91	)	)	-RRB-
10_1101-2020_09_02_279521	223	92	0.3	0.3	CD
10_1101-2020_09_02_279521	223	93	,	,	,
10_1101-2020_09_02_279521	223	94	(	(	-LRB-
10_1101-2020_09_02_279521	223	95	0.2	0.2	CD
10_1101-2020_09_02_279521	223	96	)	)	-RRB-
10_1101-2020_09_02_279521	223	97	0.1	0.1	CD
10_1101-2020_09_02_279521	223	98	,	,	,
10_1101-2020_09_02_279521	223	99	(	(	-LRB-
10_1101-2020_09_02_279521	223	100	0.1	0.1	CD
10_1101-2020_09_02_279521	223	101	)	)	-RRB-
10_1101-2020_09_02_279521	223	102	0.0	0.0	CD
10_1101-2020_09_02_279521	223	103	,	,	,
10_1101-2020_09_02_279521	223	104	(	(	-LRB-
10_1101-2020_09_02_279521	223	105	0.0	0.0	CD
10_1101-2020_09_02_279521	223	106	)	)	-RRB-
10_1101-2020_09_02_279521	223	107	0.0	0.0	CD
10_1101-2020_09_02_279521	223	108	,	,	,
10_1101-2020_09_02_279521	223	109	(	(	-LRB-
10_1101-2020_09_02_279521	223	110	0.0	0.0	CD
10_1101-2020_09_02_279521	223	111	)	)	-RRB-
10_1101-2020_09_02_279521	223	112	MMSE	MMSE	NNP
10_1101-2020_09_02_279521	223	113	4.9	4.9	CD
10_1101-2020_09_02_279521	223	114	,	,	,
10_1101-2020_09_02_279521	223	115	(	(	-LRB-
10_1101-2020_09_02_279521	223	116	2.8	2.8	CD
10_1101-2020_09_02_279521	223	117	)	)	-RRB-
10_1101-2020_09_02_279521	223	118	2.3	2.3	CD
10_1101-2020_09_02_279521	223	119	,	,	,
10_1101-2020_09_02_279521	223	120	(	(	-LRB-
10_1101-2020_09_02_279521	223	121	1.3	1.3	CD
10_1101-2020_09_02_279521	223	122	)	)	-RRB-
10_1101-2020_09_02_279521	223	123	1.3	1.3	CD
10_1101-2020_09_02_279521	223	124	,	,	,
10_1101-2020_09_02_279521	223	125	(	(	-LRB-
10_1101-2020_09_02_279521	223	126	0.8	0.8	CD
10_1101-2020_09_02_279521	223	127	)	)	-RRB-
10_1101-2020_09_02_279521	223	128	0.7	0.7	CD
10_1101-2020_09_02_279521	223	129	,	,	,
10_1101-2020_09_02_279521	223	130	(	(	-LRB-
10_1101-2020_09_02_279521	223	131	0.4	0.4	CD
10_1101-2020_09_02_279521	223	132	)	)	-RRB-
10_1101-2020_09_02_279521	223	133	0.1	0.1	CD
10_1101-2020_09_02_279521	223	134	,	,	,
10_1101-2020_09_02_279521	223	135	(	(	-LRB-
10_1101-2020_09_02_279521	223	136	0.1	0.1	CD
10_1101-2020_09_02_279521	223	137	)	)	-RRB-
10_1101-2020_09_02_279521	223	138	0.0	0.0	CD
10_1101-2020_09_02_279521	223	139	,	,	,
10_1101-2020_09_02_279521	223	140	(	(	-LRB-
10_1101-2020_09_02_279521	223	141	0.0	0.0	CD
10_1101-2020_09_02_279521	223	142	)	)	-RRB-
10_1101-2020_09_02_279521	223	143	0.0	0.0	CD
10_1101-2020_09_02_279521	223	144	,	,	,
10_1101-2020_09_02_279521	223	145	(	(	-LRB-
10_1101-2020_09_02_279521	223	146	0.0	0.0	CD
10_1101-2020_09_02_279521	223	147	)	)	-RRB-
10_1101-2020_09_02_279521	223	148	0.0	0.0	CD
10_1101-2020_09_02_279521	223	149	,	,	,
10_1101-2020_09_02_279521	223	150	(	(	-LRB-
10_1101-2020_09_02_279521	223	151	0.0	0.0	LS
10_1101-2020_09_02_279521	223	152	)	)	-RRB-
10_1101-2020_09_02_279521	223	153	FAQ	FAQ	NNP
10_1101-2020_09_02_279521	223	154	9.6	9.6	CD
10_1101-2020_09_02_279521	223	155	,	,	,
10_1101-2020_09_02_279521	223	156	(	(	-LRB-
10_1101-2020_09_02_279521	223	157	5.6	5.6	CD
10_1101-2020_09_02_279521	223	158	)	)	-RRB-
10_1101-2020_09_02_279521	223	159	4.5	4.5	CD
10_1101-2020_09_02_279521	223	160	,	,	,
10_1101-2020_09_02_279521	223	161	(	(	-LRB-
10_1101-2020_09_02_279521	223	162	2.5	2.5	CD
10_1101-2020_09_02_279521	223	163	)	)	-RRB-
10_1101-2020_09_02_279521	223	164	2.6	2.6	CD
10_1101-2020_09_02_279521	223	165	,	,	,
10_1101-2020_09_02_279521	223	166	(	(	-LRB-
10_1101-2020_09_02_279521	223	167	1.5	1.5	CD
10_1101-2020_09_02_279521	223	168	)	)	-RRB-
10_1101-2020_09_02_279521	223	169	1.4	1.4	CD
10_1101-2020_09_02_279521	223	170	,	,	,
10_1101-2020_09_02_279521	223	171	(	(	-LRB-
10_1101-2020_09_02_279521	223	172	0.8	0.8	CD
10_1101-2020_09_02_279521	223	173	)	)	-RRB-
10_1101-2020_09_02_279521	223	174	0.2	0.2	CD
10_1101-2020_09_02_279521	223	175	,	,	,
10_1101-2020_09_02_279521	223	176	(	(	-LRB-
10_1101-2020_09_02_279521	223	177	0.2	0.2	CD
10_1101-2020_09_02_279521	223	178	)	)	-RRB-
10_1101-2020_09_02_279521	223	179	0.1	0.1	CD
10_1101-2020_09_02_279521	223	180	,	,	,
10_1101-2020_09_02_279521	223	181	(	(	-LRB-
10_1101-2020_09_02_279521	223	182	0.1	0.1	CD
10_1101-2020_09_02_279521	223	183	)	)	-RRB-
10_1101-2020_09_02_279521	223	184	0.0	0.0	CD
10_1101-2020_09_02_279521	223	185	,	,	,
10_1101-2020_09_02_279521	223	186	(	(	-LRB-
10_1101-2020_09_02_279521	223	187	0.0	0.0	CD
10_1101-2020_09_02_279521	223	188	)	)	-RRB-
10_1101-2020_09_02_279521	223	189	0.0	0.0	CD
10_1101-2020_09_02_279521	223	190	,	,	,
10_1101-2020_09_02_279521	223	191	(	(	-LRB-
10_1101-2020_09_02_279521	223	192	0.0	0.0	CD
10_1101-2020_09_02_279521	223	193	)	)	-RRB-
10_1101-2020_09_02_279521	223	194	RAVLT	RAVLT	NNP
10_1101-2020_09_02_279521	223	195	immediate	immediate	JJ
10_1101-2020_09_02_279521	223	196	15.3	15.3	CD
10_1101-2020_09_02_279521	223	197	,	,	,
10_1101-2020_09_02_279521	223	198	(	(	-LRB-
10_1101-2020_09_02_279521	223	199	8.9	8.9	CD
10_1101-2020_09_02_279521	223	200	)	)	-RRB-
10_1101-2020_09_02_279521	223	201	7.2	7.2	CD
10_1101-2020_09_02_279521	223	202	,	,	,
10_1101-2020_09_02_279521	223	203	(	(	-LRB-
10_1101-2020_09_02_279521	223	204	4.1	4.1	CD
10_1101-2020_09_02_279521	223	205	)	)	-RRB-
10_1101-2020_09_02_279521	223	206	4.2	4.2	CD
10_1101-2020_09_02_279521	223	207	,	,	,
10_1101-2020_09_02_279521	223	208	(	(	-LRB-
10_1101-2020_09_02_279521	223	209	2.4	2.4	CD
10_1101-2020_09_02_279521	223	210	)	)	-RRB-
10_1101-2020_09_02_279521	223	211	2.3	2.3	CD
10_1101-2020_09_02_279521	223	212	,	,	,
10_1101-2020_09_02_279521	223	213	(	(	-LRB-
10_1101-2020_09_02_279521	223	214	1.4	1.4	CD
10_1101-2020_09_02_279521	223	215	)	)	-RRB-
10_1101-2020_09_02_279521	223	216	0.5	0.5	CD
10_1101-2020_09_02_279521	223	217	,	,	,
10_1101-2020_09_02_279521	223	218	(	(	-LRB-
10_1101-2020_09_02_279521	223	219	0.3	0.3	CD
10_1101-2020_09_02_279521	223	220	)	)	-RRB-
10_1101-2020_09_02_279521	223	221	0.2	0.2	CD
10_1101-2020_09_02_279521	223	222	,	,	,
10_1101-2020_09_02_279521	223	223	(	(	-LRB-
10_1101-2020_09_02_279521	223	224	0.1	0.1	CD
10_1101-2020_09_02_279521	223	225	)	)	-RRB-
10_1101-2020_09_02_279521	223	226	0.1	0.1	CD
10_1101-2020_09_02_279521	223	227	,	,	,
10_1101-2020_09_02_279521	223	228	(	(	-LRB-
10_1101-2020_09_02_279521	223	229	0.1	0.1	CD
10_1101-2020_09_02_279521	223	230	)	)	-RRB-
10_1101-2020_09_02_279521	223	231	0.0	0.0	CD
10_1101-2020_09_02_279521	223	232	,	,	,
10_1101-2020_09_02_279521	223	233	(	(	-LRB-
10_1101-2020_09_02_279521	223	234	0.0	0.0	CD
10_1101-2020_09_02_279521	223	235	)	)	-RRB-
10_1101-2020_09_02_279521	223	236	RAVLT	RAVLT	NNP
10_1101-2020_09_02_279521	223	237	learning	learn	VBG
10_1101-2020_09_02_279521	223	238	2.7	2.7	CD
10_1101-2020_09_02_279521	223	239	,	,	,
10_1101-2020_09_02_279521	223	240	(	(	-LRB-
10_1101-2020_09_02_279521	223	241	1.6	1.6	CD
10_1101-2020_09_02_279521	223	242	)	)	-RRB-
10_1101-2020_09_02_279521	223	243	1.3	1.3	CD
10_1101-2020_09_02_279521	223	244	,	,	,
10_1101-2020_09_02_279521	223	245	(	(	-LRB-
10_1101-2020_09_02_279521	223	246	0.7	0.7	CD
10_1101-2020_09_02_279521	223	247	)	)	-RRB-
10_1101-2020_09_02_279521	223	248	0.7	0.7	CD
10_1101-2020_09_02_279521	223	249	,	,	,
10_1101-2020_09_02_279521	223	250	(	(	-LRB-
10_1101-2020_09_02_279521	223	251	0.4	0.4	CD
10_1101-2020_09_02_279521	223	252	)	)	-RRB-
10_1101-2020_09_02_279521	223	253	0.4	0.4	CD
10_1101-2020_09_02_279521	223	254	,	,	,
10_1101-2020_09_02_279521	223	255	(	(	-LRB-
10_1101-2020_09_02_279521	223	256	0.2	0.2	CD
10_1101-2020_09_02_279521	223	257	)	)	-RRB-
10_1101-2020_09_02_279521	223	258	0.1	0.1	CD
10_1101-2020_09_02_279521	223	259	,	,	,
10_1101-2020_09_02_279521	223	260	(	(	-LRB-
10_1101-2020_09_02_279521	223	261	0.1	0.1	CD
10_1101-2020_09_02_279521	223	262	)	)	-RRB-
10_1101-2020_09_02_279521	223	263	0.0	0.0	CD
10_1101-2020_09_02_279521	223	264	,	,	,
10_1101-2020_09_02_279521	223	265	(	(	-LRB-
10_1101-2020_09_02_279521	223	266	0.0	0.0	CD
10_1101-2020_09_02_279521	223	267	)	)	-RRB-
10_1101-2020_09_02_279521	223	268	0.0	0.0	CD
10_1101-2020_09_02_279521	223	269	,	,	,
10_1101-2020_09_02_279521	223	270	(	(	-LRB-
10_1101-2020_09_02_279521	223	271	0.0	0.0	CD
10_1101-2020_09_02_279521	223	272	)	)	-RRB-
10_1101-2020_09_02_279521	223	273	0.0	0.0	CD
10_1101-2020_09_02_279521	223	274	,	,	,
10_1101-2020_09_02_279521	223	275	(	(	-LRB-
10_1101-2020_09_02_279521	223	276	0.0	0.0	CD
10_1101-2020_09_02_279521	223	277	)	)	-RRB-
10_1101-2020_09_02_279521	223	278	RAVLT	RAVLT	NNP
10_1101-2020_09_02_279521	223	279	forgetting	forget	VBG
10_1101-2020_09_02_279521	223	280	37.2	37.2	CD
10_1101-2020_09_02_279521	223	281	,	,	,
10_1101-2020_09_02_279521	223	282	(	(	-LRB-
10_1101-2020_09_02_279521	223	283	21.5	21.5	CD
10_1101-2020_09_02_279521	223	284	)	)	-RRB-
10_1101-2020_09_02_279521	223	285	17.7	17.7	CD
10_1101-2020_09_02_279521	223	286	,	,	,
10_1101-2020_09_02_279521	223	287	(	(	-LRB-
10_1101-2020_09_02_279521	223	288	9.9	9.9	CD
10_1101-2020_09_02_279521	223	289	)	)	-RRB-
10_1101-2020_09_02_279521	223	290	10.5	10.5	CD
10_1101-2020_09_02_279521	223	291	,	,	,
10_1101-2020_09_02_279521	223	292	(	(	-LRB-
10_1101-2020_09_02_279521	223	293	6.0	6.0	CD
10_1101-2020_09_02_279521	223	294	)	)	-RRB-
10_1101-2020_09_02_279521	223	295	5.8	5.8	CD
10_1101-2020_09_02_279521	223	296	,	,	,
10_1101-2020_09_02_279521	223	297	(	(	-LRB-
10_1101-2020_09_02_279521	223	298	3.5	3.5	CD
10_1101-2020_09_02_279521	223	299	)	)	-RRB-
10_1101-2020_09_02_279521	223	300	1.3	1.3	CD
10_1101-2020_09_02_279521	223	301	,	,	,
10_1101-2020_09_02_279521	223	302	(	(	-LRB-
10_1101-2020_09_02_279521	223	303	0.9	0.9	CD
10_1101-2020_09_02_279521	223	304	)	)	-RRB-
10_1101-2020_09_02_279521	223	305	0.5	0.5	CD
10_1101-2020_09_02_279521	223	306	,	,	,
10_1101-2020_09_02_279521	223	307	(	(	-LRB-
10_1101-2020_09_02_279521	223	308	0.4	0.4	CD
10_1101-2020_09_02_279521	223	309	)	)	-RRB-
10_1101-2020_09_02_279521	223	310	0.2	0.2	CD
10_1101-2020_09_02_279521	223	311	,	,	,
10_1101-2020_09_02_279521	223	312	(	(	-LRB-
10_1101-2020_09_02_279521	223	313	0.2	0.2	CD
10_1101-2020_09_02_279521	223	314	)	)	-RRB-
10_1101-2020_09_02_279521	223	315	0.1	0.1	CD
10_1101-2020_09_02_279521	223	316	,	,	,
10_1101-2020_09_02_279521	223	317	(	(	-LRB-
10_1101-2020_09_02_279521	223	318	0.1	0.1	CD
10_1101-2020_09_02_279521	223	319	)	)	-RRB-
10_1101-2020_09_02_279521	223	320	CDRSB	CDRSB	NNP
10_1101-2020_09_02_279521	223	321	3.5	3.5	CD
10_1101-2020_09_02_279521	223	322	,	,	,
10_1101-2020_09_02_279521	223	323	(	(	-LRB-
10_1101-2020_09_02_279521	223	324	2.0	2.0	CD
10_1101-2020_09_02_279521	223	325	)	)	-RRB-
10_1101-2020_09_02_279521	223	326	1.6	1.6	CD
10_1101-2020_09_02_279521	223	327	,	,	,
10_1101-2020_09_02_279521	223	328	(	(	-LRB-
10_1101-2020_09_02_279521	223	329	0.9	0.9	CD
10_1101-2020_09_02_279521	223	330	)	)	-RRB-
10_1101-2020_09_02_279521	223	331	0.9	0.9	CD
10_1101-2020_09_02_279521	223	332	,	,	,
10_1101-2020_09_02_279521	223	333	(	(	-LRB-
10_1101-2020_09_02_279521	223	334	0.5	0.5	CD
10_1101-2020_09_02_279521	223	335	)	)	-RRB-
10_1101-2020_09_02_279521	223	336	0.5	0.5	CD
10_1101-2020_09_02_279521	223	337	,	,	,
10_1101-2020_09_02_279521	223	338	(	(	-LRB-
10_1101-2020_09_02_279521	223	339	0.3	0.3	CD
10_1101-2020_09_02_279521	223	340	)	)	-RRB-
10_1101-2020_09_02_279521	223	341	0.1	0.1	CD
10_1101-2020_09_02_279521	223	342	,	,	,
10_1101-2020_09_02_279521	223	343	(	(	-LRB-
10_1101-2020_09_02_279521	223	344	0.1	0.1	CD
10_1101-2020_09_02_279521	223	345	)	)	-RRB-
10_1101-2020_09_02_279521	223	346	0.0	0.0	CD
10_1101-2020_09_02_279521	223	347	,	,	,
10_1101-2020_09_02_279521	223	348	(	(	-LRB-
10_1101-2020_09_02_279521	223	349	0.0	0.0	CD
10_1101-2020_09_02_279521	223	350	)	)	-RRB-
10_1101-2020_09_02_279521	223	351	0.0	0.0	CD
10_1101-2020_09_02_279521	223	352	,	,	,
10_1101-2020_09_02_279521	223	353	(	(	-LRB-
10_1101-2020_09_02_279521	223	354	0.0	0.0	CD
10_1101-2020_09_02_279521	223	355	)	)	-RRB-
10_1101-2020_09_02_279521	223	356	0.0	0.0	CD
10_1101-2020_09_02_279521	223	357	,	,	,
10_1101-2020_09_02_279521	223	358	(	(	-LRB-
10_1101-2020_09_02_279521	223	359	0.0	0.0	LS
10_1101-2020_09_02_279521	223	360	)	)	-RRB-
10_1101-2020_09_02_279521	223	361	These	these	DT
10_1101-2020_09_02_279521	223	362	results	result	NNS
10_1101-2020_09_02_279521	223	363	allow	allow	VBP
10_1101-2020_09_02_279521	223	364	to	to	TO
10_1101-2020_09_02_279521	223	365	quantify	quantify	VB
10_1101-2020_09_02_279521	223	366	the	the	DT
10_1101-2020_09_02_279521	223	367	crucial	crucial	JJ
10_1101-2020_09_02_279521	223	368	role	role	NN
10_1101-2020_09_02_279521	223	369	of	of	IN
10_1101-2020_09_02_279521	223	370	intervention	intervention	NN
10_1101-2020_09_02_279521	223	371	time	time	NN
10_1101-2020_09_02_279521	223	372	,	,	,
10_1101-2020_09_02_279521	223	373	and	and	CC
10_1101-2020_09_02_279521	223	374	provide	provide	VB
10_1101-2020_09_02_279521	223	375	a	a	DT
10_1101-2020_09_02_279521	223	376	theoretical	theoretical	JJ
10_1101-2020_09_02_279521	223	377	justification	justification	NN
10_1101-2020_09_02_279521	223	378	for	for	IN
10_1101-2020_09_02_279521	223	379	testing	testing	NN
10_1101-2020_09_02_279521	223	380	amyloid	amyloid	NN
10_1101-2020_09_02_279521	223	381	modifying	modify	VBG
10_1101-2020_09_02_279521	223	382	drugs	drug	NNS
10_1101-2020_09_02_279521	223	383	in	in	IN
10_1101-2020_09_02_279521	223	384	the	the	DT
10_1101-2020_09_02_279521	223	385	pre	pre	JJ
10_1101-2020_09_02_279521	223	386	-	-	JJ
10_1101-2020_09_02_279521	223	387	clinical	clinical	JJ
10_1101-2020_09_02_279521	223	388	stage	stage	NN
10_1101-2020_09_02_279521	223	389	(	(	-LRB-
10_1101-2020_09_02_279521	223	390	Aisen	Aisen	NNP
10_1101-2020_09_02_279521	223	391	et	et	NNP
10_1101-2020_09_02_279521	223	392	al	al	NNP
10_1101-2020_09_02_279521	223	393	.	.	NNP
10_1101-2020_09_02_279521	223	394	,	,	,
10_1101-2020_09_02_279521	223	395	2018	2018	CD
10_1101-2020_09_02_279521	223	396	;	;	:
10_1101-2020_09_02_279521	223	397	Sperling	Sperling	NNP
10_1101-2020_09_02_279521	223	398	et	et	NNP
10_1101-2020_09_02_279521	223	399	al	al	NNP
10_1101-2020_09_02_279521	223	400	.	.	NNP
10_1101-2020_09_02_279521	223	401	,	,	,
10_1101-2020_09_02_279521	223	402	2011	2011	CD
10_1101-2020_09_02_279521	223	403	)	)	-RRB-
10_1101-2020_09_02_279521	223	404	.	.	.
10_1101-2020_09_02_279521	224	1	This	this	DT
10_1101-2020_09_02_279521	224	2	is	be	VBZ
10_1101-2020_09_02_279521	224	3	for	for	IN
10_1101-2020_09_02_279521	224	4	example	example	NN
10_1101-2020_09_02_279521	224	5	illustrated	illustrate	VBN
10_1101-2020_09_02_279521	224	6	in	in	IN
10_1101-2020_09_02_279521	224	7	Table	Table	NNP
10_1101-2020_09_02_279521	224	8	2	2	CD
10_1101-2020_09_02_279521	224	9	,	,	,
10_1101-2020_09_02_279521	224	10	in	in	IN
10_1101-2020_09_02_279521	224	11	which	which	WDT
10_1101-2020_09_02_279521	224	12	we	-PRON-	PRP
10_1101-2020_09_02_279521	224	13	notice	notice	VBP
10_1101-2020_09_02_279521	224	14	that	that	IN
10_1101-2020_09_02_279521	224	15	clinical	clinical	JJ
10_1101-2020_09_02_279521	224	16	endpoints	endpoint	NNS
10_1101-2020_09_02_279521	224	17	are	be	VBP
10_1101-2020_09_02_279521	224	18	close	close	JJ
10_1101-2020_09_02_279521	224	19	to	to	IN
10_1101-2020_09_02_279521	224	20	placebo	placebo	NN
10_1101-2020_09_02_279521	224	21	even	even	RB
10_1101-2020_09_02_279521	224	22	when	when	WRB
10_1101-2020_09_02_279521	224	23	the	the	DT
10_1101-2020_09_02_279521	224	24	simulated	simulate	VBN
10_1101-2020_09_02_279521	224	25	intervention	intervention	NN
10_1101-2020_09_02_279521	224	26	takes	take	VBZ
10_1101-2020_09_02_279521	224	27	place	place	NN
10_1101-2020_09_02_279521	224	28	10	10	CD
10_1101-2020_09_02_279521	224	29	years	year	NNS
10_1101-2020_09_02_279521	224	30	before	before	IN
10_1101-2020_09_02_279521	224	31	Table	table	NN
10_1101-2020_09_02_279521	224	32	2	2	CD
10_1101-2020_09_02_279521	224	33	:	:	:
10_1101-2020_09_02_279521	224	34	Estimated	estimate	VBN
10_1101-2020_09_02_279521	224	35	mean	mean	NN
10_1101-2020_09_02_279521	224	36	(	(	-LRB-
10_1101-2020_09_02_279521	224	37	standard	standard	JJ
10_1101-2020_09_02_279521	224	38	deviation	deviation	NN
10_1101-2020_09_02_279521	224	39	)	)	-RRB-
10_1101-2020_09_02_279521	224	40	improvement	improvement	NN
10_1101-2020_09_02_279521	224	41	of	of	IN
10_1101-2020_09_02_279521	224	42	clinical	clinical	JJ
10_1101-2020_09_02_279521	224	43	outcomes	outcome	NNS
10_1101-2020_09_02_279521	224	44	at	at	IN
10_1101-2020_09_02_279521	224	45	predicted	predict	VBN
10_1101-2020_09_02_279521	224	46	conversion	conversion	NN
10_1101-2020_09_02_279521	224	47	time	time	NN
10_1101-2020_09_02_279521	224	48	for	for	IN
10_1101-2020_09_02_279521	224	49	the	the	DT
10_1101-2020_09_02_279521	224	50	normal	normal	JJ
10_1101-2020_09_02_279521	224	51	progression	progression	NN
10_1101-2020_09_02_279521	224	52	case	case	NN
10_1101-2020_09_02_279521	224	53	by	by	IN
10_1101-2020_09_02_279521	224	54	year	year	NN
10_1101-2020_09_02_279521	224	55	of	of	IN
10_1101-2020_09_02_279521	224	56	simulated	simulate	VBN
10_1101-2020_09_02_279521	224	57	intervention	intervention	NN
10_1101-2020_09_02_279521	224	58	(	(	-LRB-
10_1101-2020_09_02_279521	224	59	100	100	CD
10_1101-2020_09_02_279521	224	60	%	%	NN
10_1101-2020_09_02_279521	224	61	and	and	CC
10_1101-2020_09_02_279521	224	62	50	50	CD
10_1101-2020_09_02_279521	224	63	%	%	NN
10_1101-2020_09_02_279521	224	64	amyloid	amyloid	NN
10_1101-2020_09_02_279521	224	65	lowering	lower	VBG
10_1101-2020_09_02_279521	224	66	interventions	intervention	NNS
10_1101-2020_09_02_279521	224	67	)	)	-RRB-
10_1101-2020_09_02_279521	224	68	.	.	.
10_1101-2020_09_02_279521	225	1	Results	result	NNS
10_1101-2020_09_02_279521	225	2	in	in	IN
10_1101-2020_09_02_279521	225	3	bold	bold	JJ
10_1101-2020_09_02_279521	225	4	indicate	indicate	VBP
10_1101-2020_09_02_279521	225	5	a	a	DT
10_1101-2020_09_02_279521	225	6	statistically	statistically	RB
10_1101-2020_09_02_279521	225	7	significant	significant	JJ
10_1101-2020_09_02_279521	225	8	difference	difference	NN
10_1101-2020_09_02_279521	225	9	between	between	IN
10_1101-2020_09_02_279521	225	10	placebo	placebo	NN
10_1101-2020_09_02_279521	225	11	and	and	CC
10_1101-2020_09_02_279521	225	12	treated	treat	VBN
10_1101-2020_09_02_279521	225	13	scenarios	scenario	NNS
10_1101-2020_09_02_279521	225	14	(	(	-LRB-
10_1101-2020_09_02_279521	225	15	p<0.01	p<0.01	CD
10_1101-2020_09_02_279521	225	16	,	,	,
10_1101-2020_09_02_279521	225	17	two	two	CD
10_1101-2020_09_02_279521	225	18	-	-	HYPH
10_1101-2020_09_02_279521	225	19	sided	sided	JJ
10_1101-2020_09_02_279521	225	20	t	t	NN
10_1101-2020_09_02_279521	225	21	-	-	HYPH
10_1101-2020_09_02_279521	225	22	test	test	NN
10_1101-2020_09_02_279521	225	23	,	,	,
10_1101-2020_09_02_279521	225	24	100	100	CD
10_1101-2020_09_02_279521	225	25	cases	case	NNS
10_1101-2020_09_02_279521	225	26	per	per	IN
10_1101-2020_09_02_279521	225	27	arm	arm	NN
10_1101-2020_09_02_279521	225	28	)	)	-RRB-
10_1101-2020_09_02_279521	225	29	.	.	.
10_1101-2020_09_02_279521	226	1	AD	ad	NN
10_1101-2020_09_02_279521	226	2	:	:	:
10_1101-2020_09_02_279521	226	3	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	226	4	's	's	POS
10_1101-2020_09_02_279521	226	5	dementia	dementia	NN
10_1101-2020_09_02_279521	226	6	,	,	,
10_1101-2020_09_02_279521	226	7	ADAS11	adas11	NN
10_1101-2020_09_02_279521	226	8	:	:	:
10_1101-2020_09_02_279521	226	9	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	226	10	's	's	POS
10_1101-2020_09_02_279521	226	11	Disease	Disease	NNP
10_1101-2020_09_02_279521	226	12	Assessment	Assessment	NNP
10_1101-2020_09_02_279521	226	13	Scale	Scale	NNP
10_1101-2020_09_02_279521	226	14	,	,	,
10_1101-2020_09_02_279521	226	15	MMSE	mmse	NN
10_1101-2020_09_02_279521	226	16	:	:	:
10_1101-2020_09_02_279521	226	17	Mini-	Mini-	NNP
10_1101-2020_09_02_279521	226	18	Mental	Mental	NNP
10_1101-2020_09_02_279521	226	19	State	State	NNP
10_1101-2020_09_02_279521	226	20	Examination	Examination	NNP
10_1101-2020_09_02_279521	226	21	,	,	,
10_1101-2020_09_02_279521	226	22	FAQ	FAQ	NNP
10_1101-2020_09_02_279521	226	23	:	:	:
10_1101-2020_09_02_279521	226	24	Functional	Functional	NNP
10_1101-2020_09_02_279521	226	25	Assessment	Assessment	NNP
10_1101-2020_09_02_279521	226	26	Questionnaire	Questionnaire	NNP
10_1101-2020_09_02_279521	226	27	,	,	,
10_1101-2020_09_02_279521	226	28	RAVLT	ravlt	NN
10_1101-2020_09_02_279521	226	29	:	:	:
10_1101-2020_09_02_279521	226	30	Rey	Rey	NNP
10_1101-2020_09_02_279521	226	31	Auditory	Auditory	NNP
10_1101-2020_09_02_279521	226	32	Verbal	Verbal	NNP
10_1101-2020_09_02_279521	226	33	Learning	Learning	NNP
10_1101-2020_09_02_279521	226	34	Test	Test	NNP
10_1101-2020_09_02_279521	226	35	,	,	,
10_1101-2020_09_02_279521	226	36	CDRSB	cdrsb	NN
10_1101-2020_09_02_279521	226	37	:	:	:
10_1101-2020_09_02_279521	226	38	Clinical	Clinical	NNP
10_1101-2020_09_02_279521	226	39	Dementia	Dementia	NNP
10_1101-2020_09_02_279521	226	40	rating	rating	NN
10_1101-2020_09_02_279521	226	41	Scale	scale	NN
10_1101-2020_09_02_279521	226	42	Sum	Sum	NNP
10_1101-2020_09_02_279521	226	43	of	of	IN
10_1101-2020_09_02_279521	226	44	Boxes	Boxes	NNP
10_1101-2020_09_02_279521	226	45	.	.	.
10_1101-2020_09_02_279521	227	1	Amyloid	Amyloid	NNP
10_1101-2020_09_02_279521	227	2	lowering	lower	VBG
10_1101-2020_09_02_279521	227	3	intervention	intervention	NN
10_1101-2020_09_02_279521	227	4	50	50	CD
10_1101-2020_09_02_279521	227	5	%	%	NN
10_1101-2020_09_02_279521	227	6	Point	point	NN
10_1101-2020_09_02_279521	227	7	improvement	improvement	NN
10_1101-2020_09_02_279521	227	8	per	per	IN
10_1101-2020_09_02_279521	227	9	intervention	intervention	NN
10_1101-2020_09_02_279521	227	10	time	time	NN
10_1101-2020_09_02_279521	227	11	-20	-20	NNP
10_1101-2020_09_02_279521	227	12	-15	-15	NNP
10_1101-2020_09_02_279521	227	13	-12.5	-12.5	:
10_1101-2020_09_02_279521	227	14	-10	-10	NNP
10_1101-2020_09_02_279521	227	15	-5	-5	NNP
10_1101-2020_09_02_279521	227	16	-3	-3	:
10_1101-2020_09_02_279521	227	17	-2	-2	NFP
10_1101-2020_09_02_279521	227	18	-1	-1	NFP
10_1101-2020_09_02_279521	227	19	ADAS11	ADAS11	NNP
10_1101-2020_09_02_279521	227	20	5.0	5.0	CD
10_1101-2020_09_02_279521	227	21	,	,	,
10_1101-2020_09_02_279521	227	22	(	(	-LRB-
10_1101-2020_09_02_279521	227	23	2.5	2.5	CD
10_1101-2020_09_02_279521	227	24	)	)	-RRB-
10_1101-2020_09_02_279521	227	25	2.4	2.4	CD
10_1101-2020_09_02_279521	227	26	,	,	,
10_1101-2020_09_02_279521	227	27	(	(	-LRB-
10_1101-2020_09_02_279521	227	28	1.2	1.2	CD
10_1101-2020_09_02_279521	227	29	)	)	-RRB-
10_1101-2020_09_02_279521	227	30	1.4	1.4	CD
10_1101-2020_09_02_279521	227	31	,	,	,
10_1101-2020_09_02_279521	227	32	(	(	-LRB-
10_1101-2020_09_02_279521	227	33	0.7	0.7	CD
10_1101-2020_09_02_279521	227	34	)	)	-RRB-
10_1101-2020_09_02_279521	227	35	0.8	0.8	CD
10_1101-2020_09_02_279521	227	36	,	,	,
10_1101-2020_09_02_279521	227	37	(	(	-LRB-
10_1101-2020_09_02_279521	227	38	0.4	0.4	CD
10_1101-2020_09_02_279521	227	39	)	)	-RRB-
10_1101-2020_09_02_279521	227	40	0.2	0.2	CD
10_1101-2020_09_02_279521	227	41	,	,	,
10_1101-2020_09_02_279521	227	42	(	(	-LRB-
10_1101-2020_09_02_279521	227	43	0.1	0.1	CD
10_1101-2020_09_02_279521	227	44	)	)	-RRB-
10_1101-2020_09_02_279521	227	45	0.1	0.1	CD
10_1101-2020_09_02_279521	227	46	,	,	,
10_1101-2020_09_02_279521	227	47	(	(	-LRB-
10_1101-2020_09_02_279521	227	48	0.0	0.0	CD
10_1101-2020_09_02_279521	227	49	)	)	-RRB-
10_1101-2020_09_02_279521	227	50	0.0	0.0	CD
10_1101-2020_09_02_279521	227	51	,	,	,
10_1101-2020_09_02_279521	227	52	(	(	-LRB-
10_1101-2020_09_02_279521	227	53	0.0	0.0	CD
10_1101-2020_09_02_279521	227	54	)	)	-RRB-
10_1101-2020_09_02_279521	227	55	0.0	0.0	CD
10_1101-2020_09_02_279521	227	56	,	,	,
10_1101-2020_09_02_279521	227	57	(	(	-LRB-
10_1101-2020_09_02_279521	227	58	0.0	0.0	CD
10_1101-2020_09_02_279521	227	59	)	)	-RRB-
10_1101-2020_09_02_279521	227	60	MMSE	mmse	NN
10_1101-2020_09_02_279521	227	61	2.2	2.2	CD
10_1101-2020_09_02_279521	227	62	,	,	,
10_1101-2020_09_02_279521	227	63	(	(	-LRB-
10_1101-2020_09_02_279521	227	64	1.1	1.1	CD
10_1101-2020_09_02_279521	227	65	)	)	-RRB-
10_1101-2020_09_02_279521	227	66	1.0	1.0	CD
10_1101-2020_09_02_279521	227	67	,	,	,
10_1101-2020_09_02_279521	227	68	(	(	-LRB-
10_1101-2020_09_02_279521	227	69	0.5	0.5	CD
10_1101-2020_09_02_279521	227	70	)	)	-RRB-
10_1101-2020_09_02_279521	227	71	0.6	0.6	CD
10_1101-2020_09_02_279521	227	72	,	,	,
10_1101-2020_09_02_279521	227	73	(	(	-LRB-
10_1101-2020_09_02_279521	227	74	0.3	0.3	CD
10_1101-2020_09_02_279521	227	75	)	)	-RRB-
10_1101-2020_09_02_279521	227	76	0.4	0.4	CD
10_1101-2020_09_02_279521	227	77	,	,	,
10_1101-2020_09_02_279521	227	78	(	(	-LRB-
10_1101-2020_09_02_279521	227	79	0.2	0.2	CD
10_1101-2020_09_02_279521	227	80	)	)	-RRB-
10_1101-2020_09_02_279521	227	81	0.1	0.1	CD
10_1101-2020_09_02_279521	227	82	,	,	,
10_1101-2020_09_02_279521	227	83	(	(	-LRB-
10_1101-2020_09_02_279521	227	84	0.0	0.0	CD
10_1101-2020_09_02_279521	227	85	)	)	-RRB-
10_1101-2020_09_02_279521	227	86	0.0	0.0	CD
10_1101-2020_09_02_279521	227	87	,	,	,
10_1101-2020_09_02_279521	227	88	(	(	-LRB-
10_1101-2020_09_02_279521	227	89	0.0	0.0	CD
10_1101-2020_09_02_279521	227	90	)	)	-RRB-
10_1101-2020_09_02_279521	227	91	0.0	0.0	CD
10_1101-2020_09_02_279521	227	92	,	,	,
10_1101-2020_09_02_279521	227	93	(	(	-LRB-
10_1101-2020_09_02_279521	227	94	0.0	0.0	CD
10_1101-2020_09_02_279521	227	95	)	)	-RRB-
10_1101-2020_09_02_279521	227	96	0.0	0.0	CD
10_1101-2020_09_02_279521	227	97	,	,	,
10_1101-2020_09_02_279521	227	98	(	(	-LRB-
10_1101-2020_09_02_279521	227	99	0.0	0.0	LS
10_1101-2020_09_02_279521	227	100	)	)	-RRB-
10_1101-2020_09_02_279521	227	101	FAQ	FAQ	NNP
10_1101-2020_09_02_279521	227	102	4.3	4.3	CD
10_1101-2020_09_02_279521	227	103	,	,	,
10_1101-2020_09_02_279521	227	104	(	(	-LRB-
10_1101-2020_09_02_279521	227	105	2.1	2.1	CD
10_1101-2020_09_02_279521	227	106	)	)	-RRB-
10_1101-2020_09_02_279521	227	107	2.0	2.0	CD
10_1101-2020_09_02_279521	227	108	,	,	,
10_1101-2020_09_02_279521	227	109	(	(	-LRB-
10_1101-2020_09_02_279521	227	110	1.0	1.0	CD
10_1101-2020_09_02_279521	227	111	)	)	-RRB-
10_1101-2020_09_02_279521	227	112	1.2	1.2	CD
10_1101-2020_09_02_279521	227	113	,	,	,
10_1101-2020_09_02_279521	227	114	(	(	-LRB-
10_1101-2020_09_02_279521	227	115	0.6	0.6	CD
10_1101-2020_09_02_279521	227	116	)	)	-RRB-
10_1101-2020_09_02_279521	227	117	0.7	0.7	CD
10_1101-2020_09_02_279521	227	118	,	,	,
10_1101-2020_09_02_279521	227	119	(	(	-LRB-
10_1101-2020_09_02_279521	227	120	0.4	0.4	CD
10_1101-2020_09_02_279521	227	121	)	)	-RRB-
10_1101-2020_09_02_279521	227	122	0.1	0.1	CD
10_1101-2020_09_02_279521	227	123	,	,	,
10_1101-2020_09_02_279521	227	124	(	(	-LRB-
10_1101-2020_09_02_279521	227	125	0.1	0.1	CD
10_1101-2020_09_02_279521	227	126	)	)	-RRB-
10_1101-2020_09_02_279521	227	127	0.0	0.0	CD
10_1101-2020_09_02_279521	227	128	,	,	,
10_1101-2020_09_02_279521	227	129	(	(	-LRB-
10_1101-2020_09_02_279521	227	130	0.0	0.0	CD
10_1101-2020_09_02_279521	227	131	)	)	-RRB-
10_1101-2020_09_02_279521	227	132	0.0	0.0	CD
10_1101-2020_09_02_279521	227	133	,	,	,
10_1101-2020_09_02_279521	227	134	(	(	-LRB-
10_1101-2020_09_02_279521	227	135	0.0	0.0	CD
10_1101-2020_09_02_279521	227	136	)	)	-RRB-
10_1101-2020_09_02_279521	227	137	0.0	0.0	CD
10_1101-2020_09_02_279521	227	138	,	,	,
10_1101-2020_09_02_279521	227	139	(	(	-LRB-
10_1101-2020_09_02_279521	227	140	0.0	0.0	CD
10_1101-2020_09_02_279521	227	141	)	)	-RRB-
10_1101-2020_09_02_279521	227	142	RAVLT	RAVLT	NNP
10_1101-2020_09_02_279521	227	143	immediate	immediate	JJ
10_1101-2020_09_02_279521	227	144	6.9	6.9	CD
10_1101-2020_09_02_279521	227	145	,	,	,
10_1101-2020_09_02_279521	227	146	(	(	-LRB-
10_1101-2020_09_02_279521	227	147	3.4	3.4	CD
10_1101-2020_09_02_279521	227	148	)	)	-RRB-
10_1101-2020_09_02_279521	227	149	3.3	3.3	CD
10_1101-2020_09_02_279521	227	150	,	,	,
10_1101-2020_09_02_279521	227	151	(	(	-LRB-
10_1101-2020_09_02_279521	227	152	1.6	1.6	CD
10_1101-2020_09_02_279521	227	153	)	)	-RRB-
10_1101-2020_09_02_279521	227	154	1.9	1.9	CD
10_1101-2020_09_02_279521	227	155	,	,	,
10_1101-2020_09_02_279521	227	156	(	(	-LRB-
10_1101-2020_09_02_279521	227	157	1.0	1.0	CD
10_1101-2020_09_02_279521	227	158	)	)	-RRB-
10_1101-2020_09_02_279521	227	159	1.2	1.2	CD
10_1101-2020_09_02_279521	227	160	,	,	,
10_1101-2020_09_02_279521	227	161	(	(	-LRB-
10_1101-2020_09_02_279521	227	162	0.6	0.6	CD
10_1101-2020_09_02_279521	227	163	)	)	-RRB-
10_1101-2020_09_02_279521	227	164	0.2	0.2	CD
10_1101-2020_09_02_279521	227	165	,	,	,
10_1101-2020_09_02_279521	227	166	(	(	-LRB-
10_1101-2020_09_02_279521	227	167	0.1	0.1	CD
10_1101-2020_09_02_279521	227	168	)	)	-RRB-
10_1101-2020_09_02_279521	227	169	0.1	0.1	CD
10_1101-2020_09_02_279521	227	170	,	,	,
10_1101-2020_09_02_279521	227	171	(	(	-LRB-
10_1101-2020_09_02_279521	227	172	0.1	0.1	CD
10_1101-2020_09_02_279521	227	173	)	)	-RRB-
10_1101-2020_09_02_279521	227	174	0.0	0.0	CD
10_1101-2020_09_02_279521	227	175	,	,	,
10_1101-2020_09_02_279521	227	176	(	(	-LRB-
10_1101-2020_09_02_279521	227	177	0.0	0.0	CD
10_1101-2020_09_02_279521	227	178	)	)	-RRB-
10_1101-2020_09_02_279521	227	179	0.0	0.0	CD
10_1101-2020_09_02_279521	227	180	,	,	,
10_1101-2020_09_02_279521	227	181	(	(	-LRB-
10_1101-2020_09_02_279521	227	182	0.0	0.0	CD
10_1101-2020_09_02_279521	227	183	)	)	-RRB-
10_1101-2020_09_02_279521	227	184	RAVLT	RAVLT	NNP
10_1101-2020_09_02_279521	227	185	learning	learning	NN
10_1101-2020_09_02_279521	227	186	1.2	1.2	CD
10_1101-2020_09_02_279521	227	187	,	,	,
10_1101-2020_09_02_279521	227	188	(	(	-LRB-
10_1101-2020_09_02_279521	227	189	0.6	0.6	CD
10_1101-2020_09_02_279521	227	190	)	)	-RRB-
10_1101-2020_09_02_279521	227	191	0.6	0.6	CD
10_1101-2020_09_02_279521	227	192	,	,	,
10_1101-2020_09_02_279521	227	193	(	(	-LRB-
10_1101-2020_09_02_279521	227	194	0.3	0.3	CD
10_1101-2020_09_02_279521	227	195	)	)	-RRB-
10_1101-2020_09_02_279521	227	196	0.3	0.3	CD
10_1101-2020_09_02_279521	227	197	,	,	,
10_1101-2020_09_02_279521	227	198	(	(	-LRB-
10_1101-2020_09_02_279521	227	199	0.2	0.2	CD
10_1101-2020_09_02_279521	227	200	)	)	-RRB-
10_1101-2020_09_02_279521	227	201	0.2	0.2	CD
10_1101-2020_09_02_279521	227	202	,	,	,
10_1101-2020_09_02_279521	227	203	(	(	-LRB-
10_1101-2020_09_02_279521	227	204	0.1	0.1	CD
10_1101-2020_09_02_279521	227	205	)	)	-RRB-
10_1101-2020_09_02_279521	227	206	0.0	0.0	CD
10_1101-2020_09_02_279521	227	207	,	,	,
10_1101-2020_09_02_279521	227	208	(	(	-LRB-
10_1101-2020_09_02_279521	227	209	0.0	0.0	CD
10_1101-2020_09_02_279521	227	210	)	)	-RRB-
10_1101-2020_09_02_279521	227	211	0.0	0.0	CD
10_1101-2020_09_02_279521	227	212	,	,	,
10_1101-2020_09_02_279521	227	213	(	(	-LRB-
10_1101-2020_09_02_279521	227	214	0.0	0.0	CD
10_1101-2020_09_02_279521	227	215	)	)	-RRB-
10_1101-2020_09_02_279521	227	216	0.0	0.0	CD
10_1101-2020_09_02_279521	227	217	,	,	,
10_1101-2020_09_02_279521	227	218	(	(	-LRB-
10_1101-2020_09_02_279521	227	219	0.0	0.0	CD
10_1101-2020_09_02_279521	227	220	)	)	-RRB-
10_1101-2020_09_02_279521	227	221	0.0	0.0	CD
10_1101-2020_09_02_279521	227	222	,	,	,
10_1101-2020_09_02_279521	227	223	(	(	-LRB-
10_1101-2020_09_02_279521	227	224	0.0	0.0	CD
10_1101-2020_09_02_279521	227	225	)	)	-RRB-
10_1101-2020_09_02_279521	227	226	RAVLT	RAVLT	NNP
10_1101-2020_09_02_279521	227	227	forgetting	forget	VBG
10_1101-2020_09_02_279521	227	228	16.7	16.7	CD
10_1101-2020_09_02_279521	227	229	,	,	,
10_1101-2020_09_02_279521	227	230	(	(	-LRB-
10_1101-2020_09_02_279521	227	231	8.2	8.2	CD
10_1101-2020_09_02_279521	227	232	)	)	-RRB-
10_1101-2020_09_02_279521	227	233	8.1	8.1	CD
10_1101-2020_09_02_279521	227	234	,	,	,
10_1101-2020_09_02_279521	227	235	(	(	-LRB-
10_1101-2020_09_02_279521	227	236	4.0	4.0	CD
10_1101-2020_09_02_279521	227	237	)	)	-RRB-
10_1101-2020_09_02_279521	227	238	4.8	4.8	CD
10_1101-2020_09_02_279521	227	239	,	,	,
10_1101-2020_09_02_279521	227	240	(	(	-LRB-
10_1101-2020_09_02_279521	227	241	2.5	2.5	CD
10_1101-2020_09_02_279521	227	242	)	)	-RRB-
10_1101-2020_09_02_279521	227	243	2.9	2.9	CD
10_1101-2020_09_02_279521	227	244	,	,	,
10_1101-2020_09_02_279521	227	245	(	(	-LRB-
10_1101-2020_09_02_279521	227	246	1.6	1.6	CD
10_1101-2020_09_02_279521	227	247	)	)	-RRB-
10_1101-2020_09_02_279521	227	248	0.6	0.6	CD
10_1101-2020_09_02_279521	227	249	,	,	,
10_1101-2020_09_02_279521	227	250	(	(	-LRB-
10_1101-2020_09_02_279521	227	251	0.4	0.4	CD
10_1101-2020_09_02_279521	227	252	)	)	-RRB-
10_1101-2020_09_02_279521	227	253	0.2	0.2	CD
10_1101-2020_09_02_279521	227	254	,	,	,
10_1101-2020_09_02_279521	227	255	(	(	-LRB-
10_1101-2020_09_02_279521	227	256	0.2	0.2	CD
10_1101-2020_09_02_279521	227	257	)	)	-RRB-
10_1101-2020_09_02_279521	227	258	0.1	0.1	CD
10_1101-2020_09_02_279521	227	259	,	,	,
10_1101-2020_09_02_279521	227	260	(	(	-LRB-
10_1101-2020_09_02_279521	227	261	0.1	0.1	CD
10_1101-2020_09_02_279521	227	262	)	)	-RRB-
10_1101-2020_09_02_279521	227	263	0.0	0.0	CD
10_1101-2020_09_02_279521	227	264	,	,	,
10_1101-2020_09_02_279521	227	265	(	(	-LRB-
10_1101-2020_09_02_279521	227	266	0.0	0.0	LS
10_1101-2020_09_02_279521	227	267	)	)	-RRB-
10_1101-2020_09_02_279521	227	268	CDRSB	CDRSB	NNP
10_1101-2020_09_02_279521	227	269	1.6	1.6	CD
10_1101-2020_09_02_279521	227	270	,	,	,
10_1101-2020_09_02_279521	227	271	(	(	-LRB-
10_1101-2020_09_02_279521	227	272	0.8	0.8	CD
10_1101-2020_09_02_279521	227	273	)	)	-RRB-
10_1101-2020_09_02_279521	227	274	0.7	0.7	CD
10_1101-2020_09_02_279521	227	275	,	,	,
10_1101-2020_09_02_279521	227	276	(	(	-LRB-
10_1101-2020_09_02_279521	227	277	0.4	0.4	CD
10_1101-2020_09_02_279521	227	278	)	)	-RRB-
10_1101-2020_09_02_279521	227	279	0.4	0.4	CD
10_1101-2020_09_02_279521	227	280	,	,	,
10_1101-2020_09_02_279521	227	281	(	(	-LRB-
10_1101-2020_09_02_279521	227	282	0.2	0.2	CD
10_1101-2020_09_02_279521	227	283	)	)	-RRB-
10_1101-2020_09_02_279521	227	284	0.2	0.2	CD
10_1101-2020_09_02_279521	227	285	,	,	,
10_1101-2020_09_02_279521	227	286	(	(	-LRB-
10_1101-2020_09_02_279521	227	287	0.1	0.1	CD
10_1101-2020_09_02_279521	227	288	)	)	-RRB-
10_1101-2020_09_02_279521	227	289	0.0	0.0	CD
10_1101-2020_09_02_279521	227	290	,	,	,
10_1101-2020_09_02_279521	227	291	(	(	-LRB-
10_1101-2020_09_02_279521	227	292	0.0	0.0	CD
10_1101-2020_09_02_279521	227	293	)	)	-RRB-
10_1101-2020_09_02_279521	227	294	0.0	0.0	CD
10_1101-2020_09_02_279521	227	295	,	,	,
10_1101-2020_09_02_279521	227	296	(	(	-LRB-
10_1101-2020_09_02_279521	227	297	0.0	0.0	CD
10_1101-2020_09_02_279521	227	298	)	)	-RRB-
10_1101-2020_09_02_279521	227	299	0.0	0.0	CD
10_1101-2020_09_02_279521	227	300	,	,	,
10_1101-2020_09_02_279521	227	301	(	(	-LRB-
10_1101-2020_09_02_279521	227	302	0.0	0.0	CD
10_1101-2020_09_02_279521	227	303	)	)	-RRB-
10_1101-2020_09_02_279521	227	304	0.0	0.0	CD
10_1101-2020_09_02_279521	227	305	,	,	,
10_1101-2020_09_02_279521	227	306	(	(	-LRB-
10_1101-2020_09_02_279521	227	307	0.0	0.0	CD
10_1101-2020_09_02_279521	227	308	)	)	-RRB-
10_1101-2020_09_02_279521	227	309	.CC	.CC	.
10_1101-2020_09_02_279521	227	310	-	-	:
10_1101-2020_09_02_279521	227	311	BY	by	IN
10_1101-2020_09_02_279521	227	312	4.0	4.0	CD
10_1101-2020_09_02_279521	227	313	International	international	JJ
10_1101-2020_09_02_279521	227	314	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	227	315	.	.	.
10_1101-2020_09_02_279521	228	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	228	2	is	be	VBZ
10_1101-2020_09_02_279521	228	3	made	make	VBN
10_1101-2020_09_02_279521	228	4	available	available	JJ
10_1101-2020_09_02_279521	228	5	under	under	IN
10_1101-2020_09_02_279521	228	6	a	a	DT
10_1101-2020_09_02_279521	228	7	preprint	preprint	NN
10_1101-2020_09_02_279521	228	8	(	(	-LRB-
10_1101-2020_09_02_279521	228	9	which	which	WDT
10_1101-2020_09_02_279521	228	10	was	be	VBD
10_1101-2020_09_02_279521	228	11	not	not	RB
10_1101-2020_09_02_279521	228	12	certified	certify	VBN
10_1101-2020_09_02_279521	228	13	by	by	IN
10_1101-2020_09_02_279521	228	14	peer	peer	NN
10_1101-2020_09_02_279521	228	15	review	review	NN
10_1101-2020_09_02_279521	228	16	)	)	-RRB-
10_1101-2020_09_02_279521	228	17	is	be	VBZ
10_1101-2020_09_02_279521	228	18	the	the	DT
10_1101-2020_09_02_279521	228	19	author	author	NN
10_1101-2020_09_02_279521	228	20	/	/	SYM
10_1101-2020_09_02_279521	228	21	funder	funder	NN
10_1101-2020_09_02_279521	228	22	,	,	,
10_1101-2020_09_02_279521	228	23	who	who	WP
10_1101-2020_09_02_279521	228	24	has	have	VBZ
10_1101-2020_09_02_279521	228	25	granted	grant	VBN
10_1101-2020_09_02_279521	228	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	228	27	a	a	DT
10_1101-2020_09_02_279521	228	28	license	license	NN
10_1101-2020_09_02_279521	228	29	to	to	TO
10_1101-2020_09_02_279521	228	30	display	display	VB
10_1101-2020_09_02_279521	228	31	the	the	DT
10_1101-2020_09_02_279521	228	32	preprint	preprint	NN
10_1101-2020_09_02_279521	228	33	in	in	IN
10_1101-2020_09_02_279521	228	34	The	the	DT
10_1101-2020_09_02_279521	228	35	copyright	copyright	NN
10_1101-2020_09_02_279521	228	36	holder	holder	NN
10_1101-2020_09_02_279521	228	37	for	for	IN
10_1101-2020_09_02_279521	228	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	228	39	version	version	NN
10_1101-2020_09_02_279521	228	40	posted	post	VBD
10_1101-2020_09_02_279521	228	41	February	February	NNP
10_1101-2020_09_02_279521	228	42	10	10	CD
10_1101-2020_09_02_279521	228	43	,	,	,
10_1101-2020_09_02_279521	228	44	2021	2021	CD
10_1101-2020_09_02_279521	228	45	.	.	.
10_1101-2020_09_02_279521	228	46	;	;	:
10_1101-2020_09_02_279521	228	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	228	48	:	:	:
10_1101-2020_09_02_279521	228	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	228	50	preprint	preprint	NN
10_1101-2020_09_02_279521	228	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	ADD
10_1101-2020_09_02_279521	228	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	-LRB-
10_1101-2020_09_02_279521	228	53	conversion	conversion	NN
10_1101-2020_09_02_279521	228	54	,	,	,
10_1101-2020_09_02_279521	228	55	while	while	IN
10_1101-2020_09_02_279521	228	56	stronger	strong	JJR
10_1101-2020_09_02_279521	228	57	cognitive	cognitive	JJ
10_1101-2020_09_02_279521	228	58	and	and	CC
10_1101-2020_09_02_279521	228	59	functional	functional	JJ
10_1101-2020_09_02_279521	228	60	changes	change	NNS
10_1101-2020_09_02_279521	228	61	happen	happen	VB
10_1101-2020_09_02_279521	228	62	when	when	WRB
10_1101-2020_09_02_279521	228	63	amyloid	amyloid	NNP
10_1101-2020_09_02_279521	228	64	is	be	VBZ
10_1101-2020_09_02_279521	228	65	lowered	lower	VBN
10_1101-2020_09_02_279521	228	66	by	by	IN
10_1101-2020_09_02_279521	228	67	100	100	CD
10_1101-2020_09_02_279521	228	68	%	%	NN
10_1101-2020_09_02_279521	228	69	or	or	CC
10_1101-2020_09_02_279521	228	70	50	50	CD
10_1101-2020_09_02_279521	228	71	%	%	NN
10_1101-2020_09_02_279521	228	72	earlier	early	RBR
10_1101-2020_09_02_279521	228	73	.	.	.
10_1101-2020_09_02_279521	229	1	These	these	DT
10_1101-2020_09_02_279521	229	2	findings	finding	NNS
10_1101-2020_09_02_279521	229	3	may	may	MD
10_1101-2020_09_02_279521	229	4	be	be	VB
10_1101-2020_09_02_279521	229	5	explained	explain	VBN
10_1101-2020_09_02_279521	229	6	by	by	IN
10_1101-2020_09_02_279521	229	7	considering	consider	VBG
10_1101-2020_09_02_279521	229	8	that	that	IN
10_1101-2020_09_02_279521	229	9	amyloid	amyloid	NN
10_1101-2020_09_02_279521	229	10	accumulates	accumulate	VBZ
10_1101-2020_09_02_279521	229	11	over	over	IN
10_1101-2020_09_02_279521	229	12	more	more	JJR
10_1101-2020_09_02_279521	229	13	than	than	IN
10_1101-2020_09_02_279521	229	14	a	a	DT
10_1101-2020_09_02_279521	229	15	decade	decade	NN
10_1101-2020_09_02_279521	229	16	,	,	,
10_1101-2020_09_02_279521	229	17	and	and	CC
10_1101-2020_09_02_279521	229	18	that	that	IN
10_1101-2020_09_02_279521	229	19	when	when	WRB
10_1101-2020_09_02_279521	229	20	amyloid	amyloid	VBP
10_1101-2020_09_02_279521	229	21	clearance	clearance	NN
10_1101-2020_09_02_279521	229	22	occurs	occur	VBZ
10_1101-2020_09_02_279521	229	23	the	the	DT
10_1101-2020_09_02_279521	229	24	pathological	pathological	JJ
10_1101-2020_09_02_279521	229	25	cascade	cascade	NN
10_1101-2020_09_02_279521	229	26	is	be	VBZ
10_1101-2020_09_02_279521	229	27	already	already	RB
10_1101-2020_09_02_279521	229	28	entrenched	entrench	VBN
10_1101-2020_09_02_279521	229	29	(	(	-LRB-
10_1101-2020_09_02_279521	229	30	Rowe	Rowe	NNP
10_1101-2020_09_02_279521	229	31	et	et	NNP
10_1101-2020_09_02_279521	229	32	al	al	NNP
10_1101-2020_09_02_279521	229	33	.	.	NNP
10_1101-2020_09_02_279521	229	34	,	,	,
10_1101-2020_09_02_279521	229	35	2010	2010	CD
10_1101-2020_09_02_279521	229	36	)	)	-RRB-
10_1101-2020_09_02_279521	229	37	.	.	.
10_1101-2020_09_02_279521	230	1	Our	-PRON-	PRP$
10_1101-2020_09_02_279521	230	2	results	result	NNS
10_1101-2020_09_02_279521	230	3	are	be	VBP
10_1101-2020_09_02_279521	230	4	thus	thus	RB
10_1101-2020_09_02_279521	230	5	supporting	support	VBG
10_1101-2020_09_02_279521	230	6	the	the	DT
10_1101-2020_09_02_279521	230	7	need	need	NN
10_1101-2020_09_02_279521	230	8	to	to	TO
10_1101-2020_09_02_279521	230	9	identify	identify	VB
10_1101-2020_09_02_279521	230	10	subjects	subject	NNS
10_1101-2020_09_02_279521	230	11	at	at	IN
10_1101-2020_09_02_279521	230	12	the	the	DT
10_1101-2020_09_02_279521	230	13	pre	pre	JJ
10_1101-2020_09_02_279521	230	14	-	-	JJ
10_1101-2020_09_02_279521	230	15	clinical	clinical	JJ
10_1101-2020_09_02_279521	230	16	stage	stage	NN
10_1101-2020_09_02_279521	230	17	,	,	,
10_1101-2020_09_02_279521	230	18	that	that	DT
10_1101-2020_09_02_279521	230	19	is	be	VBZ
10_1101-2020_09_02_279521	230	20	to	to	TO
10_1101-2020_09_02_279521	230	21	say	say	VB
10_1101-2020_09_02_279521	230	22	still	still	RB
10_1101-2020_09_02_279521	230	23	cognitively	cognitively	RB
10_1101-2020_09_02_279521	230	24	normal	normal	JJ
10_1101-2020_09_02_279521	230	25	,	,	,
10_1101-2020_09_02_279521	230	26	which	which	WDT
10_1101-2020_09_02_279521	230	27	is	be	VBZ
10_1101-2020_09_02_279521	230	28	a	a	DT
10_1101-2020_09_02_279521	230	29	challenging	challenging	JJ
10_1101-2020_09_02_279521	230	30	task	task	NN
10_1101-2020_09_02_279521	230	31	.	.	.
10_1101-2020_09_02_279521	231	1	Currently	currently	RB
10_1101-2020_09_02_279521	231	2	,	,	,
10_1101-2020_09_02_279521	231	3	one	one	CD
10_1101-2020_09_02_279521	231	4	of	of	IN
10_1101-2020_09_02_279521	231	5	the	the	DT
10_1101-2020_09_02_279521	231	6	main	main	JJ
10_1101-2020_09_02_279521	231	7	criteria	criterion	NNS
10_1101-2020_09_02_279521	231	8	to	to	TO
10_1101-2020_09_02_279521	231	9	enroll	enroll	VB
10_1101-2020_09_02_279521	231	10	subjects	subject	NNS
10_1101-2020_09_02_279521	231	11	into	into	IN
10_1101-2020_09_02_279521	231	12	clinical	clinical	JJ
10_1101-2020_09_02_279521	231	13	trials	trial	NNS
10_1101-2020_09_02_279521	231	14	is	be	VBZ
10_1101-2020_09_02_279521	231	15	the	the	DT
10_1101-2020_09_02_279521	231	16	presence	presence	NN
10_1101-2020_09_02_279521	231	17	of	of	IN
10_1101-2020_09_02_279521	231	18	amyloid	amyloid	NN
10_1101-2020_09_02_279521	231	19	in	in	IN
10_1101-2020_09_02_279521	231	20	the	the	DT
10_1101-2020_09_02_279521	231	21	brain	brain	NN
10_1101-2020_09_02_279521	231	22	,	,	,
10_1101-2020_09_02_279521	231	23	and	and	CC
10_1101-2020_09_02_279521	231	24	blood	blood	NN
10_1101-2020_09_02_279521	231	25	-	-	HYPH
10_1101-2020_09_02_279521	231	26	based	base	VBN
10_1101-2020_09_02_279521	231	27	markers	marker	NNS
10_1101-2020_09_02_279521	231	28	are	be	VBP
10_1101-2020_09_02_279521	231	29	considered	consider	VBN
10_1101-2020_09_02_279521	231	30	as	as	IN
10_1101-2020_09_02_279521	231	31	potential	potential	JJ
10_1101-2020_09_02_279521	231	32	candidates	candidate	NNS
10_1101-2020_09_02_279521	231	33	for	for	IN
10_1101-2020_09_02_279521	231	34	identifying	identify	VBG
10_1101-2020_09_02_279521	231	35	patients	patient	NNS
10_1101-2020_09_02_279521	231	36	at	at	IN
10_1101-2020_09_02_279521	231	37	risk	risk	NN
10_1101-2020_09_02_279521	231	38	for	for	IN
10_1101-2020_09_02_279521	231	39	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	231	40	’s	’s	POS
10_1101-2020_09_02_279521	231	41	disease	disease	NN
10_1101-2020_09_02_279521	231	42	(	(	-LRB-
10_1101-2020_09_02_279521	231	43	Zetterberg	Zetterberg	NNP
10_1101-2020_09_02_279521	231	44	&	&	CC
10_1101-2020_09_02_279521	231	45	Burnham	Burnham	NNP
10_1101-2020_09_02_279521	231	46	,	,	,
10_1101-2020_09_02_279521	231	47	2019	2019	CD
10_1101-2020_09_02_279521	231	48	)	)	-RRB-
10_1101-2020_09_02_279521	231	49	.	.	.
10_1101-2020_09_02_279521	232	1	Moreover	moreover	RB
10_1101-2020_09_02_279521	232	2	,	,	,
10_1101-2020_09_02_279521	232	3	recent	recent	JJ
10_1101-2020_09_02_279521	232	4	works	work	NNS
10_1101-2020_09_02_279521	232	5	such	such	JJ
10_1101-2020_09_02_279521	232	6	as	as	IN
10_1101-2020_09_02_279521	232	7	(	(	-LRB-
10_1101-2020_09_02_279521	232	8	Blennow	Blennow	NNP
10_1101-2020_09_02_279521	232	9	et	et	FW
10_1101-2020_09_02_279521	232	10	al	al	NNP
10_1101-2020_09_02_279521	232	11	.	.	NNP
10_1101-2020_09_02_279521	232	12	,	,	,
10_1101-2020_09_02_279521	232	13	2010	2010	CD
10_1101-2020_09_02_279521	232	14	;	;	:
10_1101-2020_09_02_279521	232	15	Westwood	Westwood	NNP
10_1101-2020_09_02_279521	232	16	et	et	NNP
10_1101-2020_09_02_279521	232	17	al	al	NNP
10_1101-2020_09_02_279521	232	18	.	.	NNP
10_1101-2020_09_02_279521	232	19	,	,	,
10_1101-2020_09_02_279521	232	20	2016	2016	CD
10_1101-2020_09_02_279521	232	21	)	)	-RRB-
10_1101-2020_09_02_279521	232	22	have	have	VBP
10_1101-2020_09_02_279521	232	23	proposed	propose	VBN
10_1101-2020_09_02_279521	232	24	more	more	RBR
10_1101-2020_09_02_279521	232	25	complex	complex	JJ
10_1101-2020_09_02_279521	232	26	entry	entry	NN
10_1101-2020_09_02_279521	232	27	criteria	criterion	NNS
10_1101-2020_09_02_279521	232	28	to	to	TO
10_1101-2020_09_02_279521	232	29	constitute	constitute	VB
10_1101-2020_09_02_279521	232	30	cohorts	cohort	NNS
10_1101-2020_09_02_279521	232	31	based	base	VBN
10_1101-2020_09_02_279521	232	32	on	on	IN
10_1101-2020_09_02_279521	232	33	multi	multi	JJ
10_1101-2020_09_02_279521	232	34	-	-	JJ
10_1101-2020_09_02_279521	232	35	modal	modal	JJ
10_1101-2020_09_02_279521	232	36	measurements	measurement	NNS
10_1101-2020_09_02_279521	232	37	.	.	.
10_1101-2020_09_02_279521	233	1	Within	within	IN
10_1101-2020_09_02_279521	233	2	this	this	DT
10_1101-2020_09_02_279521	233	3	context	context	NN
10_1101-2020_09_02_279521	233	4	,	,	,
10_1101-2020_09_02_279521	233	5	our	-PRON-	PRP$
10_1101-2020_09_02_279521	233	6	model	model	NN
10_1101-2020_09_02_279521	233	7	could	could	MD
10_1101-2020_09_02_279521	233	8	also	also	RB
10_1101-2020_09_02_279521	233	9	be	be	VB
10_1101-2020_09_02_279521	233	10	used	use	VBN
10_1101-2020_09_02_279521	233	11	as	as	IN
10_1101-2020_09_02_279521	233	12	an	an	DT
10_1101-2020_09_02_279521	233	13	enrichment	enrichment	NN
10_1101-2020_09_02_279521	233	14	tool	tool	NN
10_1101-2020_09_02_279521	233	15	by	by	IN
10_1101-2020_09_02_279521	233	16	quantifying	quantify	VBG
10_1101-2020_09_02_279521	233	17	the	the	DT
10_1101-2020_09_02_279521	233	18	disease	disease	NN
10_1101-2020_09_02_279521	233	19	severity	severity	NN
10_1101-2020_09_02_279521	233	20	based	base	VBN
10_1101-2020_09_02_279521	233	21	on	on	IN
10_1101-2020_09_02_279521	233	22	multi	multi	JJ
10_1101-2020_09_02_279521	233	23	-	-	JJ
10_1101-2020_09_02_279521	233	24	modal	modal	JJ
10_1101-2020_09_02_279521	233	25	data	datum	NNS
10_1101-2020_09_02_279521	233	26	as	as	IN
10_1101-2020_09_02_279521	233	27	shown	show	VBN
10_1101-2020_09_02_279521	233	28	in	in	IN
10_1101-2020_09_02_279521	233	29	Figure	figure	NN
10_1101-2020_09_02_279521	233	30	2	2	CD
10_1101-2020_09_02_279521	233	31	panel	panel	NN
10_1101-2020_09_02_279521	233	32	II	II	NNP
10_1101-2020_09_02_279521	233	33	)	)	-RRB-
10_1101-2020_09_02_279521	233	34	(	(	-LRB-
10_1101-2020_09_02_279521	233	35	right	right	UH
10_1101-2020_09_02_279521	233	36	)	)	-RRB-
10_1101-2020_09_02_279521	233	37	.	.	.
10_1101-2020_09_02_279521	234	1	Similarly	similarly	RB
10_1101-2020_09_02_279521	234	2	,	,	,
10_1101-2020_09_02_279521	234	3	the	the	DT
10_1101-2020_09_02_279521	234	4	method	method	NN
10_1101-2020_09_02_279521	234	5	could	could	MD
10_1101-2020_09_02_279521	234	6	be	be	VB
10_1101-2020_09_02_279521	234	7	applied	apply	VBN
10_1101-2020_09_02_279521	234	8	to	to	TO
10_1101-2020_09_02_279521	234	9	predict	predict	VB
10_1101-2020_09_02_279521	234	10	the	the	DT
10_1101-2020_09_02_279521	234	11	evolution	evolution	NN
10_1101-2020_09_02_279521	234	12	of	of	IN
10_1101-2020_09_02_279521	234	13	single	single	JJ
10_1101-2020_09_02_279521	234	14	patient	patient	NN
10_1101-2020_09_02_279521	234	15	given	give	VBN
10_1101-2020_09_02_279521	234	16	its	-PRON-	PRP$
10_1101-2020_09_02_279521	234	17	current	current	JJ
10_1101-2020_09_02_279521	234	18	available	available	JJ
10_1101-2020_09_02_279521	234	19	measurements	measurement	NNS
10_1101-2020_09_02_279521	234	20	.	.	.
10_1101-2020_09_02_279521	235	1	An	an	DT
10_1101-2020_09_02_279521	235	2	additional	additional	JJ
10_1101-2020_09_02_279521	235	3	critical	critical	JJ
10_1101-2020_09_02_279521	235	4	aspect	aspect	NN
10_1101-2020_09_02_279521	235	5	of	of	IN
10_1101-2020_09_02_279521	235	6	anti	anti	JJ
10_1101-2020_09_02_279521	235	7	-	-	JJ
10_1101-2020_09_02_279521	235	8	amyloid	amyloid	JJ
10_1101-2020_09_02_279521	235	9	trials	trial	NNS
10_1101-2020_09_02_279521	235	10	is	be	VBZ
10_1101-2020_09_02_279521	235	11	the	the	DT
10_1101-2020_09_02_279521	235	12	effect	effect	NN
10_1101-2020_09_02_279521	235	13	of	of	IN
10_1101-2020_09_02_279521	235	14	dose	dose	JJ
10_1101-2020_09_02_279521	235	15	exposure	exposure	NN
10_1101-2020_09_02_279521	235	16	on	on	IN
10_1101-2020_09_02_279521	235	17	the	the	DT
10_1101-2020_09_02_279521	235	18	production	production	NN
10_1101-2020_09_02_279521	235	19	of	of	IN
10_1101-2020_09_02_279521	235	20	amyloid	amyloid	NN
10_1101-2020_09_02_279521	235	21	(	(	-LRB-
10_1101-2020_09_02_279521	235	22	Klein	Klein	NNP
10_1101-2020_09_02_279521	235	23	et	et	NNP
10_1101-2020_09_02_279521	235	24	al	al	NNP
10_1101-2020_09_02_279521	235	25	.	.	NNP
10_1101-2020_09_02_279521	235	26	,	,	,
10_1101-2020_09_02_279521	235	27	2019	2019	CD
10_1101-2020_09_02_279521	235	28	)	)	-RRB-
10_1101-2020_09_02_279521	235	29	.	.	.
10_1101-2020_09_02_279521	236	1	Currently	currently	RB
10_1101-2020_09_02_279521	236	2	,	,	,
10_1101-2020_09_02_279521	236	3			JJ
10_1101-2020_09_02_279521	236	4	-site	-site	JJ
10_1101-2020_09_02_279521	236	5	amyloid	amyloid	NN
10_1101-2020_09_02_279521	236	6	precursor	precursor	NN
10_1101-2020_09_02_279521	236	7	protein	protein	NN
10_1101-2020_09_02_279521	236	8	cleaving	cleave	VBG
10_1101-2020_09_02_279521	236	9	enzyme	enzyme	NNS
10_1101-2020_09_02_279521	236	10	(	(	-LRB-
10_1101-2020_09_02_279521	236	11	BACE	BACE	NNP
10_1101-2020_09_02_279521	236	12	)	)	-RRB-
10_1101-2020_09_02_279521	236	13	inhibitors	inhibitor	NNS
10_1101-2020_09_02_279521	236	14	allow	allow	VBP
10_1101-2020_09_02_279521	236	15	to	to	TO
10_1101-2020_09_02_279521	236	16	suppress	suppress	VB
10_1101-2020_09_02_279521	236	17	amyloid	amyloid	NN
10_1101-2020_09_02_279521	236	18	production	production	NN
10_1101-2020_09_02_279521	236	19	from	from	IN
10_1101-2020_09_02_279521	236	20	50	50	CD
10_1101-2020_09_02_279521	236	21	%	%	NN
10_1101-2020_09_02_279521	236	22	to	to	TO
10_1101-2020_09_02_279521	236	23	90	90	CD
10_1101-2020_09_02_279521	236	24	%	%	NN
10_1101-2020_09_02_279521	236	25	.	.	.
10_1101-2020_09_02_279521	237	1	In	in	IN
10_1101-2020_09_02_279521	237	2	this	this	DT
10_1101-2020_09_02_279521	237	3	study	study	NN
10_1101-2020_09_02_279521	237	4	we	-PRON-	PRP
10_1101-2020_09_02_279521	237	5	showed	show	VBD
10_1101-2020_09_02_279521	237	6	that	that	IN
10_1101-2020_09_02_279521	237	7	lowering	lower	VBG
10_1101-2020_09_02_279521	237	8	amyloid	amyloid	NN
10_1101-2020_09_02_279521	237	9	by	by	IN
10_1101-2020_09_02_279521	237	10	50	50	CD
10_1101-2020_09_02_279521	237	11	%	%	NN
10_1101-2020_09_02_279521	237	12	consistently	consistently	RB
10_1101-2020_09_02_279521	237	13	decreases	decrease	VBZ
10_1101-2020_09_02_279521	237	14	the	the	DT
10_1101-2020_09_02_279521	237	15	treatment	treatment	NN
10_1101-2020_09_02_279521	237	16	effect	effect	NN
10_1101-2020_09_02_279521	237	17	compared	compare	VBN
10_1101-2020_09_02_279521	237	18	to	to	IN
10_1101-2020_09_02_279521	237	19	a	a	DT
10_1101-2020_09_02_279521	237	20	100	100	CD
10_1101-2020_09_02_279521	237	21	%	%	NN
10_1101-2020_09_02_279521	237	22	lowering	lower	VBG
10_1101-2020_09_02_279521	237	23	at	at	IN
10_1101-2020_09_02_279521	237	24	the	the	DT
10_1101-2020_09_02_279521	237	25	same	same	JJ
10_1101-2020_09_02_279521	237	26	time	time	NN
10_1101-2020_09_02_279521	237	27	.	.	.
10_1101-2020_09_02_279521	238	1	For	for	IN
10_1101-2020_09_02_279521	238	2	instance	instance	NN
10_1101-2020_09_02_279521	238	3	,	,	,
10_1101-2020_09_02_279521	238	4	if	if	IN
10_1101-2020_09_02_279521	238	5	we	-PRON-	PRP
10_1101-2020_09_02_279521	238	6	consider	consider	VBP
10_1101-2020_09_02_279521	238	7	a	a	DT
10_1101-2020_09_02_279521	238	8	sample	sample	NN
10_1101-2020_09_02_279521	238	9	size	size	NN
10_1101-2020_09_02_279521	238	10	of	of	IN
10_1101-2020_09_02_279521	238	11	1000	1000	CD
10_1101-2020_09_02_279521	238	12	subjects	subject	NNS
10_1101-2020_09_02_279521	238	13	per	per	IN
10_1101-2020_09_02_279521	238	14	arm	arm	NN
10_1101-2020_09_02_279521	238	15	in	in	IN
10_1101-2020_09_02_279521	238	16	the	the	DT
10_1101-2020_09_02_279521	238	17	case	case	NN
10_1101-2020_09_02_279521	238	18	of	of	IN
10_1101-2020_09_02_279521	238	19	a	a	DT
10_1101-2020_09_02_279521	238	20	50	50	CD
10_1101-2020_09_02_279521	238	21	%	%	NN
10_1101-2020_09_02_279521	238	22	amyloid	amyloid	NN
10_1101-2020_09_02_279521	238	23	lowering	lower	VBG
10_1101-2020_09_02_279521	238	24	intervention	intervention	NN
10_1101-2020_09_02_279521	238	25	,	,	,
10_1101-2020_09_02_279521	238	26	80	80	CD
10_1101-2020_09_02_279521	238	27	%	%	NN
10_1101-2020_09_02_279521	238	28	power	power	NN
10_1101-2020_09_02_279521	238	29	can	can	MD
10_1101-2020_09_02_279521	238	30	be	be	VB
10_1101-2020_09_02_279521	238	31	reached	reach	VBN
10_1101-2020_09_02_279521	238	32	only	only	RB
10_1101-2020_09_02_279521	238	33	10	10	CD
10_1101-2020_09_02_279521	238	34	years	year	NNS
10_1101-2020_09_02_279521	238	35	before	before	IN
10_1101-2020_09_02_279521	238	36	conversion	conversion	NN
10_1101-2020_09_02_279521	238	37	instead	instead	RB
10_1101-2020_09_02_279521	238	38	of	of	IN
10_1101-2020_09_02_279521	238	39	7	7	CD
10_1101-2020_09_02_279521	238	40	years	year	NNS
10_1101-2020_09_02_279521	238	41	for	for	IN
10_1101-2020_09_02_279521	238	42	a	a	DT
10_1101-2020_09_02_279521	238	43	100	100	CD
10_1101-2020_09_02_279521	238	44	%	%	NN
10_1101-2020_09_02_279521	238	45	amyloid	amyloid	NN
10_1101-2020_09_02_279521	238	46	lowering	lower	VBG
10_1101-2020_09_02_279521	238	47	intervention	intervention	NN
10_1101-2020_09_02_279521	238	48	.	.	.
10_1101-2020_09_02_279521	239	1	This	this	DT
10_1101-2020_09_02_279521	239	2	ability	ability	NN
10_1101-2020_09_02_279521	239	3	of	of	IN
10_1101-2020_09_02_279521	239	4	our	-PRON-	PRP$
10_1101-2020_09_02_279521	239	5	model	model	NN
10_1101-2020_09_02_279521	239	6	to	to	TO
10_1101-2020_09_02_279521	239	7	control	control	VB
10_1101-2020_09_02_279521	239	8	the	the	DT
10_1101-2020_09_02_279521	239	9	rate	rate	NN
10_1101-2020_09_02_279521	239	10	of	of	IN
10_1101-2020_09_02_279521	239	11	amyloid	amyloid	NN
10_1101-2020_09_02_279521	239	12	progression	progression	NN
10_1101-2020_09_02_279521	239	13	is	be	VBZ
10_1101-2020_09_02_279521	239	14	fundamental	fundamental	JJ
10_1101-2020_09_02_279521	239	15	in	in	IN
10_1101-2020_09_02_279521	239	16	order	order	NN
10_1101-2020_09_02_279521	239	17	to	to	TO
10_1101-2020_09_02_279521	239	18	provide	provide	VB
10_1101-2020_09_02_279521	239	19	realistic	realistic	JJ
10_1101-2020_09_02_279521	239	20	simulations	simulation	NNS
10_1101-2020_09_02_279521	239	21	of	of	IN
10_1101-2020_09_02_279521	239	22	anti	anti	JJ
10_1101-2020_09_02_279521	239	23	-	-	JJ
10_1101-2020_09_02_279521	239	24	amyloid	amyloid	JJ
10_1101-2020_09_02_279521	239	25	trials	trial	NNS
10_1101-2020_09_02_279521	239	26	.	.	.
10_1101-2020_09_02_279521	240	1	In	in	IN
10_1101-2020_09_02_279521	240	2	Figure	figure	NN
10_1101-2020_09_02_279521	240	3	2	2	CD
10_1101-2020_09_02_279521	240	4	panel	panel	NN
10_1101-2020_09_02_279521	240	5	I	i	NN
10_1101-2020_09_02_279521	240	6	)	)	-RRB-
10_1101-2020_09_02_279521	240	7	we	-PRON-	PRP
10_1101-2020_09_02_279521	240	8	showed	show	VBD
10_1101-2020_09_02_279521	240	9	that	that	IN
10_1101-2020_09_02_279521	240	10	amyloid	amyloid	NN
10_1101-2020_09_02_279521	240	11	triggers	trigger	VBZ
10_1101-2020_09_02_279521	240	12	the	the	DT
10_1101-2020_09_02_279521	240	13	pathological	pathological	JJ
10_1101-2020_09_02_279521	240	14	cascade	cascade	NN
10_1101-2020_09_02_279521	240	15	affecting	affect	VBG
10_1101-2020_09_02_279521	240	16	the	the	DT
10_1101-2020_09_02_279521	240	17	other	other	JJ
10_1101-2020_09_02_279521	240	18	markers	marker	NNS
10_1101-2020_09_02_279521	240	19	,	,	,
10_1101-2020_09_02_279521	240	20	thus	thus	RB
10_1101-2020_09_02_279521	240	21	confirming	confirm	VBG
10_1101-2020_09_02_279521	240	22	its	-PRON-	PRP$
10_1101-2020_09_02_279521	240	23	dominating	dominating	JJ
10_1101-2020_09_02_279521	240	24	role	role	NN
10_1101-2020_09_02_279521	240	25	on	on	IN
10_1101-2020_09_02_279521	240	26	disease	disease	NN
10_1101-2020_09_02_279521	240	27	progression	progression	NN
10_1101-2020_09_02_279521	240	28	.	.	.
10_1101-2020_09_02_279521	241	1	Assuming	assume	VBG
10_1101-2020_09_02_279521	241	2	that	that	IN
10_1101-2020_09_02_279521	241	3	the	the	DT
10_1101-2020_09_02_279521	241	4	data	datum	NNS
10_1101-2020_09_02_279521	241	5	used	use	VBN
10_1101-2020_09_02_279521	241	6	to	to	TO
10_1101-2020_09_02_279521	241	7	estimate	estimate	VB
10_1101-2020_09_02_279521	241	8	the	the	DT
10_1101-2020_09_02_279521	241	9	model	model	NN
10_1101-2020_09_02_279521	241	10	is	be	VBZ
10_1101-2020_09_02_279521	241	11	sufficient	sufficient	JJ
10_1101-2020_09_02_279521	241	12	to	to	TO
10_1101-2020_09_02_279521	241	13	completely	completely	RB
10_1101-2020_09_02_279521	241	14	depict	depict	VB
10_1101-2020_09_02_279521	241	15	the	the	DT
10_1101-2020_09_02_279521	241	16	history	history	NN
10_1101-2020_09_02_279521	241	17	of	of	IN
10_1101-2020_09_02_279521	241	18	the	the	DT
10_1101-2020_09_02_279521	241	19	pathology	pathology	NN
10_1101-2020_09_02_279521	241	20	,	,	,
10_1101-2020_09_02_279521	241	21	our	-PRON-	PRP$
10_1101-2020_09_02_279521	241	22	model	model	NN
10_1101-2020_09_02_279521	241	23	can	can	MD
10_1101-2020_09_02_279521	241	24	be	be	VB
10_1101-2020_09_02_279521	241	25	interpreted	interpret	VBN
10_1101-2020_09_02_279521	241	26	from	from	IN
10_1101-2020_09_02_279521	241	27	a	a	DT
10_1101-2020_09_02_279521	241	28	causal	causal	JJ
10_1101-2020_09_02_279521	241	29	perspective	perspective	NN
10_1101-2020_09_02_279521	241	30	.	.	.
10_1101-2020_09_02_279521	242	1	However	however	RB
10_1101-2020_09_02_279521	242	2	,	,	,
10_1101-2020_09_02_279521	242	3	we	-PRON-	PRP
10_1101-2020_09_02_279521	242	4	can	can	MD
10_1101-2020_09_02_279521	242	5	not	not	RB
10_1101-2020_09_02_279521	242	6	exclude	exclude	VB
10_1101-2020_09_02_279521	242	7	the	the	DT
10_1101-2020_09_02_279521	242	8	existence	existence	NN
10_1101-2020_09_02_279521	242	9	of	of	IN
10_1101-2020_09_02_279521	242	10	other	other	JJ
10_1101-2020_09_02_279521	242	11	mechanisms	mechanism	NNS
10_1101-2020_09_02_279521	242	12	driving	drive	VBG
10_1101-2020_09_02_279521	242	13	amyloid	amyloid	NN
10_1101-2020_09_02_279521	242	14	accumulation	accumulation	NN
10_1101-2020_09_02_279521	242	15	,	,	,
10_1101-2020_09_02_279521	242	16	which	which	WDT
10_1101-2020_09_02_279521	242	17	our	-PRON-	PRP$
10_1101-2020_09_02_279521	242	18	model	model	NN
10_1101-2020_09_02_279521	242	19	can	can	MD
10_1101-2020_09_02_279521	242	20	not	not	RB
10_1101-2020_09_02_279521	242	21	infer	infer	VB
10_1101-2020_09_02_279521	242	22	from	from	IN
10_1101-2020_09_02_279521	242	23	the	the	DT
10_1101-2020_09_02_279521	242	24	existing	exist	VBG
10_1101-2020_09_02_279521	242	25	data	datum	NNS
10_1101-2020_09_02_279521	242	26	.	.	.
10_1101-2020_09_02_279521	243	1	Therefore	therefore	RB
10_1101-2020_09_02_279521	243	2	,	,	,
10_1101-2020_09_02_279521	243	3	our	-PRON-	PRP$
10_1101-2020_09_02_279521	243	4	findings	finding	NNS
10_1101-2020_09_02_279521	243	5	should	should	MD
10_1101-2020_09_02_279521	243	6	be	be	VB
10_1101-2020_09_02_279521	243	7	considered	consider	VBN
10_1101-2020_09_02_279521	243	8	with	with	IN
10_1101-2020_09_02_279521	243	9	care	care	NN
10_1101-2020_09_02_279521	243	10	,	,	,
10_1101-2020_09_02_279521	243	11	while	while	IN
10_1101-2020_09_02_279521	243	12	the	the	DT
10_1101-2020_09_02_279521	243	13	integration	integration	NN
10_1101-2020_09_02_279521	243	14	of	of	IN
10_1101-2020_09_02_279521	243	15	additional	additional	JJ
10_1101-2020_09_02_279521	243	16	biomarkers	biomarker	NNS
10_1101-2020_09_02_279521	243	17	of	of	IN
10_1101-2020_09_02_279521	243	18	interest	interest	NN
10_1101-2020_09_02_279521	243	19	will	will	MD
10_1101-2020_09_02_279521	243	20	be	be	VB
10_1101-2020_09_02_279521	243	21	necessary	necessary	JJ
10_1101-2020_09_02_279521	243	22	to	to	TO
10_1101-2020_09_02_279521	243	23	account	account	VB
10_1101-2020_09_02_279521	243	24	for	for	IN
10_1101-2020_09_02_279521	243	25	multiple	multiple	JJ
10_1101-2020_09_02_279521	243	26	drivers	driver	NNS
10_1101-2020_09_02_279521	243	27	.CC	.CC	NFP
10_1101-2020_09_02_279521	243	28	-	-	:
10_1101-2020_09_02_279521	243	29	BY	by	IN
10_1101-2020_09_02_279521	243	30	4.0	4.0	CD
10_1101-2020_09_02_279521	243	31	International	international	JJ
10_1101-2020_09_02_279521	243	32	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	243	33	.	.	.
10_1101-2020_09_02_279521	244	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	244	2	is	be	VBZ
10_1101-2020_09_02_279521	244	3	made	make	VBN
10_1101-2020_09_02_279521	244	4	available	available	JJ
10_1101-2020_09_02_279521	244	5	under	under	IN
10_1101-2020_09_02_279521	244	6	a	a	DT
10_1101-2020_09_02_279521	244	7	preprint	preprint	NN
10_1101-2020_09_02_279521	244	8	(	(	-LRB-
10_1101-2020_09_02_279521	244	9	which	which	WDT
10_1101-2020_09_02_279521	244	10	was	be	VBD
10_1101-2020_09_02_279521	244	11	not	not	RB
10_1101-2020_09_02_279521	244	12	certified	certify	VBN
10_1101-2020_09_02_279521	244	13	by	by	IN
10_1101-2020_09_02_279521	244	14	peer	peer	NN
10_1101-2020_09_02_279521	244	15	review	review	NN
10_1101-2020_09_02_279521	244	16	)	)	-RRB-
10_1101-2020_09_02_279521	244	17	is	be	VBZ
10_1101-2020_09_02_279521	244	18	the	the	DT
10_1101-2020_09_02_279521	244	19	author	author	NN
10_1101-2020_09_02_279521	244	20	/	/	SYM
10_1101-2020_09_02_279521	244	21	funder	funder	NN
10_1101-2020_09_02_279521	244	22	,	,	,
10_1101-2020_09_02_279521	244	23	who	who	WP
10_1101-2020_09_02_279521	244	24	has	have	VBZ
10_1101-2020_09_02_279521	244	25	granted	grant	VBN
10_1101-2020_09_02_279521	244	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	244	27	a	a	DT
10_1101-2020_09_02_279521	244	28	license	license	NN
10_1101-2020_09_02_279521	244	29	to	to	TO
10_1101-2020_09_02_279521	244	30	display	display	VB
10_1101-2020_09_02_279521	244	31	the	the	DT
10_1101-2020_09_02_279521	244	32	preprint	preprint	NN
10_1101-2020_09_02_279521	244	33	in	in	IN
10_1101-2020_09_02_279521	244	34	The	the	DT
10_1101-2020_09_02_279521	244	35	copyright	copyright	NN
10_1101-2020_09_02_279521	244	36	holder	holder	NN
10_1101-2020_09_02_279521	244	37	for	for	IN
10_1101-2020_09_02_279521	244	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	244	39	version	version	NN
10_1101-2020_09_02_279521	244	40	posted	post	VBD
10_1101-2020_09_02_279521	244	41	February	February	NNP
10_1101-2020_09_02_279521	244	42	10	10	CD
10_1101-2020_09_02_279521	244	43	,	,	,
10_1101-2020_09_02_279521	244	44	2021	2021	CD
10_1101-2020_09_02_279521	244	45	.	.	.
10_1101-2020_09_02_279521	244	46	;	;	:
10_1101-2020_09_02_279521	244	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	244	48	:	:	:
10_1101-2020_09_02_279521	244	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	244	50	preprint	preprint	NN
10_1101-2020_09_02_279521	244	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	ADD
10_1101-2020_09_02_279521	244	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	ADD
10_1101-2020_09_02_279521	244	53	of	of	IN
10_1101-2020_09_02_279521	244	54	the	the	DT
10_1101-2020_09_02_279521	244	55	disease	disease	NN
10_1101-2020_09_02_279521	244	56	.	.	.
10_1101-2020_09_02_279521	245	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	245	2	is	be	VBZ
10_1101-2020_09_02_279521	245	3	worth	worth	JJ
10_1101-2020_09_02_279521	245	4	noting	note	VBG
10_1101-2020_09_02_279521	245	5	that	that	IN
10_1101-2020_09_02_279521	245	6	recent	recent	JJ
10_1101-2020_09_02_279521	245	7	works	work	NNS
10_1101-2020_09_02_279521	245	8	ventured	venture	VBD
10_1101-2020_09_02_279521	245	9	the	the	DT
10_1101-2020_09_02_279521	245	10	idea	idea	NN
10_1101-2020_09_02_279521	245	11	to	to	TO
10_1101-2020_09_02_279521	245	12	combine	combine	VB
10_1101-2020_09_02_279521	245	13	drugs	drug	NNS
10_1101-2020_09_02_279521	245	14	targeting	target	VBG
10_1101-2020_09_02_279521	245	15	multiple	multiple	JJ
10_1101-2020_09_02_279521	245	16	mechanisms	mechanism	NNS
10_1101-2020_09_02_279521	245	17	at	at	IN
10_1101-2020_09_02_279521	245	18	the	the	DT
10_1101-2020_09_02_279521	245	19	same	same	JJ
10_1101-2020_09_02_279521	245	20	time	time	NN
10_1101-2020_09_02_279521	245	21	(	(	-LRB-
10_1101-2020_09_02_279521	245	22	Gauthier	Gauthier	NNP
10_1101-2020_09_02_279521	245	23	et	et	NNP
10_1101-2020_09_02_279521	245	24	al	al	NNP
10_1101-2020_09_02_279521	245	25	.	.	NNP
10_1101-2020_09_02_279521	245	26	,	,	,
10_1101-2020_09_02_279521	245	27	2019	2019	CD
10_1101-2020_09_02_279521	245	28	)	)	-RRB-
10_1101-2020_09_02_279521	245	29	.	.	.
10_1101-2020_09_02_279521	246	1	For	for	IN
10_1101-2020_09_02_279521	246	2	instance	instance	NN
10_1101-2020_09_02_279521	246	3	,	,	,
10_1101-2020_09_02_279521	246	4	pathologists	pathologist	NNS
10_1101-2020_09_02_279521	246	5	have	have	VBP
10_1101-2020_09_02_279521	246	6	shown	show	VBN
10_1101-2020_09_02_279521	246	7	tau	tau	DT
10_1101-2020_09_02_279521	246	8	deposition	deposition	NN
10_1101-2020_09_02_279521	246	9	in	in	IN
10_1101-2020_09_02_279521	246	10	brainstem	brainstem	NN
10_1101-2020_09_02_279521	246	11	nuclei	nucleus	NNS
10_1101-2020_09_02_279521	246	12	in	in	IN
10_1101-2020_09_02_279521	246	13	adolescents	adolescent	NNS
10_1101-2020_09_02_279521	246	14	and	and	CC
10_1101-2020_09_02_279521	246	15	children	child	NNS
10_1101-2020_09_02_279521	246	16	(	(	-LRB-
10_1101-2020_09_02_279521	246	17	Kaufman	Kaufman	NNP
10_1101-2020_09_02_279521	246	18	et	et	NNP
10_1101-2020_09_02_279521	246	19	al	al	NNP
10_1101-2020_09_02_279521	246	20	.	.	NNP
10_1101-2020_09_02_279521	246	21	,	,	,
10_1101-2020_09_02_279521	246	22	2018	2018	CD
10_1101-2020_09_02_279521	246	23	)	)	-RRB-
10_1101-2020_09_02_279521	246	24	,	,	,
10_1101-2020_09_02_279521	246	25	and	and	CC
10_1101-2020_09_02_279521	246	26	clinicians	clinician	NNS
10_1101-2020_09_02_279521	246	27	are	be	VBP
10_1101-2020_09_02_279521	246	28	currently	currently	RB
10_1101-2020_09_02_279521	246	29	investigating	investigate	VBG
10_1101-2020_09_02_279521	246	30	the	the	DT
10_1101-2020_09_02_279521	246	31	pathological	pathological	JJ
10_1101-2020_09_02_279521	246	32	effect	effect	NN
10_1101-2020_09_02_279521	246	33	of	of	IN
10_1101-2020_09_02_279521	246	34	early	early	JJ
10_1101-2020_09_02_279521	246	35	tau	tau	NN
10_1101-2020_09_02_279521	246	36	spreading	spread	VBG
10_1101-2020_09_02_279521	246	37	on	on	IN
10_1101-2020_09_02_279521	246	38	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	246	39	’s	’s	POS
10_1101-2020_09_02_279521	246	40	disease	disease	NN
10_1101-2020_09_02_279521	246	41	progression	progression	NN
10_1101-2020_09_02_279521	246	42	(	(	-LRB-
10_1101-2020_09_02_279521	246	43	Pontecorvo	Pontecorvo	NNP
10_1101-2020_09_02_279521	246	44	et	et	NNP
10_1101-2020_09_02_279521	246	45	al	al	NNP
10_1101-2020_09_02_279521	246	46	.	.	NNP
10_1101-2020_09_02_279521	246	47	,	,	,
10_1101-2020_09_02_279521	246	48	2019	2019	CD
10_1101-2020_09_02_279521	246	49	)	)	-RRB-
10_1101-2020_09_02_279521	246	50	,	,	,
10_1101-2020_09_02_279521	246	51	raising	raise	VBG
10_1101-2020_09_02_279521	246	52	crucial	crucial	JJ
10_1101-2020_09_02_279521	246	53	questions	question	NNS
10_1101-2020_09_02_279521	246	54	about	about	IN
10_1101-2020_09_02_279521	246	55	its	-PRON-	PRP$
10_1101-2020_09_02_279521	246	56	relationship	relationship	NN
10_1101-2020_09_02_279521	246	57	with	with	IN
10_1101-2020_09_02_279521	246	58	amyloid	amyloid	NN
10_1101-2020_09_02_279521	246	59	accumulation	accumulation	NN
10_1101-2020_09_02_279521	246	60	,	,	,
10_1101-2020_09_02_279521	246	61	and	and	CC
10_1101-2020_09_02_279521	246	62	the	the	DT
10_1101-2020_09_02_279521	246	63	impact	impact	NN
10_1101-2020_09_02_279521	246	64	on	on	IN
10_1101-2020_09_02_279521	246	65	cognitive	cognitive	JJ
10_1101-2020_09_02_279521	246	66	impairment	impairment	NN
10_1101-2020_09_02_279521	246	67	(	(	-LRB-
10_1101-2020_09_02_279521	246	68	Cummings	Cummings	NNP
10_1101-2020_09_02_279521	246	69	,	,	,
10_1101-2020_09_02_279521	246	70	Blennow	Blennow	NNP
10_1101-2020_09_02_279521	246	71	,	,	,
10_1101-2020_09_02_279521	246	72	et	et	NNP
10_1101-2020_09_02_279521	246	73	al	al	NNP
10_1101-2020_09_02_279521	246	74	.	.	NNP
10_1101-2020_09_02_279521	246	75	,	,	,
10_1101-2020_09_02_279521	246	76	2019	2019	CD
10_1101-2020_09_02_279521	246	77	)	)	-RRB-
10_1101-2020_09_02_279521	246	78	.	.	.
10_1101-2020_09_02_279521	247	1	In	in	IN
10_1101-2020_09_02_279521	247	2	this	this	DT
10_1101-2020_09_02_279521	247	3	study	study	NN
10_1101-2020_09_02_279521	247	4	,	,	,
10_1101-2020_09_02_279521	247	5	190	190	CD
10_1101-2020_09_02_279521	247	6	subjects	subject	NNS
10_1101-2020_09_02_279521	247	7	underwent	undergo	VBD
10_1101-2020_09_02_279521	247	8	at	at	RB
10_1101-2020_09_02_279521	247	9	least	least	JJS
10_1101-2020_09_02_279521	247	10	one	one	CD
10_1101-2020_09_02_279521	247	11	Tau	Tau	NNP
10_1101-2020_09_02_279521	247	12	-	-	HYPH
10_1101-2020_09_02_279521	247	13	PET	PET	NNP
10_1101-2020_09_02_279521	247	14	scan	scan	NN
10_1101-2020_09_02_279521	247	15	.	.	.
10_1101-2020_09_02_279521	248	1	However	however	RB
10_1101-2020_09_02_279521	248	2	,	,	,
10_1101-2020_09_02_279521	248	3	when	when	WRB
10_1101-2020_09_02_279521	248	4	considering	consider	VBG
10_1101-2020_09_02_279521	248	5	the	the	DT
10_1101-2020_09_02_279521	248	6	subjects	subject	NNS
10_1101-2020_09_02_279521	248	7	for	for	IN
10_1101-2020_09_02_279521	248	8	whom	whom	WP
10_1101-2020_09_02_279521	248	9	there	there	EX
10_1101-2020_09_02_279521	248	10	exists	exist	VBZ
10_1101-2020_09_02_279521	248	11	one	one	CD
10_1101-2020_09_02_279521	248	12	visit	visit	NN
10_1101-2020_09_02_279521	248	13	in	in	IN
10_1101-2020_09_02_279521	248	14	which	which	WDT
10_1101-2020_09_02_279521	248	15	all	all	PDT
10_1101-2020_09_02_279521	248	16	the	the	DT
10_1101-2020_09_02_279521	248	17	data	data	NN
10_1101-2020_09_02_279521	248	18	modalities	modality	NNS
10_1101-2020_09_02_279521	248	19	were	be	VBD
10_1101-2020_09_02_279521	248	20	available	available	JJ
10_1101-2020_09_02_279521	248	21	,	,	,
10_1101-2020_09_02_279521	248	22	the	the	DT
10_1101-2020_09_02_279521	248	23	number	number	NN
10_1101-2020_09_02_279521	248	24	of	of	IN
10_1101-2020_09_02_279521	248	25	patients	patient	NNS
10_1101-2020_09_02_279521	248	26	in	in	IN
10_1101-2020_09_02_279521	248	27	the	the	DT
10_1101-2020_09_02_279521	248	28	study	study	NN
10_1101-2020_09_02_279521	248	29	cohort	cohort	NN
10_1101-2020_09_02_279521	248	30	decreased	decrease	VBD
10_1101-2020_09_02_279521	248	31	to	to	IN
10_1101-2020_09_02_279521	248	32	33	33	CD
10_1101-2020_09_02_279521	248	33	.	.	.
10_1101-2020_09_02_279521	249	1	This	this	DT
10_1101-2020_09_02_279521	249	2	low	low	JJ
10_1101-2020_09_02_279521	249	3	sample	sample	NN
10_1101-2020_09_02_279521	249	4	size	size	NN
10_1101-2020_09_02_279521	249	5	prevented	prevent	VBD
10_1101-2020_09_02_279521	249	6	us	-PRON-	PRP
10_1101-2020_09_02_279521	249	7	from	from	IN
10_1101-2020_09_02_279521	249	8	estimating	estimate	VBG
10_1101-2020_09_02_279521	249	9	reliable	reliable	JJ
10_1101-2020_09_02_279521	249	10	trajectories	trajectory	NNS
10_1101-2020_09_02_279521	249	11	for	for	IN
10_1101-2020_09_02_279521	249	12	this	this	DT
10_1101-2020_09_02_279521	249	13	biomarker	biomarker	NN
10_1101-2020_09_02_279521	249	14	.	.	.
10_1101-2020_09_02_279521	250	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	250	2	is	be	VBZ
10_1101-2020_09_02_279521	250	3	also	also	RB
10_1101-2020_09_02_279521	250	4	important	important	JJ
10_1101-2020_09_02_279521	250	5	to	to	TO
10_1101-2020_09_02_279521	250	6	note	note	VB
10_1101-2020_09_02_279521	250	7	that	that	IN
10_1101-2020_09_02_279521	250	8	among	among	IN
10_1101-2020_09_02_279521	250	9	the	the	DT
10_1101-2020_09_02_279521	250	10	190	190	CD
10_1101-2020_09_02_279521	250	11	subjects	subject	NNS
10_1101-2020_09_02_279521	250	12	with	with	IN
10_1101-2020_09_02_279521	250	13	at	at	RB
10_1101-2020_09_02_279521	250	14	least	least	RBS
10_1101-2020_09_02_279521	250	15	one	one	CD
10_1101-2020_09_02_279521	250	16	Tau	Tau	NNP
10_1101-2020_09_02_279521	250	17	-	-	HYPH
10_1101-2020_09_02_279521	250	18	PET	PET	NNP
10_1101-2020_09_02_279521	250	19	scan	scan	NN
10_1101-2020_09_02_279521	250	20	,	,	,
10_1101-2020_09_02_279521	250	21	only	only	RB
10_1101-2020_09_02_279521	250	22	19	19	CD
10_1101-2020_09_02_279521	250	23	of	of	IN
10_1101-2020_09_02_279521	250	24	them	-PRON-	PRP
10_1101-2020_09_02_279521	250	25	had	have	VBD
10_1101-2020_09_02_279521	250	26	one	one	CD
10_1101-2020_09_02_279521	250	27	follow	follow	VB
10_1101-2020_09_02_279521	250	28	-	-	HYPH
10_1101-2020_09_02_279521	250	29	up	up	RP
10_1101-2020_09_02_279521	250	30	visit	visit	NN
10_1101-2020_09_02_279521	250	31	.	.	.
10_1101-2020_09_02_279521	251	1	This	this	DT
10_1101-2020_09_02_279521	251	2	means	mean	VBZ
10_1101-2020_09_02_279521	251	3	that	that	IN
10_1101-2020_09_02_279521	251	4	tau	tau	NNP
10_1101-2020_09_02_279521	251	5	markers	marker	NNS
10_1101-2020_09_02_279521	251	6	dynamics	dynamic	NNS
10_1101-2020_09_02_279521	251	7	can	can	MD
10_1101-2020_09_02_279521	251	8	not	not	RB
10_1101-2020_09_02_279521	251	9	be	be	VB
10_1101-2020_09_02_279521	251	10	reliably	reliably	RB
10_1101-2020_09_02_279521	251	11	estimated	estimate	VBN
10_1101-2020_09_02_279521	251	12	.	.	.
10_1101-2020_09_02_279521	252	1	Including	include	VBG
10_1101-2020_09_02_279521	252	2	tau	tau	CD
10_1101-2020_09_02_279521	252	3	data	datum	NNS
10_1101-2020_09_02_279521	252	4	will	will	MD
10_1101-2020_09_02_279521	252	5	require	require	VB
10_1101-2020_09_02_279521	252	6	studies	study	NNS
10_1101-2020_09_02_279521	252	7	on	on	IN
10_1101-2020_09_02_279521	252	8	larger	large	JJR
10_1101-2020_09_02_279521	252	9	cohorts	cohort	NNS
10_1101-2020_09_02_279521	252	10	with	with	IN
10_1101-2020_09_02_279521	252	11	complete	complete	JJ
10_1101-2020_09_02_279521	252	12	sets	set	NNS
10_1101-2020_09_02_279521	252	13	of	of	IN
10_1101-2020_09_02_279521	252	14	PET	PET	NNP
10_1101-2020_09_02_279521	252	15	imaging	imaging	NN
10_1101-2020_09_02_279521	252	16	acquisitions	acquisition	NNS
10_1101-2020_09_02_279521	252	17	.	.	.
10_1101-2020_09_02_279521	253	1	This	this	DT
10_1101-2020_09_02_279521	253	2	could	could	MD
10_1101-2020_09_02_279521	253	3	be	be	VB
10_1101-2020_09_02_279521	253	4	part	part	NN
10_1101-2020_09_02_279521	253	5	of	of	IN
10_1101-2020_09_02_279521	253	6	future	future	JJ
10_1101-2020_09_02_279521	253	7	extensions	extension	NNS
10_1101-2020_09_02_279521	253	8	of	of	IN
10_1101-2020_09_02_279521	253	9	this	this	DT
10_1101-2020_09_02_279521	253	10	work	work	NN
10_1101-2020_09_02_279521	253	11	,	,	,
10_1101-2020_09_02_279521	253	12	where	where	WRB
10_1101-2020_09_02_279521	253	13	the	the	DT
10_1101-2020_09_02_279521	253	14	inclusion	inclusion	NN
10_1101-2020_09_02_279521	253	15	of	of	IN
10_1101-2020_09_02_279521	253	16	tau	tau	NNP
10_1101-2020_09_02_279521	253	17	markers	marker	NNS
10_1101-2020_09_02_279521	253	18	will	will	MD
10_1101-2020_09_02_279521	253	19	allow	allow	VB
10_1101-2020_09_02_279521	253	20	to	to	TO
10_1101-2020_09_02_279521	253	21	simulate	simulate	VB
10_1101-2020_09_02_279521	253	22	scenarios	scenario	NNS
10_1101-2020_09_02_279521	253	23	of	of	IN
10_1101-2020_09_02_279521	253	24	production	production	NN
10_1101-2020_09_02_279521	253	25	blockage	blockage	NN
10_1101-2020_09_02_279521	253	26	of	of	IN
10_1101-2020_09_02_279521	253	27	both	both	DT
10_1101-2020_09_02_279521	253	28	amyloid	amyloid	NN
10_1101-2020_09_02_279521	253	29	and	and	CC
10_1101-2020_09_02_279521	253	30	tau	tau	NN
10_1101-2020_09_02_279521	253	31	at	at	IN
10_1101-2020_09_02_279521	253	32	different	different	JJ
10_1101-2020_09_02_279521	253	33	rates	rate	NNS
10_1101-2020_09_02_279521	253	34	or	or	CC
10_1101-2020_09_02_279521	253	35	intervention	intervention	NN
10_1101-2020_09_02_279521	253	36	time	time	NN
10_1101-2020_09_02_279521	253	37	.	.	.
10_1101-2020_09_02_279521	254	1	Lately	lately	RB
10_1101-2020_09_02_279521	254	2	,	,	,
10_1101-2020_09_02_279521	254	3	disappointing	disappointing	JJ
10_1101-2020_09_02_279521	254	4	results	result	NNS
10_1101-2020_09_02_279521	254	5	of	of	IN
10_1101-2020_09_02_279521	254	6	clinical	clinical	JJ
10_1101-2020_09_02_279521	254	7	studies	study	NNS
10_1101-2020_09_02_279521	254	8	led	lead	VBN
10_1101-2020_09_02_279521	254	9	to	to	TO
10_1101-2020_09_02_279521	254	10	hypothesize	hypothesize	VB
10_1101-2020_09_02_279521	254	11	specific	specific	JJ
10_1101-2020_09_02_279521	254	12	treatments	treatment	NNS
10_1101-2020_09_02_279521	254	13	targeting	target	VBG
10_1101-2020_09_02_279521	254	14	AD	ad	NN
10_1101-2020_09_02_279521	254	15	sub	sub	NN
10_1101-2020_09_02_279521	254	16	-	-	NNS
10_1101-2020_09_02_279521	254	17	populations	population	NNS
10_1101-2020_09_02_279521	254	18	based	base	VBN
10_1101-2020_09_02_279521	254	19	on	on	IN
10_1101-2020_09_02_279521	254	20	their	-PRON-	PRP$
10_1101-2020_09_02_279521	254	21	genotype	genotype	NN
10_1101-2020_09_02_279521	254	22	(	(	-LRB-
10_1101-2020_09_02_279521	254	23	Safieh	Safieh	NNP
10_1101-2020_09_02_279521	254	24	et	et	NNP
10_1101-2020_09_02_279521	254	25	al	al	NNP
10_1101-2020_09_02_279521	254	26	.	.	NNP
10_1101-2020_09_02_279521	254	27	,	,	,
10_1101-2020_09_02_279521	254	28	2019	2019	CD
10_1101-2020_09_02_279521	254	29	)	)	-RRB-
10_1101-2020_09_02_279521	254	30	.	.	.
10_1101-2020_09_02_279521	255	1	While	while	IN
10_1101-2020_09_02_279521	255	2	in	in	IN
10_1101-2020_09_02_279521	255	3	our	-PRON-	PRP$
10_1101-2020_09_02_279521	255	4	work	work	NN
10_1101-2020_09_02_279521	255	5	we	-PRON-	PRP
10_1101-2020_09_02_279521	255	6	describe	describe	VBP
10_1101-2020_09_02_279521	255	7	a	a	DT
10_1101-2020_09_02_279521	255	8	global	global	JJ
10_1101-2020_09_02_279521	255	9	progression	progression	NN
10_1101-2020_09_02_279521	255	10	of	of	IN
10_1101-2020_09_02_279521	255	11	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	255	12	’s	’s	POS
10_1101-2020_09_02_279521	255	13	disease	disease	NN
10_1101-2020_09_02_279521	255	14	,	,	,
10_1101-2020_09_02_279521	255	15	in	in	IN
10_1101-2020_09_02_279521	255	16	the	the	DT
10_1101-2020_09_02_279521	255	17	future	future	NN
10_1101-2020_09_02_279521	255	18	we	-PRON-	PRP
10_1101-2020_09_02_279521	255	19	will	will	MD
10_1101-2020_09_02_279521	255	20	account	account	VB
10_1101-2020_09_02_279521	255	21	for	for	IN
10_1101-2020_09_02_279521	255	22	sub-	sub-	DT
10_1101-2020_09_02_279521	255	23	trajectories	trajectory	NNS
10_1101-2020_09_02_279521	255	24	due	due	JJ
10_1101-2020_09_02_279521	255	25	to	to	IN
10_1101-2020_09_02_279521	255	26	genetic	genetic	JJ
10_1101-2020_09_02_279521	255	27	factors	factor	NNS
10_1101-2020_09_02_279521	255	28	,	,	,
10_1101-2020_09_02_279521	255	29	such	such	JJ
10_1101-2020_09_02_279521	255	30	as	as	IN
10_1101-2020_09_02_279521	255	31	the	the	DT
10_1101-2020_09_02_279521	255	32	presence	presence	NN
10_1101-2020_09_02_279521	255	33	of	of	IN
10_1101-2020_09_02_279521	255	34	4	4	CD
10_1101-2020_09_02_279521	255	35	allele	allele	NNS
10_1101-2020_09_02_279521	255	36	of	of	IN
10_1101-2020_09_02_279521	255	37	apolipoprotein	apolipoprotein	NNP
10_1101-2020_09_02_279521	255	38	(	(	-LRB-
10_1101-2020_09_02_279521	255	39	APOE4	APOE4	NNP
10_1101-2020_09_02_279521	255	40	)	)	-RRB-
10_1101-2020_09_02_279521	255	41	,	,	,
10_1101-2020_09_02_279521	255	42	which	which	WDT
10_1101-2020_09_02_279521	255	43	is	be	VBZ
10_1101-2020_09_02_279521	255	44	a	a	DT
10_1101-2020_09_02_279521	255	45	major	major	JJ
10_1101-2020_09_02_279521	255	46	risk	risk	NN
10_1101-2020_09_02_279521	255	47	for	for	IN
10_1101-2020_09_02_279521	255	48	developing	develop	VBG
10_1101-2020_09_02_279521	255	49	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	255	50	’s	’s	POS
10_1101-2020_09_02_279521	255	51	disease	disease	NN
10_1101-2020_09_02_279521	255	52	influencing	influence	VBG
10_1101-2020_09_02_279521	255	53	both	both	DT
10_1101-2020_09_02_279521	255	54	disease	disease	NNP
10_1101-2020_09_02_279521	255	55	onset	onset	NN
10_1101-2020_09_02_279521	255	56	and	and	CC
10_1101-2020_09_02_279521	255	57	progression	progression	NN
10_1101-2020_09_02_279521	255	58	(	(	-LRB-
10_1101-2020_09_02_279521	255	59	Kim	Kim	NNP
10_1101-2020_09_02_279521	255	60	et	et	FW
10_1101-2020_09_02_279521	255	61	al	al	NNP
10_1101-2020_09_02_279521	255	62	.	.	NNP
10_1101-2020_09_02_279521	255	63	,	,	,
10_1101-2020_09_02_279521	255	64	2009	2009	CD
10_1101-2020_09_02_279521	255	65	)	)	-RRB-
10_1101-2020_09_02_279521	255	66	.	.	.
10_1101-2020_09_02_279521	256	1	This	this	DT
10_1101-2020_09_02_279521	256	2	could	could	MD
10_1101-2020_09_02_279521	256	3	be	be	VB
10_1101-2020_09_02_279521	256	4	done	do	VBN
10_1101-2020_09_02_279521	256	5	by	by	IN
10_1101-2020_09_02_279521	256	6	estimating	estimate	VBG
10_1101-2020_09_02_279521	256	7	dynamical	dynamical	JJ
10_1101-2020_09_02_279521	256	8	systems	system	NNS
10_1101-2020_09_02_279521	256	9	specific	specific	JJ
10_1101-2020_09_02_279521	256	10	to	to	IN
10_1101-2020_09_02_279521	256	11	the	the	DT
10_1101-2020_09_02_279521	256	12	genetic	genetic	JJ
10_1101-2020_09_02_279521	256	13	condition	condition	NN
10_1101-2020_09_02_279521	256	14	of	of	IN
10_1101-2020_09_02_279521	256	15	each	each	DT
10_1101-2020_09_02_279521	256	16	patient	patient	NN
10_1101-2020_09_02_279521	256	17	.	.	.
10_1101-2020_09_02_279521	257	1	This	this	DT
10_1101-2020_09_02_279521	257	2	was	be	VBD
10_1101-2020_09_02_279521	257	3	not	not	RB
10_1101-2020_09_02_279521	257	4	possible	possible	JJ
10_1101-2020_09_02_279521	257	5	in	in	IN
10_1101-2020_09_02_279521	257	6	this	this	DT
10_1101-2020_09_02_279521	257	7	study	study	NN
10_1101-2020_09_02_279521	257	8	due	due	IN
10_1101-2020_09_02_279521	257	9	to	to	IN
10_1101-2020_09_02_279521	257	10	a	a	DT
10_1101-2020_09_02_279521	257	11	strong	strong	JJ
10_1101-2020_09_02_279521	257	12	imbalance	imbalance	NN
10_1101-2020_09_02_279521	257	13	between	between	IN
10_1101-2020_09_02_279521	257	14	the	the	DT
10_1101-2020_09_02_279521	257	15	number	number	NN
10_1101-2020_09_02_279521	257	16	of	of	IN
10_1101-2020_09_02_279521	257	17	carriers	carrier	NNS
10_1101-2020_09_02_279521	257	18	and	and	CC
10_1101-2020_09_02_279521	257	19	non	non	NNS
10_1101-2020_09_02_279521	257	20	-	-	NNS
10_1101-2020_09_02_279521	257	21	carriers	carrier	NNS
10_1101-2020_09_02_279521	257	22	across	across	IN
10_1101-2020_09_02_279521	257	23	the	the	DT
10_1101-2020_09_02_279521	257	24	different	different	JJ
10_1101-2020_09_02_279521	257	25	clinical	clinical	JJ
10_1101-2020_09_02_279521	257	26	groups	group	NNS
10_1101-2020_09_02_279521	257	27	(	(	-LRB-
10_1101-2020_09_02_279521	257	28	cf	cf	NN
10_1101-2020_09_02_279521	257	29	.	.	.
10_1101-2020_09_02_279521	258	1	Table	table	NN
10_1101-2020_09_02_279521	258	2	1	1	CD
10_1101-2020_09_02_279521	258	3	)	)	-RRB-
10_1101-2020_09_02_279521	258	4	.	.	.
10_1101-2020_09_02_279521	259	1	Indeed	indeed	RB
10_1101-2020_09_02_279521	259	2	,	,	,
10_1101-2020_09_02_279521	259	3	we	-PRON-	PRP
10_1101-2020_09_02_279521	259	4	observe	observe	VBP
10_1101-2020_09_02_279521	259	5	that	that	IN
10_1101-2020_09_02_279521	259	6	the	the	DT
10_1101-2020_09_02_279521	259	7	number	number	NN
10_1101-2020_09_02_279521	259	8	of	of	IN
10_1101-2020_09_02_279521	259	9	ADNI	ADNI	NNP
10_1101-2020_09_02_279521	259	10	non	non	NNS
10_1101-2020_09_02_279521	259	11	-	-	NNS
10_1101-2020_09_02_279521	259	12	carriers	carrier	NNS
10_1101-2020_09_02_279521	259	13	is	be	VBZ
10_1101-2020_09_02_279521	259	14	much	much	RB
10_1101-2020_09_02_279521	259	15	lower	low	JJR
10_1101-2020_09_02_279521	259	16	than	than	IN
10_1101-2020_09_02_279521	259	17	the	the	DT
10_1101-2020_09_02_279521	259	18	number	number	NN
10_1101-2020_09_02_279521	259	19	of	of	IN
10_1101-2020_09_02_279521	259	20	carriers	carrier	NNS
10_1101-2020_09_02_279521	259	21	,	,	,
10_1101-2020_09_02_279521	259	22	especially	especially	RB
10_1101-2020_09_02_279521	259	23	in	in	IN
10_1101-2020_09_02_279521	259	24	the	the	DT
10_1101-2020_09_02_279521	259	25	latest	late	JJS
10_1101-2020_09_02_279521	259	26	stages	stage	NNS
10_1101-2020_09_02_279521	259	27	of	of	IN
10_1101-2020_09_02_279521	259	28	the	the	DT
10_1101-2020_09_02_279521	259	29	disease	disease	NN
10_1101-2020_09_02_279521	259	30	(	(	-LRB-
10_1101-2020_09_02_279521	259	31	MCI	MCI	NNP
10_1101-2020_09_02_279521	259	32	converters	converter	NNS
10_1101-2020_09_02_279521	259	33	and	and	CC
10_1101-2020_09_02_279521	259	34	AD	ad	NN
10_1101-2020_09_02_279521	259	35	)	)	-RRB-
10_1101-2020_09_02_279521	259	36	.	.	.
10_1101-2020_09_02_279521	260	1	On	on	IN
10_1101-2020_09_02_279521	260	2	the	the	DT
10_1101-2020_09_02_279521	260	3	contrary	contrary	NN
10_1101-2020_09_02_279521	260	4	,	,	,
10_1101-2020_09_02_279521	260	5	the	the	DT
10_1101-2020_09_02_279521	260	6	majority	majority	NN
10_1101-2020_09_02_279521	260	7	of	of	IN
10_1101-2020_09_02_279521	260	8	NL	NL	NNP
10_1101-2020_09_02_279521	260	9	stable	stable	JJ
10_1101-2020_09_02_279521	260	10	subjects	subject	NNS
10_1101-2020_09_02_279521	260	11	are	be	VBP
10_1101-2020_09_02_279521	260	12	non	non	JJ
10_1101-2020_09_02_279521	260	13	-	-	NNS
10_1101-2020_09_02_279521	260	14	carriers	carrier	NNS
10_1101-2020_09_02_279521	260	15	.	.	.
10_1101-2020_09_02_279521	261	1	Therefore	therefore	RB
10_1101-2020_09_02_279521	261	2	,	,	,
10_1101-2020_09_02_279521	261	3	applying	apply	VBG
10_1101-2020_09_02_279521	261	4	the	the	DT
10_1101-2020_09_02_279521	261	5	model	model	NN
10_1101-2020_09_02_279521	261	6	in	in	IN
10_1101-2020_09_02_279521	261	7	such	such	JJ
10_1101-2020_09_02_279521	261	8	conditions	condition	NNS
10_1101-2020_09_02_279521	261	9	would	would	MD
10_1101-2020_09_02_279521	261	10	lead	lead	VB
10_1101-2020_09_02_279521	261	11	to	to	IN
10_1101-2020_09_02_279521	261	12	a	a	DT
10_1101-2020_09_02_279521	261	13	bias	bias	NN
10_1101-2020_09_02_279521	261	14	towards	towards	IN
10_1101-2020_09_02_279521	261	15	more	more	RBR
10_1101-2020_09_02_279521	261	16	represented	represent	VBN
10_1101-2020_09_02_279521	261	17	groups	group	NNS
10_1101-2020_09_02_279521	261	18	during	during	IN
10_1101-2020_09_02_279521	261	19	the	the	DT
10_1101-2020_09_02_279521	261	20	different	different	JJ
10_1101-2020_09_02_279521	261	21	stages	stage	NNS
10_1101-2020_09_02_279521	261	22	of	of	IN
10_1101-2020_09_02_279521	261	23	the	the	DT
10_1101-2020_09_02_279521	261	24	disease	disease	NN
10_1101-2020_09_02_279521	261	25	progression	progression	NN
10_1101-2020_09_02_279521	261	26	(	(	-LRB-
10_1101-2020_09_02_279521	261	27	APOE4-	APOE4-	NNS
10_1101-2020_09_02_279521	261	28	at	at	IN
10_1101-2020_09_02_279521	261	29	early	early	JJ
10_1101-2020_09_02_279521	261	30	stages	stage	NNS
10_1101-2020_09_02_279521	261	31	and	and	CC
10_1101-2020_09_02_279521	261	32	APOE4	APOE4	NNS
10_1101-2020_09_02_279521	261	33	+	+	CC
10_1101-2020_09_02_279521	261	34	at	at	IN
10_1101-2020_09_02_279521	261	35	late	late	JJ
10_1101-2020_09_02_279521	261	36	ones	one	NNS
10_1101-2020_09_02_279521	261	37	)	)	-RRB-
10_1101-2020_09_02_279521	261	38	,	,	,
10_1101-2020_09_02_279521	261	39	thus	thus	RB
10_1101-2020_09_02_279521	261	40	preventing	prevent	VBG
10_1101-2020_09_02_279521	261	41	us	-PRON-	PRP
10_1101-2020_09_02_279521	261	42	from	from	IN
10_1101-2020_09_02_279521	261	43	differentiating	differentiate	VBG
10_1101-2020_09_02_279521	261	44	the	the	DT
10_1101-2020_09_02_279521	261	45	biomarkers	biomarker	NNS
10_1101-2020_09_02_279521	261	46	dynamics	dynamic	NNS
10_1101-2020_09_02_279521	261	47	based	base	VBN
10_1101-2020_09_02_279521	261	48	on	on	IN
10_1101-2020_09_02_279521	261	49	the	the	DT
10_1101-2020_09_02_279521	261	50	genetic	genetic	JJ
10_1101-2020_09_02_279521	261	51	status	status	NN
10_1101-2020_09_02_279521	261	52	.	.	.
10_1101-2020_09_02_279521	262	1	Yet	yet	RB
10_1101-2020_09_02_279521	262	2	,	,	,
10_1101-2020_09_02_279521	262	3	simulating	simulate	VBG
10_1101-2020_09_02_279521	262	4	dynamical	dynamical	JJ
10_1101-2020_09_02_279521	262	5	relationships	relationship	NNS
10_1101-2020_09_02_279521	262	6	specific	specific	JJ
10_1101-2020_09_02_279521	262	7	to	to	IN
10_1101-2020_09_02_279521	262	8	genetic	genetic	JJ
10_1101-2020_09_02_279521	262	9	factors	factor	NNS
10_1101-2020_09_02_279521	262	10	is	be	VBZ
10_1101-2020_09_02_279521	262	11	a	a	DT
10_1101-2020_09_02_279521	262	12	crucial	crucial	JJ
10_1101-2020_09_02_279521	262	13	avenue	avenue	NN
10_1101-2020_09_02_279521	262	14	of	of	IN
10_1101-2020_09_02_279521	262	15	improvement	improvement	NN
10_1101-2020_09_02_279521	262	16	of	of	IN
10_1101-2020_09_02_279521	262	17	our	-PRON-	PRP$
10_1101-2020_09_02_279521	262	18	approach	approach	NN
10_1101-2020_09_02_279521	262	19	,	,	,
10_1101-2020_09_02_279521	262	20	as	as	IN
10_1101-2020_09_02_279521	262	21	it	-PRON-	PRP
10_1101-2020_09_02_279521	262	22	would	would	MD
10_1101-2020_09_02_279521	262	23	allow	allow	VB
10_1101-2020_09_02_279521	262	24	to	to	TO
10_1101-2020_09_02_279521	262	25	evaluate	evaluate	VB
10_1101-2020_09_02_279521	262	26	the	the	DT
10_1101-2020_09_02_279521	262	27	effect	effect	NN
10_1101-2020_09_02_279521	262	28	of	of	IN
10_1101-2020_09_02_279521	262	29	APOE4	apoe4	PRP
10_1101-2020_09_02_279521	262	30	on	on	RB
10_1101-2020_09_02_279521	262	31	.CC	.CC	,
10_1101-2020_09_02_279521	262	32	-	-	:
10_1101-2020_09_02_279521	262	33	BY	by	IN
10_1101-2020_09_02_279521	262	34	4.0	4.0	CD
10_1101-2020_09_02_279521	262	35	International	international	JJ
10_1101-2020_09_02_279521	262	36	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	262	37	.	.	.
10_1101-2020_09_02_279521	263	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	263	2	is	be	VBZ
10_1101-2020_09_02_279521	263	3	made	make	VBN
10_1101-2020_09_02_279521	263	4	available	available	JJ
10_1101-2020_09_02_279521	263	5	under	under	IN
10_1101-2020_09_02_279521	263	6	a	a	DT
10_1101-2020_09_02_279521	263	7	preprint	preprint	NN
10_1101-2020_09_02_279521	263	8	(	(	-LRB-
10_1101-2020_09_02_279521	263	9	which	which	WDT
10_1101-2020_09_02_279521	263	10	was	be	VBD
10_1101-2020_09_02_279521	263	11	not	not	RB
10_1101-2020_09_02_279521	263	12	certified	certify	VBN
10_1101-2020_09_02_279521	263	13	by	by	IN
10_1101-2020_09_02_279521	263	14	peer	peer	NN
10_1101-2020_09_02_279521	263	15	review	review	NN
10_1101-2020_09_02_279521	263	16	)	)	-RRB-
10_1101-2020_09_02_279521	263	17	is	be	VBZ
10_1101-2020_09_02_279521	263	18	the	the	DT
10_1101-2020_09_02_279521	263	19	author	author	NN
10_1101-2020_09_02_279521	263	20	/	/	SYM
10_1101-2020_09_02_279521	263	21	funder	funder	NN
10_1101-2020_09_02_279521	263	22	,	,	,
10_1101-2020_09_02_279521	263	23	who	who	WP
10_1101-2020_09_02_279521	263	24	has	have	VBZ
10_1101-2020_09_02_279521	263	25	granted	grant	VBN
10_1101-2020_09_02_279521	263	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	263	27	a	a	DT
10_1101-2020_09_02_279521	263	28	license	license	NN
10_1101-2020_09_02_279521	263	29	to	to	TO
10_1101-2020_09_02_279521	263	30	display	display	VB
10_1101-2020_09_02_279521	263	31	the	the	DT
10_1101-2020_09_02_279521	263	32	preprint	preprint	NN
10_1101-2020_09_02_279521	263	33	in	in	IN
10_1101-2020_09_02_279521	263	34	The	the	DT
10_1101-2020_09_02_279521	263	35	copyright	copyright	NN
10_1101-2020_09_02_279521	263	36	holder	holder	NN
10_1101-2020_09_02_279521	263	37	for	for	IN
10_1101-2020_09_02_279521	263	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	263	39	version	version	NN
10_1101-2020_09_02_279521	263	40	posted	post	VBD
10_1101-2020_09_02_279521	263	41	February	February	NNP
10_1101-2020_09_02_279521	263	42	10	10	CD
10_1101-2020_09_02_279521	263	43	,	,	,
10_1101-2020_09_02_279521	263	44	2021	2021	CD
10_1101-2020_09_02_279521	263	45	.	.	.
10_1101-2020_09_02_279521	263	46	;	;	:
10_1101-2020_09_02_279521	263	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	263	48	:	:	:
10_1101-2020_09_02_279521	263	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	263	50	preprint	preprint	NN
10_1101-2020_09_02_279521	263	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	ADD
10_1101-2020_09_02_279521	263	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	UH
10_1101-2020_09_02_279521	263	53	intervention	intervention	NN
10_1101-2020_09_02_279521	263	54	time	time	NN
10_1101-2020_09_02_279521	263	55	or	or	CC
10_1101-2020_09_02_279521	263	56	drug	drug	NN
10_1101-2020_09_02_279521	263	57	dosage	dosage	NN
10_1101-2020_09_02_279521	263	58	.	.	.
10_1101-2020_09_02_279521	264	1	In	in	IN
10_1101-2020_09_02_279521	264	2	addition	addition	NN
10_1101-2020_09_02_279521	264	3	to	to	IN
10_1101-2020_09_02_279521	264	4	this	this	DT
10_1101-2020_09_02_279521	264	5	example	example	NN
10_1101-2020_09_02_279521	264	6	,	,	,
10_1101-2020_09_02_279521	264	7	there	there	EX
10_1101-2020_09_02_279521	264	8	exist	exist	VBP
10_1101-2020_09_02_279521	264	9	numerous	numerous	JJ
10_1101-2020_09_02_279521	264	10	non	non	JJ
10_1101-2020_09_02_279521	264	11	-	-	JJ
10_1101-2020_09_02_279521	264	12	genetic	genetic	JJ
10_1101-2020_09_02_279521	264	13	aggravating	aggravating	NN
10_1101-2020_09_02_279521	264	14	factors	factor	NNS
10_1101-2020_09_02_279521	264	15	that	that	WDT
10_1101-2020_09_02_279521	264	16	may	may	MD
10_1101-2020_09_02_279521	264	17	also	also	RB
10_1101-2020_09_02_279521	264	18	affect	affect	VB
10_1101-2020_09_02_279521	264	19	disease	disease	NN
10_1101-2020_09_02_279521	264	20	evolution	evolution	NN
10_1101-2020_09_02_279521	264	21	,	,	,
10_1101-2020_09_02_279521	264	22	such	such	JJ
10_1101-2020_09_02_279521	264	23	as	as	IN
10_1101-2020_09_02_279521	264	24	diabetes	diabetes	NN
10_1101-2020_09_02_279521	264	25	,	,	,
10_1101-2020_09_02_279521	264	26	obesity	obesity	NN
10_1101-2020_09_02_279521	264	27	or	or	CC
10_1101-2020_09_02_279521	264	28	smoking	smoking	NN
10_1101-2020_09_02_279521	264	29	.	.	.
10_1101-2020_09_02_279521	265	1	Extending	extend	VBG
10_1101-2020_09_02_279521	265	2	our	-PRON-	PRP$
10_1101-2020_09_02_279521	265	3	model	model	NN
10_1101-2020_09_02_279521	265	4	to	to	TO
10_1101-2020_09_02_279521	265	5	account	account	VB
10_1101-2020_09_02_279521	265	6	for	for	IN
10_1101-2020_09_02_279521	265	7	panels	panel	NNS
10_1101-2020_09_02_279521	265	8	of	of	IN
10_1101-2020_09_02_279521	265	9	risk	risk	NN
10_1101-2020_09_02_279521	265	10	factors	factor	NNS
10_1101-2020_09_02_279521	265	11	would	would	MD
10_1101-2020_09_02_279521	265	12	ultimately	ultimately	RB
10_1101-2020_09_02_279521	265	13	allow	allow	VB
10_1101-2020_09_02_279521	265	14	to	to	TO
10_1101-2020_09_02_279521	265	15	test	test	VB
10_1101-2020_09_02_279521	265	16	in	in	IN
10_1101-2020_09_02_279521	265	17	silico	silico	NNP
10_1101-2020_09_02_279521	265	18	personalized	personalize	VBN
10_1101-2020_09_02_279521	265	19	intervention	intervention	NN
10_1101-2020_09_02_279521	265	20	strategies	strategy	NNS
10_1101-2020_09_02_279521	265	21	.	.	.
10_1101-2020_09_02_279521	266	1	Moreover	moreover	RB
10_1101-2020_09_02_279521	266	2	,	,	,
10_1101-2020_09_02_279521	266	3	a	a	DT
10_1101-2020_09_02_279521	266	4	key	key	JJ
10_1101-2020_09_02_279521	266	5	aspect	aspect	NN
10_1101-2020_09_02_279521	266	6	of	of	IN
10_1101-2020_09_02_279521	266	7	clinical	clinical	JJ
10_1101-2020_09_02_279521	266	8	trials	trial	NNS
10_1101-2020_09_02_279521	266	9	is	be	VBZ
10_1101-2020_09_02_279521	266	10	their	-PRON-	PRP$
10_1101-2020_09_02_279521	266	11	economic	economic	JJ
10_1101-2020_09_02_279521	266	12	cost	cost	NN
10_1101-2020_09_02_279521	266	13	.	.	.
10_1101-2020_09_02_279521	267	1	Our	-PRON-	PRP$
10_1101-2020_09_02_279521	267	2	model	model	NN
10_1101-2020_09_02_279521	267	3	could	could	MD
10_1101-2020_09_02_279521	267	4	be	be	VB
10_1101-2020_09_02_279521	267	5	extended	extend	VBN
10_1101-2020_09_02_279521	267	6	to	to	TO
10_1101-2020_09_02_279521	267	7	help	help	VB
10_1101-2020_09_02_279521	267	8	designing	design	VBG
10_1101-2020_09_02_279521	267	9	clinical	clinical	JJ
10_1101-2020_09_02_279521	267	10	trials	trial	NNS
10_1101-2020_09_02_279521	267	11	by	by	IN
10_1101-2020_09_02_279521	267	12	optimizing	optimize	VBG
10_1101-2020_09_02_279521	267	13	intervention	intervention	NN
10_1101-2020_09_02_279521	267	14	with	with	IN
10_1101-2020_09_02_279521	267	15	respect	respect	NN
10_1101-2020_09_02_279521	267	16	to	to	IN
10_1101-2020_09_02_279521	267	17	the	the	DT
10_1101-2020_09_02_279521	267	18	available	available	JJ
10_1101-2020_09_02_279521	267	19	funding	funding	NN
10_1101-2020_09_02_279521	267	20	.	.	.
10_1101-2020_09_02_279521	268	1	Given	give	VBN
10_1101-2020_09_02_279521	268	2	a	a	DT
10_1101-2020_09_02_279521	268	3	budget	budget	NN
10_1101-2020_09_02_279521	268	4	,	,	,
10_1101-2020_09_02_279521	268	5	we	-PRON-	PRP
10_1101-2020_09_02_279521	268	6	could	could	MD
10_1101-2020_09_02_279521	268	7	simulate	simulate	VB
10_1101-2020_09_02_279521	268	8	scenarios	scenario	NNS
10_1101-2020_09_02_279521	268	9	based	base	VBN
10_1101-2020_09_02_279521	268	10	on	on	IN
10_1101-2020_09_02_279521	268	11	different	different	JJ
10_1101-2020_09_02_279521	268	12	sample	sample	NN
10_1101-2020_09_02_279521	268	13	size	size	NN
10_1101-2020_09_02_279521	268	14	,	,	,
10_1101-2020_09_02_279521	268	15	and	and	CC
10_1101-2020_09_02_279521	268	16	trials	trial	NNS
10_1101-2020_09_02_279521	268	17	duration	duration	NN
10_1101-2020_09_02_279521	268	18	,	,	,
10_1101-2020_09_02_279521	268	19	while	while	IN
10_1101-2020_09_02_279521	268	20	estimating	estimate	VBG
10_1101-2020_09_02_279521	268	21	the	the	DT
10_1101-2020_09_02_279521	268	22	expected	expect	VBN
10_1101-2020_09_02_279521	268	23	cognitive	cognitive	JJ
10_1101-2020_09_02_279521	268	24	outcome	outcome	NN
10_1101-2020_09_02_279521	268	25	.	.	.
10_1101-2020_09_02_279521	269	1	Results	result	NNS
10_1101-2020_09_02_279521	269	2	presented	present	VBD
10_1101-2020_09_02_279521	269	3	in	in	IN
10_1101-2020_09_02_279521	269	4	this	this	DT
10_1101-2020_09_02_279521	269	5	work	work	NN
10_1101-2020_09_02_279521	269	6	are	be	VBP
10_1101-2020_09_02_279521	269	7	based	base	VBN
10_1101-2020_09_02_279521	269	8	on	on	IN
10_1101-2020_09_02_279521	269	9	a	a	DT
10_1101-2020_09_02_279521	269	10	model	model	NN
10_1101-2020_09_02_279521	269	11	estimated	estimate	VBN
10_1101-2020_09_02_279521	269	12	by	by	IN
10_1101-2020_09_02_279521	269	13	relying	rely	VBG
10_1101-2020_09_02_279521	269	14	solely	solely	RB
10_1101-2020_09_02_279521	269	15	on	on	IN
10_1101-2020_09_02_279521	269	16	a	a	DT
10_1101-2020_09_02_279521	269	17	subset	subset	NN
10_1101-2020_09_02_279521	269	18	of	of	IN
10_1101-2020_09_02_279521	269	19	subjects	subject	NNS
10_1101-2020_09_02_279521	269	20	and	and	CC
10_1101-2020_09_02_279521	269	21	measures	measure	NNS
10_1101-2020_09_02_279521	269	22	from	from	IN
10_1101-2020_09_02_279521	269	23	the	the	DT
10_1101-2020_09_02_279521	269	24	ADNI	ADNI	NNP
10_1101-2020_09_02_279521	269	25	cohort	cohort	NN
10_1101-2020_09_02_279521	269	26	,	,	,
10_1101-2020_09_02_279521	269	27	and	and	CC
10_1101-2020_09_02_279521	269	28	therefore	therefore	RB
10_1101-2020_09_02_279521	269	29	they	-PRON-	PRP
10_1101-2020_09_02_279521	269	30	may	may	MD
10_1101-2020_09_02_279521	269	31	not	not	RB
10_1101-2020_09_02_279521	269	32	be	be	VB
10_1101-2020_09_02_279521	269	33	fully	fully	RB
10_1101-2020_09_02_279521	269	34	representative	representative	JJ
10_1101-2020_09_02_279521	269	35	of	of	IN
10_1101-2020_09_02_279521	269	36	the	the	DT
10_1101-2020_09_02_279521	269	37	general	general	JJ
10_1101-2020_09_02_279521	269	38	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	269	39	’s	’s	POS
10_1101-2020_09_02_279521	269	40	disease	disease	NNP
10_1101-2020_09_02_279521	269	41	progression	progression	NN
10_1101-2020_09_02_279521	269	42	.	.	.
10_1101-2020_09_02_279521	270	1	Indeed	indeed	RB
10_1101-2020_09_02_279521	270	2	,	,	,
10_1101-2020_09_02_279521	270	3	subjects	subject	NNS
10_1101-2020_09_02_279521	270	4	included	include	VBN
10_1101-2020_09_02_279521	270	5	in	in	IN
10_1101-2020_09_02_279521	270	6	this	this	DT
10_1101-2020_09_02_279521	270	7	cohort	cohort	NN
10_1101-2020_09_02_279521	270	8	were	be	VBD
10_1101-2020_09_02_279521	270	9	either	either	DT
10_1101-2020_09_02_279521	270	10	amyloid	amyloid	NN
10_1101-2020_09_02_279521	270	11	-	-	HYPH
10_1101-2020_09_02_279521	270	12	positive	positive	JJ
10_1101-2020_09_02_279521	270	13	at	at	IN
10_1101-2020_09_02_279521	270	14	baseline	baseline	NN
10_1101-2020_09_02_279521	270	15	,	,	,
10_1101-2020_09_02_279521	270	16	or	or	CC
10_1101-2020_09_02_279521	270	17	became	become	VBD
10_1101-2020_09_02_279521	270	18	amyloid	amyloid	NN
10_1101-2020_09_02_279521	270	19	-	-	HYPH
10_1101-2020_09_02_279521	270	20	positive	positive	JJ
10_1101-2020_09_02_279521	270	21	during	during	IN
10_1101-2020_09_02_279521	270	22	their	-PRON-	PRP$
10_1101-2020_09_02_279521	270	23	follow	follow	VB
10_1101-2020_09_02_279521	270	24	-	-	HYPH
10_1101-2020_09_02_279521	270	25	up	up	RP
10_1101-2020_09_02_279521	270	26	visits	visit	NNS
10_1101-2020_09_02_279521	270	27	.	.	.
10_1101-2020_09_02_279521	271	1	This	this	DT
10_1101-2020_09_02_279521	271	2	was	be	VBD
10_1101-2020_09_02_279521	271	3	motivated	motivate	VBN
10_1101-2020_09_02_279521	271	4	by	by	IN
10_1101-2020_09_02_279521	271	5	the	the	DT
10_1101-2020_09_02_279521	271	6	consideration	consideration	NN
10_1101-2020_09_02_279521	271	7	that	that	IN
10_1101-2020_09_02_279521	271	8	evidence	evidence	NN
10_1101-2020_09_02_279521	271	9	of	of	IN
10_1101-2020_09_02_279521	271	10	pathological	pathological	JJ
10_1101-2020_09_02_279521	271	11	amyloid	amyloid	NN
10_1101-2020_09_02_279521	271	12	levels	level	NNS
10_1101-2020_09_02_279521	271	13	is	be	VBZ
10_1101-2020_09_02_279521	271	14	a	a	DT
10_1101-2020_09_02_279521	271	15	necessary	necessary	JJ
10_1101-2020_09_02_279521	271	16	condition	condition	NN
10_1101-2020_09_02_279521	271	17	for	for	IN
10_1101-2020_09_02_279521	271	18	diagnosing	diagnose	VBG
10_1101-2020_09_02_279521	271	19	AD	ad	NN
10_1101-2020_09_02_279521	271	20	as	as	IN
10_1101-2020_09_02_279521	271	21	it	-PRON-	PRP
10_1101-2020_09_02_279521	271	22	puts	put	VBZ
10_1101-2020_09_02_279521	271	23	subjects	subject	NNS
10_1101-2020_09_02_279521	271	24	within	within	IN
10_1101-2020_09_02_279521	271	25	the	the	DT
10_1101-2020_09_02_279521	271	26	“	"	``
10_1101-2020_09_02_279521	271	27	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	271	28	’s	’s	POS
10_1101-2020_09_02_279521	271	29	disease	disease	NN
10_1101-2020_09_02_279521	271	30	continuum	continuum	NN
10_1101-2020_09_02_279521	271	31	”	"	''
10_1101-2020_09_02_279521	271	32	(	(	-LRB-
10_1101-2020_09_02_279521	271	33	Jack	Jack	NNP
10_1101-2020_09_02_279521	271	34	et	et	NNP
10_1101-2020_09_02_279521	271	35	al	al	NNP
10_1101-2020_09_02_279521	271	36	.	.	NNP
10_1101-2020_09_02_279521	271	37	,	,	,
10_1101-2020_09_02_279521	271	38	2018	2018	CD
10_1101-2020_09_02_279521	271	39	)	)	-RRB-
10_1101-2020_09_02_279521	271	40	.	.	.
10_1101-2020_09_02_279521	272	1	By	by	IN
10_1101-2020_09_02_279521	272	2	narrowing	narrow	VBG
10_1101-2020_09_02_279521	272	3	the	the	DT
10_1101-2020_09_02_279521	272	4	list	list	NN
10_1101-2020_09_02_279521	272	5	of	of	IN
10_1101-2020_09_02_279521	272	6	subjects	subject	NNS
10_1101-2020_09_02_279521	272	7	to	to	IN
10_1101-2020_09_02_279521	272	8	a	a	DT
10_1101-2020_09_02_279521	272	9	subgroup	subgroup	NN
10_1101-2020_09_02_279521	272	10	of	of	IN
10_1101-2020_09_02_279521	272	11	amyloid	amyloid	NN
10_1101-2020_09_02_279521	272	12	positive	positive	JJ
10_1101-2020_09_02_279521	272	13	we	-PRON-	PRP
10_1101-2020_09_02_279521	272	14	increase	increase	VBP
10_1101-2020_09_02_279521	272	15	the	the	DT
10_1101-2020_09_02_279521	272	16	chances	chance	NNS
10_1101-2020_09_02_279521	272	17	of	of	IN
10_1101-2020_09_02_279521	272	18	selecting	select	VBG
10_1101-2020_09_02_279521	272	19	a	a	DT
10_1101-2020_09_02_279521	272	20	set	set	NN
10_1101-2020_09_02_279521	272	21	of	of	IN
10_1101-2020_09_02_279521	272	22	patients	patient	NNS
10_1101-2020_09_02_279521	272	23	likely	likely	JJ
10_1101-2020_09_02_279521	272	24	to	to	TO
10_1101-2020_09_02_279521	272	25	develop	develop	VB
10_1101-2020_09_02_279521	272	26	the	the	DT
10_1101-2020_09_02_279521	272	27	disease	disease	NN
10_1101-2020_09_02_279521	272	28	.	.	.
10_1101-2020_09_02_279521	273	1	Moreover	moreover	RB
10_1101-2020_09_02_279521	273	2	,	,	,
10_1101-2020_09_02_279521	273	3	the	the	DT
10_1101-2020_09_02_279521	273	4	inclusion	inclusion	NN
10_1101-2020_09_02_279521	273	5	of	of	IN
10_1101-2020_09_02_279521	273	6	subjects	subject	NNS
10_1101-2020_09_02_279521	273	7	at	at	IN
10_1101-2020_09_02_279521	273	8	various	various	JJ
10_1101-2020_09_02_279521	273	9	clinical	clinical	JJ
10_1101-2020_09_02_279521	273	10	stages	stage	NNS
10_1101-2020_09_02_279521	273	11	allows	allow	VBZ
10_1101-2020_09_02_279521	273	12	to	to	TO
10_1101-2020_09_02_279521	273	13	span	span	VB
10_1101-2020_09_02_279521	273	14	the	the	DT
10_1101-2020_09_02_279521	273	15	entire	entire	JJ
10_1101-2020_09_02_279521	273	16	spectrum	spectrum	NN
10_1101-2020_09_02_279521	273	17	of	of	IN
10_1101-2020_09_02_279521	273	18	morphological	morphological	JJ
10_1101-2020_09_02_279521	273	19	and	and	CC
10_1101-2020_09_02_279521	273	20	physiological	physiological	JJ
10_1101-2020_09_02_279521	273	21	changes	change	NNS
10_1101-2020_09_02_279521	273	22	affecting	affect	VBG
10_1101-2020_09_02_279521	273	23	the	the	DT
10_1101-2020_09_02_279521	273	24	brain	brain	NN
10_1101-2020_09_02_279521	273	25	.	.	.
10_1101-2020_09_02_279521	274	1	Through	through	IN
10_1101-2020_09_02_279521	274	2	the	the	DT
10_1101-2020_09_02_279521	274	3	joint	joint	JJ
10_1101-2020_09_02_279521	274	4	analysis	analysis	NN
10_1101-2020_09_02_279521	274	5	of	of	IN
10_1101-2020_09_02_279521	274	6	markers	marker	NNS
10_1101-2020_09_02_279521	274	7	of	of	IN
10_1101-2020_09_02_279521	274	8	amyloid	amyloid	NN
10_1101-2020_09_02_279521	274	9	,	,	,
10_1101-2020_09_02_279521	274	10	neurodegeneration	neurodegeneration	NN
10_1101-2020_09_02_279521	274	11	and	and	CC
10_1101-2020_09_02_279521	274	12	cognition	cognition	NN
10_1101-2020_09_02_279521	274	13	,	,	,
10_1101-2020_09_02_279521	274	14	our	-PRON-	PRP$
10_1101-2020_09_02_279521	274	15	model	model	NN
10_1101-2020_09_02_279521	274	16	estimates	estimate	VBZ
10_1101-2020_09_02_279521	274	17	the	the	DT
10_1101-2020_09_02_279521	274	18	average	average	JJ
10_1101-2020_09_02_279521	274	19	trajectory	trajectory	NN
10_1101-2020_09_02_279521	274	20	that	that	WDT
10_1101-2020_09_02_279521	274	21	best	well	RBS
10_1101-2020_09_02_279521	274	22	describes	describe	VBZ
10_1101-2020_09_02_279521	274	23	the	the	DT
10_1101-2020_09_02_279521	274	24	progression	progression	NN
10_1101-2020_09_02_279521	274	25	of	of	IN
10_1101-2020_09_02_279521	274	26	the	the	DT
10_1101-2020_09_02_279521	274	27	observed	observed	JJ
10_1101-2020_09_02_279521	274	28	measures	measure	NNS
10_1101-2020_09_02_279521	274	29	when	when	WRB
10_1101-2020_09_02_279521	274	30	going	go	VBG
10_1101-2020_09_02_279521	274	31	from	from	IN
10_1101-2020_09_02_279521	274	32	NL	NL	NNP
10_1101-2020_09_02_279521	274	33	individuals	individual	NNS
10_1101-2020_09_02_279521	274	34	towards	towards	IN
10_1101-2020_09_02_279521	274	35	AD	ad	NN
10_1101-2020_09_02_279521	274	36	patients	patient	NNS
10_1101-2020_09_02_279521	274	37	.	.	.
10_1101-2020_09_02_279521	275	1	The	the	DT
10_1101-2020_09_02_279521	275	2	selection	selection	NN
10_1101-2020_09_02_279521	275	3	of	of	IN
10_1101-2020_09_02_279521	275	4	amyloid	amyloid	JJ
10_1101-2020_09_02_279521	275	5	positive	positive	JJ
10_1101-2020_09_02_279521	275	6	patients	patient	NNS
10_1101-2020_09_02_279521	275	7	aims	aim	VBZ
10_1101-2020_09_02_279521	275	8	at	at	IN
10_1101-2020_09_02_279521	275	9	increasing	increase	VBG
10_1101-2020_09_02_279521	275	10	the	the	DT
10_1101-2020_09_02_279521	275	11	signal	signal	NN
10_1101-2020_09_02_279521	275	12	of	of	IN
10_1101-2020_09_02_279521	275	13	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	275	14	’s	’s	POS
10_1101-2020_09_02_279521	275	15	pathological	pathological	JJ
10_1101-2020_09_02_279521	275	16	changes	change	NNS
10_1101-2020_09_02_279521	275	17	within	within	IN
10_1101-2020_09_02_279521	275	18	this	this	DT
10_1101-2020_09_02_279521	275	19	cohort	cohort	NN
10_1101-2020_09_02_279521	275	20	,	,	,
10_1101-2020_09_02_279521	275	21	in	in	IN
10_1101-2020_09_02_279521	275	22	order	order	NN
10_1101-2020_09_02_279521	275	23	to	to	TO
10_1101-2020_09_02_279521	275	24	estimate	estimate	VB
10_1101-2020_09_02_279521	275	25	long	long	JJ
10_1101-2020_09_02_279521	275	26	-	-	HYPH
10_1101-2020_09_02_279521	275	27	term	term	NN
10_1101-2020_09_02_279521	275	28	dynamics	dynamic	NNS
10_1101-2020_09_02_279521	275	29	for	for	IN
10_1101-2020_09_02_279521	275	30	the	the	DT
10_1101-2020_09_02_279521	275	31	biomarkers	biomarker	NNS
10_1101-2020_09_02_279521	275	32	that	that	WDT
10_1101-2020_09_02_279521	275	33	can	can	MD
10_1101-2020_09_02_279521	275	34	be	be	VB
10_1101-2020_09_02_279521	275	35	associated	associate	VBN
10_1101-2020_09_02_279521	275	36	to	to	IN
10_1101-2020_09_02_279521	275	37	the	the	DT
10_1101-2020_09_02_279521	275	38	disease	disease	NN
10_1101-2020_09_02_279521	275	39	.	.	.
10_1101-2020_09_02_279521	276	1	We	-PRON-	PRP
10_1101-2020_09_02_279521	276	2	believe	believe	VBP
10_1101-2020_09_02_279521	276	3	that	that	IN
10_1101-2020_09_02_279521	276	4	this	this	DT
10_1101-2020_09_02_279521	276	5	modeling	modeling	NN
10_1101-2020_09_02_279521	276	6	choice	choice	NN
10_1101-2020_09_02_279521	276	7	is	be	VBZ
10_1101-2020_09_02_279521	276	8	based	base	VBN
10_1101-2020_09_02_279521	276	9	on	on	IN
10_1101-2020_09_02_279521	276	10	a	a	DT
10_1101-2020_09_02_279521	276	11	clinically	clinically	RB
10_1101-2020_09_02_279521	276	12	plausible	plausible	JJ
10_1101-2020_09_02_279521	276	13	rationale	rationale	NN
10_1101-2020_09_02_279521	276	14	,	,	,
10_1101-2020_09_02_279521	276	15	and	and	CC
10_1101-2020_09_02_279521	276	16	allows	allow	VBZ
10_1101-2020_09_02_279521	276	17	us	-PRON-	PRP
10_1101-2020_09_02_279521	276	18	to	to	TO
10_1101-2020_09_02_279521	276	19	perform	perform	VB
10_1101-2020_09_02_279521	276	20	our	-PRON-	PRP$
10_1101-2020_09_02_279521	276	21	study	study	NN
10_1101-2020_09_02_279521	276	22	on	on	IN
10_1101-2020_09_02_279521	276	23	a	a	DT
10_1101-2020_09_02_279521	276	24	sufficiently	sufficiently	RB
10_1101-2020_09_02_279521	276	25	large	large	JJ
10_1101-2020_09_02_279521	276	26	cohort	cohort	NN
10_1101-2020_09_02_279521	276	27	enabling	enable	VBG
10_1101-2020_09_02_279521	276	28	the	the	DT
10_1101-2020_09_02_279521	276	29	estimation	estimation	NN
10_1101-2020_09_02_279521	276	30	of	of	IN
10_1101-2020_09_02_279521	276	31	our	-PRON-	PRP$
10_1101-2020_09_02_279521	276	32	model	model	NN
10_1101-2020_09_02_279521	276	33	.	.	.
10_1101-2020_09_02_279521	277	1	Bearing	bear	VBG
10_1101-2020_09_02_279521	277	2	this	this	DT
10_1101-2020_09_02_279521	277	3	in	in	IN
10_1101-2020_09_02_279521	277	4	mind	mind	NN
10_1101-2020_09_02_279521	277	5	,	,	,
10_1101-2020_09_02_279521	277	6	we	-PRON-	PRP
10_1101-2020_09_02_279521	277	7	acknowledge	acknowledge	VBP
10_1101-2020_09_02_279521	277	8	the	the	DT
10_1101-2020_09_02_279521	277	9	potential	potential	JJ
10_1101-2020_09_02_279521	277	10	presence	presence	NN
10_1101-2020_09_02_279521	277	11	of	of	IN
10_1101-2020_09_02_279521	277	12	bias	bias	NN
10_1101-2020_09_02_279521	277	13	towards	towards	IN
10_1101-2020_09_02_279521	277	14	the	the	DT
10_1101-2020_09_02_279521	277	15	specific	specific	JJ
10_1101-2020_09_02_279521	277	16	inclusion	inclusion	NN
10_1101-2020_09_02_279521	277	17	criterion	criterion	NN
10_1101-2020_09_02_279521	277	18	adopted	adopt	VBN
10_1101-2020_09_02_279521	277	19	in	in	IN
10_1101-2020_09_02_279521	277	20	this	this	DT
10_1101-2020_09_02_279521	277	21	work	work	NN
10_1101-2020_09_02_279521	277	22	.	.	.
10_1101-2020_09_02_279521	278	1	Indeed	indeed	RB
10_1101-2020_09_02_279521	278	2	,	,	,
10_1101-2020_09_02_279521	278	3	the	the	DT
10_1101-2020_09_02_279521	278	4	present	present	JJ
10_1101-2020_09_02_279521	278	5	results	result	NNS
10_1101-2020_09_02_279521	278	6	may	may	MD
10_1101-2020_09_02_279521	278	7	provide	provide	VB
10_1101-2020_09_02_279521	278	8	a	a	DT
10_1101-2020_09_02_279521	278	9	limited	limited	JJ
10_1101-2020_09_02_279521	278	10	representation	representation	NN
10_1101-2020_09_02_279521	278	11	of	of	IN
10_1101-2020_09_02_279521	278	12	the	the	DT
10_1101-2020_09_02_279521	278	13	pathological	pathological	JJ
10_1101-2020_09_02_279521	278	14	temporal	temporal	JJ
10_1101-2020_09_02_279521	278	15	window	window	NN
10_1101-2020_09_02_279521	278	16	captured	capture	VBN
10_1101-2020_09_02_279521	278	17	by	by	IN
10_1101-2020_09_02_279521	278	18	the	the	DT
10_1101-2020_09_02_279521	278	19	model	model	NN
10_1101-2020_09_02_279521	278	20	.	.	.
10_1101-2020_09_02_279521	279	1	For	for	IN
10_1101-2020_09_02_279521	279	2	example	example	NN
10_1101-2020_09_02_279521	279	3	,	,	,
10_1101-2020_09_02_279521	279	4	applying	apply	VBG
10_1101-2020_09_02_279521	279	5	the	the	DT
10_1101-2020_09_02_279521	279	6	model	model	NN
10_1101-2020_09_02_279521	279	7	on	on	IN
10_1101-2020_09_02_279521	279	8	a	a	DT
10_1101-2020_09_02_279521	279	9	cohort	cohort	NN
10_1101-2020_09_02_279521	279	10	containing	contain	VBG
10_1101-2020_09_02_279521	279	11	amyloid	amyloid	NN
10_1101-2020_09_02_279521	279	12	-	-	HYPH
10_1101-2020_09_02_279521	279	13	negative	negative	JJ
10_1101-2020_09_02_279521	279	14	subjects	subject	NNS
10_1101-2020_09_02_279521	279	15	may	may	MD
10_1101-2020_09_02_279521	279	16	provide	provide	VB
10_1101-2020_09_02_279521	279	17	additional	additional	JJ
10_1101-2020_09_02_279521	279	18	insights	insight	NNS
10_1101-2020_09_02_279521	279	19	on	on	IN
10_1101-2020_09_02_279521	279	20	the	the	DT
10_1101-2020_09_02_279521	279	21	overall	overall	JJ
10_1101-2020_09_02_279521	279	22	disease	disease	NN
10_1101-2020_09_02_279521	279	23	history	history	NN
10_1101-2020_09_02_279521	279	24	.	.	.
10_1101-2020_09_02_279521	280	1	However	however	RB
10_1101-2020_09_02_279521	280	2	,	,	,
10_1101-2020_09_02_279521	280	3	this	this	DT
10_1101-2020_09_02_279521	280	4	is	be	VBZ
10_1101-2020_09_02_279521	280	5	a	a	DT
10_1101-2020_09_02_279521	280	6	challenging	challenging	JJ
10_1101-2020_09_02_279521	280	7	task	task	NN
10_1101-2020_09_02_279521	280	8	as	as	IN
10_1101-2020_09_02_279521	280	9	it	-PRON-	PRP
10_1101-2020_09_02_279521	280	10	would	would	MD
10_1101-2020_09_02_279521	280	11	require	require	VB
10_1101-2020_09_02_279521	280	12	to	to	TO
10_1101-2020_09_02_279521	280	13	identify	identify	VB
10_1101-2020_09_02_279521	280	14	sub	sub	NN
10_1101-2020_09_02_279521	280	15	-	-	HYPH
10_1101-2020_09_02_279521	280	16	trajectories	trajectory	NNS
10_1101-2020_09_02_279521	280	17	dissociated	dissociate	VBN
10_1101-2020_09_02_279521	280	18	from	from	IN
10_1101-2020_09_02_279521	280	19	normal	normal	JJ
10_1101-2020_09_02_279521	280	20	ageing	ageing	NN
10_1101-2020_09_02_279521	280	21	(	(	-LRB-
10_1101-2020_09_02_279521	280	22	Lorenzi	Lorenzi	NNP
10_1101-2020_09_02_279521	280	23	et	et	NNP
10_1101-2020_09_02_279521	280	24	al	al	NNP
10_1101-2020_09_02_279521	280	25	.	.	NNP
10_1101-2020_09_02_279521	280	26	,	,	,
10_1101-2020_09_02_279521	280	27	2015	2015	CD
10_1101-2020_09_02_279521	280	28	;	;	:
10_1101-2020_09_02_279521	280	29	Sivera	Sivera	NNP
10_1101-2020_09_02_279521	280	30	et	et	FW
10_1101-2020_09_02_279521	280	31	al	al	NNP
10_1101-2020_09_02_279521	280	32	.	.	NNP
10_1101-2020_09_02_279521	280	33	,	,	,
10_1101-2020_09_02_279521	280	34	2020	2020	CD
10_1101-2020_09_02_279521	280	35	)	)	-RRB-
10_1101-2020_09_02_279521	280	36	.	.	.
10_1101-2020_09_02_279521	281	1	Another	another	DT
10_1101-2020_09_02_279521	281	2	potential	potential	JJ
10_1101-2020_09_02_279521	281	3	bias	bias	NN
10_1101-2020_09_02_279521	281	4	affecting	affect	VBG
10_1101-2020_09_02_279521	281	5	the	the	DT
10_1101-2020_09_02_279521	281	6	results	result	NNS
10_1101-2020_09_02_279521	281	7	may	may	MD
10_1101-2020_09_02_279521	281	8	come	come	VB
10_1101-2020_09_02_279521	281	9	from	from	IN
10_1101-2020_09_02_279521	281	10	the	the	DT
10_1101-2020_09_02_279521	281	11	.CC	.CC	NFP
10_1101-2020_09_02_279521	281	12	-	-	:
10_1101-2020_09_02_279521	281	13	BY	by	IN
10_1101-2020_09_02_279521	281	14	4.0	4.0	CD
10_1101-2020_09_02_279521	281	15	International	international	JJ
10_1101-2020_09_02_279521	281	16	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	281	17	.	.	.
10_1101-2020_09_02_279521	282	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	282	2	is	be	VBZ
10_1101-2020_09_02_279521	282	3	made	make	VBN
10_1101-2020_09_02_279521	282	4	available	available	JJ
10_1101-2020_09_02_279521	282	5	under	under	IN
10_1101-2020_09_02_279521	282	6	a	a	DT
10_1101-2020_09_02_279521	282	7	preprint	preprint	NN
10_1101-2020_09_02_279521	282	8	(	(	-LRB-
10_1101-2020_09_02_279521	282	9	which	which	WDT
10_1101-2020_09_02_279521	282	10	was	be	VBD
10_1101-2020_09_02_279521	282	11	not	not	RB
10_1101-2020_09_02_279521	282	12	certified	certify	VBN
10_1101-2020_09_02_279521	282	13	by	by	IN
10_1101-2020_09_02_279521	282	14	peer	peer	NN
10_1101-2020_09_02_279521	282	15	review	review	NN
10_1101-2020_09_02_279521	282	16	)	)	-RRB-
10_1101-2020_09_02_279521	282	17	is	be	VBZ
10_1101-2020_09_02_279521	282	18	the	the	DT
10_1101-2020_09_02_279521	282	19	author	author	NN
10_1101-2020_09_02_279521	282	20	/	/	SYM
10_1101-2020_09_02_279521	282	21	funder	funder	NN
10_1101-2020_09_02_279521	282	22	,	,	,
10_1101-2020_09_02_279521	282	23	who	who	WP
10_1101-2020_09_02_279521	282	24	has	have	VBZ
10_1101-2020_09_02_279521	282	25	granted	grant	VBN
10_1101-2020_09_02_279521	282	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	282	27	a	a	DT
10_1101-2020_09_02_279521	282	28	license	license	NN
10_1101-2020_09_02_279521	282	29	to	to	TO
10_1101-2020_09_02_279521	282	30	display	display	VB
10_1101-2020_09_02_279521	282	31	the	the	DT
10_1101-2020_09_02_279521	282	32	preprint	preprint	NN
10_1101-2020_09_02_279521	282	33	in	in	IN
10_1101-2020_09_02_279521	282	34	The	the	DT
10_1101-2020_09_02_279521	282	35	copyright	copyright	NN
10_1101-2020_09_02_279521	282	36	holder	holder	NN
10_1101-2020_09_02_279521	282	37	for	for	IN
10_1101-2020_09_02_279521	282	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	282	39	version	version	NN
10_1101-2020_09_02_279521	282	40	posted	post	VBD
10_1101-2020_09_02_279521	282	41	February	February	NNP
10_1101-2020_09_02_279521	282	42	10	10	CD
10_1101-2020_09_02_279521	282	43	,	,	,
10_1101-2020_09_02_279521	282	44	2021	2021	CD
10_1101-2020_09_02_279521	282	45	.	.	.
10_1101-2020_09_02_279521	282	46	;	;	:
10_1101-2020_09_02_279521	282	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	282	48	:	:	:
10_1101-2020_09_02_279521	282	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	282	50	preprint	preprint	NN
10_1101-2020_09_02_279521	282	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	ADD
10_1101-2020_09_02_279521	282	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	ADD
10_1101-2020_09_02_279521	282	53	choice	choice	NN
10_1101-2020_09_02_279521	282	54	of	of	IN
10_1101-2020_09_02_279521	282	55	the	the	DT
10_1101-2020_09_02_279521	282	56	clinical	clinical	JJ
10_1101-2020_09_02_279521	282	57	scores	score	NNS
10_1101-2020_09_02_279521	282	58	used	use	VBN
10_1101-2020_09_02_279521	282	59	to	to	TO
10_1101-2020_09_02_279521	282	60	estimate	estimate	VB
10_1101-2020_09_02_279521	282	61	our	-PRON-	PRP$
10_1101-2020_09_02_279521	282	62	model	model	NN
10_1101-2020_09_02_279521	282	63	.	.	.
10_1101-2020_09_02_279521	283	1	In	in	IN
10_1101-2020_09_02_279521	283	2	this	this	DT
10_1101-2020_09_02_279521	283	3	study	study	NN
10_1101-2020_09_02_279521	283	4	,	,	,
10_1101-2020_09_02_279521	283	5	we	-PRON-	PRP
10_1101-2020_09_02_279521	283	6	relied	rely	VBD
10_1101-2020_09_02_279521	283	7	on	on	IN
10_1101-2020_09_02_279521	283	8	a	a	DT
10_1101-2020_09_02_279521	283	9	panel	panel	NN
10_1101-2020_09_02_279521	283	10	of	of	IN
10_1101-2020_09_02_279521	283	11	7	7	CD
10_1101-2020_09_02_279521	283	12	neuro	neuro	JJ
10_1101-2020_09_02_279521	283	13	-	-	HYPH
10_1101-2020_09_02_279521	283	14	psychological	psychological	JJ
10_1101-2020_09_02_279521	283	15	assessments	assessment	NNS
10_1101-2020_09_02_279521	283	16	providing	provide	VBG
10_1101-2020_09_02_279521	283	17	a	a	DT
10_1101-2020_09_02_279521	283	18	comprehensive	comprehensive	JJ
10_1101-2020_09_02_279521	283	19	representation	representation	NN
10_1101-2020_09_02_279521	283	20	of	of	IN
10_1101-2020_09_02_279521	283	21	cognitive	cognitive	JJ
10_1101-2020_09_02_279521	283	22	,	,	,
10_1101-2020_09_02_279521	283	23	memory	memory	NN
10_1101-2020_09_02_279521	283	24	and	and	CC
10_1101-2020_09_02_279521	283	25	functional	functional	JJ
10_1101-2020_09_02_279521	283	26	abilities	ability	NNS
10_1101-2020_09_02_279521	283	27	:	:	:
10_1101-2020_09_02_279521	283	28	ADAS11	adas11	NN
10_1101-2020_09_02_279521	283	29	,	,	,
10_1101-2020_09_02_279521	283	30	MMSE	MMSE	NNP
10_1101-2020_09_02_279521	283	31	,	,	,
10_1101-2020_09_02_279521	283	32	RAVLT	RAVLT	NNP
10_1101-2020_09_02_279521	283	33	immediate	immediate	JJ
10_1101-2020_09_02_279521	283	34	,	,	,
10_1101-2020_09_02_279521	283	35	RAVLT	RAVLT	NNP
10_1101-2020_09_02_279521	283	36	learning	learning	NN
10_1101-2020_09_02_279521	283	37	,	,	,
10_1101-2020_09_02_279521	283	38	RAVLT	RAVLT	NNP
10_1101-2020_09_02_279521	283	39	forgetting	forgetting	NN
10_1101-2020_09_02_279521	283	40	,	,	,
10_1101-2020_09_02_279521	283	41	FAQ	FAQ	NNP
10_1101-2020_09_02_279521	283	42	,	,	,
10_1101-2020_09_02_279521	283	43	and	and	CC
10_1101-2020_09_02_279521	283	44	CDRSB	CDRSB	NNP
10_1101-2020_09_02_279521	283	45	.	.	.
10_1101-2020_09_02_279521	284	1	The	the	DT
10_1101-2020_09_02_279521	284	2	choice	choice	NN
10_1101-2020_09_02_279521	284	3	of	of	IN
10_1101-2020_09_02_279521	284	4	these	these	DT
10_1101-2020_09_02_279521	284	5	particular	particular	JJ
10_1101-2020_09_02_279521	284	6	scores	score	NNS
10_1101-2020_09_02_279521	284	7	is	be	VBZ
10_1101-2020_09_02_279521	284	8	consistent	consistent	JJ
10_1101-2020_09_02_279521	284	9	with	with	IN
10_1101-2020_09_02_279521	284	10	previous	previous	JJ
10_1101-2020_09_02_279521	284	11	literature	literature	NN
10_1101-2020_09_02_279521	284	12	on	on	IN
10_1101-2020_09_02_279521	284	13	DPM	DPM	NNP
10_1101-2020_09_02_279521	284	14	(	(	-LRB-
10_1101-2020_09_02_279521	284	15	Donohue	Donohue	NNP
10_1101-2020_09_02_279521	284	16	et	et	NNP
10_1101-2020_09_02_279521	284	17	al	al	NNP
10_1101-2020_09_02_279521	284	18	.	.	NNP
10_1101-2020_09_02_279521	284	19	,	,	,
10_1101-2020_09_02_279521	284	20	2014	2014	CD
10_1101-2020_09_02_279521	284	21	;	;	:
10_1101-2020_09_02_279521	284	22	Lorenzi	Lorenzi	NNP
10_1101-2020_09_02_279521	284	23	et	et	NNP
10_1101-2020_09_02_279521	284	24	al	al	NNP
10_1101-2020_09_02_279521	284	25	.	.	NNP
10_1101-2020_09_02_279521	284	26	,	,	,
10_1101-2020_09_02_279521	284	27	2017	2017	CD
10_1101-2020_09_02_279521	284	28	)	)	-RRB-
10_1101-2020_09_02_279521	284	29	.	.	.
10_1101-2020_09_02_279521	285	1	However	however	RB
10_1101-2020_09_02_279521	285	2	,	,	,
10_1101-2020_09_02_279521	285	3	it	-PRON-	PRP
10_1101-2020_09_02_279521	285	4	is	be	VBZ
10_1101-2020_09_02_279521	285	5	important	important	JJ
10_1101-2020_09_02_279521	285	6	to	to	TO
10_1101-2020_09_02_279521	285	7	note	note	VB
10_1101-2020_09_02_279521	285	8	that	that	IN
10_1101-2020_09_02_279521	285	9	our	-PRON-	PRP$
10_1101-2020_09_02_279521	285	10	model	model	NN
10_1101-2020_09_02_279521	285	11	can	can	MD
10_1101-2020_09_02_279521	285	12	handle	handle	VB
10_1101-2020_09_02_279521	285	13	any	any	DT
10_1101-2020_09_02_279521	285	14	type	type	NN
10_1101-2020_09_02_279521	285	15	of	of	IN
10_1101-2020_09_02_279521	285	16	clinical	clinical	JJ
10_1101-2020_09_02_279521	285	17	assessment	assessment	NN
10_1101-2020_09_02_279521	285	18	.	.	.
10_1101-2020_09_02_279521	286	1	Therefore	therefore	RB
10_1101-2020_09_02_279521	286	2	,	,	,
10_1101-2020_09_02_279521	286	3	investigating	investigate	VBG
10_1101-2020_09_02_279521	286	4	the	the	DT
10_1101-2020_09_02_279521	286	5	effect	effect	NN
10_1101-2020_09_02_279521	286	6	of	of	IN
10_1101-2020_09_02_279521	286	7	adding	add	VBG
10_1101-2020_09_02_279521	286	8	supplementary	supplementary	JJ
10_1101-2020_09_02_279521	286	9	clinical	clinical	JJ
10_1101-2020_09_02_279521	286	10	scores	score	NNS
10_1101-2020_09_02_279521	286	11	on	on	IN
10_1101-2020_09_02_279521	286	12	the	the	DT
10_1101-2020_09_02_279521	286	13	model	model	NN
10_1101-2020_09_02_279521	286	14	’s	’s	POS
10_1101-2020_09_02_279521	286	15	findings	finding	NNS
10_1101-2020_09_02_279521	286	16	would	would	MD
10_1101-2020_09_02_279521	286	17	be	be	VB
10_1101-2020_09_02_279521	286	18	an	an	DT
10_1101-2020_09_02_279521	286	19	interesting	interesting	JJ
10_1101-2020_09_02_279521	286	20	future	future	JJ
10_1101-2020_09_02_279521	286	21	application	application	NN
10_1101-2020_09_02_279521	286	22	of	of	IN
10_1101-2020_09_02_279521	286	23	our	-PRON-	PRP$
10_1101-2020_09_02_279521	286	24	approach	approach	NN
10_1101-2020_09_02_279521	286	25	,	,	,
10_1101-2020_09_02_279521	286	26	and	and	CC
10_1101-2020_09_02_279521	286	27	could	could	MD
10_1101-2020_09_02_279521	286	28	be	be	VB
10_1101-2020_09_02_279521	286	29	done	do	VBN
10_1101-2020_09_02_279521	286	30	without	without	IN
10_1101-2020_09_02_279521	286	31	any	any	DT
10_1101-2020_09_02_279521	286	32	modification	modification	NN
10_1101-2020_09_02_279521	286	33	of	of	IN
10_1101-2020_09_02_279521	286	34	its	-PRON-	PRP$
10_1101-2020_09_02_279521	286	35	current	current	JJ
10_1101-2020_09_02_279521	286	36	formulation	formulation	NN
10_1101-2020_09_02_279521	286	37	.	.	.
10_1101-2020_09_02_279521	287	1	Finally	finally	RB
10_1101-2020_09_02_279521	287	2	,	,	,
10_1101-2020_09_02_279521	287	3	in	in	IN
10_1101-2020_09_02_279521	287	4	addition	addition	NN
10_1101-2020_09_02_279521	287	5	to	to	IN
10_1101-2020_09_02_279521	287	6	these	these	DT
10_1101-2020_09_02_279521	287	7	specific	specific	JJ
10_1101-2020_09_02_279521	287	8	characteristics	characteristic	NNS
10_1101-2020_09_02_279521	287	9	of	of	IN
10_1101-2020_09_02_279521	287	10	the	the	DT
10_1101-2020_09_02_279521	287	11	cohort	cohort	NN
10_1101-2020_09_02_279521	287	12	,	,	,
10_1101-2020_09_02_279521	287	13	there	there	EX
10_1101-2020_09_02_279521	287	14	exists	exist	VBZ
10_1101-2020_09_02_279521	287	15	additional	additional	JJ
10_1101-2020_09_02_279521	287	16	biases	bias	NNS
10_1101-2020_09_02_279521	287	17	impacting	impact	VBG
10_1101-2020_09_02_279521	287	18	the	the	DT
10_1101-2020_09_02_279521	287	19	model	model	NN
10_1101-2020_09_02_279521	287	20	estimation	estimation	NN
10_1101-2020_09_02_279521	287	21	.	.	.
10_1101-2020_09_02_279521	288	1	For	for	IN
10_1101-2020_09_02_279521	288	2	instance	instance	NN
10_1101-2020_09_02_279521	288	3	,	,	,
10_1101-2020_09_02_279521	288	4	the	the	DT
10_1101-2020_09_02_279521	288	5	fact	fact	NN
10_1101-2020_09_02_279521	288	6	that	that	IN
10_1101-2020_09_02_279521	288	7	gray	gray	JJ
10_1101-2020_09_02_279521	288	8	matter	matter	NN
10_1101-2020_09_02_279521	288	9	atrophy	atrophy	NN
10_1101-2020_09_02_279521	288	10	and	and	CC
10_1101-2020_09_02_279521	288	11	glucose	glucose	VB
10_1101-2020_09_02_279521	288	12	metabolism	metabolism	NN
10_1101-2020_09_02_279521	288	13	become	become	VBP
10_1101-2020_09_02_279521	288	14	abnormal	abnormal	JJ
10_1101-2020_09_02_279521	288	15	approximately	approximately	RB
10_1101-2020_09_02_279521	288	16	at	at	IN
10_1101-2020_09_02_279521	288	17	the	the	DT
10_1101-2020_09_02_279521	288	18	same	same	JJ
10_1101-2020_09_02_279521	288	19	time	time	NN
10_1101-2020_09_02_279521	288	20	in	in	IN
10_1101-2020_09_02_279521	288	21	Figure	figure	NN
10_1101-2020_09_02_279521	288	22	3	3	CD
10_1101-2020_09_02_279521	288	23	can	can	MD
10_1101-2020_09_02_279521	288	24	be	be	VB
10_1101-2020_09_02_279521	288	25	explained	explain	VBN
10_1101-2020_09_02_279521	288	26	by	by	IN
10_1101-2020_09_02_279521	288	27	the	the	DT
10_1101-2020_09_02_279521	288	28	high	high	JJ
10_1101-2020_09_02_279521	288	29	atrophy	atrophy	NN
10_1101-2020_09_02_279521	288	30	rate	rate	NN
10_1101-2020_09_02_279521	288	31	of	of	IN
10_1101-2020_09_02_279521	288	32	change	change	NN
10_1101-2020_09_02_279521	288	33	in	in	IN
10_1101-2020_09_02_279521	288	34	some	some	DT
10_1101-2020_09_02_279521	288	35	key	key	JJ
10_1101-2020_09_02_279521	288	36	regions	region	NNS
10_1101-2020_09_02_279521	288	37	in	in	IN
10_1101-2020_09_02_279521	288	38	normal	normal	JJ
10_1101-2020_09_02_279521	288	39	elders	elder	NNS
10_1101-2020_09_02_279521	288	40	,	,	,
10_1101-2020_09_02_279521	288	41	such	such	JJ
10_1101-2020_09_02_279521	288	42	as	as	IN
10_1101-2020_09_02_279521	288	43	in	in	IN
10_1101-2020_09_02_279521	288	44	the	the	DT
10_1101-2020_09_02_279521	288	45	hippocampus	hippocampus	NN
10_1101-2020_09_02_279521	288	46	,	,	,
10_1101-2020_09_02_279521	288	47	compared	compare	VBN
10_1101-2020_09_02_279521	288	48	to	to	IN
10_1101-2020_09_02_279521	288	49	the	the	DT
10_1101-2020_09_02_279521	288	50	rate	rate	NN
10_1101-2020_09_02_279521	288	51	of	of	IN
10_1101-2020_09_02_279521	288	52	change	change	NN
10_1101-2020_09_02_279521	288	53	of	of	IN
10_1101-2020_09_02_279521	288	54	FDG	FDG	NNP
10_1101-2020_09_02_279521	288	55	(	(	-LRB-
10_1101-2020_09_02_279521	288	56	see	see	VB
10_1101-2020_09_02_279521	288	57	Table	table	NN
10_1101-2020_09_02_279521	288	58	1	1	CD
10_1101-2020_09_02_279521	288	59	)	)	-RRB-
10_1101-2020_09_02_279521	288	60	.	.	.
10_1101-2020_09_02_279521	289	1	We	-PRON-	PRP
10_1101-2020_09_02_279521	289	2	note	note	VBP
10_1101-2020_09_02_279521	289	3	that	that	IN
10_1101-2020_09_02_279521	289	4	this	this	DT
10_1101-2020_09_02_279521	289	5	stronger	strong	JJR
10_1101-2020_09_02_279521	289	6	change	change	NN
10_1101-2020_09_02_279521	289	7	of	of	IN
10_1101-2020_09_02_279521	289	8	atrophy	atrophy	NN
10_1101-2020_09_02_279521	289	9	with	with	IN
10_1101-2020_09_02_279521	289	10	respect	respect	NN
10_1101-2020_09_02_279521	289	11	to	to	TO
10_1101-2020_09_02_279521	289	12	glucose	glucose	VB
10_1101-2020_09_02_279521	289	13	metabolism	metabolism	NN
10_1101-2020_09_02_279521	289	14	can	can	MD
10_1101-2020_09_02_279521	289	15	already	already	RB
10_1101-2020_09_02_279521	289	16	be	be	VB
10_1101-2020_09_02_279521	289	17	appreciated	appreciate	VBN
10_1101-2020_09_02_279521	289	18	in	in	IN
10_1101-2020_09_02_279521	289	19	the	the	DT
10_1101-2020_09_02_279521	289	20	clinically	clinically	RB
10_1101-2020_09_02_279521	289	21	healthy	healthy	JJ
10_1101-2020_09_02_279521	289	22	group	group	NN
10_1101-2020_09_02_279521	289	23	.	.	.
10_1101-2020_09_02_279521	290	1	Conclusion	conclusion	NN
10_1101-2020_09_02_279521	290	2	In	in	IN
10_1101-2020_09_02_279521	290	3	this	this	DT
10_1101-2020_09_02_279521	290	4	study	study	NN
10_1101-2020_09_02_279521	290	5	we	-PRON-	PRP
10_1101-2020_09_02_279521	290	6	investigated	investigate	VBD
10_1101-2020_09_02_279521	290	7	a	a	DT
10_1101-2020_09_02_279521	290	8	novel	novel	JJ
10_1101-2020_09_02_279521	290	9	quantitative	quantitative	JJ
10_1101-2020_09_02_279521	290	10	instrument	instrument	NN
10_1101-2020_09_02_279521	290	11	for	for	IN
10_1101-2020_09_02_279521	290	12	the	the	DT
10_1101-2020_09_02_279521	290	13	development	development	NN
10_1101-2020_09_02_279521	290	14	of	of	IN
10_1101-2020_09_02_279521	290	15	intervention	intervention	NN
10_1101-2020_09_02_279521	290	16	strategies	strategy	NNS
10_1101-2020_09_02_279521	290	17	for	for	IN
10_1101-2020_09_02_279521	290	18	disease	disease	NN
10_1101-2020_09_02_279521	290	19	modifying	modify	VBG
10_1101-2020_09_02_279521	290	20	drugs	drug	NNS
10_1101-2020_09_02_279521	290	21	in	in	IN
10_1101-2020_09_02_279521	290	22	AD	ad	NN
10_1101-2020_09_02_279521	290	23	.	.	.
10_1101-2020_09_02_279521	291	1	Our	-PRON-	PRP$
10_1101-2020_09_02_279521	291	2	framework	framework	NN
10_1101-2020_09_02_279521	291	3	enables	enable	VBZ
10_1101-2020_09_02_279521	291	4	the	the	DT
10_1101-2020_09_02_279521	291	5	simulation	simulation	NN
10_1101-2020_09_02_279521	291	6	of	of	IN
10_1101-2020_09_02_279521	291	7	the	the	DT
10_1101-2020_09_02_279521	291	8	effect	effect	NN
10_1101-2020_09_02_279521	291	9	of	of	IN
10_1101-2020_09_02_279521	291	10	intervention	intervention	NN
10_1101-2020_09_02_279521	291	11	time	time	NN
10_1101-2020_09_02_279521	291	12	and	and	CC
10_1101-2020_09_02_279521	291	13	drug	drug	NN
10_1101-2020_09_02_279521	291	14	dosage	dosage	NN
10_1101-2020_09_02_279521	291	15	on	on	IN
10_1101-2020_09_02_279521	291	16	the	the	DT
10_1101-2020_09_02_279521	291	17	evolution	evolution	NN
10_1101-2020_09_02_279521	291	18	of	of	IN
10_1101-2020_09_02_279521	291	19	imaging	imaging	NN
10_1101-2020_09_02_279521	291	20	and	and	CC
10_1101-2020_09_02_279521	291	21	clinical	clinical	JJ
10_1101-2020_09_02_279521	291	22	biomarkers	biomarker	NNS
10_1101-2020_09_02_279521	291	23	in	in	IN
10_1101-2020_09_02_279521	291	24	clinical	clinical	JJ
10_1101-2020_09_02_279521	291	25	trials	trial	NNS
10_1101-2020_09_02_279521	291	26	.	.	.
10_1101-2020_09_02_279521	292	1	The	the	DT
10_1101-2020_09_02_279521	292	2	proposed	propose	VBN
10_1101-2020_09_02_279521	292	3	data	data	NN
10_1101-2020_09_02_279521	292	4	-	-	HYPH
10_1101-2020_09_02_279521	292	5	driven	drive	VBN
10_1101-2020_09_02_279521	292	6	approach	approach	NN
10_1101-2020_09_02_279521	292	7	is	be	VBZ
10_1101-2020_09_02_279521	292	8	based	base	VBN
10_1101-2020_09_02_279521	292	9	on	on	IN
10_1101-2020_09_02_279521	292	10	the	the	DT
10_1101-2020_09_02_279521	292	11	modeling	modeling	NN
10_1101-2020_09_02_279521	292	12	of	of	IN
10_1101-2020_09_02_279521	292	13	the	the	DT
10_1101-2020_09_02_279521	292	14	spatio	spatio	NN
10_1101-2020_09_02_279521	292	15	-	-	HYPH
10_1101-2020_09_02_279521	292	16	temporal	temporal	JJ
10_1101-2020_09_02_279521	292	17	dynamics	dynamic	NNS
10_1101-2020_09_02_279521	292	18	governing	govern	VBG
10_1101-2020_09_02_279521	292	19	the	the	DT
10_1101-2020_09_02_279521	292	20	joint	joint	JJ
10_1101-2020_09_02_279521	292	21	evolution	evolution	NN
10_1101-2020_09_02_279521	292	22	of	of	IN
10_1101-2020_09_02_279521	292	23	imaging	imaging	NN
10_1101-2020_09_02_279521	292	24	and	and	CC
10_1101-2020_09_02_279521	292	25	clinical	clinical	JJ
10_1101-2020_09_02_279521	292	26	measurements	measurement	NNS
10_1101-2020_09_02_279521	292	27	throughout	throughout	IN
10_1101-2020_09_02_279521	292	28	the	the	DT
10_1101-2020_09_02_279521	292	29	disease	disease	NN
10_1101-2020_09_02_279521	292	30	.	.	.
10_1101-2020_09_02_279521	293	1	The	the	DT
10_1101-2020_09_02_279521	293	2	model	model	NN
10_1101-2020_09_02_279521	293	3	is	be	VBZ
10_1101-2020_09_02_279521	293	4	formulated	formulate	VBN
10_1101-2020_09_02_279521	293	5	within	within	IN
10_1101-2020_09_02_279521	293	6	a	a	DT
10_1101-2020_09_02_279521	293	7	Bayesian	bayesian	JJ
10_1101-2020_09_02_279521	293	8	framework	framework	NN
10_1101-2020_09_02_279521	293	9	,	,	,
10_1101-2020_09_02_279521	293	10	where	where	WRB
10_1101-2020_09_02_279521	293	11	the	the	DT
10_1101-2020_09_02_279521	293	12	latent	latent	NN
10_1101-2020_09_02_279521	293	13	representation	representation	NN
10_1101-2020_09_02_279521	293	14	and	and	CC
10_1101-2020_09_02_279521	293	15	dynamics	dynamic	NNS
10_1101-2020_09_02_279521	293	16	are	be	VBP
10_1101-2020_09_02_279521	293	17	efficiently	efficiently	RB
10_1101-2020_09_02_279521	293	18	estimated	estimate	VBN
10_1101-2020_09_02_279521	293	19	through	through	IN
10_1101-2020_09_02_279521	293	20	stochastic	stochastic	JJ
10_1101-2020_09_02_279521	293	21	variational	variational	JJ
10_1101-2020_09_02_279521	293	22	inference	inference	NN
10_1101-2020_09_02_279521	293	23	.	.	.
10_1101-2020_09_02_279521	294	1	To	to	TO
10_1101-2020_09_02_279521	294	2	generate	generate	VB
10_1101-2020_09_02_279521	294	3	hypothetical	hypothetical	JJ
10_1101-2020_09_02_279521	294	4	scenarios	scenario	NNS
10_1101-2020_09_02_279521	294	5	of	of	IN
10_1101-2020_09_02_279521	294	6	amyloid	amyloid	NN
10_1101-2020_09_02_279521	294	7	lowering	lower	VBG
10_1101-2020_09_02_279521	294	8	interventions	intervention	NNS
10_1101-2020_09_02_279521	294	9	,	,	,
10_1101-2020_09_02_279521	294	10	we	-PRON-	PRP
10_1101-2020_09_02_279521	294	11	applied	apply	VBD
10_1101-2020_09_02_279521	294	12	our	-PRON-	PRP$
10_1101-2020_09_02_279521	294	13	approach	approach	NN
10_1101-2020_09_02_279521	294	14	to	to	IN
10_1101-2020_09_02_279521	294	15	multi	multi	JJ
10_1101-2020_09_02_279521	294	16	-	-	JJ
10_1101-2020_09_02_279521	294	17	modal	modal	JJ
10_1101-2020_09_02_279521	294	18	imaging	imaging	NN
10_1101-2020_09_02_279521	294	19	and	and	CC
10_1101-2020_09_02_279521	294	20	clinical	clinical	JJ
10_1101-2020_09_02_279521	294	21	data	datum	NNS
10_1101-2020_09_02_279521	294	22	from	from	IN
10_1101-2020_09_02_279521	294	23	ADNI	ADNI	NNP
10_1101-2020_09_02_279521	294	24	.	.	.
10_1101-2020_09_02_279521	295	1	The	the	DT
10_1101-2020_09_02_279521	295	2	results	result	NNS
10_1101-2020_09_02_279521	295	3	quantify	quantify	VBP
10_1101-2020_09_02_279521	295	4	the	the	DT
10_1101-2020_09_02_279521	295	5	crucial	crucial	JJ
10_1101-2020_09_02_279521	295	6	role	role	NN
10_1101-2020_09_02_279521	295	7	of	of	IN
10_1101-2020_09_02_279521	295	8	intervention	intervention	NN
10_1101-2020_09_02_279521	295	9	time	time	NN
10_1101-2020_09_02_279521	295	10	,	,	,
10_1101-2020_09_02_279521	295	11	and	and	CC
10_1101-2020_09_02_279521	295	12	provide	provide	VB
10_1101-2020_09_02_279521	295	13	a	a	DT
10_1101-2020_09_02_279521	295	14	theoretical	theoretical	JJ
10_1101-2020_09_02_279521	295	15	justification	justification	NN
10_1101-2020_09_02_279521	295	16	for	for	IN
10_1101-2020_09_02_279521	295	17	testing	testing	NN
10_1101-2020_09_02_279521	295	18	amyloid	amyloid	NN
10_1101-2020_09_02_279521	295	19	modifying	modify	VBG
10_1101-2020_09_02_279521	295	20	drugs	drug	NNS
10_1101-2020_09_02_279521	295	21	in	in	IN
10_1101-2020_09_02_279521	295	22	the	the	DT
10_1101-2020_09_02_279521	295	23	pre	pre	JJ
10_1101-2020_09_02_279521	295	24	-	-	JJ
10_1101-2020_09_02_279521	295	25	clinical	clinical	JJ
10_1101-2020_09_02_279521	295	26	stage	stage	NN
10_1101-2020_09_02_279521	295	27	.	.	.
10_1101-2020_09_02_279521	296	1	Our	-PRON-	PRP$
10_1101-2020_09_02_279521	296	2	experimental	experimental	JJ
10_1101-2020_09_02_279521	296	3	simulations	simulation	NNS
10_1101-2020_09_02_279521	296	4	are	be	VBP
10_1101-2020_09_02_279521	296	5	compatible	compatible	JJ
10_1101-2020_09_02_279521	296	6	with	with	IN
10_1101-2020_09_02_279521	296	7	the	the	DT
10_1101-2020_09_02_279521	296	8	outcomes	outcome	NNS
10_1101-2020_09_02_279521	296	9	observed	observe	VBN
10_1101-2020_09_02_279521	296	10	in	in	IN
10_1101-2020_09_02_279521	296	11	past	past	JJ
10_1101-2020_09_02_279521	296	12	clinical	clinical	JJ
10_1101-2020_09_02_279521	296	13	trials	trial	NNS
10_1101-2020_09_02_279521	296	14	and	and	CC
10_1101-2020_09_02_279521	296	15	suggest	suggest	VBP
10_1101-2020_09_02_279521	296	16	that	that	IN
10_1101-2020_09_02_279521	296	17	anti	anti	JJ
10_1101-2020_09_02_279521	296	18	-	-	JJ
10_1101-2020_09_02_279521	296	19	amyloid	amyloid	JJ
10_1101-2020_09_02_279521	296	20	treatments	treatment	NNS
10_1101-2020_09_02_279521	296	21	should	should	MD
10_1101-2020_09_02_279521	296	22	be	be	VB
10_1101-2020_09_02_279521	296	23	administered	administer	VBN
10_1101-2020_09_02_279521	296	24	at	at	IN
10_1101-2020_09_02_279521	296	25	least	least	RBS
10_1101-2020_09_02_279521	296	26	7	7	CD
10_1101-2020_09_02_279521	296	27	years	year	NNS
10_1101-2020_09_02_279521	296	28	earlier	early	RBR
10_1101-2020_09_02_279521	296	29	than	than	IN
10_1101-2020_09_02_279521	296	30	what	what	WP
10_1101-2020_09_02_279521	296	31	is	be	VBZ
10_1101-2020_09_02_279521	296	32	currently	currently	RB
10_1101-2020_09_02_279521	296	33	being	be	VBG
10_1101-2020_09_02_279521	296	34	done	do	VBN
10_1101-2020_09_02_279521	296	35	in	in	IN
10_1101-2020_09_02_279521	296	36	order	order	NN
10_1101-2020_09_02_279521	296	37	to	to	TO
10_1101-2020_09_02_279521	296	38	obtain	obtain	VB
10_1101-2020_09_02_279521	296	39	statistically	statistically	RB
10_1101-2020_09_02_279521	296	40	powered	power	VBN
10_1101-2020_09_02_279521	296	41	improvement	improvement	NN
10_1101-2020_09_02_279521	296	42	of	of	IN
10_1101-2020_09_02_279521	296	43	clinical	clinical	JJ
10_1101-2020_09_02_279521	296	44	endpoints	endpoint	NNS
10_1101-2020_09_02_279521	296	45	.	.	.
10_1101-2020_09_02_279521	297	1	.CC	.CC	NFP
10_1101-2020_09_02_279521	297	2	-	-	:
10_1101-2020_09_02_279521	297	3	BY	by	IN
10_1101-2020_09_02_279521	297	4	4.0	4.0	CD
10_1101-2020_09_02_279521	297	5	International	international	JJ
10_1101-2020_09_02_279521	297	6	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	297	7	.	.	.
10_1101-2020_09_02_279521	298	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	298	2	is	be	VBZ
10_1101-2020_09_02_279521	298	3	made	make	VBN
10_1101-2020_09_02_279521	298	4	available	available	JJ
10_1101-2020_09_02_279521	298	5	under	under	IN
10_1101-2020_09_02_279521	298	6	a	a	DT
10_1101-2020_09_02_279521	298	7	preprint	preprint	NN
10_1101-2020_09_02_279521	298	8	(	(	-LRB-
10_1101-2020_09_02_279521	298	9	which	which	WDT
10_1101-2020_09_02_279521	298	10	was	be	VBD
10_1101-2020_09_02_279521	298	11	not	not	RB
10_1101-2020_09_02_279521	298	12	certified	certify	VBN
10_1101-2020_09_02_279521	298	13	by	by	IN
10_1101-2020_09_02_279521	298	14	peer	peer	NN
10_1101-2020_09_02_279521	298	15	review	review	NN
10_1101-2020_09_02_279521	298	16	)	)	-RRB-
10_1101-2020_09_02_279521	298	17	is	be	VBZ
10_1101-2020_09_02_279521	298	18	the	the	DT
10_1101-2020_09_02_279521	298	19	author	author	NN
10_1101-2020_09_02_279521	298	20	/	/	SYM
10_1101-2020_09_02_279521	298	21	funder	funder	NN
10_1101-2020_09_02_279521	298	22	,	,	,
10_1101-2020_09_02_279521	298	23	who	who	WP
10_1101-2020_09_02_279521	298	24	has	have	VBZ
10_1101-2020_09_02_279521	298	25	granted	grant	VBN
10_1101-2020_09_02_279521	298	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	298	27	a	a	DT
10_1101-2020_09_02_279521	298	28	license	license	NN
10_1101-2020_09_02_279521	298	29	to	to	TO
10_1101-2020_09_02_279521	298	30	display	display	VB
10_1101-2020_09_02_279521	298	31	the	the	DT
10_1101-2020_09_02_279521	298	32	preprint	preprint	NN
10_1101-2020_09_02_279521	298	33	in	in	IN
10_1101-2020_09_02_279521	298	34	The	the	DT
10_1101-2020_09_02_279521	298	35	copyright	copyright	NN
10_1101-2020_09_02_279521	298	36	holder	holder	NN
10_1101-2020_09_02_279521	298	37	for	for	IN
10_1101-2020_09_02_279521	298	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	298	39	version	version	NN
10_1101-2020_09_02_279521	298	40	posted	post	VBD
10_1101-2020_09_02_279521	298	41	February	February	NNP
10_1101-2020_09_02_279521	298	42	10	10	CD
10_1101-2020_09_02_279521	298	43	,	,	,
10_1101-2020_09_02_279521	298	44	2021	2021	CD
10_1101-2020_09_02_279521	298	45	.	.	.
10_1101-2020_09_02_279521	298	46	;	;	:
10_1101-2020_09_02_279521	298	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	298	48	:	:	:
10_1101-2020_09_02_279521	298	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	298	50	preprint	preprint	NN
10_1101-2020_09_02_279521	298	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	UH
10_1101-2020_09_02_279521	298	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	ADD
10_1101-2020_09_02_279521	298	53	Funding	Funding	NNP
10_1101-2020_09_02_279521	298	54	This	this	DT
10_1101-2020_09_02_279521	298	55	work	work	NN
10_1101-2020_09_02_279521	298	56	has	have	VBZ
10_1101-2020_09_02_279521	298	57	been	be	VBN
10_1101-2020_09_02_279521	298	58	supported	support	VBN
10_1101-2020_09_02_279521	298	59	by	by	IN
10_1101-2020_09_02_279521	298	60	the	the	DT
10_1101-2020_09_02_279521	298	61	French	french	JJ
10_1101-2020_09_02_279521	298	62	government	government	NN
10_1101-2020_09_02_279521	298	63	,	,	,
10_1101-2020_09_02_279521	298	64	through	through	IN
10_1101-2020_09_02_279521	298	65	the	the	DT
10_1101-2020_09_02_279521	298	66	UCAJEDI	UCAJEDI	NNP
10_1101-2020_09_02_279521	298	67	and	and	CC
10_1101-2020_09_02_279521	298	68	3IA	3IA	NNP
10_1101-2020_09_02_279521	298	69	Côte	Côte	NNP
10_1101-2020_09_02_279521	298	70	d'Azur	d'Azur	NNP
10_1101-2020_09_02_279521	298	71	Investments	Investments	NNPS
10_1101-2020_09_02_279521	298	72	in	in	IN
10_1101-2020_09_02_279521	298	73	the	the	DT
10_1101-2020_09_02_279521	298	74	Future	future	JJ
10_1101-2020_09_02_279521	298	75	project	project	NN
10_1101-2020_09_02_279521	298	76	managed	manage	VBN
10_1101-2020_09_02_279521	298	77	by	by	IN
10_1101-2020_09_02_279521	298	78	the	the	DT
10_1101-2020_09_02_279521	298	79	National	National	NNP
10_1101-2020_09_02_279521	298	80	Research	Research	NNP
10_1101-2020_09_02_279521	298	81	Agency	Agency	NNP
10_1101-2020_09_02_279521	298	82	(	(	-LRB-
10_1101-2020_09_02_279521	298	83	ref.n	ref.n	NNP
10_1101-2020_09_02_279521	298	84	ANR-15-IDEX-01	ANR-15-IDEX-01	NNP
10_1101-2020_09_02_279521	298	85	and	and	CC
10_1101-2020_09_02_279521	298	86	ANR-19-P3IA-0002	ANR-19-P3IA-0002	NNP
10_1101-2020_09_02_279521	298	87	)	)	-RRB-
10_1101-2020_09_02_279521	298	88	,	,	,
10_1101-2020_09_02_279521	298	89	the	the	DT
10_1101-2020_09_02_279521	298	90	grant	grant	NN
10_1101-2020_09_02_279521	298	91	AAP	AAP	NNP
10_1101-2020_09_02_279521	298	92	Santé	Santé	NNP
10_1101-2020_09_02_279521	298	93	06	06	CD
10_1101-2020_09_02_279521	298	94	2017	2017	CD
10_1101-2020_09_02_279521	298	95	-	-	SYM
10_1101-2020_09_02_279521	298	96	260	260	CD
10_1101-2020_09_02_279521	298	97	DGA	DGA	NNP
10_1101-2020_09_02_279521	298	98	-	-	HYPH
10_1101-2020_09_02_279521	298	99	DSH	DSH	NNP
10_1101-2020_09_02_279521	298	100	,	,	,
10_1101-2020_09_02_279521	298	101	and	and	CC
10_1101-2020_09_02_279521	298	102	by	by	IN
10_1101-2020_09_02_279521	298	103	the	the	DT
10_1101-2020_09_02_279521	298	104	INRIA	INRIA	NNP
10_1101-2020_09_02_279521	298	105	Sophia	Sophia	NNP
10_1101-2020_09_02_279521	298	106	-	-	HYPH
10_1101-2020_09_02_279521	298	107	Antipolis	Antipolis	NNP
10_1101-2020_09_02_279521	298	108	-	-	HYPH
10_1101-2020_09_02_279521	298	109	Méditerranée	Méditerranée	NNP
10_1101-2020_09_02_279521	298	110	,	,	,
10_1101-2020_09_02_279521	298	111	"	"	''
10_1101-2020_09_02_279521	298	112	NEF	NEF	NNP
10_1101-2020_09_02_279521	298	113	"	"	''
10_1101-2020_09_02_279521	298	114	computation	computation	NN
10_1101-2020_09_02_279521	298	115	cluster	cluster	NN
10_1101-2020_09_02_279521	298	116	.	.	.
10_1101-2020_09_02_279521	299	1	Acknowledgements	Acknowledgements	NNP
10_1101-2020_09_02_279521	299	2	Data	Data	NNP
10_1101-2020_09_02_279521	299	3	collection	collection	NN
10_1101-2020_09_02_279521	299	4	and	and	CC
10_1101-2020_09_02_279521	299	5	sharing	share	VBG
10_1101-2020_09_02_279521	299	6	for	for	IN
10_1101-2020_09_02_279521	299	7	this	this	DT
10_1101-2020_09_02_279521	299	8	project	project	NN
10_1101-2020_09_02_279521	299	9	was	be	VBD
10_1101-2020_09_02_279521	299	10	funded	fund	VBN
10_1101-2020_09_02_279521	299	11	by	by	IN
10_1101-2020_09_02_279521	299	12	the	the	DT
10_1101-2020_09_02_279521	299	13	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	299	14	's	's	POS
10_1101-2020_09_02_279521	299	15	Disease	Disease	NNP
10_1101-2020_09_02_279521	299	16	Neuroimaging	Neuroimaging	NNP
10_1101-2020_09_02_279521	299	17	Initiative	Initiative	NNP
10_1101-2020_09_02_279521	299	18	(	(	-LRB-
10_1101-2020_09_02_279521	299	19	ADNI	ADNI	NNP
10_1101-2020_09_02_279521	299	20	)	)	-RRB-
10_1101-2020_09_02_279521	299	21	and	and	CC
10_1101-2020_09_02_279521	299	22	DOD	DOD	NNP
10_1101-2020_09_02_279521	299	23	ADNI	ADNI	NNP
10_1101-2020_09_02_279521	299	24	.	.	.
10_1101-2020_09_02_279521	300	1	ADNI	ADNI	NNP
10_1101-2020_09_02_279521	300	2	is	be	VBZ
10_1101-2020_09_02_279521	300	3	funded	fund	VBN
10_1101-2020_09_02_279521	300	4	by	by	IN
10_1101-2020_09_02_279521	300	5	the	the	DT
10_1101-2020_09_02_279521	300	6	National	National	NNP
10_1101-2020_09_02_279521	300	7	Institute	Institute	NNP
10_1101-2020_09_02_279521	300	8	on	on	IN
10_1101-2020_09_02_279521	300	9	Aging	Aging	NNP
10_1101-2020_09_02_279521	300	10	,	,	,
10_1101-2020_09_02_279521	300	11	the	the	DT
10_1101-2020_09_02_279521	300	12	National	National	NNP
10_1101-2020_09_02_279521	300	13	Institute	Institute	NNP
10_1101-2020_09_02_279521	300	14	of	of	IN
10_1101-2020_09_02_279521	300	15	Biomedical	Biomedical	NNP
10_1101-2020_09_02_279521	300	16	Imaging	Imaging	NNP
10_1101-2020_09_02_279521	300	17	and	and	CC
10_1101-2020_09_02_279521	300	18	Bioengineering	Bioengineering	NNP
10_1101-2020_09_02_279521	300	19	,	,	,
10_1101-2020_09_02_279521	300	20	and	and	CC
10_1101-2020_09_02_279521	300	21	through	through	IN
10_1101-2020_09_02_279521	300	22	generous	generous	JJ
10_1101-2020_09_02_279521	300	23	contributions	contribution	NNS
10_1101-2020_09_02_279521	300	24	from	from	IN
10_1101-2020_09_02_279521	300	25	the	the	DT
10_1101-2020_09_02_279521	300	26	following	follow	VBG
10_1101-2020_09_02_279521	300	27	:	:	:
10_1101-2020_09_02_279521	300	28	AbbVie	AbbVie	NNP
10_1101-2020_09_02_279521	300	29	,	,	,
10_1101-2020_09_02_279521	300	30	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	300	31	’s	’s	POS
10_1101-2020_09_02_279521	300	32	Association	Association	NNP
10_1101-2020_09_02_279521	300	33	;	;	:
10_1101-2020_09_02_279521	300	34	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	300	35	’s	’s	POS
10_1101-2020_09_02_279521	300	36	Drug	Drug	NNP
10_1101-2020_09_02_279521	300	37	Discovery	Discovery	NNP
10_1101-2020_09_02_279521	300	38	Foundation	Foundation	NNP
10_1101-2020_09_02_279521	300	39	;	;	:
10_1101-2020_09_02_279521	300	40	Araclon	Araclon	NNP
10_1101-2020_09_02_279521	300	41	Biotech	Biotech	NNP
10_1101-2020_09_02_279521	300	42	;	;	:
10_1101-2020_09_02_279521	300	43	BioClinica	BioClinica	NNP
10_1101-2020_09_02_279521	300	44	,	,	,
10_1101-2020_09_02_279521	300	45	Inc.	Inc.	NNP
10_1101-2020_09_02_279521	300	46	;	;	:
10_1101-2020_09_02_279521	300	47	Biogen	Biogen	NNP
10_1101-2020_09_02_279521	300	48	;	;	:
10_1101-2020_09_02_279521	300	49	Bristol	Bristol	NNP
10_1101-2020_09_02_279521	300	50	-	-	HYPH
10_1101-2020_09_02_279521	300	51	Myers	Myers	NNP
10_1101-2020_09_02_279521	300	52	Squibb	Squibb	NNP
10_1101-2020_09_02_279521	300	53	Company;CereSpir	Company;CereSpir	NNP
10_1101-2020_09_02_279521	300	54	,	,	,
10_1101-2020_09_02_279521	300	55	Inc.;Cogstate;Eisai	Inc.;Cogstate;Eisai	NNP
10_1101-2020_09_02_279521	300	56	Inc.	Inc.	NNP
10_1101-2020_09_02_279521	300	57	;	;	:
10_1101-2020_09_02_279521	300	58	Elan	Elan	NNP
10_1101-2020_09_02_279521	300	59	Pharmaceuticals	Pharmaceuticals	NNP
10_1101-2020_09_02_279521	300	60	,	,	,
10_1101-2020_09_02_279521	300	61	Inc.	Inc.	NNP
10_1101-2020_09_02_279521	300	62	;	;	:
10_1101-2020_09_02_279521	300	63	Eli	Eli	NNP
10_1101-2020_09_02_279521	300	64	Lilly	Lilly	NNP
10_1101-2020_09_02_279521	300	65	and	and	CC
10_1101-2020_09_02_279521	300	66	Company	Company	NNP
10_1101-2020_09_02_279521	300	67	;	;	:
10_1101-2020_09_02_279521	300	68	EuroImmun	EuroImmun	NNP
10_1101-2020_09_02_279521	300	69	;	;	:
10_1101-2020_09_02_279521	300	70	F.	F.	NNP
10_1101-2020_09_02_279521	300	71	Hoffmann	Hoffmann	NNP
10_1101-2020_09_02_279521	300	72	-	-	HYPH
10_1101-2020_09_02_279521	300	73	La	La	NNP
10_1101-2020_09_02_279521	300	74	Roche	Roche	NNP
10_1101-2020_09_02_279521	300	75	Ltd	Ltd	NNP
10_1101-2020_09_02_279521	300	76	and	and	CC
10_1101-2020_09_02_279521	300	77	its	-PRON-	PRP$
10_1101-2020_09_02_279521	300	78	affiliated	affiliated	JJ
10_1101-2020_09_02_279521	300	79	company	company	NN
10_1101-2020_09_02_279521	300	80	Genentech	Genentech	NNP
10_1101-2020_09_02_279521	300	81	,	,	,
10_1101-2020_09_02_279521	300	82	Inc.	Inc.	NNP
10_1101-2020_09_02_279521	300	83	;	;	:
10_1101-2020_09_02_279521	300	84	Fujirebio	Fujirebio	NNP
10_1101-2020_09_02_279521	300	85	;	;	:
10_1101-2020_09_02_279521	300	86	GE	GE	NNP
10_1101-2020_09_02_279521	300	87	Healthcare	Healthcare	NNP
10_1101-2020_09_02_279521	300	88	;	;	:
10_1101-2020_09_02_279521	300	89	IXICO	IXICO	NNP
10_1101-2020_09_02_279521	300	90	Ltd.	Ltd.	NNP
10_1101-2020_09_02_279521	300	91	;	;	:
10_1101-2020_09_02_279521	300	92	Janssen	Janssen	NNP
10_1101-2020_09_02_279521	300	93	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	300	94	Immunotherapy	Immunotherapy	NNP
10_1101-2020_09_02_279521	300	95	Research	Research	NNP
10_1101-2020_09_02_279521	300	96	&	&	CC
10_1101-2020_09_02_279521	300	97	Development	Development	NNP
10_1101-2020_09_02_279521	300	98	,	,	,
10_1101-2020_09_02_279521	300	99	LLC	LLC	NNP
10_1101-2020_09_02_279521	300	100	.	.	.
10_1101-2020_09_02_279521	301	1	;	;	:
10_1101-2020_09_02_279521	301	2	Johnson\	Johnson\	NNP
10_1101-2020_09_02_279521	301	3	&	&	CC
10_1101-2020_09_02_279521	301	4	Johnson	Johnson	NNP
10_1101-2020_09_02_279521	301	5	Pharmaceutical	Pharmaceutical	NNP
10_1101-2020_09_02_279521	301	6	Research	Research	NNP
10_1101-2020_09_02_279521	301	7	&	&	CC
10_1101-2020_09_02_279521	301	8	Development	Development	NNP
10_1101-2020_09_02_279521	301	9	LLC	LLC	NNP
10_1101-2020_09_02_279521	301	10	.	.	.
10_1101-2020_09_02_279521	302	1	;	;	:
10_1101-2020_09_02_279521	302	2	Lumosity;Lundbeck;Merck	Lumosity;Lundbeck;Merck	NNP
10_1101-2020_09_02_279521	302	3	&	&	CC
10_1101-2020_09_02_279521	302	4	Co.	Co.	NNP
10_1101-2020_09_02_279521	302	5	,	,	,
10_1101-2020_09_02_279521	302	6	Inc.	Inc.	NNP
10_1101-2020_09_02_279521	302	7	;	;	:
10_1101-2020_09_02_279521	302	8	Meso	Meso	NNP
10_1101-2020_09_02_279521	302	9	Scale	Scale	NNP
10_1101-2020_09_02_279521	302	10	Diagnostics	Diagnostics	NNPS
10_1101-2020_09_02_279521	302	11	,	,	,
10_1101-2020_09_02_279521	302	12	LLC	LLC	NNP
10_1101-2020_09_02_279521	302	13	.	.	.
10_1101-2020_09_02_279521	303	1	;	;	:
10_1101-2020_09_02_279521	303	2	NeuroRx	NeuroRx	NNP
10_1101-2020_09_02_279521	303	3	Research	Research	NNP
10_1101-2020_09_02_279521	303	4	;	;	:
10_1101-2020_09_02_279521	303	5	Neurotrack	Neurotrack	NNP
10_1101-2020_09_02_279521	303	6	Technologies;Novartis	Technologies;Novartis	NNP
10_1101-2020_09_02_279521	303	7	Pharmaceuticals	Pharmaceuticals	NNP
10_1101-2020_09_02_279521	303	8	Corporation	Corporation	NNP
10_1101-2020_09_02_279521	303	9	;	;	:
10_1101-2020_09_02_279521	303	10	Pfizer	Pfizer	NNP
10_1101-2020_09_02_279521	303	11	Inc.	Inc.	NNP
10_1101-2020_09_02_279521	303	12	;	;	:
10_1101-2020_09_02_279521	303	13	Piramal	Piramal	NNP
10_1101-2020_09_02_279521	303	14	Imaging;Servier	Imaging;Servier	NNP
10_1101-2020_09_02_279521	303	15	;	;	:
10_1101-2020_09_02_279521	303	16	Takeda	Takeda	NNP
10_1101-2020_09_02_279521	303	17	Pharmaceutical	Pharmaceutical	NNP
10_1101-2020_09_02_279521	303	18	Company	Company	NNP
10_1101-2020_09_02_279521	303	19	;	;	:
10_1101-2020_09_02_279521	303	20	and	and	CC
10_1101-2020_09_02_279521	303	21	Transition	Transition	NNP
10_1101-2020_09_02_279521	303	22	Therapeutics	Therapeutics	NNP
10_1101-2020_09_02_279521	303	23	.	.	.
10_1101-2020_09_02_279521	303	24	The	the	DT
10_1101-2020_09_02_279521	303	25	Canadian	canadian	JJ
10_1101-2020_09_02_279521	303	26	Institutes	Institutes	NNPS
10_1101-2020_09_02_279521	303	27	of	of	IN
10_1101-2020_09_02_279521	303	28	Health	Health	NNP
10_1101-2020_09_02_279521	303	29	Research	Research	NNP
10_1101-2020_09_02_279521	303	30	is	be	VBZ
10_1101-2020_09_02_279521	303	31	providing	provide	VBG
10_1101-2020_09_02_279521	303	32	funds	fund	NNS
10_1101-2020_09_02_279521	303	33	to	to	TO
10_1101-2020_09_02_279521	303	34	support	support	VB
10_1101-2020_09_02_279521	303	35	ADNI	ADNI	NNP
10_1101-2020_09_02_279521	303	36	clinical	clinical	JJ
10_1101-2020_09_02_279521	303	37	sites	site	NNS
10_1101-2020_09_02_279521	303	38	in	in	IN
10_1101-2020_09_02_279521	303	39	Canada	Canada	NNP
10_1101-2020_09_02_279521	303	40	.	.	.
10_1101-2020_09_02_279521	304	1	Private	private	JJ
10_1101-2020_09_02_279521	304	2	sector	sector	NN
10_1101-2020_09_02_279521	304	3	contributions	contribution	NNS
10_1101-2020_09_02_279521	304	4	are	be	VBP
10_1101-2020_09_02_279521	304	5	facilitated	facilitate	VBN
10_1101-2020_09_02_279521	304	6	by	by	IN
10_1101-2020_09_02_279521	304	7	the	the	DT
10_1101-2020_09_02_279521	304	8	Foundation	Foundation	NNP
10_1101-2020_09_02_279521	304	9	for	for	IN
10_1101-2020_09_02_279521	304	10	the	the	DT
10_1101-2020_09_02_279521	304	11	National	National	NNP
10_1101-2020_09_02_279521	304	12	Institutes	Institutes	NNPS
10_1101-2020_09_02_279521	304	13	of	of	IN
10_1101-2020_09_02_279521	304	14	Health	Health	NNP
10_1101-2020_09_02_279521	304	15	(	(	-LRB-
10_1101-2020_09_02_279521	304	16	www.fnih.org	www.fnih.org	NNP
10_1101-2020_09_02_279521	304	17	)	)	-RRB-
10_1101-2020_09_02_279521	304	18	.	.	.
10_1101-2020_09_02_279521	305	1	The	the	DT
10_1101-2020_09_02_279521	305	2	grantee	grantee	NN
10_1101-2020_09_02_279521	305	3	organization	organization	NN
10_1101-2020_09_02_279521	305	4	is	be	VBZ
10_1101-2020_09_02_279521	305	5	the	the	DT
10_1101-2020_09_02_279521	305	6	Northern	Northern	NNP
10_1101-2020_09_02_279521	305	7	California	California	NNP
10_1101-2020_09_02_279521	305	8	Institute	Institute	NNP
10_1101-2020_09_02_279521	305	9	for	for	IN
10_1101-2020_09_02_279521	305	10	Research	Research	NNP
10_1101-2020_09_02_279521	305	11	and	and	CC
10_1101-2020_09_02_279521	305	12	Education	Education	NNP
10_1101-2020_09_02_279521	305	13	,	,	,
10_1101-2020_09_02_279521	305	14	and	and	CC
10_1101-2020_09_02_279521	305	15	the	the	DT
10_1101-2020_09_02_279521	305	16	study	study	NN
10_1101-2020_09_02_279521	305	17	is	be	VBZ
10_1101-2020_09_02_279521	305	18	coordinated	coordinate	VBN
10_1101-2020_09_02_279521	305	19	by	by	IN
10_1101-2020_09_02_279521	305	20	the	the	DT
10_1101-2020_09_02_279521	305	21	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	305	22	’s	’s	POS
10_1101-2020_09_02_279521	305	23	Therapeutic	Therapeutic	NNP
10_1101-2020_09_02_279521	305	24	Research	Research	NNP
10_1101-2020_09_02_279521	305	25	Institute	Institute	NNP
10_1101-2020_09_02_279521	305	26	at	at	IN
10_1101-2020_09_02_279521	305	27	the	the	DT
10_1101-2020_09_02_279521	305	28	University	University	NNP
10_1101-2020_09_02_279521	305	29	of	of	IN
10_1101-2020_09_02_279521	305	30	Southern	Southern	NNP
10_1101-2020_09_02_279521	305	31	California	California	NNP
10_1101-2020_09_02_279521	305	32	.	.	.
10_1101-2020_09_02_279521	306	1	ADNI	ADNI	NNP
10_1101-2020_09_02_279521	306	2	data	datum	NNS
10_1101-2020_09_02_279521	306	3	are	be	VBP
10_1101-2020_09_02_279521	306	4	disseminated	disseminate	VBN
10_1101-2020_09_02_279521	306	5	by	by	IN
10_1101-2020_09_02_279521	306	6	the	the	DT
10_1101-2020_09_02_279521	306	7	Laboratory	Laboratory	NNP
10_1101-2020_09_02_279521	306	8	for	for	IN
10_1101-2020_09_02_279521	306	9	Neuro	Neuro	NNP
10_1101-2020_09_02_279521	306	10	Imaging	Imaging	NNP
10_1101-2020_09_02_279521	306	11	at	at	IN
10_1101-2020_09_02_279521	306	12	the	the	DT
10_1101-2020_09_02_279521	306	13	University	University	NNP
10_1101-2020_09_02_279521	306	14	of	of	IN
10_1101-2020_09_02_279521	306	15	Southern	Southern	NNP
10_1101-2020_09_02_279521	306	16	California	California	NNP
10_1101-2020_09_02_279521	306	17	.	.	.
10_1101-2020_09_02_279521	307	1	Competing	compete	VBG
10_1101-2020_09_02_279521	307	2	interests	interest	NNS
10_1101-2020_09_02_279521	307	3	The	the	DT
10_1101-2020_09_02_279521	307	4	authors	author	NNS
10_1101-2020_09_02_279521	307	5	declare	declare	VBP
10_1101-2020_09_02_279521	307	6	no	no	DT
10_1101-2020_09_02_279521	307	7	competing	compete	VBG
10_1101-2020_09_02_279521	307	8	interests	interest	NNS
10_1101-2020_09_02_279521	307	9	.	.	.
10_1101-2020_09_02_279521	308	1	.CC	.CC	NFP
10_1101-2020_09_02_279521	308	2	-	-	:
10_1101-2020_09_02_279521	308	3	BY	by	IN
10_1101-2020_09_02_279521	308	4	4.0	4.0	CD
10_1101-2020_09_02_279521	308	5	International	international	JJ
10_1101-2020_09_02_279521	308	6	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	308	7	.	.	.
10_1101-2020_09_02_279521	309	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	309	2	is	be	VBZ
10_1101-2020_09_02_279521	309	3	made	make	VBN
10_1101-2020_09_02_279521	309	4	available	available	JJ
10_1101-2020_09_02_279521	309	5	under	under	IN
10_1101-2020_09_02_279521	309	6	a	a	DT
10_1101-2020_09_02_279521	309	7	preprint	preprint	NN
10_1101-2020_09_02_279521	309	8	(	(	-LRB-
10_1101-2020_09_02_279521	309	9	which	which	WDT
10_1101-2020_09_02_279521	309	10	was	be	VBD
10_1101-2020_09_02_279521	309	11	not	not	RB
10_1101-2020_09_02_279521	309	12	certified	certify	VBN
10_1101-2020_09_02_279521	309	13	by	by	IN
10_1101-2020_09_02_279521	309	14	peer	peer	NN
10_1101-2020_09_02_279521	309	15	review	review	NN
10_1101-2020_09_02_279521	309	16	)	)	-RRB-
10_1101-2020_09_02_279521	309	17	is	be	VBZ
10_1101-2020_09_02_279521	309	18	the	the	DT
10_1101-2020_09_02_279521	309	19	author	author	NN
10_1101-2020_09_02_279521	309	20	/	/	SYM
10_1101-2020_09_02_279521	309	21	funder	funder	NN
10_1101-2020_09_02_279521	309	22	,	,	,
10_1101-2020_09_02_279521	309	23	who	who	WP
10_1101-2020_09_02_279521	309	24	has	have	VBZ
10_1101-2020_09_02_279521	309	25	granted	grant	VBN
10_1101-2020_09_02_279521	309	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	309	27	a	a	DT
10_1101-2020_09_02_279521	309	28	license	license	NN
10_1101-2020_09_02_279521	309	29	to	to	TO
10_1101-2020_09_02_279521	309	30	display	display	VB
10_1101-2020_09_02_279521	309	31	the	the	DT
10_1101-2020_09_02_279521	309	32	preprint	preprint	NN
10_1101-2020_09_02_279521	309	33	in	in	IN
10_1101-2020_09_02_279521	309	34	The	the	DT
10_1101-2020_09_02_279521	309	35	copyright	copyright	NN
10_1101-2020_09_02_279521	309	36	holder	holder	NN
10_1101-2020_09_02_279521	309	37	for	for	IN
10_1101-2020_09_02_279521	309	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	309	39	version	version	NN
10_1101-2020_09_02_279521	309	40	posted	post	VBD
10_1101-2020_09_02_279521	309	41	February	February	NNP
10_1101-2020_09_02_279521	309	42	10	10	CD
10_1101-2020_09_02_279521	309	43	,	,	,
10_1101-2020_09_02_279521	309	44	2021	2021	CD
10_1101-2020_09_02_279521	309	45	.	.	.
10_1101-2020_09_02_279521	309	46	;	;	:
10_1101-2020_09_02_279521	309	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	309	48	:	:	:
10_1101-2020_09_02_279521	309	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	309	50	preprint	preprint	NN
10_1101-2020_09_02_279521	309	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	NN
10_1101-2020_09_02_279521	309	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	-LRB-
10_1101-2020_09_02_279521	309	53	References	References	NNP
10_1101-2020_09_02_279521	309	54	Aisen	Aisen	NNP
10_1101-2020_09_02_279521	309	55	,	,	,
10_1101-2020_09_02_279521	309	56	P.	P.	NNP
10_1101-2020_09_02_279521	309	57	S.	S.	NNP
10_1101-2020_09_02_279521	309	58	,	,	,
10_1101-2020_09_02_279521	309	59	Siemers	Siemers	NNP
10_1101-2020_09_02_279521	309	60	,	,	,
10_1101-2020_09_02_279521	309	61	E.	E.	NNP
10_1101-2020_09_02_279521	309	62	,	,	,
10_1101-2020_09_02_279521	309	63	Michelson	Michelson	NNP
10_1101-2020_09_02_279521	309	64	,	,	,
10_1101-2020_09_02_279521	309	65	D.	D.	NNP
10_1101-2020_09_02_279521	309	66	,	,	,
10_1101-2020_09_02_279521	309	67	Salloway	Salloway	NNP
10_1101-2020_09_02_279521	309	68	,	,	,
10_1101-2020_09_02_279521	309	69	S.	S.	NNP
10_1101-2020_09_02_279521	309	70	,	,	,
10_1101-2020_09_02_279521	309	71	Sampaio	Sampaio	NNP
10_1101-2020_09_02_279521	309	72	,	,	,
10_1101-2020_09_02_279521	309	73	C.	C.	NNP
10_1101-2020_09_02_279521	309	74	,	,	,
10_1101-2020_09_02_279521	309	75	Carrillo	Carrillo	NNP
10_1101-2020_09_02_279521	309	76	,	,	,
10_1101-2020_09_02_279521	309	77	M.	M.	NNP
10_1101-2020_09_02_279521	309	78	C.	C.	NNP
10_1101-2020_09_02_279521	309	79	,	,	,
10_1101-2020_09_02_279521	309	80	Sperling	Sperling	NNP
10_1101-2020_09_02_279521	309	81	,	,	,
10_1101-2020_09_02_279521	309	82	R.	R.	NNP
10_1101-2020_09_02_279521	309	83	,	,	,
10_1101-2020_09_02_279521	309	84	Doody	Doody	NNP
10_1101-2020_09_02_279521	309	85	,	,	,
10_1101-2020_09_02_279521	309	86	R.	R.	NNP
10_1101-2020_09_02_279521	309	87	,	,	,
10_1101-2020_09_02_279521	309	88	Scheltens	Scheltens	NNP
10_1101-2020_09_02_279521	309	89	,	,	,
10_1101-2020_09_02_279521	309	90	P.	P.	NNP
10_1101-2020_09_02_279521	309	91	,	,	,
10_1101-2020_09_02_279521	309	92	Bateman	Bateman	NNP
10_1101-2020_09_02_279521	309	93	,	,	,
10_1101-2020_09_02_279521	309	94	R.	R.	NNP
10_1101-2020_09_02_279521	309	95	,	,	,
10_1101-2020_09_02_279521	309	96	Weiner	Weiner	NNP
10_1101-2020_09_02_279521	309	97	,	,	,
10_1101-2020_09_02_279521	309	98	M.	M.	NNP
10_1101-2020_09_02_279521	309	99	,	,	,
10_1101-2020_09_02_279521	309	100	&	&	CC
10_1101-2020_09_02_279521	309	101	Vellas	Vellas	NNP
10_1101-2020_09_02_279521	309	102	,	,	,
10_1101-2020_09_02_279521	309	103	B.	B.	NNP
10_1101-2020_09_02_279521	310	1	(	(	-LRB-
10_1101-2020_09_02_279521	310	2	2018	2018	CD
10_1101-2020_09_02_279521	310	3	)	)	-RRB-
10_1101-2020_09_02_279521	310	4	.	.	.
10_1101-2020_09_02_279521	311	1	What	what	WP
10_1101-2020_09_02_279521	311	2	Have	have	VBP
10_1101-2020_09_02_279521	311	3	We	-PRON-	PRP
10_1101-2020_09_02_279521	311	4	Learned	learn	VBN
10_1101-2020_09_02_279521	311	5	from	from	IN
10_1101-2020_09_02_279521	311	6	Expedition	Expedition	NNP
10_1101-2020_09_02_279521	311	7	III	III	NNP
10_1101-2020_09_02_279521	311	8	and	and	CC
10_1101-2020_09_02_279521	311	9	EPOCH	epoch	NN
10_1101-2020_09_02_279521	311	10	Trials	trial	NNS
10_1101-2020_09_02_279521	311	11	?	?	.
10_1101-2020_09_02_279521	312	1	Perspective	perspective	NN
10_1101-2020_09_02_279521	312	2	of	of	IN
10_1101-2020_09_02_279521	312	3	the	the	DT
10_1101-2020_09_02_279521	312	4	CTAD	CTAD	NNP
10_1101-2020_09_02_279521	312	5	Task	Task	NNP
10_1101-2020_09_02_279521	312	6	Force	Force	NNP
10_1101-2020_09_02_279521	312	7	.	.	.
10_1101-2020_09_02_279521	313	1	J	J	NNP
10_1101-2020_09_02_279521	313	2	Prev	Prev	NNP
10_1101-2020_09_02_279521	313	3	Alzheimers	Alzheimers	NNPS
10_1101-2020_09_02_279521	313	4	Dis	Dis	NNP
10_1101-2020_09_02_279521	313	5	,	,	,
10_1101-2020_09_02_279521	313	6	5(3	5(3	NNP
10_1101-2020_09_02_279521	313	7	)	)	-RRB-
10_1101-2020_09_02_279521	313	8	,	,	,
10_1101-2020_09_02_279521	313	9	171–174	171–174	CD
10_1101-2020_09_02_279521	313	10	.	.	.
10_1101-2020_09_02_279521	314	1	Akaike	Akaike	NNP
10_1101-2020_09_02_279521	314	2	,	,	,
10_1101-2020_09_02_279521	314	3	H.	H.	NNP
10_1101-2020_09_02_279521	314	4	(	(	-LRB-
10_1101-2020_09_02_279521	314	5	1998	1998	CD
10_1101-2020_09_02_279521	314	6	)	)	-RRB-
10_1101-2020_09_02_279521	314	7	.	.	.
10_1101-2020_09_02_279521	315	1	Information	Information	NNP
10_1101-2020_09_02_279521	315	2	Theory	Theory	NNP
10_1101-2020_09_02_279521	315	3	and	and	CC
10_1101-2020_09_02_279521	315	4	an	an	DT
10_1101-2020_09_02_279521	315	5	Extension	extension	NN
10_1101-2020_09_02_279521	315	6	of	of	IN
10_1101-2020_09_02_279521	315	7	the	the	DT
10_1101-2020_09_02_279521	315	8	Maximum	Maximum	NNP
10_1101-2020_09_02_279521	315	9	Likelihood	Likelihood	NNP
10_1101-2020_09_02_279521	315	10	Principle	Principle	NNP
10_1101-2020_09_02_279521	315	11	.	.	.
10_1101-2020_09_02_279521	316	1	In	in	IN
10_1101-2020_09_02_279521	316	2	Selected	Selected	NNP
10_1101-2020_09_02_279521	316	3	Papers	Papers	NNPS
10_1101-2020_09_02_279521	316	4	of	of	IN
10_1101-2020_09_02_279521	316	5	Hirotugu	Hirotugu	NNP
10_1101-2020_09_02_279521	316	6	Akaike	Akaike	NNP
10_1101-2020_09_02_279521	316	7	(	(	-LRB-
10_1101-2020_09_02_279521	316	8	pp	pp	NNP
10_1101-2020_09_02_279521	316	9	.	.	.
10_1101-2020_09_02_279521	317	1	199–213	199–213	CD
10_1101-2020_09_02_279521	317	2	)	)	-RRB-
10_1101-2020_09_02_279521	317	3	.	.	.
10_1101-2020_09_02_279521	318	1	Springer	Springer	NNP
10_1101-2020_09_02_279521	318	2	New	New	NNP
10_1101-2020_09_02_279521	318	3	York	York	NNP
10_1101-2020_09_02_279521	318	4	.	.	.
10_1101-2020_09_02_279521	319	1	https://doi.org/10.1007/978-1-4612-1694-0_15	https://doi.org/10.1007/978-1-4612-1694-0_15	NNP
10_1101-2020_09_02_279521	319	2	Antelmi	Antelmi	NNP
10_1101-2020_09_02_279521	319	3	,	,	,
10_1101-2020_09_02_279521	319	4	L.	L.	NNP
10_1101-2020_09_02_279521	319	5	,	,	,
10_1101-2020_09_02_279521	319	6	Ayache	Ayache	NNP
10_1101-2020_09_02_279521	319	7	,	,	,
10_1101-2020_09_02_279521	319	8	N.	N.	NNP
10_1101-2020_09_02_279521	319	9	,	,	,
10_1101-2020_09_02_279521	319	10	Robert	Robert	NNP
10_1101-2020_09_02_279521	319	11	,	,	,
10_1101-2020_09_02_279521	319	12	P.	P.	NNP
10_1101-2020_09_02_279521	319	13	,	,	,
10_1101-2020_09_02_279521	319	14	&	&	CC
10_1101-2020_09_02_279521	319	15	Lorenzi	Lorenzi	NNP
10_1101-2020_09_02_279521	319	16	,	,	,
10_1101-2020_09_02_279521	319	17	M.	M.	NNP
10_1101-2020_09_02_279521	319	18	(	(	-LRB-
10_1101-2020_09_02_279521	319	19	2019	2019	CD
10_1101-2020_09_02_279521	319	20	,	,	,
10_1101-2020_09_02_279521	319	21	June	June	NNP
10_1101-2020_09_02_279521	319	22	)	)	-RRB-
10_1101-2020_09_02_279521	319	23	.	.	.
10_1101-2020_09_02_279521	320	1	Sparse	Sparse	NNP
10_1101-2020_09_02_279521	320	2	Multi	Multi	NNP
10_1101-2020_09_02_279521	320	3	-	-	HYPH
10_1101-2020_09_02_279521	320	4	Channel	Channel	NNP
10_1101-2020_09_02_279521	320	5	Variational	Variational	NNP
10_1101-2020_09_02_279521	320	6	Autoencoder	Autoencoder	NNP
10_1101-2020_09_02_279521	320	7	for	for	IN
10_1101-2020_09_02_279521	320	8	the	the	DT
10_1101-2020_09_02_279521	320	9	Joint	Joint	NNP
10_1101-2020_09_02_279521	320	10	Analysis	Analysis	NNP
10_1101-2020_09_02_279521	320	11	of	of	IN
10_1101-2020_09_02_279521	320	12	Heterogeneous	Heterogeneous	NNP
10_1101-2020_09_02_279521	320	13	Data	Data	NNP
10_1101-2020_09_02_279521	320	14	.	.	.
10_1101-2020_09_02_279521	321	1	ICML	ICML	NNP
10_1101-2020_09_02_279521	321	2	2019	2019	CD
10_1101-2020_09_02_279521	321	3	-	-	HYPH
10_1101-2020_09_02_279521	321	4	36th	36th	JJ
10_1101-2020_09_02_279521	321	5	International	International	NNP
10_1101-2020_09_02_279521	321	6	Conference	Conference	NNP
10_1101-2020_09_02_279521	321	7	on	on	IN
10_1101-2020_09_02_279521	321	8	Machine	Machine	NNP
10_1101-2020_09_02_279521	321	9	Learning	Learning	NNP
10_1101-2020_09_02_279521	321	10	.	.	.
10_1101-2020_09_02_279521	322	1	Bateman	Bateman	NNP
10_1101-2020_09_02_279521	322	2	,	,	,
10_1101-2020_09_02_279521	322	3	R.	R.	NNP
10_1101-2020_09_02_279521	322	4	J.	J.	NNP
10_1101-2020_09_02_279521	322	5	,	,	,
10_1101-2020_09_02_279521	322	6	Xiong	Xiong	NNP
10_1101-2020_09_02_279521	322	7	,	,	,
10_1101-2020_09_02_279521	322	8	C.	C.	NNP
10_1101-2020_09_02_279521	322	9	,	,	,
10_1101-2020_09_02_279521	322	10	Benzinger	Benzinger	NNP
10_1101-2020_09_02_279521	322	11	,	,	,
10_1101-2020_09_02_279521	322	12	T.	T.	NNP
10_1101-2020_09_02_279521	322	13	L.	L.	NNP
10_1101-2020_09_02_279521	322	14	S.	S.	NNP
10_1101-2020_09_02_279521	322	15	,	,	,
10_1101-2020_09_02_279521	322	16	Fagan	Fagan	NNP
10_1101-2020_09_02_279521	322	17	,	,	,
10_1101-2020_09_02_279521	322	18	A.	A.	NNP
10_1101-2020_09_02_279521	322	19	M.	M.	NNP
10_1101-2020_09_02_279521	322	20	,	,	,
10_1101-2020_09_02_279521	322	21	Goate	Goate	NNP
10_1101-2020_09_02_279521	322	22	,	,	,
10_1101-2020_09_02_279521	322	23	A.	a.	NN
10_1101-2020_09_02_279521	322	24	,	,	,
10_1101-2020_09_02_279521	322	25	Fox	Fox	NNP
10_1101-2020_09_02_279521	322	26	,	,	,
10_1101-2020_09_02_279521	322	27	N.	N.	NNP
10_1101-2020_09_02_279521	322	28	C.	C.	NNP
10_1101-2020_09_02_279521	322	29	,	,	,
10_1101-2020_09_02_279521	322	30	Marcus	Marcus	NNP
10_1101-2020_09_02_279521	322	31	,	,	,
10_1101-2020_09_02_279521	322	32	D.	D.	NNP
10_1101-2020_09_02_279521	322	33	S.	S.	NNP
10_1101-2020_09_02_279521	322	34	,	,	,
10_1101-2020_09_02_279521	322	35	Cairns	Cairns	NNP
10_1101-2020_09_02_279521	322	36	,	,	,
10_1101-2020_09_02_279521	322	37	N.	N.	NNP
10_1101-2020_09_02_279521	322	38	J.	J.	NNP
10_1101-2020_09_02_279521	322	39	,	,	,
10_1101-2020_09_02_279521	322	40	Xie	Xie	NNP
10_1101-2020_09_02_279521	322	41	,	,	,
10_1101-2020_09_02_279521	322	42	X.	X.	NNP
10_1101-2020_09_02_279521	322	43	,	,	,
10_1101-2020_09_02_279521	322	44	Blazey	Blazey	NNP
10_1101-2020_09_02_279521	322	45	,	,	,
10_1101-2020_09_02_279521	322	46	T.	T.	NNP
10_1101-2020_09_02_279521	322	47	M.	M.	NNP
10_1101-2020_09_02_279521	322	48	,	,	,
10_1101-2020_09_02_279521	322	49	Holtzman	Holtzman	NNP
10_1101-2020_09_02_279521	322	50	,	,	,
10_1101-2020_09_02_279521	322	51	D.	D.	NNP
10_1101-2020_09_02_279521	322	52	M.	M.	NNP
10_1101-2020_09_02_279521	322	53	,	,	,
10_1101-2020_09_02_279521	322	54	Santacruz	Santacruz	NNP
10_1101-2020_09_02_279521	322	55	,	,	,
10_1101-2020_09_02_279521	322	56	A.	A.	NNP
10_1101-2020_09_02_279521	322	57	,	,	,
10_1101-2020_09_02_279521	322	58	Buckles	Buckles	NNP
10_1101-2020_09_02_279521	322	59	,	,	,
10_1101-2020_09_02_279521	322	60	V.	V.	NNP
10_1101-2020_09_02_279521	322	61	,	,	,
10_1101-2020_09_02_279521	322	62	Oliver	Oliver	NNP
10_1101-2020_09_02_279521	322	63	,	,	,
10_1101-2020_09_02_279521	322	64	A.	A.	NNP
10_1101-2020_09_02_279521	322	65	,	,	,
10_1101-2020_09_02_279521	322	66	Moulder	Moulder	NNP
10_1101-2020_09_02_279521	322	67	,	,	,
10_1101-2020_09_02_279521	322	68	K.	K.	NNP
10_1101-2020_09_02_279521	322	69	,	,	,
10_1101-2020_09_02_279521	322	70	Aisen	Aisen	NNP
10_1101-2020_09_02_279521	322	71	,	,	,
10_1101-2020_09_02_279521	322	72	P.	P.	NNP
10_1101-2020_09_02_279521	322	73	S.	S.	NNP
10_1101-2020_09_02_279521	322	74	,	,	,
10_1101-2020_09_02_279521	322	75	Ghetti	Ghetti	NNP
10_1101-2020_09_02_279521	322	76	,	,	,
10_1101-2020_09_02_279521	322	77	B.	B.	NNP
10_1101-2020_09_02_279521	322	78	,	,	,
10_1101-2020_09_02_279521	322	79	Klunk	Klunk	NNP
10_1101-2020_09_02_279521	322	80	,	,	,
10_1101-2020_09_02_279521	322	81	W.	W.	NNP
10_1101-2020_09_02_279521	322	82	E.	E.	NNP
10_1101-2020_09_02_279521	322	83	,	,	,
10_1101-2020_09_02_279521	322	84	McDade	McDade	NNP
10_1101-2020_09_02_279521	322	85	,	,	,
10_1101-2020_09_02_279521	322	86	E.	E.	NNP
10_1101-2020_09_02_279521	322	87	,	,	,
10_1101-2020_09_02_279521	322	88	…	…	NFP
10_1101-2020_09_02_279521	322	89	Morris	Morris	NNP
10_1101-2020_09_02_279521	322	90	,	,	,
10_1101-2020_09_02_279521	322	91	J.	J.	NNP
10_1101-2020_09_02_279521	322	92	C.	C.	NNP
10_1101-2020_09_02_279521	322	93	(	(	-LRB-
10_1101-2020_09_02_279521	322	94	2012	2012	CD
10_1101-2020_09_02_279521	322	95	)	)	-RRB-
10_1101-2020_09_02_279521	322	96	.	.	.
10_1101-2020_09_02_279521	323	1	Clinical	clinical	JJ
10_1101-2020_09_02_279521	323	2	and	and	CC
10_1101-2020_09_02_279521	323	3	Biomarker	Biomarker	NNP
10_1101-2020_09_02_279521	323	4	Changes	Changes	NNPS
10_1101-2020_09_02_279521	323	5	in	in	IN
10_1101-2020_09_02_279521	323	6	Dominantly	dominantly	RB
10_1101-2020_09_02_279521	323	7	Inherited	Inherited	NNP
10_1101-2020_09_02_279521	323	8	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	323	9	’s	’s	POS
10_1101-2020_09_02_279521	323	10	Disease	Disease	NNP
10_1101-2020_09_02_279521	323	11	.	.	.
10_1101-2020_09_02_279521	324	1	New	New	NNP
10_1101-2020_09_02_279521	324	2	England	England	NNP
10_1101-2020_09_02_279521	324	3	Journal	Journal	NNP
10_1101-2020_09_02_279521	324	4	of	of	IN
10_1101-2020_09_02_279521	324	5	Medicine	Medicine	NNP
10_1101-2020_09_02_279521	324	6	,	,	,
10_1101-2020_09_02_279521	324	7	367(9	367(9	CD
10_1101-2020_09_02_279521	324	8	)	)	-RRB-
10_1101-2020_09_02_279521	324	9	,	,	,
10_1101-2020_09_02_279521	324	10	795–804	795–804	CD
10_1101-2020_09_02_279521	324	11	.	.	.
10_1101-2020_09_02_279521	325	1	Bilgel	Bilgel	NNP
10_1101-2020_09_02_279521	325	2	,	,	,
10_1101-2020_09_02_279521	325	3	M.	M.	NNP
10_1101-2020_09_02_279521	325	4	,	,	,
10_1101-2020_09_02_279521	325	5	Jedynak	Jedynak	NNP
10_1101-2020_09_02_279521	325	6	,	,	,
10_1101-2020_09_02_279521	325	7	B.	B.	NNP
10_1101-2020_09_02_279521	325	8	,	,	,
10_1101-2020_09_02_279521	325	9	Wong	Wong	NNP
10_1101-2020_09_02_279521	325	10	,	,	,
10_1101-2020_09_02_279521	325	11	D.	D.	NNP
10_1101-2020_09_02_279521	325	12	F.	F.	NNP
10_1101-2020_09_02_279521	325	13	,	,	,
10_1101-2020_09_02_279521	325	14	Resnick	Resnick	NNP
10_1101-2020_09_02_279521	325	15	,	,	,
10_1101-2020_09_02_279521	325	16	S.	S.	NNP
10_1101-2020_09_02_279521	325	17	M.	M.	NNP
10_1101-2020_09_02_279521	325	18	,	,	,
10_1101-2020_09_02_279521	325	19	&	&	CC
10_1101-2020_09_02_279521	325	20	Prince	Prince	NNP
10_1101-2020_09_02_279521	325	21	,	,	,
10_1101-2020_09_02_279521	325	22	J.	J.	NNP
10_1101-2020_09_02_279521	325	23	L.	L.	NNP
10_1101-2020_09_02_279521	325	24	(	(	-LRB-
10_1101-2020_09_02_279521	325	25	2015	2015	CD
10_1101-2020_09_02_279521	325	26	)	)	-RRB-
10_1101-2020_09_02_279521	325	27	.	.	.
10_1101-2020_09_02_279521	326	1	Temporal	temporal	JJ
10_1101-2020_09_02_279521	326	2	Trajectory	Trajectory	NNP
10_1101-2020_09_02_279521	326	3	and	and	CC
10_1101-2020_09_02_279521	326	4	Progression	Progression	NNP
10_1101-2020_09_02_279521	326	5	Score	Score	NNP
10_1101-2020_09_02_279521	326	6	Estimation	Estimation	NNP
10_1101-2020_09_02_279521	326	7	from	from	IN
10_1101-2020_09_02_279521	326	8	Voxelwise	Voxelwise	NNP
10_1101-2020_09_02_279521	326	9	Longitudinal	Longitudinal	NNP
10_1101-2020_09_02_279521	326	10	Imaging	Imaging	NNP
10_1101-2020_09_02_279521	326	11	Measures	Measures	NNPS
10_1101-2020_09_02_279521	326	12	:	:	:
10_1101-2020_09_02_279521	326	13	Application	application	NN
10_1101-2020_09_02_279521	326	14	to	to	IN
10_1101-2020_09_02_279521	326	15	Amyloid	Amyloid	NNP
10_1101-2020_09_02_279521	326	16	Imaging	Imaging	NNP
10_1101-2020_09_02_279521	326	17	.	.	.
10_1101-2020_09_02_279521	327	1	Inf	inf	NN
10_1101-2020_09_02_279521	327	2	Process	process	NN
10_1101-2020_09_02_279521	327	3	Med	Med	NNP
10_1101-2020_09_02_279521	327	4	Imaging	Imaging	NNP
10_1101-2020_09_02_279521	327	5	,	,	,
10_1101-2020_09_02_279521	327	6	24	24	CD
10_1101-2020_09_02_279521	327	7	,	,	,
10_1101-2020_09_02_279521	327	8	424–436	424–436	CD
10_1101-2020_09_02_279521	327	9	.	.	.
10_1101-2020_09_02_279521	328	1	Blennow	Blennow	NNP
10_1101-2020_09_02_279521	328	2	,	,	,
10_1101-2020_09_02_279521	328	3	K.	K.	NNP
10_1101-2020_09_02_279521	328	4	,	,	,
10_1101-2020_09_02_279521	328	5	Hampel	Hampel	NNP
10_1101-2020_09_02_279521	328	6	,	,	,
10_1101-2020_09_02_279521	328	7	H.	H.	NNP
10_1101-2020_09_02_279521	328	8	,	,	,
10_1101-2020_09_02_279521	328	9	Weiner	Weiner	NNP
10_1101-2020_09_02_279521	328	10	,	,	,
10_1101-2020_09_02_279521	328	11	M.	M.	NNP
10_1101-2020_09_02_279521	328	12	,	,	,
10_1101-2020_09_02_279521	328	13	&	&	CC
10_1101-2020_09_02_279521	328	14	Zetterberg	Zetterberg	NNP
10_1101-2020_09_02_279521	328	15	,	,	,
10_1101-2020_09_02_279521	328	16	H.	H.	NNP
10_1101-2020_09_02_279521	328	17	(	(	-LRB-
10_1101-2020_09_02_279521	328	18	2010	2010	CD
10_1101-2020_09_02_279521	328	19	)	)	-RRB-
10_1101-2020_09_02_279521	328	20	.	.	.
10_1101-2020_09_02_279521	329	1	Cerebrospinal	cerebrospinal	JJ
10_1101-2020_09_02_279521	329	2	fluid	fluid	NN
10_1101-2020_09_02_279521	329	3	and	and	CC
10_1101-2020_09_02_279521	329	4	plasma	plasma	NN
10_1101-2020_09_02_279521	329	5	biomarkers	biomarker	NNS
10_1101-2020_09_02_279521	329	6	in	in	IN
10_1101-2020_09_02_279521	329	7	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	329	8	disease	disease	NN
10_1101-2020_09_02_279521	329	9	.	.	.
10_1101-2020_09_02_279521	330	1	Nat	Nat	NNP
10_1101-2020_09_02_279521	330	2	Rev	Rev	NNP
10_1101-2020_09_02_279521	330	3	Neurol	Neurol	NNP
10_1101-2020_09_02_279521	330	4	,	,	,
10_1101-2020_09_02_279521	330	5	6(3	6(3	NNP
10_1101-2020_09_02_279521	330	6	)	)	-RRB-
10_1101-2020_09_02_279521	330	7	,	,	,
10_1101-2020_09_02_279521	330	8	131–144	131–144	CD
10_1101-2020_09_02_279521	330	9	.	.	.
10_1101-2020_09_02_279521	331	1	Braak	Braak	NNP
10_1101-2020_09_02_279521	331	2	,	,	,
10_1101-2020_09_02_279521	331	3	H.	H.	NNP
10_1101-2020_09_02_279521	331	4	,	,	,
10_1101-2020_09_02_279521	331	5	&	&	CC
10_1101-2020_09_02_279521	331	6	Braak	Braak	NNP
10_1101-2020_09_02_279521	331	7	,	,	,
10_1101-2020_09_02_279521	331	8	E.	E.	NNP
10_1101-2020_09_02_279521	331	9	(	(	-LRB-
10_1101-2020_09_02_279521	331	10	1991	1991	CD
10_1101-2020_09_02_279521	331	11	)	)	-RRB-
10_1101-2020_09_02_279521	331	12	.	.	.
10_1101-2020_09_02_279521	332	1	Neuropathological	neuropathological	JJ
10_1101-2020_09_02_279521	332	2	stageing	stageing	NN
10_1101-2020_09_02_279521	332	3	of	of	IN
10_1101-2020_09_02_279521	332	4	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	332	5	-	-	HYPH
10_1101-2020_09_02_279521	332	6	related	relate	VBN
10_1101-2020_09_02_279521	332	7	changes	change	NNS
10_1101-2020_09_02_279521	332	8	.	.	.
10_1101-2020_09_02_279521	333	1	Acta	Acta	NNP
10_1101-2020_09_02_279521	333	2	Neuropathol	Neuropathol	NNP
10_1101-2020_09_02_279521	333	3	.	.	NNP
10_1101-2020_09_02_279521	333	4	,	,	,
10_1101-2020_09_02_279521	333	5	82(4	82(4	CD
10_1101-2020_09_02_279521	333	6	)	)	-RRB-
10_1101-2020_09_02_279521	333	7	,	,	,
10_1101-2020_09_02_279521	333	8	239–259	239–259	CD
10_1101-2020_09_02_279521	333	9	.	.	.
10_1101-2020_09_02_279521	334	1	Burnham	Burnham	NNP
10_1101-2020_09_02_279521	334	2	,	,	,
10_1101-2020_09_02_279521	334	3	S.	S.	NNP
10_1101-2020_09_02_279521	334	4	C.	C.	NNP
10_1101-2020_09_02_279521	334	5	,	,	,
10_1101-2020_09_02_279521	334	6	Fandos	Fandos	NNP
10_1101-2020_09_02_279521	334	7	,	,	,
10_1101-2020_09_02_279521	334	8	N.	N.	NNP
10_1101-2020_09_02_279521	334	9	,	,	,
10_1101-2020_09_02_279521	334	10	Fowler	Fowler	NNP
10_1101-2020_09_02_279521	334	11	,	,	,
10_1101-2020_09_02_279521	334	12	C.	C.	NNP
10_1101-2020_09_02_279521	334	13	,	,	,
10_1101-2020_09_02_279521	334	14	Pérez	Pérez	NNP
10_1101-2020_09_02_279521	334	15	-	-	HYPH
10_1101-2020_09_02_279521	334	16	Grijalba	Grijalba	NNP
10_1101-2020_09_02_279521	334	17	,	,	,
10_1101-2020_09_02_279521	334	18	V.	V.	NNP
10_1101-2020_09_02_279521	334	19	,	,	,
10_1101-2020_09_02_279521	334	20	Dore	Dore	NNP
10_1101-2020_09_02_279521	334	21	,	,	,
10_1101-2020_09_02_279521	334	22	V.	V.	NNP
10_1101-2020_09_02_279521	334	23	,	,	,
10_1101-2020_09_02_279521	334	24	Doecke	Doecke	NNP
10_1101-2020_09_02_279521	334	25	,	,	,
10_1101-2020_09_02_279521	334	26	J.	J.	NNP
10_1101-2020_09_02_279521	334	27	D.	D.	NNP
10_1101-2020_09_02_279521	334	28	,	,	,
10_1101-2020_09_02_279521	334	29	Shishegar	Shishegar	NNP
10_1101-2020_09_02_279521	334	30	,	,	,
10_1101-2020_09_02_279521	334	31	R.	R.	NNP
10_1101-2020_09_02_279521	334	32	,	,	,
10_1101-2020_09_02_279521	334	33	Cox	Cox	NNP
10_1101-2020_09_02_279521	334	34	,	,	,
10_1101-2020_09_02_279521	334	35	T.	T.	NNP
10_1101-2020_09_02_279521	334	36	,	,	,
10_1101-2020_09_02_279521	334	37	Fripp	Fripp	NNP
10_1101-2020_09_02_279521	334	38	,	,	,
10_1101-2020_09_02_279521	334	39	J.	J.	NNP
10_1101-2020_09_02_279521	334	40	,	,	,
10_1101-2020_09_02_279521	334	41	Rowe	Rowe	NNP
10_1101-2020_09_02_279521	334	42	,	,	,
10_1101-2020_09_02_279521	334	43	C.	C.	NNP
10_1101-2020_09_02_279521	334	44	,	,	,
10_1101-2020_09_02_279521	334	45	Sarasa	Sarasa	NNP
10_1101-2020_09_02_279521	334	46	,	,	,
10_1101-2020_09_02_279521	334	47	M.	M.	NNP
10_1101-2020_09_02_279521	334	48	,	,	,
10_1101-2020_09_02_279521	334	49	Masters	Masters	NNP
10_1101-2020_09_02_279521	334	50	,	,	,
10_1101-2020_09_02_279521	334	51	C.	C.	NNP
10_1101-2020_09_02_279521	334	52	L.	L.	NNP
10_1101-2020_09_02_279521	334	53	,	,	,
10_1101-2020_09_02_279521	334	54	Pesini	Pesini	NNP
10_1101-2020_09_02_279521	334	55	,	,	,
10_1101-2020_09_02_279521	334	56	P.	P.	NNP
10_1101-2020_09_02_279521	334	57	,	,	,
10_1101-2020_09_02_279521	334	58	&	&	CC
10_1101-2020_09_02_279521	334	59	Villemagne	Villemagne	NNP
10_1101-2020_09_02_279521	334	60	,	,	,
10_1101-2020_09_02_279521	334	61	V.	V.	NNP
10_1101-2020_09_02_279521	334	62	L.	L.	NNP
10_1101-2020_09_02_279521	334	63	(	(	-LRB-
10_1101-2020_09_02_279521	334	64	2020	2020	CD
10_1101-2020_09_02_279521	334	65	)	)	-RRB-
10_1101-2020_09_02_279521	334	66	.	.	.
10_1101-2020_09_02_279521	335	1	Longitudinal	longitudinal	JJ
10_1101-2020_09_02_279521	335	2	evaluation	evaluation	NN
10_1101-2020_09_02_279521	335	3	of	of	IN
10_1101-2020_09_02_279521	335	4	the	the	DT
10_1101-2020_09_02_279521	335	5	natural	natural	JJ
10_1101-2020_09_02_279521	335	6	history	history	NN
10_1101-2020_09_02_279521	335	7	of	of	IN
10_1101-2020_09_02_279521	335	8	amyloid	amyloid	NNP
10_1101-2020_09_02_279521	335	9	-	-	HYPH
10_1101-2020_09_02_279521	335	10	β	β	NNP
10_1101-2020_09_02_279521	335	11	in	in	IN
10_1101-2020_09_02_279521	335	12	plasma	plasma	NN
10_1101-2020_09_02_279521	335	13	and	and	CC
10_1101-2020_09_02_279521	335	14	brain	brain	NN
10_1101-2020_09_02_279521	335	15	.	.	.
10_1101-2020_09_02_279521	336	1	Brain	Brain	NNP
10_1101-2020_09_02_279521	336	2	Communications	Communications	NNPS
10_1101-2020_09_02_279521	336	3	,	,	,
10_1101-2020_09_02_279521	336	4	2(1	2(1	NNP
10_1101-2020_09_02_279521	336	5	)	)	-RRB-
10_1101-2020_09_02_279521	336	6	.	.	.
10_1101-2020_09_02_279521	337	1	https://doi.org/10.1093/braincomms/fcaa041	https://doi.org/10.1093/braincomms/fcaa041	NNP
10_1101-2020_09_02_279521	337	2	Cash	Cash	NNP
10_1101-2020_09_02_279521	337	3	,	,	,
10_1101-2020_09_02_279521	337	4	D.	D.	NNP
10_1101-2020_09_02_279521	337	5	M.	M.	NNP
10_1101-2020_09_02_279521	337	6	,	,	,
10_1101-2020_09_02_279521	337	7	Frost	Frost	NNP
10_1101-2020_09_02_279521	337	8	,	,	,
10_1101-2020_09_02_279521	337	9	C.	C.	NNP
10_1101-2020_09_02_279521	337	10	,	,	,
10_1101-2020_09_02_279521	337	11	Iheme	Iheme	NNP
10_1101-2020_09_02_279521	337	12	,	,	,
10_1101-2020_09_02_279521	337	13	L.	L.	NNP
10_1101-2020_09_02_279521	337	14	O.	O.	NNP
10_1101-2020_09_02_279521	337	15	,	,	,
10_1101-2020_09_02_279521	337	16	Ünay	Ünay	NNP
10_1101-2020_09_02_279521	337	17	,	,	,
10_1101-2020_09_02_279521	337	18	D.	D.	NNP
10_1101-2020_09_02_279521	337	19	,	,	,
10_1101-2020_09_02_279521	337	20	Kandemir	Kandemir	NNP
10_1101-2020_09_02_279521	337	21	,	,	,
10_1101-2020_09_02_279521	337	22	M.	M.	NNP
10_1101-2020_09_02_279521	337	23	,	,	,
10_1101-2020_09_02_279521	337	24	Fripp	Fripp	NNP
10_1101-2020_09_02_279521	337	25	,	,	,
10_1101-2020_09_02_279521	337	26	J.	J.	NNP
10_1101-2020_09_02_279521	337	27	,	,	,
10_1101-2020_09_02_279521	337	28	Salvado	Salvado	NNP
10_1101-2020_09_02_279521	337	29	,	,	,
10_1101-2020_09_02_279521	337	30	O.	O.	NNP
10_1101-2020_09_02_279521	337	31	,	,	,
10_1101-2020_09_02_279521	337	32	Bourgeat	Bourgeat	NNP
10_1101-2020_09_02_279521	337	33	,	,	,
10_1101-2020_09_02_279521	337	34	P.	P.	NNP
10_1101-2020_09_02_279521	337	35	,	,	,
10_1101-2020_09_02_279521	337	36	Reuter	Reuter	NNP
10_1101-2020_09_02_279521	337	37	,	,	,
10_1101-2020_09_02_279521	337	38	M.	M.	NNP
10_1101-2020_09_02_279521	337	39	,	,	,
10_1101-2020_09_02_279521	337	40	Fischl	Fischl	NNP
10_1101-2020_09_02_279521	337	41	,	,	,
10_1101-2020_09_02_279521	337	42	B.	B.	NNP
10_1101-2020_09_02_279521	337	43	,	,	,
10_1101-2020_09_02_279521	337	44	Lorenzi	Lorenzi	NNP
10_1101-2020_09_02_279521	337	45	,	,	,
10_1101-2020_09_02_279521	337	46	M.	M.	NNP
10_1101-2020_09_02_279521	337	47	,	,	,
10_1101-2020_09_02_279521	337	48	Frisoni	Frisoni	NNP
10_1101-2020_09_02_279521	337	49	,	,	,
10_1101-2020_09_02_279521	337	50	G.	G.	NNP
10_1101-2020_09_02_279521	337	51	B.	B.	NNP
10_1101-2020_09_02_279521	337	52	,	,	,
10_1101-2020_09_02_279521	337	53	Pennec	Pennec	NNP
10_1101-2020_09_02_279521	337	54	,	,	,
10_1101-2020_09_02_279521	337	55	X.	X.	NNP
10_1101-2020_09_02_279521	337	56	,	,	,
10_1101-2020_09_02_279521	337	57	Pierson	Pierson	NNP
10_1101-2020_09_02_279521	337	58	,	,	,
10_1101-2020_09_02_279521	337	59	R.	R.	NNP
10_1101-2020_09_02_279521	337	60	K.	K.	NNP
10_1101-2020_09_02_279521	337	61	,	,	,
10_1101-2020_09_02_279521	337	62	Gunter	Gunter	NNP
10_1101-2020_09_02_279521	337	63	,	,	,
10_1101-2020_09_02_279521	337	64	J.	J.	NNP
10_1101-2020_09_02_279521	337	65	L.	L.	NNP
10_1101-2020_09_02_279521	337	66	,	,	,
10_1101-2020_09_02_279521	337	67	Senjem	Senjem	NNP
10_1101-2020_09_02_279521	337	68	,	,	,
10_1101-2020_09_02_279521	337	69	M.	M.	NNP
10_1101-2020_09_02_279521	337	70	L.	L.	NNP
10_1101-2020_09_02_279521	337	71	,	,	,
10_1101-2020_09_02_279521	337	72	Jack	Jack	NNP
10_1101-2020_09_02_279521	337	73	,	,	,
10_1101-2020_09_02_279521	337	74	C.	C.	NNP
10_1101-2020_09_02_279521	337	75	R.	R.	NNP
10_1101-2020_09_02_279521	337	76	,	,	,
10_1101-2020_09_02_279521	337	77	Guizard	Guizard	NNP
10_1101-2020_09_02_279521	337	78	,	,	,
10_1101-2020_09_02_279521	337	79	N.	N.	NNP
10_1101-2020_09_02_279521	337	80	,	,	,
10_1101-2020_09_02_279521	337	81	Fonov	Fonov	NNP
10_1101-2020_09_02_279521	337	82	,	,	,
10_1101-2020_09_02_279521	337	83	V.	V.	NNP
10_1101-2020_09_02_279521	337	84	S.	S.	NNP
10_1101-2020_09_02_279521	337	85	,	,	,
10_1101-2020_09_02_279521	337	86	…	…	NFP
10_1101-2020_09_02_279521	337	87	Ourselin	Ourselin	NNP
10_1101-2020_09_02_279521	337	88	,	,	,
10_1101-2020_09_02_279521	337	89	S.	S.	NNP
10_1101-2020_09_02_279521	337	90	.CC	.CC	,
10_1101-2020_09_02_279521	337	91	-	-	:
10_1101-2020_09_02_279521	337	92	BY	by	IN
10_1101-2020_09_02_279521	337	93	4.0	4.0	CD
10_1101-2020_09_02_279521	337	94	International	international	JJ
10_1101-2020_09_02_279521	337	95	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	337	96	.	.	.
10_1101-2020_09_02_279521	338	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	338	2	is	be	VBZ
10_1101-2020_09_02_279521	338	3	made	make	VBN
10_1101-2020_09_02_279521	338	4	available	available	JJ
10_1101-2020_09_02_279521	338	5	under	under	IN
10_1101-2020_09_02_279521	338	6	a	a	DT
10_1101-2020_09_02_279521	338	7	preprint	preprint	NN
10_1101-2020_09_02_279521	338	8	(	(	-LRB-
10_1101-2020_09_02_279521	338	9	which	which	WDT
10_1101-2020_09_02_279521	338	10	was	be	VBD
10_1101-2020_09_02_279521	338	11	not	not	RB
10_1101-2020_09_02_279521	338	12	certified	certify	VBN
10_1101-2020_09_02_279521	338	13	by	by	IN
10_1101-2020_09_02_279521	338	14	peer	peer	NN
10_1101-2020_09_02_279521	338	15	review	review	NN
10_1101-2020_09_02_279521	338	16	)	)	-RRB-
10_1101-2020_09_02_279521	338	17	is	be	VBZ
10_1101-2020_09_02_279521	338	18	the	the	DT
10_1101-2020_09_02_279521	338	19	author	author	NN
10_1101-2020_09_02_279521	338	20	/	/	SYM
10_1101-2020_09_02_279521	338	21	funder	funder	NN
10_1101-2020_09_02_279521	338	22	,	,	,
10_1101-2020_09_02_279521	338	23	who	who	WP
10_1101-2020_09_02_279521	338	24	has	have	VBZ
10_1101-2020_09_02_279521	338	25	granted	grant	VBN
10_1101-2020_09_02_279521	338	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	338	27	a	a	DT
10_1101-2020_09_02_279521	338	28	license	license	NN
10_1101-2020_09_02_279521	338	29	to	to	TO
10_1101-2020_09_02_279521	338	30	display	display	VB
10_1101-2020_09_02_279521	338	31	the	the	DT
10_1101-2020_09_02_279521	338	32	preprint	preprint	NN
10_1101-2020_09_02_279521	338	33	in	in	IN
10_1101-2020_09_02_279521	338	34	The	the	DT
10_1101-2020_09_02_279521	338	35	copyright	copyright	NN
10_1101-2020_09_02_279521	338	36	holder	holder	NN
10_1101-2020_09_02_279521	338	37	for	for	IN
10_1101-2020_09_02_279521	338	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	338	39	version	version	NN
10_1101-2020_09_02_279521	338	40	posted	post	VBD
10_1101-2020_09_02_279521	338	41	February	February	NNP
10_1101-2020_09_02_279521	338	42	10	10	CD
10_1101-2020_09_02_279521	338	43	,	,	,
10_1101-2020_09_02_279521	338	44	2021	2021	CD
10_1101-2020_09_02_279521	338	45	.	.	.
10_1101-2020_09_02_279521	338	46	;	;	:
10_1101-2020_09_02_279521	338	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	338	48	:	:	:
10_1101-2020_09_02_279521	338	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	338	50	preprint	preprint	NN
10_1101-2020_09_02_279521	338	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	ADD
10_1101-2020_09_02_279521	338	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	ADD
10_1101-2020_09_02_279521	338	53	(	(	-LRB-
10_1101-2020_09_02_279521	338	54	2015	2015	CD
10_1101-2020_09_02_279521	338	55	)	)	-RRB-
10_1101-2020_09_02_279521	338	56	.	.	.
10_1101-2020_09_02_279521	339	1	Assessing	assess	VBG
10_1101-2020_09_02_279521	339	2	atrophy	atrophy	NN
10_1101-2020_09_02_279521	339	3	measurement	measurement	NN
10_1101-2020_09_02_279521	339	4	techniques	technique	NNS
10_1101-2020_09_02_279521	339	5	in	in	IN
10_1101-2020_09_02_279521	339	6	dementia	dementia	NN
10_1101-2020_09_02_279521	339	7	:	:	:
10_1101-2020_09_02_279521	339	8	Results	result	NNS
10_1101-2020_09_02_279521	339	9	from	from	IN
10_1101-2020_09_02_279521	339	10	the	the	DT
10_1101-2020_09_02_279521	339	11	MIRIAD	MIRIAD	NNP
10_1101-2020_09_02_279521	339	12	atrophy	atrophy	NN
10_1101-2020_09_02_279521	339	13	challenge	challenge	NN
10_1101-2020_09_02_279521	339	14	.	.	.
10_1101-2020_09_02_279521	340	1	Neuroimage	neuroimage	NN
10_1101-2020_09_02_279521	340	2	,	,	,
10_1101-2020_09_02_279521	340	3	123	123	CD
10_1101-2020_09_02_279521	340	4	,	,	,
10_1101-2020_09_02_279521	340	5	149–164	149–164	CD
10_1101-2020_09_02_279521	340	6	.	.	.
10_1101-2020_09_02_279521	341	1	Cummings	Cummings	NNP
10_1101-2020_09_02_279521	341	2	,	,	,
10_1101-2020_09_02_279521	341	3	J.	J.	NNP
10_1101-2020_09_02_279521	341	4	,	,	,
10_1101-2020_09_02_279521	341	5	Blennow	Blennow	NNP
10_1101-2020_09_02_279521	341	6	,	,	,
10_1101-2020_09_02_279521	341	7	K.	K.	NNP
10_1101-2020_09_02_279521	341	8	,	,	,
10_1101-2020_09_02_279521	341	9	Johnson	Johnson	NNP
10_1101-2020_09_02_279521	341	10	,	,	,
10_1101-2020_09_02_279521	341	11	K.	K.	NNP
10_1101-2020_09_02_279521	341	12	,	,	,
10_1101-2020_09_02_279521	341	13	Keeley	Keeley	NNP
10_1101-2020_09_02_279521	341	14	,	,	,
10_1101-2020_09_02_279521	341	15	M.	M.	NNP
10_1101-2020_09_02_279521	341	16	,	,	,
10_1101-2020_09_02_279521	341	17	Bateman	Bateman	NNP
10_1101-2020_09_02_279521	341	18	,	,	,
10_1101-2020_09_02_279521	341	19	R.	R.	NNP
10_1101-2020_09_02_279521	341	20	J.	J.	NNP
10_1101-2020_09_02_279521	341	21	,	,	,
10_1101-2020_09_02_279521	341	22	Molinuevo	Molinuevo	NNP
10_1101-2020_09_02_279521	341	23	,	,	,
10_1101-2020_09_02_279521	341	24	J.	J.	NNP
10_1101-2020_09_02_279521	341	25	L.	L.	NNP
10_1101-2020_09_02_279521	341	26	,	,	,
10_1101-2020_09_02_279521	341	27	Touchon	Touchon	NNP
10_1101-2020_09_02_279521	341	28	,	,	,
10_1101-2020_09_02_279521	341	29	J.	J.	NNP
10_1101-2020_09_02_279521	341	30	,	,	,
10_1101-2020_09_02_279521	341	31	Aisen	Aisen	NNP
10_1101-2020_09_02_279521	341	32	,	,	,
10_1101-2020_09_02_279521	341	33	P.	P.	NNP
10_1101-2020_09_02_279521	341	34	,	,	,
10_1101-2020_09_02_279521	341	35	&	&	CC
10_1101-2020_09_02_279521	341	36	Vellas	Vellas	NNP
10_1101-2020_09_02_279521	341	37	,	,	,
10_1101-2020_09_02_279521	341	38	B.	B.	NNP
10_1101-2020_09_02_279521	342	1	(	(	-LRB-
10_1101-2020_09_02_279521	342	2	2019	2019	CD
10_1101-2020_09_02_279521	342	3	)	)	-RRB-
10_1101-2020_09_02_279521	342	4	.	.	.
10_1101-2020_09_02_279521	343	1	Anti	anti	JJ
10_1101-2020_09_02_279521	343	2	-	-	JJ
10_1101-2020_09_02_279521	343	3	Tau	tau	JJ
10_1101-2020_09_02_279521	343	4	Trials	Trials	NNPS
10_1101-2020_09_02_279521	343	5	for	for	IN
10_1101-2020_09_02_279521	343	6	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	343	7	’s	’s	NNP
10_1101-2020_09_02_279521	343	8	Disease	Disease	NNP
10_1101-2020_09_02_279521	343	9	:	:	:
10_1101-2020_09_02_279521	343	10	A	a	DT
10_1101-2020_09_02_279521	343	11	Report	report	NN
10_1101-2020_09_02_279521	343	12	from	from	IN
10_1101-2020_09_02_279521	343	13	the	the	DT
10_1101-2020_09_02_279521	343	14	EU	EU	NNP
10_1101-2020_09_02_279521	343	15	/	/	SYM
10_1101-2020_09_02_279521	343	16	US	US	NNP
10_1101-2020_09_02_279521	343	17	/	/	SYM
10_1101-2020_09_02_279521	343	18	CTAD	CTAD	NNP
10_1101-2020_09_02_279521	343	19	Task	Task	NNP
10_1101-2020_09_02_279521	343	20	Force	Force	NNP
10_1101-2020_09_02_279521	343	21	.	.	.
10_1101-2020_09_02_279521	344	1	J	J	NNP
10_1101-2020_09_02_279521	344	2	Prev	Prev	NNP
10_1101-2020_09_02_279521	344	3	Alzheimers	Alzheimers	NNPS
10_1101-2020_09_02_279521	344	4	Dis	Dis	NNP
10_1101-2020_09_02_279521	344	5	,	,	,
10_1101-2020_09_02_279521	344	6	6(3	6(3	NNP
10_1101-2020_09_02_279521	344	7	)	)	-RRB-
10_1101-2020_09_02_279521	344	8	,	,	,
10_1101-2020_09_02_279521	344	9	157–163	157–163	CD
10_1101-2020_09_02_279521	344	10	.	.	.
10_1101-2020_09_02_279521	345	1	Cummings	Cummings	NNP
10_1101-2020_09_02_279521	345	2	,	,	,
10_1101-2020_09_02_279521	345	3	J.	J.	NNP
10_1101-2020_09_02_279521	345	4	,	,	,
10_1101-2020_09_02_279521	345	5	Lee	Lee	NNP
10_1101-2020_09_02_279521	345	6	,	,	,
10_1101-2020_09_02_279521	345	7	G.	G.	NNP
10_1101-2020_09_02_279521	345	8	,	,	,
10_1101-2020_09_02_279521	345	9	Ritter	Ritter	NNP
10_1101-2020_09_02_279521	345	10	,	,	,
10_1101-2020_09_02_279521	345	11	A.	A.	NNP
10_1101-2020_09_02_279521	345	12	,	,	,
10_1101-2020_09_02_279521	345	13	Sabbagh	Sabbagh	NNP
10_1101-2020_09_02_279521	345	14	,	,	,
10_1101-2020_09_02_279521	345	15	M.	M.	NNP
10_1101-2020_09_02_279521	345	16	,	,	,
10_1101-2020_09_02_279521	345	17	&	&	CC
10_1101-2020_09_02_279521	345	18	Zhong	Zhong	NNP
10_1101-2020_09_02_279521	345	19	,	,	,
10_1101-2020_09_02_279521	345	20	K.	K.	NNP
10_1101-2020_09_02_279521	345	21	(	(	-LRB-
10_1101-2020_09_02_279521	345	22	2019	2019	CD
10_1101-2020_09_02_279521	345	23	)	)	-RRB-
10_1101-2020_09_02_279521	345	24	.	.	.
10_1101-2020_09_02_279521	346	1	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	346	2	’s	’s	POS
10_1101-2020_09_02_279521	346	3	disease	disease	NNP
10_1101-2020_09_02_279521	346	4	drug	drug	NNP
10_1101-2020_09_02_279521	346	5	development	development	NNP
10_1101-2020_09_02_279521	346	6	pipeline	pipeline	NN
10_1101-2020_09_02_279521	346	7	:	:	:
10_1101-2020_09_02_279521	346	8	2019	2019	CD
10_1101-2020_09_02_279521	346	9	.	.	.
10_1101-2020_09_02_279521	347	1	Alzheimers	Alzheimers	NNP
10_1101-2020_09_02_279521	347	2	Dement	Dement	NNP
10_1101-2020_09_02_279521	347	3	(	(	-LRB-
10_1101-2020_09_02_279521	347	4	N	N	NNP
10_1101-2020_09_02_279521	347	5	Y	Y	NNP
10_1101-2020_09_02_279521	347	6	)	)	-RRB-
10_1101-2020_09_02_279521	347	7	,	,	,
10_1101-2020_09_02_279521	347	8	5	5	CD
10_1101-2020_09_02_279521	347	9	,	,	,
10_1101-2020_09_02_279521	347	10	272–293	272–293	CD
10_1101-2020_09_02_279521	347	11	.	.	.
10_1101-2020_09_02_279521	348	1	Delacourte	Delacourte	NNP
10_1101-2020_09_02_279521	348	2	,	,	,
10_1101-2020_09_02_279521	348	3	A.	A.	NNP
10_1101-2020_09_02_279521	348	4	,	,	,
10_1101-2020_09_02_279521	348	5	David	David	NNP
10_1101-2020_09_02_279521	348	6	,	,	,
10_1101-2020_09_02_279521	348	7	J.	J.	NNP
10_1101-2020_09_02_279521	348	8	P.	P.	NNP
10_1101-2020_09_02_279521	348	9	,	,	,
10_1101-2020_09_02_279521	348	10	Sergeant	Sergeant	NNP
10_1101-2020_09_02_279521	348	11	,	,	,
10_1101-2020_09_02_279521	348	12	N.	N.	NNP
10_1101-2020_09_02_279521	348	13	,	,	,
10_1101-2020_09_02_279521	348	14	Buée	Buée	NNP
10_1101-2020_09_02_279521	348	15	,	,	,
10_1101-2020_09_02_279521	348	16	L.	L.	NNP
10_1101-2020_09_02_279521	348	17	,	,	,
10_1101-2020_09_02_279521	348	18	Wattez	Wattez	NNP
10_1101-2020_09_02_279521	348	19	,	,	,
10_1101-2020_09_02_279521	348	20	A.	A.	NNP
10_1101-2020_09_02_279521	348	21	,	,	,
10_1101-2020_09_02_279521	348	22	Vermersch	Vermersch	NNP
10_1101-2020_09_02_279521	348	23	,	,	,
10_1101-2020_09_02_279521	348	24	P.	P.	NNP
10_1101-2020_09_02_279521	348	25	,	,	,
10_1101-2020_09_02_279521	348	26	Ghozali	Ghozali	NNP
10_1101-2020_09_02_279521	348	27	,	,	,
10_1101-2020_09_02_279521	348	28	F.	F.	NNP
10_1101-2020_09_02_279521	348	29	,	,	,
10_1101-2020_09_02_279521	348	30	Fallet	Fallet	NNP
10_1101-2020_09_02_279521	348	31	-	-	HYPH
10_1101-2020_09_02_279521	348	32	Bianco	Bianco	NNP
10_1101-2020_09_02_279521	348	33	,	,	,
10_1101-2020_09_02_279521	348	34	C.	C.	NNP
10_1101-2020_09_02_279521	348	35	,	,	,
10_1101-2020_09_02_279521	348	36	Pasquier	Pasquier	NNP
10_1101-2020_09_02_279521	348	37	,	,	,
10_1101-2020_09_02_279521	348	38	F.	F.	NNP
10_1101-2020_09_02_279521	348	39	,	,	,
10_1101-2020_09_02_279521	348	40	Lebert	Lebert	NNP
10_1101-2020_09_02_279521	348	41	,	,	,
10_1101-2020_09_02_279521	348	42	F.	F.	NNP
10_1101-2020_09_02_279521	348	43	,	,	,
10_1101-2020_09_02_279521	348	44	Petit	Petit	NNP
10_1101-2020_09_02_279521	348	45	,	,	,
10_1101-2020_09_02_279521	348	46	H.	H.	NNP
10_1101-2020_09_02_279521	348	47	,	,	,
10_1101-2020_09_02_279521	348	48	&	&	CC
10_1101-2020_09_02_279521	348	49	Di	Di	NNP
10_1101-2020_09_02_279521	348	50	Menza	Menza	NNP
10_1101-2020_09_02_279521	348	51	,	,	,
10_1101-2020_09_02_279521	348	52	C.	C.	NNP
10_1101-2020_09_02_279521	348	53	(	(	-LRB-
10_1101-2020_09_02_279521	348	54	1999	1999	CD
10_1101-2020_09_02_279521	348	55	)	)	-RRB-
10_1101-2020_09_02_279521	348	56	.	.	.
10_1101-2020_09_02_279521	349	1	The	the	DT
10_1101-2020_09_02_279521	349	2	biochemical	biochemical	JJ
10_1101-2020_09_02_279521	349	3	pathway	pathway	NN
10_1101-2020_09_02_279521	349	4	of	of	IN
10_1101-2020_09_02_279521	349	5	neurofibrillary	neurofibrillary	JJ
10_1101-2020_09_02_279521	349	6	degeneration	degeneration	NN
10_1101-2020_09_02_279521	349	7	in	in	IN
10_1101-2020_09_02_279521	349	8	aging	age	VBG
10_1101-2020_09_02_279521	349	9	and	and	CC
10_1101-2020_09_02_279521	349	10	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	349	11	’s	’s	POS
10_1101-2020_09_02_279521	349	12	disease	disease	NN
10_1101-2020_09_02_279521	349	13	.	.	.
10_1101-2020_09_02_279521	350	1	Neurology	neurology	NN
10_1101-2020_09_02_279521	350	2	,	,	,
10_1101-2020_09_02_279521	350	3	52(6	52(6	CD
10_1101-2020_09_02_279521	350	4	)	)	-RRB-
10_1101-2020_09_02_279521	350	5	,	,	,
10_1101-2020_09_02_279521	350	6	1158–1165	1158–1165	CD
10_1101-2020_09_02_279521	350	7	.	.	.
10_1101-2020_09_02_279521	351	1	Desikan	Desikan	NNP
10_1101-2020_09_02_279521	351	2	,	,	,
10_1101-2020_09_02_279521	351	3	R.	R.	NNP
10_1101-2020_09_02_279521	351	4	S.	S.	NNP
10_1101-2020_09_02_279521	351	5	,	,	,
10_1101-2020_09_02_279521	351	6	Ségonne	Ségonne	NNP
10_1101-2020_09_02_279521	351	7	,	,	,
10_1101-2020_09_02_279521	351	8	F.	F.	NNP
10_1101-2020_09_02_279521	351	9	,	,	,
10_1101-2020_09_02_279521	351	10	Fischl	Fischl	NNP
10_1101-2020_09_02_279521	351	11	,	,	,
10_1101-2020_09_02_279521	351	12	B.	B.	NNP
10_1101-2020_09_02_279521	351	13	,	,	,
10_1101-2020_09_02_279521	351	14	Quinn	Quinn	NNP
10_1101-2020_09_02_279521	351	15	,	,	,
10_1101-2020_09_02_279521	351	16	B.	B.	NNP
10_1101-2020_09_02_279521	351	17	T.	T.	NNP
10_1101-2020_09_02_279521	351	18	,	,	,
10_1101-2020_09_02_279521	351	19	Dickerson	Dickerson	NNP
10_1101-2020_09_02_279521	351	20	,	,	,
10_1101-2020_09_02_279521	351	21	B.	B.	NNP
10_1101-2020_09_02_279521	351	22	C.	C.	NNP
10_1101-2020_09_02_279521	351	23	,	,	,
10_1101-2020_09_02_279521	351	24	Blacker	Blacker	NNP
10_1101-2020_09_02_279521	351	25	,	,	,
10_1101-2020_09_02_279521	351	26	D.	D.	NNP
10_1101-2020_09_02_279521	351	27	,	,	,
10_1101-2020_09_02_279521	351	28	Buckner	Buckner	NNP
10_1101-2020_09_02_279521	351	29	,	,	,
10_1101-2020_09_02_279521	351	30	R.	R.	NNP
10_1101-2020_09_02_279521	351	31	L.	L.	NNP
10_1101-2020_09_02_279521	351	32	,	,	,
10_1101-2020_09_02_279521	351	33	Dale	Dale	NNP
10_1101-2020_09_02_279521	351	34	,	,	,
10_1101-2020_09_02_279521	351	35	A.	a.	NN
10_1101-2020_09_02_279521	351	36	M.	M.	NNP
10_1101-2020_09_02_279521	351	37	,	,	,
10_1101-2020_09_02_279521	351	38	Maguire	Maguire	NNP
10_1101-2020_09_02_279521	351	39	,	,	,
10_1101-2020_09_02_279521	351	40	R.	R.	NNP
10_1101-2020_09_02_279521	351	41	P.	P.	NNP
10_1101-2020_09_02_279521	351	42	,	,	,
10_1101-2020_09_02_279521	351	43	Hyman	Hyman	NNP
10_1101-2020_09_02_279521	351	44	,	,	,
10_1101-2020_09_02_279521	351	45	B.	B.	NNP
10_1101-2020_09_02_279521	351	46	T.	T.	NNP
10_1101-2020_09_02_279521	351	47	,	,	,
10_1101-2020_09_02_279521	351	48	Albert	Albert	NNP
10_1101-2020_09_02_279521	351	49	,	,	,
10_1101-2020_09_02_279521	351	50	M.	M.	NNP
10_1101-2020_09_02_279521	351	51	S.	S.	NNP
10_1101-2020_09_02_279521	351	52	,	,	,
10_1101-2020_09_02_279521	351	53	&	&	CC
10_1101-2020_09_02_279521	351	54	Killiany	Killiany	NNP
10_1101-2020_09_02_279521	351	55	,	,	,
10_1101-2020_09_02_279521	351	56	R.	R.	NNP
10_1101-2020_09_02_279521	351	57	J.	J.	NNP
10_1101-2020_09_02_279521	352	1	(	(	-LRB-
10_1101-2020_09_02_279521	352	2	2006	2006	CD
10_1101-2020_09_02_279521	352	3	)	)	-RRB-
10_1101-2020_09_02_279521	352	4	.	.	.
10_1101-2020_09_02_279521	353	1	An	an	DT
10_1101-2020_09_02_279521	353	2	automated	automate	VBN
10_1101-2020_09_02_279521	353	3	labeling	labeling	NN
10_1101-2020_09_02_279521	353	4	system	system	NN
10_1101-2020_09_02_279521	353	5	for	for	IN
10_1101-2020_09_02_279521	353	6	subdividing	subdivide	VBG
10_1101-2020_09_02_279521	353	7	the	the	DT
10_1101-2020_09_02_279521	353	8	human	human	JJ
10_1101-2020_09_02_279521	353	9	cerebral	cerebral	JJ
10_1101-2020_09_02_279521	353	10	cortex	cortex	NN
10_1101-2020_09_02_279521	353	11	on	on	IN
10_1101-2020_09_02_279521	353	12	MRI	MRI	NNP
10_1101-2020_09_02_279521	353	13	scans	scan	NNS
10_1101-2020_09_02_279521	353	14	into	into	IN
10_1101-2020_09_02_279521	353	15	gyral	gyral	JJ
10_1101-2020_09_02_279521	353	16	based	base	VBN
10_1101-2020_09_02_279521	353	17	regions	region	NNS
10_1101-2020_09_02_279521	353	18	of	of	IN
10_1101-2020_09_02_279521	353	19	interest	interest	NN
10_1101-2020_09_02_279521	353	20	.	.	.
10_1101-2020_09_02_279521	354	1	NeuroImage	NeuroImage	NNP
10_1101-2020_09_02_279521	354	2	,	,	,
10_1101-2020_09_02_279521	354	3	31(3	31(3	CD
10_1101-2020_09_02_279521	354	4	)	)	-RRB-
10_1101-2020_09_02_279521	354	5	,	,	,
10_1101-2020_09_02_279521	354	6	968–980	968–980	CD
10_1101-2020_09_02_279521	354	7	.	.	.
10_1101-2020_09_02_279521	355	1	Donohue	Donohue	NNP
10_1101-2020_09_02_279521	355	2	,	,	,
10_1101-2020_09_02_279521	355	3	M.	M.	NNP
10_1101-2020_09_02_279521	355	4	C.	C.	NNP
10_1101-2020_09_02_279521	355	5	,	,	,
10_1101-2020_09_02_279521	355	6	Jacqmin	Jacqmin	NNP
10_1101-2020_09_02_279521	355	7	-	-	HYPH
10_1101-2020_09_02_279521	355	8	Gadda	Gadda	NNP
10_1101-2020_09_02_279521	355	9	,	,	,
10_1101-2020_09_02_279521	355	10	H.	H.	NNP
10_1101-2020_09_02_279521	355	11	,	,	,
10_1101-2020_09_02_279521	355	12	Goff	Goff	NNP
10_1101-2020_09_02_279521	355	13	,	,	,
10_1101-2020_09_02_279521	355	14	M.	M.	NNP
10_1101-2020_09_02_279521	355	15	Le	Le	NNP
10_1101-2020_09_02_279521	355	16	,	,	,
10_1101-2020_09_02_279521	355	17	Thomas	Thomas	NNP
10_1101-2020_09_02_279521	355	18	,	,	,
10_1101-2020_09_02_279521	355	19	R.	R.	NNP
10_1101-2020_09_02_279521	355	20	G.	G.	NNP
10_1101-2020_09_02_279521	355	21	,	,	,
10_1101-2020_09_02_279521	355	22	Raman	Raman	NNP
10_1101-2020_09_02_279521	355	23	,	,	,
10_1101-2020_09_02_279521	355	24	R.	R.	NNP
10_1101-2020_09_02_279521	355	25	,	,	,
10_1101-2020_09_02_279521	355	26	Gamst	Gamst	NNP
10_1101-2020_09_02_279521	355	27	,	,	,
10_1101-2020_09_02_279521	355	28	A.	a.	NN
10_1101-2020_09_02_279521	355	29	C.	C.	NNP
10_1101-2020_09_02_279521	355	30	,	,	,
10_1101-2020_09_02_279521	355	31	Beckett	Beckett	NNP
10_1101-2020_09_02_279521	355	32	,	,	,
10_1101-2020_09_02_279521	355	33	L.	L.	NNP
10_1101-2020_09_02_279521	355	34	A.	A.	NNP
10_1101-2020_09_02_279521	355	35	,	,	,
10_1101-2020_09_02_279521	355	36	Jack	Jack	NNP
10_1101-2020_09_02_279521	355	37	,	,	,
10_1101-2020_09_02_279521	355	38	C.	C.	NNP
10_1101-2020_09_02_279521	355	39	R.	R.	NNP
10_1101-2020_09_02_279521	355	40	,	,	,
10_1101-2020_09_02_279521	355	41	Weiner	Weiner	NNP
10_1101-2020_09_02_279521	355	42	,	,	,
10_1101-2020_09_02_279521	355	43	M.	M.	NNP
10_1101-2020_09_02_279521	355	44	W.	W.	NNP
10_1101-2020_09_02_279521	355	45	,	,	,
10_1101-2020_09_02_279521	355	46	Dartigues	Dartigues	NNP
10_1101-2020_09_02_279521	355	47	,	,	,
10_1101-2020_09_02_279521	355	48	J.-F.	J.-F.	NNP
10_1101-2020_09_02_279521	355	49	,	,	,
10_1101-2020_09_02_279521	355	50	&	&	CC
10_1101-2020_09_02_279521	355	51	Aisen	Aisen	NNP
10_1101-2020_09_02_279521	355	52	,	,	,
10_1101-2020_09_02_279521	355	53	P.	P.	NNP
10_1101-2020_09_02_279521	355	54	S.	S.	NNP
10_1101-2020_09_02_279521	355	55	(	(	-LRB-
10_1101-2020_09_02_279521	355	56	2014	2014	CD
10_1101-2020_09_02_279521	355	57	)	)	-RRB-
10_1101-2020_09_02_279521	355	58	.	.	.
10_1101-2020_09_02_279521	356	1	Estimating	estimate	VBG
10_1101-2020_09_02_279521	356	2	long	long	JJ
10_1101-2020_09_02_279521	356	3	-	-	HYPH
10_1101-2020_09_02_279521	356	4	term	term	NN
10_1101-2020_09_02_279521	356	5	multivariate	multivariate	JJ
10_1101-2020_09_02_279521	356	6	progression	progression	NN
10_1101-2020_09_02_279521	356	7	from	from	IN
10_1101-2020_09_02_279521	356	8	short	short	JJ
10_1101-2020_09_02_279521	356	9	-	-	HYPH
10_1101-2020_09_02_279521	356	10	term	term	NN
10_1101-2020_09_02_279521	356	11	data	datum	NNS
10_1101-2020_09_02_279521	356	12	.	.	.
10_1101-2020_09_02_279521	357	1	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	357	2	’s	’s	NNP
10_1101-2020_09_02_279521	357	3	&	&	CC
10_1101-2020_09_02_279521	357	4	Dementia	Dementia	NNP
10_1101-2020_09_02_279521	357	5	,	,	,
10_1101-2020_09_02_279521	357	6	10(5	10(5	CD
10_1101-2020_09_02_279521	357	7	,	,	,
10_1101-2020_09_02_279521	357	8	Supplement	Supplement	NNP
10_1101-2020_09_02_279521	357	9	)	)	-RRB-
10_1101-2020_09_02_279521	357	10	,	,	,
10_1101-2020_09_02_279521	357	11	S400–S410	S400–S410	NNP
10_1101-2020_09_02_279521	357	12	.	.	.
10_1101-2020_09_02_279521	358	1	https://doi.org/https://doi.org/10.1016/j.jalz.2013.10.003	https://doi.org/https://doi.org/10.1016/j.jalz.2013.10.003	NNP
10_1101-2020_09_02_279521	358	2	Egan	Egan	NNP
10_1101-2020_09_02_279521	358	3	,	,	,
10_1101-2020_09_02_279521	358	4	M.	M.	NNP
10_1101-2020_09_02_279521	358	5	F.	F.	NNP
10_1101-2020_09_02_279521	358	6	,	,	,
10_1101-2020_09_02_279521	358	7	Kost	Kost	NNP
10_1101-2020_09_02_279521	358	8	,	,	,
10_1101-2020_09_02_279521	358	9	J.	J.	NNP
10_1101-2020_09_02_279521	358	10	,	,	,
10_1101-2020_09_02_279521	358	11	Voss	Voss	NNP
10_1101-2020_09_02_279521	358	12	,	,	,
10_1101-2020_09_02_279521	358	13	T.	T.	NNP
10_1101-2020_09_02_279521	358	14	,	,	,
10_1101-2020_09_02_279521	358	15	Mukai	Mukai	NNP
10_1101-2020_09_02_279521	358	16	,	,	,
10_1101-2020_09_02_279521	358	17	Y.	Y.	NNP
10_1101-2020_09_02_279521	358	18	,	,	,
10_1101-2020_09_02_279521	358	19	Aisen	Aisen	NNP
10_1101-2020_09_02_279521	358	20	,	,	,
10_1101-2020_09_02_279521	358	21	P.	P.	NNP
10_1101-2020_09_02_279521	358	22	S.	S.	NNP
10_1101-2020_09_02_279521	358	23	,	,	,
10_1101-2020_09_02_279521	358	24	Cummings	Cummings	NNP
10_1101-2020_09_02_279521	358	25	,	,	,
10_1101-2020_09_02_279521	358	26	J.	J.	NNP
10_1101-2020_09_02_279521	358	27	L.	L.	NNP
10_1101-2020_09_02_279521	358	28	,	,	,
10_1101-2020_09_02_279521	358	29	Tariot	Tariot	NNP
10_1101-2020_09_02_279521	358	30	,	,	,
10_1101-2020_09_02_279521	358	31	P.	P.	NNP
10_1101-2020_09_02_279521	358	32	N.	N.	NNP
10_1101-2020_09_02_279521	358	33	,	,	,
10_1101-2020_09_02_279521	358	34	Vellas	Vellas	NNP
10_1101-2020_09_02_279521	358	35	,	,	,
10_1101-2020_09_02_279521	358	36	B.	B.	NNP
10_1101-2020_09_02_279521	358	37	,	,	,
10_1101-2020_09_02_279521	358	38	van	van	NNP
10_1101-2020_09_02_279521	358	39	Dyck	Dyck	NNP
10_1101-2020_09_02_279521	358	40	,	,	,
10_1101-2020_09_02_279521	358	41	C.	C.	NNP
10_1101-2020_09_02_279521	358	42	H.	H.	NNP
10_1101-2020_09_02_279521	358	43	,	,	,
10_1101-2020_09_02_279521	358	44	Boada	Boada	NNP
10_1101-2020_09_02_279521	358	45	,	,	,
10_1101-2020_09_02_279521	358	46	M.	M.	NNP
10_1101-2020_09_02_279521	358	47	,	,	,
10_1101-2020_09_02_279521	358	48	Zhang	Zhang	NNP
10_1101-2020_09_02_279521	358	49	,	,	,
10_1101-2020_09_02_279521	358	50	Y.	Y.	NNP
10_1101-2020_09_02_279521	358	51	,	,	,
10_1101-2020_09_02_279521	358	52	Li	Li	NNP
10_1101-2020_09_02_279521	358	53	,	,	,
10_1101-2020_09_02_279521	358	54	W.	W.	NNP
10_1101-2020_09_02_279521	358	55	,	,	,
10_1101-2020_09_02_279521	358	56	Furtek	Furtek	NNP
10_1101-2020_09_02_279521	358	57	,	,	,
10_1101-2020_09_02_279521	358	58	C.	C.	NNP
10_1101-2020_09_02_279521	358	59	,	,	,
10_1101-2020_09_02_279521	358	60	Mahoney	Mahoney	NNP
10_1101-2020_09_02_279521	358	61	,	,	,
10_1101-2020_09_02_279521	358	62	E.	E.	NNP
10_1101-2020_09_02_279521	358	63	,	,	,
10_1101-2020_09_02_279521	358	64	Harper	Harper	NNP
10_1101-2020_09_02_279521	358	65	Mozley	Mozley	NNP
10_1101-2020_09_02_279521	358	66	,	,	,
10_1101-2020_09_02_279521	358	67	L.	L.	NNP
10_1101-2020_09_02_279521	358	68	,	,	,
10_1101-2020_09_02_279521	358	69	Mo	Mo	NNP
10_1101-2020_09_02_279521	358	70	,	,	,
10_1101-2020_09_02_279521	358	71	Y.	Y.	NNP
10_1101-2020_09_02_279521	358	72	,	,	,
10_1101-2020_09_02_279521	358	73	Sur	Sur	NNP
10_1101-2020_09_02_279521	358	74	,	,	,
10_1101-2020_09_02_279521	358	75	C.	C.	NNP
10_1101-2020_09_02_279521	358	76	,	,	,
10_1101-2020_09_02_279521	358	77	&	&	CC
10_1101-2020_09_02_279521	358	78	Michelson	Michelson	NNP
10_1101-2020_09_02_279521	358	79	,	,	,
10_1101-2020_09_02_279521	358	80	D.	D.	NNP
10_1101-2020_09_02_279521	358	81	(	(	-LRB-
10_1101-2020_09_02_279521	358	82	2019	2019	CD
10_1101-2020_09_02_279521	358	83	)	)	-RRB-
10_1101-2020_09_02_279521	358	84	.	.	.
10_1101-2020_09_02_279521	359	1	Randomized	randomized	JJ
10_1101-2020_09_02_279521	359	2	Trial	Trial	NNP
10_1101-2020_09_02_279521	359	3	of	of	IN
10_1101-2020_09_02_279521	359	4	Verubecestat	Verubecestat	NNP
10_1101-2020_09_02_279521	359	5	for	for	IN
10_1101-2020_09_02_279521	359	6	Prodromal	Prodromal	NNP
10_1101-2020_09_02_279521	359	7	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	359	8	’s	’s	POS
10_1101-2020_09_02_279521	359	9	Disease	Disease	NNP
10_1101-2020_09_02_279521	359	10	.	.	.
10_1101-2020_09_02_279521	360	1	N.	N.	NNP
10_1101-2020_09_02_279521	360	2	Engl	Engl	NNP
10_1101-2020_09_02_279521	360	3	.	.	.
10_1101-2020_09_02_279521	361	1	J.	J.	NNP
10_1101-2020_09_02_279521	362	1	Med	Med	NNP
10_1101-2020_09_02_279521	362	2	.	.	.
10_1101-2020_09_02_279521	362	3	,	,	,
10_1101-2020_09_02_279521	362	4	380(15	380(15	CD
10_1101-2020_09_02_279521	362	5	)	)	-RRB-
10_1101-2020_09_02_279521	362	6	,	,	,
10_1101-2020_09_02_279521	362	7	1408–1420	1408–1420	CD
10_1101-2020_09_02_279521	362	8	.	.	.
10_1101-2020_09_02_279521	363	1	Fonteijn	Fonteijn	NNP
10_1101-2020_09_02_279521	363	2	,	,	,
10_1101-2020_09_02_279521	363	3	H.	H.	NNP
10_1101-2020_09_02_279521	363	4	M.	M.	NNP
10_1101-2020_09_02_279521	363	5	,	,	,
10_1101-2020_09_02_279521	363	6	Modat	Modat	NNP
10_1101-2020_09_02_279521	363	7	,	,	,
10_1101-2020_09_02_279521	363	8	M.	M.	NNP
10_1101-2020_09_02_279521	363	9	,	,	,
10_1101-2020_09_02_279521	363	10	Clarkson	Clarkson	NNP
10_1101-2020_09_02_279521	363	11	,	,	,
10_1101-2020_09_02_279521	363	12	M.	M.	NNP
10_1101-2020_09_02_279521	363	13	J.	J.	NNP
10_1101-2020_09_02_279521	363	14	,	,	,
10_1101-2020_09_02_279521	363	15	Barnes	Barnes	NNP
10_1101-2020_09_02_279521	363	16	,	,	,
10_1101-2020_09_02_279521	363	17	J.	J.	NNP
10_1101-2020_09_02_279521	363	18	,	,	,
10_1101-2020_09_02_279521	363	19	Lehmann	Lehmann	NNP
10_1101-2020_09_02_279521	363	20	,	,	,
10_1101-2020_09_02_279521	363	21	M.	M.	NNP
10_1101-2020_09_02_279521	363	22	,	,	,
10_1101-2020_09_02_279521	363	23	Hobbs	Hobbs	NNP
10_1101-2020_09_02_279521	363	24	,	,	,
10_1101-2020_09_02_279521	363	25	N.	N.	NNP
10_1101-2020_09_02_279521	363	26	Z.	Z.	NNP
10_1101-2020_09_02_279521	363	27	,	,	,
10_1101-2020_09_02_279521	363	28	Scahill	Scahill	NNP
10_1101-2020_09_02_279521	363	29	,	,	,
10_1101-2020_09_02_279521	363	30	R.	R.	NNP
10_1101-2020_09_02_279521	363	31	I.	I.	NNP
10_1101-2020_09_02_279521	363	32	,	,	,
10_1101-2020_09_02_279521	363	33	Tabrizi	Tabrizi	NNP
10_1101-2020_09_02_279521	363	34	,	,	,
10_1101-2020_09_02_279521	363	35	S.	S.	NNP
10_1101-2020_09_02_279521	363	36	J.	J.	NNP
10_1101-2020_09_02_279521	363	37	,	,	,
10_1101-2020_09_02_279521	363	38	Ourselin	Ourselin	NNP
10_1101-2020_09_02_279521	363	39	,	,	,
10_1101-2020_09_02_279521	363	40	S.	S.	NNP
10_1101-2020_09_02_279521	363	41	,	,	,
10_1101-2020_09_02_279521	363	42	Fox	Fox	NNP
10_1101-2020_09_02_279521	363	43	,	,	,
10_1101-2020_09_02_279521	363	44	N.	N.	NNP
10_1101-2020_09_02_279521	363	45	C.	C.	NNP
10_1101-2020_09_02_279521	363	46	,	,	,
10_1101-2020_09_02_279521	363	47	&	&	CC
10_1101-2020_09_02_279521	363	48	Alexander	Alexander	NNP
10_1101-2020_09_02_279521	363	49	,	,	,
10_1101-2020_09_02_279521	363	50	D.	D.	NNP
10_1101-2020_09_02_279521	363	51	C.	C.	NNP
10_1101-2020_09_02_279521	363	52	(	(	-LRB-
10_1101-2020_09_02_279521	363	53	2012	2012	CD
10_1101-2020_09_02_279521	363	54	)	)	-RRB-
10_1101-2020_09_02_279521	363	55	.	.	.
10_1101-2020_09_02_279521	364	1	An	an	DT
10_1101-2020_09_02_279521	364	2	event	event	NN
10_1101-2020_09_02_279521	364	3	-	-	HYPH
10_1101-2020_09_02_279521	364	4	based	base	VBN
10_1101-2020_09_02_279521	364	5	model	model	NN
10_1101-2020_09_02_279521	364	6	for	for	IN
10_1101-2020_09_02_279521	364	7	disease	disease	NNP
10_1101-2020_09_02_279521	364	8	progression	progression	NNP
10_1101-2020_09_02_279521	364	9	and	and	CC
10_1101-2020_09_02_279521	364	10	its	-PRON-	PRP$
10_1101-2020_09_02_279521	364	11	application	application	NN
10_1101-2020_09_02_279521	364	12	in	in	IN
10_1101-2020_09_02_279521	364	13	familial	familial	JJ
10_1101-2020_09_02_279521	364	14	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	364	15	’s	’s	POS
10_1101-2020_09_02_279521	364	16	disease	disease	NN
10_1101-2020_09_02_279521	364	17	and	and	CC
10_1101-2020_09_02_279521	364	18	Huntington	Huntington	NNP
10_1101-2020_09_02_279521	364	19	’s	’s	POS
10_1101-2020_09_02_279521	364	20	disease	disease	NN
10_1101-2020_09_02_279521	364	21	.	.	.
10_1101-2020_09_02_279521	365	1	NeuroImage	NeuroImage	NNP
10_1101-2020_09_02_279521	365	2	,	,	,
10_1101-2020_09_02_279521	365	3	60(3	60(3	CD
10_1101-2020_09_02_279521	365	4	)	)	-RRB-
10_1101-2020_09_02_279521	365	5	,	,	,
10_1101-2020_09_02_279521	365	6	1880–1889	1880–1889	CD
10_1101-2020_09_02_279521	365	7	.	.	.
10_1101-2020_09_02_279521	366	1	Gamberger	Gamberger	NNP
10_1101-2020_09_02_279521	366	2	,	,	,
10_1101-2020_09_02_279521	366	3	D.	D.	NNP
10_1101-2020_09_02_279521	366	4	,	,	,
10_1101-2020_09_02_279521	366	5	Lavrač	Lavrač	NNP
10_1101-2020_09_02_279521	366	6	,	,	,
10_1101-2020_09_02_279521	366	7	N.	N.	NNP
10_1101-2020_09_02_279521	366	8	,	,	,
10_1101-2020_09_02_279521	366	9	Srivatsa	Srivatsa	NNP
10_1101-2020_09_02_279521	366	10	,	,	,
10_1101-2020_09_02_279521	366	11	S.	S.	NNP
10_1101-2020_09_02_279521	366	12	,	,	,
10_1101-2020_09_02_279521	366	13	Tanzi	Tanzi	NNP
10_1101-2020_09_02_279521	366	14	,	,	,
10_1101-2020_09_02_279521	366	15	R.	R.	NNP
10_1101-2020_09_02_279521	366	16	E.	E.	NNP
10_1101-2020_09_02_279521	366	17	,	,	,
10_1101-2020_09_02_279521	366	18	&	&	CC
10_1101-2020_09_02_279521	366	19	Doraiswamy	Doraiswamy	NNP
10_1101-2020_09_02_279521	366	20	,	,	,
10_1101-2020_09_02_279521	366	21	P.	P.	NNP
10_1101-2020_09_02_279521	366	22	M.	M.	NNP
10_1101-2020_09_02_279521	366	23	(	(	-LRB-
10_1101-2020_09_02_279521	366	24	2017	2017	CD
10_1101-2020_09_02_279521	366	25	)	)	-RRB-
10_1101-2020_09_02_279521	366	26	.	.	.
10_1101-2020_09_02_279521	367	1	Identification	identification	NN
10_1101-2020_09_02_279521	367	2	of	of	IN
10_1101-2020_09_02_279521	367	3	clusters	cluster	NNS
10_1101-2020_09_02_279521	367	4	of	of	IN
10_1101-2020_09_02_279521	367	5	rapid	rapid	JJ
10_1101-2020_09_02_279521	367	6	and	and	CC
10_1101-2020_09_02_279521	367	7	slow	slow	JJ
10_1101-2020_09_02_279521	367	8	decliners	decliner	NNS
10_1101-2020_09_02_279521	367	9	among	among	IN
10_1101-2020_09_02_279521	367	10	subjects	subject	NNS
10_1101-2020_09_02_279521	367	11	at	at	IN
10_1101-2020_09_02_279521	367	12	risk	risk	NN
10_1101-2020_09_02_279521	367	13	for	for	IN
10_1101-2020_09_02_279521	367	14	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	367	15	’s	’s	POS
10_1101-2020_09_02_279521	367	16	disease	disease	NN
10_1101-2020_09_02_279521	367	17	.	.	.
10_1101-2020_09_02_279521	368	1	Sci	Sci	NNP
10_1101-2020_09_02_279521	368	2	Rep	Rep	NNP
10_1101-2020_09_02_279521	368	3	,	,	,
10_1101-2020_09_02_279521	368	4	7(1	7(1	NNP
10_1101-2020_09_02_279521	368	5	)	)	-RRB-
10_1101-2020_09_02_279521	368	6	,	,	,
10_1101-2020_09_02_279521	368	7	6763	6763	CD
10_1101-2020_09_02_279521	368	8	.	.	.
10_1101-2020_09_02_279521	369	1	.CC	.CC	NFP
10_1101-2020_09_02_279521	369	2	-	-	:
10_1101-2020_09_02_279521	369	3	BY	by	IN
10_1101-2020_09_02_279521	369	4	4.0	4.0	CD
10_1101-2020_09_02_279521	369	5	International	international	JJ
10_1101-2020_09_02_279521	369	6	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	369	7	.	.	.
10_1101-2020_09_02_279521	370	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	370	2	is	be	VBZ
10_1101-2020_09_02_279521	370	3	made	make	VBN
10_1101-2020_09_02_279521	370	4	available	available	JJ
10_1101-2020_09_02_279521	370	5	under	under	IN
10_1101-2020_09_02_279521	370	6	a	a	DT
10_1101-2020_09_02_279521	370	7	preprint	preprint	NN
10_1101-2020_09_02_279521	370	8	(	(	-LRB-
10_1101-2020_09_02_279521	370	9	which	which	WDT
10_1101-2020_09_02_279521	370	10	was	be	VBD
10_1101-2020_09_02_279521	370	11	not	not	RB
10_1101-2020_09_02_279521	370	12	certified	certify	VBN
10_1101-2020_09_02_279521	370	13	by	by	IN
10_1101-2020_09_02_279521	370	14	peer	peer	NN
10_1101-2020_09_02_279521	370	15	review	review	NN
10_1101-2020_09_02_279521	370	16	)	)	-RRB-
10_1101-2020_09_02_279521	370	17	is	be	VBZ
10_1101-2020_09_02_279521	370	18	the	the	DT
10_1101-2020_09_02_279521	370	19	author	author	NN
10_1101-2020_09_02_279521	370	20	/	/	SYM
10_1101-2020_09_02_279521	370	21	funder	funder	NN
10_1101-2020_09_02_279521	370	22	,	,	,
10_1101-2020_09_02_279521	370	23	who	who	WP
10_1101-2020_09_02_279521	370	24	has	have	VBZ
10_1101-2020_09_02_279521	370	25	granted	grant	VBN
10_1101-2020_09_02_279521	370	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	370	27	a	a	DT
10_1101-2020_09_02_279521	370	28	license	license	NN
10_1101-2020_09_02_279521	370	29	to	to	TO
10_1101-2020_09_02_279521	370	30	display	display	VB
10_1101-2020_09_02_279521	370	31	the	the	DT
10_1101-2020_09_02_279521	370	32	preprint	preprint	NN
10_1101-2020_09_02_279521	370	33	in	in	IN
10_1101-2020_09_02_279521	370	34	The	the	DT
10_1101-2020_09_02_279521	370	35	copyright	copyright	NN
10_1101-2020_09_02_279521	370	36	holder	holder	NN
10_1101-2020_09_02_279521	370	37	for	for	IN
10_1101-2020_09_02_279521	370	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	370	39	version	version	NN
10_1101-2020_09_02_279521	370	40	posted	post	VBD
10_1101-2020_09_02_279521	370	41	February	February	NNP
10_1101-2020_09_02_279521	370	42	10	10	CD
10_1101-2020_09_02_279521	370	43	,	,	,
10_1101-2020_09_02_279521	370	44	2021	2021	CD
10_1101-2020_09_02_279521	370	45	.	.	.
10_1101-2020_09_02_279521	370	46	;	;	:
10_1101-2020_09_02_279521	370	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	370	48	:	:	:
10_1101-2020_09_02_279521	370	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	370	50	preprint	preprint	NN
10_1101-2020_09_02_279521	370	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	ADD
10_1101-2020_09_02_279521	370	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	ADD
10_1101-2020_09_02_279521	370	53	Garbarino	Garbarino	NNP
10_1101-2020_09_02_279521	370	54	,	,	,
10_1101-2020_09_02_279521	370	55	S.	S.	NNP
10_1101-2020_09_02_279521	370	56	,	,	,
10_1101-2020_09_02_279521	370	57	&	&	CC
10_1101-2020_09_02_279521	370	58	Lorenzi	Lorenzi	NNP
10_1101-2020_09_02_279521	370	59	,	,	,
10_1101-2020_09_02_279521	370	60	M.	M.	NNP
10_1101-2020_09_02_279521	370	61	(	(	-LRB-
10_1101-2020_09_02_279521	370	62	2019	2019	CD
10_1101-2020_09_02_279521	370	63	)	)	-RRB-
10_1101-2020_09_02_279521	370	64	.	.	.
10_1101-2020_09_02_279521	371	1	Modeling	modeling	NN
10_1101-2020_09_02_279521	371	2	and	and	CC
10_1101-2020_09_02_279521	371	3	Inference	Inference	NNP
10_1101-2020_09_02_279521	371	4	of	of	IN
10_1101-2020_09_02_279521	371	5	Spatio	Spatio	NNP
10_1101-2020_09_02_279521	371	6	-	-	HYPH
10_1101-2020_09_02_279521	371	7	Temporal	Temporal	NNP
10_1101-2020_09_02_279521	371	8	Protein	Protein	NNP
10_1101-2020_09_02_279521	371	9	Dynamics	Dynamics	NNPS
10_1101-2020_09_02_279521	371	10	Across	across	IN
10_1101-2020_09_02_279521	371	11	Brain	Brain	NNP
10_1101-2020_09_02_279521	371	12	Networks	Networks	NNP
10_1101-2020_09_02_279521	371	13	.	.	.
10_1101-2020_09_02_279521	372	1	IPMI	IPMI	NNP
10_1101-2020_09_02_279521	372	2	2019	2019	CD
10_1101-2020_09_02_279521	372	3	-	-	HYPH
10_1101-2020_09_02_279521	372	4	26th	26th	NN
10_1101-2020_09_02_279521	372	5	International	International	NNP
10_1101-2020_09_02_279521	372	6	Conference	Conference	NNP
10_1101-2020_09_02_279521	372	7	on	on	IN
10_1101-2020_09_02_279521	372	8	Information	Information	NNP
10_1101-2020_09_02_279521	372	9	Processing	Processing	NNP
10_1101-2020_09_02_279521	372	10	in	in	IN
10_1101-2020_09_02_279521	372	11	Medical	Medical	NNP
10_1101-2020_09_02_279521	372	12	Imaging	Imaging	NNP
10_1101-2020_09_02_279521	372	13	,	,	,
10_1101-2020_09_02_279521	372	14	11492	11492	CD
10_1101-2020_09_02_279521	372	15	,	,	,
10_1101-2020_09_02_279521	372	16	57–69	57–69	CD
10_1101-2020_09_02_279521	372	17	.	.	.
10_1101-2020_09_02_279521	373	1	https://hal.inria.fr/hal-	https://hal.inria.fr/hal-	NNP
10_1101-2020_09_02_279521	373	2	02165021	02165021	CD
10_1101-2020_09_02_279521	373	3	Gauthier	Gauthier	NNP
10_1101-2020_09_02_279521	373	4	,	,	,
10_1101-2020_09_02_279521	373	5	S.	S.	NNP
10_1101-2020_09_02_279521	373	6	,	,	,
10_1101-2020_09_02_279521	373	7	Alam	Alam	NNP
10_1101-2020_09_02_279521	373	8	,	,	,
10_1101-2020_09_02_279521	373	9	J.	J.	NNP
10_1101-2020_09_02_279521	373	10	,	,	,
10_1101-2020_09_02_279521	373	11	Fillit	Fillit	NNP
10_1101-2020_09_02_279521	373	12	,	,	,
10_1101-2020_09_02_279521	373	13	H.	H.	NNP
10_1101-2020_09_02_279521	373	14	,	,	,
10_1101-2020_09_02_279521	373	15	Iwatsubo	Iwatsubo	NNP
10_1101-2020_09_02_279521	373	16	,	,	,
10_1101-2020_09_02_279521	373	17	T.	T.	NNP
10_1101-2020_09_02_279521	373	18	,	,	,
10_1101-2020_09_02_279521	373	19	Liu	Liu	NNP
10_1101-2020_09_02_279521	373	20	-	-	HYPH
10_1101-2020_09_02_279521	373	21	Seifert	Seifert	NNP
10_1101-2020_09_02_279521	373	22	,	,	,
10_1101-2020_09_02_279521	373	23	H.	H.	NNP
10_1101-2020_09_02_279521	373	24	,	,	,
10_1101-2020_09_02_279521	373	25	Sabbagh	Sabbagh	NNP
10_1101-2020_09_02_279521	373	26	,	,	,
10_1101-2020_09_02_279521	373	27	M.	M.	NNP
10_1101-2020_09_02_279521	373	28	,	,	,
10_1101-2020_09_02_279521	373	29	Salloway	Salloway	NNP
10_1101-2020_09_02_279521	373	30	,	,	,
10_1101-2020_09_02_279521	373	31	S.	S.	NNP
10_1101-2020_09_02_279521	373	32	,	,	,
10_1101-2020_09_02_279521	373	33	Sampaio	Sampaio	NNP
10_1101-2020_09_02_279521	373	34	,	,	,
10_1101-2020_09_02_279521	373	35	C.	C.	NNP
10_1101-2020_09_02_279521	373	36	,	,	,
10_1101-2020_09_02_279521	373	37	Sims	Sims	NNP
10_1101-2020_09_02_279521	373	38	,	,	,
10_1101-2020_09_02_279521	373	39	J.	J.	NNP
10_1101-2020_09_02_279521	373	40	R.	R.	NNP
10_1101-2020_09_02_279521	373	41	,	,	,
10_1101-2020_09_02_279521	373	42	Sperling	Sperling	NNP
10_1101-2020_09_02_279521	373	43	,	,	,
10_1101-2020_09_02_279521	373	44	B.	B.	NNP
10_1101-2020_09_02_279521	373	45	,	,	,
10_1101-2020_09_02_279521	373	46	Sperling	Sperling	NNP
10_1101-2020_09_02_279521	373	47	,	,	,
10_1101-2020_09_02_279521	373	48	R.	R.	NNP
10_1101-2020_09_02_279521	373	49	,	,	,
10_1101-2020_09_02_279521	373	50	Welsh	Welsh	NNP
10_1101-2020_09_02_279521	373	51	-	-	HYPH
10_1101-2020_09_02_279521	373	52	Bohmer	Bohmer	NNP
10_1101-2020_09_02_279521	373	53	,	,	,
10_1101-2020_09_02_279521	373	54	K.	K.	NNP
10_1101-2020_09_02_279521	373	55	A.	A.	NNP
10_1101-2020_09_02_279521	373	56	,	,	,
10_1101-2020_09_02_279521	373	57	Touchon	Touchon	NNP
10_1101-2020_09_02_279521	373	58	,	,	,
10_1101-2020_09_02_279521	373	59	J.	J.	NNP
10_1101-2020_09_02_279521	373	60	,	,	,
10_1101-2020_09_02_279521	373	61	Vellas	Vellas	NNP
10_1101-2020_09_02_279521	373	62	,	,	,
10_1101-2020_09_02_279521	373	63	B.	B.	NNP
10_1101-2020_09_02_279521	373	64	,	,	,
10_1101-2020_09_02_279521	373	65	&	&	CC
10_1101-2020_09_02_279521	373	66	Aisen	Aisen	NNP
10_1101-2020_09_02_279521	373	67	,	,	,
10_1101-2020_09_02_279521	373	68	P.	P.	NNP
10_1101-2020_09_02_279521	373	69	(	(	-LRB-
10_1101-2020_09_02_279521	373	70	2019	2019	CD
10_1101-2020_09_02_279521	373	71	)	)	-RRB-
10_1101-2020_09_02_279521	373	72	.	.	.
10_1101-2020_09_02_279521	374	1	Combination	combination	NN
10_1101-2020_09_02_279521	374	2	Therapy	Therapy	NNP
10_1101-2020_09_02_279521	374	3	for	for	IN
10_1101-2020_09_02_279521	374	4	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	374	5	’s	’s	POS
10_1101-2020_09_02_279521	374	6	Disease	Disease	NNP
10_1101-2020_09_02_279521	374	7	:	:	:
10_1101-2020_09_02_279521	374	8	Perspectives	perspective	NNS
10_1101-2020_09_02_279521	374	9	of	of	IN
10_1101-2020_09_02_279521	374	10	the	the	DT
10_1101-2020_09_02_279521	374	11	EU	EU	NNP
10_1101-2020_09_02_279521	374	12	/	/	SYM
10_1101-2020_09_02_279521	374	13	US	US	NNP
10_1101-2020_09_02_279521	374	14	CTAD	CTAD	NNP
10_1101-2020_09_02_279521	374	15	Task	Task	NNP
10_1101-2020_09_02_279521	374	16	Force	Force	NNP
10_1101-2020_09_02_279521	374	17	.	.	.
10_1101-2020_09_02_279521	375	1	J	J	NNP
10_1101-2020_09_02_279521	375	2	Prev	Prev	NNP
10_1101-2020_09_02_279521	375	3	Alzheimers	Alzheimers	NNPS
10_1101-2020_09_02_279521	375	4	Dis	Dis	NNP
10_1101-2020_09_02_279521	375	5	,	,	,
10_1101-2020_09_02_279521	375	6	6(3	6(3	NNP
10_1101-2020_09_02_279521	375	7	)	)	-RRB-
10_1101-2020_09_02_279521	375	8	,	,	,
10_1101-2020_09_02_279521	375	9	164–168	164–168	CD
10_1101-2020_09_02_279521	375	10	.	.	.
10_1101-2020_09_02_279521	376	1	Hao	Hao	NNP
10_1101-2020_09_02_279521	376	2	,	,	,
10_1101-2020_09_02_279521	376	3	W.	W.	NNP
10_1101-2020_09_02_279521	376	4	,	,	,
10_1101-2020_09_02_279521	376	5	&	&	CC
10_1101-2020_09_02_279521	376	6	Friedman	Friedman	NNP
10_1101-2020_09_02_279521	376	7	,	,	,
10_1101-2020_09_02_279521	376	8	A.	a.	NN
10_1101-2020_09_02_279521	377	1	(	(	-LRB-
10_1101-2020_09_02_279521	377	2	2016	2016	CD
10_1101-2020_09_02_279521	377	3	)	)	-RRB-
10_1101-2020_09_02_279521	377	4	.	.	.
10_1101-2020_09_02_279521	378	1	Mathematical	mathematical	JJ
10_1101-2020_09_02_279521	378	2	model	model	NN
10_1101-2020_09_02_279521	378	3	on	on	IN
10_1101-2020_09_02_279521	378	4	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	378	5	’s	’s	POS
10_1101-2020_09_02_279521	378	6	disease	disease	NN
10_1101-2020_09_02_279521	378	7	.	.	.
10_1101-2020_09_02_279521	379	1	BMC	BMC	NNP
10_1101-2020_09_02_279521	379	2	Syst	Syst	NNP
10_1101-2020_09_02_279521	379	3	Biol	Biol	NNP
10_1101-2020_09_02_279521	379	4	,	,	,
10_1101-2020_09_02_279521	379	5	10(1	10(1	CD
10_1101-2020_09_02_279521	379	6	)	)	-RRB-
10_1101-2020_09_02_279521	379	7	,	,	,
10_1101-2020_09_02_279521	379	8	108	108	CD
10_1101-2020_09_02_279521	379	9	.	.	.
10_1101-2020_09_02_279521	379	10	Henley	Henley	NNP
10_1101-2020_09_02_279521	379	11	,	,	,
10_1101-2020_09_02_279521	379	12	D.	D.	NNP
10_1101-2020_09_02_279521	379	13	,	,	,
10_1101-2020_09_02_279521	379	14	Raghavan	Raghavan	NNP
10_1101-2020_09_02_279521	379	15	,	,	,
10_1101-2020_09_02_279521	379	16	N.	N.	NNP
10_1101-2020_09_02_279521	379	17	,	,	,
10_1101-2020_09_02_279521	379	18	Sperling	Sperling	NNP
10_1101-2020_09_02_279521	379	19	,	,	,
10_1101-2020_09_02_279521	379	20	R.	R.	NNP
10_1101-2020_09_02_279521	379	21	,	,	,
10_1101-2020_09_02_279521	379	22	Aisen	Aisen	NNP
10_1101-2020_09_02_279521	379	23	,	,	,
10_1101-2020_09_02_279521	379	24	P.	P.	NNP
10_1101-2020_09_02_279521	379	25	,	,	,
10_1101-2020_09_02_279521	379	26	Raman	Raman	NNP
10_1101-2020_09_02_279521	379	27	,	,	,
10_1101-2020_09_02_279521	379	28	R.	R.	NNP
10_1101-2020_09_02_279521	379	29	,	,	,
10_1101-2020_09_02_279521	379	30	&	&	CC
10_1101-2020_09_02_279521	379	31	Romano	Romano	NNP
10_1101-2020_09_02_279521	379	32	,	,	,
10_1101-2020_09_02_279521	379	33	G.	G.	NNP
10_1101-2020_09_02_279521	379	34	(	(	-LRB-
10_1101-2020_09_02_279521	379	35	2019	2019	CD
10_1101-2020_09_02_279521	379	36	)	)	-RRB-
10_1101-2020_09_02_279521	379	37	.	.	.
10_1101-2020_09_02_279521	380	1	Preliminary	preliminary	JJ
10_1101-2020_09_02_279521	380	2	Results	result	NNS
10_1101-2020_09_02_279521	380	3	of	of	IN
10_1101-2020_09_02_279521	380	4	a	a	DT
10_1101-2020_09_02_279521	380	5	Trial	Trial	NNP
10_1101-2020_09_02_279521	380	6	of	of	IN
10_1101-2020_09_02_279521	380	7	Atabecestat	Atabecestat	NNP
10_1101-2020_09_02_279521	380	8	in	in	IN
10_1101-2020_09_02_279521	380	9	Preclinical	Preclinical	NNP
10_1101-2020_09_02_279521	380	10	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	380	11	’s	’s	POS
10_1101-2020_09_02_279521	380	12	Disease	Disease	NNP
10_1101-2020_09_02_279521	380	13	.	.	.
10_1101-2020_09_02_279521	381	1	N.	N.	NNP
10_1101-2020_09_02_279521	381	2	Engl	Engl	NNP
10_1101-2020_09_02_279521	381	3	.	.	.
10_1101-2020_09_02_279521	382	1	J.	J.	NNP
10_1101-2020_09_02_279521	383	1	Med	Med	NNP
10_1101-2020_09_02_279521	383	2	.	.	.
10_1101-2020_09_02_279521	383	3	,	,	,
10_1101-2020_09_02_279521	383	4	380(15	380(15	CD
10_1101-2020_09_02_279521	383	5	)	)	-RRB-
10_1101-2020_09_02_279521	383	6	,	,	,
10_1101-2020_09_02_279521	383	7	1483–1485	1483–1485	CD
10_1101-2020_09_02_279521	383	8	.	.	.
10_1101-2020_09_02_279521	384	1	Honig	Honig	NNP
10_1101-2020_09_02_279521	384	2	,	,	,
10_1101-2020_09_02_279521	384	3	L.	L.	NNP
10_1101-2020_09_02_279521	384	4	S.	S.	NNP
10_1101-2020_09_02_279521	384	5	,	,	,
10_1101-2020_09_02_279521	384	6	Vellas	Vellas	NNP
10_1101-2020_09_02_279521	384	7	,	,	,
10_1101-2020_09_02_279521	384	8	B.	B.	NNP
10_1101-2020_09_02_279521	384	9	,	,	,
10_1101-2020_09_02_279521	384	10	Woodward	Woodward	NNP
10_1101-2020_09_02_279521	384	11	,	,	,
10_1101-2020_09_02_279521	384	12	M.	M.	NNP
10_1101-2020_09_02_279521	384	13	,	,	,
10_1101-2020_09_02_279521	384	14	Boada	Boada	NNP
10_1101-2020_09_02_279521	384	15	,	,	,
10_1101-2020_09_02_279521	384	16	M.	M.	NNP
10_1101-2020_09_02_279521	384	17	,	,	,
10_1101-2020_09_02_279521	384	18	Bullock	Bullock	NNP
10_1101-2020_09_02_279521	384	19	,	,	,
10_1101-2020_09_02_279521	384	20	R.	R.	NNP
10_1101-2020_09_02_279521	384	21	,	,	,
10_1101-2020_09_02_279521	384	22	Borrie	Borrie	NNP
10_1101-2020_09_02_279521	384	23	,	,	,
10_1101-2020_09_02_279521	384	24	M.	M.	NNP
10_1101-2020_09_02_279521	384	25	,	,	,
10_1101-2020_09_02_279521	384	26	Hager	Hager	NNP
10_1101-2020_09_02_279521	384	27	,	,	,
10_1101-2020_09_02_279521	384	28	K.	K.	NNP
10_1101-2020_09_02_279521	384	29	,	,	,
10_1101-2020_09_02_279521	384	30	Andreasen	Andreasen	NNP
10_1101-2020_09_02_279521	384	31	,	,	,
10_1101-2020_09_02_279521	384	32	N.	N.	NNP
10_1101-2020_09_02_279521	384	33	,	,	,
10_1101-2020_09_02_279521	384	34	Scarpini	Scarpini	NNP
10_1101-2020_09_02_279521	384	35	,	,	,
10_1101-2020_09_02_279521	384	36	E.	E.	NNP
10_1101-2020_09_02_279521	384	37	,	,	,
10_1101-2020_09_02_279521	384	38	Liu	Liu	NNP
10_1101-2020_09_02_279521	384	39	-	-	HYPH
10_1101-2020_09_02_279521	384	40	Seifert	Seifert	NNP
10_1101-2020_09_02_279521	384	41	,	,	,
10_1101-2020_09_02_279521	384	42	H.	H.	NNP
10_1101-2020_09_02_279521	384	43	,	,	,
10_1101-2020_09_02_279521	384	44	Case	Case	NNP
10_1101-2020_09_02_279521	384	45	,	,	,
10_1101-2020_09_02_279521	384	46	M.	M.	NNP
10_1101-2020_09_02_279521	384	47	,	,	,
10_1101-2020_09_02_279521	384	48	Dean	Dean	NNP
10_1101-2020_09_02_279521	384	49	,	,	,
10_1101-2020_09_02_279521	384	50	R.	R.	NNP
10_1101-2020_09_02_279521	384	51	A.	A.	NNP
10_1101-2020_09_02_279521	384	52	,	,	,
10_1101-2020_09_02_279521	384	53	Hake	Hake	NNP
10_1101-2020_09_02_279521	384	54	,	,	,
10_1101-2020_09_02_279521	384	55	A.	A.	NNP
10_1101-2020_09_02_279521	384	56	,	,	,
10_1101-2020_09_02_279521	384	57	Sundell	Sundell	NNP
10_1101-2020_09_02_279521	384	58	,	,	,
10_1101-2020_09_02_279521	384	59	K.	K.	NNP
10_1101-2020_09_02_279521	384	60	,	,	,
10_1101-2020_09_02_279521	384	61	Poole	Poole	NNP
10_1101-2020_09_02_279521	384	62	Hoffmann	Hoffmann	NNP
10_1101-2020_09_02_279521	384	63	,	,	,
10_1101-2020_09_02_279521	384	64	V.	V.	NNP
10_1101-2020_09_02_279521	384	65	,	,	,
10_1101-2020_09_02_279521	384	66	Carlson	Carlson	NNP
10_1101-2020_09_02_279521	384	67	,	,	,
10_1101-2020_09_02_279521	384	68	C.	C.	NNP
10_1101-2020_09_02_279521	384	69	,	,	,
10_1101-2020_09_02_279521	384	70	Khanna	Khanna	NNP
10_1101-2020_09_02_279521	384	71	,	,	,
10_1101-2020_09_02_279521	384	72	R.	R.	NNP
10_1101-2020_09_02_279521	384	73	,	,	,
10_1101-2020_09_02_279521	384	74	Mintun	Mintun	NNP
10_1101-2020_09_02_279521	384	75	,	,	,
10_1101-2020_09_02_279521	384	76	M.	M.	NNP
10_1101-2020_09_02_279521	384	77	,	,	,
10_1101-2020_09_02_279521	384	78	DeMattos	DeMattos	NNP
10_1101-2020_09_02_279521	384	79	,	,	,
10_1101-2020_09_02_279521	384	80	R.	R.	NNP
10_1101-2020_09_02_279521	384	81	,	,	,
10_1101-2020_09_02_279521	384	82	…	…	NFP
10_1101-2020_09_02_279521	384	83	Siemers	Siemers	NNP
10_1101-2020_09_02_279521	384	84	,	,	,
10_1101-2020_09_02_279521	384	85	E.	E.	NNP
10_1101-2020_09_02_279521	384	86	(	(	-LRB-
10_1101-2020_09_02_279521	384	87	2018	2018	CD
10_1101-2020_09_02_279521	384	88	)	)	-RRB-
10_1101-2020_09_02_279521	384	89	.	.	.
10_1101-2020_09_02_279521	385	1	Trial	trial	NN
10_1101-2020_09_02_279521	385	2	of	of	IN
10_1101-2020_09_02_279521	385	3	Solanezumab	Solanezumab	NNP
10_1101-2020_09_02_279521	385	4	for	for	IN
10_1101-2020_09_02_279521	385	5	Mild	Mild	NNP
10_1101-2020_09_02_279521	385	6	Dementia	Dementia	NNP
10_1101-2020_09_02_279521	385	7	Due	due	IN
10_1101-2020_09_02_279521	385	8	to	to	IN
10_1101-2020_09_02_279521	385	9	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	385	10	’s	’s	POS
10_1101-2020_09_02_279521	385	11	Disease	Disease	NNP
10_1101-2020_09_02_279521	385	12	.	.	.
10_1101-2020_09_02_279521	386	1	N.	N.	NNP
10_1101-2020_09_02_279521	386	2	Engl	Engl	NNP
10_1101-2020_09_02_279521	386	3	.	.	.
10_1101-2020_09_02_279521	387	1	J.	J.	NNP
10_1101-2020_09_02_279521	388	1	Med	Med	NNP
10_1101-2020_09_02_279521	388	2	.	.	.
10_1101-2020_09_02_279521	388	3	,	,	,
10_1101-2020_09_02_279521	388	4	378(4	378(4	CD
10_1101-2020_09_02_279521	388	5	)	)	-RRB-
10_1101-2020_09_02_279521	388	6	,	,	,
10_1101-2020_09_02_279521	388	7	321–330	321–330	NNP
10_1101-2020_09_02_279521	388	8	.	.	.
10_1101-2020_09_02_279521	389	1	Howard	Howard	NNP
10_1101-2020_09_02_279521	389	2	,	,	,
10_1101-2020_09_02_279521	389	3	R.	R.	NNP
10_1101-2020_09_02_279521	389	4	,	,	,
10_1101-2020_09_02_279521	389	5	&	&	CC
10_1101-2020_09_02_279521	389	6	Liu	Liu	NNP
10_1101-2020_09_02_279521	389	7	,	,	,
10_1101-2020_09_02_279521	389	8	K.	K.	NNP
10_1101-2020_09_02_279521	389	9	Y.	Y.	NNP
10_1101-2020_09_02_279521	390	1	(	(	-LRB-
10_1101-2020_09_02_279521	390	2	2020	2020	CD
10_1101-2020_09_02_279521	390	3	)	)	-RRB-
10_1101-2020_09_02_279521	390	4	.	.	.
10_1101-2020_09_02_279521	391	1	Questions	question	NNS
10_1101-2020_09_02_279521	391	2	EMERGE	emerge	CC
10_1101-2020_09_02_279521	391	3	as	as	IN
10_1101-2020_09_02_279521	391	4	Biogen	Biogen	NNP
10_1101-2020_09_02_279521	391	5	claims	claim	VBZ
10_1101-2020_09_02_279521	391	6	aducanumab	aducanumab	VBZ
10_1101-2020_09_02_279521	391	7	turnaround	turnaround	NN
10_1101-2020_09_02_279521	391	8	.	.	.
10_1101-2020_09_02_279521	392	1	Nat	Nat	NNP
10_1101-2020_09_02_279521	392	2	Rev	Rev	NNP
10_1101-2020_09_02_279521	392	3	Neurol	Neurol	NNP
10_1101-2020_09_02_279521	392	4	,	,	,
10_1101-2020_09_02_279521	392	5	16(2	16(2	CD
10_1101-2020_09_02_279521	392	6	)	)	-RRB-
10_1101-2020_09_02_279521	392	7	,	,	,
10_1101-2020_09_02_279521	392	8	63–64	63–64	CD
10_1101-2020_09_02_279521	392	9	.	.	.
10_1101-2020_09_02_279521	393	1	Insel	Insel	NNP
10_1101-2020_09_02_279521	393	2	,	,	,
10_1101-2020_09_02_279521	393	3	P.	P.	NNP
10_1101-2020_09_02_279521	393	4	S.	S.	NNP
10_1101-2020_09_02_279521	393	5	,	,	,
10_1101-2020_09_02_279521	393	6	Mormino	Mormino	NNP
10_1101-2020_09_02_279521	393	7	,	,	,
10_1101-2020_09_02_279521	393	8	E.	E.	NNP
10_1101-2020_09_02_279521	393	9	C.	C.	NNP
10_1101-2020_09_02_279521	393	10	,	,	,
10_1101-2020_09_02_279521	393	11	Aisen	Aisen	NNP
10_1101-2020_09_02_279521	393	12	,	,	,
10_1101-2020_09_02_279521	393	13	P.	P.	NNP
10_1101-2020_09_02_279521	393	14	S.	S.	NNP
10_1101-2020_09_02_279521	393	15	,	,	,
10_1101-2020_09_02_279521	393	16	Thompson	Thompson	NNP
10_1101-2020_09_02_279521	393	17	,	,	,
10_1101-2020_09_02_279521	393	18	W.	W.	NNP
10_1101-2020_09_02_279521	393	19	K.	K.	NNP
10_1101-2020_09_02_279521	393	20	,	,	,
10_1101-2020_09_02_279521	393	21	&	&	CC
10_1101-2020_09_02_279521	393	22	Donohue	Donohue	NNP
10_1101-2020_09_02_279521	393	23	,	,	,
10_1101-2020_09_02_279521	393	24	M.	M.	NNP
10_1101-2020_09_02_279521	393	25	C.	C.	NNP
10_1101-2020_09_02_279521	393	26	(	(	-LRB-
10_1101-2020_09_02_279521	393	27	2020	2020	CD
10_1101-2020_09_02_279521	393	28	)	)	-RRB-
10_1101-2020_09_02_279521	393	29	.	.	.
10_1101-2020_09_02_279521	394	1	Neuroanatomical	neuroanatomical	JJ
10_1101-2020_09_02_279521	394	2	spread	spread	NN
10_1101-2020_09_02_279521	394	3	of	of	IN
10_1101-2020_09_02_279521	394	4	amyloid	amyloid	NNP
10_1101-2020_09_02_279521	394	5	β	β	NNP
10_1101-2020_09_02_279521	394	6	and	and	CC
10_1101-2020_09_02_279521	394	7	tau	tau	NNP
10_1101-2020_09_02_279521	394	8	in	in	IN
10_1101-2020_09_02_279521	394	9	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	394	10	’s	’s	POS
10_1101-2020_09_02_279521	394	11	disease	disease	NN
10_1101-2020_09_02_279521	394	12	:	:	:
10_1101-2020_09_02_279521	394	13	implications	implication	NNS
10_1101-2020_09_02_279521	394	14	for	for	IN
10_1101-2020_09_02_279521	394	15	primary	primary	JJ
10_1101-2020_09_02_279521	394	16	prevention	prevention	NN
10_1101-2020_09_02_279521	394	17	.	.	.
10_1101-2020_09_02_279521	395	1	Brain	Brain	NNP
10_1101-2020_09_02_279521	395	2	Communications	Communications	NNPS
10_1101-2020_09_02_279521	395	3	,	,	,
10_1101-2020_09_02_279521	395	4	2(1	2(1	NNP
10_1101-2020_09_02_279521	395	5	)	)	-RRB-
10_1101-2020_09_02_279521	395	6	.	.	.
10_1101-2020_09_02_279521	396	1	https://doi.org/10.1093/braincomms/fcaa007	https://doi.org/10.1093/braincomms/fcaa007	NNP
10_1101-2020_09_02_279521	396	2	Iturria	Iturria	NNP
10_1101-2020_09_02_279521	396	3	-	-	HYPH
10_1101-2020_09_02_279521	396	4	Medina	Medina	NNP
10_1101-2020_09_02_279521	396	5	,	,	,
10_1101-2020_09_02_279521	396	6	Y	Y	NNP
10_1101-2020_09_02_279521	396	7	,	,	,
10_1101-2020_09_02_279521	396	8	Sotero	Sotero	NNP
10_1101-2020_09_02_279521	396	9	,	,	,
10_1101-2020_09_02_279521	396	10	R.	R.	NNP
10_1101-2020_09_02_279521	396	11	C.	C.	NNP
10_1101-2020_09_02_279521	396	12	,	,	,
10_1101-2020_09_02_279521	396	13	Toussaint	Toussaint	NNP
10_1101-2020_09_02_279521	396	14	,	,	,
10_1101-2020_09_02_279521	396	15	P.	P.	NNP
10_1101-2020_09_02_279521	396	16	J.	J.	NNP
10_1101-2020_09_02_279521	396	17	,	,	,
10_1101-2020_09_02_279521	396	18	Mateos	Mateos	NNP
10_1101-2020_09_02_279521	396	19	-	-	HYPH
10_1101-2020_09_02_279521	396	20	P?rez	P?rez	NNP
10_1101-2020_09_02_279521	396	21	,	,	,
10_1101-2020_09_02_279521	396	22	J.	J.	NNP
10_1101-2020_09_02_279521	396	23	M.	M.	NNP
10_1101-2020_09_02_279521	396	24	,	,	,
10_1101-2020_09_02_279521	396	25	Evans	Evans	NNP
10_1101-2020_09_02_279521	396	26	,	,	,
10_1101-2020_09_02_279521	396	27	A.	a.	NN
10_1101-2020_09_02_279521	396	28	C.	C.	NNP
10_1101-2020_09_02_279521	396	29	,	,	,
10_1101-2020_09_02_279521	396	30	&	&	CC
10_1101-2020_09_02_279521	396	31	Initiative	Initiative	NNP
10_1101-2020_09_02_279521	396	32	.	.	NNP
10_1101-2020_09_02_279521	396	33	,	,	,
10_1101-2020_09_02_279521	396	34	A.	A.	NNP
10_1101-2020_09_02_279521	396	35	D.	D.	NNP
10_1101-2020_09_02_279521	396	36	N.	N.	NNP
10_1101-2020_09_02_279521	396	37	(	(	-LRB-
10_1101-2020_09_02_279521	396	38	2016	2016	CD
10_1101-2020_09_02_279521	396	39	)	)	-RRB-
10_1101-2020_09_02_279521	396	40	.	.	.
10_1101-2020_09_02_279521	397	1	Early	early	JJ
10_1101-2020_09_02_279521	397	2	role	role	NN
10_1101-2020_09_02_279521	397	3	of	of	IN
10_1101-2020_09_02_279521	397	4	vascular	vascular	JJ
10_1101-2020_09_02_279521	397	5	dysregulation	dysregulation	NN
10_1101-2020_09_02_279521	397	6	on	on	IN
10_1101-2020_09_02_279521	397	7	late	late	JJ
10_1101-2020_09_02_279521	397	8	-	-	HYPH
10_1101-2020_09_02_279521	397	9	onset	onset	NN
10_1101-2020_09_02_279521	397	10	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	397	11	’s	’s	POS
10_1101-2020_09_02_279521	397	12	disease	disease	NN
10_1101-2020_09_02_279521	397	13	based	base	VBN
10_1101-2020_09_02_279521	397	14	on	on	IN
10_1101-2020_09_02_279521	397	15	multifactorial	multifactorial	JJ
10_1101-2020_09_02_279521	397	16	data	datum	NNS
10_1101-2020_09_02_279521	397	17	-	-	HYPH
10_1101-2020_09_02_279521	397	18	driven	drive	VBN
10_1101-2020_09_02_279521	397	19	analysis	analysis	NN
10_1101-2020_09_02_279521	397	20	.	.	.
10_1101-2020_09_02_279521	398	1	Nat	Nat	NNP
10_1101-2020_09_02_279521	398	2	Commun	Commun	NNP
10_1101-2020_09_02_279521	398	3	,	,	,
10_1101-2020_09_02_279521	398	4	7	7	CD
10_1101-2020_09_02_279521	398	5	,	,	,
10_1101-2020_09_02_279521	398	6	11934	11934	CD
10_1101-2020_09_02_279521	398	7	.	.	.
10_1101-2020_09_02_279521	399	1	Iturria	Iturria	NNP
10_1101-2020_09_02_279521	399	2	-	-	HYPH
10_1101-2020_09_02_279521	399	3	Medina	Medina	NNP
10_1101-2020_09_02_279521	399	4	,	,	,
10_1101-2020_09_02_279521	399	5	Yasser	Yasser	NNP
10_1101-2020_09_02_279521	399	6	,	,	,
10_1101-2020_09_02_279521	399	7	Carbonell	Carbonell	NNP
10_1101-2020_09_02_279521	399	8	,	,	,
10_1101-2020_09_02_279521	399	9	F.	F.	NNP
10_1101-2020_09_02_279521	399	10	M.	M.	NNP
10_1101-2020_09_02_279521	399	11	,	,	,
10_1101-2020_09_02_279521	399	12	Sotero	Sotero	NNP
10_1101-2020_09_02_279521	399	13	,	,	,
10_1101-2020_09_02_279521	399	14	R.	R.	NNP
10_1101-2020_09_02_279521	399	15	C.	C.	NNP
10_1101-2020_09_02_279521	399	16	,	,	,
10_1101-2020_09_02_279521	399	17	Chouinard	Chouinard	NNP
10_1101-2020_09_02_279521	399	18	-	-	HYPH
10_1101-2020_09_02_279521	399	19	Decorte	Decorte	NNP
10_1101-2020_09_02_279521	399	20	,	,	,
10_1101-2020_09_02_279521	399	21	F.	F.	NNP
10_1101-2020_09_02_279521	399	22	,	,	,
10_1101-2020_09_02_279521	399	23	&	&	CC
10_1101-2020_09_02_279521	399	24	Evans	Evans	NNP
10_1101-2020_09_02_279521	399	25	,	,	,
10_1101-2020_09_02_279521	399	26	A.	a.	NN
10_1101-2020_09_02_279521	399	27	C.	C.	NNP
10_1101-2020_09_02_279521	399	28	(	(	-LRB-
10_1101-2020_09_02_279521	399	29	2017	2017	CD
10_1101-2020_09_02_279521	399	30	)	)	-RRB-
10_1101-2020_09_02_279521	399	31	.	.	.
10_1101-2020_09_02_279521	400	1	Multifactorial	multifactorial	JJ
10_1101-2020_09_02_279521	400	2	causal	causal	JJ
10_1101-2020_09_02_279521	400	3	model	model	NN
10_1101-2020_09_02_279521	400	4	of	of	IN
10_1101-2020_09_02_279521	400	5	brain	brain	NN
10_1101-2020_09_02_279521	400	6	(	(	-LRB-
10_1101-2020_09_02_279521	400	7	dis)organization	dis)organization	NN
10_1101-2020_09_02_279521	400	8	and	and	CC
10_1101-2020_09_02_279521	400	9	therapeutic	therapeutic	JJ
10_1101-2020_09_02_279521	400	10	intervention	intervention	NN
10_1101-2020_09_02_279521	400	11	:	:	:
10_1101-2020_09_02_279521	400	12	Application	application	NN
10_1101-2020_09_02_279521	400	13	to	to	IN
10_1101-2020_09_02_279521	400	14	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	400	15	’s	’s	POS
10_1101-2020_09_02_279521	400	16	disease	disease	NN
10_1101-2020_09_02_279521	400	17	.	.	.
10_1101-2020_09_02_279521	401	1	NeuroImage	NeuroImage	NNP
10_1101-2020_09_02_279521	401	2	,	,	,
10_1101-2020_09_02_279521	401	3	152	152	CD
10_1101-2020_09_02_279521	401	4	,	,	,
10_1101-2020_09_02_279521	401	5	60–77	60–77	CD
10_1101-2020_09_02_279521	401	6	.	.	.
10_1101-2020_09_02_279521	402	1	.CC	.CC	NFP
10_1101-2020_09_02_279521	402	2	-	-	:
10_1101-2020_09_02_279521	402	3	BY	by	IN
10_1101-2020_09_02_279521	402	4	4.0	4.0	CD
10_1101-2020_09_02_279521	402	5	International	international	JJ
10_1101-2020_09_02_279521	402	6	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	402	7	.	.	.
10_1101-2020_09_02_279521	403	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	403	2	is	be	VBZ
10_1101-2020_09_02_279521	403	3	made	make	VBN
10_1101-2020_09_02_279521	403	4	available	available	JJ
10_1101-2020_09_02_279521	403	5	under	under	IN
10_1101-2020_09_02_279521	403	6	a	a	DT
10_1101-2020_09_02_279521	403	7	preprint	preprint	NN
10_1101-2020_09_02_279521	403	8	(	(	-LRB-
10_1101-2020_09_02_279521	403	9	which	which	WDT
10_1101-2020_09_02_279521	403	10	was	be	VBD
10_1101-2020_09_02_279521	403	11	not	not	RB
10_1101-2020_09_02_279521	403	12	certified	certify	VBN
10_1101-2020_09_02_279521	403	13	by	by	IN
10_1101-2020_09_02_279521	403	14	peer	peer	NN
10_1101-2020_09_02_279521	403	15	review	review	NN
10_1101-2020_09_02_279521	403	16	)	)	-RRB-
10_1101-2020_09_02_279521	403	17	is	be	VBZ
10_1101-2020_09_02_279521	403	18	the	the	DT
10_1101-2020_09_02_279521	403	19	author	author	NN
10_1101-2020_09_02_279521	403	20	/	/	SYM
10_1101-2020_09_02_279521	403	21	funder	funder	NN
10_1101-2020_09_02_279521	403	22	,	,	,
10_1101-2020_09_02_279521	403	23	who	who	WP
10_1101-2020_09_02_279521	403	24	has	have	VBZ
10_1101-2020_09_02_279521	403	25	granted	grant	VBN
10_1101-2020_09_02_279521	403	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	403	27	a	a	DT
10_1101-2020_09_02_279521	403	28	license	license	NN
10_1101-2020_09_02_279521	403	29	to	to	TO
10_1101-2020_09_02_279521	403	30	display	display	VB
10_1101-2020_09_02_279521	403	31	the	the	DT
10_1101-2020_09_02_279521	403	32	preprint	preprint	NN
10_1101-2020_09_02_279521	403	33	in	in	IN
10_1101-2020_09_02_279521	403	34	The	the	DT
10_1101-2020_09_02_279521	403	35	copyright	copyright	NN
10_1101-2020_09_02_279521	403	36	holder	holder	NN
10_1101-2020_09_02_279521	403	37	for	for	IN
10_1101-2020_09_02_279521	403	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	403	39	version	version	NN
10_1101-2020_09_02_279521	403	40	posted	post	VBD
10_1101-2020_09_02_279521	403	41	February	February	NNP
10_1101-2020_09_02_279521	403	42	10	10	CD
10_1101-2020_09_02_279521	403	43	,	,	,
10_1101-2020_09_02_279521	403	44	2021	2021	CD
10_1101-2020_09_02_279521	403	45	.	.	.
10_1101-2020_09_02_279521	403	46	;	;	:
10_1101-2020_09_02_279521	403	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	403	48	:	:	:
10_1101-2020_09_02_279521	403	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	403	50	preprint	preprint	NN
10_1101-2020_09_02_279521	403	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	ADD
10_1101-2020_09_02_279521	403	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	ADD
10_1101-2020_09_02_279521	403	53	https://doi.org/https://doi.org/10.1016/j.neuroimage.2017.02.058	https://doi.org/https://doi.org/10.1016/j.neuroimage.2017.02.058	NNP
10_1101-2020_09_02_279521	403	54	Jack	Jack	NNP
10_1101-2020_09_02_279521	403	55	,	,	,
10_1101-2020_09_02_279521	403	56	C.	C.	NNP
10_1101-2020_09_02_279521	403	57	R.	R.	NNP
10_1101-2020_09_02_279521	403	58	,	,	,
10_1101-2020_09_02_279521	403	59	Bennett	Bennett	NNP
10_1101-2020_09_02_279521	403	60	,	,	,
10_1101-2020_09_02_279521	403	61	D.	D.	NNP
10_1101-2020_09_02_279521	403	62	A.	A.	NNP
10_1101-2020_09_02_279521	403	63	,	,	,
10_1101-2020_09_02_279521	403	64	Blennow	Blennow	NNP
10_1101-2020_09_02_279521	403	65	,	,	,
10_1101-2020_09_02_279521	403	66	K.	K.	NNP
10_1101-2020_09_02_279521	403	67	,	,	,
10_1101-2020_09_02_279521	403	68	Carrillo	Carrillo	NNP
10_1101-2020_09_02_279521	403	69	,	,	,
10_1101-2020_09_02_279521	403	70	M.	M.	NNP
10_1101-2020_09_02_279521	403	71	C.	C.	NNP
10_1101-2020_09_02_279521	403	72	,	,	,
10_1101-2020_09_02_279521	403	73	Dunn	Dunn	NNP
10_1101-2020_09_02_279521	403	74	,	,	,
10_1101-2020_09_02_279521	403	75	B.	B.	NNP
10_1101-2020_09_02_279521	403	76	,	,	,
10_1101-2020_09_02_279521	403	77	Haeberlein	Haeberlein	NNP
10_1101-2020_09_02_279521	403	78	,	,	,
10_1101-2020_09_02_279521	403	79	S.	S.	NNP
10_1101-2020_09_02_279521	403	80	B.	B.	NNP
10_1101-2020_09_02_279521	403	81	,	,	,
10_1101-2020_09_02_279521	403	82	Holtzman	Holtzman	NNP
10_1101-2020_09_02_279521	403	83	,	,	,
10_1101-2020_09_02_279521	403	84	D.	D.	NNP
10_1101-2020_09_02_279521	403	85	M.	M.	NNP
10_1101-2020_09_02_279521	403	86	,	,	,
10_1101-2020_09_02_279521	403	87	Jagust	Jagust	NNP
10_1101-2020_09_02_279521	403	88	,	,	,
10_1101-2020_09_02_279521	403	89	W.	W.	NNP
10_1101-2020_09_02_279521	403	90	,	,	,
10_1101-2020_09_02_279521	403	91	Jessen	Jessen	NNP
10_1101-2020_09_02_279521	403	92	,	,	,
10_1101-2020_09_02_279521	403	93	F.	F.	NNP
10_1101-2020_09_02_279521	403	94	,	,	,
10_1101-2020_09_02_279521	403	95	Karlawish	Karlawish	NNP
10_1101-2020_09_02_279521	403	96	,	,	,
10_1101-2020_09_02_279521	403	97	J.	J.	NNP
10_1101-2020_09_02_279521	403	98	,	,	,
10_1101-2020_09_02_279521	403	99	Liu	Liu	NNP
10_1101-2020_09_02_279521	403	100	,	,	,
10_1101-2020_09_02_279521	403	101	E.	E.	NNP
10_1101-2020_09_02_279521	403	102	,	,	,
10_1101-2020_09_02_279521	403	103	Molinuevo	Molinuevo	NNP
10_1101-2020_09_02_279521	403	104	,	,	,
10_1101-2020_09_02_279521	403	105	J.	J.	NNP
10_1101-2020_09_02_279521	403	106	L.	L.	NNP
10_1101-2020_09_02_279521	403	107	,	,	,
10_1101-2020_09_02_279521	403	108	Montine	Montine	NNP
10_1101-2020_09_02_279521	403	109	,	,	,
10_1101-2020_09_02_279521	403	110	T.	T.	NNP
10_1101-2020_09_02_279521	403	111	,	,	,
10_1101-2020_09_02_279521	403	112	Phelps	Phelps	NNP
10_1101-2020_09_02_279521	403	113	,	,	,
10_1101-2020_09_02_279521	403	114	C.	C.	NNP
10_1101-2020_09_02_279521	403	115	,	,	,
10_1101-2020_09_02_279521	403	116	Rankin	Rankin	NNP
10_1101-2020_09_02_279521	403	117	,	,	,
10_1101-2020_09_02_279521	403	118	K.	K.	NNP
10_1101-2020_09_02_279521	403	119	P.	P.	NNP
10_1101-2020_09_02_279521	403	120	,	,	,
10_1101-2020_09_02_279521	403	121	Rowe	Rowe	NNP
10_1101-2020_09_02_279521	403	122	,	,	,
10_1101-2020_09_02_279521	403	123	C.	C.	NNP
10_1101-2020_09_02_279521	403	124	C.	C.	NNP
10_1101-2020_09_02_279521	403	125	,	,	,
10_1101-2020_09_02_279521	403	126	Scheltens	Scheltens	NNP
10_1101-2020_09_02_279521	403	127	,	,	,
10_1101-2020_09_02_279521	403	128	P.	P.	NNP
10_1101-2020_09_02_279521	403	129	,	,	,
10_1101-2020_09_02_279521	403	130	Siemers	Siemers	NNP
10_1101-2020_09_02_279521	403	131	,	,	,
10_1101-2020_09_02_279521	403	132	E.	E.	NNP
10_1101-2020_09_02_279521	403	133	,	,	,
10_1101-2020_09_02_279521	403	134	Snyder	Snyder	NNP
10_1101-2020_09_02_279521	403	135	,	,	,
10_1101-2020_09_02_279521	403	136	H.	H.	NNP
10_1101-2020_09_02_279521	403	137	M.	M.	NNP
10_1101-2020_09_02_279521	403	138	,	,	,
10_1101-2020_09_02_279521	403	139	…	…	NFP
10_1101-2020_09_02_279521	403	140	Silverberg	Silverberg	NNP
10_1101-2020_09_02_279521	403	141	,	,	,
10_1101-2020_09_02_279521	403	142	N.	N.	NNP
10_1101-2020_09_02_279521	403	143	(	(	-LRB-
10_1101-2020_09_02_279521	403	144	2018	2018	CD
10_1101-2020_09_02_279521	403	145	)	)	-RRB-
10_1101-2020_09_02_279521	403	146	.	.	.
10_1101-2020_09_02_279521	404	1	NIA	NIA	NNP
10_1101-2020_09_02_279521	404	2	-	-	HYPH
10_1101-2020_09_02_279521	404	3	AA	AA	NNP
10_1101-2020_09_02_279521	404	4	Research	Research	NNP
10_1101-2020_09_02_279521	404	5	Framework	Framework	NNP
10_1101-2020_09_02_279521	404	6	:	:	:
10_1101-2020_09_02_279521	404	7	Toward	toward	IN
10_1101-2020_09_02_279521	404	8	a	a	DT
10_1101-2020_09_02_279521	404	9	biological	biological	JJ
10_1101-2020_09_02_279521	404	10	definition	definition	NN
10_1101-2020_09_02_279521	404	11	of	of	IN
10_1101-2020_09_02_279521	404	12	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	404	13	’s	’s	POS
10_1101-2020_09_02_279521	404	14	disease	disease	NN
10_1101-2020_09_02_279521	404	15	.	.	.
10_1101-2020_09_02_279521	405	1	Alzheimers	Alzheimers	NNP
10_1101-2020_09_02_279521	405	2	Dement	Dement	NNP
10_1101-2020_09_02_279521	405	3	,	,	,
10_1101-2020_09_02_279521	405	4	14(4	14(4	CD
10_1101-2020_09_02_279521	405	5	)	)	-RRB-
10_1101-2020_09_02_279521	405	6	,	,	,
10_1101-2020_09_02_279521	405	7	535–562	535–562	CD
10_1101-2020_09_02_279521	405	8	.	.	.
10_1101-2020_09_02_279521	406	1	Jack	Jack	NNP
10_1101-2020_09_02_279521	406	2	,	,	,
10_1101-2020_09_02_279521	406	3	C.	C.	NNP
10_1101-2020_09_02_279521	406	4	R.	R.	NNP
10_1101-2020_09_02_279521	406	5	,	,	,
10_1101-2020_09_02_279521	406	6	&	&	CC
10_1101-2020_09_02_279521	406	7	Holtzman	Holtzman	NNP
10_1101-2020_09_02_279521	406	8	,	,	,
10_1101-2020_09_02_279521	406	9	D.	D.	NNP
10_1101-2020_09_02_279521	406	10	M.	M.	NNP
10_1101-2020_09_02_279521	406	11	(	(	-LRB-
10_1101-2020_09_02_279521	406	12	2013	2013	CD
10_1101-2020_09_02_279521	406	13	)	)	-RRB-
10_1101-2020_09_02_279521	406	14	.	.	.
10_1101-2020_09_02_279521	407	1	Biomarker	biomarker	NN
10_1101-2020_09_02_279521	407	2	modeling	modeling	NN
10_1101-2020_09_02_279521	407	3	of	of	IN
10_1101-2020_09_02_279521	407	4	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	407	5	’s	’s	POS
10_1101-2020_09_02_279521	407	6	disease	disease	NN
10_1101-2020_09_02_279521	407	7	.	.	.
10_1101-2020_09_02_279521	408	1	Neuron	Neuron	NNP
10_1101-2020_09_02_279521	408	2	,	,	,
10_1101-2020_09_02_279521	408	3	80(6	80(6	CD
10_1101-2020_09_02_279521	408	4	)	)	-RRB-
10_1101-2020_09_02_279521	408	5	,	,	,
10_1101-2020_09_02_279521	408	6	1347–1358	1347–1358	CD
10_1101-2020_09_02_279521	408	7	.	.	.
10_1101-2020_09_02_279521	409	1	Jack	Jack	NNP
10_1101-2020_09_02_279521	409	2	,	,	,
10_1101-2020_09_02_279521	409	3	C.	C.	NNP
10_1101-2020_09_02_279521	409	4	R.	R.	NNP
10_1101-2020_09_02_279521	409	5	,	,	,
10_1101-2020_09_02_279521	409	6	Knopman	Knopman	NNP
10_1101-2020_09_02_279521	409	7	,	,	,
10_1101-2020_09_02_279521	409	8	D.	D.	NNP
10_1101-2020_09_02_279521	409	9	S.	S.	NNP
10_1101-2020_09_02_279521	409	10	,	,	,
10_1101-2020_09_02_279521	409	11	Jagust	Jagust	NNP
10_1101-2020_09_02_279521	409	12	,	,	,
10_1101-2020_09_02_279521	409	13	W.	W.	NNP
10_1101-2020_09_02_279521	409	14	J.	J.	NNP
10_1101-2020_09_02_279521	409	15	,	,	,
10_1101-2020_09_02_279521	409	16	Petersen	Petersen	NNP
10_1101-2020_09_02_279521	409	17	,	,	,
10_1101-2020_09_02_279521	409	18	R.	R.	NNP
10_1101-2020_09_02_279521	409	19	C.	C.	NNP
10_1101-2020_09_02_279521	409	20	,	,	,
10_1101-2020_09_02_279521	409	21	Weiner	Weiner	NNP
10_1101-2020_09_02_279521	409	22	,	,	,
10_1101-2020_09_02_279521	409	23	M.	M.	NNP
10_1101-2020_09_02_279521	409	24	W.	W.	NNP
10_1101-2020_09_02_279521	409	25	,	,	,
10_1101-2020_09_02_279521	409	26	Aisen	Aisen	NNP
10_1101-2020_09_02_279521	409	27	,	,	,
10_1101-2020_09_02_279521	409	28	P.	P.	NNP
10_1101-2020_09_02_279521	409	29	S.	S.	NNP
10_1101-2020_09_02_279521	409	30	,	,	,
10_1101-2020_09_02_279521	409	31	Shaw	Shaw	NNP
10_1101-2020_09_02_279521	409	32	,	,	,
10_1101-2020_09_02_279521	409	33	L.	L.	NNP
10_1101-2020_09_02_279521	409	34	M.	M.	NNP
10_1101-2020_09_02_279521	409	35	,	,	,
10_1101-2020_09_02_279521	409	36	Vemuri	Vemuri	NNP
10_1101-2020_09_02_279521	409	37	,	,	,
10_1101-2020_09_02_279521	409	38	P.	P.	NNP
10_1101-2020_09_02_279521	409	39	,	,	,
10_1101-2020_09_02_279521	409	40	Wiste	Wiste	NNP
10_1101-2020_09_02_279521	409	41	,	,	,
10_1101-2020_09_02_279521	409	42	H.	H.	NNP
10_1101-2020_09_02_279521	409	43	J.	J.	NNP
10_1101-2020_09_02_279521	409	44	,	,	,
10_1101-2020_09_02_279521	409	45	Weigand	Weigand	NNP
10_1101-2020_09_02_279521	409	46	,	,	,
10_1101-2020_09_02_279521	409	47	S.	S.	NNP
10_1101-2020_09_02_279521	409	48	D.	D.	NNP
10_1101-2020_09_02_279521	409	49	,	,	,
10_1101-2020_09_02_279521	409	50	Lesnick	Lesnick	NNP
10_1101-2020_09_02_279521	409	51	,	,	,
10_1101-2020_09_02_279521	409	52	T.	T.	NNP
10_1101-2020_09_02_279521	409	53	G.	G.	NNP
10_1101-2020_09_02_279521	409	54	,	,	,
10_1101-2020_09_02_279521	409	55	Pankratz	Pankratz	NNP
10_1101-2020_09_02_279521	409	56	,	,	,
10_1101-2020_09_02_279521	409	57	V.	V.	NNP
10_1101-2020_09_02_279521	409	58	S.	S.	NNP
10_1101-2020_09_02_279521	409	59	,	,	,
10_1101-2020_09_02_279521	409	60	Donohue	Donohue	NNP
10_1101-2020_09_02_279521	409	61	,	,	,
10_1101-2020_09_02_279521	409	62	M.	M.	NNP
10_1101-2020_09_02_279521	409	63	C.	C.	NNP
10_1101-2020_09_02_279521	409	64	,	,	,
10_1101-2020_09_02_279521	409	65	&	&	CC
10_1101-2020_09_02_279521	409	66	Trojanowski	Trojanowski	NNP
10_1101-2020_09_02_279521	409	67	,	,	,
10_1101-2020_09_02_279521	409	68	J.	J.	NNP
10_1101-2020_09_02_279521	409	69	Q.	Q.	NNP
10_1101-2020_09_02_279521	410	1	(	(	-LRB-
10_1101-2020_09_02_279521	410	2	2013	2013	CD
10_1101-2020_09_02_279521	410	3	)	)	-RRB-
10_1101-2020_09_02_279521	410	4	.	.	.
10_1101-2020_09_02_279521	411	1	Tracking	track	VBG
10_1101-2020_09_02_279521	411	2	pathophysiological	pathophysiological	JJ
10_1101-2020_09_02_279521	411	3	processes	process	NNS
10_1101-2020_09_02_279521	411	4	in	in	IN
10_1101-2020_09_02_279521	411	5	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	411	6	’s	’s	POS
10_1101-2020_09_02_279521	411	7	disease	disease	NN
10_1101-2020_09_02_279521	411	8	:	:	:
10_1101-2020_09_02_279521	411	9	an	an	DT
10_1101-2020_09_02_279521	411	10	updated	update	VBN
10_1101-2020_09_02_279521	411	11	hypothetical	hypothetical	JJ
10_1101-2020_09_02_279521	411	12	model	model	NN
10_1101-2020_09_02_279521	411	13	of	of	IN
10_1101-2020_09_02_279521	411	14	dynamic	dynamic	JJ
10_1101-2020_09_02_279521	411	15	biomarkers	biomarker	NNS
10_1101-2020_09_02_279521	411	16	.	.	.
10_1101-2020_09_02_279521	412	1	Lancet	Lancet	NNP
10_1101-2020_09_02_279521	412	2	Neurol	Neurol	NNP
10_1101-2020_09_02_279521	412	3	,	,	,
10_1101-2020_09_02_279521	412	4	12(2	12(2	CD
10_1101-2020_09_02_279521	412	5	)	)	-RRB-
10_1101-2020_09_02_279521	412	6	,	,	,
10_1101-2020_09_02_279521	412	7	207–216	207–216	CD
10_1101-2020_09_02_279521	412	8	.	.	.
10_1101-2020_09_02_279521	413	1	Jedynak	Jedynak	NNP
10_1101-2020_09_02_279521	413	2	,	,	,
10_1101-2020_09_02_279521	413	3	B.	B.	NNP
10_1101-2020_09_02_279521	413	4	M.	M.	NNP
10_1101-2020_09_02_279521	413	5	,	,	,
10_1101-2020_09_02_279521	413	6	Lang	Lang	NNP
10_1101-2020_09_02_279521	413	7	,	,	,
10_1101-2020_09_02_279521	413	8	A.	A.	NNP
10_1101-2020_09_02_279521	413	9	,	,	,
10_1101-2020_09_02_279521	413	10	Liu	Liu	NNP
10_1101-2020_09_02_279521	413	11	,	,	,
10_1101-2020_09_02_279521	413	12	B.	B.	NNP
10_1101-2020_09_02_279521	413	13	,	,	,
10_1101-2020_09_02_279521	413	14	Katz	Katz	NNP
10_1101-2020_09_02_279521	413	15	,	,	,
10_1101-2020_09_02_279521	413	16	E.	E.	NNP
10_1101-2020_09_02_279521	413	17	,	,	,
10_1101-2020_09_02_279521	413	18	Zhang	Zhang	NNP
10_1101-2020_09_02_279521	413	19	,	,	,
10_1101-2020_09_02_279521	413	20	Y.	Y.	NNP
10_1101-2020_09_02_279521	413	21	,	,	,
10_1101-2020_09_02_279521	413	22	Wyman	Wyman	NNP
10_1101-2020_09_02_279521	413	23	,	,	,
10_1101-2020_09_02_279521	413	24	B.	B.	NNP
10_1101-2020_09_02_279521	413	25	T.	T.	NNP
10_1101-2020_09_02_279521	413	26	,	,	,
10_1101-2020_09_02_279521	413	27	Raunig	Raunig	NNP
10_1101-2020_09_02_279521	413	28	,	,	,
10_1101-2020_09_02_279521	413	29	D.	D.	NNP
10_1101-2020_09_02_279521	413	30	,	,	,
10_1101-2020_09_02_279521	413	31	Jedynak	Jedynak	NNP
10_1101-2020_09_02_279521	413	32	,	,	,
10_1101-2020_09_02_279521	413	33	C.	C.	NNP
10_1101-2020_09_02_279521	413	34	P.	P.	NNP
10_1101-2020_09_02_279521	413	35	,	,	,
10_1101-2020_09_02_279521	413	36	Caffo	Caffo	NNP
10_1101-2020_09_02_279521	413	37	,	,	,
10_1101-2020_09_02_279521	413	38	B.	B.	NNP
10_1101-2020_09_02_279521	413	39	,	,	,
10_1101-2020_09_02_279521	413	40	&	&	CC
10_1101-2020_09_02_279521	413	41	Prince	Prince	NNP
10_1101-2020_09_02_279521	413	42	,	,	,
10_1101-2020_09_02_279521	413	43	J.	J.	NNP
10_1101-2020_09_02_279521	413	44	L.	L.	NNP
10_1101-2020_09_02_279521	413	45	(	(	-LRB-
10_1101-2020_09_02_279521	413	46	2012	2012	CD
10_1101-2020_09_02_279521	413	47	)	)	-RRB-
10_1101-2020_09_02_279521	413	48	.	.	.
10_1101-2020_09_02_279521	414	1	A	a	DT
10_1101-2020_09_02_279521	414	2	computational	computational	JJ
10_1101-2020_09_02_279521	414	3	neurodegenerative	neurodegenerative	JJ
10_1101-2020_09_02_279521	414	4	disease	disease	NN
10_1101-2020_09_02_279521	414	5	progression	progression	NN
10_1101-2020_09_02_279521	414	6	score	score	NN
10_1101-2020_09_02_279521	414	7	:	:	:
10_1101-2020_09_02_279521	414	8	method	method	NN
10_1101-2020_09_02_279521	414	9	and	and	CC
10_1101-2020_09_02_279521	414	10	results	result	NNS
10_1101-2020_09_02_279521	414	11	with	with	IN
10_1101-2020_09_02_279521	414	12	the	the	DT
10_1101-2020_09_02_279521	414	13	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	414	14	’s	’s	POS
10_1101-2020_09_02_279521	414	15	disease	disease	NN
10_1101-2020_09_02_279521	414	16	Neuroimaging	Neuroimaging	NNP
10_1101-2020_09_02_279521	414	17	Initiative	Initiative	NNP
10_1101-2020_09_02_279521	414	18	cohort	cohort	NN
10_1101-2020_09_02_279521	414	19	.	.	.
10_1101-2020_09_02_279521	415	1	NeuroImage	NeuroImage	NNP
10_1101-2020_09_02_279521	415	2	,	,	,
10_1101-2020_09_02_279521	415	3	63(3	63(3	CD
10_1101-2020_09_02_279521	415	4	)	)	-RRB-
10_1101-2020_09_02_279521	415	5	,	,	,
10_1101-2020_09_02_279521	415	6	1478–1486	1478–1486	CD
10_1101-2020_09_02_279521	415	7	.	.	.
10_1101-2020_09_02_279521	416	1	Kaufman	Kaufman	NNP
10_1101-2020_09_02_279521	416	2	,	,	,
10_1101-2020_09_02_279521	416	3	S.	S.	NNP
10_1101-2020_09_02_279521	416	4	K.	K.	NNP
10_1101-2020_09_02_279521	416	5	,	,	,
10_1101-2020_09_02_279521	416	6	Del	Del	NNP
10_1101-2020_09_02_279521	416	7	Tredici	Tredici	NNP
10_1101-2020_09_02_279521	416	8	,	,	,
10_1101-2020_09_02_279521	416	9	K.	K.	NNP
10_1101-2020_09_02_279521	416	10	,	,	,
10_1101-2020_09_02_279521	416	11	Thomas	Thomas	NNP
10_1101-2020_09_02_279521	416	12	,	,	,
10_1101-2020_09_02_279521	416	13	T.	T.	NNP
10_1101-2020_09_02_279521	416	14	L.	L.	NNP
10_1101-2020_09_02_279521	416	15	,	,	,
10_1101-2020_09_02_279521	416	16	Braak	Braak	NNP
10_1101-2020_09_02_279521	416	17	,	,	,
10_1101-2020_09_02_279521	416	18	H.	H.	NNP
10_1101-2020_09_02_279521	416	19	,	,	,
10_1101-2020_09_02_279521	416	20	&	&	CC
10_1101-2020_09_02_279521	416	21	Diamond	Diamond	NNP
10_1101-2020_09_02_279521	416	22	,	,	,
10_1101-2020_09_02_279521	416	23	M.	M.	NNP
10_1101-2020_09_02_279521	416	24	I.	I.	NNP
10_1101-2020_09_02_279521	417	1	(	(	-LRB-
10_1101-2020_09_02_279521	417	2	2018	2018	CD
10_1101-2020_09_02_279521	417	3	)	)	-RRB-
10_1101-2020_09_02_279521	417	4	.	.	.
10_1101-2020_09_02_279521	418	1	Tau	tau	NN
10_1101-2020_09_02_279521	418	2	seeding	seed	VBG
10_1101-2020_09_02_279521	418	3	activity	activity	NN
10_1101-2020_09_02_279521	418	4	begins	begin	VBZ
10_1101-2020_09_02_279521	418	5	in	in	IN
10_1101-2020_09_02_279521	418	6	the	the	DT
10_1101-2020_09_02_279521	418	7	transentorhinal	transentorhinal	JJ
10_1101-2020_09_02_279521	418	8	/	/	SYM
10_1101-2020_09_02_279521	418	9	entorhinal	entorhinal	NN
10_1101-2020_09_02_279521	418	10	regions	region	NNS
10_1101-2020_09_02_279521	418	11	and	and	CC
10_1101-2020_09_02_279521	418	12	anticipates	anticipate	VBZ
10_1101-2020_09_02_279521	418	13	phospho	phospho	NNP
10_1101-2020_09_02_279521	418	14	-	-	HYPH
10_1101-2020_09_02_279521	418	15	tau	tau	NN
10_1101-2020_09_02_279521	418	16	pathology	pathology	NN
10_1101-2020_09_02_279521	418	17	in	in	IN
10_1101-2020_09_02_279521	418	18	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	418	19	’s	’s	POS
10_1101-2020_09_02_279521	418	20	disease	disease	NN
10_1101-2020_09_02_279521	418	21	and	and	CC
10_1101-2020_09_02_279521	418	22	PART	PART	NNP
10_1101-2020_09_02_279521	418	23	.	.	.
10_1101-2020_09_02_279521	419	1	Acta	Acta	NNP
10_1101-2020_09_02_279521	419	2	Neuropathologica	Neuropathologica	NNP
10_1101-2020_09_02_279521	419	3	,	,	,
10_1101-2020_09_02_279521	419	4	136(1	136(1	CD
10_1101-2020_09_02_279521	419	5	)	)	-RRB-
10_1101-2020_09_02_279521	419	6	,	,	,
10_1101-2020_09_02_279521	419	7	57–67	57–67	CD
10_1101-2020_09_02_279521	419	8	.	.	.
10_1101-2020_09_02_279521	420	1	https://doi.org/10.1007/s00401-018-1855-6	https://doi.org/10.1007/s00401-018-1855-6	NNP
10_1101-2020_09_02_279521	420	2	Kim	Kim	NNP
10_1101-2020_09_02_279521	420	3	,	,	,
10_1101-2020_09_02_279521	420	4	J.	J.	NNP
10_1101-2020_09_02_279521	420	5	,	,	,
10_1101-2020_09_02_279521	420	6	Basak	Basak	NNP
10_1101-2020_09_02_279521	420	7	,	,	,
10_1101-2020_09_02_279521	420	8	J.	J.	NNP
10_1101-2020_09_02_279521	420	9	M.	M.	NNP
10_1101-2020_09_02_279521	420	10	,	,	,
10_1101-2020_09_02_279521	420	11	&	&	CC
10_1101-2020_09_02_279521	420	12	Holtzman	Holtzman	NNP
10_1101-2020_09_02_279521	420	13	,	,	,
10_1101-2020_09_02_279521	420	14	D.	D.	NNP
10_1101-2020_09_02_279521	420	15	M.	M.	NNP
10_1101-2020_09_02_279521	420	16	(	(	-LRB-
10_1101-2020_09_02_279521	420	17	2009	2009	CD
10_1101-2020_09_02_279521	420	18	)	)	-RRB-
10_1101-2020_09_02_279521	420	19	.	.	.
10_1101-2020_09_02_279521	421	1	The	the	DT
10_1101-2020_09_02_279521	421	2	role	role	NN
10_1101-2020_09_02_279521	421	3	of	of	IN
10_1101-2020_09_02_279521	421	4	apolipoprotein	apolipoprotein	JJ
10_1101-2020_09_02_279521	421	5	E	e	NN
10_1101-2020_09_02_279521	421	6	in	in	IN
10_1101-2020_09_02_279521	421	7	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	421	8	’s	’s	POS
10_1101-2020_09_02_279521	421	9	disease	disease	NN
10_1101-2020_09_02_279521	421	10	.	.	.
10_1101-2020_09_02_279521	422	1	Neuron	Neuron	NNP
10_1101-2020_09_02_279521	422	2	,	,	,
10_1101-2020_09_02_279521	422	3	63(3	63(3	CD
10_1101-2020_09_02_279521	422	4	)	)	-RRB-
10_1101-2020_09_02_279521	422	5	,	,	,
10_1101-2020_09_02_279521	422	6	287–303	287–303	CD
10_1101-2020_09_02_279521	422	7	.	.	.
10_1101-2020_09_02_279521	423	1	Klein	Klein	NNP
10_1101-2020_09_02_279521	423	2	,	,	,
10_1101-2020_09_02_279521	423	3	G.	G.	NNP
10_1101-2020_09_02_279521	423	4	,	,	,
10_1101-2020_09_02_279521	423	5	Delmar	Delmar	NNP
10_1101-2020_09_02_279521	423	6	,	,	,
10_1101-2020_09_02_279521	423	7	P.	P.	NNP
10_1101-2020_09_02_279521	423	8	,	,	,
10_1101-2020_09_02_279521	423	9	Voyle	Voyle	NNP
10_1101-2020_09_02_279521	423	10	,	,	,
10_1101-2020_09_02_279521	423	11	N.	N.	NNP
10_1101-2020_09_02_279521	423	12	,	,	,
10_1101-2020_09_02_279521	423	13	Rehal	Rehal	NNP
10_1101-2020_09_02_279521	423	14	,	,	,
10_1101-2020_09_02_279521	423	15	S.	S.	NNP
10_1101-2020_09_02_279521	423	16	,	,	,
10_1101-2020_09_02_279521	423	17	Hofmann	Hofmann	NNP
10_1101-2020_09_02_279521	423	18	,	,	,
10_1101-2020_09_02_279521	423	19	C.	C.	NNP
10_1101-2020_09_02_279521	423	20	,	,	,
10_1101-2020_09_02_279521	423	21	Abi	Abi	NNP
10_1101-2020_09_02_279521	423	22	-	-	HYPH
10_1101-2020_09_02_279521	423	23	Saab	Saab	NNP
10_1101-2020_09_02_279521	423	24	,	,	,
10_1101-2020_09_02_279521	423	25	D.	D.	NNP
10_1101-2020_09_02_279521	423	26	,	,	,
10_1101-2020_09_02_279521	423	27	Andjelkovic	Andjelkovic	NNP
10_1101-2020_09_02_279521	423	28	,	,	,
10_1101-2020_09_02_279521	423	29	M.	M.	NNP
10_1101-2020_09_02_279521	423	30	,	,	,
10_1101-2020_09_02_279521	423	31	Ristic	Ristic	NNP
10_1101-2020_09_02_279521	423	32	,	,	,
10_1101-2020_09_02_279521	423	33	S.	S.	NNP
10_1101-2020_09_02_279521	423	34	,	,	,
10_1101-2020_09_02_279521	423	35	Wang	Wang	NNP
10_1101-2020_09_02_279521	423	36	,	,	,
10_1101-2020_09_02_279521	423	37	G.	G.	NNP
10_1101-2020_09_02_279521	423	38	,	,	,
10_1101-2020_09_02_279521	423	39	Bateman	Bateman	NNP
10_1101-2020_09_02_279521	423	40	,	,	,
10_1101-2020_09_02_279521	423	41	R.	R.	NNP
10_1101-2020_09_02_279521	423	42	,	,	,
10_1101-2020_09_02_279521	423	43	Kerchner	Kerchner	NNP
10_1101-2020_09_02_279521	423	44	,	,	,
10_1101-2020_09_02_279521	423	45	G.	G.	NNP
10_1101-2020_09_02_279521	423	46	A.	A.	NNP
10_1101-2020_09_02_279521	423	47	,	,	,
10_1101-2020_09_02_279521	423	48	Baudler	Baudler	NNP
10_1101-2020_09_02_279521	423	49	,	,	,
10_1101-2020_09_02_279521	423	50	M.	M.	NNP
10_1101-2020_09_02_279521	423	51	,	,	,
10_1101-2020_09_02_279521	423	52	Fontoura	Fontoura	NNP
10_1101-2020_09_02_279521	423	53	,	,	,
10_1101-2020_09_02_279521	423	54	P.	P.	NNP
10_1101-2020_09_02_279521	423	55	,	,	,
10_1101-2020_09_02_279521	423	56	&	&	CC
10_1101-2020_09_02_279521	423	57	Doody	Doody	NNP
10_1101-2020_09_02_279521	423	58	,	,	,
10_1101-2020_09_02_279521	423	59	R.	R.	NNP
10_1101-2020_09_02_279521	423	60	(	(	-LRB-
10_1101-2020_09_02_279521	423	61	2019	2019	CD
10_1101-2020_09_02_279521	423	62	)	)	-RRB-
10_1101-2020_09_02_279521	423	63	.	.	.
10_1101-2020_09_02_279521	424	1	Gantenerumab	Gantenerumab	NNS
10_1101-2020_09_02_279521	424	2	reduces	reduce	VBZ
10_1101-2020_09_02_279521	424	3	amyloid-$β$	amyloid-$β$	NNP
10_1101-2020_09_02_279521	424	4	plaques	plaque	NNS
10_1101-2020_09_02_279521	424	5	in	in	IN
10_1101-2020_09_02_279521	424	6	patients	patient	NNS
10_1101-2020_09_02_279521	424	7	with	with	IN
10_1101-2020_09_02_279521	424	8	prodromal	prodromal	NN
10_1101-2020_09_02_279521	424	9	to	to	IN
10_1101-2020_09_02_279521	424	10	moderate	moderate	VB
10_1101-2020_09_02_279521	424	11	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	424	12	’s	’s	POS
10_1101-2020_09_02_279521	424	13	disease	disease	NN
10_1101-2020_09_02_279521	424	14	:	:	:
10_1101-2020_09_02_279521	424	15	a	a	DT
10_1101-2020_09_02_279521	424	16	PET	PET	NNP
10_1101-2020_09_02_279521	424	17	substudy	substudy	JJ
10_1101-2020_09_02_279521	424	18	interim	interim	JJ
10_1101-2020_09_02_279521	424	19	analysis	analysis	NN
10_1101-2020_09_02_279521	424	20	.	.	.
10_1101-2020_09_02_279521	425	1	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	425	2	’s	’s	POS
10_1101-2020_09_02_279521	425	3	Research	Research	NNP
10_1101-2020_09_02_279521	425	4	&	&	CC
10_1101-2020_09_02_279521	425	5	Therapy	Therapy	NNP
10_1101-2020_09_02_279521	425	6	,	,	,
10_1101-2020_09_02_279521	425	7	11(1	11(1	CD
10_1101-2020_09_02_279521	425	8	)	)	-RRB-
10_1101-2020_09_02_279521	425	9	,	,	,
10_1101-2020_09_02_279521	425	10	101	101	CD
10_1101-2020_09_02_279521	425	11	.	.	.
10_1101-2020_09_02_279521	425	12	https://doi.org/10.1186/s13195-019-0559-z	https://doi.org/10.1186/s13195-019-0559-z	NNP
10_1101-2020_09_02_279521	425	13	Kochhann	Kochhann	NNP
10_1101-2020_09_02_279521	425	14	,	,	,
10_1101-2020_09_02_279521	425	15	R.	R.	NNP
10_1101-2020_09_02_279521	425	16	,	,	,
10_1101-2020_09_02_279521	425	17	Varela	Varela	NNP
10_1101-2020_09_02_279521	425	18	,	,	,
10_1101-2020_09_02_279521	425	19	J.	J.	NNP
10_1101-2020_09_02_279521	425	20	S.	S.	NNP
10_1101-2020_09_02_279521	425	21	,	,	,
10_1101-2020_09_02_279521	425	22	Lisboa	Lisboa	NNP
10_1101-2020_09_02_279521	425	23	,	,	,
10_1101-2020_09_02_279521	425	24	C.	C.	NNP
10_1101-2020_09_02_279521	425	25	S.	S.	NNP
10_1101-2020_09_02_279521	425	26	M.	M.	NNP
10_1101-2020_09_02_279521	425	27	,	,	,
10_1101-2020_09_02_279521	425	28	&	&	CC
10_1101-2020_09_02_279521	425	29	Chaves	Chaves	NNP
10_1101-2020_09_02_279521	425	30	,	,	,
10_1101-2020_09_02_279521	425	31	M.	M.	NNP
10_1101-2020_09_02_279521	425	32	L.	L.	NNP
10_1101-2020_09_02_279521	425	33	F.	F.	NNP
10_1101-2020_09_02_279521	425	34	(	(	-LRB-
10_1101-2020_09_02_279521	425	35	2010	2010	CD
10_1101-2020_09_02_279521	425	36	)	)	-RRB-
10_1101-2020_09_02_279521	425	37	.	.	.
10_1101-2020_09_02_279521	426	1	The	the	DT
10_1101-2020_09_02_279521	426	2	Mini	Mini	NNP
10_1101-2020_09_02_279521	426	3	Mental	Mental	NNP
10_1101-2020_09_02_279521	426	4	State	State	NNP
10_1101-2020_09_02_279521	426	5	Examination	Examination	NNP
10_1101-2020_09_02_279521	426	6	:	:	:
10_1101-2020_09_02_279521	426	7	Review	review	NN
10_1101-2020_09_02_279521	426	8	of	of	IN
10_1101-2020_09_02_279521	426	9	cutoff	cutoff	NN
10_1101-2020_09_02_279521	426	10	points	point	NNS
10_1101-2020_09_02_279521	426	11	adjusted	adjust	VBN
10_1101-2020_09_02_279521	426	12	for	for	IN
10_1101-2020_09_02_279521	426	13	schooling	school	VBG
10_1101-2020_09_02_279521	426	14	in	in	IN
10_1101-2020_09_02_279521	426	15	a	a	DT
10_1101-2020_09_02_279521	426	16	large	large	JJ
10_1101-2020_09_02_279521	426	17	Southern	southern	JJ
10_1101-2020_09_02_279521	426	18	Brazilian	brazilian	JJ
10_1101-2020_09_02_279521	426	19	sample	sample	NN
10_1101-2020_09_02_279521	426	20	.	.	.
10_1101-2020_09_02_279521	427	1	Dement	Dement	NNP
10_1101-2020_09_02_279521	427	2	Neuropsychol	Neuropsychol	NNP
10_1101-2020_09_02_279521	427	3	,	,	,
10_1101-2020_09_02_279521	427	4	4(1	4(1	NNP
10_1101-2020_09_02_279521	427	5	)	)	-RRB-
10_1101-2020_09_02_279521	427	6	,	,	,
10_1101-2020_09_02_279521	427	7	35–41	35–41	CD
10_1101-2020_09_02_279521	427	8	.	.	.
10_1101-2020_09_02_279521	428	1	.CC	.CC	NFP
10_1101-2020_09_02_279521	428	2	-	-	:
10_1101-2020_09_02_279521	428	3	BY	by	IN
10_1101-2020_09_02_279521	428	4	4.0	4.0	CD
10_1101-2020_09_02_279521	428	5	International	international	JJ
10_1101-2020_09_02_279521	428	6	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	428	7	.	.	.
10_1101-2020_09_02_279521	429	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	429	2	is	be	VBZ
10_1101-2020_09_02_279521	429	3	made	make	VBN
10_1101-2020_09_02_279521	429	4	available	available	JJ
10_1101-2020_09_02_279521	429	5	under	under	IN
10_1101-2020_09_02_279521	429	6	a	a	DT
10_1101-2020_09_02_279521	429	7	preprint	preprint	NN
10_1101-2020_09_02_279521	429	8	(	(	-LRB-
10_1101-2020_09_02_279521	429	9	which	which	WDT
10_1101-2020_09_02_279521	429	10	was	be	VBD
10_1101-2020_09_02_279521	429	11	not	not	RB
10_1101-2020_09_02_279521	429	12	certified	certify	VBN
10_1101-2020_09_02_279521	429	13	by	by	IN
10_1101-2020_09_02_279521	429	14	peer	peer	NN
10_1101-2020_09_02_279521	429	15	review	review	NN
10_1101-2020_09_02_279521	429	16	)	)	-RRB-
10_1101-2020_09_02_279521	429	17	is	be	VBZ
10_1101-2020_09_02_279521	429	18	the	the	DT
10_1101-2020_09_02_279521	429	19	author	author	NN
10_1101-2020_09_02_279521	429	20	/	/	SYM
10_1101-2020_09_02_279521	429	21	funder	funder	NN
10_1101-2020_09_02_279521	429	22	,	,	,
10_1101-2020_09_02_279521	429	23	who	who	WP
10_1101-2020_09_02_279521	429	24	has	have	VBZ
10_1101-2020_09_02_279521	429	25	granted	grant	VBN
10_1101-2020_09_02_279521	429	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	429	27	a	a	DT
10_1101-2020_09_02_279521	429	28	license	license	NN
10_1101-2020_09_02_279521	429	29	to	to	TO
10_1101-2020_09_02_279521	429	30	display	display	VB
10_1101-2020_09_02_279521	429	31	the	the	DT
10_1101-2020_09_02_279521	429	32	preprint	preprint	NN
10_1101-2020_09_02_279521	429	33	in	in	IN
10_1101-2020_09_02_279521	429	34	The	the	DT
10_1101-2020_09_02_279521	429	35	copyright	copyright	NN
10_1101-2020_09_02_279521	429	36	holder	holder	NN
10_1101-2020_09_02_279521	429	37	for	for	IN
10_1101-2020_09_02_279521	429	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	429	39	version	version	NN
10_1101-2020_09_02_279521	429	40	posted	post	VBD
10_1101-2020_09_02_279521	429	41	February	February	NNP
10_1101-2020_09_02_279521	429	42	10	10	CD
10_1101-2020_09_02_279521	429	43	,	,	,
10_1101-2020_09_02_279521	429	44	2021	2021	CD
10_1101-2020_09_02_279521	429	45	.	.	.
10_1101-2020_09_02_279521	429	46	;	;	:
10_1101-2020_09_02_279521	429	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	429	48	:	:	:
10_1101-2020_09_02_279521	429	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	429	50	preprint	preprint	NN
10_1101-2020_09_02_279521	429	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	NN
10_1101-2020_09_02_279521	429	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	ADD
10_1101-2020_09_02_279521	429	53	Koval	Koval	NNP
10_1101-2020_09_02_279521	429	54	,	,	,
10_1101-2020_09_02_279521	429	55	I.	I.	NNP
10_1101-2020_09_02_279521	429	56	,	,	,
10_1101-2020_09_02_279521	429	57	Schiratti	Schiratti	NNP
10_1101-2020_09_02_279521	429	58	,	,	,
10_1101-2020_09_02_279521	429	59	J.-B.	J.-B.	NNP
10_1101-2020_09_02_279521	429	60	,	,	,
10_1101-2020_09_02_279521	429	61	Routier	Routier	NNP
10_1101-2020_09_02_279521	429	62	,	,	,
10_1101-2020_09_02_279521	429	63	A.	a.	NN
10_1101-2020_09_02_279521	429	64	,	,	,
10_1101-2020_09_02_279521	429	65	Bacci	Bacci	NNP
10_1101-2020_09_02_279521	429	66	,	,	,
10_1101-2020_09_02_279521	429	67	M.	M.	NNP
10_1101-2020_09_02_279521	429	68	,	,	,
10_1101-2020_09_02_279521	429	69	Colliot	Colliot	NNP
10_1101-2020_09_02_279521	429	70	,	,	,
10_1101-2020_09_02_279521	429	71	O.	O.	NNP
10_1101-2020_09_02_279521	429	72	,	,	,
10_1101-2020_09_02_279521	429	73	Allassonnière	Allassonnière	NNP
10_1101-2020_09_02_279521	429	74	,	,	,
10_1101-2020_09_02_279521	429	75	S.	S.	NNP
10_1101-2020_09_02_279521	429	76	,	,	,
10_1101-2020_09_02_279521	429	77	&	&	CC
10_1101-2020_09_02_279521	429	78	Durrleman	Durrleman	NNP
10_1101-2020_09_02_279521	429	79	,	,	,
10_1101-2020_09_02_279521	429	80	S.	S.	NNP
10_1101-2020_09_02_279521	429	81	(	(	-LRB-
10_1101-2020_09_02_279521	429	82	2018	2018	CD
10_1101-2020_09_02_279521	429	83	)	)	-RRB-
10_1101-2020_09_02_279521	429	84	.	.	.
10_1101-2020_09_02_279521	430	1	Spatiotemporal	Spatiotemporal	NNP
10_1101-2020_09_02_279521	430	2	Propagation	Propagation	NNP
10_1101-2020_09_02_279521	430	3	of	of	IN
10_1101-2020_09_02_279521	430	4	the	the	DT
10_1101-2020_09_02_279521	430	5	Cortical	Cortical	NNP
10_1101-2020_09_02_279521	430	6	Atrophy	Atrophy	NNP
10_1101-2020_09_02_279521	430	7	:	:	:
10_1101-2020_09_02_279521	430	8	Population	Population	NNP
10_1101-2020_09_02_279521	430	9	and	and	CC
10_1101-2020_09_02_279521	430	10	Individual	Individual	NNP
10_1101-2020_09_02_279521	430	11	Patterns	Patterns	NNPS
10_1101-2020_09_02_279521	430	12	.	.	.
10_1101-2020_09_02_279521	431	1	Frontiers	Frontiers	NNP
10_1101-2020_09_02_279521	431	2	in	in	IN
10_1101-2020_09_02_279521	431	3	Neurology	Neurology	NNP
10_1101-2020_09_02_279521	431	4	,	,	,
10_1101-2020_09_02_279521	431	5	9	9	CD
10_1101-2020_09_02_279521	431	6	,	,	,
10_1101-2020_09_02_279521	431	7	235	235	CD
10_1101-2020_09_02_279521	431	8	.	.	.
10_1101-2020_09_02_279521	431	9	https://doi.org/10.3389/fneur.2018.00235	https://doi.org/10.3389/fneur.2018.00235	NNP
10_1101-2020_09_02_279521	431	10	Li	Li	NNP
10_1101-2020_09_02_279521	431	11	,	,	,
10_1101-2020_09_02_279521	431	12	D.	D.	NNP
10_1101-2020_09_02_279521	431	13	,	,	,
10_1101-2020_09_02_279521	431	14	Iddi	Iddi	NNP
10_1101-2020_09_02_279521	431	15	,	,	,
10_1101-2020_09_02_279521	431	16	S.	S.	NNP
10_1101-2020_09_02_279521	431	17	,	,	,
10_1101-2020_09_02_279521	431	18	Thompson	Thompson	NNP
10_1101-2020_09_02_279521	431	19	,	,	,
10_1101-2020_09_02_279521	431	20	W.	W.	NNP
10_1101-2020_09_02_279521	431	21	K.	K.	NNP
10_1101-2020_09_02_279521	431	22	,	,	,
10_1101-2020_09_02_279521	431	23	&	&	CC
10_1101-2020_09_02_279521	431	24	Donohue	Donohue	NNP
10_1101-2020_09_02_279521	431	25	,	,	,
10_1101-2020_09_02_279521	431	26	M.	M.	NNP
10_1101-2020_09_02_279521	431	27	C.	C.	NNP
10_1101-2020_09_02_279521	431	28	(	(	-LRB-
10_1101-2020_09_02_279521	431	29	2019	2019	CD
10_1101-2020_09_02_279521	431	30	)	)	-RRB-
10_1101-2020_09_02_279521	431	31	.	.	.
10_1101-2020_09_02_279521	432	1	Bayesian	bayesian	JJ
10_1101-2020_09_02_279521	432	2	latent	latent	NN
10_1101-2020_09_02_279521	432	3	time	time	NN
10_1101-2020_09_02_279521	432	4	joint	joint	JJ
10_1101-2020_09_02_279521	432	5	mixed	mixed	JJ
10_1101-2020_09_02_279521	432	6	effect	effect	NN
10_1101-2020_09_02_279521	432	7	models	model	NNS
10_1101-2020_09_02_279521	432	8	for	for	IN
10_1101-2020_09_02_279521	432	9	multicohort	multicohort	JJ
10_1101-2020_09_02_279521	432	10	longitudinal	longitudinal	JJ
10_1101-2020_09_02_279521	432	11	data	datum	NNS
10_1101-2020_09_02_279521	432	12	.	.	.
10_1101-2020_09_02_279521	433	1	Stat	stat	JJ
10_1101-2020_09_02_279521	433	2	Methods	method	NNS
10_1101-2020_09_02_279521	433	3	Med	Med	NNP
10_1101-2020_09_02_279521	433	4	Res	res	NN
10_1101-2020_09_02_279521	433	5	,	,	,
10_1101-2020_09_02_279521	433	6	28(3	28(3	CD
10_1101-2020_09_02_279521	433	7	)	)	-RRB-
10_1101-2020_09_02_279521	433	8	,	,	,
10_1101-2020_09_02_279521	433	9	835–845	835–845	CD
10_1101-2020_09_02_279521	433	10	.	.	.
10_1101-2020_09_02_279521	434	1	Lorenzi	Lorenzi	NNP
10_1101-2020_09_02_279521	434	2	,	,	,
10_1101-2020_09_02_279521	434	3	M.	M.	NNP
10_1101-2020_09_02_279521	434	4	,	,	,
10_1101-2020_09_02_279521	434	5	Filippone	Filippone	NNP
10_1101-2020_09_02_279521	434	6	,	,	,
10_1101-2020_09_02_279521	434	7	M.	M.	NNP
10_1101-2020_09_02_279521	434	8	,	,	,
10_1101-2020_09_02_279521	434	9	Frisoni	Frisoni	NNP
10_1101-2020_09_02_279521	434	10	,	,	,
10_1101-2020_09_02_279521	434	11	G.	G.	NNP
10_1101-2020_09_02_279521	434	12	B.	B.	NNP
10_1101-2020_09_02_279521	434	13	,	,	,
10_1101-2020_09_02_279521	434	14	Alexander	Alexander	NNP
10_1101-2020_09_02_279521	434	15	,	,	,
10_1101-2020_09_02_279521	434	16	D.	D.	NNP
10_1101-2020_09_02_279521	434	17	C.	C.	NNP
10_1101-2020_09_02_279521	434	18	,	,	,
10_1101-2020_09_02_279521	434	19	&	&	CC
10_1101-2020_09_02_279521	434	20	Ourselin	Ourselin	NNP
10_1101-2020_09_02_279521	434	21	,	,	,
10_1101-2020_09_02_279521	434	22	S.	S.	NNP
10_1101-2020_09_02_279521	434	23	(	(	-LRB-
10_1101-2020_09_02_279521	434	24	2017	2017	CD
10_1101-2020_09_02_279521	434	25	)	)	-RRB-
10_1101-2020_09_02_279521	434	26	.	.	.
10_1101-2020_09_02_279521	435	1	Probabilistic	probabilistic	JJ
10_1101-2020_09_02_279521	435	2	disease	disease	NN
10_1101-2020_09_02_279521	435	3	progression	progression	NN
10_1101-2020_09_02_279521	435	4	modeling	model	VBG
10_1101-2020_09_02_279521	435	5	to	to	TO
10_1101-2020_09_02_279521	435	6	characterize	characterize	VB
10_1101-2020_09_02_279521	435	7	diagnostic	diagnostic	JJ
10_1101-2020_09_02_279521	435	8	uncertainty	uncertainty	NN
10_1101-2020_09_02_279521	435	9	:	:	:
10_1101-2020_09_02_279521	435	10	Application	application	NN
10_1101-2020_09_02_279521	435	11	to	to	IN
10_1101-2020_09_02_279521	435	12	staging	staging	NN
10_1101-2020_09_02_279521	435	13	and	and	CC
10_1101-2020_09_02_279521	435	14	prediction	prediction	NN
10_1101-2020_09_02_279521	435	15	in	in	IN
10_1101-2020_09_02_279521	435	16	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	435	17	’s	’s	POS
10_1101-2020_09_02_279521	435	18	disease	disease	NN
10_1101-2020_09_02_279521	435	19	.	.	.
10_1101-2020_09_02_279521	436	1	NeuroImage	NeuroImage	NNP
10_1101-2020_09_02_279521	436	2	.	.	.
10_1101-2020_09_02_279521	437	1	https://doi.org/https://doi.org/10.1016/j.Neuroimage.2017.08.059	https://doi.org/https://doi.org/10.1016/j.neuroimage.2017.08.059	IN
10_1101-2020_09_02_279521	437	2	Lorenzi	Lorenzi	NNP
10_1101-2020_09_02_279521	437	3	,	,	,
10_1101-2020_09_02_279521	437	4	M.	M.	NNP
10_1101-2020_09_02_279521	437	5	,	,	,
10_1101-2020_09_02_279521	437	6	Pennec	Pennec	NNP
10_1101-2020_09_02_279521	437	7	,	,	,
10_1101-2020_09_02_279521	437	8	X.	X.	NNP
10_1101-2020_09_02_279521	437	9	,	,	,
10_1101-2020_09_02_279521	437	10	Frisoni	Frisoni	NNP
10_1101-2020_09_02_279521	437	11	,	,	,
10_1101-2020_09_02_279521	437	12	G.	G.	NNP
10_1101-2020_09_02_279521	437	13	B.	B.	NNP
10_1101-2020_09_02_279521	437	14	,	,	,
10_1101-2020_09_02_279521	437	15	&	&	CC
10_1101-2020_09_02_279521	437	16	Ayache	Ayache	NNP
10_1101-2020_09_02_279521	437	17	,	,	,
10_1101-2020_09_02_279521	437	18	N.	N.	NNP
10_1101-2020_09_02_279521	437	19	(	(	-LRB-
10_1101-2020_09_02_279521	437	20	2015	2015	CD
10_1101-2020_09_02_279521	437	21	)	)	-RRB-
10_1101-2020_09_02_279521	437	22	.	.	.
10_1101-2020_09_02_279521	438	1	Disentangling	disentangle	VBG
10_1101-2020_09_02_279521	438	2	normal	normal	JJ
10_1101-2020_09_02_279521	438	3	aging	aging	NN
10_1101-2020_09_02_279521	438	4	from	from	IN
10_1101-2020_09_02_279521	438	5	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	438	6	’s	’s	POS
10_1101-2020_09_02_279521	438	7	disease	disease	NN
10_1101-2020_09_02_279521	438	8	in	in	IN
10_1101-2020_09_02_279521	438	9	structural	structural	JJ
10_1101-2020_09_02_279521	438	10	magnetic	magnetic	JJ
10_1101-2020_09_02_279521	438	11	resonance	resonance	NN
10_1101-2020_09_02_279521	438	12	images	image	NNS
10_1101-2020_09_02_279521	438	13	.	.	.
10_1101-2020_09_02_279521	439	1	Neurobiology	neurobiology	NN
10_1101-2020_09_02_279521	439	2	of	of	IN
10_1101-2020_09_02_279521	439	3	Aging	Aging	NNP
10_1101-2020_09_02_279521	439	4	,	,	,
10_1101-2020_09_02_279521	439	5	36	36	CD
10_1101-2020_09_02_279521	439	6	,	,	,
10_1101-2020_09_02_279521	439	7	S42–S52	s42–s52	ADD
10_1101-2020_09_02_279521	439	8	.	.	.
10_1101-2020_09_02_279521	440	1	https://doi.org/https://doi.org/10.1016/j.neurobiolaging.2014.07.046	https://doi.org/https://doi.org/10.1016/j.neurobiolaging.2014.07.046	NNP
10_1101-2020_09_02_279521	440	2	Marinescu	Marinescu	NNP
10_1101-2020_09_02_279521	440	3	,	,	,
10_1101-2020_09_02_279521	440	4	R.	R.	NNP
10_1101-2020_09_02_279521	440	5	V	V	NNP
10_1101-2020_09_02_279521	440	6	,	,	,
10_1101-2020_09_02_279521	440	7	Eshaghi	Eshaghi	NNP
10_1101-2020_09_02_279521	440	8	,	,	,
10_1101-2020_09_02_279521	440	9	A.	a.	NN
10_1101-2020_09_02_279521	440	10	,	,	,
10_1101-2020_09_02_279521	440	11	Lorenzi	Lorenzi	NNP
10_1101-2020_09_02_279521	440	12	,	,	,
10_1101-2020_09_02_279521	440	13	M.	M.	NNP
10_1101-2020_09_02_279521	440	14	,	,	,
10_1101-2020_09_02_279521	440	15	Young	Young	NNP
10_1101-2020_09_02_279521	440	16	,	,	,
10_1101-2020_09_02_279521	440	17	A.	a.	NN
10_1101-2020_09_02_279521	440	18	L.	L.	NNP
10_1101-2020_09_02_279521	440	19	,	,	,
10_1101-2020_09_02_279521	440	20	Oxtoby	Oxtoby	NNP
10_1101-2020_09_02_279521	440	21	,	,	,
10_1101-2020_09_02_279521	440	22	N.	N.	NNP
10_1101-2020_09_02_279521	440	23	P.	P.	NNP
10_1101-2020_09_02_279521	440	24	,	,	,
10_1101-2020_09_02_279521	440	25	Garbarino	Garbarino	NNP
10_1101-2020_09_02_279521	440	26	,	,	,
10_1101-2020_09_02_279521	440	27	S.	S.	NNP
10_1101-2020_09_02_279521	440	28	,	,	,
10_1101-2020_09_02_279521	440	29	Crutch	Crutch	NNP
10_1101-2020_09_02_279521	440	30	,	,	,
10_1101-2020_09_02_279521	440	31	S.	S.	NNP
10_1101-2020_09_02_279521	440	32	J.	J.	NNP
10_1101-2020_09_02_279521	440	33	,	,	,
10_1101-2020_09_02_279521	440	34	&	&	CC
10_1101-2020_09_02_279521	440	35	Alexander	Alexander	NNP
10_1101-2020_09_02_279521	440	36	,	,	,
10_1101-2020_09_02_279521	440	37	D.	D.	NNP
10_1101-2020_09_02_279521	440	38	C.	C.	NNP
10_1101-2020_09_02_279521	440	39	(	(	-LRB-
10_1101-2020_09_02_279521	440	40	2019	2019	CD
10_1101-2020_09_02_279521	440	41	)	)	-RRB-
10_1101-2020_09_02_279521	440	42	.	.	.
10_1101-2020_09_02_279521	441	1	DIVE	dive	NN
10_1101-2020_09_02_279521	441	2	:	:	:
10_1101-2020_09_02_279521	441	3	A	a	DT
10_1101-2020_09_02_279521	441	4	spatiotemporal	spatiotemporal	JJ
10_1101-2020_09_02_279521	441	5	progression	progression	NN
10_1101-2020_09_02_279521	441	6	model	model	NN
10_1101-2020_09_02_279521	441	7	of	of	IN
10_1101-2020_09_02_279521	441	8	brain	brain	NN
10_1101-2020_09_02_279521	441	9	pathology	pathology	NN
10_1101-2020_09_02_279521	441	10	in	in	IN
10_1101-2020_09_02_279521	441	11	neurodegenerative	neurodegenerative	JJ
10_1101-2020_09_02_279521	441	12	disorders	disorder	NNS
10_1101-2020_09_02_279521	441	13	.	.	.
10_1101-2020_09_02_279521	442	1	NeuroImage	NeuroImage	NNP
10_1101-2020_09_02_279521	442	2	,	,	,
10_1101-2020_09_02_279521	442	3	192	192	CD
10_1101-2020_09_02_279521	442	4	,	,	,
10_1101-2020_09_02_279521	442	5	166–177	166–177	CD
10_1101-2020_09_02_279521	442	6	.	.	.
10_1101-2020_09_02_279521	443	1	Murphy	Murphy	NNP
10_1101-2020_09_02_279521	443	2	,	,	,
10_1101-2020_09_02_279521	443	3	M.	M.	NNP
10_1101-2020_09_02_279521	443	4	P.	P.	NNP
10_1101-2020_09_02_279521	443	5	,	,	,
10_1101-2020_09_02_279521	443	6	&	&	CC
10_1101-2020_09_02_279521	443	7	LeVine	LeVine	NNP
10_1101-2020_09_02_279521	443	8	,	,	,
10_1101-2020_09_02_279521	443	9	H.	H.	NNP
10_1101-2020_09_02_279521	443	10	(	(	-LRB-
10_1101-2020_09_02_279521	443	11	2010	2010	CD
10_1101-2020_09_02_279521	443	12	)	)	-RRB-
10_1101-2020_09_02_279521	443	13	.	.	.
10_1101-2020_09_02_279521	444	1	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	444	2	’s	’s	POS
10_1101-2020_09_02_279521	444	3	disease	disease	NN
10_1101-2020_09_02_279521	444	4	and	and	CC
10_1101-2020_09_02_279521	444	5	the	the	DT
10_1101-2020_09_02_279521	444	6	amyloid	amyloid	VB
10_1101-2020_09_02_279521	444	7	-	-	HYPH
10_1101-2020_09_02_279521	444	8	beta	beta	NN
10_1101-2020_09_02_279521	444	9	peptide	peptide	NN
10_1101-2020_09_02_279521	444	10	.	.	.
10_1101-2020_09_02_279521	445	1	J.	J.	NNP
10_1101-2020_09_02_279521	445	2	Alzheimers	Alzheimers	NNP
10_1101-2020_09_02_279521	445	3	Dis	Dis	NNP
10_1101-2020_09_02_279521	445	4	.	.	NNP
10_1101-2020_09_02_279521	445	5	,	,	,
10_1101-2020_09_02_279521	445	6	19(1	19(1	CD
10_1101-2020_09_02_279521	445	7	)	)	-RRB-
10_1101-2020_09_02_279521	445	8	,	,	,
10_1101-2020_09_02_279521	445	9	311–323	311–323	CD
10_1101-2020_09_02_279521	445	10	.	.	.
10_1101-2020_09_02_279521	446	1	Nader	Nader	NNP
10_1101-2020_09_02_279521	446	2	,	,	,
10_1101-2020_09_02_279521	446	3	C.	C.	NNP
10_1101-2020_09_02_279521	446	4	A.	A.	NNP
10_1101-2020_09_02_279521	446	5	,	,	,
10_1101-2020_09_02_279521	446	6	Ayache	Ayache	NNP
10_1101-2020_09_02_279521	446	7	,	,	,
10_1101-2020_09_02_279521	446	8	N.	N.	NNP
10_1101-2020_09_02_279521	446	9	,	,	,
10_1101-2020_09_02_279521	446	10	Robert	Robert	NNP
10_1101-2020_09_02_279521	446	11	,	,	,
10_1101-2020_09_02_279521	446	12	P.	P.	NNP
10_1101-2020_09_02_279521	446	13	,	,	,
10_1101-2020_09_02_279521	446	14	Lorenzi	Lorenzi	NNP
10_1101-2020_09_02_279521	446	15	,	,	,
10_1101-2020_09_02_279521	446	16	M.	M.	NNP
10_1101-2020_09_02_279521	446	17	,	,	,
10_1101-2020_09_02_279521	446	18	&	&	CC
10_1101-2020_09_02_279521	446	19	Initiative	Initiative	NNP
10_1101-2020_09_02_279521	446	20	,	,	,
10_1101-2020_09_02_279521	446	21	A.	A.	NNP
10_1101-2020_09_02_279521	446	22	D.	D.	NNP
10_1101-2020_09_02_279521	446	23	N.	N.	NNP
10_1101-2020_09_02_279521	446	24	(	(	-LRB-
10_1101-2020_09_02_279521	446	25	2020	2020	CD
10_1101-2020_09_02_279521	446	26	)	)	-RRB-
10_1101-2020_09_02_279521	446	27	.	.	.
10_1101-2020_09_02_279521	447	1	Monotonic	Monotonic	NNP
10_1101-2020_09_02_279521	447	2	Gaussian	Gaussian	NNP
10_1101-2020_09_02_279521	447	3	Process	Process	NNP
10_1101-2020_09_02_279521	447	4	for	for	IN
10_1101-2020_09_02_279521	447	5	spatio	spatio	NN
10_1101-2020_09_02_279521	447	6	-	-	HYPH
10_1101-2020_09_02_279521	447	7	temporal	temporal	JJ
10_1101-2020_09_02_279521	447	8	disease	disease	NN
10_1101-2020_09_02_279521	447	9	progression	progression	NN
10_1101-2020_09_02_279521	447	10	modeling	model	VBG
10_1101-2020_09_02_279521	447	11	in	in	IN
10_1101-2020_09_02_279521	447	12	brain	brain	NN
10_1101-2020_09_02_279521	447	13	imaging	imaging	NN
10_1101-2020_09_02_279521	447	14	data	datum	NNS
10_1101-2020_09_02_279521	447	15	.	.	.
10_1101-2020_09_02_279521	448	1	NeuroImage	NeuroImage	NNP
10_1101-2020_09_02_279521	448	2	,	,	,
10_1101-2020_09_02_279521	448	3	205	205	CD
10_1101-2020_09_02_279521	448	4	.	.	.
10_1101-2020_09_02_279521	448	5	https://doi.org/10.1016/j.neuroimage.2019.116266	https://doi.org/10.1016/j.neuroimage.2019.116266	NNP
10_1101-2020_09_02_279521	448	6	Oxtoby	Oxtoby	NNP
10_1101-2020_09_02_279521	448	7	,	,	,
10_1101-2020_09_02_279521	448	8	N.	N.	NNP
10_1101-2020_09_02_279521	448	9	P.	P.	NNP
10_1101-2020_09_02_279521	448	10	,	,	,
10_1101-2020_09_02_279521	448	11	Garbarino	Garbarino	NNP
10_1101-2020_09_02_279521	448	12	,	,	,
10_1101-2020_09_02_279521	448	13	S.	S.	NNP
10_1101-2020_09_02_279521	448	14	,	,	,
10_1101-2020_09_02_279521	448	15	Firth	Firth	NNP
10_1101-2020_09_02_279521	448	16	,	,	,
10_1101-2020_09_02_279521	448	17	N.	N.	NNP
10_1101-2020_09_02_279521	448	18	C.	C.	NNP
10_1101-2020_09_02_279521	448	19	,	,	,
10_1101-2020_09_02_279521	448	20	Warren	Warren	NNP
10_1101-2020_09_02_279521	448	21	,	,	,
10_1101-2020_09_02_279521	448	22	J.	J.	NNP
10_1101-2020_09_02_279521	448	23	D.	D.	NNP
10_1101-2020_09_02_279521	448	24	,	,	,
10_1101-2020_09_02_279521	448	25	Schott	Schott	NNP
10_1101-2020_09_02_279521	448	26	,	,	,
10_1101-2020_09_02_279521	448	27	J.	J.	NNP
10_1101-2020_09_02_279521	448	28	M.	M.	NNP
10_1101-2020_09_02_279521	448	29	,	,	,
10_1101-2020_09_02_279521	448	30	&	&	CC
10_1101-2020_09_02_279521	448	31	Alexander	Alexander	NNP
10_1101-2020_09_02_279521	448	32	,	,	,
10_1101-2020_09_02_279521	448	33	D.	D.	NNP
10_1101-2020_09_02_279521	448	34	C.	C.	NNP
10_1101-2020_09_02_279521	448	35	(	(	-LRB-
10_1101-2020_09_02_279521	448	36	2017	2017	CD
10_1101-2020_09_02_279521	448	37	)	)	-RRB-
10_1101-2020_09_02_279521	448	38	.	.	.
10_1101-2020_09_02_279521	449	1	Data	datum	NNS
10_1101-2020_09_02_279521	449	2	-	-	HYPH
10_1101-2020_09_02_279521	449	3	Driven	drive	VBN
10_1101-2020_09_02_279521	449	4	Sequence	Sequence	NNP
10_1101-2020_09_02_279521	449	5	of	of	IN
10_1101-2020_09_02_279521	449	6	Changes	change	NNS
10_1101-2020_09_02_279521	449	7	to	to	IN
10_1101-2020_09_02_279521	449	8	Anatomical	Anatomical	NNP
10_1101-2020_09_02_279521	449	9	Brain	Brain	NNP
10_1101-2020_09_02_279521	449	10	Connectivity	Connectivity	NNP
10_1101-2020_09_02_279521	449	11	in	in	IN
10_1101-2020_09_02_279521	449	12	Sporadic	Sporadic	NNP
10_1101-2020_09_02_279521	449	13	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	449	14	’s	’s	POS
10_1101-2020_09_02_279521	449	15	Disease	Disease	NNP
10_1101-2020_09_02_279521	449	16	.	.	.
10_1101-2020_09_02_279521	450	1	Front	Front	NNP
10_1101-2020_09_02_279521	450	2	Neurol	Neurol	NNP
10_1101-2020_09_02_279521	450	3	,	,	,
10_1101-2020_09_02_279521	450	4	8	8	CD
10_1101-2020_09_02_279521	450	5	,	,	,
10_1101-2020_09_02_279521	450	6	580	580	CD
10_1101-2020_09_02_279521	450	7	.	.	.
10_1101-2020_09_02_279521	451	1	Oxtoby	Oxtoby	NNP
10_1101-2020_09_02_279521	451	2	,	,	,
10_1101-2020_09_02_279521	451	3	N.	N.	NNP
10_1101-2020_09_02_279521	451	4	P.	P.	NNP
10_1101-2020_09_02_279521	451	5	,	,	,
10_1101-2020_09_02_279521	451	6	Young	Young	NNP
10_1101-2020_09_02_279521	451	7	,	,	,
10_1101-2020_09_02_279521	451	8	A.	a.	NN
10_1101-2020_09_02_279521	451	9	L.	L.	NNP
10_1101-2020_09_02_279521	451	10	,	,	,
10_1101-2020_09_02_279521	451	11	Cash	Cash	NNP
10_1101-2020_09_02_279521	451	12	,	,	,
10_1101-2020_09_02_279521	451	13	D.	D.	NNP
10_1101-2020_09_02_279521	451	14	M.	M.	NNP
10_1101-2020_09_02_279521	451	15	,	,	,
10_1101-2020_09_02_279521	451	16	Benzinger	Benzinger	NNP
10_1101-2020_09_02_279521	451	17	,	,	,
10_1101-2020_09_02_279521	451	18	T.	T.	NNP
10_1101-2020_09_02_279521	451	19	L.	L.	NNP
10_1101-2020_09_02_279521	451	20	S.	S.	NNP
10_1101-2020_09_02_279521	451	21	,	,	,
10_1101-2020_09_02_279521	451	22	Fagan	Fagan	NNP
10_1101-2020_09_02_279521	451	23	,	,	,
10_1101-2020_09_02_279521	451	24	A.	A.	NNP
10_1101-2020_09_02_279521	451	25	M.	M.	NNP
10_1101-2020_09_02_279521	451	26	,	,	,
10_1101-2020_09_02_279521	451	27	Morris	Morris	NNP
10_1101-2020_09_02_279521	451	28	,	,	,
10_1101-2020_09_02_279521	451	29	J.	J.	NNP
10_1101-2020_09_02_279521	451	30	C.	C.	NNP
10_1101-2020_09_02_279521	451	31	,	,	,
10_1101-2020_09_02_279521	451	32	Bateman	Bateman	NNP
10_1101-2020_09_02_279521	451	33	,	,	,
10_1101-2020_09_02_279521	451	34	R.	R.	NNP
10_1101-2020_09_02_279521	451	35	J.	J.	NNP
10_1101-2020_09_02_279521	451	36	,	,	,
10_1101-2020_09_02_279521	451	37	Fox	Fox	NNP
10_1101-2020_09_02_279521	451	38	,	,	,
10_1101-2020_09_02_279521	451	39	N.	N.	NNP
10_1101-2020_09_02_279521	451	40	C.	C.	NNP
10_1101-2020_09_02_279521	451	41	,	,	,
10_1101-2020_09_02_279521	451	42	Schott	Schott	NNP
10_1101-2020_09_02_279521	451	43	,	,	,
10_1101-2020_09_02_279521	451	44	J.	J.	NNP
10_1101-2020_09_02_279521	451	45	M.	M.	NNP
10_1101-2020_09_02_279521	451	46	,	,	,
10_1101-2020_09_02_279521	451	47	&	&	CC
10_1101-2020_09_02_279521	451	48	Alexander	Alexander	NNP
10_1101-2020_09_02_279521	451	49	,	,	,
10_1101-2020_09_02_279521	451	50	D.	D.	NNP
10_1101-2020_09_02_279521	451	51	C.	C.	NNP
10_1101-2020_09_02_279521	451	52	(	(	-LRB-
10_1101-2020_09_02_279521	451	53	2018	2018	CD
10_1101-2020_09_02_279521	451	54	)	)	-RRB-
10_1101-2020_09_02_279521	451	55	.	.	.
10_1101-2020_09_02_279521	452	1	Data	datum	NNS
10_1101-2020_09_02_279521	452	2	-	-	HYPH
10_1101-2020_09_02_279521	452	3	driven	drive	VBN
10_1101-2020_09_02_279521	452	4	models	model	NNS
10_1101-2020_09_02_279521	452	5	of	of	IN
10_1101-2020_09_02_279521	452	6	dominantly	dominantly	RB
10_1101-2020_09_02_279521	452	7	-	-	HYPH
10_1101-2020_09_02_279521	452	8	inherited	inherit	VBN
10_1101-2020_09_02_279521	452	9	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	452	10	’s	’s	POS
10_1101-2020_09_02_279521	452	11	disease	disease	NN
10_1101-2020_09_02_279521	452	12	progression	progression	NN
10_1101-2020_09_02_279521	452	13	.	.	.
10_1101-2020_09_02_279521	453	1	Brain	brain	NN
10_1101-2020_09_02_279521	453	2	,	,	,
10_1101-2020_09_02_279521	453	3	141(5	141(5	CD
10_1101-2020_09_02_279521	453	4	)	)	-RRB-
10_1101-2020_09_02_279521	453	5	,	,	,
10_1101-2020_09_02_279521	453	6	1529	1529	CD
10_1101-2020_09_02_279521	453	7	–	–	:
10_1101-2020_09_02_279521	453	8	1544	1544	CD
10_1101-2020_09_02_279521	453	9	.	.	.
10_1101-2020_09_02_279521	454	1	Paszke	Paszke	NNP
10_1101-2020_09_02_279521	454	2	,	,	,
10_1101-2020_09_02_279521	454	3	A.	a.	NN
10_1101-2020_09_02_279521	454	4	,	,	,
10_1101-2020_09_02_279521	454	5	Gross	Gross	NNP
10_1101-2020_09_02_279521	454	6	,	,	,
10_1101-2020_09_02_279521	454	7	S.	S.	NNP
10_1101-2020_09_02_279521	454	8	,	,	,
10_1101-2020_09_02_279521	454	9	Massa	Massa	NNP
10_1101-2020_09_02_279521	454	10	,	,	,
10_1101-2020_09_02_279521	454	11	F.	F.	NNP
10_1101-2020_09_02_279521	454	12	,	,	,
10_1101-2020_09_02_279521	454	13	Lerer	Lerer	NNP
10_1101-2020_09_02_279521	454	14	,	,	,
10_1101-2020_09_02_279521	454	15	A.	A.	NNP
10_1101-2020_09_02_279521	454	16	,	,	,
10_1101-2020_09_02_279521	454	17	Bradbury	Bradbury	NNP
10_1101-2020_09_02_279521	454	18	,	,	,
10_1101-2020_09_02_279521	454	19	J.	J.	NNP
10_1101-2020_09_02_279521	454	20	,	,	,
10_1101-2020_09_02_279521	454	21	Chanan	Chanan	NNP
10_1101-2020_09_02_279521	454	22	,	,	,
10_1101-2020_09_02_279521	454	23	G.	G.	NNP
10_1101-2020_09_02_279521	454	24	,	,	,
10_1101-2020_09_02_279521	454	25	Killeen	Killeen	NNP
10_1101-2020_09_02_279521	454	26	,	,	,
10_1101-2020_09_02_279521	454	27	T.	T.	NNP
10_1101-2020_09_02_279521	454	28	,	,	,
10_1101-2020_09_02_279521	454	29	Lin	Lin	NNP
10_1101-2020_09_02_279521	454	30	,	,	,
10_1101-2020_09_02_279521	454	31	Z.	Z.	NNP
10_1101-2020_09_02_279521	454	32	,	,	,
10_1101-2020_09_02_279521	454	33	.CC	.CC	:
10_1101-2020_09_02_279521	454	34	-	-	:
10_1101-2020_09_02_279521	454	35	BY	by	IN
10_1101-2020_09_02_279521	454	36	4.0	4.0	CD
10_1101-2020_09_02_279521	454	37	International	international	JJ
10_1101-2020_09_02_279521	454	38	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	454	39	.	.	.
10_1101-2020_09_02_279521	455	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	455	2	is	be	VBZ
10_1101-2020_09_02_279521	455	3	made	make	VBN
10_1101-2020_09_02_279521	455	4	available	available	JJ
10_1101-2020_09_02_279521	455	5	under	under	IN
10_1101-2020_09_02_279521	455	6	a	a	DT
10_1101-2020_09_02_279521	455	7	preprint	preprint	NN
10_1101-2020_09_02_279521	455	8	(	(	-LRB-
10_1101-2020_09_02_279521	455	9	which	which	WDT
10_1101-2020_09_02_279521	455	10	was	be	VBD
10_1101-2020_09_02_279521	455	11	not	not	RB
10_1101-2020_09_02_279521	455	12	certified	certify	VBN
10_1101-2020_09_02_279521	455	13	by	by	IN
10_1101-2020_09_02_279521	455	14	peer	peer	NN
10_1101-2020_09_02_279521	455	15	review	review	NN
10_1101-2020_09_02_279521	455	16	)	)	-RRB-
10_1101-2020_09_02_279521	455	17	is	be	VBZ
10_1101-2020_09_02_279521	455	18	the	the	DT
10_1101-2020_09_02_279521	455	19	author	author	NN
10_1101-2020_09_02_279521	455	20	/	/	SYM
10_1101-2020_09_02_279521	455	21	funder	funder	NN
10_1101-2020_09_02_279521	455	22	,	,	,
10_1101-2020_09_02_279521	455	23	who	who	WP
10_1101-2020_09_02_279521	455	24	has	have	VBZ
10_1101-2020_09_02_279521	455	25	granted	grant	VBN
10_1101-2020_09_02_279521	455	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	455	27	a	a	DT
10_1101-2020_09_02_279521	455	28	license	license	NN
10_1101-2020_09_02_279521	455	29	to	to	TO
10_1101-2020_09_02_279521	455	30	display	display	VB
10_1101-2020_09_02_279521	455	31	the	the	DT
10_1101-2020_09_02_279521	455	32	preprint	preprint	NN
10_1101-2020_09_02_279521	455	33	in	in	IN
10_1101-2020_09_02_279521	455	34	The	the	DT
10_1101-2020_09_02_279521	455	35	copyright	copyright	NN
10_1101-2020_09_02_279521	455	36	holder	holder	NN
10_1101-2020_09_02_279521	455	37	for	for	IN
10_1101-2020_09_02_279521	455	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	455	39	version	version	NN
10_1101-2020_09_02_279521	455	40	posted	post	VBD
10_1101-2020_09_02_279521	455	41	February	February	NNP
10_1101-2020_09_02_279521	455	42	10	10	CD
10_1101-2020_09_02_279521	455	43	,	,	,
10_1101-2020_09_02_279521	455	44	2021	2021	CD
10_1101-2020_09_02_279521	455	45	.	.	.
10_1101-2020_09_02_279521	455	46	;	;	:
10_1101-2020_09_02_279521	455	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	455	48	:	:	:
10_1101-2020_09_02_279521	455	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	455	50	preprint	preprint	NN
10_1101-2020_09_02_279521	455	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	NN
10_1101-2020_09_02_279521	455	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	ADD
10_1101-2020_09_02_279521	455	53	Gimelshein	Gimelshein	NNP
10_1101-2020_09_02_279521	455	54	,	,	,
10_1101-2020_09_02_279521	455	55	N.	N.	NNP
10_1101-2020_09_02_279521	455	56	,	,	,
10_1101-2020_09_02_279521	455	57	Antiga	Antiga	NNP
10_1101-2020_09_02_279521	455	58	,	,	,
10_1101-2020_09_02_279521	455	59	L.	L.	NNP
10_1101-2020_09_02_279521	455	60	,	,	,
10_1101-2020_09_02_279521	455	61	Desmaison	Desmaison	NNP
10_1101-2020_09_02_279521	455	62	,	,	,
10_1101-2020_09_02_279521	455	63	A.	A.	NNP
10_1101-2020_09_02_279521	455	64	,	,	,
10_1101-2020_09_02_279521	455	65	Kopf	Kopf	NNP
10_1101-2020_09_02_279521	455	66	,	,	,
10_1101-2020_09_02_279521	455	67	A.	A.	NNP
10_1101-2020_09_02_279521	455	68	,	,	,
10_1101-2020_09_02_279521	455	69	Yang	Yang	NNP
10_1101-2020_09_02_279521	455	70	,	,	,
10_1101-2020_09_02_279521	455	71	E.	E.	NNP
10_1101-2020_09_02_279521	455	72	,	,	,
10_1101-2020_09_02_279521	455	73	DeVito	DeVito	NNP
10_1101-2020_09_02_279521	455	74	,	,	,
10_1101-2020_09_02_279521	455	75	Z.	Z.	NNP
10_1101-2020_09_02_279521	455	76	,	,	,
10_1101-2020_09_02_279521	455	77	Raison	Raison	NNP
10_1101-2020_09_02_279521	455	78	,	,	,
10_1101-2020_09_02_279521	455	79	M.	M.	NNP
10_1101-2020_09_02_279521	455	80	,	,	,
10_1101-2020_09_02_279521	455	81	Tejani	Tejani	NNP
10_1101-2020_09_02_279521	455	82	,	,	,
10_1101-2020_09_02_279521	455	83	A.	a.	NN
10_1101-2020_09_02_279521	455	84	,	,	,
10_1101-2020_09_02_279521	455	85	Chilamkurthy	Chilamkurthy	NNP
10_1101-2020_09_02_279521	455	86	,	,	,
10_1101-2020_09_02_279521	455	87	S.	S.	NNP
10_1101-2020_09_02_279521	455	88	,	,	,
10_1101-2020_09_02_279521	455	89	Steiner	Steiner	NNP
10_1101-2020_09_02_279521	455	90	,	,	,
10_1101-2020_09_02_279521	455	91	B.	B.	NNP
10_1101-2020_09_02_279521	455	92	,	,	,
10_1101-2020_09_02_279521	455	93	Fang	Fang	NNP
10_1101-2020_09_02_279521	455	94	,	,	,
10_1101-2020_09_02_279521	455	95	L.	L.	NNP
10_1101-2020_09_02_279521	455	96	,	,	,
10_1101-2020_09_02_279521	455	97	…	…	NFP
10_1101-2020_09_02_279521	455	98	Chintala	Chintala	NNP
10_1101-2020_09_02_279521	455	99	,	,	,
10_1101-2020_09_02_279521	455	100	S.	S.	NNP
10_1101-2020_09_02_279521	455	101	(	(	-LRB-
10_1101-2020_09_02_279521	455	102	2019	2019	CD
10_1101-2020_09_02_279521	455	103	)	)	-RRB-
10_1101-2020_09_02_279521	455	104	.	.	.
10_1101-2020_09_02_279521	456	1	PyTorch	pytorch	NN
10_1101-2020_09_02_279521	456	2	:	:	:
10_1101-2020_09_02_279521	456	3	An	an	DT
10_1101-2020_09_02_279521	456	4	Imperative	Imperative	NNP
10_1101-2020_09_02_279521	456	5	Style	Style	NNP
10_1101-2020_09_02_279521	456	6	,	,	,
10_1101-2020_09_02_279521	456	7	High	High	NNP
10_1101-2020_09_02_279521	456	8	-	-	HYPH
10_1101-2020_09_02_279521	456	9	Performance	Performance	NNP
10_1101-2020_09_02_279521	456	10	Deep	Deep	NNP
10_1101-2020_09_02_279521	456	11	Learning	Learning	NNP
10_1101-2020_09_02_279521	456	12	Library	Library	NNP
10_1101-2020_09_02_279521	456	13	.	.	.
10_1101-2020_09_02_279521	457	1	In	in	IN
10_1101-2020_09_02_279521	457	2	H.	H.	NNP
10_1101-2020_09_02_279521	457	3	Wallach	Wallach	NNP
10_1101-2020_09_02_279521	457	4	,	,	,
10_1101-2020_09_02_279521	457	5	H.	H.	NNP
10_1101-2020_09_02_279521	457	6	Larochelle	Larochelle	NNP
10_1101-2020_09_02_279521	457	7	,	,	,
10_1101-2020_09_02_279521	457	8	A.	A.	NNP
10_1101-2020_09_02_279521	457	9	Beygelzimer	Beygelzimer	NNP
10_1101-2020_09_02_279521	457	10	,	,	,
10_1101-2020_09_02_279521	457	11	F.	F.	NNP
10_1101-2020_09_02_279521	457	12	d\textquotesingle	d\textquotesingle	NN
10_1101-2020_09_02_279521	457	13	Alché	Alché	NNP
10_1101-2020_09_02_279521	457	14	-	-	HYPH
10_1101-2020_09_02_279521	457	15	Buc	Buc	NNP
10_1101-2020_09_02_279521	457	16	,	,	,
10_1101-2020_09_02_279521	457	17	E.	E.	NNP
10_1101-2020_09_02_279521	457	18	Fox	Fox	NNP
10_1101-2020_09_02_279521	457	19	,	,	,
10_1101-2020_09_02_279521	457	20	&	&	CC
10_1101-2020_09_02_279521	457	21	R.	R.	NNP
10_1101-2020_09_02_279521	457	22	Garnett	Garnett	NNP
10_1101-2020_09_02_279521	457	23	(	(	-LRB-
10_1101-2020_09_02_279521	457	24	Eds	Eds	NNP
10_1101-2020_09_02_279521	457	25	.	.	.
10_1101-2020_09_02_279521	458	1	)	)	-RRB-
10_1101-2020_09_02_279521	458	2	,	,	,
10_1101-2020_09_02_279521	458	3	Advances	advance	NNS
10_1101-2020_09_02_279521	458	4	in	in	IN
10_1101-2020_09_02_279521	458	5	Neural	Neural	NNP
10_1101-2020_09_02_279521	458	6	Information	Information	NNP
10_1101-2020_09_02_279521	458	7	Processing	Processing	NNP
10_1101-2020_09_02_279521	458	8	Systems	Systems	NNP
10_1101-2020_09_02_279521	458	9	32	32	CD
10_1101-2020_09_02_279521	458	10	(	(	-LRB-
10_1101-2020_09_02_279521	458	11	pp	pp	NNP
10_1101-2020_09_02_279521	458	12	.	.	.
10_1101-2020_09_02_279521	459	1	8024–8035	8024–8035	LS
10_1101-2020_09_02_279521	459	2	)	)	-RRB-
10_1101-2020_09_02_279521	459	3	.	.	.
10_1101-2020_09_02_279521	460	1	Curran	Curran	NNP
10_1101-2020_09_02_279521	460	2	Associates	Associates	NNPS
10_1101-2020_09_02_279521	460	3	,	,	,
10_1101-2020_09_02_279521	460	4	Inc.	Inc.	NNP
10_1101-2020_09_02_279521	460	5	http://papers.neurips.cc/paper/9015-pytorch-an-imperative-style-high-	http://papers.neurips.cc/paper/9015-pytorch-an-imperative-style-high-	CD
10_1101-2020_09_02_279521	460	6	performance-deep-learning-library.pdf	performance-deep-learning-library.pdf	NNP
10_1101-2020_09_02_279521	460	7	Petrella	Petrella	NNP
10_1101-2020_09_02_279521	460	8	,	,	,
10_1101-2020_09_02_279521	460	9	J.	J.	NNP
10_1101-2020_09_02_279521	460	10	R.	R.	NNP
10_1101-2020_09_02_279521	460	11	,	,	,
10_1101-2020_09_02_279521	460	12	Hao	Hao	NNP
10_1101-2020_09_02_279521	460	13	,	,	,
10_1101-2020_09_02_279521	460	14	W.	W.	NNP
10_1101-2020_09_02_279521	460	15	,	,	,
10_1101-2020_09_02_279521	460	16	Rao	Rao	NNP
10_1101-2020_09_02_279521	460	17	,	,	,
10_1101-2020_09_02_279521	460	18	A.	a.	NN
10_1101-2020_09_02_279521	460	19	,	,	,
10_1101-2020_09_02_279521	460	20	&	&	CC
10_1101-2020_09_02_279521	460	21	Doraiswamy	Doraiswamy	NNP
10_1101-2020_09_02_279521	460	22	,	,	,
10_1101-2020_09_02_279521	460	23	P.	P.	NNP
10_1101-2020_09_02_279521	460	24	M.	M.	NNP
10_1101-2020_09_02_279521	460	25	(	(	-LRB-
10_1101-2020_09_02_279521	460	26	2019	2019	CD
10_1101-2020_09_02_279521	460	27	)	)	-RRB-
10_1101-2020_09_02_279521	460	28	.	.	.
10_1101-2020_09_02_279521	461	1	Computational	computational	JJ
10_1101-2020_09_02_279521	461	2	Causal	Causal	NNP
10_1101-2020_09_02_279521	461	3	Modeling	Modeling	NNP
10_1101-2020_09_02_279521	461	4	of	of	IN
10_1101-2020_09_02_279521	461	5	the	the	DT
10_1101-2020_09_02_279521	461	6	Dynamic	Dynamic	NNP
10_1101-2020_09_02_279521	461	7	Biomarker	Biomarker	NNP
10_1101-2020_09_02_279521	461	8	Cascade	Cascade	NNP
10_1101-2020_09_02_279521	461	9	in	in	IN
10_1101-2020_09_02_279521	461	10	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	461	11	’s	’s	POS
10_1101-2020_09_02_279521	461	12	Disease	Disease	NNP
10_1101-2020_09_02_279521	461	13	.	.	.
10_1101-2020_09_02_279521	462	1	Comput	comput	NN
10_1101-2020_09_02_279521	462	2	Math	math	NN
10_1101-2020_09_02_279521	462	3	Methods	Methods	NNP
10_1101-2020_09_02_279521	462	4	Med	Med	NNP
10_1101-2020_09_02_279521	462	5	,	,	,
10_1101-2020_09_02_279521	462	6	2019	2019	CD
10_1101-2020_09_02_279521	462	7	,	,	,
10_1101-2020_09_02_279521	462	8	6216530	6216530	CD
10_1101-2020_09_02_279521	462	9	.	.	.
10_1101-2020_09_02_279521	463	1	Pontecorvo	Pontecorvo	NNP
10_1101-2020_09_02_279521	463	2	,	,	,
10_1101-2020_09_02_279521	463	3	M.	M.	NNP
10_1101-2020_09_02_279521	463	4	J.	J.	NNP
10_1101-2020_09_02_279521	463	5	,	,	,
10_1101-2020_09_02_279521	463	6	Devous	Devous	NNP
10_1101-2020_09_02_279521	463	7	,	,	,
10_1101-2020_09_02_279521	463	8	M.	M.	NNP
10_1101-2020_09_02_279521	463	9	D.	D.	NNP
10_1101-2020_09_02_279521	463	10	,	,	,
10_1101-2020_09_02_279521	463	11	Kennedy	Kennedy	NNP
10_1101-2020_09_02_279521	463	12	,	,	,
10_1101-2020_09_02_279521	463	13	I.	I.	NNP
10_1101-2020_09_02_279521	463	14	,	,	,
10_1101-2020_09_02_279521	463	15	Navitsky	Navitsky	NNP
10_1101-2020_09_02_279521	463	16	,	,	,
10_1101-2020_09_02_279521	463	17	M.	M.	NNP
10_1101-2020_09_02_279521	463	18	,	,	,
10_1101-2020_09_02_279521	463	19	Lu	Lu	NNP
10_1101-2020_09_02_279521	463	20	,	,	,
10_1101-2020_09_02_279521	463	21	M.	M.	NNP
10_1101-2020_09_02_279521	463	22	,	,	,
10_1101-2020_09_02_279521	463	23	Galante	Galante	NNP
10_1101-2020_09_02_279521	463	24	,	,	,
10_1101-2020_09_02_279521	463	25	N.	N.	NNP
10_1101-2020_09_02_279521	463	26	,	,	,
10_1101-2020_09_02_279521	463	27	Salloway	Salloway	NNP
10_1101-2020_09_02_279521	463	28	,	,	,
10_1101-2020_09_02_279521	463	29	S.	S.	NNP
10_1101-2020_09_02_279521	463	30	,	,	,
10_1101-2020_09_02_279521	463	31	Doraiswamy	Doraiswamy	NNP
10_1101-2020_09_02_279521	463	32	,	,	,
10_1101-2020_09_02_279521	463	33	P.	P.	NNP
10_1101-2020_09_02_279521	463	34	M.	M.	NNP
10_1101-2020_09_02_279521	463	35	,	,	,
10_1101-2020_09_02_279521	463	36	Southekal	Southekal	NNP
10_1101-2020_09_02_279521	463	37	,	,	,
10_1101-2020_09_02_279521	463	38	S.	S.	NNP
10_1101-2020_09_02_279521	463	39	,	,	,
10_1101-2020_09_02_279521	463	40	Arora	Arora	NNP
10_1101-2020_09_02_279521	463	41	,	,	,
10_1101-2020_09_02_279521	463	42	A.	A.	NNP
10_1101-2020_09_02_279521	463	43	K.	K.	NNP
10_1101-2020_09_02_279521	463	44	,	,	,
10_1101-2020_09_02_279521	463	45	McGeehan	McGeehan	NNP
10_1101-2020_09_02_279521	463	46	,	,	,
10_1101-2020_09_02_279521	463	47	A.	A.	NNP
10_1101-2020_09_02_279521	463	48	,	,	,
10_1101-2020_09_02_279521	463	49	Lim	Lim	NNP
10_1101-2020_09_02_279521	463	50	,	,	,
10_1101-2020_09_02_279521	463	51	N.	N.	NNP
10_1101-2020_09_02_279521	463	52	C.	C.	NNP
10_1101-2020_09_02_279521	463	53	,	,	,
10_1101-2020_09_02_279521	463	54	Xiong	Xiong	NNP
10_1101-2020_09_02_279521	463	55	,	,	,
10_1101-2020_09_02_279521	463	56	H.	H.	NNP
10_1101-2020_09_02_279521	463	57	,	,	,
10_1101-2020_09_02_279521	463	58	Truocchio	Truocchio	NNP
10_1101-2020_09_02_279521	463	59	,	,	,
10_1101-2020_09_02_279521	463	60	S.	S.	NNP
10_1101-2020_09_02_279521	463	61	P.	P.	NNP
10_1101-2020_09_02_279521	463	62	,	,	,
10_1101-2020_09_02_279521	463	63	Joshi	Joshi	NNP
10_1101-2020_09_02_279521	463	64	,	,	,
10_1101-2020_09_02_279521	463	65	A.	A.	NNP
10_1101-2020_09_02_279521	463	66	D.	D.	NNP
10_1101-2020_09_02_279521	463	67	,	,	,
10_1101-2020_09_02_279521	463	68	Shcherbinin	Shcherbinin	NNP
10_1101-2020_09_02_279521	463	69	,	,	,
10_1101-2020_09_02_279521	463	70	S.	S.	NNP
10_1101-2020_09_02_279521	463	71	,	,	,
10_1101-2020_09_02_279521	463	72	Teske	Teske	NNP
10_1101-2020_09_02_279521	463	73	,	,	,
10_1101-2020_09_02_279521	463	74	B.	B.	NNP
10_1101-2020_09_02_279521	463	75	,	,	,
10_1101-2020_09_02_279521	463	76	Fleisher	Fleisher	NNP
10_1101-2020_09_02_279521	463	77	,	,	,
10_1101-2020_09_02_279521	463	78	A.	A.	NNP
10_1101-2020_09_02_279521	463	79	S.	S.	NNP
10_1101-2020_09_02_279521	463	80	,	,	,
10_1101-2020_09_02_279521	463	81	&	&	CC
10_1101-2020_09_02_279521	463	82	Mintun	Mintun	NNP
10_1101-2020_09_02_279521	463	83	,	,	,
10_1101-2020_09_02_279521	463	84	M.	M.	NNP
10_1101-2020_09_02_279521	463	85	A.	A.	NNP
10_1101-2020_09_02_279521	464	1	(	(	-LRB-
10_1101-2020_09_02_279521	464	2	2019	2019	CD
10_1101-2020_09_02_279521	464	3	)	)	-RRB-
10_1101-2020_09_02_279521	464	4	.	.	.
10_1101-2020_09_02_279521	465	1	A	a	DT
10_1101-2020_09_02_279521	465	2	multicentre	multicentre	NNP
10_1101-2020_09_02_279521	465	3	longitudinal	longitudinal	JJ
10_1101-2020_09_02_279521	465	4	study	study	NN
10_1101-2020_09_02_279521	465	5	of	of	IN
10_1101-2020_09_02_279521	465	6	flortaucipir	flortaucipir	NN
10_1101-2020_09_02_279521	465	7	(	(	-LRB-
10_1101-2020_09_02_279521	465	8	18F	18F	NNP
10_1101-2020_09_02_279521	465	9	)	)	-RRB-
10_1101-2020_09_02_279521	465	10	in	in	IN
10_1101-2020_09_02_279521	465	11	normal	normal	JJ
10_1101-2020_09_02_279521	465	12	ageing	ageing	NN
10_1101-2020_09_02_279521	465	13	,	,	,
10_1101-2020_09_02_279521	465	14	mild	mild	JJ
10_1101-2020_09_02_279521	465	15	cognitive	cognitive	JJ
10_1101-2020_09_02_279521	465	16	impairment	impairment	NN
10_1101-2020_09_02_279521	465	17	and	and	CC
10_1101-2020_09_02_279521	465	18	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	465	19	’s	’s	POS
10_1101-2020_09_02_279521	465	20	disease	disease	NN
10_1101-2020_09_02_279521	465	21	dementia	dementia	NN
10_1101-2020_09_02_279521	465	22	.	.	.
10_1101-2020_09_02_279521	466	1	Brain	brain	NN
10_1101-2020_09_02_279521	466	2	,	,	,
10_1101-2020_09_02_279521	466	3	142(6	142(6	CD
10_1101-2020_09_02_279521	466	4	)	)	-RRB-
10_1101-2020_09_02_279521	466	5	,	,	,
10_1101-2020_09_02_279521	466	6	1723	1723	CD
10_1101-2020_09_02_279521	466	7	–	–	:
10_1101-2020_09_02_279521	466	8	1735	1735	CD
10_1101-2020_09_02_279521	466	9	.	.	.
10_1101-2020_09_02_279521	467	1	Prince	Prince	NNP
10_1101-2020_09_02_279521	467	2	,	,	,
10_1101-2020_09_02_279521	467	3	M.	M.	NNP
10_1101-2020_09_02_279521	467	4	J.	J.	NNP
10_1101-2020_09_02_279521	467	5	,	,	,
10_1101-2020_09_02_279521	467	6	Wimo	Wimo	NNP
10_1101-2020_09_02_279521	467	7	,	,	,
10_1101-2020_09_02_279521	467	8	A.	A.	NNP
10_1101-2020_09_02_279521	467	9	,	,	,
10_1101-2020_09_02_279521	467	10	Guerchet	Guerchet	NNP
10_1101-2020_09_02_279521	467	11	,	,	,
10_1101-2020_09_02_279521	467	12	M.	M.	NNP
10_1101-2020_09_02_279521	467	13	M.	M.	NNP
10_1101-2020_09_02_279521	467	14	,	,	,
10_1101-2020_09_02_279521	467	15	Ali	Ali	NNP
10_1101-2020_09_02_279521	467	16	,	,	,
10_1101-2020_09_02_279521	467	17	G.	G.	NNP
10_1101-2020_09_02_279521	467	18	C.	C.	NNP
10_1101-2020_09_02_279521	467	19	,	,	,
10_1101-2020_09_02_279521	467	20	Wu	Wu	NNP
10_1101-2020_09_02_279521	467	21	,	,	,
10_1101-2020_09_02_279521	467	22	Y.-T.	Y.-T.	NNP
10_1101-2020_09_02_279521	467	23	,	,	,
10_1101-2020_09_02_279521	467	24	&	&	CC
10_1101-2020_09_02_279521	467	25	Prina	Prina	NNP
10_1101-2020_09_02_279521	467	26	,	,	,
10_1101-2020_09_02_279521	467	27	M.	M.	NNP
10_1101-2020_09_02_279521	467	28	(	(	-LRB-
10_1101-2020_09_02_279521	467	29	2015	2015	CD
10_1101-2020_09_02_279521	467	30	)	)	-RRB-
10_1101-2020_09_02_279521	467	31	.	.	.
10_1101-2020_09_02_279521	468	1	World	World	NNP
10_1101-2020_09_02_279521	468	2	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	468	3	Report	Report	NNP
10_1101-2020_09_02_279521	468	4	2015	2015	CD
10_1101-2020_09_02_279521	468	5	-	-	:
10_1101-2020_09_02_279521	468	6	The	The	NNP
10_1101-2020_09_02_279521	468	7	Global	Global	NNP
10_1101-2020_09_02_279521	468	8	Impact	Impact	NNP
10_1101-2020_09_02_279521	468	9	of	of	IN
10_1101-2020_09_02_279521	468	10	Dementia	Dementia	NNP
10_1101-2020_09_02_279521	468	11	:	:	:
10_1101-2020_09_02_279521	468	12	An	an	DT
10_1101-2020_09_02_279521	468	13	analysis	analysis	NN
10_1101-2020_09_02_279521	468	14	of	of	IN
10_1101-2020_09_02_279521	468	15	prevalence	prevalence	NN
10_1101-2020_09_02_279521	468	16	,	,	,
10_1101-2020_09_02_279521	468	17	incidence	incidence	NN
10_1101-2020_09_02_279521	468	18	,	,	,
10_1101-2020_09_02_279521	468	19	cost	cost	NN
10_1101-2020_09_02_279521	468	20	and	and	CC
10_1101-2020_09_02_279521	468	21	trends	trend	NNS
10_1101-2020_09_02_279521	468	22	.	.	.
10_1101-2020_09_02_279521	469	1	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	469	2	’s	’s	POS
10_1101-2020_09_02_279521	469	3	Disease	Disease	NNP
10_1101-2020_09_02_279521	469	4	International	International	NNP
10_1101-2020_09_02_279521	469	5	.	.	.
10_1101-2020_09_02_279521	470	1	Reuter	Reuter	NNP
10_1101-2020_09_02_279521	470	2	,	,	,
10_1101-2020_09_02_279521	470	3	M.	M.	NNP
10_1101-2020_09_02_279521	470	4	,	,	,
10_1101-2020_09_02_279521	470	5	Schmansky	Schmansky	NNP
10_1101-2020_09_02_279521	470	6	,	,	,
10_1101-2020_09_02_279521	470	7	N.	N.	NNP
10_1101-2020_09_02_279521	470	8	J.	J.	NNP
10_1101-2020_09_02_279521	470	9	,	,	,
10_1101-2020_09_02_279521	470	10	Rosas	Rosas	NNP
10_1101-2020_09_02_279521	470	11	,	,	,
10_1101-2020_09_02_279521	470	12	H.	H.	NNP
10_1101-2020_09_02_279521	470	13	D.	D.	NNP
10_1101-2020_09_02_279521	470	14	,	,	,
10_1101-2020_09_02_279521	470	15	&	&	CC
10_1101-2020_09_02_279521	470	16	Fischl	Fischl	NNP
10_1101-2020_09_02_279521	470	17	,	,	,
10_1101-2020_09_02_279521	470	18	B.	B.	NNP
10_1101-2020_09_02_279521	471	1	(	(	-LRB-
10_1101-2020_09_02_279521	471	2	2012	2012	CD
10_1101-2020_09_02_279521	471	3	)	)	-RRB-
10_1101-2020_09_02_279521	471	4	.	.	.
10_1101-2020_09_02_279521	472	1	Within	within	IN
10_1101-2020_09_02_279521	472	2	-	-	HYPH
10_1101-2020_09_02_279521	472	3	subject	subject	JJ
10_1101-2020_09_02_279521	472	4	template	template	NN
10_1101-2020_09_02_279521	472	5	estimation	estimation	NN
10_1101-2020_09_02_279521	472	6	for	for	IN
10_1101-2020_09_02_279521	472	7	unbiased	unbiased	JJ
10_1101-2020_09_02_279521	472	8	longitudinal	longitudinal	JJ
10_1101-2020_09_02_279521	472	9	image	image	NN
10_1101-2020_09_02_279521	472	10	analysis	analysis	NN
10_1101-2020_09_02_279521	472	11	.	.	.
10_1101-2020_09_02_279521	473	1	NeuroImage	NeuroImage	NNP
10_1101-2020_09_02_279521	473	2	,	,	,
10_1101-2020_09_02_279521	473	3	61(4	61(4	CD
10_1101-2020_09_02_279521	473	4	)	)	-RRB-
10_1101-2020_09_02_279521	473	5	,	,	,
10_1101-2020_09_02_279521	473	6	1402–1418	1402–1418	CD
10_1101-2020_09_02_279521	473	7	.	.	.
10_1101-2020_09_02_279521	474	1	Rowe	Rowe	NNP
10_1101-2020_09_02_279521	474	2	,	,	,
10_1101-2020_09_02_279521	474	3	C.	C.	NNP
10_1101-2020_09_02_279521	474	4	C.	C.	NNP
10_1101-2020_09_02_279521	474	5	,	,	,
10_1101-2020_09_02_279521	474	6	Ellis	Ellis	NNP
10_1101-2020_09_02_279521	474	7	,	,	,
10_1101-2020_09_02_279521	474	8	K.	K.	NNP
10_1101-2020_09_02_279521	474	9	A.	A.	NNP
10_1101-2020_09_02_279521	474	10	,	,	,
10_1101-2020_09_02_279521	474	11	Rimajova	Rimajova	NNP
10_1101-2020_09_02_279521	474	12	,	,	,
10_1101-2020_09_02_279521	474	13	M.	M.	NNP
10_1101-2020_09_02_279521	474	14	,	,	,
10_1101-2020_09_02_279521	474	15	Bourgeat	Bourgeat	NNP
10_1101-2020_09_02_279521	474	16	,	,	,
10_1101-2020_09_02_279521	474	17	P.	P.	NNP
10_1101-2020_09_02_279521	474	18	,	,	,
10_1101-2020_09_02_279521	474	19	Pike	Pike	NNP
10_1101-2020_09_02_279521	474	20	,	,	,
10_1101-2020_09_02_279521	474	21	K.	K.	NNP
10_1101-2020_09_02_279521	474	22	E.	E.	NNP
10_1101-2020_09_02_279521	474	23	,	,	,
10_1101-2020_09_02_279521	474	24	Jones	Jones	NNP
10_1101-2020_09_02_279521	474	25	,	,	,
10_1101-2020_09_02_279521	474	26	G.	G.	NNP
10_1101-2020_09_02_279521	474	27	,	,	,
10_1101-2020_09_02_279521	474	28	Fripp	Fripp	NNP
10_1101-2020_09_02_279521	474	29	,	,	,
10_1101-2020_09_02_279521	474	30	J.	J.	NNP
10_1101-2020_09_02_279521	474	31	,	,	,
10_1101-2020_09_02_279521	474	32	Tochon	Tochon	NNP
10_1101-2020_09_02_279521	474	33	-	-	HYPH
10_1101-2020_09_02_279521	474	34	Danguy	Danguy	NNP
10_1101-2020_09_02_279521	474	35	,	,	,
10_1101-2020_09_02_279521	474	36	H.	H.	NNP
10_1101-2020_09_02_279521	474	37	,	,	,
10_1101-2020_09_02_279521	474	38	Morandeau	Morandeau	NNP
10_1101-2020_09_02_279521	474	39	,	,	,
10_1101-2020_09_02_279521	474	40	L.	L.	NNP
10_1101-2020_09_02_279521	474	41	,	,	,
10_1101-2020_09_02_279521	474	42	O’Keefe	O’Keefe	NNP
10_1101-2020_09_02_279521	474	43	,	,	,
10_1101-2020_09_02_279521	474	44	G.	G.	NNP
10_1101-2020_09_02_279521	474	45	,	,	,
10_1101-2020_09_02_279521	474	46	Price	Price	NNP
10_1101-2020_09_02_279521	474	47	,	,	,
10_1101-2020_09_02_279521	474	48	R.	R.	NNP
10_1101-2020_09_02_279521	474	49	,	,	,
10_1101-2020_09_02_279521	474	50	Raniga	Raniga	NNP
10_1101-2020_09_02_279521	474	51	,	,	,
10_1101-2020_09_02_279521	474	52	P.	P.	NNP
10_1101-2020_09_02_279521	474	53	,	,	,
10_1101-2020_09_02_279521	474	54	Robins	Robins	NNP
10_1101-2020_09_02_279521	474	55	,	,	,
10_1101-2020_09_02_279521	474	56	P.	P.	NNP
10_1101-2020_09_02_279521	474	57	,	,	,
10_1101-2020_09_02_279521	474	58	Acosta	Acosta	NNP
10_1101-2020_09_02_279521	474	59	,	,	,
10_1101-2020_09_02_279521	474	60	O.	O.	NNP
10_1101-2020_09_02_279521	474	61	,	,	,
10_1101-2020_09_02_279521	474	62	Lenzo	Lenzo	NNP
10_1101-2020_09_02_279521	474	63	,	,	,
10_1101-2020_09_02_279521	474	64	N.	N.	NNP
10_1101-2020_09_02_279521	474	65	,	,	,
10_1101-2020_09_02_279521	474	66	Szoeke	Szoeke	NNP
10_1101-2020_09_02_279521	474	67	,	,	,
10_1101-2020_09_02_279521	474	68	C.	C.	NNP
10_1101-2020_09_02_279521	474	69	,	,	,
10_1101-2020_09_02_279521	474	70	Salvado	Salvado	NNP
10_1101-2020_09_02_279521	474	71	,	,	,
10_1101-2020_09_02_279521	474	72	O.	O.	NNP
10_1101-2020_09_02_279521	474	73	,	,	,
10_1101-2020_09_02_279521	474	74	Head	Head	NNP
10_1101-2020_09_02_279521	474	75	,	,	,
10_1101-2020_09_02_279521	474	76	R.	R.	NNP
10_1101-2020_09_02_279521	474	77	,	,	,
10_1101-2020_09_02_279521	474	78	Martins	Martins	NNP
10_1101-2020_09_02_279521	474	79	,	,	,
10_1101-2020_09_02_279521	474	80	R.	R.	NNP
10_1101-2020_09_02_279521	474	81	,	,	,
10_1101-2020_09_02_279521	474	82	…	…	NFP
10_1101-2020_09_02_279521	474	83	Villemagne	Villemagne	NNP
10_1101-2020_09_02_279521	474	84	,	,	,
10_1101-2020_09_02_279521	474	85	V.	V.	NNP
10_1101-2020_09_02_279521	474	86	L.	L.	NNP
10_1101-2020_09_02_279521	474	87	(	(	-LRB-
10_1101-2020_09_02_279521	474	88	2010	2010	CD
10_1101-2020_09_02_279521	474	89	)	)	-RRB-
10_1101-2020_09_02_279521	474	90	.	.	.
10_1101-2020_09_02_279521	475	1	Amyloid	amyloid	JJ
10_1101-2020_09_02_279521	475	2	imaging	imaging	NN
10_1101-2020_09_02_279521	475	3	results	result	NNS
10_1101-2020_09_02_279521	475	4	from	from	IN
10_1101-2020_09_02_279521	475	5	the	the	DT
10_1101-2020_09_02_279521	475	6	Australian	Australian	NNP
10_1101-2020_09_02_279521	475	7	Imaging	Imaging	NNP
10_1101-2020_09_02_279521	475	8	,	,	,
10_1101-2020_09_02_279521	475	9	Biomarkers	Biomarkers	NNPS
10_1101-2020_09_02_279521	475	10	and	and	CC
10_1101-2020_09_02_279521	475	11	Lifestyle	Lifestyle	NNP
10_1101-2020_09_02_279521	475	12	(	(	-LRB-
10_1101-2020_09_02_279521	475	13	AIBL	AIBL	NNP
10_1101-2020_09_02_279521	475	14	)	)	-RRB-
10_1101-2020_09_02_279521	475	15	study	study	NN
10_1101-2020_09_02_279521	475	16	of	of	IN
10_1101-2020_09_02_279521	475	17	aging	aging	NN
10_1101-2020_09_02_279521	475	18	.	.	.
10_1101-2020_09_02_279521	476	1	Neurobiol	Neurobiol	NNP
10_1101-2020_09_02_279521	476	2	.	.	.
10_1101-2020_09_02_279521	477	1	Aging	age	VBG
10_1101-2020_09_02_279521	477	2	,	,	,
10_1101-2020_09_02_279521	477	3	31(8	31(8	CD
10_1101-2020_09_02_279521	477	4	)	)	-RRB-
10_1101-2020_09_02_279521	477	5	,	,	,
10_1101-2020_09_02_279521	477	6	1275–1283	1275–1283	CD
10_1101-2020_09_02_279521	477	7	.	.	.
10_1101-2020_09_02_279521	478	1	Safieh	Safieh	NNP
10_1101-2020_09_02_279521	478	2	,	,	,
10_1101-2020_09_02_279521	478	3	M.	M.	NNP
10_1101-2020_09_02_279521	478	4	,	,	,
10_1101-2020_09_02_279521	478	5	Korczyn	Korczyn	NNP
10_1101-2020_09_02_279521	478	6	,	,	,
10_1101-2020_09_02_279521	478	7	A.	A.	NNP
10_1101-2020_09_02_279521	478	8	D.	D.	NNP
10_1101-2020_09_02_279521	478	9	,	,	,
10_1101-2020_09_02_279521	478	10	&	&	CC
10_1101-2020_09_02_279521	478	11	Michaelson	Michaelson	NNP
10_1101-2020_09_02_279521	478	12	,	,	,
10_1101-2020_09_02_279521	478	13	D.	D.	NNP
10_1101-2020_09_02_279521	478	14	M.	M.	NNP
10_1101-2020_09_02_279521	478	15	(	(	-LRB-
10_1101-2020_09_02_279521	478	16	2019	2019	CD
10_1101-2020_09_02_279521	478	17	)	)	-RRB-
10_1101-2020_09_02_279521	478	18	.	.	.
10_1101-2020_09_02_279521	479	1	ApoE4	apoe4	NN
10_1101-2020_09_02_279521	479	2	:	:	:
10_1101-2020_09_02_279521	479	3	an	an	DT
10_1101-2020_09_02_279521	479	4	emerging	emerge	VBG
10_1101-2020_09_02_279521	479	5	therapeutic	therapeutic	JJ
10_1101-2020_09_02_279521	479	6	target	target	NN
10_1101-2020_09_02_279521	479	7	for	for	IN
10_1101-2020_09_02_279521	479	8	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	479	9	’s	’s	POS
10_1101-2020_09_02_279521	479	10	disease	disease	NN
10_1101-2020_09_02_279521	479	11	.	.	.
10_1101-2020_09_02_279521	480	1	BMC	BMC	NNP
10_1101-2020_09_02_279521	480	2	Medicine	Medicine	NNP
10_1101-2020_09_02_279521	480	3	,	,	,
10_1101-2020_09_02_279521	480	4	17	17	CD
10_1101-2020_09_02_279521	480	5	.	.	.
10_1101-2020_09_02_279521	481	1	Schiratti	Schiratti	NNP
10_1101-2020_09_02_279521	481	2	,	,	,
10_1101-2020_09_02_279521	481	3	J.-B.	J.-B.	NNP
10_1101-2020_09_02_279521	481	4	,	,	,
10_1101-2020_09_02_279521	481	5	Allassonnière	Allassonnière	NNP
10_1101-2020_09_02_279521	481	6	,	,	,
10_1101-2020_09_02_279521	481	7	S.	S.	NNP
10_1101-2020_09_02_279521	481	8	,	,	,
10_1101-2020_09_02_279521	481	9	Colliot	Colliot	NNP
10_1101-2020_09_02_279521	481	10	,	,	,
10_1101-2020_09_02_279521	481	11	O.	O.	NNP
10_1101-2020_09_02_279521	481	12	,	,	,
10_1101-2020_09_02_279521	481	13	&	&	CC
10_1101-2020_09_02_279521	481	14	Durrleman	Durrleman	NNP
10_1101-2020_09_02_279521	481	15	,	,	,
10_1101-2020_09_02_279521	481	16	S.	S.	NNP
10_1101-2020_09_02_279521	481	17	(	(	-LRB-
10_1101-2020_09_02_279521	481	18	2015	2015	CD
10_1101-2020_09_02_279521	481	19	)	)	-RRB-
10_1101-2020_09_02_279521	481	20	.	.	.
10_1101-2020_09_02_279521	482	1	Learning	learn	VBG
10_1101-2020_09_02_279521	482	2	spatiotemporal	spatiotemporal	JJ
10_1101-2020_09_02_279521	482	3	trajectories	trajectory	NNS
10_1101-2020_09_02_279521	482	4	from	from	IN
10_1101-2020_09_02_279521	482	5	manifold	manifold	NN
10_1101-2020_09_02_279521	482	6	-	-	HYPH
10_1101-2020_09_02_279521	482	7	valued	value	VBN
10_1101-2020_09_02_279521	482	8	longitudinal	longitudinal	JJ
10_1101-2020_09_02_279521	482	9	data	datum	NNS
10_1101-2020_09_02_279521	482	10	.	.	.
10_1101-2020_09_02_279521	483	1	NIPS	NIPS	NNP
10_1101-2020_09_02_279521	483	2	,	,	,
10_1101-2020_09_02_279521	483	3	2404–2412	2404–2412	CD
10_1101-2020_09_02_279521	483	4	.	.	.
10_1101-2020_09_02_279521	484	1	Schuff	Schuff	NNP
10_1101-2020_09_02_279521	484	2	,	,	,
10_1101-2020_09_02_279521	484	3	N.	N.	NNP
10_1101-2020_09_02_279521	484	4	,	,	,
10_1101-2020_09_02_279521	484	5	Woerner	Woerner	NNP
10_1101-2020_09_02_279521	484	6	,	,	,
10_1101-2020_09_02_279521	484	7	N.	N.	NNP
10_1101-2020_09_02_279521	484	8	,	,	,
10_1101-2020_09_02_279521	484	9	Boreta	Boreta	NNP
10_1101-2020_09_02_279521	484	10	,	,	,
10_1101-2020_09_02_279521	484	11	L.	L.	NNP
10_1101-2020_09_02_279521	484	12	,	,	,
10_1101-2020_09_02_279521	484	13	Kornfield	Kornfield	NNP
10_1101-2020_09_02_279521	484	14	,	,	,
10_1101-2020_09_02_279521	484	15	T.	T.	NNP
10_1101-2020_09_02_279521	484	16	,	,	,
10_1101-2020_09_02_279521	484	17	Shaw	Shaw	NNP
10_1101-2020_09_02_279521	484	18	,	,	,
10_1101-2020_09_02_279521	484	19	L.	L.	NNP
10_1101-2020_09_02_279521	484	20	M.	M.	NNP
10_1101-2020_09_02_279521	484	21	,	,	,
10_1101-2020_09_02_279521	484	22	Trojanowski	Trojanowski	NNP
10_1101-2020_09_02_279521	484	23	,	,	,
10_1101-2020_09_02_279521	484	24	J.	J.	NNP
10_1101-2020_09_02_279521	484	25	Q.	Q.	NNP
10_1101-2020_09_02_279521	484	26	,	,	,
10_1101-2020_09_02_279521	484	27	.CC	.CC	:
10_1101-2020_09_02_279521	484	28	-	-	:
10_1101-2020_09_02_279521	484	29	BY	by	IN
10_1101-2020_09_02_279521	484	30	4.0	4.0	CD
10_1101-2020_09_02_279521	484	31	International	international	JJ
10_1101-2020_09_02_279521	484	32	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	484	33	.	.	.
10_1101-2020_09_02_279521	485	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	485	2	is	be	VBZ
10_1101-2020_09_02_279521	485	3	made	make	VBN
10_1101-2020_09_02_279521	485	4	available	available	JJ
10_1101-2020_09_02_279521	485	5	under	under	IN
10_1101-2020_09_02_279521	485	6	a	a	DT
10_1101-2020_09_02_279521	485	7	preprint	preprint	NN
10_1101-2020_09_02_279521	485	8	(	(	-LRB-
10_1101-2020_09_02_279521	485	9	which	which	WDT
10_1101-2020_09_02_279521	485	10	was	be	VBD
10_1101-2020_09_02_279521	485	11	not	not	RB
10_1101-2020_09_02_279521	485	12	certified	certify	VBN
10_1101-2020_09_02_279521	485	13	by	by	IN
10_1101-2020_09_02_279521	485	14	peer	peer	NN
10_1101-2020_09_02_279521	485	15	review	review	NN
10_1101-2020_09_02_279521	485	16	)	)	-RRB-
10_1101-2020_09_02_279521	485	17	is	be	VBZ
10_1101-2020_09_02_279521	485	18	the	the	DT
10_1101-2020_09_02_279521	485	19	author	author	NN
10_1101-2020_09_02_279521	485	20	/	/	SYM
10_1101-2020_09_02_279521	485	21	funder	funder	NN
10_1101-2020_09_02_279521	485	22	,	,	,
10_1101-2020_09_02_279521	485	23	who	who	WP
10_1101-2020_09_02_279521	485	24	has	have	VBZ
10_1101-2020_09_02_279521	485	25	granted	grant	VBN
10_1101-2020_09_02_279521	485	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	485	27	a	a	DT
10_1101-2020_09_02_279521	485	28	license	license	NN
10_1101-2020_09_02_279521	485	29	to	to	TO
10_1101-2020_09_02_279521	485	30	display	display	VB
10_1101-2020_09_02_279521	485	31	the	the	DT
10_1101-2020_09_02_279521	485	32	preprint	preprint	NN
10_1101-2020_09_02_279521	485	33	in	in	IN
10_1101-2020_09_02_279521	485	34	The	the	DT
10_1101-2020_09_02_279521	485	35	copyright	copyright	NN
10_1101-2020_09_02_279521	485	36	holder	holder	NN
10_1101-2020_09_02_279521	485	37	for	for	IN
10_1101-2020_09_02_279521	485	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	485	39	version	version	NN
10_1101-2020_09_02_279521	485	40	posted	post	VBD
10_1101-2020_09_02_279521	485	41	February	February	NNP
10_1101-2020_09_02_279521	485	42	10	10	CD
10_1101-2020_09_02_279521	485	43	,	,	,
10_1101-2020_09_02_279521	485	44	2021	2021	CD
10_1101-2020_09_02_279521	485	45	.	.	.
10_1101-2020_09_02_279521	485	46	;	;	:
10_1101-2020_09_02_279521	485	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	485	48	:	:	:
10_1101-2020_09_02_279521	485	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	485	50	preprint	preprint	NN
10_1101-2020_09_02_279521	485	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	ADD
10_1101-2020_09_02_279521	485	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	ADD
10_1101-2020_09_02_279521	485	53	Thompson	Thompson	NNP
10_1101-2020_09_02_279521	485	54	,	,	,
10_1101-2020_09_02_279521	485	55	P.	P.	NNP
10_1101-2020_09_02_279521	485	56	M.	M.	NNP
10_1101-2020_09_02_279521	485	57	,	,	,
10_1101-2020_09_02_279521	485	58	Jack	Jack	NNP
10_1101-2020_09_02_279521	485	59	,	,	,
10_1101-2020_09_02_279521	485	60	C.	C.	NNP
10_1101-2020_09_02_279521	485	61	R.	R.	NNP
10_1101-2020_09_02_279521	485	62	,	,	,
10_1101-2020_09_02_279521	485	63	&	&	CC
10_1101-2020_09_02_279521	485	64	Weiner	Weiner	NNP
10_1101-2020_09_02_279521	485	65	,	,	,
10_1101-2020_09_02_279521	485	66	M.	M.	NNP
10_1101-2020_09_02_279521	485	67	W.	W.	NNP
10_1101-2020_09_02_279521	485	68	(	(	-LRB-
10_1101-2020_09_02_279521	485	69	2009	2009	CD
10_1101-2020_09_02_279521	485	70	)	)	-RRB-
10_1101-2020_09_02_279521	485	71	.	.	.
10_1101-2020_09_02_279521	486	1	MRI	MRI	NNP
10_1101-2020_09_02_279521	486	2	of	of	IN
10_1101-2020_09_02_279521	486	3	hippocampal	hippocampal	JJ
10_1101-2020_09_02_279521	486	4	volume	volume	NN
10_1101-2020_09_02_279521	486	5	loss	loss	NN
10_1101-2020_09_02_279521	486	6	in	in	IN
10_1101-2020_09_02_279521	486	7	early	early	JJ
10_1101-2020_09_02_279521	486	8	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	486	9	’s	’s	POS
10_1101-2020_09_02_279521	486	10	disease	disease	NN
10_1101-2020_09_02_279521	486	11	in	in	IN
10_1101-2020_09_02_279521	486	12	relation	relation	NN
10_1101-2020_09_02_279521	486	13	to	to	IN
10_1101-2020_09_02_279521	486	14	ApoE	ApoE	NNP
10_1101-2020_09_02_279521	486	15	genotype	genotype	NN
10_1101-2020_09_02_279521	486	16	and	and	CC
10_1101-2020_09_02_279521	486	17	biomarkers	biomarker	NNS
10_1101-2020_09_02_279521	486	18	.	.	.
10_1101-2020_09_02_279521	487	1	Brain	brain	NN
10_1101-2020_09_02_279521	487	2	,	,	,
10_1101-2020_09_02_279521	487	3	132(Pt	132(Pt	NNP
10_1101-2020_09_02_279521	487	4	4	4	CD
10_1101-2020_09_02_279521	487	5	)	)	-RRB-
10_1101-2020_09_02_279521	487	6	,	,	,
10_1101-2020_09_02_279521	487	7	1067–1077	1067–1077	CD
10_1101-2020_09_02_279521	487	8	.	.	.
10_1101-2020_09_02_279521	488	1	Schwarz	Schwarz	NNP
10_1101-2020_09_02_279521	488	2	,	,	,
10_1101-2020_09_02_279521	488	3	A.	a.	NN
10_1101-2020_09_02_279521	488	4	J.	J.	NNP
10_1101-2020_09_02_279521	488	5	,	,	,
10_1101-2020_09_02_279521	488	6	Sundell	Sundell	NNP
10_1101-2020_09_02_279521	488	7	,	,	,
10_1101-2020_09_02_279521	488	8	K.	K.	NNP
10_1101-2020_09_02_279521	488	9	L.	L.	NNP
10_1101-2020_09_02_279521	488	10	,	,	,
10_1101-2020_09_02_279521	488	11	Charil	Charil	NNP
10_1101-2020_09_02_279521	488	12	,	,	,
10_1101-2020_09_02_279521	488	13	A.	a.	NN
10_1101-2020_09_02_279521	488	14	,	,	,
10_1101-2020_09_02_279521	488	15	Case	Case	NNP
10_1101-2020_09_02_279521	488	16	,	,	,
10_1101-2020_09_02_279521	488	17	M.	M.	NNP
10_1101-2020_09_02_279521	488	18	G.	G.	NNP
10_1101-2020_09_02_279521	488	19	,	,	,
10_1101-2020_09_02_279521	488	20	Jaeger	Jaeger	NNP
10_1101-2020_09_02_279521	488	21	,	,	,
10_1101-2020_09_02_279521	488	22	R.	R.	NNP
10_1101-2020_09_02_279521	488	23	K.	K.	NNP
10_1101-2020_09_02_279521	488	24	,	,	,
10_1101-2020_09_02_279521	488	25	Scott	Scott	NNP
10_1101-2020_09_02_279521	488	26	,	,	,
10_1101-2020_09_02_279521	488	27	D.	D.	NNP
10_1101-2020_09_02_279521	488	28	,	,	,
10_1101-2020_09_02_279521	488	29	Bracoud	Bracoud	NNP
10_1101-2020_09_02_279521	488	30	,	,	,
10_1101-2020_09_02_279521	488	31	L.	L.	NNP
10_1101-2020_09_02_279521	488	32	,	,	,
10_1101-2020_09_02_279521	488	33	Oh	oh	UH
10_1101-2020_09_02_279521	488	34	,	,	,
10_1101-2020_09_02_279521	488	35	J.	J.	NNP
10_1101-2020_09_02_279521	488	36	,	,	,
10_1101-2020_09_02_279521	488	37	Suhy	Suhy	NNP
10_1101-2020_09_02_279521	488	38	,	,	,
10_1101-2020_09_02_279521	488	39	J.	J.	NNP
10_1101-2020_09_02_279521	488	40	,	,	,
10_1101-2020_09_02_279521	488	41	Pontecorvo	Pontecorvo	NNP
10_1101-2020_09_02_279521	488	42	,	,	,
10_1101-2020_09_02_279521	488	43	M.	M.	NNP
10_1101-2020_09_02_279521	488	44	J.	J.	NNP
10_1101-2020_09_02_279521	488	45	,	,	,
10_1101-2020_09_02_279521	488	46	Dickerson	Dickerson	NNP
10_1101-2020_09_02_279521	488	47	,	,	,
10_1101-2020_09_02_279521	488	48	B.	B.	NNP
10_1101-2020_09_02_279521	488	49	C.	C.	NNP
10_1101-2020_09_02_279521	488	50	,	,	,
10_1101-2020_09_02_279521	488	51	&	&	CC
10_1101-2020_09_02_279521	488	52	Siemers	Siemers	NNP
10_1101-2020_09_02_279521	488	53	,	,	,
10_1101-2020_09_02_279521	488	54	E.	E.	NNP
10_1101-2020_09_02_279521	488	55	R.	R.	NNP
10_1101-2020_09_02_279521	488	56	(	(	-LRB-
10_1101-2020_09_02_279521	488	57	2019	2019	CD
10_1101-2020_09_02_279521	488	58	)	)	-RRB-
10_1101-2020_09_02_279521	488	59	.	.	.
10_1101-2020_09_02_279521	489	1	Magnetic	magnetic	JJ
10_1101-2020_09_02_279521	489	2	resonance	resonance	NN
10_1101-2020_09_02_279521	489	3	imaging	image	VBG
10_1101-2020_09_02_279521	489	4	measures	measure	NNS
10_1101-2020_09_02_279521	489	5	of	of	IN
10_1101-2020_09_02_279521	489	6	brain	brain	NN
10_1101-2020_09_02_279521	489	7	atrophy	atrophy	NN
10_1101-2020_09_02_279521	489	8	from	from	IN
10_1101-2020_09_02_279521	489	9	the	the	DT
10_1101-2020_09_02_279521	489	10	EXPEDITION3	EXPEDITION3	NNP
10_1101-2020_09_02_279521	489	11	trial	trial	NN
10_1101-2020_09_02_279521	489	12	in	in	IN
10_1101-2020_09_02_279521	489	13	mild	mild	JJ
10_1101-2020_09_02_279521	489	14	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	489	15	’s	’s	POS
10_1101-2020_09_02_279521	489	16	disease	disease	NN
10_1101-2020_09_02_279521	489	17	.	.	.
10_1101-2020_09_02_279521	490	1	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	490	2	’s	’s	NNP
10_1101-2020_09_02_279521	490	3	&	&	CC
10_1101-2020_09_02_279521	490	4	Dementia	Dementia	NNP
10_1101-2020_09_02_279521	490	5	:	:	:
10_1101-2020_09_02_279521	490	6	Translational	Translational	NNP
10_1101-2020_09_02_279521	490	7	Research	Research	NNP
10_1101-2020_09_02_279521	490	8	&	&	CC
10_1101-2020_09_02_279521	490	9	Clinical	Clinical	NNP
10_1101-2020_09_02_279521	490	10	Interventions	Interventions	NNPS
10_1101-2020_09_02_279521	490	11	,	,	,
10_1101-2020_09_02_279521	490	12	5(1	5(1	NNP
10_1101-2020_09_02_279521	490	13	)	)	-RRB-
10_1101-2020_09_02_279521	490	14	,	,	,
10_1101-2020_09_02_279521	490	15	328–337	328–337	CD
10_1101-2020_09_02_279521	490	16	.	.	.
10_1101-2020_09_02_279521	491	1	https://doi.org/https://doi.org/10.1016/j.trci.2019.05.007	https://doi.org/https://doi.org/10.1016/j.trci.2019.05.007	NNP
10_1101-2020_09_02_279521	491	2	Sivera	Sivera	NNP
10_1101-2020_09_02_279521	491	3	,	,	,
10_1101-2020_09_02_279521	491	4	R.	R.	NNP
10_1101-2020_09_02_279521	491	5	,	,	,
10_1101-2020_09_02_279521	491	6	Capet	Capet	NNP
10_1101-2020_09_02_279521	491	7	,	,	,
10_1101-2020_09_02_279521	491	8	N.	N.	NNP
10_1101-2020_09_02_279521	491	9	,	,	,
10_1101-2020_09_02_279521	491	10	Manera	Manera	NNP
10_1101-2020_09_02_279521	491	11	,	,	,
10_1101-2020_09_02_279521	491	12	V.	V.	NNP
10_1101-2020_09_02_279521	491	13	,	,	,
10_1101-2020_09_02_279521	491	14	Fabre	Fabre	NNP
10_1101-2020_09_02_279521	491	15	,	,	,
10_1101-2020_09_02_279521	491	16	R.	R.	NNP
10_1101-2020_09_02_279521	491	17	,	,	,
10_1101-2020_09_02_279521	491	18	Lorenzi	Lorenzi	NNP
10_1101-2020_09_02_279521	491	19	,	,	,
10_1101-2020_09_02_279521	491	20	M.	M.	NNP
10_1101-2020_09_02_279521	491	21	,	,	,
10_1101-2020_09_02_279521	491	22	Delingette	Delingette	NNP
10_1101-2020_09_02_279521	491	23	,	,	,
10_1101-2020_09_02_279521	491	24	H.	H.	NNP
10_1101-2020_09_02_279521	491	25	,	,	,
10_1101-2020_09_02_279521	491	26	Pennec	Pennec	NNP
10_1101-2020_09_02_279521	491	27	,	,	,
10_1101-2020_09_02_279521	491	28	X.	X.	NNP
10_1101-2020_09_02_279521	491	29	,	,	,
10_1101-2020_09_02_279521	491	30	Ayache	Ayache	NNP
10_1101-2020_09_02_279521	491	31	,	,	,
10_1101-2020_09_02_279521	491	32	N.	N.	NNP
10_1101-2020_09_02_279521	491	33	,	,	,
10_1101-2020_09_02_279521	491	34	&	&	CC
10_1101-2020_09_02_279521	491	35	Robert	Robert	NNP
10_1101-2020_09_02_279521	491	36	,	,	,
10_1101-2020_09_02_279521	491	37	P.	P.	NNP
10_1101-2020_09_02_279521	491	38	(	(	-LRB-
10_1101-2020_09_02_279521	491	39	2020	2020	CD
10_1101-2020_09_02_279521	491	40	)	)	-RRB-
10_1101-2020_09_02_279521	491	41	.	.	.
10_1101-2020_09_02_279521	492	1	Voxel	Voxel	NNP
10_1101-2020_09_02_279521	492	2	-	-	HYPH
10_1101-2020_09_02_279521	492	3	based	base	VBN
10_1101-2020_09_02_279521	492	4	assessments	assessment	NNS
10_1101-2020_09_02_279521	492	5	of	of	IN
10_1101-2020_09_02_279521	492	6	treatment	treatment	NN
10_1101-2020_09_02_279521	492	7	effects	effect	NNS
10_1101-2020_09_02_279521	492	8	on	on	IN
10_1101-2020_09_02_279521	492	9	longitudinal	longitudinal	JJ
10_1101-2020_09_02_279521	492	10	brain	brain	NN
10_1101-2020_09_02_279521	492	11	changes	change	NNS
10_1101-2020_09_02_279521	492	12	in	in	IN
10_1101-2020_09_02_279521	492	13	the	the	DT
10_1101-2020_09_02_279521	492	14	Multidomain	Multidomain	NNP
10_1101-2020_09_02_279521	492	15	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	492	16	Preventive	Preventive	NNP
10_1101-2020_09_02_279521	492	17	Trial	Trial	NNP
10_1101-2020_09_02_279521	492	18	cohort	cohort	NN
10_1101-2020_09_02_279521	492	19	.	.	.
10_1101-2020_09_02_279521	493	1	Neurobiology	neurobiology	NN
10_1101-2020_09_02_279521	493	2	of	of	IN
10_1101-2020_09_02_279521	493	3	Aging	Aging	NNP
10_1101-2020_09_02_279521	493	4	,	,	,
10_1101-2020_09_02_279521	493	5	94	94	CD
10_1101-2020_09_02_279521	493	6	,	,	,
10_1101-2020_09_02_279521	493	7	50–59	50–59	CD
10_1101-2020_09_02_279521	493	8	.	.	.
10_1101-2020_09_02_279521	494	1	https://doi.org/https://doi.org/10.1016/j.neurobiolaging.2019.11.020	https://doi.org/https://doi.org/10.1016/j.neurobiolaging.2019.11.020	NNP
10_1101-2020_09_02_279521	494	2	Sperling	Sperling	NNP
10_1101-2020_09_02_279521	494	3	,	,	,
10_1101-2020_09_02_279521	494	4	R.	R.	NNP
10_1101-2020_09_02_279521	494	5	A.	A.	NNP
10_1101-2020_09_02_279521	494	6	,	,	,
10_1101-2020_09_02_279521	494	7	Jack	Jack	NNP
10_1101-2020_09_02_279521	494	8	,	,	,
10_1101-2020_09_02_279521	494	9	C.	C.	NNP
10_1101-2020_09_02_279521	494	10	R.	R.	NNP
10_1101-2020_09_02_279521	494	11	,	,	,
10_1101-2020_09_02_279521	494	12	&	&	CC
10_1101-2020_09_02_279521	494	13	Aisen	Aisen	NNP
10_1101-2020_09_02_279521	494	14	,	,	,
10_1101-2020_09_02_279521	494	15	P.	P.	NNP
10_1101-2020_09_02_279521	494	16	S.	S.	NNP
10_1101-2020_09_02_279521	494	17	(	(	-LRB-
10_1101-2020_09_02_279521	494	18	2011	2011	CD
10_1101-2020_09_02_279521	494	19	)	)	-RRB-
10_1101-2020_09_02_279521	494	20	.	.	.
10_1101-2020_09_02_279521	495	1	Testing	test	VBG
10_1101-2020_09_02_279521	495	2	the	the	DT
10_1101-2020_09_02_279521	495	3	right	right	JJ
10_1101-2020_09_02_279521	495	4	target	target	NN
10_1101-2020_09_02_279521	495	5	and	and	CC
10_1101-2020_09_02_279521	495	6	right	right	JJ
10_1101-2020_09_02_279521	495	7	drug	drug	NN
10_1101-2020_09_02_279521	495	8	at	at	IN
10_1101-2020_09_02_279521	495	9	the	the	DT
10_1101-2020_09_02_279521	495	10	right	right	JJ
10_1101-2020_09_02_279521	495	11	stage	stage	NN
10_1101-2020_09_02_279521	495	12	.	.	.
10_1101-2020_09_02_279521	496	1	Sci	Sci	NNP
10_1101-2020_09_02_279521	496	2	Transl	Transl	NNP
10_1101-2020_09_02_279521	496	3	Med	Med	NNP
10_1101-2020_09_02_279521	496	4	,	,	,
10_1101-2020_09_02_279521	496	5	3(111	3(111	NNP
10_1101-2020_09_02_279521	496	6	)	)	-RRB-
10_1101-2020_09_02_279521	496	7	,	,	,
10_1101-2020_09_02_279521	496	8	111cm33	111cm33	CD
10_1101-2020_09_02_279521	496	9	.	.	.
10_1101-2020_09_02_279521	497	1	Villemagne	Villemagne	NNP
10_1101-2020_09_02_279521	497	2	,	,	,
10_1101-2020_09_02_279521	497	3	V.	V.	NNP
10_1101-2020_09_02_279521	497	4	L.	L.	NNP
10_1101-2020_09_02_279521	497	5	,	,	,
10_1101-2020_09_02_279521	497	6	Burnham	Burnham	NNP
10_1101-2020_09_02_279521	497	7	,	,	,
10_1101-2020_09_02_279521	497	8	S.	S.	NNP
10_1101-2020_09_02_279521	497	9	,	,	,
10_1101-2020_09_02_279521	497	10	Bourgeat	Bourgeat	NNP
10_1101-2020_09_02_279521	497	11	,	,	,
10_1101-2020_09_02_279521	497	12	P.	P.	NNP
10_1101-2020_09_02_279521	497	13	,	,	,
10_1101-2020_09_02_279521	497	14	Brown	Brown	NNP
10_1101-2020_09_02_279521	497	15	,	,	,
10_1101-2020_09_02_279521	497	16	B.	B.	NNP
10_1101-2020_09_02_279521	497	17	,	,	,
10_1101-2020_09_02_279521	497	18	Ellis	Ellis	NNP
10_1101-2020_09_02_279521	497	19	,	,	,
10_1101-2020_09_02_279521	497	20	K.	K.	NNP
10_1101-2020_09_02_279521	497	21	A.	A.	NNP
10_1101-2020_09_02_279521	497	22	,	,	,
10_1101-2020_09_02_279521	497	23	Salvado	Salvado	NNP
10_1101-2020_09_02_279521	497	24	,	,	,
10_1101-2020_09_02_279521	497	25	O.	O.	NNP
10_1101-2020_09_02_279521	497	26	,	,	,
10_1101-2020_09_02_279521	497	27	Szoeke	Szoeke	NNP
10_1101-2020_09_02_279521	497	28	,	,	,
10_1101-2020_09_02_279521	497	29	C.	C.	NNP
10_1101-2020_09_02_279521	497	30	,	,	,
10_1101-2020_09_02_279521	497	31	Macaulay	Macaulay	NNP
10_1101-2020_09_02_279521	497	32	,	,	,
10_1101-2020_09_02_279521	497	33	S.	S.	NNP
10_1101-2020_09_02_279521	497	34	L.	L.	NNP
10_1101-2020_09_02_279521	497	35	,	,	,
10_1101-2020_09_02_279521	497	36	Martins	Martins	NNP
10_1101-2020_09_02_279521	497	37	,	,	,
10_1101-2020_09_02_279521	497	38	R.	R.	NNP
10_1101-2020_09_02_279521	497	39	,	,	,
10_1101-2020_09_02_279521	497	40	Maruff	Maruff	NNP
10_1101-2020_09_02_279521	497	41	,	,	,
10_1101-2020_09_02_279521	497	42	P.	P.	NNP
10_1101-2020_09_02_279521	497	43	,	,	,
10_1101-2020_09_02_279521	497	44	Ames	Ames	NNP
10_1101-2020_09_02_279521	497	45	,	,	,
10_1101-2020_09_02_279521	497	46	D.	D.	NNP
10_1101-2020_09_02_279521	497	47	,	,	,
10_1101-2020_09_02_279521	497	48	Rowe	Rowe	NNP
10_1101-2020_09_02_279521	497	49	,	,	,
10_1101-2020_09_02_279521	497	50	C.	C.	NNP
10_1101-2020_09_02_279521	497	51	C.	C.	NNP
10_1101-2020_09_02_279521	497	52	,	,	,
10_1101-2020_09_02_279521	497	53	&	&	CC
10_1101-2020_09_02_279521	497	54	Masters	Masters	NNP
10_1101-2020_09_02_279521	497	55	,	,	,
10_1101-2020_09_02_279521	497	56	C.	C.	NNP
10_1101-2020_09_02_279521	497	57	L.	L.	NNP
10_1101-2020_09_02_279521	497	58	(	(	-LRB-
10_1101-2020_09_02_279521	497	59	2013	2013	CD
10_1101-2020_09_02_279521	497	60	)	)	-RRB-
10_1101-2020_09_02_279521	497	61	.	.	.
10_1101-2020_09_02_279521	498	1	Amyloid	Amyloid	NNP
10_1101-2020_09_02_279521	498	2	Î2	Î2	NNP
10_1101-2020_09_02_279521	498	3	deposition	deposition	NN
10_1101-2020_09_02_279521	498	4	,	,	,
10_1101-2020_09_02_279521	498	5	neurodegeneration	neurodegeneration	NN
10_1101-2020_09_02_279521	498	6	,	,	,
10_1101-2020_09_02_279521	498	7	and	and	CC
10_1101-2020_09_02_279521	498	8	cognitive	cognitive	JJ
10_1101-2020_09_02_279521	498	9	decline	decline	NN
10_1101-2020_09_02_279521	498	10	in	in	IN
10_1101-2020_09_02_279521	498	11	sporadic	sporadic	JJ
10_1101-2020_09_02_279521	498	12	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	498	13	’s	’s	POS
10_1101-2020_09_02_279521	498	14	disease	disease	NN
10_1101-2020_09_02_279521	498	15	:	:	:
10_1101-2020_09_02_279521	498	16	a	a	DT
10_1101-2020_09_02_279521	498	17	prospective	prospective	JJ
10_1101-2020_09_02_279521	498	18	cohort	cohort	NN
10_1101-2020_09_02_279521	498	19	study	study	NN
10_1101-2020_09_02_279521	498	20	.	.	.
10_1101-2020_09_02_279521	499	1	Lancet	Lancet	NNP
10_1101-2020_09_02_279521	499	2	Neurol	Neurol	NNP
10_1101-2020_09_02_279521	499	3	,	,	,
10_1101-2020_09_02_279521	499	4	12(4	12(4	CD
10_1101-2020_09_02_279521	499	5	)	)	-RRB-
10_1101-2020_09_02_279521	499	6	,	,	,
10_1101-2020_09_02_279521	499	7	357–367	357–367	CD
10_1101-2020_09_02_279521	499	8	.	.	.
10_1101-2020_09_02_279521	500	1	Wessels	Wessels	NNP
10_1101-2020_09_02_279521	500	2	,	,	,
10_1101-2020_09_02_279521	500	3	A.	a.	NN
10_1101-2020_09_02_279521	500	4	M.	M.	NNP
10_1101-2020_09_02_279521	500	5	,	,	,
10_1101-2020_09_02_279521	500	6	Tariot	Tariot	NNP
10_1101-2020_09_02_279521	500	7	,	,	,
10_1101-2020_09_02_279521	500	8	P.	P.	NNP
10_1101-2020_09_02_279521	500	9	N.	N.	NNP
10_1101-2020_09_02_279521	500	10	,	,	,
10_1101-2020_09_02_279521	500	11	Zimmer	Zimmer	NNP
10_1101-2020_09_02_279521	500	12	,	,	,
10_1101-2020_09_02_279521	500	13	J.	J.	NNP
10_1101-2020_09_02_279521	501	1	A.	A.	NNP
10_1101-2020_09_02_279521	501	2	,	,	,
10_1101-2020_09_02_279521	501	3	Selzler	Selzler	NNP
10_1101-2020_09_02_279521	501	4	,	,	,
10_1101-2020_09_02_279521	501	5	K.	K.	NNP
10_1101-2020_09_02_279521	501	6	J.	J.	NNP
10_1101-2020_09_02_279521	501	7	,	,	,
10_1101-2020_09_02_279521	501	8	Bragg	Bragg	NNP
10_1101-2020_09_02_279521	501	9	,	,	,
10_1101-2020_09_02_279521	501	10	S.	S.	NNP
10_1101-2020_09_02_279521	501	11	M.	M.	NNP
10_1101-2020_09_02_279521	501	12	,	,	,
10_1101-2020_09_02_279521	501	13	Andersen	Andersen	NNP
10_1101-2020_09_02_279521	501	14	,	,	,
10_1101-2020_09_02_279521	501	15	S.	S.	NNP
10_1101-2020_09_02_279521	501	16	W.	W.	NNP
10_1101-2020_09_02_279521	501	17	,	,	,
10_1101-2020_09_02_279521	501	18	Landry	Landry	NNP
10_1101-2020_09_02_279521	501	19	,	,	,
10_1101-2020_09_02_279521	501	20	J.	J.	NNP
10_1101-2020_09_02_279521	501	21	,	,	,
10_1101-2020_09_02_279521	501	22	Krull	Krull	NNP
10_1101-2020_09_02_279521	501	23	,	,	,
10_1101-2020_09_02_279521	501	24	J.	J.	NNP
10_1101-2020_09_02_279521	501	25	H.	H.	NNP
10_1101-2020_09_02_279521	501	26	,	,	,
10_1101-2020_09_02_279521	501	27	Downing	Downing	NNP
10_1101-2020_09_02_279521	501	28	,	,	,
10_1101-2020_09_02_279521	501	29	A.	a.	NN
10_1101-2020_09_02_279521	501	30	M.	M.	NNP
10_1101-2020_09_02_279521	501	31	,	,	,
10_1101-2020_09_02_279521	501	32	Willis	Willis	NNP
10_1101-2020_09_02_279521	501	33	,	,	,
10_1101-2020_09_02_279521	501	34	B.	B.	NNP
10_1101-2020_09_02_279521	502	1	A.	A.	NNP
10_1101-2020_09_02_279521	502	2	,	,	,
10_1101-2020_09_02_279521	502	3	Shcherbinin	Shcherbinin	NNP
10_1101-2020_09_02_279521	502	4	,	,	,
10_1101-2020_09_02_279521	502	5	S.	S.	NNP
10_1101-2020_09_02_279521	502	6	,	,	,
10_1101-2020_09_02_279521	502	7	Mullen	Mullen	NNP
10_1101-2020_09_02_279521	502	8	,	,	,
10_1101-2020_09_02_279521	502	9	J.	J.	NNP
10_1101-2020_09_02_279521	502	10	,	,	,
10_1101-2020_09_02_279521	502	11	Barker	Barker	NNP
10_1101-2020_09_02_279521	502	12	,	,	,
10_1101-2020_09_02_279521	502	13	P.	P.	NNP
10_1101-2020_09_02_279521	502	14	,	,	,
10_1101-2020_09_02_279521	502	15	Schumi	Schumi	NNP
10_1101-2020_09_02_279521	502	16	,	,	,
10_1101-2020_09_02_279521	502	17	J.	J.	NNP
10_1101-2020_09_02_279521	502	18	,	,	,
10_1101-2020_09_02_279521	502	19	Shering	Shering	NNP
10_1101-2020_09_02_279521	502	20	,	,	,
10_1101-2020_09_02_279521	502	21	C.	C.	NNP
10_1101-2020_09_02_279521	502	22	,	,	,
10_1101-2020_09_02_279521	502	23	Matthews	Matthews	NNP
10_1101-2020_09_02_279521	502	24	,	,	,
10_1101-2020_09_02_279521	502	25	B.	B.	NNP
10_1101-2020_09_02_279521	502	26	R.	R.	NNP
10_1101-2020_09_02_279521	502	27	,	,	,
10_1101-2020_09_02_279521	502	28	Stern	Stern	NNP
10_1101-2020_09_02_279521	502	29	,	,	,
10_1101-2020_09_02_279521	502	30	R.	R.	NNP
10_1101-2020_09_02_279521	502	31	A.	A.	NNP
10_1101-2020_09_02_279521	502	32	,	,	,
10_1101-2020_09_02_279521	502	33	Vellas	Vellas	NNP
10_1101-2020_09_02_279521	502	34	,	,	,
10_1101-2020_09_02_279521	502	35	B.	B.	NNP
10_1101-2020_09_02_279521	502	36	,	,	,
10_1101-2020_09_02_279521	502	37	Cohen	Cohen	NNP
10_1101-2020_09_02_279521	502	38	,	,	,
10_1101-2020_09_02_279521	502	39	S.	S.	NNP
10_1101-2020_09_02_279521	502	40	,	,	,
10_1101-2020_09_02_279521	502	41	…	…	NFP
10_1101-2020_09_02_279521	502	42	Sims	sims	UH
10_1101-2020_09_02_279521	502	43	,	,	,
10_1101-2020_09_02_279521	502	44	J.	J.	NNP
10_1101-2020_09_02_279521	502	45	R.	R.	NNP
10_1101-2020_09_02_279521	502	46	(	(	-LRB-
10_1101-2020_09_02_279521	502	47	2019	2019	CD
10_1101-2020_09_02_279521	502	48	)	)	-RRB-
10_1101-2020_09_02_279521	502	49	.	.	.
10_1101-2020_09_02_279521	503	1	Efficacy	efficacy	NN
10_1101-2020_09_02_279521	503	2	and	and	CC
10_1101-2020_09_02_279521	503	3	Safety	Safety	NNP
10_1101-2020_09_02_279521	503	4	of	of	IN
10_1101-2020_09_02_279521	503	5	Lanabecestat	Lanabecestat	NNP
10_1101-2020_09_02_279521	503	6	for	for	IN
10_1101-2020_09_02_279521	503	7	Treatment	Treatment	NNP
10_1101-2020_09_02_279521	503	8	of	of	IN
10_1101-2020_09_02_279521	503	9	Early	early	JJ
10_1101-2020_09_02_279521	503	10	and	and	CC
10_1101-2020_09_02_279521	503	11	Mild	Mild	NNP
10_1101-2020_09_02_279521	503	12	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	503	13	Disease	Disease	NNP
10_1101-2020_09_02_279521	503	14	:	:	:
10_1101-2020_09_02_279521	503	15	The	the	DT
10_1101-2020_09_02_279521	503	16	AMARANTH	AMARANTH	NNP
10_1101-2020_09_02_279521	503	17	and	and	CC
10_1101-2020_09_02_279521	503	18	DAYBREAK	DAYBREAK	NNP
10_1101-2020_09_02_279521	503	19	-	-	HYPH
10_1101-2020_09_02_279521	503	20	ALZ	ALZ	NNP
10_1101-2020_09_02_279521	503	21	Randomized	Randomized	NNP
10_1101-2020_09_02_279521	503	22	Clinical	Clinical	NNP
10_1101-2020_09_02_279521	503	23	Trials	Trials	NNPS
10_1101-2020_09_02_279521	503	24	.	.	.
10_1101-2020_09_02_279521	504	1	JAMA	JAMA	NNP
10_1101-2020_09_02_279521	504	2	Neurol	Neurol	NNP
10_1101-2020_09_02_279521	504	3	.	.	.
10_1101-2020_09_02_279521	505	1	Westwood	Westwood	NNP
10_1101-2020_09_02_279521	505	2	,	,	,
10_1101-2020_09_02_279521	505	3	S.	S.	NNP
10_1101-2020_09_02_279521	505	4	,	,	,
10_1101-2020_09_02_279521	505	5	Leoni	Leoni	NNP
10_1101-2020_09_02_279521	505	6	,	,	,
10_1101-2020_09_02_279521	505	7	E.	E.	NNP
10_1101-2020_09_02_279521	505	8	,	,	,
10_1101-2020_09_02_279521	505	9	Hye	Hye	NNP
10_1101-2020_09_02_279521	505	10	,	,	,
10_1101-2020_09_02_279521	505	11	A.	a.	NN
10_1101-2020_09_02_279521	505	12	,	,	,
10_1101-2020_09_02_279521	505	13	Lynham	Lynham	NNP
10_1101-2020_09_02_279521	505	14	,	,	,
10_1101-2020_09_02_279521	505	15	S.	S.	NNP
10_1101-2020_09_02_279521	505	16	,	,	,
10_1101-2020_09_02_279521	505	17	Khondoker	Khondoker	NNP
10_1101-2020_09_02_279521	505	18	,	,	,
10_1101-2020_09_02_279521	505	19	M.	M.	NNP
10_1101-2020_09_02_279521	505	20	R.	R.	NNP
10_1101-2020_09_02_279521	505	21	,	,	,
10_1101-2020_09_02_279521	505	22	Ashton	Ashton	NNP
10_1101-2020_09_02_279521	505	23	,	,	,
10_1101-2020_09_02_279521	505	24	N.	N.	NNP
10_1101-2020_09_02_279521	505	25	J.	J.	NNP
10_1101-2020_09_02_279521	505	26	,	,	,
10_1101-2020_09_02_279521	505	27	Kiddle	Kiddle	NNP
10_1101-2020_09_02_279521	505	28	,	,	,
10_1101-2020_09_02_279521	505	29	S.	S.	NNP
10_1101-2020_09_02_279521	505	30	J.	J.	NNP
10_1101-2020_09_02_279521	505	31	,	,	,
10_1101-2020_09_02_279521	505	32	Baird	Baird	NNP
10_1101-2020_09_02_279521	505	33	,	,	,
10_1101-2020_09_02_279521	505	34	A.	A.	NNP
10_1101-2020_09_02_279521	505	35	L.	L.	NNP
10_1101-2020_09_02_279521	505	36	,	,	,
10_1101-2020_09_02_279521	505	37	Sainz	Sainz	NNP
10_1101-2020_09_02_279521	505	38	-	-	HYPH
10_1101-2020_09_02_279521	505	39	Fuertes	Fuertes	NNP
10_1101-2020_09_02_279521	505	40	,	,	,
10_1101-2020_09_02_279521	505	41	R.	R.	NNP
10_1101-2020_09_02_279521	505	42	,	,	,
10_1101-2020_09_02_279521	505	43	Leung	Leung	NNP
10_1101-2020_09_02_279521	505	44	,	,	,
10_1101-2020_09_02_279521	505	45	R.	R.	NNP
10_1101-2020_09_02_279521	505	46	,	,	,
10_1101-2020_09_02_279521	505	47	Graf	Graf	NNP
10_1101-2020_09_02_279521	505	48	,	,	,
10_1101-2020_09_02_279521	505	49	J.	J.	NNP
10_1101-2020_09_02_279521	505	50	,	,	,
10_1101-2020_09_02_279521	505	51	Hehir	Hehir	NNP
10_1101-2020_09_02_279521	505	52	,	,	,
10_1101-2020_09_02_279521	505	53	C.	C.	NNP
10_1101-2020_09_02_279521	505	54	T.	T.	NNP
10_1101-2020_09_02_279521	505	55	,	,	,
10_1101-2020_09_02_279521	505	56	Baker	Baker	NNP
10_1101-2020_09_02_279521	505	57	,	,	,
10_1101-2020_09_02_279521	505	58	D.	D.	NNP
10_1101-2020_09_02_279521	505	59	,	,	,
10_1101-2020_09_02_279521	505	60	Cereda	Cereda	NNP
10_1101-2020_09_02_279521	505	61	,	,	,
10_1101-2020_09_02_279521	505	62	C.	C.	NNP
10_1101-2020_09_02_279521	505	63	,	,	,
10_1101-2020_09_02_279521	505	64	Bazenet	Bazenet	NNP
10_1101-2020_09_02_279521	505	65	,	,	,
10_1101-2020_09_02_279521	505	66	C.	C.	NNP
10_1101-2020_09_02_279521	505	67	,	,	,
10_1101-2020_09_02_279521	505	68	Ward	Ward	NNP
10_1101-2020_09_02_279521	505	69	,	,	,
10_1101-2020_09_02_279521	505	70	M.	M.	NNP
10_1101-2020_09_02_279521	505	71	,	,	,
10_1101-2020_09_02_279521	505	72	Thambisetty	Thambisetty	NNP
10_1101-2020_09_02_279521	505	73	,	,	,
10_1101-2020_09_02_279521	505	74	M.	M.	NNP
10_1101-2020_09_02_279521	505	75	,	,	,
10_1101-2020_09_02_279521	505	76	&	&	CC
10_1101-2020_09_02_279521	505	77	Lovestone	Lovestone	NNP
10_1101-2020_09_02_279521	505	78	,	,	,
10_1101-2020_09_02_279521	505	79	S.	S.	NNP
10_1101-2020_09_02_279521	505	80	(	(	-LRB-
10_1101-2020_09_02_279521	505	81	2016	2016	CD
10_1101-2020_09_02_279521	505	82	)	)	-RRB-
10_1101-2020_09_02_279521	505	83	.	.	.
10_1101-2020_09_02_279521	506	1	Blood	blood	NN
10_1101-2020_09_02_279521	506	2	-	-	HYPH
10_1101-2020_09_02_279521	506	3	Based	base	VBN
10_1101-2020_09_02_279521	506	4	Biomarker	Biomarker	NNP
10_1101-2020_09_02_279521	506	5	Candidates	Candidates	NNPS
10_1101-2020_09_02_279521	506	6	of	of	IN
10_1101-2020_09_02_279521	506	7	Cerebral	Cerebral	NNP
10_1101-2020_09_02_279521	506	8	Amyloid	Amyloid	NNP
10_1101-2020_09_02_279521	506	9	Using	use	VBG
10_1101-2020_09_02_279521	506	10	PiB	pib	NN
10_1101-2020_09_02_279521	506	11	PET	PET	NNP
10_1101-2020_09_02_279521	506	12	in	in	IN
10_1101-2020_09_02_279521	506	13	Non	Non	NNP
10_1101-2020_09_02_279521	506	14	-	-	JJ
10_1101-2020_09_02_279521	506	15	Demented	demented	JJ
10_1101-2020_09_02_279521	506	16	Elderly	Elderly	NNP
10_1101-2020_09_02_279521	506	17	.	.	.
10_1101-2020_09_02_279521	507	1	J.	J.	NNP
10_1101-2020_09_02_279521	507	2	Alzheimers	Alzheimers	NNP
10_1101-2020_09_02_279521	507	3	Dis	Dis	NNP
10_1101-2020_09_02_279521	507	4	.	.	NNP
10_1101-2020_09_02_279521	507	5	,	,	,
10_1101-2020_09_02_279521	507	6	52(2	52(2	CD
10_1101-2020_09_02_279521	507	7	)	)	-RRB-
10_1101-2020_09_02_279521	507	8	,	,	,
10_1101-2020_09_02_279521	507	9	561–572	561–572	CD
10_1101-2020_09_02_279521	507	10	.	.	.
10_1101-2020_09_02_279521	508	1	Young	young	JJ
10_1101-2020_09_02_279521	508	2	,	,	,
10_1101-2020_09_02_279521	508	3	A.	a.	NN
10_1101-2020_09_02_279521	508	4	L.	L.	NNP
10_1101-2020_09_02_279521	508	5	,	,	,
10_1101-2020_09_02_279521	508	6	Oxtoby	Oxtoby	NNP
10_1101-2020_09_02_279521	508	7	,	,	,
10_1101-2020_09_02_279521	508	8	N.	N.	NNP
10_1101-2020_09_02_279521	508	9	P.	P.	NNP
10_1101-2020_09_02_279521	508	10	,	,	,
10_1101-2020_09_02_279521	508	11	Daga	Daga	NNP
10_1101-2020_09_02_279521	508	12	,	,	,
10_1101-2020_09_02_279521	508	13	P.	P.	NNP
10_1101-2020_09_02_279521	508	14	,	,	,
10_1101-2020_09_02_279521	508	15	Cash	Cash	NNP
10_1101-2020_09_02_279521	508	16	,	,	,
10_1101-2020_09_02_279521	508	17	D.	D.	NNP
10_1101-2020_09_02_279521	508	18	M.	M.	NNP
10_1101-2020_09_02_279521	508	19	,	,	,
10_1101-2020_09_02_279521	508	20	Fox	Fox	NNP
10_1101-2020_09_02_279521	508	21	,	,	,
10_1101-2020_09_02_279521	508	22	N.	N.	NNP
10_1101-2020_09_02_279521	508	23	C.	C.	NNP
10_1101-2020_09_02_279521	508	24	,	,	,
10_1101-2020_09_02_279521	508	25	Ourselin	Ourselin	NNP
10_1101-2020_09_02_279521	508	26	,	,	,
10_1101-2020_09_02_279521	508	27	S.	S.	NNP
10_1101-2020_09_02_279521	508	28	,	,	,
10_1101-2020_09_02_279521	508	29	Schott	Schott	NNP
10_1101-2020_09_02_279521	508	30	,	,	,
10_1101-2020_09_02_279521	508	31	J.	J.	NNP
10_1101-2020_09_02_279521	508	32	M.	M.	NNP
10_1101-2020_09_02_279521	508	33	,	,	,
10_1101-2020_09_02_279521	508	34	&	&	CC
10_1101-2020_09_02_279521	508	35	Alexander	Alexander	NNP
10_1101-2020_09_02_279521	508	36	,	,	,
10_1101-2020_09_02_279521	508	37	D.	D.	NNP
10_1101-2020_09_02_279521	508	38	C.	C.	NNP
10_1101-2020_09_02_279521	508	39	(	(	-LRB-
10_1101-2020_09_02_279521	508	40	2014	2014	CD
10_1101-2020_09_02_279521	508	41	)	)	-RRB-
10_1101-2020_09_02_279521	508	42	.	.	.
10_1101-2020_09_02_279521	509	1	A	a	DT
10_1101-2020_09_02_279521	509	2	data	data	NN
10_1101-2020_09_02_279521	509	3	-	-	HYPH
10_1101-2020_09_02_279521	509	4	driven	drive	VBN
10_1101-2020_09_02_279521	509	5	model	model	NN
10_1101-2020_09_02_279521	509	6	of	of	IN
10_1101-2020_09_02_279521	509	7	biomarker	biomarker	NN
10_1101-2020_09_02_279521	509	8	changes	change	NNS
10_1101-2020_09_02_279521	509	9	in	in	IN
10_1101-2020_09_02_279521	509	10	sporadic	sporadic	JJ
10_1101-2020_09_02_279521	509	11	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	509	12	’s	’s	POS
10_1101-2020_09_02_279521	509	13	disease	disease	NN
10_1101-2020_09_02_279521	509	14	.	.	.
10_1101-2020_09_02_279521	510	1	Brain	brain	NN
10_1101-2020_09_02_279521	510	2	,	,	,
10_1101-2020_09_02_279521	510	3	137(Pt	137(pt	CD
10_1101-2020_09_02_279521	510	4	9	9	CD
10_1101-2020_09_02_279521	510	5	)	)	-RRB-
10_1101-2020_09_02_279521	510	6	,	,	,
10_1101-2020_09_02_279521	510	7	2564–2577	2564–2577	CD
10_1101-2020_09_02_279521	510	8	.	.	.
10_1101-2020_09_02_279521	511	1	.CC	.CC	NFP
10_1101-2020_09_02_279521	511	2	-	-	:
10_1101-2020_09_02_279521	511	3	BY	by	IN
10_1101-2020_09_02_279521	511	4	4.0	4.0	CD
10_1101-2020_09_02_279521	511	5	International	international	JJ
10_1101-2020_09_02_279521	511	6	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	511	7	.	.	.
10_1101-2020_09_02_279521	512	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	512	2	is	be	VBZ
10_1101-2020_09_02_279521	512	3	made	make	VBN
10_1101-2020_09_02_279521	512	4	available	available	JJ
10_1101-2020_09_02_279521	512	5	under	under	IN
10_1101-2020_09_02_279521	512	6	a	a	DT
10_1101-2020_09_02_279521	512	7	preprint	preprint	NN
10_1101-2020_09_02_279521	512	8	(	(	-LRB-
10_1101-2020_09_02_279521	512	9	which	which	WDT
10_1101-2020_09_02_279521	512	10	was	be	VBD
10_1101-2020_09_02_279521	512	11	not	not	RB
10_1101-2020_09_02_279521	512	12	certified	certify	VBN
10_1101-2020_09_02_279521	512	13	by	by	IN
10_1101-2020_09_02_279521	512	14	peer	peer	NN
10_1101-2020_09_02_279521	512	15	review	review	NN
10_1101-2020_09_02_279521	512	16	)	)	-RRB-
10_1101-2020_09_02_279521	512	17	is	be	VBZ
10_1101-2020_09_02_279521	512	18	the	the	DT
10_1101-2020_09_02_279521	512	19	author	author	NN
10_1101-2020_09_02_279521	512	20	/	/	SYM
10_1101-2020_09_02_279521	512	21	funder	funder	NN
10_1101-2020_09_02_279521	512	22	,	,	,
10_1101-2020_09_02_279521	512	23	who	who	WP
10_1101-2020_09_02_279521	512	24	has	have	VBZ
10_1101-2020_09_02_279521	512	25	granted	grant	VBN
10_1101-2020_09_02_279521	512	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	512	27	a	a	DT
10_1101-2020_09_02_279521	512	28	license	license	NN
10_1101-2020_09_02_279521	512	29	to	to	TO
10_1101-2020_09_02_279521	512	30	display	display	VB
10_1101-2020_09_02_279521	512	31	the	the	DT
10_1101-2020_09_02_279521	512	32	preprint	preprint	NN
10_1101-2020_09_02_279521	512	33	in	in	IN
10_1101-2020_09_02_279521	512	34	The	the	DT
10_1101-2020_09_02_279521	512	35	copyright	copyright	NN
10_1101-2020_09_02_279521	512	36	holder	holder	NN
10_1101-2020_09_02_279521	512	37	for	for	IN
10_1101-2020_09_02_279521	512	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	512	39	version	version	NN
10_1101-2020_09_02_279521	512	40	posted	post	VBD
10_1101-2020_09_02_279521	512	41	February	February	NNP
10_1101-2020_09_02_279521	512	42	10	10	CD
10_1101-2020_09_02_279521	512	43	,	,	,
10_1101-2020_09_02_279521	512	44	2021	2021	CD
10_1101-2020_09_02_279521	512	45	.	.	.
10_1101-2020_09_02_279521	512	46	;	;	:
10_1101-2020_09_02_279521	512	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	512	48	:	:	:
10_1101-2020_09_02_279521	512	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	512	50	preprint	preprint	NN
10_1101-2020_09_02_279521	512	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	NN
10_1101-2020_09_02_279521	512	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	-LRB-
10_1101-2020_09_02_279521	512	53	Zetterberg	Zetterberg	NNP
10_1101-2020_09_02_279521	512	54	,	,	,
10_1101-2020_09_02_279521	512	55	H.	H.	NNP
10_1101-2020_09_02_279521	512	56	,	,	,
10_1101-2020_09_02_279521	512	57	&	&	CC
10_1101-2020_09_02_279521	512	58	Burnham	Burnham	NNP
10_1101-2020_09_02_279521	512	59	,	,	,
10_1101-2020_09_02_279521	512	60	S.	S.	NNP
10_1101-2020_09_02_279521	512	61	C.	C.	NNP
10_1101-2020_09_02_279521	512	62	(	(	-LRB-
10_1101-2020_09_02_279521	512	63	2019	2019	CD
10_1101-2020_09_02_279521	512	64	)	)	-RRB-
10_1101-2020_09_02_279521	512	65	.	.	.
10_1101-2020_09_02_279521	513	1	Blood	blood	NN
10_1101-2020_09_02_279521	513	2	-	-	HYPH
10_1101-2020_09_02_279521	513	3	based	base	VBN
10_1101-2020_09_02_279521	513	4	molecular	molecular	JJ
10_1101-2020_09_02_279521	513	5	biomarkers	biomarker	NNS
10_1101-2020_09_02_279521	513	6	for	for	IN
10_1101-2020_09_02_279521	513	7	Alzheimer	Alzheimer	NNP
10_1101-2020_09_02_279521	513	8	’s	’s	POS
10_1101-2020_09_02_279521	513	9	disease	disease	NN
10_1101-2020_09_02_279521	513	10	.	.	.
10_1101-2020_09_02_279521	514	1	Molecular	Molecular	NNP
10_1101-2020_09_02_279521	514	2	Brain	Brain	NNP
10_1101-2020_09_02_279521	514	3	,	,	,
10_1101-2020_09_02_279521	514	4	12(1	12(1	CD
10_1101-2020_09_02_279521	514	5	)	)	-RRB-
10_1101-2020_09_02_279521	514	6	,	,	,
10_1101-2020_09_02_279521	514	7	26	26	CD
10_1101-2020_09_02_279521	514	8	.	.	.
10_1101-2020_09_02_279521	514	9	https://doi.org/10.1186/s13041-019-0448-1	https://doi.org/10.1186/s13041-019-0448-1	CD
10_1101-2020_09_02_279521	514	10	.CC	.CC	:
10_1101-2020_09_02_279521	514	11	-	-	:
10_1101-2020_09_02_279521	514	12	BY	by	IN
10_1101-2020_09_02_279521	514	13	4.0	4.0	CD
10_1101-2020_09_02_279521	514	14	International	international	JJ
10_1101-2020_09_02_279521	514	15	licenseperpetuity	licenseperpetuity	NN
10_1101-2020_09_02_279521	514	16	.	.	.
10_1101-2020_09_02_279521	515	1	It	-PRON-	PRP
10_1101-2020_09_02_279521	515	2	is	be	VBZ
10_1101-2020_09_02_279521	515	3	made	make	VBN
10_1101-2020_09_02_279521	515	4	available	available	JJ
10_1101-2020_09_02_279521	515	5	under	under	IN
10_1101-2020_09_02_279521	515	6	a	a	DT
10_1101-2020_09_02_279521	515	7	preprint	preprint	NN
10_1101-2020_09_02_279521	515	8	(	(	-LRB-
10_1101-2020_09_02_279521	515	9	which	which	WDT
10_1101-2020_09_02_279521	515	10	was	be	VBD
10_1101-2020_09_02_279521	515	11	not	not	RB
10_1101-2020_09_02_279521	515	12	certified	certify	VBN
10_1101-2020_09_02_279521	515	13	by	by	IN
10_1101-2020_09_02_279521	515	14	peer	peer	NN
10_1101-2020_09_02_279521	515	15	review	review	NN
10_1101-2020_09_02_279521	515	16	)	)	-RRB-
10_1101-2020_09_02_279521	515	17	is	be	VBZ
10_1101-2020_09_02_279521	515	18	the	the	DT
10_1101-2020_09_02_279521	515	19	author	author	NN
10_1101-2020_09_02_279521	515	20	/	/	SYM
10_1101-2020_09_02_279521	515	21	funder	funder	NN
10_1101-2020_09_02_279521	515	22	,	,	,
10_1101-2020_09_02_279521	515	23	who	who	WP
10_1101-2020_09_02_279521	515	24	has	have	VBZ
10_1101-2020_09_02_279521	515	25	granted	grant	VBN
10_1101-2020_09_02_279521	515	26	bioRxiv	biorxiv	IN
10_1101-2020_09_02_279521	515	27	a	a	DT
10_1101-2020_09_02_279521	515	28	license	license	NN
10_1101-2020_09_02_279521	515	29	to	to	TO
10_1101-2020_09_02_279521	515	30	display	display	VB
10_1101-2020_09_02_279521	515	31	the	the	DT
10_1101-2020_09_02_279521	515	32	preprint	preprint	NN
10_1101-2020_09_02_279521	515	33	in	in	IN
10_1101-2020_09_02_279521	515	34	The	the	DT
10_1101-2020_09_02_279521	515	35	copyright	copyright	NN
10_1101-2020_09_02_279521	515	36	holder	holder	NN
10_1101-2020_09_02_279521	515	37	for	for	IN
10_1101-2020_09_02_279521	515	38	thisthis	thisthis	DT
10_1101-2020_09_02_279521	515	39	version	version	NN
10_1101-2020_09_02_279521	515	40	posted	post	VBD
10_1101-2020_09_02_279521	515	41	February	February	NNP
10_1101-2020_09_02_279521	515	42	10	10	CD
10_1101-2020_09_02_279521	515	43	,	,	,
10_1101-2020_09_02_279521	515	44	2021	2021	CD
10_1101-2020_09_02_279521	515	45	.	.	.
10_1101-2020_09_02_279521	515	46	;	;	:
10_1101-2020_09_02_279521	515	47	https://doi.org/10.1101/2020.09.02.279521doi	https://doi.org/10.1101/2020.09.02.279521doi	ADD
10_1101-2020_09_02_279521	515	48	:	:	:
10_1101-2020_09_02_279521	515	49	bioRxiv	biorxiv	VB
10_1101-2020_09_02_279521	515	50	preprint	preprint	NN
10_1101-2020_09_02_279521	515	51	https://doi.org/10.1101/2020.09.02.279521	https://doi.org/10.1101/2020.09.02.279521	ADD
10_1101-2020_09_02_279521	515	52	http://creativecommons.org/licenses/by/4.0/	http://creativecommons.org/licenses/by/4.0/	ADD